{"docstore/data": {"50518c17-70e0-49ab-acc9-52fc13113b17": {"__data__": {"id_": "50518c17-70e0-49ab-acc9-52fc13113b17", "embedding": null, "metadata": {"source": "Data.FI Nigeria_LAMISPlus Mobile User Guide V.2_TL-24-11_KM revised.pdf", "page_label": "1"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "f43c593e-89ed-466f-b6c5-bb24c6a815e1", "node_type": "4", "metadata": {"source": "Data.FI Nigeria_LAMISPlus Mobile User Guide V.2_TL-24-11_KM revised.pdf", "page_label": "1"}, "hash": "cff2b7939cbbc2d2c585c5f23a985ef7a646e9e7a402ceb342c74b578c6a63c4", "class_name": "RelatedNodeInfo"}}, "text": "FEDERAL MINISTRY OF\n                        HEALTH\n   LAMISPlus Mobile\n   User Manual\n   Version 1.0.7\n   JULY 2024\n   Data.FI/Nigeria Manual\nDalaF              USAID USAID       DataFI\n   PEPFAR         MorlDEVEL  FROM THE AMERICAN PEOPLE  Data for Implementation\nData ior Implemenlation", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 288, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3f1d571b-2021-4509-a361-8c30df814751": {"__data__": {"id_": "3f1d571b-2021-4509-a361-8c30df814751", "embedding": null, "metadata": {"source": "Data.FI Nigeria_LAMISPlus Mobile User Guide V.2_TL-24-11_KM revised.pdf", "page_label": "2"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "33cfe3c1-14e1-49ff-b2f4-1204ec745a13", "node_type": "4", "metadata": {"source": "Data.FI Nigeria_LAMISPlus Mobile User Guide V.2_TL-24-11_KM revised.pdf", "page_label": "2"}, "hash": "bb4493850a4bb8a14390ae3b7adf9e230dc281c1d246552369b10a5c8604cae6", "class_name": "RelatedNodeInfo"}}, "text": "This document (version 1.0.7) is subject to updates and improvements as the system development\nprogresses.\n                                   LAMISPlus\n                                   Lafiya Managment Information System\nThis manual was prepared by the Data for Implementation (Data.FI)/Nigeria team.\nSuggested citation: Data.FI. (2024). Lafia Management Information System Plus (LAMISPlus) Training Guide\nand User Manual: Version 1.0.7. Washington, DC, USA: Data.FI, Palladium\nThis manual was produced for review by the U.S. Agency for International Development. It was prepared by\nData.FI. The information provided in this report is not official U.S. Government information and does not\nnecessarily reflect the views or positions of the U.S. Agency for International Development or the U.S.\nGovernment.\n2                                                          LAMISPlus Mobile Training Manual and User Guide", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 913, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "81a53cc0-056c-42d5-98c2-b2045020e78a": {"__data__": {"id_": "81a53cc0-056c-42d5-98c2-b2045020e78a", "embedding": null, "metadata": {"source": "Data.FI Nigeria_LAMISPlus Mobile User Guide V.2_TL-24-11_KM revised.pdf", "page_label": "3"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "5740e021-9ec2-4533-98b4-38e359f67d99", "node_type": "4", "metadata": {"source": "Data.FI Nigeria_LAMISPlus Mobile User Guide V.2_TL-24-11_KM revised.pdf", "page_label": "3"}, "hash": "4ade35138f807af8f8a4f9e1b600d9f22398e65a2f3fc77f0b78416a64978ae7", "class_name": "RelatedNodeInfo"}}, "text": "Acknowledgments\nThis training manual and user guide for the LAMISPlus Mobile application was made possible through\nthe support of the United States Agency for International Development (USAID) and the U.S.\nPresident\u2019s Emergency Plan for AIDS Relief (PEPFAR) through the Data.FI project. We thank them.\nLAMISPlus Mobile Training Manual and User Guide                                               i", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 397, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "992c25fa-a72a-402f-8d0e-ae9198581c3c": {"__data__": {"id_": "992c25fa-a72a-402f-8d0e-ae9198581c3c", "embedding": null, "metadata": {"source": "Data.FI Nigeria_LAMISPlus Mobile User Guide V.2_TL-24-11_KM revised.pdf", "page_label": "4"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "48a1d039-dad7-4de1-bba3-f1ab011f0d4f", "node_type": "4", "metadata": {"source": "Data.FI Nigeria_LAMISPlus Mobile User Guide V.2_TL-24-11_KM revised.pdf", "page_label": "4"}, "hash": "c398eb8e1e802e53a698462b8a200823ad205747c87b27d897786df68f6df080", "class_name": "RelatedNodeInfo"}}, "text": "Table of Contents\nAcknowledgments                                                                  i\nAbbreviations                                                                 vviv\n1.   Overview                                                                  665\n   1.1 Purpose of the Manual                                                   665\n   1.2 Content of the Manual                                                   665\n2.   Navigating through the system                                             665\n   Login Page                                                                  776\n   Landing Page                                                                887\n   Settings Page                                                               998\n3.   HIV Testing Services                                                    10109\n   Features of HTS Module                                                   111110\n   HTS Module Dashboard                                                     111110\n   Risk Stratification                                                      121211\n   Client Intake Form                                                       141413\n   Pre-Test Form                                                            151514\n   Request and Result Form                                                  161615\n   Post Test Form                                                           171716\n   Recency Form                                                             181817\n   Index Notification and Elicitation Services                              191918\n4.  Prevention of Mother to Child Transmission                              202019\n   Features of the PMTCT Module                                             202019\n   New PMTCT                                                                202019\n   Patient Registration \u2013 ANC Enrollment                                    212120\n   Patient Registration \u2013 PMTCT Enrollment                                  222221\n   Patient Registration \u2013 Labour and Delivery                               222221\n   Infant Registration                                                      242423\n   Partners Registration                                                    252524\n   PMTCT Services                                                           262625\n   Follow-up Visit                                                          262625\n5.   Hepatitis                                                              282827\n   Features of the Hepatitis Module                                         282827\n   Hepatitis Services                                                       303029\n   Hepatitis Enrolment                                                      313130\n   Hepatitis Diagnosis                                                      323231\n   Hepatitis Treatment                                                      323231\n6.   Differentiated Service Delivery                                        333332\n   Feature of the DSD Module                                                333332\n   DSD Client\u2019s List                                                        343433\nii                                            LAMISPlus Mobile Training Manual and User Guide", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 3265, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f8cb1ffc-b06c-45fe-b45a-6c0a00e293ef": {"__data__": {"id_": "f8cb1ffc-b06c-45fe-b45a-6c0a00e293ef", "embedding": null, "metadata": {"source": "Data.FI Nigeria_LAMISPlus Mobile User Guide V.2_TL-24-11_KM revised.pdf", "page_label": "5"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "2707617b-f4f3-4996-82a9-0713064cdaa6", "node_type": "4", "metadata": {"source": "Data.FI Nigeria_LAMISPlus Mobile User Guide V.2_TL-24-11_KM revised.pdf", "page_label": "5"}, "hash": "0a422fa6fedb4184fa2a5000bd4cc25fe814ad5b8828c553a4715740ecb71baf", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "badb5fd5-d87b-4df8-884a-756d70136d49", "node_type": "1", "metadata": {}, "hash": "2acb432ead46806c20bd7d9c8413d96b9cb29dac76a4cda0cb63c6d9bbd17c71", "class_name": "RelatedNodeInfo"}}, "text": "DSD Services                                                             353534\n7.   All Clients                                                            363635\n   Features of the All-Clients Module                                       373736\n   Patient Profile                                                          373736\n   Patient Dashboard                                                        383837\n   Patient Biometrics                                                       414140\n   Secugen Biometrics                                                       424241\n   Futronic Neurotec Biometrics                                             434342\n8.   Sync Status                                                            454544\n   Feature of the Sync Status Module                                        464645\n9.   Connect to Server                                                      474746\n   Features of the Connect to Server Module                                 474746\n   Pull Patients from Server                                                484847\n   Pull Patients without Biometrics from Server                             494948\n   Pull Patients with Biometrics from Server                                505049\nFigures\nFigure 2.0. Access the IPv4 address on the system\u2019s Command Prompt             667\nFigure 2.1. LAMISPlus login page                                                 7\nFigure 2.2. LAMISPlus user login page (after first access)                       8\nFigure 2.3. Landing page \u201cadd\u201d icon to register new clients                      9\nFigure 2.4. LAMISPlus configurations on settings page                           10\nFigure 3.0. HIV testing services page                                           11\nFigure 3.1. HTS Module dashboard                                                12\nFigure 3.2. Risk Stratification form                                            13\nFigure 3.3. Clinic Intake form                                                  14\nFigure 3.4. Pre-Test form to assess HIV risk factors                            15\nFigure 3.5. Request & Result form for various testing details                   16\nFigure 3.6. HIV Post-Test counseling form                                       17\nFigure 3.7. Recency form showing client\u2019s recent infections                     18\nFigure 3.8. Index Notification Services form                                    19\nFigure 4.1. Tab for PMTCT Client\u2019s List                                         21\nFigure 4.2. Patient Registration tab                                            22\nFigure 4.3. Labour and Delivery form                                            23\nFigure 4.4.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2672, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "badb5fd5-d87b-4df8-884a-756d70136d49": {"__data__": {"id_": "badb5fd5-d87b-4df8-884a-756d70136d49", "embedding": null, "metadata": {"source": "Data.FI Nigeria_LAMISPlus Mobile User Guide V.2_TL-24-11_KM revised.pdf", "page_label": "5"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "2707617b-f4f3-4996-82a9-0713064cdaa6", "node_type": "4", "metadata": {"source": "Data.FI Nigeria_LAMISPlus Mobile User Guide V.2_TL-24-11_KM revised.pdf", "page_label": "5"}, "hash": "0a422fa6fedb4184fa2a5000bd4cc25fe814ad5b8828c553a4715740ecb71baf", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f8cb1ffc-b06c-45fe-b45a-6c0a00e293ef", "node_type": "1", "metadata": {"source": "Data.FI Nigeria_LAMISPlus Mobile User Guide V.2_TL-24-11_KM revised.pdf", "page_label": "5"}, "hash": "bbc141b15a82249d24e63a27f4902584b8c7962cbc1c1e7b0288bf08106836c0", "class_name": "RelatedNodeInfo"}}, "text": "Tab for PMTCT Client\u2019s List                                         21\nFigure 4.2. Patient Registration tab                                            22\nFigure 4.3. Labour and Delivery form                                            23\nFigure 4.4. Infant Registration form                                            24\nFigure 4.5. Partners form, including partner HIV status                         25\nFigure 4.6. Tab on Patient Dashboard for follow-up visit                        26\nFigure 4.7. Child Follow-Up Visit form                                          27\nFigure 5.0. Main page of Hepatitis module                                       28\nLAMISPlus Mobile Training Manual and User Guide                                iii", "mimetype": "text/plain", "start_char_idx": 2424, "end_char_idx": 3158, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1af01015-e8a9-4684-b600-d5aa1cb379b1": {"__data__": {"id_": "1af01015-e8a9-4684-b600-d5aa1cb379b1", "embedding": null, "metadata": {"source": "Data.FI Nigeria_LAMISPlus Mobile User Guide V.2_TL-24-11_KM revised.pdf", "page_label": "6"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "1a8f068a-802e-4756-bf9c-5fd772fccfe8", "node_type": "4", "metadata": {"source": "Data.FI Nigeria_LAMISPlus Mobile User Guide V.2_TL-24-11_KM revised.pdf", "page_label": "6"}, "hash": "1acc61b3dbd0360d3e75024ca9def0f21b9ce0f72fe8eab8c976900ec099cf4b", "class_name": "RelatedNodeInfo"}}, "text": "Figure 5.1. List of all registered hepatitis clients...................................................................................29\nFigure 5.2. Service forms available in the Hepatitis module.................................................................30\nFigure 5.3. Hepatitis Enrollment form ...................................................................................................31\nFigure 5.4. Hepatitis Diagnosis form.....................................................................................................32\nFigure 5.5. Hepatitis Treatment form ....................................................................................................32\nFigure 6.0. DSD Module main page......................................................................................................33\nFigure 6.1. List of registered clients eligible for DSD............................................................................34\nFigure 6.2. DSD Services form .............................................................................................................35\nFigure 6.3. DSD Assessment and Acceptance form ............................................................................36\nFigure 7.0. List of all registered patients...............................................................................................37\nFigure 7.1. Form to edit patient\u2019s profile and to enroll patient...............................................................38\nFigure 7.2. Patient Dashboard ..............................................................................................................39\nFigure 7.3. Tab to select Fingerprints ...................................................................................................40\nin Patient Dashboard.............................................................................................................................40\nFigure 7.4. Main page for use of SecuGen biometrics system.............................................................41\nFigure 7.5. Secugen Biometrics tab showing successful fingerprint capture                                               .......................................42\nFigure 7.6. Main page for use of Futronic Neurotec Biometrics system...............................................43\nFigure 7.7. Futronic Neurotec biometrics tab showing successful fingerprint capture .........................44\nFigure 8.0. Main page of Sync Status module......................................................................................45\nFigure 8.1. Sync status list tab..............................................................................................................46\nFigure 9.0. Main page of Connect to Server module............................................................................47\nFigure 9.1. Landing page for Connect to Server module......................................................................48\nFigure 9.2. Tab to pull list of patients without biometrics......................................................................49\nFigure 9.3. Tab to pull list of patients with biometrics...........................................................................50\niv                                                                                          LAMISPlus Mobile Training Manual and User Guide", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 3377, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9de5bb69-e271-4caa-80b0-2a2c5a21c2a2": {"__data__": {"id_": "9de5bb69-e271-4caa-80b0-2a2c5a21c2a2", "embedding": null, "metadata": {"source": "Data.FI Nigeria_LAMISPlus Mobile User Guide V.2_TL-24-11_KM revised.pdf", "page_label": "7"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "865919fb-e6b1-4c75-a31f-12c593829279", "node_type": "4", "metadata": {"source": "Data.FI Nigeria_LAMISPlus Mobile User Guide V.2_TL-24-11_KM revised.pdf", "page_label": "7"}, "hash": "edda193ff2be919686a67ae789fa1725391540a4da09c3e559c6d918711616af", "class_name": "RelatedNodeInfo"}}, "text": "Abbreviations\nANC            antenatal care\nDSD            differentiated service delivery\nEMR            electronic medical record(s)\nHTS            HIV testing services\nIP             implementing partner\nLAMISPlus      Lafiya Management Information System Plus\nMER            Monitoring, Evaluation, and Reporting\nPEPFAR         United States President\u2019s Emergency Fund for AIDS Relief\nPMTCT          prevention of mother-to-child transmission\nUSAID          United States Agency for International Development\nLAMISPlus Mobile Training Manual and User Guide                                              v", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 607, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "dfc139a8-33c8-4e52-b414-59bbce40475d": {"__data__": {"id_": "dfc139a8-33c8-4e52-b414-59bbce40475d", "embedding": null, "metadata": {"source": "Data.FI Nigeria_LAMISPlus Mobile User Guide V.2_TL-24-11_KM revised.pdf", "page_label": "8"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "900e7684-a187-4634-80a6-ea378566b7a2", "node_type": "4", "metadata": {"source": "Data.FI Nigeria_LAMISPlus Mobile User Guide V.2_TL-24-11_KM revised.pdf", "page_label": "8"}, "hash": "7b2c407f2cfe8739987739b5f295b89885047624c58f3f233e6de485ecf2ac74", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7e39e4d7-18f9-4c49-9455-2eb8ea80ef38", "node_type": "1", "metadata": {}, "hash": "c896fa792f40e0396cbaffd2a2993b6340f754e59098a3eb955923f7d700b341", "class_name": "RelatedNodeInfo"}}, "text": "1. Overview\nLAMISPlus is an open-source modular software and a more robust Electronic Medical Record System that is\nsuitable for all types of healthcare services in different settings to support the management of patient-level\ndata. it is designed and developed through a collaborative approach, to serve as a global good that can be used\nby any health institution and can be widely accessible.\nThe LAMISPlus mobile application is designed to complement the LAMISPlus EMR web application. Running on\nan Android operating system, this mobile version supports mobile health services and data collection at various\nservice points where the web version is not deployable, including community-level services. It aims to enhance\nservice delivery and ease of access, facilitating the documentation of patient health services. The LAMISPlus\nmobile application is tailored for recording patient information across different health domains.\n1.1 PURPOSE OF THE MANUAL\nThe manual serves as a reference guide for questions users may have during the use of the system.\nIt contains step by step navigation of the LAMISPlus Mobile system. The LAMISPlus Mobile\napplication is designed to complement the web version of LAMISPlus 2.0. This mobile application\nruns on the Android operating system. It facilitates data collection at service points where the web\nversion is not deployable. It is designed to support and improve service delivery and ease of access\nand thereby to support the documentation of patient health services. The LAMISPlus Mobile\napplication is designed for recording patient information for different medical domains.\n1.2 CONTENT OF THE MANUAL\nThe manual contains practical guidelines on how to navigate and use the LAMISPlus Mobile\napplication.\n2. Navigating through the system\nUpon completion of the download and installation of the application on your device, you can always\nhave access.\nAs a first-time user, you will need the URL (a combination of the IP address of the host system and\nthe port number of the current running LAMISPlus) including the username and password created for\nthe user. Ensure that the host system is online and running before connecting.\nTo get the host system IP address, open the host system command prompt and type the command,\nipconfig. A list of the IP addresses will be displayed.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2319, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7e39e4d7-18f9-4c49-9455-2eb8ea80ef38": {"__data__": {"id_": "7e39e4d7-18f9-4c49-9455-2eb8ea80ef38", "embedding": null, "metadata": {"source": "Data.FI Nigeria_LAMISPlus Mobile User Guide V.2_TL-24-11_KM revised.pdf", "page_label": "8"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "900e7684-a187-4634-80a6-ea378566b7a2", "node_type": "4", "metadata": {"source": "Data.FI Nigeria_LAMISPlus Mobile User Guide V.2_TL-24-11_KM revised.pdf", "page_label": "8"}, "hash": "7b2c407f2cfe8739987739b5f295b89885047624c58f3f233e6de485ecf2ac74", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "dfc139a8-33c8-4e52-b414-59bbce40475d", "node_type": "1", "metadata": {"source": "Data.FI Nigeria_LAMISPlus Mobile User Guide V.2_TL-24-11_KM revised.pdf", "page_label": "8"}, "hash": "f44adafa3c318c92abbfd9d712b1e136c8e4a106c74ebf455b374350896cea77", "class_name": "RelatedNodeInfo"}}, "text": "Ensure that the host system is online and running before connecting.\nTo get the host system IP address, open the host system command prompt and type the command,\nipconfig. A list of the IP addresses will be displayed. Copy the IPv4 address and paste it on the login\nURL field of the mobile application in addition to the port number. E.g., http://192.168.9.92:8787\nFigure 2.0. Access the IPv4 address on the system\u2019s Command Prompt\n6                                                        LAMISPlus Mobile Training Manual and User Guide", "mimetype": "text/plain", "start_char_idx": 2102, "end_char_idx": 2638, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cdbcdf29-23ad-4f81-9580-eb1de933e417": {"__data__": {"id_": "cdbcdf29-23ad-4f81-9580-eb1de933e417", "embedding": null, "metadata": {"source": "Data.FI Nigeria_LAMISPlus Mobile User Guide V.2_TL-24-11_KM revised.pdf", "page_label": "9"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "06f00cd4-3235-419c-8b97-af2b12125874", "node_type": "4", "metadata": {"source": "Data.FI Nigeria_LAMISPlus Mobile User Guide V.2_TL-24-11_KM revised.pdf", "page_label": "9"}, "hash": "84a2ab863f2135fcbf5775797cd9bade2052b7597b9564797cab231717b12149", "class_name": "RelatedNodeInfo"}}, "text": "Windows IP Configuration\nWireless LAN adapter Local Area Connection* 1:\n  Media State                        Media disconnected\n  Connection-specific DNS Suffix\nWireless LAN adapter Local Area Connection* 2:\n  Media State                        Media disconnected\n  Connection-specific DNS Suffix\nWireless LAN adapter Wi-Fi:\n  Connection-specific DNS Suffix     fe80: :4c0: 8a3e:ab46:efa8%9\n  Link-local IPv6 Address\n  IPv4 Address:                      192.168.9.92\n  Subnet Mask                        255.255.255\n  Default Gateway                    192.168 9.52\nEthernet adapter Bluetooth Network Connection:\n  Media State                        Media disconnected\n  Connection-specific DNS Suffix\nLOGIN PAGE\nFigure 2.1. LAMISPlus login page\n                      LAMISPlus Lite\n      Enter vour details below to Iogin\n                                  LAMIS\n                                PLUS\n    Scrvcr Addccs,\n   https: / {lamisplus.org\n   Email\n   Password\n                             Login\n                           Version 1.0.7.1\nSubsequent login will require the user to only provide a username and password, as seen in Figure\n2.2.\nLAMISPlus Mobile Training Manual and User Guide                                                                  7", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1262, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8c0e79bf-c0fe-4664-9a1a-b79ca9785e06": {"__data__": {"id_": "8c0e79bf-c0fe-4664-9a1a-b79ca9785e06", "embedding": null, "metadata": {"source": "Data.FI Nigeria_LAMISPlus Mobile User Guide V.2_TL-24-11_KM revised.pdf", "page_label": "10"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "0e4b47d9-a774-48bb-9b4c-12501018e172", "node_type": "4", "metadata": {"source": "Data.FI Nigeria_LAMISPlus Mobile User Guide V.2_TL-24-11_KM revised.pdf", "page_label": "10"}, "hash": "dbce0a3a39491895968ed713059f86837cdc4bf0964f48eda13081753cca11a7", "class_name": "RelatedNodeInfo"}}, "text": "Figure 2.2. LAMISPlus user login page (after first access)\n                LAMISPlus Lite\n      Enter mour cetails below ro Iogin\n                        LAMIS\n                        PLus\n   Email\n   Passwvord\n                      Login\n                  Login with Device Bicmetrics\n                    Vetsion 1.0.7.1\nThis is for subsequent login. Enter the user credentials provided (Username and Password).\nLANDING PAGE\nThe landing page displays the program services, HIV Testing Services (HTS), Prevention of Mother-\nto-Child Transmission (PMTCT), Hepatitis, and All Clients and Sync Status tab.\n  \u25aa  The three dots on the top right of the page have the settings options and logout options.\n  \u25aa  The settings icon is used to configure different features of the application\u2014e.g., the server URL\n     and the facility location.\n  \u25aa  New clients can be registered on the application using the \u201cadd\u201d icon at the right side of the\n     screen.\n8                                                         LAMISPlus Mobile Training Manual and User Guide", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1051, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b46a55ab-92e7-4051-828e-fd5c56a53bf3": {"__data__": {"id_": "b46a55ab-92e7-4051-828e-fd5c56a53bf3", "embedding": null, "metadata": {"source": "Data.FI Nigeria_LAMISPlus Mobile User Guide V.2_TL-24-11_KM revised.pdf", "page_label": "11"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "48f508d2-1ddc-4317-9957-7fd98a03f7d0", "node_type": "4", "metadata": {"source": "Data.FI Nigeria_LAMISPlus Mobile User Guide V.2_TL-24-11_KM revised.pdf", "page_label": "11"}, "hash": "01002e52491da08ae6222b68750247462edb5074f4b19d60264c859215ed3bac", "class_name": "RelatedNodeInfo"}}, "text": "Figure 2.3. Landing page \u201cadd\u201d icon to register new clients\n                                                        1212000\nHi User!                                                Hi Userl\n                        Tcatina Servlo :\n                        DSD                                                  DSD\nSETTINGS PAGE\nOn the settings page (see Figure 2.4), you can configure the server URL, the PCR laboratory used by\nthe facility, and the facility location; test the connection of the mobile application to the server; update\nthe login credentials; and unsync all encounters, all patients, all baseline biometrics, and all baseline\nbiometric recapture.\nLAMISPlus Mobile Training Manual and User Guide                                                   9", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 760, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9d74f21b-eca2-49f3-a3f0-7ed25b0a43ca": {"__data__": {"id_": "9d74f21b-eca2-49f3-a3f0-7ed25b0a43ca", "embedding": null, "metadata": {"source": "Data.FI Nigeria_LAMISPlus Mobile User Guide V.2_TL-24-11_KM revised.pdf", "page_label": "12"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "0c2fc187-a867-4749-bce5-de989b6f2d6f", "node_type": "4", "metadata": {"source": "Data.FI Nigeria_LAMISPlus Mobile User Guide V.2_TL-24-11_KM revised.pdf", "page_label": "12"}, "hash": "6c3192b1325a5aa8c03d4509c5247f266e4e23dfcbdd669265384ada626ea4d6", "class_name": "RelatedNodeInfo"}}, "text": "Figure 2.4. LAMISPlus configurations on settings page\n     LAMISPlus Configurations\n                     5445Changee\n   Default PCR Leb:\n                    Save PcA Lab\n   CumenlLoceLen:\n   Tet Cannecuoll\n   Change Lcgin Credentials:\n                           (UlNcw)\n                     Sava Chanen\n3. HIV Testing Services\nThe HTS module is used for the documentation of HIV testing services. To navigate the HTS module,\nselect \u201cHIV Testing Services\u201d on the menu pane.\n10                                                      LAMISPlus Mobile Training Manual and User Guide", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 576, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "38ee5dcf-6976-4456-b42b-4dc6e1238147": {"__data__": {"id_": "38ee5dcf-6976-4456-b42b-4dc6e1238147", "embedding": null, "metadata": {"source": "Data.FI Nigeria_LAMISPlus Mobile User Guide V.2_TL-24-11_KM revised.pdf", "page_label": "13"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "9f98d8d1-8b4f-460b-b844-9900d87d592e", "node_type": "4", "metadata": {"source": "Data.FI Nigeria_LAMISPlus Mobile User Guide V.2_TL-24-11_KM revised.pdf", "page_label": "13"}, "hash": "7302826d084341be20ed30ad6c5fdf8cc92833c2b591d71bf33784795cbfa2a1", "class_name": "RelatedNodeInfo"}}, "text": "Figure 3.0. HIV testing services page\n  1035em0\n  Hi Userl\n                       prict\n                      DSD\nFEATURES OF HTS MODULE\n  \u25aa  Risk Stratification\n  \u25aa  Client Intake\n  \u25aa  Pre-Test Counseling\n  \u25aa  Request a Result Form\n  \u25aa  Post-Test Counseling\n  \u25aa  Recency\nIndex Notification and Elicitation Services\nHTS MODULE DASHBOARD\nThe HTS module dashboard (see Figure 3.1) displays the list of clients registered in the facility and\nwho have undergone HTS service in the facility. A new client can be registered by clicking on \u201cNew\nHTS\u201d on the dashboard.\nLAMISPlus Mobile Training Manual and User Guide                                           11", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 653, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0999f6fb-11e8-4b81-a703-8a9093115c4f": {"__data__": {"id_": "0999f6fb-11e8-4b81-a703-8a9093115c4f", "embedding": null, "metadata": {"source": "Data.FI Nigeria_LAMISPlus Mobile User Guide V.2_TL-24-11_KM revised.pdf", "page_label": "14"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "a9e414c2-0ad2-4f86-b027-7d5464d9db35", "node_type": "4", "metadata": {"source": "Data.FI Nigeria_LAMISPlus Mobile User Guide V.2_TL-24-11_KM revised.pdf", "page_label": "14"}, "hash": "bf4d24a369422db025ee6d3f72ee655546fb0aaca3330cb9c5f4310c4df577b2", "class_name": "RelatedNodeInfo"}}, "text": "Figure 3.1. HTS Module dashboard\n                           8 0\n           HTS Client's List\n                New HTS 2+\n  1110   1986-03-15        Prince Asogwa\n   Male\n   1111                       Aisha Sani\n   Fenalf  1993-03-15\n   1110                     Angel Ruth\n   Female  1993-03-15\nRISK STRATIFICATION\nThe first step to documenting client HTS information is to risk stratify the client to assess client HIV\nrisks and eligibility for testing. The Risk Stratification section is only available for clients older than 15\nyears.\nFill in the Risk Stratifications information (Figure 3.2) and select \u201cSave\u201d to follow the succeeding steps\nand complete the HTS forms.\n12                                                      LAMISPlus Mobile Training Manual and User Guide", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 774, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7c7167b9-515e-4057-8310-f175626727c5": {"__data__": {"id_": "7c7167b9-515e-4057-8310-f175626727c5", "embedding": null, "metadata": {"source": "Data.FI Nigeria_LAMISPlus Mobile User Guide V.2_TL-24-11_KM revised.pdf", "page_label": "15"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "38105d1e-ada4-4286-ba63-95302fd7a6cf", "node_type": "4", "metadata": {"source": "Data.FI Nigeria_LAMISPlus Mobile User Guide V.2_TL-24-11_KM revised.pdf", "page_label": "15"}, "hash": "f42602de4a373f0342b2c8dc8aee9668b9d0bb8f5f0b0359e539f4bec524226c", "class_name": "RelatedNodeInfo"}}, "text": "Figure 3.2. Risk Stratification form\n         Risk Stratification Form\n    Entry Point*\n    Entry Point\"\n    Settings*             Modality\n    Settings\"             Modality\n    Visit Date\"           Target Group\"\n    Visit Date\"           Target Group\n    Date of Birth         Date of Birth\"\n      Actual\n      Estimated\n    Is this HIV test based on  Clinicianl\n    Is this HIV test based on  ClinicianDoctoriHealth\n    Care Provider's request?\n                                                 Save\nThe succeeding steps are:\n  \u25aa  Client Intake Form\n  \u25aa  Pre-Test Form\n  \u25aa  Request and Result Form\n  \u25aa  Post-Test Form\n  \u25aa  Recency Form\n  \u25aa  Index Notification Services \u2013 Elicitation\nLAMISPlus Mobile Training Manual and User Guide                                              13", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 781, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b08f35ca-997b-4603-b100-a0d1c77b9a55": {"__data__": {"id_": "b08f35ca-997b-4603-b100-a0d1c77b9a55", "embedding": null, "metadata": {"source": "Data.FI Nigeria_LAMISPlus Mobile User Guide V.2_TL-24-11_KM revised.pdf", "page_label": "16"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "43c55b8f-10fe-48ab-9054-bd2060453080", "node_type": "4", "metadata": {"source": "Data.FI Nigeria_LAMISPlus Mobile User Guide V.2_TL-24-11_KM revised.pdf", "page_label": "16"}, "hash": "14383ab2204c35a0e854d10b618379444d6c3db432a55dc0fa20c70a8aa21f64", "class_name": "RelatedNodeInfo"}}, "text": "CLIENT INTAKE FORM\nThe HTS Client Intake Form is used to collect clients\u2019 demographic information, access risk factors,\nobtain informed consent, document test details, and provide counseling.\nFigure 3.3. Clinic Intake form\n     CUrit Intake Form                                   Cllent Intake Forin\n                                                      7071 405\n                                                      Date &' Birth         1993-0!-06\n  0uan\n                                                           Chdter              Ta\n14                                                        LAMISPlus Mobile Training Manual and User Guide", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 644, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e661668d-5cdd-4824-96b0-6b0890c63be1": {"__data__": {"id_": "e661668d-5cdd-4824-96b0-6b0890c63be1", "embedding": null, "metadata": {"source": "Data.FI Nigeria_LAMISPlus Mobile User Guide V.2_TL-24-11_KM revised.pdf", "page_label": "17"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "4d0239dc-1a6b-4bf9-9057-795128282e1d", "node_type": "4", "metadata": {"source": "Data.FI Nigeria_LAMISPlus Mobile User Guide V.2_TL-24-11_KM revised.pdf", "page_label": "17"}, "hash": "3a6a3680ca604cfcf1ec0b5dc099833e7d5c850d13a59fb650ef6c1a7db8e4b9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cd046753-2159-428d-b8c9-725dba206a56", "node_type": "1", "metadata": {}, "hash": "b29bf73587902a538bfded00b663bd4b9b6f8037f86c5eb54534b96897f091ca", "class_name": "RelatedNodeInfo"}}, "text": "PRE-TEST FORM\nThe Pre-test form is used to assess clients\u2019 HIV risk factors.\nFigure 3.4. Pre-Test form to assess HIV risk factors\n         Pre Test Form                                         Pre TestForm\n   Night sweats                                          condom burst with vour     needles/syringesother\n                                                         partner during sexual      sharp objects or used\n                                                         intercourse?               Jousc drug substances\n   Night sweats                                                                     ofany kind?\n  HIV Risk Assessment (Last 3 months)                    Have youlpar_.             Have youlpart__.\n   Have youlyo_.             Have voulpart_.             Have youlpartner had       Have voulpartner\n                                                         any  lood or blood         experienced coughing;\n   Have youlvour partner     Have voufpartner had        product transfusion?       weight lossfever, night\n                                                                                    sweats consistentlv?\n   experienced\u02e1\u1d52\u02b7\u1d49           sex without condom\n   abdomina  pain; smelly    with someone                Have youlpartner paid or sold vagina\n   discharge, blisters and   unknown HIV status;\n   wounds around Youi        youlpartner raped                                      vaginal; anal or oral\n   partner vagina penis      person with unknown         Have youlpartnerPaidor sold\n   anus or mouthz            HIV status?                 20x7\n   Have you haz              Do youlpartn_.             Sex Partner Risk Assessment (Last 3\n   Have you had              Do voulpartner share       months)\n   condomburst with vour     needles/syringes; other     Have you had sex with       partner who_.\n   Durinerduring sexual      sharp objects or used\n   ntercalrce                Jousedrug substances                               partner who is HIV positive?\n                             ofany kind?                 Have You had sex with\n   Have youlpar__            Have youlpart_.            Syndromic STI Screening\n   Have youlpartner had      Have voulpartner            Complaints                 Complaints of_\n       blood  blood          experienced coughing\n   product transfusion?      weight loss, fever; night   Complaints of vaginal      Complaints of lower\n                             sweatsconsistently?         discharge   burning        abdlominaipains with\n                                                         when urinating?", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2589, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cd046753-2159-428d-b8c9-725dba206a56": {"__data__": {"id_": "cd046753-2159-428d-b8c9-725dba206a56", "embedding": null, "metadata": {"source": "Data.FI Nigeria_LAMISPlus Mobile User Guide V.2_TL-24-11_KM revised.pdf", "page_label": "17"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "4d0239dc-1a6b-4bf9-9057-795128282e1d", "node_type": "4", "metadata": {"source": "Data.FI Nigeria_LAMISPlus Mobile User Guide V.2_TL-24-11_KM revised.pdf", "page_label": "17"}, "hash": "3a6a3680ca604cfcf1ec0b5dc099833e7d5c850d13a59fb650ef6c1a7db8e4b9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e661668d-5cdd-4824-96b0-6b0890c63be1", "node_type": "1", "metadata": {"source": "Data.FI Nigeria_LAMISPlus Mobile User Guide V.2_TL-24-11_KM revised.pdf", "page_label": "17"}, "hash": "d21c0fd77156bbe7f3e7e01166da2f41710c9f2cb0c47408cb0e0f6edea095f6", "class_name": "RelatedNodeInfo"}}, "text": "weight loss, fever; night   Complaints of vaginal      Complaints of lower\n                             sweatsconsistently?         discharge   burning        abdlominaipains with\n                                                         when urinating?              without vaginal\n   Have youlpartner\u1d56\u1d43\u2071\u1d48or sold vagina                                               discharge?\n   Have voulpartner paid or sold vaginal; anal 0r oral                                          Save\n   sex?\nLAMISPlus Mobile Training Manual and User Guide                                                                                                 15", "mimetype": "text/plain", "start_char_idx": 2337, "end_char_idx": 2969, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1098ee4c-cc4a-4fa4-a61e-08ebb06f9859": {"__data__": {"id_": "1098ee4c-cc4a-4fa4-a61e-08ebb06f9859", "embedding": null, "metadata": {"source": "Data.FI Nigeria_LAMISPlus Mobile User Guide V.2_TL-24-11_KM revised.pdf", "page_label": "18"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "85d58af4-3b02-4044-9918-549d94ae4597", "node_type": "4", "metadata": {"source": "Data.FI Nigeria_LAMISPlus Mobile User Guide V.2_TL-24-11_KM revised.pdf", "page_label": "18"}, "hash": "a4f33ce3efe0c4a7845a7d34c0121eef8121955e469150cbd736ee4b01eb23d8", "class_name": "RelatedNodeInfo"}}, "text": "REQUEST AND RESULT FORM\nThe Request and Result form is used to request for HIV testing, and document testing details.\nFigure 3.5. Request & Result form for various testing details\n        Request & Result Form                 Adhoc Code\n  HIV Test Result                             Adhoc Code\n  Initial Test:\n   Date*                   Result*                                            Save\n   Date                    Result\"\n  CD4\n   CD4 Count\n   CD4 Count\n  Syphilis Testing\n   Syphilis test result\n   Syphilis test result\n  Hepatitis Testing\n   Hepatitis B vi__.   Hepatitis \u20acC vi__.\n   Hepatitis B virus test  Hepatitis virus test\n   result                  result\n   Others\n   Longitude               Latitude\n   7.5006777               9.0379483\n   Longitude               Latitude\n16                                                                             LAMISPlus Mobile Training Manual and User Guide", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 916, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "baddc56b-8c64-4068-b306-f88fcefa0ee5": {"__data__": {"id_": "baddc56b-8c64-4068-b306-f88fcefa0ee5", "embedding": null, "metadata": {"source": "Data.FI Nigeria_LAMISPlus Mobile User Guide V.2_TL-24-11_KM revised.pdf", "page_label": "19"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "e4c46efc-0f35-4a29-86f1-65aef502d37c", "node_type": "4", "metadata": {"source": "Data.FI Nigeria_LAMISPlus Mobile User Guide V.2_TL-24-11_KM revised.pdf", "page_label": "19"}, "hash": "466b9198c8553541608bdf2481810b5299af5eafacdf8f6ce1220e620432e5a5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c91099d5-b81b-42c7-a721-8add5215bfb4", "node_type": "1", "metadata": {}, "hash": "597d36b5f0aa085f316071f45012f0f31b98eae89f471b5ba39799cc71fab370", "class_name": "RelatedNodeInfo"}}, "text": "POST-TEST FORM\nThe HTS post-test counseling form is used to document the post-test counseling session, discussion\nof test results, education, and risk-reduction strategies.\nFigure 3.6. HIV Post-Test counseling form\n       Post Test Form                               Post Test Form\n   HIV test resull\"                                 Risk reductio .            Post test disc:-.\n   Positive Post Test Form\n                              Have you be_          Risk reduction plan                Post Test Form\n   HIV test result\"           Have you been tested  developed                  Post test disclosure\n    HIV test resull\"          for HIV before within                            plan developed\n    Positive                  this vear?     Have you be_                              Risk reductio .            Post test disc:-.\n                                                    Will bringpa .             Willbring0-\n    HIV test result\"                         Have you been tested                      Risk reduction plan        Post test disclosure\n   HIV Request .              HIV Request _  for HIV before within                     developed                  plan developed\n                                                    Will bring partner(s) for  Will bring own children\n                                             this vear?\n                                                    HIV testing                Years for HIV                      bring\n   HIV Request and Result     HIV Request and Result                           testing Will bring pa .            Will  0-\n   form signed by tester      form filled with CT\n    HIV Request .Intake Form                 HIV Request _                             Will bring partner(s) for  Will bring own children\n                                                    Provided wit.              ClientiPartn\n    HIV Request and Result                   HIV Request and Result                    HIV testing                Years for HIV\n    form signed by tester                    form filled with CT               ClientiPartner use                 testing\n   Client receiv__            Post test cou         Provided with                      FP\n                                             information on FP and\n                                             Intake Form                       methods (other than\n   Client received HIV test   Post test counseling  dual contraception         condom)Provided wit.               ClientiPartn\n   result                     done                                                     Provided with              ClientiPartner use FP\n    Client receiv__                          Post test cou                     information on FP and              methods (other than\n                                                    Client/Partn .             Correct cond:\n    Client received HIV test                 Post test counseling                      dual contraception         condom)\n   Risk reductio.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 3006, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c91099d5-b81b-42c7-a721-8add5215bfb4": {"__data__": {"id_": "c91099d5-b81b-42c7-a721-8add5215bfb4", "embedding": null, "metadata": {"source": "Data.FI Nigeria_LAMISPlus Mobile User Guide V.2_TL-24-11_KM revised.pdf", "page_label": "19"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "e4c46efc-0f35-4a29-86f1-65aef502d37c", "node_type": "4", "metadata": {"source": "Data.FI Nigeria_LAMISPlus Mobile User Guide V.2_TL-24-11_KM revised.pdf", "page_label": "19"}, "hash": "466b9198c8553541608bdf2481810b5299af5eafacdf8f6ce1220e620432e5a5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "baddc56b-8c64-4068-b306-f88fcefa0ee5", "node_type": "1", "metadata": {"source": "Data.FI Nigeria_LAMISPlus Mobile User Guide V.2_TL-24-11_KM revised.pdf", "page_label": "19"}, "hash": "b608923e69b6a09fb04bd9392ba0ddb2da1d7f0fcd73d2ff757c38c3f80231ff", "class_name": "RelatedNodeInfo"}}, "text": "Correct cond:\n    Client received HIV test                 Post test counseling                      dual contraception         condom)\n   Risk reductio.             Post test disc:       ClientiPartner use         Correct condom use\n    result                                   done   condoms as (one) FP        demonstrated\n   Risk reduction plan        Post test disclosure  method                             Client/Partn .             Correct cond:\n   developed                  plan developed\n    Risk reductio.                           Post test disc:                           ClientiPartner use         Correct condom use\n                                                    Condoms                            condoms as (one) FP        demonstrated\n    Risk reduction plan                             pro                        Unprotected_-.\n   Will bring                 Will bring 0   Post test disclosure                      method\n    developed\n           paa                               plan developed                    Unprotected sex with\n                                                    Condoms provided to\n                                                    client                     regular partner\n                                                                                       Condoms\n   Will bring partner(s) for  Will bring own children                                  the  pro                   Unprotected_-.\n    Will bring                               Will bring 0                      last 3months\n   HIV testing    paa         years for HIV                                                                       Unprotected sex with\n                              testing                                                  Condoms provided to\n    Will bring partner(s) for                Will bring own children                   client                     regular partner  the\n    HIV testing                                     Client referred to other services                             last 3months\n   Provided wit:..            Client/Partn .  years for HIV\n                                             testingClient referred to other services  Client referred to other services\n   Provided with              ClientiPartner use FP\n    Provided wit:..                          Client/Partn .                            Save\n   information on FP and      methods (other than                                      Client referred to other services\n   dual contraception         condom)        ClientiPartner use FP\n    Provided with                                                                                                 Save\n    information on FP and                    methods (other than\n    dual contraception                       condom)\nLAMISPlus Mobile Training Manual and User Guide                                                                        17", "mimetype": "text/plain", "start_char_idx": 2853, "end_char_idx": 5772, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "369f0351-2c85-4b9b-9917-f7c937734690": {"__data__": {"id_": "369f0351-2c85-4b9b-9917-f7c937734690", "embedding": null, "metadata": {"source": "Data.FI Nigeria_LAMISPlus Mobile User Guide V.2_TL-24-11_KM revised.pdf", "page_label": "20"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "e6371965-5bfe-47d0-9767-59ab3816f25d", "node_type": "4", "metadata": {"source": "Data.FI Nigeria_LAMISPlus Mobile User Guide V.2_TL-24-11_KM revised.pdf", "page_label": "20"}, "hash": "915c68692f0d5055158628ba235776ef9463c09247de03dc51e4a297f36ff73b", "class_name": "RelatedNodeInfo"}}, "text": "RECENCY FORM\nThe HTS Recency form is used to assess clients\u2019 recent infections, analyze trends, and for public\nhealth surveillance.\nFigure 3.7. Recency form showing client\u2019s recent infections\n        RecencyForm                              Recency Form\n   Opt Out of RTRI? \"                       Opt Out of RTRI?\"\n                                            No\n   Opt Oul oi RTRIZI                        Opt Out 6f Rtri?=\n                              Save          Test Name             Test Date\n                                            Test Name             Test Date\n                                            Recency ID            Control Line\n                                            Recency ID            Control Line\n                                            Verification L-       Long Term Li__-\n                                            VerificationLin       Long Term Line\n                                            Recency Interpretation\n                                            Recency Interpretation\n                                                                            Save\n18                                                             LAMISPlus Mobile Training Manual and User Guide", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1223, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "88567eaf-e135-43b1-a9ac-99285c9b6d15": {"__data__": {"id_": "88567eaf-e135-43b1-a9ac-99285c9b6d15", "embedding": null, "metadata": {"source": "Data.FI Nigeria_LAMISPlus Mobile User Guide V.2_TL-24-11_KM revised.pdf", "page_label": "21"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "8e172500-8da7-4265-b4fd-0e01a6b90194", "node_type": "4", "metadata": {"source": "Data.FI Nigeria_LAMISPlus Mobile User Guide V.2_TL-24-11_KM revised.pdf", "page_label": "21"}, "hash": "3b87593cd2a352fcd00e2c3494f1f2f9c24c6402c1395bf34c27f650dda81dd2", "class_name": "RelatedNodeInfo"}}, "text": "INDEX NOTIFICATION AND ELICITATION SERVICES\nThe Index Notification and Elicitation Services form is used for the Identification of sexual partners\nand contacts, early diagnosis and treatment, prevention of HIV transmission, support and counseling,\nand partner notification services.\nFigure 3.8. Index Notification Services form\n        Index Notification Ser_.                       Index Notification Ser__\n   Offered INS?           Accepted INS?\n   Yes                    Yes                     Hang-out spots          Relationship-_\n   Offered INS?           Accepted INS?           Hang-out spots          Relationship to Index\n   First Name*                                                            Client\"\n                          Middle Name             Do you curre:           As far as you_\n   First Name\"            Middle Name             Do you currently live   As far as you knowhas\n                                                  with this partner?      this partner ever tested\n                                                                          positive for HIV\n   Last Name*             Sex\"\n   Last Name*             Sex\"                    Has this part_          Has this part_\n                                                  Has this partner ever   Has this partner ever\n   Date of Birth          Date of Birth*          hit, kick, slapped or   threaten to hurt you?\n                                                  otherwise physical hurt\n                                                  you?\n     Actual               Date of Birth\"\n                                                  Has this part_.         Notification__.\n     Estimated                                    Has this partner        Notification Method\n                                                  ever threaten force     selected-\n                                                  youto dosomething\n   Phone Number*          Alt; Phone Number       sexually that made vou\n                                                  uncomfortable ?\n   Phone Number*                                 If contracted, by which date will partner \u20ac_\n   Address                                        If contractedby which date will partner come for\n                                                  testing?\n                                                                                    Save A\nLAMISPlus Mobile Training Manual and User Guide                                                                            19", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2515, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a6e38fcb-0a27-49d5-aab3-1efba5aa9376": {"__data__": {"id_": "a6e38fcb-0a27-49d5-aab3-1efba5aa9376", "embedding": null, "metadata": {"source": "Data.FI Nigeria_LAMISPlus Mobile User Guide V.2_TL-24-11_KM revised.pdf", "page_label": "22"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "363e1eb8-1ad6-4c2b-ab5b-d984c7e3ae18", "node_type": "4", "metadata": {"source": "Data.FI Nigeria_LAMISPlus Mobile User Guide V.2_TL-24-11_KM revised.pdf", "page_label": "22"}, "hash": "4f3dfab2b019df6b487992bf8cb9f82dd844dc3476a6dc6e17e2ab61b8f15822", "class_name": "RelatedNodeInfo"}}, "text": "4. Prevention of Mother-to-Child Transmission\nThe Prevention of Mother-to-Child Transmission (PMTCT) module is used to document all services\nprovided in the prevention of HIV transmission from infected women to their children.\nFEATURES OF THE PMTCT MODULE\n  \u25aa  Entry Points (ANC, L&D, and Post Partum)\n  \u25aa  ANC Enrollment\n  \u25aa  PMTCT Enrollment\n  \u25aa  Labour and Delivery\n  \u25aa  Infant Registration\n  \u25aa  Partners Registration\nFollow-up Visit\nNEW PMTCT\nThe PMTCT Client\u2019s List displays the list of all registered clients.\n  \u25aa  Click on New PMTCT\n  \u25aa  A client can be enrolled in PMTCT through three entry points.\n      \u25aa  ANC\n      \u25aa  L&D\n      \u25aa  Post Partum\n20                                                 LAMISPlus Mobile Training Manual and User Guide", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 752, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e3881d48-fff3-4801-81ba-04ef34258e2d": {"__data__": {"id_": "e3881d48-fff3-4801-81ba-04ef34258e2d", "embedding": null, "metadata": {"source": "Data.FI Nigeria_LAMISPlus Mobile User Guide V.2_TL-24-11_KM revised.pdf", "page_label": "23"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "483f9eee-bb1b-4dd6-a8b5-fc84080aa764", "node_type": "4", "metadata": {"source": "Data.FI Nigeria_LAMISPlus Mobile User Guide V.2_TL-24-11_KM revised.pdf", "page_label": "23"}, "hash": "891f48cd242f510501a81ce273de0b8d31795cb1df7eefef5a16501f21372480", "class_name": "RelatedNodeInfo"}}, "text": "Figure 4.1. Tab for PMTCT Client\u2019s List\n                                                PMTCT Entry Paint\n               PMTCT Client'$ List\ncrthh\n    7014-19\n                                                                     ANC\n                                                                     L8d\n                                                               Pett Parung\n                                                                    rument\n                                                                6 mGrity  Miununs\n  PATIENT REGISTRATION \u2013 ANC ENROLLMENT\n    \u25aa  Enter the patient basic information.\n    \u25aa  Fill in all required fields under the antenatal care (ANC) enrolment section.\n    \u25aa  Click the Save button.\n  LAMISPlus Mobile Training Manual and User Guide                                                 21", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 836, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4897978d-c7a1-4bd9-880c-db86c00e386e": {"__data__": {"id_": "4897978d-c7a1-4bd9-880c-db86c00e386e", "embedding": null, "metadata": {"source": "Data.FI Nigeria_LAMISPlus Mobile User Guide V.2_TL-24-11_KM revised.pdf", "page_label": "24"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "706c9d10-8f5f-40d7-bcd4-8d1954d74ccb", "node_type": "4", "metadata": {"source": "Data.FI Nigeria_LAMISPlus Mobile User Guide V.2_TL-24-11_KM revised.pdf", "page_label": "24"}, "hash": "27f89b7448d6b8d7b835efdf11879753e10e6e30a24603dae1609f4ea8f4eca8", "class_name": "RelatedNodeInfo"}}, "text": "Figure 4.2.  Enrolling a new patient from ANC\n                                                 70080\n      Patient Rcgi_Uation                           Paticnt Ragistration\n   Basic Information\n                                                 Relationstip\n  Dale 0/ Br                                     ANC Enrollment\n                                                 AkSing\n  Ccatact Deta L\n  ahone\n                         Landme t\n  Relationship / Next Of Kin\nPATIENT REGISTRATION \u2013 PMTCT ENROLLMENT\nThe following fields are auto-populated:\n   \u25aa  ANC ID\n   \u25aa  Date of Last Menstrual Period\n   \u25aa  Gestation Age (Weeks)\n   \u25aa  Gravida\n   \u25aa  HIV Status\n   \u25aa  Fill in all required fields.\n   \u25aa  Click the Save button.\nPATIENT REGISTRATION \u2013 LABOUR AND DELIVERY\n   \u25aa  Fill in all required fields.\n   \u25aa  Gestation Age (Weeks) is auto-populated.\n   \u25aa  Click the Save button.\n22                                                    LAMISPlus Mobile Training Manual and User Guide", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 973, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d4fb2855-9795-4388-8c11-de2f72ff19ab": {"__data__": {"id_": "d4fb2855-9795-4388-8c11-de2f72ff19ab", "embedding": null, "metadata": {"source": "Data.FI Nigeria_LAMISPlus Mobile User Guide V.2_TL-24-11_KM revised.pdf", "page_label": "25"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "534b29d7-3ad4-499d-8598-798ee3004ddb", "node_type": "4", "metadata": {"source": "Data.FI Nigeria_LAMISPlus Mobile User Guide V.2_TL-24-11_KM revised.pdf", "page_label": "25"}, "hash": "cf47ab23941350781219ea9d79ff3db31af468d0207594a5cfd0fefb4ff0f124", "class_name": "RelatedNodeInfo"}}, "text": "Figure 4.\n                 3. Labour and Delivery form\n        Labout  Dcllvery Form                                                Labour        Fotm\n                                                                         Plare  Deuveiy\n    Dato Dulit                                                                  D\n                                                                         Lpdolay\n    ROM Dslety Intetval\n    Va\n    Ecgictomy                                                            OnART7\n    vagnal Teac                                                            snosed Intant Qrven Hep Manin  hne 0l Dinn\n                                                                                 [6D ward *\n    OnAKM:                                                                      Snlu\n         HIv Dlunozis                                                   Maternal Outcome\n    HetalLe Slln\n                                                                                                                                  Sav\nLA\n   MISPlus Mobile Training Manual and User Guide                                                                                                                             23", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1226, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "09d75f31-6eb3-4aff-8c9f-a78fbdabdf80": {"__data__": {"id_": "09d75f31-6eb3-4aff-8c9f-a78fbdabdf80", "embedding": null, "metadata": {"source": "Data.FI Nigeria_LAMISPlus Mobile User Guide V.2_TL-24-11_KM revised.pdf", "page_label": "26"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "6f0bb102-26dc-4d53-8118-ce7e5ec2e6fa", "node_type": "4", "metadata": {"source": "Data.FI Nigeria_LAMISPlus Mobile User Guide V.2_TL-24-11_KM revised.pdf", "page_label": "26"}, "hash": "e636ea679ef7a569c16ec2c96408d33088dcb5eb4f88a45c22374c4cda441197", "class_name": "RelatedNodeInfo"}}, "text": "INFANT REGISTRATION\n  \u25aa  Fill in all required fields.\n  \u25aa  ANC number and Date of Delivery fields are auto-populated.\n  \u25aa  Click the Save button.\nFigure 4.4. Infant Registration form\n                                         141604e\n     Intant Rcglsbation Form               Infant Regtstration Form\n                                         Infant ARV &CTX\n   J0z4-0-04\n                                            C\n   Intant ARV CTX\n24                                                      LAMISPlus Mobile Training Manual and User Guide", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 537, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "497e6490-1ed1-4933-bb46-cefdbed3c66d": {"__data__": {"id_": "497e6490-1ed1-4933-bb46-cefdbed3c66d", "embedding": null, "metadata": {"source": "Data.FI Nigeria_LAMISPlus Mobile User Guide V.2_TL-24-11_KM revised.pdf", "page_label": "27"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "b3b39082-bb34-46df-ab7c-515bebfd721c", "node_type": "4", "metadata": {"source": "Data.FI Nigeria_LAMISPlus Mobile User Guide V.2_TL-24-11_KM revised.pdf", "page_label": "27"}, "hash": "00224703c80feb7cbc7b76ec1a85a39d730a19516ad1b120cbb8d86da9a94a80", "class_name": "RelatedNodeInfo"}}, "text": "PARTNERS REGISTRATION\n  \u25aa   Fill in all required fields.\n  \u25aa   ANC number and Partners HIV Status fields are auto-populated.\n  \u25aa   Click the Save button.\nFigure 4.5. Partners form, including partner HIV status\n          Partrcrs Formn\n     Parinc; Full Rig\n          ceH Fest\n     Parine?  Slatua\n     HBv Sttk\n     HCv Saat;\n                                                               Savo\nLAMISPlus Mobile Training Manual and User Guide                                                   25", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 494, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "73965777-ae9f-4e50-a8bc-0996070aa62c": {"__data__": {"id_": "73965777-ae9f-4e50-a8bc-0996070aa62c", "embedding": null, "metadata": {"source": "Data.FI Nigeria_LAMISPlus Mobile User Guide V.2_TL-24-11_KM revised.pdf", "page_label": "28"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "5916f592-b89c-463d-aca3-16d46036741f", "node_type": "4", "metadata": {"source": "Data.FI Nigeria_LAMISPlus Mobile User Guide V.2_TL-24-11_KM revised.pdf", "page_label": "28"}, "hash": "873e5068f9d1750e616bd3455db5ce25c2c07596a1c4fa65317750ba10fd4ed4", "class_name": "RelatedNodeInfo"}}, "text": "PMTCT SERVICES\nThis page displays the list of all forms on the PMTCT module.\n  \u25aa  Selecting the Follow-up Visit takes the user to the Patient Dashboard.\nFOLLOW-UP VISIT\n  \u25aa  On the patient dashboard, select the Follow-up Visit tab then select Mother Follow-up Visit.\n  \u25aa  Fill in all required fields.\n  \u25aa  ANC number and Point of Entry fields are auto-populated.\n  \u25aa  Click the Save button\nFigure 4.6. Tab on Patient Dashboard for follow-up visit\n    Patient Dashboard                         Mother Follow Up Visit\n          Toam Dutails                     VITAL SIGNS\n              Mother Follov Up veslt\n               Child Follow Up Vislt\n                                                  Delvey\n                                           VIRAL LOAD\n                                            Ga Vi\n                                           DSD MODEL OUTCOME\n                                            Data  Outcoma\n                                                                                Savc\nOn the Patient Dashboard, select the Follow-up Visit tab, then select Child Follow-up Visit.\n  \u25aa  Fill in all required fields.\n  \u25aa  Mother\u2019s ANC number field is auto-populated.\n  \u25aa  Click the Save button.\n26                                                      LAMISPlus Mobile Training Manual and User Guide", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1318, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "51e1e2a1-84b4-4f0f-a244-f0b8c1dce220": {"__data__": {"id_": "51e1e2a1-84b4-4f0f-a244-f0b8c1dce220", "embedding": null, "metadata": {"source": "Data.FI Nigeria_LAMISPlus Mobile User Guide V.2_TL-24-11_KM revised.pdf", "page_label": "29"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "9b5fa04d-bf79-4afe-b62d-d7a960e59f4e", "node_type": "4", "metadata": {"source": "Data.FI Nigeria_LAMISPlus Mobile User Guide V.2_TL-24-11_KM revised.pdf", "page_label": "29"}, "hash": "f2a338e059cc7eaf144c2cbeb21b447552e6d914e37edaa711344b8868efa569", "class_name": "RelatedNodeInfo"}}, "text": "Figure 4.\n                   7. Child Follow-Up Visit form\n  7502 dod\n         Child Follow Up Visit                                                                        Child Follow Up Visit\n  Mother $ ART                                                                                  Tinra   ARV Prophylaxls\n    Uming  mother'< ART Initiation\n                                                                                                Pldct  Delivery\n   Oriqirial Rctinter Line\n                                                                                               Infant PCRIHIV test\n   Owlqina Rcginten\n                                                                                                Agn at Tastlmanths)\n  Infant ARV    CTX                                                                             SampleTyoe\n   Aqe at CTX Initiation\n                                                                                                Date sampla collactnd\n   Intani4PVTMps\n                                                                                                Dale Resull Recalved 4l Fecility\n           ARV Prophvlaxis\n                                                                                                Date Caregive Gwven Result\n   Pltce  Ucuter\n  Infant PCRIHIV test\n                                                                                                Result\n         Tesenenths\n                                                                                               Rapid Antibody Test\n   Samiple Type\n                                                                                                         IRapid Test}\n   Date g mple collected\n                                                                                                Age : Test(manths)\n             Reocoived at Facilty\n   Dato Pesult\n                                                                                                Dale Oi Te_l\n   Date ( teniver Given Result\n                                                                                                Result \"\n   Date Sumple Sent\n                                                                                                                                                                                   Save\nLA\n    MISPlus Mobile Training Manual and User Guide                                                                                                                                               27", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2531, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c91c3709-ca09-41d5-8cef-6a0622e55dcd": {"__data__": {"id_": "c91c3709-ca09-41d5-8cef-6a0622e55dcd", "embedding": null, "metadata": {"source": "Data.FI Nigeria_LAMISPlus Mobile User Guide V.2_TL-24-11_KM revised.pdf", "page_label": "30"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "e9466e68-19c6-4fb3-b354-f5472c997aa1", "node_type": "4", "metadata": {"source": "Data.FI Nigeria_LAMISPlus Mobile User Guide V.2_TL-24-11_KM revised.pdf", "page_label": "30"}, "hash": "4b8f3c6f5da13d26e2b5dc32c1da2b46d08e047f1812127ba53b67e5670795cc", "class_name": "RelatedNodeInfo"}}, "text": "5. Hepatitis\nThe Hepatitis module is used to document clients\u2019 viral hepatitis enrollment, diagnosis, and treatment\nhistory.\nFigure 5.0. Main page of Hepatitis module\n 120+000\n Hi User!\n                  Testing Senyiccs\n                  DSD\n                 DSD Servlcc Fonm\nFEATURES OF THE HEPATITIS MODULE\n  \u25aa  Hepatitis Enrollment\n  \u25aa  Hepatitis Diagnosis\n  \u25aa  Hepatitis Treatment\n28                                                 LAMISPlus Mobile Training Manual and User Guide", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 484, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f15b87a1-e498-44b4-a567-bf8b26c90bc3": {"__data__": {"id_": "f15b87a1-e498-44b4-a567-bf8b26c90bc3", "embedding": null, "metadata": {"source": "Data.FI Nigeria_LAMISPlus Mobile User Guide V.2_TL-24-11_KM revised.pdf", "page_label": "31"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "f3c32bbe-05d4-44cd-b05a-b02bd9d8068e", "node_type": "4", "metadata": {"source": "Data.FI Nigeria_LAMISPlus Mobile User Guide V.2_TL-24-11_KM revised.pdf", "page_label": "31"}, "hash": "a19ea08ecf07f3c9d1ff8c5e3361dde651065bf7f37abaa900a4cd9c22d757fe", "class_name": "RelatedNodeInfo"}}, "text": "Hepatitis Client\u2019s List\n  \u25aa  This page (Figure 5.1) displays the list of all registered clients.\n  \u25aa  To enroll a new patient on Hepatitis, select New Patient.\n  \u25aa  Select an already registered patient to see the list of Hepatitis services.\nFigure 5.1. List of all registered hepatitis clients\n                        Hepatitis Client'$ List\n   nodauut\n   oodatn\n   dohy\n                                                         Tob Juuiiin ~bl\n   0onarrr\n         1704-10\nLAMISPlus Mobile Training Manual and User Guide                                                    29", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 573, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fae5aab6-515f-4110-a0d2-e42bf3c11fb5": {"__data__": {"id_": "fae5aab6-515f-4110-a0d2-e42bf3c11fb5", "embedding": null, "metadata": {"source": "Data.FI Nigeria_LAMISPlus Mobile User Guide V.2_TL-24-11_KM revised.pdf", "page_label": "32"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "93f21b34-a1a4-48c4-b494-3ac20cd1ef45", "node_type": "4", "metadata": {"source": "Data.FI Nigeria_LAMISPlus Mobile User Guide V.2_TL-24-11_KM revised.pdf", "page_label": "32"}, "hash": "192864d26715bc5979b7173318d5c03ce0e5d33f704056be83b6c012193c2ee0", "class_name": "RelatedNodeInfo"}}, "text": "HEPATITIS SERVICES\nThis page (Figure 5.2) displays all service forms on the Hepatitis module.\nFigure 5.2. Service forms available in the Hepatitis module\n                  Hepatitis Services\n30                                                 LAMISPlus Mobile Training Manual and User Guide", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 289, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "79bf1dc7-78e7-4601-8dc4-5ffb469afcc3": {"__data__": {"id_": "79bf1dc7-78e7-4601-8dc4-5ffb469afcc3", "embedding": null, "metadata": {"source": "Data.FI Nigeria_LAMISPlus Mobile User Guide V.2_TL-24-11_KM revised.pdf", "page_label": "33"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "c0700c85-55a6-4343-9498-9140ce49596a", "node_type": "4", "metadata": {"source": "Data.FI Nigeria_LAMISPlus Mobile User Guide V.2_TL-24-11_KM revised.pdf", "page_label": "33"}, "hash": "56ef1c219a2a1f8cfd96e9cb540fef26c73e96b569c1fc6a31fc7ff415029c7f", "class_name": "RelatedNodeInfo"}}, "text": "HEPATITIS ENROLLMENT\nFill in all the required fields and save the form.\nFigure 5.3. Hepatitis Enrollment form\n            Form                         Gleie\n   Enrolmtent\n   J0z4 04-0}\n                                          Save\nLAMISPlus Mobile Training Manual and User Guide                                                 31", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 330, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2f1dfd95-94bd-4bcc-9aa0-880231d4d1e9": {"__data__": {"id_": "2f1dfd95-94bd-4bcc-9aa0-880231d4d1e9", "embedding": null, "metadata": {"source": "Data.FI Nigeria_LAMISPlus Mobile User Guide V.2_TL-24-11_KM revised.pdf", "page_label": "34"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "aea93032-3dad-4e39-b175-da0f3b305434", "node_type": "4", "metadata": {"source": "Data.FI Nigeria_LAMISPlus Mobile User Guide V.2_TL-24-11_KM revised.pdf", "page_label": "34"}, "hash": "7755220697242e657ed01c8a844d0452bb708cc6a83016508a06a7a733716551", "class_name": "RelatedNodeInfo"}}, "text": "HEPATITIS DIAGNOSIS\n       Fill in all the required fields and save the form.\n       Figure 5.4. Hepatitis Diagnosis form\n           Diaonosis Forn                              Dlagnosis Form                          Dlagnosis Form\n        Hcpatitia                                   Hcpatitis\n        J074 03.01                                  Latected\n        7074-04-07\n       HEPATITIS TREATMENT\n       Fill in all the required fields and save the form.\n       Figure 5.5. Hepatitis Treatment form\n      Disgnosis Form                        oane      Dagnosis Fotm                            0agnosts form                      Mlnt\nHepatiis B Treaiment                                                                        7024 01 0>            701401 01\n                                                                                            Sva _2Teunq\n                                                    8342Tc-brg\n         Irestent [Lele\n         Tth\n       32                                                                          LAMISPlus Mobile Training Manual and User Guide", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1096, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4e5a7826-a3ed-4947-9981-cc333bf0c006": {"__data__": {"id_": "4e5a7826-a3ed-4947-9981-cc333bf0c006", "embedding": null, "metadata": {"source": "Data.FI Nigeria_LAMISPlus Mobile User Guide V.2_TL-24-11_KM revised.pdf", "page_label": "35"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "a00b51d9-5ea3-448f-abf1-d7192d2d2d4b", "node_type": "4", "metadata": {"source": "Data.FI Nigeria_LAMISPlus Mobile User Guide V.2_TL-24-11_KM revised.pdf", "page_label": "35"}, "hash": "02816bdfafccfdc2232efc8533b7638e73c6da1627ec60254d2af7a7d5f2b1e5", "class_name": "RelatedNodeInfo"}}, "text": "6. Differentiated Service Delivery\nThe Differentiated Service Delivery (DSD) module is used to document the responsive, client-\ncentered approach that simplifies and adapts HIV services across the cascade to better serve\nindividual needs.\nFigure 6.0. DSD Module main page\n                      DSD\nFEATURE OF THE DSD MODULE\n  \u25aa  DSD Service Form\nLAMISPlus Mobile Training Manual and User Guide                                        33", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 435, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1b8de6c2-23aa-4c85-a86d-dfe7e74165f2": {"__data__": {"id_": "1b8de6c2-23aa-4c85-a86d-dfe7e74165f2", "embedding": null, "metadata": {"source": "Data.FI Nigeria_LAMISPlus Mobile User Guide V.2_TL-24-11_KM revised.pdf", "page_label": "36"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "d3247f64-6274-4438-bb74-0524b6af3641", "node_type": "4", "metadata": {"source": "Data.FI Nigeria_LAMISPlus Mobile User Guide V.2_TL-24-11_KM revised.pdf", "page_label": "36"}, "hash": "3d0288751cf93bf3bbd0a9e425d6442df096a73f187c13bd4899f6e6064c73c0", "class_name": "RelatedNodeInfo"}}, "text": "DSD CLIENT\u2019S LIST\nThis page displays the list of all registered clients that are eligible for DSD.\n   \u25aa  Select a client to fill the DSD service form.\nFigure 6.1. List of registered clients eligible for DSD\n            Mod\n                         DSD Clicnt = List\n                                                     VyvuihYu\n   C18813/20241712918368634\n   C1831737024/1712917673738\n   TS-00003\n    ~00021\n        0001-02\n34                                                            LAMISPlus Mobile Training Manual and User Guide", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 533, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "df532087-72ba-4d31-8414-073ec200d3c2": {"__data__": {"id_": "df532087-72ba-4d31-8414-073ec200d3c2", "embedding": null, "metadata": {"source": "Data.FI Nigeria_LAMISPlus Mobile User Guide V.2_TL-24-11_KM revised.pdf", "page_label": "37"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "ef06c418-da71-4fef-9f7c-f445ce54f8ee", "node_type": "4", "metadata": {"source": "Data.FI Nigeria_LAMISPlus Mobile User Guide V.2_TL-24-11_KM revised.pdf", "page_label": "37"}, "hash": "7f406728dc2312a0943f31e80004c255a6dc24ea509a745efff2b065b8a24b68", "class_name": "RelatedNodeInfo"}}, "text": "DSD SERVICES\nThis page displays the DSD Services form.\nFigure 6.2. DSD Services form\n           Crd\n                       DSD Services\nFill in all required fields and click on Save to complete the service form.\nLAMISPlus Mobile Training Manual and User Guide                                             35", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 306, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d7bc0c14-cd01-4d34-8cb2-a12bee562cae": {"__data__": {"id_": "d7bc0c14-cd01-4d34-8cb2-a12bee562cae", "embedding": null, "metadata": {"source": "Data.FI Nigeria_LAMISPlus Mobile User Guide V.2_TL-24-11_KM revised.pdf", "page_label": "38"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "a22575b0-6773-4ddb-ab69-b23a7c9af473", "node_type": "4", "metadata": {"source": "Data.FI Nigeria_LAMISPlus Mobile User Guide V.2_TL-24-11_KM revised.pdf", "page_label": "38"}, "hash": "7fbb79e23290e33794b8b6d37f34e4b1a583401ca36cd9677ec0af94e3ceb124", "class_name": "RelatedNodeInfo"}}, "text": "Figure 6.3. DSD Assessment and Acceptance form\n                                                       ET' -\n  MTur\n7. All Clients\nThis page (Figure 7.0) displays a list of all registered patients.\n  \u25aa  To register a new client, select Create Patient.\n  \u25aa  To search for an existing client, click on the search icon, and type the client's hospital number\n     or name.\n  \u25aa  To view the patient\u2019s profile, click on the patient\u2019s name.\n36                                                      LAMISPlus Mobile Training Manual and User Guide", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 536, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8f27a5dc-bb16-4518-9706-835da560527b": {"__data__": {"id_": "8f27a5dc-bb16-4518-9706-835da560527b", "embedding": null, "metadata": {"source": "Data.FI Nigeria_LAMISPlus Mobile User Guide V.2_TL-24-11_KM revised.pdf", "page_label": "39"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "98fe2058-5865-4ec4-a278-702605d64998", "node_type": "4", "metadata": {"source": "Data.FI Nigeria_LAMISPlus Mobile User Guide V.2_TL-24-11_KM revised.pdf", "page_label": "39"}, "hash": "922b7cef5bafb40bc56598afa5615d91927defbd13ce01b6481ce164e3e13e22", "class_name": "RelatedNodeInfo"}}, "text": "Figure 7.0. List of all registered patients\n 10359m0\n                                                       Find Patient\n Hi Userl                                                     Client's List\n                                                            Create Patient 2+\n                   HIY Tesbira Strvlcc :\n                                                  1110                    Prince Asogwa\n                                                  Male   1986-03-15\n                                                  1111                        Aisha Sani\n                                                  Female  1993-03-15\n                                                  1110                      Angel Ruth\n                                                  Female  1998-03-15\n                    DSD\nFEATURES OF THE ALL-CLIENTS MODULE\n  \u25aa  HIV Enrollment\n  \u25aa  Patient Services\n  \u25aa  Fingerprints\nPATIENT PROFILE\nThe patient profile displays the patient\u2019s basic information.\n  \u25aa  To edit any information on the patient profile, click on Edit Patient.\n  \u25aa  To enroll a patient into the HIV program, click on HIV Enrollment.\n  \u25aa  To view a patient\u2019s dashboard, click on Go to Patient Services.\nLAMISPlus Mobile Training Manual and User Guide                                              37", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1295, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "eadc4862-6600-4062-87ab-3b9b7689db0a": {"__data__": {"id_": "eadc4862-6600-4062-87ab-3b9b7689db0a", "embedding": null, "metadata": {"source": "Data.FI Nigeria_LAMISPlus Mobile User Guide V.2_TL-24-11_KM revised.pdf", "page_label": "40"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "a8492db5-e2d5-48fa-833a-9063c0bb44bf", "node_type": "4", "metadata": {"source": "Data.FI Nigeria_LAMISPlus Mobile User Guide V.2_TL-24-11_KM revised.pdf", "page_label": "40"}, "hash": "ff5169a9a70f543b64ba4a7c54f0a0bbc153380b588897ed31fc25e5e970c8ea", "class_name": "RelatedNodeInfo"}}, "text": "Figure 7.1. Form to edit patient\u2019s profile and to enroll patient\n                                             HIv Enrollment\n                 eryhj's Profile           Uniaus\n                                           Care Entry Point ~\n                                    Nol Cantue\n                  Hiv                          Rrgicuation\n                                           mala\n                                              Reicual\n                                           Enraulmcnt Setting\n    1994-01-27\n                                           Prconancy\n    Murd\n                                            Stlug\n     Putin\n    17cyhuy I                                                            Sovo\n       Ri\n    Nnen:\n                  Edit\n PATIENT DASHBOARD\nThe Patient Dashboard (Figure 7.2) displays the form details of all the program services provided to a\npatient, e.g., HIV testing services (HTS) and HIV Enrollment.\n  \u25aa  The green tick color displayed on \u201cRisk Stratification\u201d shows that the Risk Stratification form has\n     successfully synced to the facility database, while the red tick color displayed on the other forms\n     indicates that the forms have not been synced to the facility database.\n  \u25aa  Select Update to edit a form.\n  \u25aa  Select Delete to delete a form.\n38                                                          LAMISPlus Mobile Training Manual and User Guide", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1416, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d443a6b8-d505-4d96-910d-591bf60ab08c": {"__data__": {"id_": "d443a6b8-d505-4d96-910d-591bf60ab08c", "embedding": null, "metadata": {"source": "Data.FI Nigeria_LAMISPlus Mobile User Guide V.2_TL-24-11_KM revised.pdf", "page_label": "41"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "cc0e96c3-6274-43b2-a897-5247c8aad6ea", "node_type": "4", "metadata": {"source": "Data.FI Nigeria_LAMISPlus Mobile User Guide V.2_TL-24-11_KM revised.pdf", "page_label": "41"}, "hash": "c272f092fbf4f1f3fb5ef51a638b469a749efb01f71c1fc0c6bba0454fbfe275", "class_name": "RelatedNodeInfo"}}, "text": "Figure 7.2. Patient Dashboard\n    12010od\n         Patient Dashboard\n                                DETAILS   Fingerprints\n     Risk StratificaItion\n     Clicnt Intakc Form\n     Pre Tcst Counsoling Form\n     Rcqucat Rczult Form\n     Post Tcst Counscling Form\n         Rccency Formn\n     Indcr Notificaton Sorvic Elciintion\n         Entellment\n                                                                  elete\nLAMISPlus Mobile Training Manual and User Guide                                                                            39", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 541, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8071ab23-00d2-4ed7-9c5e-a61f3f8185e8": {"__data__": {"id_": "8071ab23-00d2-4ed7-9c5e-a61f3f8185e8", "embedding": null, "metadata": {"source": "Data.FI Nigeria_LAMISPlus Mobile User Guide V.2_TL-24-11_KM revised.pdf", "page_label": "42"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "5a15611e-286d-4f94-a182-168bde4d2ea2", "node_type": "4", "metadata": {"source": "Data.FI Nigeria_LAMISPlus Mobile User Guide V.2_TL-24-11_KM revised.pdf", "page_label": "42"}, "hash": "71d0bdcc9f43d6cafb92dd56124f1aad58e7a67383e90271d36d32917df06def", "class_name": "RelatedNodeInfo"}}, "text": "\u25aa  On the Patient Dashboard, select Fingerprints and click on the biometric icon.\n  \u25aa  The biometric implementation supports both Secugen and Neurotech SDKs.\nFigure 7.3. Tab to select Fingerprints in Patient Dashboard\n         Patient Dashboard\n                        FORM DETAIS Eingfrarints\n                                                       Nol ceotued\n           Recapture Statu::                           Not Cdoutcd\n40                                                      LAMISPlus Mobile Training Manual and User Guide", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 531, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ca62f555-e01e-40fe-9638-532092146784": {"__data__": {"id_": "ca62f555-e01e-40fe-9638-532092146784", "embedding": null, "metadata": {"source": "Data.FI Nigeria_LAMISPlus Mobile User Guide V.2_TL-24-11_KM revised.pdf", "page_label": "43"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "363389a7-cc41-4927-baa5-b90552a62131", "node_type": "4", "metadata": {"source": "Data.FI Nigeria_LAMISPlus Mobile User Guide V.2_TL-24-11_KM revised.pdf", "page_label": "43"}, "hash": "b5116a2df4f1190dbbc830e57c0758e96f4e4763ca33ba6bd11ee3fcfcbaf177", "class_name": "RelatedNodeInfo"}}, "text": "PATIENT BIOMETRICS\n \u25aa  Select Secugen Biometrics (Figure 7.4) to capture patients\u2019 fingerprints using the Secugen\n    device, and FUTORNIC Neurotech Biometric. The patient biometrics capture page is\n    displayed.\n \u25aa  Click on \u201cSelect fingerprint to capture\u201d to choose the finger you want to capture.\n \u25aa  Place the selected finger on the Secugen scanner and click on the green tick icon to capture\n    fingerprints.\n \u25aa  Select Save to save captured fingerprints.\n \u25aa  Select Clear Prints to delete captured fingerprints.\nNote: A minimum of six fingerprints are to be captured for biometrics fingerprints to be\nsaved successfully.\nFigure 7.4. Main page for use of SecuGen biometrics system\n                Select Biometrics Environment\n            SecuGen\n                        Secugen Biometrics\n                          FUTRONIC\n                        NcurotcrBiomctrics\nLAMISPlus Mobile Training Manual and User Guide                                              41", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 970, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7a053b45-d71f-4aaa-bd21-68fba9936314": {"__data__": {"id_": "7a053b45-d71f-4aaa-bd21-68fba9936314", "embedding": null, "metadata": {"source": "Data.FI Nigeria_LAMISPlus Mobile User Guide V.2_TL-24-11_KM revised.pdf", "page_label": "44"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "655b9702-cad0-4212-8c9b-73559011b941", "node_type": "4", "metadata": {"source": "Data.FI Nigeria_LAMISPlus Mobile User Guide V.2_TL-24-11_KM revised.pdf", "page_label": "44"}, "hash": "f0fb01ceded354e5459e6f090d6089331dbbe48d1c9abe21293dce8ea18dbc81", "class_name": "RelatedNodeInfo"}}, "text": "SECUGEN BIOMETRICS\nThe green tick icon on the fingerprint symbol signifies that the fingerprint has been successfully\ncaptured.\nFigure 7.5. Secugen Biometrics tab showing successful fingerprint capture\n            Patient Biometrics                                                                                                    Patient Biometrics\n      Left Thumb Finger     Left IndexFinger      Left Mddle Finger      Left Ring Finger   Left Little Finger                                            Figer                Finger              Fingzr\n                                                                                                                            Left Thumb Finger    Left Index           Left Middle          Left Ring           Left LittleFinger\n     Right Thumb Finger               Finger                                                            Finger\n                            Right Index          Right MiddleFinger     Right RingFinger      Right Little                             Finger              Finger    Right MiddleFinger   Right Ring \"\n                                                                                                                            Right Thumb         Right Index                                         Firger              Finger\n                                                                                                                                                                                                               Right Little\n        Select Fingerprint to capture\"                                                                                        Select Fingerprint t9 cepture\"\n                                                                                                                              Left ThumbFinger\n        Select Fingerprint to capture                                                                                          Seiect Fingerprintcapture\n                       Save                                               ClearPrints                                                        Save                                          Clear Prints\n42                                                                                                                             LAMISPlus Mobile Training Manual and User Guide", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2358, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ded2182e-77f9-4b4f-96a6-e0cea13c284e": {"__data__": {"id_": "ded2182e-77f9-4b4f-96a6-e0cea13c284e", "embedding": null, "metadata": {"source": "Data.FI Nigeria_LAMISPlus Mobile User Guide V.2_TL-24-11_KM revised.pdf", "page_label": "45"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "33a76e83-b18f-4a99-b55d-322bb71774da", "node_type": "4", "metadata": {"source": "Data.FI Nigeria_LAMISPlus Mobile User Guide V.2_TL-24-11_KM revised.pdf", "page_label": "45"}, "hash": "a4975fa1286d0b8649798b3afbe770aedcf101912ac1e2b6737cae88df816b99", "class_name": "RelatedNodeInfo"}}, "text": "FUTRONIC NEUROTEC BIOMETRICS\n  \u25aa  Select Futronic Neurotec Biometrics to capture the patient\u2019s fingerprint using the Futronic\n     device.\n  \u25aa  Click on the three dots at the top right of the screen to configure the Futronic biometrics capture\n     settings.\n  \u25aa  The options Preferences, Database, Activation, and About are used for the settings.\n  \u25aa  Select Preferences and ensure that the quality threshold is at a minimum of 60.\n  \u25aa  Select Activation to activate the license.\nFigure 7.6. Main page for use of Futronic Neurotec Biometrics system\n                   Select Biometrics Environment\n              SecuGen\n                             Secugen Biometrics\n                              FUTRONIC\n                             Neuroiec Diometrice\nLAMISPlus Mobile Training Manual and User Guide                                             43", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 851, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "aa0f495d-e9bc-42bb-a7d5-47ec2c2e8390": {"__data__": {"id_": "aa0f495d-e9bc-42bb-a7d5-47ec2c2e8390", "embedding": null, "metadata": {"source": "Data.FI Nigeria_LAMISPlus Mobile User Guide V.2_TL-24-11_KM revised.pdf", "page_label": "46"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "b8f0f2d0-0c91-43c4-8515-cfdec3f09737", "node_type": "4", "metadata": {"source": "Data.FI Nigeria_LAMISPlus Mobile User Guide V.2_TL-24-11_KM revised.pdf", "page_label": "46"}, "hash": "31fa98c40d5c5881216f08b8c91e13e047fec933177b3716033604a52a0370bf", "class_name": "RelatedNodeInfo"}}, "text": "Figure 7.\n                  7. Futronic Neurotec biometrics tab showing successful fingerprint capture\n           Patient Biometrics                                                                                  Patient Biometrics\n                                                                                                                                                                                  Preferences\n                                                                                                                                                                                  Database\n                                  Fingor     Left Middle Finger   Left Ring Finger           Flnget                 Funget                                Flnge      Left Rong Fing\n      Left Thumb /         Left lader                                                 Left Little         Left Thumb)          Lelt Index Finger  Left Middle [                   Activation\n                                                                                                                                                                                  About\n                                   FingeT              Fing\"t             fing\"t                                    Flnget             Firgci              Angc                                  Finge\n      Right Thurnb Finger Right Index E      Right Middle         Right Ring     Right Litfe Finger       Right Thumb         Right Index          Right Middle      Right Ring Finger  Rlight Llttle\n                                                   Capture                                                                                         [0] Capture\n                                           Add                                      ~SELECT FINGER                                            Add                                       SELECT FINGER\n                        Capture More                                       Save                                             Capture More                                      Save\n44                                                                                                        LAMISPlus Mobile Training Manual and User Guide", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2249, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0c2c9a9b-e858-444e-a0a7-a0b112005eeb": {"__data__": {"id_": "0c2c9a9b-e858-444e-a0a7-a0b112005eeb", "embedding": null, "metadata": {"source": "Data.FI Nigeria_LAMISPlus Mobile User Guide V.2_TL-24-11_KM revised.pdf", "page_label": "47"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "6c92f981-ed42-438a-bf4c-6bf56d956a1d", "node_type": "4", "metadata": {"source": "Data.FI Nigeria_LAMISPlus Mobile User Guide V.2_TL-24-11_KM revised.pdf", "page_label": "47"}, "hash": "e30b3307c74009c7d041d2df069f002456b9ff84df36f8a618c9be352449931a", "class_name": "RelatedNodeInfo"}}, "text": "8. Sync Status\nThis Sync Status module displays the status of patients\u2019 records synced to the facility server.\nFigure 8.0. Main page of Sync Status module\n   12,16 000\n                             DATGT\n                            DSD\n                          DSD Servece Form\n                            AIL Clnta\nLAMISPlus Mobile Training Manual and User Guide                                            45", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 409, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ce5ea23f-709c-4be4-9e25-6b27bbb2a251": {"__data__": {"id_": "ce5ea23f-709c-4be4-9e25-6b27bbb2a251", "embedding": null, "metadata": {"source": "Data.FI Nigeria_LAMISPlus Mobile User Guide V.2_TL-24-11_KM revised.pdf", "page_label": "48"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "39dce267-57a0-4fb1-ac51-76f577721550", "node_type": "4", "metadata": {"source": "Data.FI Nigeria_LAMISPlus Mobile User Guide V.2_TL-24-11_KM revised.pdf", "page_label": "48"}, "hash": "c599068944a1a0075f94d74e3237c61489a796c8b5827a652ed43afba1938554", "class_name": "RelatedNodeInfo"}}, "text": "FEATURE OF THE SYNC STATUS MODULE\n  \u25aa   Sync Status List\n  \u25aa   When the Synced status list is blank, it means that all information captured on the mobile\n      application has been successfully synced to the server.\n  \u25aa   The Cloud icon on the top right corner of the screen is used to connect to the server when the\n      device used is connected to the internet.\nFigure 8.1. Sync status list tab\n                                    0\n            Synced Status List                         Synced Status List\n    1110                      Prince Asogwa\n     Male  1986-03-15            Not Synced\n    1111                         Aisha Sani\n     Female  1993-03-15          Not Synced\n46                                                 LAMISPlus Mobile Training Manual and User Guide", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 784, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "db087328-49c9-4f57-9ee3-72c1e03ee1fc": {"__data__": {"id_": "db087328-49c9-4f57-9ee3-72c1e03ee1fc", "embedding": null, "metadata": {"source": "Data.FI Nigeria_LAMISPlus Mobile User Guide V.2_TL-24-11_KM revised.pdf", "page_label": "49"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "b999b205-e144-4245-9107-181e5dc5abb6", "node_type": "4", "metadata": {"source": "Data.FI Nigeria_LAMISPlus Mobile User Guide V.2_TL-24-11_KM revised.pdf", "page_label": "49"}, "hash": "f7fb5bcd230b5c448209815bfbcc8e97a10731e3755b059d5dcc3b70599f3c19", "class_name": "RelatedNodeInfo"}}, "text": "9. Connect to Server\nThe Connect to Server module is used to pull patient information from the server.\nFigure 9.0. Main page of Connect to Server module\n                       HIY Ietnq scrlces\n                          DATGT\n                         DSD\n                        OS0 Scry Co Form\n                         All Clicnte\n                        Konn ct\nFEATURES OF THE CONNECT TO SERVER MODULE\n  \u25aa  Pull patients from server.\n  \u25aa  Pull patients without biometrics.\n  \u25aa  Pull patients with biometrics.\nLAMISPlus Mobile Training Manual and User Guide                                        47", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 602, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "71fefab7-5f21-4cc5-b669-d5578ad0f891": {"__data__": {"id_": "71fefab7-5f21-4cc5-b669-d5578ad0f891", "embedding": null, "metadata": {"source": "Data.FI Nigeria_LAMISPlus Mobile User Guide V.2_TL-24-11_KM revised.pdf", "page_label": "50"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "80ef6957-225f-4973-86c5-5f015bb439f3", "node_type": "4", "metadata": {"source": "Data.FI Nigeria_LAMISPlus Mobile User Guide V.2_TL-24-11_KM revised.pdf", "page_label": "50"}, "hash": "03afd913ac7f69fe5a05851a01cdf333387e19cc97489e808046897045e08af3", "class_name": "RelatedNodeInfo"}}, "text": "PULL PATIENTS FROM SERVER\n  \u25aa  To pull client information from the server, select Connect to Server from the landing page.\n  \u25aa  A page showing Search and Pull patients from server, Pull patients without biometrics, and Pull\n     patients with biometrics is displayed.\n  \u25aa  Select Search and Pull patients from server.\n  \u25aa  Click on the Search icon and type in the name of the patient that is to be pulled from the server.\n  \u25aa  Click on Download to download the patient from the server.\n  \u25aa  Go to All Clients module to view the downloaded patient.\nFigure 9.1. Landing page for Connect to Server module\n                                                               FindDownload Patient i=  Sealch\n                     Connect to Server                                       Download Patients\n                                                               muss\n                                                                                                      Iztatu\n                                                                                     Downlodd\n                                                           C18BV01HP 2O241712303963310\n                                                            1990 04 0                Downluad\n                                                           C1e81OTH3/o24/1712216783872\n                     Pul pouthl                            1944-04-64\n                                                           Cibavo1hanoz41717[45597346               calamatu\n                                                                                     Downlord\n                     PLl Ditlenta  blomotnse\n                                                                                     Downlodd\n                                                           C18BV01H320241712143942211\n                                                           1992 01 03\n                                                           C1e81'0THeno241712141281405\n                                                           CiBVo1Hnnoz41712134279999                 Sahat\n                                                            acel04-03                Downlodd\n                                                           C14a1omPn024/1712130662999\n48                                                          LAMISPlus Mobile Training Manual and User Guide", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2380, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "515cd16c-bd47-459f-b649-e1b6e319eb47": {"__data__": {"id_": "515cd16c-bd47-459f-b649-e1b6e319eb47", "embedding": null, "metadata": {"source": "Data.FI Nigeria_LAMISPlus Mobile User Guide V.2_TL-24-11_KM revised.pdf", "page_label": "51"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "26f48a53-ead4-4644-b019-697d49cf85c8", "node_type": "4", "metadata": {"source": "Data.FI Nigeria_LAMISPlus Mobile User Guide V.2_TL-24-11_KM revised.pdf", "page_label": "51"}, "hash": "b312c132a62df4a0ecf387db2512842e4d668ce5c882d0b856c46ec2dfc8addc", "class_name": "RelatedNodeInfo"}}, "text": "PULL PATIENTS WITHOUT BIOMETRICS FROM SERVER\n  \u25aa  Select Pull patients without biometrics, the list of patients without biometrics is displayed.\n  \u25aa  Click the Download button to download the information of a patient.\n  \u25aa  Go to All Clients to view the downloaded patient.\n  \u25aa  Pull patients without biometrics displays all patients whose biometrics have not been captured\n     but have been enrolled on HIV.\nFigure 9.2. Tab to pull list of patients without biometrics\n                                                     Find Patients With .          8\n                 Connect to Server                     Download Patients\n                                                555                              Tem Fred\n                                                Male:  2010 01-01      Download\n                                                555                              Tem Fred\n                                                Male   2010-01-01      Download\n                                                554                               Zed Zea\n                                                Female   1990-01-01     Download\n                                                ECT1822                       Lucia James\n                                                Femalc   1999 01-15     Download\n                                                0000078/2015               Daniella James\n                                                Female   1986 05 10     Download\n                                                0002837                      Sandra James\n                                                Female   1995-06-16\nLAMISPlus Mobile Training Manual and User Guide                                        49", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1727, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "76587d14-cedf-4272-9cb2-aa93845f7861": {"__data__": {"id_": "76587d14-cedf-4272-9cb2-aa93845f7861", "embedding": null, "metadata": {"source": "Data.FI Nigeria_LAMISPlus Mobile User Guide V.2_TL-24-11_KM revised.pdf", "page_label": "52"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "abccca78-2ff9-4942-b9f3-b39cab0240ba", "node_type": "4", "metadata": {"source": "Data.FI Nigeria_LAMISPlus Mobile User Guide V.2_TL-24-11_KM revised.pdf", "page_label": "52"}, "hash": "ae35f7b719a02babfbcd3e9277750e4106af3963b8d046e0be5b41a5ed5f7a42", "class_name": "RelatedNodeInfo"}}, "text": "PULL PATIENTS WITH BIOMETRICS FROM SERVER\n  \u25aa  Select Pull patients with biometrics, the list of patients with biometrics is displayed.\n  \u25aa  Click the Download button to download the information of a patient.\n  \u25aa  Go to All Clients to view the downloaded patients\u2019 records.\n  \u25aa  Retrieve patients with biometrics feature displays all patients whose biometric have been\n     captured on LAMISPlus.\nFigure 9.3. Tab to pull list of patients with biometrics\n                                                     18.53 002\n                                                          Find Patients W_         0\n                   Connectto Server                        Download Patients\n                                                             clickto download#u\n                   Loarch                             TS-00003                   Stan Aza\n                                                      Male  200306-15    Downlond\n                                                      TS- 00001                  Fred Ibe\n                                                      Female  2000-0208   Downoad\n50                                                     LAMISPlus Mobile Training Manual and User Guide", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1205, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0432597b-320d-4eab-84d1-8617b41c3bc0": {"__data__": {"id_": "0432597b-320d-4eab-84d1-8617b41c3bc0", "embedding": null, "metadata": {"source": "Data.FI Nigeria_LAMISPlus Mobile User Guide V.2_TL-24-11_KM revised.pdf", "page_label": "53"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "7ae25cc6-5f07-4ef4-874a-95825f79171d", "node_type": "4", "metadata": {"source": "Data.FI Nigeria_LAMISPlus Mobile User Guide V.2_TL-24-11_KM revised.pdf", "page_label": "53"}, "hash": "9420cbef63eacbc5c5947b5621ef8e43c14671116aedc9993ab4c4fac2c43367", "class_name": "RelatedNodeInfo"}}, "text": "TL-24-11\nData for Implementation (Data.FI) is a five-year cooperative agreement   FOR MORE INFORMATION\nfunded by PEPFAR through USAID under Agreement No.                       Contact Data.FI:\n7200AA19CA0004, beginning April 15, 2019. It is implemented by\nPalladium, in partnership with JSI Research & Training Institute, Johns  Madeline Schneider, Data.FI AOR\nHopkins University Department of Epidemiology, Right to Care,            mschneider@usaid.gov\nCooper/Smith, DT Global, Jembi Health Systems, and Pendulum, and\nsupported by expert local resource partners.                             Shreshth Mawandia, Data.FI Project\nThis document was produced for review by the U.S. President\u2019s            Director\nEmergency Plan for AIDS Relief through the United States Agency          datafiproject@thepalladiumgroup.com\nfor International Development. It was prepared by Data for               https://datafi.thepalladiumgroup.com/\nJuly 2024\n          PEPFAR                            USAID USAID                              Data.FI\n                                           nort    FROM THE AMERICAN PEOPLE          Data for Implementation\n          LAMISPlus Mobile Training Manual and User Guide                                                   51", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1252, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a460504b-ff2a-4081-a0a2-fdadf046ca6b": {"__data__": {"id_": "a460504b-ff2a-4081-a0a2-fdadf046ca6b", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "1"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "1507bdbb-4cbc-493e-b123-8e16993523da", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "1"}, "hash": "03e1cfafa33881b7662eebb5d16ac36be978993f682f382133725d1a16659879", "class_name": "RelatedNodeInfo"}}, "text": "NATIONAL GUIDELINES\n      FOR HIV PREVENTION,\n      TREATMENT AND CARE\nNATIONAL AIDS AND STIs CONTROL PROGRAMME\n       FEDERAL MINISTRY OF HEALTH NIGERIA\n                  2020", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 176, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "65a4de50-405b-4c13-8f20-60112112a9a8": {"__data__": {"id_": "65a4de50-405b-4c13-8f20-60112112a9a8", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "2"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "fe6b3108-616a-43b0-9bd2-4596b175e8c1", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "2"}, "hash": "89ba83cf2e49233a2da3bbf374cb2fced1d04fdf25b2eebe10edc1d85c74c1ec", "class_name": "RelatedNodeInfo"}}, "text": "NATIONAL GUIDELINES\n   FOR HIV PREVENTION,\n  TREATMENT AND CARE\n             Copyright 2020.\nFederal Ministry of Health, Abuja Nigeria\n  NATIONAL AIDS AND STIs CONTROL PROGRAMME\n         ISBN: 978-978-980-273-9\n     FEDERAL MINISTRY OF HEALTH NIGERIA\n                    2020", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 275, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1d01d112-1e91-4b76-93cc-1837967f0166": {"__data__": {"id_": "1d01d112-1e91-4b76-93cc-1837967f0166", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "3"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "fb71b03f-5018-4516-bd78-44b5f932b6f4", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "3"}, "hash": "3d7805b46cc481adaffc9742906016d4d207f413a75be0262c94ff5004740ae3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2e8bf8d5-9762-4752-b5c2-c6204a71a26e", "node_type": "1", "metadata": {}, "hash": "f946106f894d8660a975b63b1b14d8ecd8a944e22ffdb65a423b0a57ce1c4d7b", "class_name": "RelatedNodeInfo"}}, "text": "Foreword\nOver the years, the Federal Ministry of Health has put in place several response mechanisms aimed at\nreducing the impact of HIV and AIDS and ensuring people living with HIV (PLHIV) in Nigeria\nreceive quality services by formulating national policies, protocols and standard operating\nprocedures to guide implementation.\nThese new 2020 National Guidelines for HIV Prevention Treatment and Care further underscores the\ngovernment's commitment to the welfare of all Nigerian children, adolescents, young persons,\npregnant women and adults living with HIV. It was developed through extensive consultations\ninvolving government, bilateral and multilateral organizations, civil society organizations, the\nacademia, and the patient community. The wellbeing of the recipients of care remained the principal\nconsideration.\nThese new Guidelines support evidence-based interventions that can improve efficiency and\neffectiveness despite the limited resources in the country's HIV programme. Its implementation will\nrequire increased investment and shared responsibility from all arms of government, donors and\nimplementing agencies. Implementing the guidelines fully will have an unprecedented impact on\npreventing new infections and reducing the number of people dying from HIV-related causes over\nthe coming years.\nThe key recommendations of these guidelines include the use of novel testing strategies for improved\ncase finding, initiating antiretroviral therapy (ART) in all HIV positive people including children,\nadolescents, adults, pregnant and breastfeeding women, regardless of clinical and immunological\nstages of the disease. Other recommendations include re-testing of patients prior to initiating ART,\nadoption of pre-exposure prophylaxis (PrEP) for individuals at high risk of acquiring the infection,\nTB/HIV co-infection management, provision of a specialized package of care for patients with\nAdvanced HIV Disease (AHD), and one-off administration of tuberculosis preventive treatment\n(TPT), differentiated service delivery models (DSD), as well as the establishment of adolescent-\nfriendly services.\nThese Guidelines provide all the guidance that health workers require to deliver comprehensive\npackage of high-quality HIV prevention, treatment and care interventions that addresses the needs of\nPLHIV, individuals at a high risk of acquiring HIV infection and the general population.\nI am optimistic that proper deployment and application of all the recommendations contained here\nwill help in effective management of HIV infections, bolster the HIV response, and ensure an\nirreversible decline of the epidemic.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2628, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2e8bf8d5-9762-4752-b5c2-c6204a71a26e": {"__data__": {"id_": "2e8bf8d5-9762-4752-b5c2-c6204a71a26e", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "3"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "fb71b03f-5018-4516-bd78-44b5f932b6f4", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "3"}, "hash": "3d7805b46cc481adaffc9742906016d4d207f413a75be0262c94ff5004740ae3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1d01d112-1e91-4b76-93cc-1837967f0166", "node_type": "1", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "3"}, "hash": "683714cb33fc9fef351a0f1eac7788feacd39f5ddc586ec48af523cd90264296", "class_name": "RelatedNodeInfo"}}, "text": "I am optimistic that proper deployment and application of all the recommendations contained here\nwill help in effective management of HIV infections, bolster the HIV response, and ensure an\nirreversible decline of the epidemic.\nI therefore endorse and recommend this 2020 National Guidelines for HIV prevention, Treatment\nand Care for use across all the health facilities and service delivery points in the country and also for\nindividuals and organizations involved in the management of HIV andAIDS.\nDr Osagie E. Ehanire MD, FWACS\nHonourable Minister for Health\n           NATIONAL GUIDELINES FOR HIV PREVENTION TREATMENT AND CARE 2020               i", "mimetype": "text/plain", "start_char_idx": 2401, "end_char_idx": 3053, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "714548f2-e984-486d-8294-c4c8847814e9": {"__data__": {"id_": "714548f2-e984-486d-8294-c4c8847814e9", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "4"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "c02786c3-e1cb-46bc-9780-4a425a99c063", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "4"}, "hash": "f55238966d1acbcb00224ee59a9dc353b011a9c41d809c4a8502c96f56111b42", "class_name": "RelatedNodeInfo"}}, "text": "Acknowledgements\nThis document is the result of collaborative efforts led by the Federal Ministry of Health through\nits National HIV/AIDS, STIs & Hepatitis Control Programme (NASCP) with support from\nimplementing partners, bilaterals, multilaterals, civil society organizations and donor agencies.\nThe Federal Ministry of Health acknowledges with utmost gratitude, the inputs of all individuals\nwho devoted their time, amidst the COVID-19 pandemic, to review and contribute to this very\nimportant document. We also extend our appreciation to representatives of the following\norganizations who carefully reviewed the various chapters and sections of the document and\nprovided their invaluable contributions: UNICEF, UNAIDS, CDC, USAID & DOD and their\nimplementing partners andAHF.\nOur special thanks go to WHO, Clinton Health Access Initiative (CHAI), the academia under the\numbrella of the National Task Team on Antiretroviral Therapy, and the core editorial team for\nproviding all the needed technical and/or financial support to convene the meetings that\nculminated in the development of the 2020 National Guidelines for HIV Prevention, Treatment\nand Care.\nWe also appreciate the patient community for providing insight into some of the strategies and\nprogrammatic considerations that were harnessed for inclusion into this document. We are\ngrateful to the representatives of the departments of family health and hospital services, the\nNational Tuberculosis and Leprosy Control Programme of the Federal Ministry of Health, the\nNPHCDA, NAFDAC, NACA, NEPWHAN,ASWHAN, CISHAN andAPYIN.\nFinally, I thank the Honourable Minister of Health and the entire Ministry leadership for the\ncreation of an enabling environment for the staff to work. I also commend the staff in the Office\nof the Director Public Health for the immense support to the various programmes/divisions in the\ndepartment. I appreciate the efforts of NASCP staff under the leadership of the National\nCoordinator, and especially the staff of the Treatment, Care and Support component of NASCP\nthat coordinated all the activities and meetings that ultimately led to the completion of this\ndocument in a timely manner.\nDr. Umo Mildred Ene-Obong\nHead/Director, Public Health Department\n          NATIONAL GUIDELINES FOR HIV PREVENTION TREATMENT AND CARE 2020           ii", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2329, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6a31c926-9a66-4e21-b50a-096748e2e86a": {"__data__": {"id_": "6a31c926-9a66-4e21-b50a-096748e2e86a", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "5"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "c40f7665-4cd4-4afc-bfec-d6af3452c3cc", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "5"}, "hash": "75aa2f6bf88f5df7abc639de6ae23f116d451a28a52b5d1b7357d57709215df2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8eb3c645-2a60-4047-b445-d26cd87ed486", "node_type": "1", "metadata": {}, "hash": "5409405d835e644fb7881e7c99702136338cc110d49a0d649703496dd79537c4", "class_name": "RelatedNodeInfo"}}, "text": "Executive Summary\nThe 2020 National Prevention, Treatment and Care Guidelines is a ten-chapter consolidated\ndocument that provides general and specific guidance on the diagnosis of HIV infection, the use\nof antiretroviral (ARV) drugs for preventing and treating HIV infection, and the care of people\nliving with HIV using a broad range of current technological innovations, interventions and\nevidence-based practices. This guideline is structured along the continuum of HIV testing,\nprevention, treatment and care.\nThe first chapter introduces the guidelines in general, its guiding principles, the process of\nreviewing and evaluating its implementation across service delivery points, the epidemiology of\nHIV in Nigeria, and a summary of the new inclusions into the 2020 Guidelines.\nChapter two provides guidance on HIV testing services (HTS), novel testing strategies including\nHIV self-testing, recency testing, use of HIV risk stratification checklists, and Nucleic acid\ntesting at birth. It also provides guidance on laboratory and clinical diagnosis of HIV infection.\nChapter three focuses on the use of antiretroviral therapy (ART), with emphasis on the\ncharacteristics and mechanisms of action of ARVs, criteria for initiating ART in different age\ngroups, the approved regimens for ART and management of treatment failure. It also provides\nguidance on the use of Tenofovir, Lamivudine and Dolutegravir (TLD) as the preferred first-line\nregimen for all adults and adolescents, the use of Dolutegravir in second-line ART for adults\nand adolescents, and the use of Dolutegravir based regimen as preferred first-line for children\nweighing 3kg and above. Chapter four recognizes the need to track and manage adverse drug\nreactions and provides guidance for effective pharmacovigilance inART.\nIn the fifth chapter, the focus is on adherence to ART, its importance in achieving viral\nsuppression, and guidance on monitoring and improving adherence. Chapter six is dedicated to\nthe prevention of mother to child transmission (PMTCT) of HIV using ART and non-ART\ninterventions including prophylaxis for the HIV exposed infant.\nIn chapter seven, preventive management of HIV is presented.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2186, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8eb3c645-2a60-4047-b445-d26cd87ed486": {"__data__": {"id_": "8eb3c645-2a60-4047-b445-d26cd87ed486", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "5"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "c40f7665-4cd4-4afc-bfec-d6af3452c3cc", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "5"}, "hash": "75aa2f6bf88f5df7abc639de6ae23f116d451a28a52b5d1b7357d57709215df2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6a31c926-9a66-4e21-b50a-096748e2e86a", "node_type": "1", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "5"}, "hash": "9cedfc9d17b361011b307307fc6f682b4fdc6dab6b60ea7e1f1ae9d353a8532e", "class_name": "RelatedNodeInfo"}}, "text": "In chapter seven, preventive management of HIV is presented. This chapter provides detailed\nguidance for offering pre and post-exposure prophylaxis (PrEP and PEP). Chapter eight focuses\non Advanced HIV Disease (AHD), Opportunistic infections (OIs) and the comorbidities. It\nprovides guidance on the implementation of the AHD package of care, cotrimoxazole preventive\ntherapy, tuberculosis preventive therapy, as well as the management of common opportunistic\ninfections.\nChapter Nine focuses on improving the efficiency of service delivery by using Differentiated\nService Delivery (DSD) models, and decentralized services. Special attention is given to\ndifferentiated service delivery based on clinical characteristics and sub-groups including key\npopulations.\n          NATIONAL GUIDELINES FOR HIV PREVENTION TREATMENT AND CARE 2020             iii", "mimetype": "text/plain", "start_char_idx": 2126, "end_char_idx": 2975, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5d625c9d-a782-43c7-8e7a-b50d1dd396af": {"__data__": {"id_": "5d625c9d-a782-43c7-8e7a-b50d1dd396af", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "6"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "fce8dc94-f1eb-4132-be4e-22cce801620e", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "6"}, "hash": "3573495763ab64a0072356225dc3556a379745cecda7d5f44d4d2bf5c2885930", "class_name": "RelatedNodeInfo"}}, "text": "Finally, the tenth and the last chapter deals with the monitoring and evaluation of all the various\nstrategies and interventions involved in the health sector response. It also provides basic\ninformation on the strategies for monitoring the implementation of HIV services under these\nguidelines, and relevant indicators used for measuring the impact as well as the effectiveness of\nall the HIV Interventions.\nDrAkudo. E. Ikpeazu\nNational Coordinator\nNASCP\n           NATIONAL GUIDELINES FOR HIV PREVENTION TREATMENT AND CARE 2020           iv", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 542, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "47b79629-7d7e-4d81-907d-f1058f199cc5": {"__data__": {"id_": "47b79629-7d7e-4d81-907d-f1058f199cc5", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "7"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "6fc149aa-c829-4482-b779-0f9aea27357b", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "7"}, "hash": "815c67048675b025b86dbaa913b3c64a870b87d1437256cc39a4ffc313a5b56c", "class_name": "RelatedNodeInfo"}}, "text": "Editorial Team\nDr Bilkisu Jibrin          Head Treatment, Care & Support NASCP - Coordinating Editor\nDr Nwaokenneya Peter       Assistant Director,AdultART/TB/HIV- NASCP\nDr. Urhioke Ochuko         Assistant Director, Childhood TB - NTBLCP\nMrsAtu Uzoma               Assistant Director, Logistics Unit - NASCP\nProf. SulaimonAkanmu       Chairman NTTA/ Haematologist LUTH Lagos\nProf. OcheAgbaji           Member NTTA/ Physician JUTH Jos\nProf. Oliver Ezechi        Director of Research NIMR Lagos\nDr Eugenia Ofondu          Member NTTA/ Physician FMC Owerri\nDr DamienAnweh             Member NTTA/ Physician FMC Markurdi\nDrAli Onoja                Member HTS Task team / CEOAfrican Health Project\nDr Tolulope Oladele        Assistant Director, Health Sector Response Support NACA\nDr Olufemi Oke             TechnicalAdvisor, Paediatric HIV treatment\n                           and OVC Services, CRS\nEmmanuel Clifford          National Secretary NEPWHAN\nNere Otubu                 Program Manager CHAI\nPharm Williams Eigege      Associate CHAI\nOluwakemi Sowale           Senior Analyst CHAI\n         NATIONAL GUIDELINES FOR HIV PREVENTION TREATMENT AND CARE 2020      v", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1165, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "66cd5319-fa32-41da-a606-1844b15b8e67": {"__data__": {"id_": "66cd5319-fa32-41da-a606-1844b15b8e67", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "8"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "ab0e4de8-321c-4733-af3a-5eae30cfe581", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "8"}, "hash": "f109b8d5ef41a576fc59a890518e35b670b39faeb163d20801a34301e891c6c9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "075b3b31-93dd-460c-bf5f-6d6aa56bbda9", "node_type": "1", "metadata": {}, "hash": "13aa1ca692f0d66bd58a1a6a71d291539cb4447b274e6b9780d206d54f76aa40", "class_name": "RelatedNodeInfo"}}, "text": "Abbreviations and Acronyms\n3TC        Lamivudine                                 CrAg   Cryptococcal Antigen\nABC        Abacavir                                   CrCl   Creatinine Clearance\nABUTH      Ahmadu Bello University Teaching Hospital  CRRF   Combined Report and Requisition Form\nACT        Artemisin-based Combination Therapy        CS     Cesarean Section\nADR        Adverse Drug Reaction                      CSF    Cerebrospinal Fluid\nAHD        Advanced HIV disease                       CSO    Civil Society Organization\nAIDS       Acquired Immunodeficiency Syndrome         CT     Computed Tomography\nAKTH       Aminu Kano University Teaching Hospital    CTX    Cotrimoxazole\nALP        Alkaline Phosphatase                       CXR    Chest X-Ray\nALT        Alanine Transaminase                       D4T    Stavudine\nANC        Antenatal Care                             DAA    Directly Acting Antiviral\nAPIN       AIDS Prevention Initiative in Nigeria      DBS    Dried Blood Spot\nARM        Artificial Rupture of Membrane             Ddl    Didanosine\nART        Antiretroviral Therapy                     DHOS   Department of Hospital Services\nARV        Antiretroviral drugs                       DLV    Delavirine\nAST        Aspartase Transaminase                     DNA    Deoxyribonucleic Acid\nASWHAN     Association of Women Living with           DOTS   Direct Observed Treatment Short Course\n           HIV/AIDS in Nigeria                        DRESS  Drug Reaction, Eosinophilia,", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1510, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "075b3b31-93dd-460c-bf5f-6d6aa56bbda9": {"__data__": {"id_": "075b3b31-93dd-460c-bf5f-6d6aa56bbda9", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "8"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "ab0e4de8-321c-4733-af3a-5eae30cfe581", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "8"}, "hash": "f109b8d5ef41a576fc59a890518e35b670b39faeb163d20801a34301e891c6c9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "66cd5319-fa32-41da-a606-1844b15b8e67", "node_type": "1", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "8"}, "hash": "8975a2680112c1d60f64e29962348830a6643c91ba1e8e49a4c6baf31dfee2bb", "class_name": "RelatedNodeInfo"}}, "text": "Eosinophilia, Systemic\nATV/r      ritonavir boosted Atazanavir                      Symptoms\nAUC        Area under the curve                       DRV/r  Ritonavir boosted Darunavir\nUATH       University of Abuja Teaching Hospital      DRTB   Drug Resistant Tuberculosis\nAZT        Zidovudine                                 DTG    Dolutegravir\nc-ART      Combination ART                            ED     Erectile Dysfunction\nCD4+       Cluster of Differentiation Antigen 4       EFV    Efavirenz\nCDC        Centres for Disease Control                EID    Early Infant Diagnosis\nCFCC       Client and Family Centred Care             ELISA  Enzyme Linked Immunosorbent Assay\nCHAI       Clinton Health Access Initiative           Emtct  Elimination of Mother to child\n                                                             transmission of HIV\nCHEW       Community Health Extension Worker          ENT    Ear Nose Throat\nCIHP       Centres for Integrated Health Programs     EPTB   Extra Pulmonary Tuberculosis\nCiSHAN     Civil Society for HIV/AIDS in Nigeria      EQA    External Quality Assurance\nCKD        Chronic Kidney Disease                     ESRD   End Stage Renal Disease\nCmax       Maximum Concentration                      ETR    Etravirine\nCMS        Central Medical Stores Oshodi              ECV    External Cephalic Version\nCMV        Cytomegalovirus                            EVG    Elvitegravir\nCNS        Central Nervous System                     FBO    Faith based Organization\nCOBI       Cobicistat                                 FBS    Fasting Blood Sugar\nCOPD       Chronic Obstructive Pulmonary Disease      FCT    Federal Capital Territory\nCPK        Creatinine Phospokinase                    FCTA   Federal Capital Territory Administration\nCPT        Cotrimoxazole preventive Therapy           FDC    Fixed Dose Combination\n         NATIONAL GUIDELINES FOR HIV PREVENTION TREATMENT AND CARE 2020           vi", "mimetype": "text/plain", "start_char_idx": 1497, "end_char_idx": 3444, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d68ecb37-d7a8-4b80-9569-3e9260496f62": {"__data__": {"id_": "d68ecb37-d7a8-4b80-9569-3e9260496f62", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "9"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "3ae57e02-320a-452e-93c4-fdd7d303e773", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "9"}, "hash": "d25e58c49ac51988efc5bea61e3efc4c51c84f50fd36e37afa86cc0490979ba1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b1ce24d4-aa5f-4ebf-96a3-6a94fa983f2b", "node_type": "1", "metadata": {}, "hash": "1537d043999de8d3872430846d8ba5bdac9b76ac393697f43c9253eab50bf7e6", "class_name": "RelatedNodeInfo"}}, "text": "FETH       Federal Teaching Hospital               LUTH        Lagos University Teaching Hospital\nFMC        Federal Medical Centre                  M&E         Monitoring and Evaluation\nFMOH       Federal Ministry of Health              MAC         Mycobacterium Avium Complex\nFP         Family Planning                         MARPs       Most at Risk Populations\nFPV        Fosamprenavir                           MCH         Maternal and Child Health\nFTC        Emtricitabine                           MLSCN       Medical Laboratory Science Council\nGFR        Glomerular Filtration Rate              MNCH        of Nigeria\n                                                               Maternal, Newborn and Child Health\nHAART      Highly Active Antiretroviral Therapy    MOH         Ministry of Health\nHb         Haemoglobin                             MP          Malaria Parasites\nHbsAg      Hepatitis B surface Antigen             MTB         Multidrug Resistance TB\nHBV        Hepatitis B Virus                       MTCT        Mother to Child Transmission\nHCT        HIV Counselling and Testing             MUAC        Mid Upper Arm Circumference\nHCV        Hepatitis C Virus                       NACA        National Agency for the Control of AIDS\nHCW        Health Care Worker                      NACS        Nutrition Assessment Counselling\nHIV        Human Immunodeficiency Virus            NARH        and Support\nHLA", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1435, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b1ce24d4-aa5f-4ebf-96a3-6a94fa983f2b": {"__data__": {"id_": "b1ce24d4-aa5f-4ebf-96a3-6a94fa983f2b", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "9"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "3ae57e02-320a-452e-93c4-fdd7d303e773", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "9"}, "hash": "d25e58c49ac51988efc5bea61e3efc4c51c84f50fd36e37afa86cc0490979ba1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d68ecb37-d7a8-4b80-9569-3e9260496f62", "node_type": "1", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "9"}, "hash": "cdd13fd085dad0d7b51599d100b5696b95f852e365f85d267cfb01ec813dd6d4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e60d60ff-1cb0-476d-9251-c41b6a0016d7", "node_type": "1", "metadata": {}, "hash": "a7b82447b923037afc0994232d450d38aac1cbc007f3479609d8e1cfd3981cde", "class_name": "RelatedNodeInfo"}}, "text": "Nutrition Assessment Counselling\nHIV        Human Immunodeficiency Virus            NARH        and Support\nHLA        Human Leucocyte Antigen                             National AIDS and Reproductive\n                                                               Health Survey\nHPV        Human Papilloma Virus                   NASCP       National AIDS and STIs Control\nHSR        Hypersensitivity Reaction               NAUTH       Programmed\n                                                               Nnamdi Azikiwe University Teaching\nHSV        Herpes Simplex Virus                    NBBFSW      Hospital\nHTS        HIV Testing Services                    NEPWHAN     Non-Brothel Based Female Sex Worker\nHU-PACE    Howard University Pharmacy and                      Network of People Living with HIV\n           continuing Education                    NFV", "mimetype": "text/plain", "start_char_idx": 1324, "end_char_idx": 2191, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e60d60ff-1cb0-476d-9251-c41b6a0016d7": {"__data__": {"id_": "e60d60ff-1cb0-476d-9251-c41b6a0016d7", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "9"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "3ae57e02-320a-452e-93c4-fdd7d303e773", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "9"}, "hash": "d25e58c49ac51988efc5bea61e3efc4c51c84f50fd36e37afa86cc0490979ba1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b1ce24d4-aa5f-4ebf-96a3-6a94fa983f2b", "node_type": "1", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "9"}, "hash": "1e1b30908e660bed78e504d829673bcaac1d0d7ab159c07bc664dcc96f024a6d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "dc913588-6fa4-4b63-82fe-638a6c62b661", "node_type": "1", "metadata": {}, "hash": "f10540ff4a3566fcd2b8adff10a9a9bc003dfaf3085f9804dc6b3e78916430eb", "class_name": "RelatedNodeInfo"}}, "text": "Network of People Living with HIV\n           continuing Education                    NFV         in Nigeria\nIBBSS      Integrated Biological Behavioural       NIMR        Nelfinavir\n           Sentinel Survey                         NNRTI       Nigeria Institute of Medical Research\nIDV        Indinavir                                           Non-Nucleoside Transcriptase Inhibitors\nIHVN       Institute of Human Virology Nigeria     NPHCDA      National Primary Health Care\nINH        Isoniazid                               NRTI        Development Agency\nINSTI      Integrase Strand Transfer inhibitor                 Nucleoside Reverse Transcriptase\n                                                               Inhibitors\nIPT        Isoniazid Preventive Therapy            NSAIDS      Non-SteroidalAnti-Inflammatory Drugs\nIPV        Intramuscular Polio Vaccine             NTTA        National Task Team on ART\nIRIS", "mimetype": "text/plain", "start_char_idx": 2103, "end_char_idx": 3026, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "dc913588-6fa4-4b63-82fe-638a6c62b661": {"__data__": {"id_": "dc913588-6fa4-4b63-82fe-638a6c62b661", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "9"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "3ae57e02-320a-452e-93c4-fdd7d303e773", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "9"}, "hash": "d25e58c49ac51988efc5bea61e3efc4c51c84f50fd36e37afa86cc0490979ba1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e60d60ff-1cb0-476d-9251-c41b6a0016d7", "node_type": "1", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "9"}, "hash": "e2c5ee48e2e421c6c1fc902115fab16c1a1e6510ace3e3567f58ec73ecd45d9e", "class_name": "RelatedNodeInfo"}}, "text": "Intramuscular Polio Vaccine             NTTA        National Task Team on ART\nIRIS       Immune Reconstitution inflammatory      NVP         Nevirapine\nJUTH       Syndrome                                OIs         Opportunistic infections\nLF-LAM     Jos University Teaching Hospital        Pap         Papanicolaou Test for cervical\n           Lateral Flow Lipoarabinomannan                      cancer screening\nLGBTI      Lesbian, Gay Bisexual Transgender and   PCR         Polymerase Chain Reaction\nLIP        Intersex                                PCV         Packed Cell Volume\nLMCU       Lymphoid Interstitial Pneumonia         PDSA cycle  Plan, Do, Study, Act\nLMIS       Logistic Management Coordinating Units  PEP         Post Exposure Prophylaxis\nLP         Logistic Management Information System PEPFAR       US President Emergency Plan For\n           Lumbar Puncture                                     AIDS Relief\nLPV/r      Lopinavir/ritonavir                     PHC      Primary Health Care\n          NATIONAL GUIDELINES FOR HIV PREVENTION TREATMENT AND CARE 2020                vii", "mimetype": "text/plain", "start_char_idx": 2944, "end_char_idx": 4043, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fabd3392-dc0a-430e-b01e-af8c62102ead": {"__data__": {"id_": "fabd3392-dc0a-430e-b01e-af8c62102ead", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "10"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "3940fa73-df36-4c12-ac50-d8eeb5b80b07", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "10"}, "hash": "a6e4d12cbded543885bcbc4381eb4fb91814145deb18c837c73466af990194d0", "class_name": "RelatedNodeInfo"}}, "text": "PHDP      Positive Health Dignity and Prevention  tARVp    Triple Antiretroviral Drug Prophylaxis\nPI        Protease Inhibitor                      TB       Tuberculosis\nPI/r      Ritonavir boosted Protease Inhibitor    TDF      Tenoforvir\nPITC      Provider Initiated HIV Testing and      TPT      Tuberculosis Preventive Therapy\n          Counselling                             TPV      Tipranavir\nPJP       Pneumocystis Jiroveci Pneumonia\nPLHIV     People Living with HIV                  TT       Tetanus Toxoid\nPME       Programme Monitoring and Evaluation     UBTH     University of Benin Teaching Hospital\nPMM       Patient Management and Monitoring       UCH      University College Hospital Ibadan\nPMTCT     Prevention of Mother to Child           UCTH     University of Calabar Teaching Hospital\n          Transmission                            UNAIDS   Joint United Nations Programme on\nPrEP      Pre-Exposure Prophylaxis                         HIV/AIDS\nQA        Quality Assurance                       UNICEF   United Nations Children Emergency Fund\nQI        Quality Improvement                     UNN      University of Nigeria\nRAL       Raltegravir                             UNTH     University of Nigeria Teaching Hospital\nRNA       Ribonucleic Acid                        USAID    United States Agency for International\nRTI       Reproductive Tract Infection                     Development\n                                                  VIA      Visual Inspection Acetic Acid for cervical\nRVP       Rilpivirine                             VL       cancer screening\nSACA      State Agency for the Control of AIDS    WBC      Viral Load\nSQV       Saquinavir                                       White Blood Cell\nSTI       Sexually Transmitted Infection          WHO      World Health Organization\n         NATIONAL GUIDELINES FOR HIV PREVENTION TREATMENT AND CARE 2020                   viii", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1918, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "71cde287-8a10-4ff9-a726-242eff8874a5": {"__data__": {"id_": "71cde287-8a10-4ff9-a726-242eff8874a5", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "11"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "349a13db-2381-4ea4-b093-f882978006d5", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "11"}, "hash": "14d72c800a5750ce935d747ede593f0a301fd68d051158baf46d38db663ee9f0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e17bbb93-259c-4fc1-8bb3-0c21fe858b69", "node_type": "1", "metadata": {}, "hash": "a0a7664c6bf34f7385704d87ebcedab296d97786f37ae75cc5a9a43169fbffa0", "class_name": "RelatedNodeInfo"}}, "text": "Definition of Terms\nHIV-Retesting: This is a second HIV test conducted after a positive first test result. Re-testing is\nrecommended before initiation ofART.\nHIV sero-discordant couples: Sexual relationship in which one partner is HIV positive and the\nother HIV negative.\nKey populations: These are groups of individuals who bear a high burden of HIV and are\nexposed to a higher risk of acquiring the infection.\nARVs: These are medicines used to treat HIV.\nART: This is the use of a combination of three or more ARVs to treat HIV in order to achieve\nbetter viral suppression. Highly active anti-retroviral therapy (HAART) or combination Anti-\nRetroviral Therapy (cART) is used interchangeably.\nViral load: It is the number of HIV RNAcopies in a millilitre of plasma.\nSustained viral suppression: This is an optimal response to ART such that the viral load\nremains below the detection threshold usually at less than 20 copies of HIV RNA/ml.\nStable on ART: These are PLHIV who have received ART for at least one year and have no\nadverse drug reactions that require regular monitoring, no current illnesses, have a good\nunderstanding of lifelong adherence with evidence of treatment success (i.e. two consecutive\nviral load measurements below 1000 copies/mL).\nClinical failure in adults and adolescents: It is the presence of new or recurrent clinical event\nindicating severe immunodeficiency (WHO clinical stage 4 condition) following 6 months of\neffective treatment.\nClinical failure in Children: It is the presence of new or recurrent clinical event indicating\nadvanced or severe immunodeficiency (WHO clinical stage 3 and 4 clinical condition with the\nexception of TB) after 6 months of effective treatment.\nImmunological failure in adults and adolescents: This is when the CD4+ cell count fall to or\nbelow pre-treatment baseline value or persistent CD4 levels below 100 cells/mm or 50% decline\n                                                                             3\nfrom on-therapy CD4+ cell count peak level.\nImmunological failure in Children younger than 5 years: It is persistent CD4 levels below\n200 cells/mm or <10%.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2130, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e17bbb93-259c-4fc1-8bb3-0c21fe858b69": {"__data__": {"id_": "e17bbb93-259c-4fc1-8bb3-0c21fe858b69", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "11"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "349a13db-2381-4ea4-b093-f882978006d5", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "11"}, "hash": "14d72c800a5750ce935d747ede593f0a301fd68d051158baf46d38db663ee9f0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "71cde287-8a10-4ff9-a726-242eff8874a5", "node_type": "1", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "11"}, "hash": "9eaa1d21831014ed035446aed2f4600400bfcda3462013f369394a20ce451581", "class_name": "RelatedNodeInfo"}}, "text": "Immunological failure in Children younger than 5 years: It is persistent CD4 levels below\n200 cells/mm or <10%.\n              3\nImmunological failure in Children older than 5 years: It is persistent CD4 levels below 100\ncells/mm\u00b3\n           NATIONAL GUIDELINES FOR HIV PREVENTION TREATMENT AND CARE 2020            ix", "mimetype": "text/plain", "start_char_idx": 2019, "end_char_idx": 2336, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "25f2c40a-3b24-4c47-83f8-d60f86e55a12": {"__data__": {"id_": "25f2c40a-3b24-4c47-83f8-d60f86e55a12", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "12"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "d5b7f9bd-c988-4ad1-a3c2-0bf105a1c0ee", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "12"}, "hash": "c685229040fec33c7c33e3b99a8adac368e05bd30e6ad792c7b338836e9a68ff", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d16f899c-3ca5-45a6-b8c2-019a8fa6580b", "node_type": "1", "metadata": {}, "hash": "85424f4d2678751d8437491e8aad9315f26d05eb0effed3cdad5fa6c16c06f63", "class_name": "RelatedNodeInfo"}}, "text": "Virologic failure: It is a persistently detectable viral load exceeding 1000 copies/ml (that is, 2\nconsecutive viral load measurements within a 3-month interval, with adherence support between\nmeasurements) after at least six months of usingARV drugs.\nPharmacovigilance in HIV: This is also known as drug safety. It is the collection, detection,\nassessment, monitoring, and prevention of adverse effects in patients on antiretroviral drugs and\nother medicines associated with the management of HIV/AIDS.\nAdherence to ART: It is the extent to which a PLHIV      behaviour coincides with the ART\nregimen as agreed through mutual decision-making between the PLHIV and the adherence\ncounsellor.\nMTCT of HIV: This is mother to child transmission of HIV, which can occur in pregnancy,\nlabour and delivery, or through breastfeeding.\nPMTCT: Prevention of mother to child transmission of HIV is the strategy for ensuring that HIV\ninfection is not transmitted to an infant during pregnancy and lactation period\nHIV-exposed infants:These are infants delivered to HIV positive women.\nHigh-risk infants: These are infants delivered to HIV positive women with an increased risk\nof viral transmission. These women may not have had ARVs or have had less than 4 weeks of\nARV or have a viral load of greater than 1000copies/ml in the last month prior to delivery.\nInfant ARV prophylaxis: These are ARVs administered to all HIV exposed infants to prevent\nthem from acquiring HIV infection.\nEID: Early infant diagnosis of HIV is the testing of all HIV exposed babies to determine their\nHIV infection status by detecting the presence of HIV DNAusing PCR.\nDBS: Dried blood spot testing (DBS) is a form of biosampling where blood samples are blotted\nand dried on filter paper. The dried samples can easily be shipped to an analytical laboratory and\nanalysed using various methods such as DNAamplification.\nPCR DNA: Polymerase chain reaction is the use of an enzyme to multiply both HIV DNA and\nRNAin blood sample.\nPrEP: It is the use of oral ARVs to prevent HIV infection in individuals exposed to high risk of\nacquiring HIV.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2102, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d16f899c-3ca5-45a6-b8c2-019a8fa6580b": {"__data__": {"id_": "d16f899c-3ca5-45a6-b8c2-019a8fa6580b", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "12"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "d5b7f9bd-c988-4ad1-a3c2-0bf105a1c0ee", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "12"}, "hash": "c685229040fec33c7c33e3b99a8adac368e05bd30e6ad792c7b338836e9a68ff", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "25f2c40a-3b24-4c47-83f8-d60f86e55a12", "node_type": "1", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "12"}, "hash": "1ac618971c9a01b78926fdd6b53804b0d1a9b8eeb284ba8d616c37f6df3bc0a5", "class_name": "RelatedNodeInfo"}}, "text": "PrEP: It is the use of oral ARVs to prevent HIV infection in individuals exposed to high risk of\nacquiring HIV.\nPEP: It is the use of oral ARVs by individuals exposed to HIV in order to block the acquisition of\nHIV.\nTB Preventive Therapy: TB Preventive Therapy (TPT), previously referred to as Isoniazid\npreventive therapy (IPT) is the treatment offered to individuals who are considered to be at risk of\ndeveloping active TB disease, in order to reduce that risk. It is also referred to as the treatment of\n          NATIONAL GUIDELINES FOR HIV PREVENTION TREATMENT AND CARE 2020           x", "mimetype": "text/plain", "start_char_idx": 1991, "end_char_idx": 2583, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f9f78d36-11b6-4d59-8693-eb1dc862091c": {"__data__": {"id_": "f9f78d36-11b6-4d59-8693-eb1dc862091c", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "13"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "035a0d1f-18d5-423e-a9b7-ee78ba2be488", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "13"}, "hash": "c3b3f4871aa84ad94f3117de49ba37b5de9c83899666fa2873c5b041dd5464be", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3fb203e3-7841-4564-ac7d-8e06dd9c751c", "node_type": "1", "metadata": {}, "hash": "cc192170f38c69bd937b16c714edc44b159a2053a82944ce88504561299e7b04", "class_name": "RelatedNodeInfo"}}, "text": "Latent TB Infection (LTBI) .\nCPT: Cotrimoxazole preventive therapy is the routine administration of cotrimoxazole in all\nHIV positive individuals to prevent the development of a variety of infections.\nCo-infection:      Co-infection is the spontaneous existence of two or more infections in an\nindividual.\nCo-morbidity: Co-morbidity is the occurrence of one or more illnesses in an individual with a\nprimary disease.\nOpportunistic infection:       Opportunistic infections (OIs) are infections that occur more\nfrequently and can become severe in individuals with HIV when their immune system becomes\nweakened.\nDifferentiated care: Differentiated care is the delivery of a minimum package of HIV/AIDS\ntreatment care and support services according to the diversity of the care needs for people living\nwith HIV.\nDecentralization in the context of HIV:           Decentralization is the devolution of part\nresponsibility for the offer of HIV treatment and care from the tertiary and secondary level ART\ncentres to the primary level health facilities.\nRetention in HIV care: It is the number of individuals on ART who are retained in the same\nfacility or are transferred out to another facility offeringART services over a period of time.\nLinkage to HIV prevention, care, treatment and support: Proportion/number of individuals\nwho complete a medical visit within 3 months of the diagnosis of HIV\nTask shifting/sharing: It is a rational redistribution of tasks among health workforce teams,\nallowing a wider range of cadres to offer certain services, safely and effectively as a means of\nrapidly expanding access and improving health care.\nContinuum of care: it is an integrated system of care that guides and tracks clients over time,\nthrough a comprehensive range of health services starting from screening for HIV, through to\ninitiation ofART, retention in care and psychosocial support.\nMonitoring in HIV: Monitoring in HIV is the regular observation, recording and process of\nroutinely gathering information of activities taking place in HIV programme.\nEvaluation: Evaluation in HIV is a systematic assessment which focuses on expected and\nachieved accomplishments in HIV programmes.\nHIV Data flow: Data flow is the transmission of HIV data from source (health facilities) through\nlocal governments and states data platforms to the Federal Ministry of health as the final data\nrepository.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2388, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3fb203e3-7841-4564-ac7d-8e06dd9c751c": {"__data__": {"id_": "3fb203e3-7841-4564-ac7d-8e06dd9c751c", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "13"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "035a0d1f-18d5-423e-a9b7-ee78ba2be488", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "13"}, "hash": "c3b3f4871aa84ad94f3117de49ba37b5de9c83899666fa2873c5b041dd5464be", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f9f78d36-11b6-4d59-8693-eb1dc862091c", "node_type": "1", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "13"}, "hash": "09c2a65282b5650e481c1c308726ef064b56a28928789b603e05f6d2d710d595", "class_name": "RelatedNodeInfo"}}, "text": "HIV Data flow: Data flow is the transmission of HIV data from source (health facilities) through\nlocal governments and states data platforms to the Federal Ministry of health as the final data\nrepository.\n           NATIONAL GUIDELINES FOR HIV PREVENTION TREATMENT AND CARE 2020           xi", "mimetype": "text/plain", "start_char_idx": 2184, "end_char_idx": 2475, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a7265232-49b2-45de-af78-14a9bc213cf8": {"__data__": {"id_": "a7265232-49b2-45de-af78-14a9bc213cf8", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "14"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "8cdcef1e-40b7-41a6-b303-f17a8fd785e7", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "14"}, "hash": "76da35456e7a9dcc037cdd861c86e0b8a368614b4dbd1fc02e408a63e7e9bf38", "class_name": "RelatedNodeInfo"}}, "text": "HIV Data validation: Data validation is defined as the checking of all collected HIV data for\ncompleteness, thoroughness and reasonableness, and the elimination of errors.\nData Quality Assurance: Data Quality Assurance is a routine measure to ensure quality of data\nthrough a process of validation, reliability, precision, integrity and timeliness.\n           NATIONAL GUIDELINES FOR HIV PREVENTION TREATMENT AND CARE 2020                xii", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 441, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "df41fe27-1008-4cd7-ace6-39214a032696": {"__data__": {"id_": "df41fe27-1008-4cd7-ace6-39214a032696", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "15"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "6fa5849b-43eb-44b2-b32a-bb68edeaba16", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "15"}, "hash": "18d5cd610d1966b560dac40f54f35b10ae43bbc1cf8d555d2d67e59d9c99b0c7", "class_name": "RelatedNodeInfo"}}, "text": "Table of Contents\nForeword                                                                             i\nAcknowledgements                                                                     ii\nExecutive Summary                                                                    iii\nEditorial Team                                                                       v\nAbbreviations & Acronyms                                                             vi\nDefinition of terms                                                                  ix\nTable of Contents                                                                    xiii\nCHAPTER 1 \u2013INTRODUCTION                                                              1\n1.1 Objectives of the Guidelines                                                     3\n1.2 Epidemiology of HIV in Nigeria                                                   6\n   1.2.1 HIV Transmission                                                            6\n1.3 Natural History of HIV                                                           7\n   1.3.1 Adults and Children older than 5 years                                      7\n   1.3.2 HIV in Pregnancy                                                            7\n   1.3.3 HIV infection in children under 5 years                                     8\nCHAPTER 2 - DIAGNOSIS OF HIV INFECTION                                               10\n2.1 Introduction                                                                     11\n2.2 HIV Testing Services                                                             11\n   2.2.1 Risk Stratification                                                         11\n   2.2.2 Pre -test services                                                          11\n   2.2.3 Post -test services                                                         11\n   2.2.4 Index Testing Services                                                      12\n   2.2.5 Social Network Testing                                                      13\n   2.2.6 Blended Index and Social Network Strategies                                 13\n   2.2.7 HIV Self-testing                                                            13\n   2.2.8 Recency Testing                                                             14\n2.3 HTS in Pregnancy                                                                 14\n   2.3.1 Approach to HTS in Pregnant Women                                           14\n   2.3.2 Essential Components of HTS for PMTCT                                       14\n   2.3.3 HTS for women in labour                                                     15\n   2.3.4 HTS for post-partum women                                                   15\n          NATIONAL GUIDELINES FOR HIV PREVENTION TREATMENT AND CARE 2020           xiii", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2826, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d5fe4d38-8210-4adc-aed5-7605e096ed9a": {"__data__": {"id_": "d5fe4d38-8210-4adc-aed5-7605e096ed9a", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "16"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "c5816b76-96d2-4e10-8bf4-4e39d5b65e8f", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "16"}, "hash": "9b184d204f609c77ef42d7adbe5e731c003d00214641c8d1511a99bd5ba90e77", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "88de8c8f-9fbf-4dc7-a7f1-d6450bb818dd", "node_type": "1", "metadata": {}, "hash": "7b9f418f8d90edd7600c879e8b8759b1bbee94d2288ee7f45210ce77b52698c0", "class_name": "RelatedNodeInfo"}}, "text": "2.4 Re-testing                                                                         15\n2.5 Repeat HIV Testing                                                                 15\n2.6 Disclosure Scenarios                                                               16\n2.7 Linkage of HTS to care and ART                                                     16\n2.8 Laboratory Diagnosis of HIV Infection                                              17\n    2.8.1 Antibody Assays                                                              17\n    2.8.2 Enzyme-Linked Immunosorbent Assay (ELISA) or Enzyme\n        Immunoassay (EIA) for Blood Screening                                          18\n    2.8.3 Nucleic Acid -based Testing                                                  19\n    2.8.4 HIV DNA Polymerase Chain Reaction (PCR)                                      19\n    2.8.5 Viral Load Assay - Reverse Transcriptase Polymerase Chain Reaction (RT-PCR)  19\n2.9 Laboratory Diagnosis of HIV Infection in Children by Age Group                     20\n   2.9.1 Children aged \u226418 months                                                      20\n   2.9.2 Children aged \u226518 months                                                      22\n2.10 Clinical Diagnosis and Staging of HIV Infection                                   22\nCHAPTER 3 - ANTIRETROVIRAL THERAPY                                                     26\n3.1 Introduction                                                                       27\n3.2 Classes of Antiretroviral Drugs                                                    27\n3.3.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1596, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "88de8c8f-9fbf-4dc7-a7f1-d6450bb818dd": {"__data__": {"id_": "88de8c8f-9fbf-4dc7-a7f1-d6450bb818dd", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "16"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "c5816b76-96d2-4e10-8bf4-4e39d5b65e8f", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "16"}, "hash": "9b184d204f609c77ef42d7adbe5e731c003d00214641c8d1511a99bd5ba90e77", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d5fe4d38-8210-4adc-aed5-7605e096ed9a", "node_type": "1", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "16"}, "hash": "112dd9e5a7d0fe515d267f9d7f4d8caa941ce81d069d56c66e12224becc4e7a3", "class_name": "RelatedNodeInfo"}}, "text": "Preparation of Adults, Adolescents and Children for ART                           29\n     3.3.1 Baseline Assessment for ART                                                 29\n     3.3.2 Further Baseline Assessment                                                 29\n     3.3.3 Initiating ART in Adults                                                    30\n     3.3.4 Initiating ART in Adolescents (10-19 years of age)                          30\n     3.3.5 Initiation of ART in infants and children younger than 10 years of age      30\n     3.3.6 Recommendations for Use of ART in TB/HIV Co-infection                       30\n     3.3.7 Key considerations when treating PLHIV with TB:                             31\n     3.3.8 Recommendations for use of ART in HIV/Hepatitis Co-infection                32\n3.4 Recommended ART Regimen for Adults, Adolescents and Children                       33\n     3.4.1 First -line ART regimens for adults and adolescents                         33\n     3.4.2 First -line ART for children                                                33\n     3.4.3 Programming Transitioning to DTG -based regimen                             34\n3.5 Monitoring Patients on ART                                                         34\n          NATIONAL GUIDELINES FOR HIV PREVENTION TREATMENT AND CARE 2020           xiv", "mimetype": "text/plain", "start_char_idx": 1597, "end_char_idx": 2938, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "88ccce6e-b750-42c6-8219-c1ca56019a96": {"__data__": {"id_": "88ccce6e-b750-42c6-8219-c1ca56019a96", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "17"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "21922845-92f7-4b0b-9a68-565b4698a080", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "17"}, "hash": "befdb1e8cb1944f7c41a98bddc1cc5e7ec8fd7f222572416d5cb91ec2fccf124", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a696c461-b9d5-4700-885f-7c0a261d29a4", "node_type": "1", "metadata": {}, "hash": "a427872bd9e4ba1c3cf63af73b031e372ccf3d33e28faa3eb22178d6a3c60600", "class_name": "RelatedNodeInfo"}}, "text": "3.5.1 Monitoring and Follow-up in Adults                                      34\n    3.5.2 Monitoring Children and Adolescents on ART                              35\n3.6 Management of HIV Treatment Failure                                           37\n    3.6.1 Definitionof HIV Treatment Failure                                      37\n    3.6.2 Causes of HIV Treatment Failure                                         39\n    3.6.3 Substitution and switch of ARV drugs                                    40\n    3.6.4 Second-line ART Regimens                                                40\n3.7 Third-line ART                                                                42\n    3.7.1 Criteria for Switch to Third-Line ART                                   42\n    3.7.2 Operational Guidance for Third-Line ART                                 42\n3.8 Low-Level Viremia (LLV)                                                       43\n    3.8.1 Management of Low -level viremia (LLV)                                  43\n3.9 ART inSpecial Circumstances                                                   44\n    3.9.1 Kidney impairment                                                       44\n    3.9.2 Cardiomyopathy                                                          44\n    3.9.3 Osteoporosis                                                            44\nCHAPTER 4- PHARMACOVIGILANCE IN ANTIRETROVIRAL THERAPY                            47\n4.1 Introduction                                                                  48\n    4.1.1 Active Pharmacovigilance                                                48\n4.2 Pregnancy Monitoring for Patients on ARVs                                     48\n4.3 HIV Drug Resistance (HIVDR)                                                   49\n4.4 Adverse drug reactions (ADRs)                                                 49\n    4.4.1 Classification of Adverse Drug Reactions (ADRs)                         49\n4.5 Drug toxicity                                                                 50\n    4.5.1 Laboratory monitoring of toxicity:                                      50\n4.6 Steps to Recognize ADRs                                                       54\n4.7 Who is to Report ADRs?                                                        54\n4.8 What ADRs Should be Reported?", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2324, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a696c461-b9d5-4700-885f-7c0a261d29a4": {"__data__": {"id_": "a696c461-b9d5-4700-885f-7c0a261d29a4", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "17"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "21922845-92f7-4b0b-9a68-565b4698a080", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "17"}, "hash": "befdb1e8cb1944f7c41a98bddc1cc5e7ec8fd7f222572416d5cb91ec2fccf124", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "88ccce6e-b750-42c6-8219-c1ca56019a96", "node_type": "1", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "17"}, "hash": "d103dc12088aefcfb87e9133a1cf8c07e1b807276707c8c93cdec268b4237c25", "class_name": "RelatedNodeInfo"}}, "text": "54\n4.8 What ADRs Should be Reported?                                                 54\n4.9 Pharmacovigilance Data Collection and Reporting Process                       55\n4.10 Principles of Management of Adverse Drug Reactions                           55\n    4.10.1 Management of Specific ARV Adverse Drug Reactions                      57\n4.1 1 Prevention of Adverse Drug Reactions                                        61\n4.1 2 ARV Drug Interactions                                                       62\n          NATIONAL GUIDELINES FOR HIV PREVENTION TREATMENT AND CARE 2020         xv", "mimetype": "text/plain", "start_char_idx": 2288, "end_char_idx": 2884, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1c48043f-2b2d-4c05-bf46-ecb25c7de621": {"__data__": {"id_": "1c48043f-2b2d-4c05-bf46-ecb25c7de621", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "18"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "db116fb9-dbdf-4caf-a9e7-41830ec22cd7", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "18"}, "hash": "7fab19cde28471ef2ed8af3fb8032c3c08459858200f23ce3de86028ed125317", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2a2c3453-2be4-4058-a91f-168c1e73e4a3", "node_type": "1", "metadata": {}, "hash": "35426057f20bcad2b23541a6871913621530fc3e31dc1b5a0ddcde20e6c9da5b", "class_name": "RelatedNodeInfo"}}, "text": "4.12.1 Interactions Between Contraceptives and Antiretroviral Drugs                   62\nCHAPTER 5 -ADHERENCE TO ANTIRETROVIRAL THERAPY                                            65\n5.1 Introduction                                                                          66\n5.2 Adherence Preparation for ART                                                         66\n5.3 On-going adherence for clients on ART                                                 67\n5.4 Monitoring of Adherence                                                               67\n   5.4.1 Factors known to improve adherence                                               68\n   5.4.2 Factors associated with poor adherence                                           68\n   5.4.3 Adherence in Specific Populations                                                69\n   5.4.4 Recommendations for improving adherence                                          70\nCHAPTER 6 -PREVENTION OF MOTHER TO CHILD\n            TRANSMISSION OF HIV INFECTION                                                 72\n6.1 Introduction                                                                          73\n6.2 Mother-to-Child Transmission of HIV                                                   73\n   6.2.1 Prevention of MTCT                                                               74\n   6.2.2 Benefit of PMTCT                                                                 77\n6.3 Pre-ART Care for HIV-positive pregnant women                                          78\n   6.3.1 Initial evaluation of HIV pregnant women                                         78\n   6.3.2 Initial Clinical Examination of HIV Positive Pregnant Women                      78\n   6.3.3 Laboratory Investigation of HIV Positive Pregnant Women                          79\n   6.3.4 Syphilis testing for pregnant women                                              80\n6.4 Use of Antiretroviral Therapy for PMTCT                                               80\n   6.4.1 Recommended first-line regimen for pregnant and breastfeeding women.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2067, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2a2c3453-2be4-4058-a91f-168c1e73e4a3": {"__data__": {"id_": "2a2c3453-2be4-4058-a91f-168c1e73e4a3", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "18"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "db116fb9-dbdf-4caf-a9e7-41830ec22cd7", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "18"}, "hash": "7fab19cde28471ef2ed8af3fb8032c3c08459858200f23ce3de86028ed125317", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1c48043f-2b2d-4c05-bf46-ecb25c7de621", "node_type": "1", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "18"}, "hash": "f7ef97d4621609f7d02b8c8e77bddde5051545623b4a8fe210c583fe77999c36", "class_name": "RelatedNodeInfo"}}, "text": "80\n   6.4.2 ARV prophylaxis for the HIV exposed infant                                       80\n   6.4.3 Cotrimoxazole Prophylaxis for HIV exposed infants                                81\n   6.4.4 Antenatal Care for HIV positive preg nant women                                  82\n6.5 Management of HIV positive women in labour, delivery and within 72 hours of delivery  82\n   6.5.1 Induction of Labour                                                              83\n   6.5.2 Conduct of Delivery                                                              83\n   6.5.3 Vaginal Delivery                                                                 83\n   6.5.4 Caesarean Section (CS)                                                           83\n   6.5.5 Specific Modification of Obstetric Care for HIV Positive Women                   84\n         NATIONAL GUIDELINES FOR HIV PREVENTION TREATMENT AND CARE 2020    xvi", "mimetype": "text/plain", "start_char_idx": 2080, "end_char_idx": 2998, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1ec4f19e-06bf-4ae4-b452-0538f409061a": {"__data__": {"id_": "1ec4f19e-06bf-4ae4-b452-0538f409061a", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "19"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "5837ff70-24ca-44c6-8fe1-5781c60ab4a4", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "19"}, "hash": "012bf56d9e1c62605ce38016bc04f49f497974c0820262535026efcbd860647c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1fdd53db-e9b6-484a-ab14-0a483d2cb0e3", "node_type": "1", "metadata": {}, "hash": "7637380136e3efcb61aab689b6596f0bcb64a1c0268be73edf510469a276d451", "class_name": "RelatedNodeInfo"}}, "text": "6.6  PMTCT/TB integration services                                                  84\n    6.6.1 Pregnant women with TB and HIV co-infection                               84\n    6.6.2 Infection Control                                                         86\n    6.6.3 Management of Newborn of a Mother/ Household contacts with LTBI           86\n6.7 Care and Support of the HIV-Exposed Infant                                      86\n    6.7.1 Immediate and on-going care of the new-born of HIV positive women         86\n    6.7.2 Infant feeding in the context of HIV                                      87\n    6.7.3 Early Infant Diagnosis (EID)                                              87\n    6.7.4 Childhood Immunizations in the Context of HIV                             87\n6.8 Special Considerations for Adolescent and Young Women in PMTCT                  90\n6.9 Linkage of PMTCT with comprehensive HIV Treatment, Care and Support\n    Services for Mothers and Infants                                                 91\n    6.9.1 Engagement of Non-Formal Health Actors (NFHA) in the (referral and Linkage)\n        of PMTCT services                                                            91\nCHAPTER 7- PREVENTIVE MANAGEMENT IN HIV                                              93\n7.1 Introduction                                                                     94\n    7.1.1 Combination prevention / Minimum Prevention Package Intervention (MPPI)    94\n7.2 Pre-Exposure Prophylaxis                                                         95\n    7.2.1 Criteria for PrEP initiation                                               95\n    7.2.2 PrEP minimum package                                                       95\n    7.2.3 PrEP effectiveness                                                         95\n    7.2.4 Approved drugs for PrEP                                                    95\n    7.2.5 PrEP administration guidance                                               96\n    7.2.6 Daily PrEP and Event -Driven PrEP                                          96\n    7.2.7 PrEP for Serodiscordant Couples                                            96\n    7.2.8 Settings where PrEP can be accessed                                        96\n    7.2.9 Contraindications for PrEP                                                 97\n    7.2.10 Client follow-up                                                          97\n    7.2.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2444, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1fdd53db-e9b6-484a-ab14-0a483d2cb0e3": {"__data__": {"id_": "1fdd53db-e9b6-484a-ab14-0a483d2cb0e3", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "19"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "5837ff70-24ca-44c6-8fe1-5781c60ab4a4", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "19"}, "hash": "012bf56d9e1c62605ce38016bc04f49f497974c0820262535026efcbd860647c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1ec4f19e-06bf-4ae4-b452-0538f409061a", "node_type": "1", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "19"}, "hash": "eca35b03ee81f1db975f3ddd27e428cb8d1912a168231557d933ddd862a58267", "class_name": "RelatedNodeInfo"}}, "text": "8 Settings where PrEP can be accessed                                        96\n    7.2.9 Contraindications for PrEP                                                 97\n    7.2.10 Client follow-up                                                          97\n    7.2.11 PrEP discontinuation                                                      99\n7.3 Post -Exposure Prophylaxis                                                       99\n    7.3.1 Post-Exposure Prophylaxis for Occupational HIV exposure                    99\n    7.3.2 Evaluation for Post-Exposure Prophylaxis                                   100\n    7.3.4 Determination of Risk and ARV drugs for PEP                                100\n          NATIONAL GUIDELINES FOR HIV PREVENTION TREATMENT AND CARE 2020           xvii", "mimetype": "text/plain", "start_char_idx": 2180, "end_char_idx": 2965, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "be259450-aec9-4e34-aa9a-2bbcb2bc03a5": {"__data__": {"id_": "be259450-aec9-4e34-aa9a-2bbcb2bc03a5", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "20"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "6408426f-40e8-4fbb-afcf-d90b4b419a1f", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "20"}, "hash": "cd491786ed7b0be7a2f9cdfc2a6d7c40b8d05dc5c69303cfc45da3a3ca921345", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "47c01386-5879-48ed-a39b-70a263ea3222", "node_type": "1", "metadata": {}, "hash": "8102f5bfe138ac905543cff7493d21b78c32c916df906cab8355777a68354091", "class_name": "RelatedNodeInfo"}}, "text": "7.3.5 Recommendations for PEP                                                    100\n    7.3.6 Recommended Drug Combinations for PEP                                      101\n 7.4 Post-Sexual Assault Exposure Prophylaxis                                        102\n    7.4.1 Recommendations                                                            103\n    7.4.2 Clinical considerations                                                    103\n 7.5 Interventions for Key Populations                                               104\n    7.5.1 Recommended comprehensive prevention package of\n         Interventions for key populations                                           104\n 7.6 Condom availability and promotion for HIV programme                             105\n    7.6.1 Elements of Condom Programing                                              105\n    7.6.2 Key Steps in Condom Programing                                             106\n7.7 Gender -Based Violence                                                           106\n    7.7.1 GBV Prevention                                                             107\n    7.7.2 GBV Case Identification and First-line Support Recommendations             107\n    7.7.3 GBV Clinical Response Recommendations                                      107\n7.8 Management of Sexually Transmitted Infections (STIs)                             108\n    7.8.1 Objectives of STIs/RTIs management                                         108\n    7.8.2 Components of syndromic management                                         108\n    7.8.3 Prevention of STIs/RTIs                                                    108\n7.9 Prevention for Adolescent and Young Persons (AYPs)                               109\n    7.9.1 Harm Reduction program                                                     109\n    7.9.2 Cervical Cancer Prevention                                                 110\nCHAPTER 8-ADVANCED HIV DISEASE, OPPORTUNISTIC INFECTIONS,\n            AND CO-MORBIDITIES                                                       112\n8.1 Advanced HIV Disease                                                             113\n    8.1.1 Introduction                                                               113\n    8.1.2 Definition of advanced HIV disease                                         114\n    8.1.3 Components of AHD package of care                                          115\n    8.1.4 Diagnostics for AHD and associated OIs                                     115\n    8.1.5 Management of opportunistic infections in AHD                              117\n    8.1.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2612, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "47c01386-5879-48ed-a39b-70a263ea3222": {"__data__": {"id_": "47c01386-5879-48ed-a39b-70a263ea3222", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "20"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "6408426f-40e8-4fbb-afcf-d90b4b419a1f", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "20"}, "hash": "cd491786ed7b0be7a2f9cdfc2a6d7c40b8d05dc5c69303cfc45da3a3ca921345", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "be259450-aec9-4e34-aa9a-2bbcb2bc03a5", "node_type": "1", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "20"}, "hash": "962f983c0138c554dee553c197ee4cef7c1d4a4a4809941e7289a11ad4724b3d", "class_name": "RelatedNodeInfo"}}, "text": "1.4 Diagnostics for AHD and associated OIs                                     115\n    8.1.5 Management of opportunistic infections in AHD                              117\n    8.1.6 ART Initiation and Intensive Adherence Support for Patients with AHD       121\n    8.1.7 Vaccination for People with AHD                                            122\n    8.1.8 Immune Reconstitution Inflammatory syndrome (IRIS)                         123\n          NATIONAL GUIDELINES FOR HIV PREVENTION TREATMENT AND CARE 2020           xviii", "mimetype": "text/plain", "start_char_idx": 2432, "end_char_idx": 2959, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "973447f0-7edf-497d-80f4-27f6da1dbe8e": {"__data__": {"id_": "973447f0-7edf-497d-80f4-27f6da1dbe8e", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "21"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "1f5e5fb4-4ef3-40d3-beba-01b553677604", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "21"}, "hash": "3e9c0a1831dd0056a1c156ed147d358e8ce0a412e5cc748eebace3ecbd537cfe", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0a58930e-29c2-474b-882a-283d5d830df4", "node_type": "1", "metadata": {}, "hash": "d58c565fc85833d18d29a129c55ab36f7f4a741172f48b54cb4ba684d0b4ed08", "class_name": "RelatedNodeInfo"}}, "text": "8.1.9 Management of AHD among Children less than ten years                  124\n8.2 Other Opportunistic Infections (OIs)                                       126\n8.3 Preventing Opportunistic Infections (OIs)                                  126\n   8.3.1 Cotrimoxazole Preventive Therapy (CPT)                                127\n   8.3.2 Tuberculosis Preventive Treatment (TPT)                               128\n8.4 HIV-RELATED CO-MORBIDITIES                                                 146\n    8.5 Mental Health and HIV                                                  146\n   8.5.1 Recommendations                                                       146\n   8.5.2 Management Considerations                                             147\nCHAPTER 9 -SERVICE DELIVERY                                                    149\n9.1 Introduction                                                               150\n9.2 Differentiated Service Delivery                                            150\n    9.2.1 Differentiated HIV Testing Service Delivery                          151\n    9.2.2 Differentiated ART Service Delivery                                  151\n    9.2.3 Differentiated Service Delivery Based on Clinical Characteristics    153\n    9.2.4 Differentiated Service Delivery based on Sub-Populations             155\n    9.2.5 Differentiated Service Delivery Based on Context                     161\n    9.2.6 Integration of Service Delivery                                      161\n    9.2.7 Family-Centred Differentiated Service Delivery                       162\n9.3 Standards for Quality HIV Service Delivery                                 163\n    9.3.1 Standards of Care                                                    163\n    9.3.2 Standard Precautions                                                 166\n9.4 Nutrition                                                                  167\n    9.4.1 Nutrition in HIV Positive Pregnant and Lactating Woman               167\n    9.4.2 Nutrition in Children Living with HIV                                167\n    9.4.3 Nutrition and Antiretroviral Therapy                                 169\n9.5 Service Delivery for Adolescents Living with HIV                           169\n    9.5.1 Adolescent Friendly Health Service                                   169\n    9.5.2 Package of services for adolescents living with HIV                  170\n    9.5.4 Psychosocial support for adolescents living with HIV                 172\n    9.5.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2495, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0a58930e-29c2-474b-882a-283d5d830df4": {"__data__": {"id_": "0a58930e-29c2-474b-882a-283d5d830df4", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "21"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "1f5e5fb4-4ef3-40d3-beba-01b553677604", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "21"}, "hash": "3e9c0a1831dd0056a1c156ed147d358e8ce0a412e5cc748eebace3ecbd537cfe", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "973447f0-7edf-497d-80f4-27f6da1dbe8e", "node_type": "1", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "21"}, "hash": "3105931f460e06cfc618e55736e5746c2d18306ba9d531cb48384adf03cc9d54", "class_name": "RelatedNodeInfo"}}, "text": "5.2 Package of services for adolescents living with HIV                  170\n    9.5.4 Psychosocial support for adolescents living with HIV                 172\n    9.5.5 Transitioning to adult care                                          172\n    9.5.6 Peer-driven adolescent service delivery models                       174\n          NATIONAL GUIDELINES FOR HIV PREVENTION TREATMENT AND CARE 2020      xix", "mimetype": "text/plain", "start_char_idx": 2327, "end_char_idx": 2734, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b6005d89-68ab-4eb2-8c65-493f7a2a7a32": {"__data__": {"id_": "b6005d89-68ab-4eb2-8c65-493f7a2a7a32", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "22"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "56775138-d8d7-4bdc-9f96-5e87129bdbbd", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "22"}, "hash": "05d3ab26aaefde9b5a7dcf6f697fdb0f35171a91b8c05a3d49a57548f4e09ffa", "class_name": "RelatedNodeInfo"}}, "text": "CHAPTER 10- MONITORING & EVALUATION                                                  176\n10.1 Introduction                                                                    177\n10.2 Selection of Indicators                                                         177\n10.3 Data Management                                                                 182\n   10.3.1 Data Collection                                                            182\n10.4 HIV Data Dissemination and Use                                                  184\n10.5 Human Resource for M&E                                                          184\n10.6 HIV M&E Logistics                                                               185\n10.7 Additional strategies in M&E                                                    185\n10.8 HIV Research                                                                    185\n10.9 Periodic monitoring of the implementation of the guidelines and content update  185\nReferences                                                                           187\nAppendix                                                                             189\n    Appendix 1: Commonly used Adult and Paediatric ARV Formulations and Dosage       190\n    Appendix 2: Mental Health Screening                                              198\n    Appendix 3: Energy and Nutritional Recommendations for PLHIV                     199\n    Appendix 4: Recommended activities for adolescent HIV service delivery           200\n    Appendix 5: Guide on Age-Appropriate Disclosure for Children and Adolescents     203\n    Appendix 6: Self-management timeline for transitioning ALHIV                     204\n    Appendix 7: Algorithm for Screening and Diagnosing TB in PLHIV                   206\n    Appendix 8: Global Standards for Quality Health-Care Services for Adolescents    210\n    Appendix 9: Pharmacovigilance or Drug and Therapeutic Committees\n    (PVC) - Terms of Reference                                                       211\n    Appendix 10: NAFDAC ADR Form                                                     212\n          NATIONAL GUIDELINES FOR HIV PREVENTION TREATMENT AND CARE 2020      xx", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2196, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "381a11a1-bb4b-4be4-b4a0-387a80331ac2": {"__data__": {"id_": "381a11a1-bb4b-4be4-b4a0-387a80331ac2", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "23"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "eb34050c-8cda-444f-8acc-288aee6129cd", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "23"}, "hash": "80288e6ab561f8ea6c5406252a922aa868d20ee458cba2e74802c9ccb533daa8", "class_name": "RelatedNodeInfo"}}, "text": "1. INTRODUCTION\nWhat\u2019s Inside:\n1.1 Objectives of the Guidelines\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026................3\n 1.1 Objectives of the Guidelines\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026..\n1.2 Epidemiology of HIV in Nigeria\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026.......\u2026\u2026.6\n 1.2 Epidemiology of HIV in Nigeria\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\n1.3 Natural History of HIV\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026........................7\n 1.3 Natural History of HIV\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026.\u2026\u2026", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 340, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3d024a8e-daca-444b-8d18-aec7dc7aee5e": {"__data__": {"id_": "3d024a8e-daca-444b-8d18-aec7dc7aee5e", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "24"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "fb8b7439-dcbd-44ea-95a6-2a3a1ac65cbf", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "24"}, "hash": "36c824331d2ac56b6f94686ec3fc428dcee710deb076a1c9697a356e7bd42230", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "eb38e7a3-760b-48b5-babb-c6ccaf6cedea", "node_type": "1", "metadata": {}, "hash": "655e0e8b35637960e781dcd5556082f7e1d99177c26d29efcc1ae89f1bbae845", "class_name": "RelatedNodeInfo"}}, "text": "The 2020 Nigeria HIV Guidelines are informed by the basic principles of equality, equity and\n   social justice and they align strongly with the universal declarations of human rights. They\npromote universal access to comprehensive HIV prevention, treatment and care for all persons in\n       Nigeria. The recommendations of these guidelines are the product of careful balancing of\n    science and public health. The core principles of these guidelines include:.\n       1.  Public Health Approach: These guidelines reinforce the objectives of the national\n           strategy for decentralization of HIV services in Nigeria. They seek to make HIV\n           prevention, treatment and care services universally available to all Nigerians\n           irrespective of socioeconomic class and creed. This approach uses simplified drug\n           formularies, fixed-dose combinations, task shifting and sharing, and simplified systems\n           for clinical mentoring.\n       2.  Promotion of human rights and equity: Access to quality health care services\n           including HIV prevention, treatment, care and support is a basic human right which is\n           the entitlement of all people regardless of nationality, sex, sexual orientation, ethnicity,\n           race, religion or other status. These rights should be recognized as fundamental to\n           realizing the universal right to health. These guidelines will support the equitable\n           provision of quality HIV services including ART and related interventions to all the\n           people who need them; especially pregnant women, children and high-risk populations.\n           These services should be provided in an environment that minimizes stigma and\n           discrimination. Basic rights and freedom of all clients will be respected in the\n           implementation of the guidelines. For example, informed consent (for HIV testing and\n           initiation of ART) and adequate health information safeguards should be put in place to\n           ensure consent and confidentiality. Priority should be given to people who are most ill\n           and those who are already on treatment.\n       3.  Implementation guided by in-country peculiarities:             Implementation of the\n           recommendations of these guidelines will be informed by local context including; HIV\n           epidemiology, availability of resources, the organization and capacity of the health\n           systems at all levels of care. Indigenous best practices will be promoted alongside global\n           standard practices.\n       4.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2591, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "eb38e7a3-760b-48b5-babb-c6ccaf6cedea": {"__data__": {"id_": "eb38e7a3-760b-48b5-babb-c6ccaf6cedea", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "24"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "fb8b7439-dcbd-44ea-95a6-2a3a1ac65cbf", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "24"}, "hash": "36c824331d2ac56b6f94686ec3fc428dcee710deb076a1c9697a356e7bd42230", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3d024a8e-daca-444b-8d18-aec7dc7aee5e", "node_type": "1", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "24"}, "hash": "3873b6995665e5d05f566508cf9cedd35cdf85fc1b09dffc395701623aebbca3", "class_name": "RelatedNodeInfo"}}, "text": "Indigenous best practices will be promoted alongside global\n           standard practices.\n       4.  Strengthening health systems through innovation and learning: Service delivery\n           approaches recommended in these guidelines will be implemented in a manner that\n           strengthens health systems and enhances the local capacity to keep pace with the rapidly\n           evolving science of HIV medicine.\n       5.   Increasing the effectiveness and efficiency of programmes: As the country scales-up\n           access to ART in the face of competing national priorities, efforts will be made to\n           optimize the effectiveness and efficiency of National HIV programmes through\n           provision of ART to people living with HIV and implementing strategies and\n           recommendations that are sustainable and less dependent on foreign aid.\n       6.  Differentiation and Integration of Services: With the UNAIDS 95-95-95 targets,\n           scale-up of HIV care, treatment and support services, and differentiating ART treatment\n              NATIONAL GUIDELINES FOR HIV PREVENTION TREATMENT AND CARE 2020            2", "mimetype": "text/plain", "start_char_idx": 2491, "end_char_idx": 3634, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5937fddf-7c87-44dc-8461-353fa0d80c4c": {"__data__": {"id_": "5937fddf-7c87-44dc-8461-353fa0d80c4c", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "25"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "cc99a405-53cf-4854-b5d1-80c3dc9ee1bc", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "25"}, "hash": "b7034ffadfb8e4c2ce2cd7e9f3e52655a413e0138cdcc4262f57b4f6fa42b23f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ab791cfd-3ce7-4422-a34f-5ec98bf49597", "node_type": "1", "metadata": {}, "hash": "86a0448d0e5387beb2c72fb3284b7a4c51a002c3ac3873075fb8f8a53190a6e6", "class_name": "RelatedNodeInfo"}}, "text": "becomes imperative for expansion and provision of patient-focused care. Strengthening\n       linkages and referrals are important components of differentiation. The integration and\n       linkage of HIV services with TB, sexual and reproductive health, maternal, newborn and\n       child health services offer opportunities for providing ART, increasing adherence and\n       reducing attrition in care.\n   7.        The HIV Continuum of Care: These guidelines are predicated on HIV continuum of\n       care. The diagnosis of HIV should be followed with timely initiation of ART and\n       retention in care, sustained virological suppression resulting in improved quality of life.\n       As many more PLHIV live longer, stable and healthier, HIV has become a chronic health\n       condition. This requires that health systems and community interventions should be\n       modified to optimize the chronic care model.\n   8.    Contribution to National and Global Health Goals: These guidelines have taken into\n       consideration the letter of the 2016 United Nations General Assembly Special Session\n       (UNGASS ) Political Declaration on HIV which affirms the 2030 agenda for sustainable\n       development including the resolve of member states to end the AIDS epidemic by 2030.\n       The 2016 guideline was designed to ensure that the UNAIDS 2014 declaration of 90-90-\n       90 was achievable; however, huge gaps still exist. In particular, the 2018 National AIDS\n       Indicator and Impact Survey (NAIIS) showed that an estimated 800,000 individuals are\n       yet to be identified. As at the end of 2019, approximately 1.14 million people were on\n       treatment out of the estimated 1.9 million people living with HIV. Thus, the country is at\n       60% ART coverage. Although there are facility reports of giant strides being made\n       concerning the third 90 at tertiary institutions in Nigeria, nationwide report showed\n       widely variable suppression rates as low as 50% in some facilities to 80% in others.\n       Specifically, the current guidelines seek to contribute towards the achievement of\n       UNAIDS 95-95-95 targets. In addition, this document will contribute to achieving the\n       goals and targets articulated in the National HIV/AIDS strategic framework (NSF 2021-\n       2025).", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2318, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ab791cfd-3ce7-4422-a34f-5ec98bf49597": {"__data__": {"id_": "ab791cfd-3ce7-4422-a34f-5ec98bf49597", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "25"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "cc99a405-53cf-4854-b5d1-80c3dc9ee1bc", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "25"}, "hash": "b7034ffadfb8e4c2ce2cd7e9f3e52655a413e0138cdcc4262f57b4f6fa42b23f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5937fddf-7c87-44dc-8461-353fa0d80c4c", "node_type": "1", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "25"}, "hash": "4746526c6f4c7278458352ff10537d215ae9d6dcba3cb96646d6805c1811aa42", "class_name": "RelatedNodeInfo"}}, "text": "In addition, this document will contribute to achieving the\n       goals and targets articulated in the National HIV/AIDS strategic framework (NSF 2021-\n       2025).\n1.1 Objectives of the Guidelines\n   \u00a7   To provide updated and evidence-based clinical recommendations for the provision of\n       HIV prevention, treatment, care and support services\n   \u00a7   To provide guidance on key service delivery and operational issues needed to increase\n       the effectiveness and efficiency of HIV service delivery and strengthen the continuum of\n       HIV care through linkage and integration\n   \u00a7   To provide programmatic guidance for the effective delivery of HIV prevention,\n       treatment, care and support services at all levels of the health care system\n   These Guidelines will support;\n   \u00a7   Early HIV diagnosis and timely initiation of lifelong combinationART\n   \u00a7   Package of care for the management of PLHIV presenting with advanced HIV disease\n   \u00a7   Use of viral load testing for monitoring ART treatment success and diagnosis of\n       treatment failure\n   \u00a7   Monitoring drug toxicity in every individual onART\n   \u00a7   ARV prophylaxis to HIV exposed infants, timely DNA PCR testing and early linkage of\n       HIV positive infants to treatment and care\n          NATIONAL GUIDELINES FOR HIV PREVENTION TREATMENT AND CARE 2020            3", "mimetype": "text/plain", "start_char_idx": 2152, "end_char_idx": 3504, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "703118b6-256b-465b-9471-fc92def9d512": {"__data__": {"id_": "703118b6-256b-465b-9471-fc92def9d512", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "26"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "51259645-995b-4f02-8a10-e641385258e3", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "26"}, "hash": "5ce7b7280899512abc021de5820fcf7c8935c54b325f0ae8bafdd64da1a9ce44", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fc6ef00f-e8df-4241-be1d-648eb49f53b3", "node_type": "1", "metadata": {}, "hash": "cca97fe8eceac47f14de48eab898bb24570a24fb54e32cf6849c9424f242fb44", "class_name": "RelatedNodeInfo"}}, "text": "\u00a7   Prevention of new HIV infections among adults, adolescents, pregnant and\n        breastfeeding women and children\n    \u00a7   Strengthened adherence toART and retention in care\n    \u00a7   Improved qualityART service delivery all over the country\nWhat is new in the 2020 National Guidelines for HIV Prevention, Treatment and Care?\nART should be initiated in all adults, adolescents, pregnant and breastfeeding women, and\nchildren with a diagnosis of HIV regardless of WHO clinical stage and CD4+ cell count. This\nrecommendation (as in the 2016 Guidelines) maintains that people who test HIV positive will be\ninitiated onART once they are willing and ready to startART for life.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 673, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fc6ef00f-e8df-4241-be1d-648eb49f53b3": {"__data__": {"id_": "fc6ef00f-e8df-4241-be1d-648eb49f53b3", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "26"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "51259645-995b-4f02-8a10-e641385258e3", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "26"}, "hash": "5ce7b7280899512abc021de5820fcf7c8935c54b325f0ae8bafdd64da1a9ce44", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "703118b6-256b-465b-9471-fc92def9d512", "node_type": "1", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "26"}, "hash": "d0430192bd6b7cb788253b49ef7fed57442c534cc4583f4993369eebd7596ed6", "class_name": "RelatedNodeInfo"}}, "text": "This\nrecommendation (as in the 2016 Guidelines) maintains that people who test HIV positive will be\ninitiated onART once they are willing and ready to startART for life.\nHowever, as a priority, health care workers should initiateART in the following;\n    \u00a7   All adults and adolescents with severe or advanced HIV clinical disease ( WHO stage 3\n        or 4 )\n    \u00a7   All adults and adolescents with HIV and CD4+ cell count of less than 350 cells/mm\n    \u00a7   All HIV positive pregnant and breastfeeding women\n    \u00a7   All HIV positive children older than 5 years of age with severe or advanced disease\n        (WHO stage 3 or 4)\n    \u00a7   All HIV positive children older than 5 years of age with CD4+ cell count less than 350\n        cells/mm\n    \u00a7   All HIV positive children less than 2 years of age\n    \u00a7   All HIV positive children less than 5 years of age with CD4+ cell count of less than 750\n        cells/mm ; or CD4+ percentage less than 25%\nTable 1.1: List of new recommendations\n  Service Area                        New update\n  HIV diagnosis         Current innovative testing strategies for improved case finding and efficient\n                        use of resources\n                        Risk stratification before HIV testing\n                        Index testing\n                        Recency testing\n                        HIV Self testing\n                        Nucleic acid testing at birth\n  HIV Treatment         Tenofovir+Lamivudine+Dolutegravir as preferred first-line ART for all\n                        adults and adolescents\n                        Use of Dolutegravir (DTG) in second-lineART regimen\n                        Use of DTG in Children less than 20kg\n                        Package of care for advanced HIV disease\n                        Use of long-acting injectables\n                        Use of reverse transcriptase translocator inhibitor\n          NATIONAL GUIDELINES FOR HIV PREVENTION TREATMENT AND CARE 2020              4", "mimetype": "text/plain", "start_char_idx": 504, "end_char_idx": 2480, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "728620d4-351f-4adb-879e-5949fe76f6f8": {"__data__": {"id_": "728620d4-351f-4adb-879e-5949fe76f6f8", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "27"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "dfcc96b8-71bd-4664-9e94-dce152098c4a", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "27"}, "hash": "f62c10e045ef6dd4290b41f4c96c29f537f3b78d1d5204c4c674e81d43181d56", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b0026f6a-75ba-4e8b-b580-bc88925d8551", "node_type": "1", "metadata": {}, "hash": "46481d4c1ce287b45b6fcbd0fb59cbe75bcad0228ea0a1d2e69446479622e7f6", "class_name": "RelatedNodeInfo"}}, "text": "Service Delivery      Expansion on models for Differentiated service delivery for specific\n                        populations\n                        Adolescent friendly services and models\n                        Integration of family planning service in ART\n   Laboratory testing   Use of point of care devices for rapid assessment of:\n                        Viral load in pregnant women presenting close to labour\n                        Early infant diagnosis in hard to reach areas\n                        Same day CD4+ cell count\n                        Diagnostics for opportunistic infections\n                        Urine Lateral Flow Lipoarabinomannan (LF-LAM) assay\n                        Stool for Xpert MTB/RIF assay in children\n                        CrAg test\n                        Histoplasma antigen test\n                        IgG/IgM ToxoplasmaAntibody Test\n   HIV exposed infants  Nucleic acid testing at birth (NAT)\n   Prevention           Event-driven Pre-Exposure Prophylaxis\nProcess of guidelines review\nThe review and development of the 2020 National Guidelines on HIV prevention, treatment, and\ncare, commenced in June 2019 when the Federal Ministry of Health established working groups\nof the National Task Team onART. These working groups included:\n    i.   PMTCT working group\n    ii.  Adult/PediatricART working group\n    iii. Service Delivery working group\n    iv.  AHD working group\n    v.   Lab/HTS working group\nThe working groups were mandated to review the respective sections of the 2016 National\nguidelines for HIV Prevention, treatment and Care in line with emerging HIV management\nmodalities. The committees worked remotely and also met in person to review the guidelines and\ndevelop recommendations for inclusion in the 2020 guidelines. Following the completion of the\ntasks by the groups, the FMOH convened series of stakeholders' meetings to review the output\nfrom the working groups and integrate into a final document.    Resources used for the review\nincluded the WHO Policy brief on Antiretroviral Regimens (July 2019), NAIIS 2018 Technical\nReport and the Nigerian National data repository amongst others.\nRecommendations contained in this document are the product of stakeholder consensus, and the\nprincipal consideration is the wellbeing of the patients.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2310, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b0026f6a-75ba-4e8b-b580-bc88925d8551": {"__data__": {"id_": "b0026f6a-75ba-4e8b-b580-bc88925d8551", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "27"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "dfcc96b8-71bd-4664-9e94-dce152098c4a", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "27"}, "hash": "f62c10e045ef6dd4290b41f4c96c29f537f3b78d1d5204c4c674e81d43181d56", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "728620d4-351f-4adb-879e-5949fe76f6f8", "node_type": "1", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "27"}, "hash": "77da86328661e660c896698c00b4e7345f3b1eb71c1b23d808a417bc9e4c064d", "class_name": "RelatedNodeInfo"}}, "text": "Recommendations contained in this document are the product of stakeholder consensus, and the\nprincipal consideration is the wellbeing of the patients. The recommendations are essentially\nguidance on HIV diagnosis, general HIV care and support, rational use of ARV drugs for treating\nand preventing HIV infection and effective delivery of services.\nStakeholders involved in the review and development of the 2020 national guidelines included\n          NATIONAL GUIDELINES FOR HIV PREVENTION TREATMENT AND CARE 2020              5", "mimetype": "text/plain", "start_char_idx": 2160, "end_char_idx": 2688, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "97ed69eb-4cd3-46f4-ad83-66fabbd6d505": {"__data__": {"id_": "97ed69eb-4cd3-46f4-ad83-66fabbd6d505", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "28"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "7fb21985-2a3c-41fa-9439-59933388b7ab", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "28"}, "hash": "340e199b6fa30b66fef809f0c0fd4cae8bd4bf0603bb48e8c684cdf3932cfc97", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6cff8427-ced7-41a3-aa0c-0400639c6612", "node_type": "1", "metadata": {}, "hash": "74612546fa75fe56be3a87902a6624cdd3b7086dd35f108e97eea7a863eff930", "class_name": "RelatedNodeInfo"}}, "text": "representatives of the FMOH, SMOH, NPHCDA, NACA, NAFDAC, NTBLCP, CHAI,\nUNAIDS, WHO, UNICEF, PEPFAR, CDC, USAID, HIV Implementing Partners, NEPWHAN,\nCSOs, National Task Teams for ART, PMTCT and HTS, facility-level HIV service providers.\nThe process was coordinated by the NASCP.\nTarget audience\nThe 2020 National Guidelines for HIV Prevention, Treatment and Care is intended primarily for\nuse by HIV programme managers and service providers at all levels of HIV service delivery. The\ncritical audiences for the guidelines include:\n    \u00a7   Health facility level service providers\n    \u00a7   National and State level HIV Programme Managers\n    \u00a7   National HIV treatment and prevention technical working groups\n    \u00a7   National TB programme managers\n    \u00a7   Managers of maternal, newborn and child health and reproductive health programmes\n    \u00a7   Clinicians and other health service providers in private practice\n    \u00a7   Managers of national laboratory services\n    \u00a7   Community-based organizations including People living with HIV\n    \u00a7   International and bilateral agencies and organizations\n1.2 Epidemiology of HIV in Nigeria\nNigeria reported the first case of AIDS in 1986. Since then, the National HIV prevalence\nincreased exponentially from 1.8% in 1991 peaking at 5.8% in 2001 and progressively declining\nthrough 4.4% in 2005, 3% in 2014. Based on the report from NAIIS, the current prevalence of\nindividuals aged 15 - 64 is 1.4%. As at 2019, Nigeria had an estimated HIV burden of 1.9 million\npeople, the fourth largest in the world. The incidence of HIV in 2018 was estimated at 8 per\n10,000 persons (NAIIS). The prevalence varied across Regions and States with the highest\nprevalence being in the South-South (3.1%) while the North-West had the lowest prevalence\n(0.6%). Akwa Ibom state had the highest prevalence (5.5%) while Katsina had the lowest\nprevalence (0.3%).", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1875, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6cff8427-ced7-41a3-aa0c-0400639c6612": {"__data__": {"id_": "6cff8427-ced7-41a3-aa0c-0400639c6612", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "28"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "7fb21985-2a3c-41fa-9439-59933388b7ab", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "28"}, "hash": "340e199b6fa30b66fef809f0c0fd4cae8bd4bf0603bb48e8c684cdf3932cfc97", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "97ed69eb-4cd3-46f4-ad83-66fabbd6d505", "node_type": "1", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "28"}, "hash": "28dc5a5ca44628b589b0502c0f8c92c00937a5c8d56eb194cebec2b2f5311ad1", "class_name": "RelatedNodeInfo"}}, "text": "Akwa Ibom state had the highest prevalence (5.5%) while Katsina had the lowest\nprevalence (0.3%).\n1.2.1 HIV Transmission\nHeterosexual sex still accounts for the majority of transmissions in Nigeria. Over 90% of\ntransmissions are via unprotected sexual intercourse between heterosexual individuals.\nHowever, current data suggest that homosexuality is contributing disproportionately to the\noverall National epidemic. It is estimated that MSM constitutes only about 1% of the Nigerian\npopulation, yet this group now contributes 20% of new infections in Nigeria. This is not\nunexpected given the fact that 2018 NAIIS documented National population HIV prevalence of\n1.4% whereas the prevalence of the infection among MSM has been rising consistently from\n14% in 2007 to 17% in 2010 and 23% in 2014.\nAnother prominent mode of transmission of HIV is from the HIV positive mother to her child.\nMost children less than 15 years living with HIV acquire the infection through mother-to-child\ntransmission (MTCT). This can occur during pregnancy, labour and delivery or during breast-\nfeeding.\n          NATIONAL GUIDELINES FOR HIV PREVENTION TREATMENT AND CARE 2020           6", "mimetype": "text/plain", "start_char_idx": 1778, "end_char_idx": 2946, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5bd05fc3-ec6f-4f70-8aa2-45f1543036ff": {"__data__": {"id_": "5bd05fc3-ec6f-4f70-8aa2-45f1543036ff", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "29"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "f56d4435-5b05-4b84-b39b-5d9f48e61593", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "29"}, "hash": "264b5d329fb665e815d9ed9fb96eff8fde00f53625d645ab5626ab234b9f8717", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2107cd9f-a41e-455d-9f68-83269e72e446", "node_type": "1", "metadata": {}, "hash": "cc6a84922d5a300bd9e1a52e740d65ec77c0e641e3991efc1973609c4e766bd0", "class_name": "RelatedNodeInfo"}}, "text": "Other modes of transmission of HIV whose incidence rate is not well documented include\ntransmission from transfusion with infected blood and blood products, contact with sharp skin-\npiercing objects used for scarifications, tattoos, and surgical procedures.\n1.3 Natural History of HIV\n1.3.1Adults and Children older than 5 years\nA typical HIV infection can be divided into three stages: primary infection, asymptomatic\ninfection, and symptomatic infection including AIDS. Following primary HIV infection, the\nCD4+ cell count decreases and the HIV RNA rises significantly. With sufficient exposure to viral\nantigens, cytotoxic T-lymphocyte responses are generated, and the HIV viral load typically\ndeclines to an equilibrium known as a virologic \u201cset-point\u201d within 6 to 12 weeks of infection.\nOnce this viral set-point is reached, the CD4+ cell count may rebound again marginally, although\nit does not often return to baseline values. Concurrent with these events are clinical\nmanifestations of acute HIV infection in 30% to 60% of individuals.\nAbout half of newly infected people experience flu-like symptoms while the rest are\nasymptomatic. Once infected, adults experience an asymptomatic clinical latency that lasts 2 to\n10 years, during which HIV is produced and removed by the immune system and CD4+ T cells\nare killed and replaced. This latency period is considerably shorter in children. During this\nasymptomatic period, the number of infected circulating CD4+ cells and free virions are\nrelatively low. Moreover, the hematopoietic system can replace most T cells that are destroyed,\nthus keeping the CD4+ cell counts in the normal range for adults and children >6 years (636-977\ncells/mm ).\n         3\nA number of opportunistic infections (OIs), including recurrent oral candidiasis and tuberculosis\nare common during the early symptomatic phase of AIDS. As the CD4+ cell count declines to an\neven lower level, additional life-threatening OIs such as herpes zoster, amoebiasis,\nmicrosporidiosis, strongyloidiasis, toxoplasmosis, dermatophytosis etc. may occur with\nincreasing frequency and severity.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2107, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2107cd9f-a41e-455d-9f68-83269e72e446": {"__data__": {"id_": "2107cd9f-a41e-455d-9f68-83269e72e446", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "29"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "f56d4435-5b05-4b84-b39b-5d9f48e61593", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "29"}, "hash": "264b5d329fb665e815d9ed9fb96eff8fde00f53625d645ab5626ab234b9f8717", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5bd05fc3-ec6f-4f70-8aa2-45f1543036ff", "node_type": "1", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "29"}, "hash": "ce8c045fdb09fc722c9d59c219207bbf979a1dfcad85be2e0fd9b0233df6366f", "class_name": "RelatedNodeInfo"}}, "text": "may occur with\nincreasing frequency and severity. In the later stages of symptomatic HIV infection, the viral\nload levels rise again. Quantitative PCR methods (viral load assays) demonstrate:\n    \u00a7  Continuous replication of HIV in nearly all infected individuals, although the rates of\n       virus production vary by as much as 70-fold in different individuals\n    \u00a7  The average half-life of an HIV infected cell in vivo is 2.1 days. Recent reports have\n       suggested an even faster turnover of plasma virus of 28 to 110 per minute\n    \u00a7  Up to 10 \u201310\n                9   10 HIV particles are produced each day, and averages of 2 x 10 CD4+\n                                                                              9\n       cells are produced each day.\n1.3.2 HIV in Pregnancy\nIn pregnancy, immune function is suppressed in both HIV-infected and uninfected women.\nThere is a decrease in immunoglobulin and complement levels in early pregnancy and a more\nsignificant decrease  in        cell-mediated immunity. Studies have shown that pregnancy may\nhowever not affect the progression of HIV or the rate of death. On the other hand, HIV infected\npregnant women are more likely to develop early     pregnancy complications such as bacterial\npneumonia, urinary tract infections, spontaneous abortion, higher rates of ectopic pregnancy and\nincreased stillbirth rates, especially from areas where the epidemic has been present for a long\ntime. The risk appears to be lower in asymptomatic HIV positive pregnant women.\n          NATIONAL GUIDELINES FOR HIV PREVENTION TREATMENT AND CARE 2020             7", "mimetype": "text/plain", "start_char_idx": 2058, "end_char_idx": 3664, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "723dc5de-91b4-4edb-8a0b-f5a949c4587f": {"__data__": {"id_": "723dc5de-91b4-4edb-8a0b-f5a949c4587f", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "30"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "09b84246-9dd9-4beb-a27d-959ce1ff617b", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "30"}, "hash": "ab265ea6e358e904cc402ed4088f92e837671fd4656deed839133fb290e67d2c", "class_name": "RelatedNodeInfo"}}, "text": "1.3.3 HIV infection in children under 5 years\nThere are critical differences between HIV progression in children and adults. Stemming largely\nfrom the lower efficiency of a child's immature immune system, these differences usually result\nin more rapid disease progression and a much shorter duration for each stage.\nAt birth, viral load is usually very low but within the first 2 months of life, it increases rapidly to\nvalues well above 100,000 copies/ml. Thereafter the viral load remains high until the age of 2 or\n3 years after which it declines gradually to reach the viral load set point. These viral dynamics are\nsignificantly different from the rapid increase and decrease of the viral load seen in horizontally\ninfected older children and adults.\nIn children, the higher viral load is associated with the level of somatic growth of the lymphatic\nsystem and the inability of their immature immune system to mount an HIV-specific response.\nWhen assessing the immune system in infants and children, it is very important to compare the\nchild's CD4+ cell count with the age-appropriate values. Lymphocyte counts are very high in\ninfancy and decline to adult levels around 6 years of age.\nHigher mortality in HIV-infected children may result from intercurrent infections, malnutrition,\nand lack of access to primary HIV care including delayed definitive diagnosis. With no\ninterventions, the majority of children who acquired HIV perinatally develop HIV-related\nsymptoms by 6 months of age.\nPerinatally infected children fit into one of three categories:\n    \u00a7   Category 1: Rapid progressors develop signs and symptoms of HIV andAIDS and die by\n        age 1 year. These children are likely to have acquired the infection in-utero or during the\n        early perinatal period (about 25 \u2013 30%)\n    \u00a7   Category 2: Children develop symptoms early in life, followed by rapid deterioration\n        and death by age 3 to 5 years (about 50 \u2013 60%)\n    \u00a7   Category 3: Long-term survivors live beyond age 8 years (5 - 25%)\n           NATIONAL GUIDELINES FOR HIV PREVENTION TREATMENT AND CARE 2020              8", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2107, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ed45b48b-5eb1-4ef0-97f8-14f42b9b2301": {"__data__": {"id_": "ed45b48b-5eb1-4ef0-97f8-14f42b9b2301", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "31"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "5480768c-287f-4c19-86b8-b3787f4e8bdd", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "31"}, "hash": "120b35fe5faddbefb93fd8ebb5b2886dc3b76d076d3a9840b4f62a3c25c6c67a", "class_name": "RelatedNodeInfo"}}, "text": "List of Contributors                                                    Chapter 1\nDr. Umo Mildred Ene-Obong    Head/Director, Public Health Department FMoH\nDr Akudo Ikpeazu             National Coordinator NASCP\nMr Araoye Segilola           Former, National Coordinator\nPharm Oloyede Yekini         Former, Director, Logistics Unit NASCP\nDr Akpan Nsebong             Deputy Director NASCP\nOmbudadu Obadiah A           Deputy Director NASCP\nDr Deborah Odoh              Deputy Director, NTTP & Performance Management NASCP\nMrs Semlek Rachael N         Chief Accountant NASCP\nDr Nwaokenneya Peter         Assistant Director, Adult ART/TB/HIV - NASCP\n                             Senior Medical Officer 1, NTTP & Performance Management\nDr Chioma Ukanwa             NASCP\nMs Rahila Agwom              Chief Scientific Officer NASCP\nDr Chinwendu Daniel          Deputy Director, Health Sector Response Support NACA\nNdukwe\nProf. Sulaimon Akanmu        Chairman NTTA / Haematologist LUTH Lagos\nDr Damien Anweh              Member NTTA / Physician FMC, Markurdi\nDr Rita O. Oladele           Member NTTA / Microbiologist LUTH Lagos\nDr Charles Olomofe           Public Health Physician FETH Ido Ekiti\nDr Oluwafunke Ilesanmi       Technical Officer, HIV and Viral Hepatitis WHO\nDr Dennis Onotu              Branch Chief, Continuum of care & treatment CDC\nDr Obinna Ogbanufe           Senior Program Specialist, HIV care and treatment CDC\nDr Igboeline Onyeka Donald   Programme Manager, Treatment USAID\nDr Abiye Kalio               Programme Manager USAID\nFolu Lufadeju                Deputy Country Director CHAI\nPharm Willams Eigege         Associate CHAI\nDr Saswata Dutt              Senior Technical Advisor, HIV/TB/DR -TB IHVN\nDr Olufemi Oke               Technical Advisor CRS\nDr Olawale Fadare            Technical Director TMEC/RISE Program\nDr Olayiwola Lanre           Senior Technical Advisor CCFN\n         NATIONAL GUIDELINES FOR HIV PREVENTION TREATMENT AND CARE 2020    9", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1972, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fd729b2d-039a-411f-9fe2-62aa14c34989": {"__data__": {"id_": "fd729b2d-039a-411f-9fe2-62aa14c34989", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "32"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "2e614534-c2cb-4295-9518-283e94b93ab8", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "32"}, "hash": "45dba05742b158e29dbeaf5dbfa6925907c9b475729067c392ebaa1ff6b00a65", "class_name": "RelatedNodeInfo"}}, "text": "2. DIAGNOSIS OF HIV\n               INFECTION\nWhat\u2019s Inside:\n 1.1 Objectives of the Guidelines\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026..\n2.1 Introduction\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026..\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026..11\n 1.2 Epidemiology of HIV in Nigeria\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\n2.2 HIV Testing Services\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026..\u2026\u2026\u2026\u2026\u2026\u202611\n 1.3 Natural History of HIV\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026.\u2026\u2026\n2.3 HTS in Pregnancy\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026..\u2026\u2026\u2026\u2026\u2026\u2026\u202614\n2.4 Re-testing\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026..\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026.15\n2.5 Repeat HIV Testing\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026..\u2026\u2026\u2026\u2026\u2026\u2026..15\n2.6 Disclosure Scenarios\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026..\u2026\u2026\u2026\u2026\u2026....16\n2.7 Linkage of HTS to care and ART\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026.....16\n2.8 Laboratory Diagnosis of HIV Infection\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u202617\n2.9 Laboratory Diagnosis of HIV Infection in Children\n  by Age Group \u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026..\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026..20\n2.10 Clinical Diagnosis and Staging of HIV Infection\u2026\u2026\u2026\u2026\u202622", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 714, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4a398e6a-65f2-4989-93b4-cf17b1f6a18e": {"__data__": {"id_": "4a398e6a-65f2-4989-93b4-cf17b1f6a18e", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "33"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "768cdfe1-e04f-4f94-869b-289d45bcf568", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "33"}, "hash": "6f102fbcd8ff9931682d6fdb856f4dde9d3cbe05962d9f3c1548c50d9c0b56b9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5ab1634d-f527-41cb-bd3c-e6aebac333e2", "node_type": "1", "metadata": {}, "hash": "685218cd79a32dab9766169895727527d248a7b2b3dc19f83d512cc54ccc1668", "class_name": "RelatedNodeInfo"}}, "text": "2.1 Introduction\nDiagnosis of HIV infection is simply a proof of the presence of HIV in an individual, and this can\nbe achieved by demonstrating either the presence of HIV antibodies in plasma or serum (indirect\ntest) or the virus in blood (direct test). Available tests for diagnosis of HIV include antibody,\nantigen and nucleic acid tests. The antibody detection tests are suitable for the diagnosis of HIV\ninfection in adults and children 18 months and above, while the nucleic acid test is used mainly\nfor the diagnosis of HIV infection in children under 18 months. The diagnosis of HIV infection\nshould not be made without first obtaining a positive result from any of the test methods\nhighlighted above. It is recommended that before commencing ART all persons who have tested\nHIV positive should be re-tested.\n2.2 HIV Testing Services\nHIV Testing Services (HTS) provides a gateway to HIV prevention, treatment and care services.\nHTS consists of a range of services that include diagnosis of HIV using HIV testing methods,\ncounselling (pre-test information and post-test counselling), linkage to HIV prevention,\ntreatment and care and other clinical services, and coordination with laboratory services for\nquality assurance and the delivery of accurate results.\nAll forms of HTS should be voluntary and should adhere to WHO's five C's: consent,\nconfidentiality, counselling, correct test results and connections to care, treatment and\nprevention services. The WHO five C's are principles that apply to all models of HTS and in all\ncircumstances. For further information, refer to the\nNational HTS Guidelines 2017.\n2.2.1 Risk Stratification\nRisk stratification is a strategy that identifies those who are likely to be infected with HIV based\non their risk exposure. The HIV risk stratification tool enables service providers to determine if a\nclient presenting at the health facility or community is eligible for an HIV test or not, following\nan assessment using a set of predetermined criteria. The Risk stratification Tool (RST) has been\nuseful in aiding the programme to be more efficient in the testing of clients.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2123, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5ab1634d-f527-41cb-bd3c-e6aebac333e2": {"__data__": {"id_": "5ab1634d-f527-41cb-bd3c-e6aebac333e2", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "33"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "768cdfe1-e04f-4f94-869b-289d45bcf568", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "33"}, "hash": "6f102fbcd8ff9931682d6fdb856f4dde9d3cbe05962d9f3c1548c50d9c0b56b9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4a398e6a-65f2-4989-93b4-cf17b1f6a18e", "node_type": "1", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "33"}, "hash": "ef8d419078dfce5bb53008682ef4eb4ea29104b03de786fc28b71c9177381081", "class_name": "RelatedNodeInfo"}}, "text": "The Risk stratification Tool (RST) has been\nuseful in aiding the programme to be more efficient in the testing of clients.\n2.2.2 Pre-test services\nPre-test information may be provided through individual or group information sessions and\nmedia such as posters, brochures, and short video clips shown in waiting rooms. When children\nand adolescents are receiving HTS, information should be presented to them in an age-\nappropriate manner and in a way their guardians can understand. Pre-test information sessions\nfor people receiving HIV testing should emphasize the benefits of HIV testing, the meaning of an\nHIV-positive and an HIV-negative test, and an assessment of clients' readiness for HIV testing.\nFor further information, refer to the National HTS Guidelines 2017.\n2.2.3 Post-test services\nPost-test information and counselling for people who test HIV negative should emphasize an\nexplanation of the test result, referral and linkage to other relevant HIV prevention services, and\nadvise to return in 4 weeks for repeat testing in the event of recent risky behaviour. For those\npeople who test HIV positive, post-test information should emphasize an explanation of the test\nresult and helping the client to cope with emotions arising from the diagnosis, clear information\n           NATIONAL GUIDELINES FOR HIV PREVENTION TREATMENT AND CARE 2020              11", "mimetype": "text/plain", "start_char_idx": 2001, "end_char_idx": 3369, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d601492b-411f-4d54-b637-5cf886d720c2": {"__data__": {"id_": "d601492b-411f-4d54-b637-5cf886d720c2", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "34"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "b66dc964-d18a-475b-b8ae-e29a58bf9a44", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "34"}, "hash": "1091474eed77535a04cc4aea40b9601f7268dda3fad9a1bbc2896d326e9fcc4d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6ecadc27-9ad7-4d09-9484-cc2fc61be463", "node_type": "1", "metadata": {}, "hash": "974f5400f5c9e5157dd834466a08414051a98283f1ed3e4dead9633470bb9844", "class_name": "RelatedNodeInfo"}}, "text": "on ART and its benefits for maintaining health and reducing the risk of HIV transmission, as well\n as proper linkage to care. For further information, refer to the National HTS Guidelines 2017.\n 2.2.4 Index Testing Services\n    Index testing services (ITS) is a focused HTS approach in which the household, family members\n    (including children) and partners of people diagnosed with HIV are offered HTS. ITS should be\noffered by a trained provider in an appropriate, safe and ethical manner. The provider should ask\n people diagnosed with HIV (index clients) to list their sexual partners, drug-injecting partners\n  (where applicable), children, and other family members. If the index client agrees, offer these\n  partners and the children HIV testing services (HTS). The process is completely voluntary. Such\n services are key to increasing HIV case finding and achieving epidemic control.\n      Implementers need to ensure that the following minimum requirements are in place to conduct\n voluntary safe and ethical ITS:\n     \u00a7   All providers conducting index testing must be trained and supervised on index testing\n         procedures including 5Cs, intimate partner violence (IPV) screening, adverse event\n         monitoring, and ethics (respect for the rights of clients, informed consent and 'do no\n         harm').\n     \u00a7   StrictAdherence to 5C's should be observed/assessed at least quarterly, as well as\n         provision of additional voluntary and ethical practices as detailed below:\n             \u00b7  Providers must offer clients a choice of all four partner notification strategies\n             (client, contract, provider, dual referral) and indicate that there are both ways to\n                 notify contacts that do not involve disclosure and ways to ensure anonymity\n             \u00b7              Providers will work with clients experiencing IPV to choose a partner\n                   notification method that ensures their safety (which may be declining of index\n                 testing service\n     \u00a7   All HIV testing clients, including index clients, should be provided with all available\n         HIV prevention, care and treatment services, regardless of whether or not they provide\n         details about their contacts. Clients must NEVER be pressured into sharing the names of\n         their contacts for fear of being denied services. Services must NEVER be withheld\n         under any circumstances.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2433, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6ecadc27-9ad7-4d09-9484-cc2fc61be463": {"__data__": {"id_": "6ecadc27-9ad7-4d09-9484-cc2fc61be463", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "34"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "b66dc964-d18a-475b-b8ae-e29a58bf9a44", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "34"}, "hash": "1091474eed77535a04cc4aea40b9601f7268dda3fad9a1bbc2896d326e9fcc4d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d601492b-411f-4d54-b637-5cf886d720c2", "node_type": "1", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "34"}, "hash": "166eaf34af7b8b62ee68f09633956848e0d7fdf326d9596026434003a8a3c087", "class_name": "RelatedNodeInfo"}}, "text": "Clients must NEVER be pressured into sharing the names of\n         their contacts for fear of being denied services. Services must NEVER be withheld\n         under any circumstances.\n     \u00a7   Clients should be informed of their right to decline participation in index testing services\n         throughout the process, not just during the elicitation interview .\n     \u00a7   IPV risk assessment should be conducted for each contact elicited, with referral options\n         to necessary services using SOPs (available at\n         www.humanitarianresponse.info/files/document/nigeria_sops_gbv_prevention_respo\n         nse_2019.pdf ).\n     \u00a7   Onsite provision of first-line services (Listen, Inquire, Validate, Ensure safety,\n         Support) for anyone reporting IPV, and additional services offered either onsite or as\n         referral.\n     \u00a7   A secure environment (e.g. lockable cabinets) to store patient information.\n            NATIONAL GUIDELINES FOR HIV PREVENTION TREATMENT AND CARE 2020              12", "mimetype": "text/plain", "start_char_idx": 2251, "end_char_idx": 3262, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c3dc768d-c408-432b-bdaf-cf5a60a936ca": {"__data__": {"id_": "c3dc768d-c408-432b-bdaf-cf5a60a936ca", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "35"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "8e4cc579-deef-4b4f-89a0-0d01946d0015", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "35"}, "hash": "63d9cdb090004ac9e9e2d0d69523c676fbaf7ee3a8213bfc9c57a931abb46418", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "983507b7-e8f3-4eca-8039-8e3f1376ebc8", "node_type": "1", "metadata": {}, "hash": "bbc6ff9c47f9bd19c017ced9a223ddcbb78b0eb924dd2e0c192e3f13e621b840", "class_name": "RelatedNodeInfo"}}, "text": "See the figure below for detailed information:\n                                        1.  Monitor\n                                            Compliance\n                                            with minimum\n                                            standards\n                   4.  Quality\n                       assurance and                       2.  Obtain Informed\n                       accountability     Safe and             consent\n                                       Ethical Index\n                                           Testing\n                  5.   Adverse Event      Services        3.  Intimate Partner\n                       Monitoring                             Violence Risk\n                                                              Assessment and\n                                                              Service Provision\n figure 2.1: Safe and Ethical Index Testing Services\n2.2.5   Social Network Testing\nSocial Network Testing (SNT) is when HIV-positive and/or high-risk HIV-negative persons,\nparticularly from key populations (KP) are enlisted as recruiters to identify individuals from\ntheir social, sexual, and drug-using networks (network associates) for HTS. Social and risk\nnetwork strategies complement traditional peer outreach by engaging previously unidentified\nKP and other high-risk populations for HIV prevention and testing. The goal is to reach hidden,\nhigh-risk networks, expand HIV case detection potential, and, as an integrated part of a\ndifferentiated model, link HIV-positive individuals to rapid treatment, and connect HIV-\nnegative individuals to services that will help them remain HIV-negative.\n2.2.6 Blended Index and Social Network Strategies\nIt is valuable to synergistically build upon a core foundation of index testing to introduce social\nnetwork strategies (SNS) to expand case-finding options for high-risk groups. The two strategies\ncan be used in concert to ensure that all high-risk, direct exposure contacts and social network\nmembers are tested and that HTS extends into harder-to-reach networks of undiagnosed PLHIV.\n2.2.7 HIV Self-testing\nHIV self-testing (HIVST) refers to a process in which a person collects his or her specimen (oral\nfluid or blood) and then performs an HIV test and interprets the result, often in a private setting,\neither alone or with someone he or she trusts. As with all approaches to HTS, HIVST should\nalways be voluntary, not coercive or mandatory. Although reported misuse and social harm are\nrare, efforts to prevent, monitor, and further mitigate related risks are essential.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2588, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "983507b7-e8f3-4eca-8039-8e3f1376ebc8": {"__data__": {"id_": "983507b7-e8f3-4eca-8039-8e3f1376ebc8", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "35"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "8e4cc579-deef-4b4f-89a0-0d01946d0015", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "35"}, "hash": "63d9cdb090004ac9e9e2d0d69523c676fbaf7ee3a8213bfc9c57a931abb46418", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c3dc768d-c408-432b-bdaf-cf5a60a936ca", "node_type": "1", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "35"}, "hash": "a1ef01f373d130dacfd46a28ecb9f87d7ebf314a70400aaaebfd3e829f0c0da9", "class_name": "RelatedNodeInfo"}}, "text": "As with all approaches to HTS, HIVST should\nalways be voluntary, not coercive or mandatory. Although reported misuse and social harm are\nrare, efforts to prevent, monitor, and further mitigate related risks are essential. A reactive (HIV-\npositive) HIVST result always requires further testing and confirmation from a trained provider,\nstarting from the beginning of the validated national testing algorithm. Importantly, HIVST is a\nscreening test and should not be used to provide a definitive HIV diagnosis. Clear messages are\nessential to ensure that HIVST users understand how to perform the test, the meaning of the test\nresults, and where and how to access follow-up services following a test, including retesting,\ncare, and treatment. Linkage to HIV testing services through a facility or HTS provider is critical\nfollowing a reactive HIVST. A negative HIVST is reliable evidence of no infection and does not\n           NATIONAL GUIDELINES FOR HIV PREVENTION TREATMENT AND CARE 2020               13", "mimetype": "text/plain", "start_char_idx": 2367, "end_char_idx": 3373, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "20e6c4b6-392d-4344-b798-00ac774d1b48": {"__data__": {"id_": "20e6c4b6-392d-4344-b798-00ac774d1b48", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "36"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "3f20f726-b6b3-4128-a98d-ee247064acb1", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "36"}, "hash": "d5cc60e73216ce43a29f36ddbb8c07dea630d3d7f4dfcc6bd8ee06c25a4fdbe6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e033d6c5-dfef-45ed-8160-3550aa0c8c16", "node_type": "1", "metadata": {}, "hash": "c3fd62fb77fd1f77a5b0ca1b3fc8757bc835b60a16f8a4793862b3899af45a5a", "class_name": "RelatedNodeInfo"}}, "text": "require additional testing unless PrEP is planned, in which case the negative result should be\nconfirmed using the national testing algorithm before PrEP initiation. Interpretation of a non-\nreactive (HIV-negative) self-test result will also depend on the ongoing risk of HIV exposure.\nIndividuals at high ongoing risk, or who test within six weeks of possible HIV exposure, should\nbe encouraged to retest. HIVST is not recommended for users with a known HIV status who are\ntaking antiretroviral drugs, as this may lead to an incorrect self-test result (false non-reactive).\nHIVST for children 2-11 years must be caregiver assisted or health care worker assisted with\ncaregiver consent. Provisions should also be made for persons with disabilities to access\nappropriate information and educational materials about HIVST and to receive support to\nconduct the HIVST as needed. For further information, refer to the National HIVST Operational\nGuidelines 2019.\n2.2.8 Recency Testing\nRecency testing refers to an anti-body-based test to distinguish recent from long-term HIV\ninfection using antibody avidity (binding strength). The recency test kit is used to indicate\nwhether a person's HIV infection was recently acquired (i.e. in the last 4-6 months). This\npromises to be a useful tool for disease monitoring and surveillance. All kits for this procedure\nshould be evaluated in line with National standards before deployment or public health use after\npost-market validation. This test should be done immediately after the client tests positive using\nthe National testing algorithm.\n2.3 HTS in Pregnancy\nThe entry-point for PMTCT services is through HIV testing of pregnant women at the earliest\nopportunity; during antenatal care, labour and delivery including post-partum. In all settings,\nHTS should be offered to all pregnant women seeking antenatal care. Retesting for HIV in late\npregnancy and early in labour is recommended for pregnant women who tested negative in early\npregnancy.\n2.3.1Approach to HTS in Pregnant Women\nHIV testing of pregnant women should be accompanied by culturally acceptable counselling\nthat highlights the benefits of knowing one's HIV status and its implications for the woman's\nhealth, pregnancy and the unborn child.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2249, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e033d6c5-dfef-45ed-8160-3550aa0c8c16": {"__data__": {"id_": "e033d6c5-dfef-45ed-8160-3550aa0c8c16", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "36"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "3f20f726-b6b3-4128-a98d-ee247064acb1", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "36"}, "hash": "d5cc60e73216ce43a29f36ddbb8c07dea630d3d7f4dfcc6bd8ee06c25a4fdbe6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "20e6c4b6-392d-4344-b798-00ac774d1b48", "node_type": "1", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "36"}, "hash": "d8796651d071d1a5c4549efde1ee6b00e2c54c85fb6f8850078c6f5ad99d2ed1", "class_name": "RelatedNodeInfo"}}, "text": "The elements of effective counselling are\nconfidentiality, timeliness, acceptance, accessibility, consistency and accuracy.\nThe recommended approach to testing and counselling is the routine approach (also referred to\nas the PITC \u201copt-out\u201d approach) where HIV testing is offered as part of routine tests in antenatal\nclinics. The pregnant woman reserves the right to refuse the test.\n2.3.2 Essential Components of HTS for PMTCT\nThese include:\n   \u00a7    Pre-test information\n   \u00a7    HIV testing with same-day result\n   \u00a7    Post-test counselling\n   \u00a7    Follow-up counselling\n          NATIONAL GUIDELINES FOR HIV PREVENTION TREATMENT AND CARE 2020             14", "mimetype": "text/plain", "start_char_idx": 2250, "end_char_idx": 2910, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4a9166df-b4ee-4776-8277-37b1d4ccbe63": {"__data__": {"id_": "4a9166df-b4ee-4776-8277-37b1d4ccbe63", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "37"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "709e5466-b7a0-4723-bfcc-64330017e4b5", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "37"}, "hash": "bef1866d30f81018cb62289259da76a315f2c93d2e29b0159965bbdb38cc33ef", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3c8f7695-ed1f-4324-b36c-4c93079b0c82", "node_type": "1", "metadata": {}, "hash": "7468d812c0dcfa1e5eac1fad251554a1c75e8d69c2fb6e463561809c5f6cfb9e", "class_name": "RelatedNodeInfo"}}, "text": "Women should be encouraged to start antenatal care early (within first trimester from 14 weeks\nof pregnancy) and HTS should be provided during the firstANC visit.\n2.3.3 HTS for women in labour\nHIV testing in labour should be provided for all women of unknown HIV status and those who\ntested negative during pregnancy. This is because some women might not have registered in the\nantenatal clinic and are presenting for the first time in labour. Such women should be offered the\nopt-out approach and given appropriate post-test counselling in the post-partum period or pre-\ntest counselling if she had declined the test. The following steps should be taken:\n   \u00a7    Determine HIV test history\n   \u00a7    Discuss the benefits of HIV testing andART\n   \u00a7    Explain the HIV testing process\n   \u00a7    Offer the test\nIf the above is not feasible at the time the woman presents, steps should be taken to offer the test\nas soon as possible after delivery.\n2.3.4 HTS for post-partum women\nTo reduce the number of new paediatric infections, additional efforts are required to reduce\nmother to child transmission post-partum (especially during breastfeeding). Breastfeeding\nmothers of unknown HIV status and those who tested negative during pregnancy should be\ncounselled and assessed to determine exposure and offered testing if indicated at the 6-week\ninfant immunization visit. If negative, breastfeeding mothers should be retested at 6-month\nintervals until the cessation of breastfeeding. Counselling on the HIV retesting schedule both in\npregnancy and the postpartum period should be integrated into routine ANC and postnatal\neducation.\n2.4 Re-testing\nWith the advent of the \u201cTest and Treat\u201d policy in Nigeria, all HIV-positive persons are now\neligible to receive ART, regardless of CD4+ cell count. To ensure that individuals are not\nneedlessly placed on life-long ART (with potential side-effects, waste of resources,\npsychological impact of misdiagnosis), all individuals should be retested to verify their HIV\nstatus before or at the time of startingART. Misdiagnosing HIV infection, irrespective of its scale\nis of critical importance. Any incorrect diagnosis, whether false-positive or false-negative has\nsevere personal and public health consequences and should be prevented.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2271, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3c8f7695-ed1f-4324-b36c-4c93079b0c82": {"__data__": {"id_": "3c8f7695-ed1f-4324-b36c-4c93079b0c82", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "37"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "709e5466-b7a0-4723-bfcc-64330017e4b5", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "37"}, "hash": "bef1866d30f81018cb62289259da76a315f2c93d2e29b0159965bbdb38cc33ef", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4a9166df-b4ee-4776-8277-37b1d4ccbe63", "node_type": "1", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "37"}, "hash": "e6cb47b9ac7bd20d5b156add6cc9afe608a02b5921e515eb83be170bb8c686e7", "class_name": "RelatedNodeInfo"}}, "text": "Misdiagnosing HIV infection, irrespective of its scale\nis of critical importance. Any incorrect diagnosis, whether false-positive or false-negative has\nsevere personal and public health consequences and should be prevented.\nRetesting should be conducted by a different provider using the same testing algorithm with a\nnew specimen. Retesting should be conducted at a different site, ideally, the site where the\ndecision about ART initiation will be made. Retesting according to this procedure aims to rule\nout possible technical or clerical errors, including specimen mix-up through mislabelling and\ntranscription errors, as well as random error either by the provider or of the test device.\n2.5 Repeat HIV Testing\nIf an antibody only test is negative, repeat HIV testing should occur at 6 weeks, 3 months and 6\nmonths following the exposure. The following scenarios are applicable for repeat HIV testing.\n   \u00a7   Window period: Post-test counselling messages should include a recommendation that\n          NATIONAL GUIDELINES FOR HIV PREVENTION TREATMENT AND CARE 2020            15", "mimetype": "text/plain", "start_char_idx": 2048, "end_char_idx": 3130, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "78538c2a-21c1-4485-ada3-26b84cc54f53": {"__data__": {"id_": "78538c2a-21c1-4485-ada3-26b84cc54f53", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "38"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "63ea3d6e-79bd-4be6-8772-2f712e8f113b", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "38"}, "hash": "eb809c195fdf69416349e2eedbe926fddf057b16082e6133a7dd72571acd72ea", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "391e091f-c15c-4c9a-aa30-31aeebc95b76", "node_type": "1", "metadata": {}, "hash": "cbe03e8de456d7a38f3166c72ab44f06df0d657ea7bbb08a5cbfdfd81adda46b", "class_name": "RelatedNodeInfo"}}, "text": "HIV-negative persons retest in 3 months to rule out acute infection that is too early for\n           rapid HIV tests to detect\u2014in other words, the window period.\n       \u00a7   General Population: HIV-negative persons from the \u201cgeneral population\u201d with low or no\n           risk of infection should not be advised to retest after three months, but rather they should\n           be retested annually, or as indicated by their risk of exposure. Providers should help HIV-\n           negative clients feel confident in their HIV test results and support them to stay HIV-\n           negative by linking them with appropriate follow-up prevention services.\n       \u00a7   Persons with Ongoing High Risk: In some instances, HIV-negative clients will require\n           more frequent retesting. Persons who are diagnosed HIV-negative but are at ongoing\n           high risk, such as some people from key populations, may benefit from retesting every\n           three to six months. This may help ensure early HIV diagnosis and ongoing health\n           education about HIV prevention.\n   2.6 Disclosure Scenarios\n   People who test HIV-negative may not need assistance or support with disclosing their HIV\n     status to others, but maintaining privacy about testing HIV-positive, and deciding whom they\n      should disclose to, are concerns for many people who test HIV-positive. Disclosure can help\n          clients get emotional support to cope with a new diagnosis and can encourage access and\n adherence to ART. Providers should support clients to disclose to persons in their life who care\n   about their health and well-being.\nDisclosure is not mandatory, and providers should assess the risk of intimate partner violence to\n   their clients and make referrals to appropriate services as needed.\n       \u00a7   Disclosure to partners who may be at risk of HIV and who need to be tested is also\n           important for the partner's health and well-being and should be supported through couple\n           HIV counselling and testing or partner notification services as described in the National\n           HTS Guidelines 2017.\n       \u00a7   In the event where efforts to encourage the client to disclose their HIV status fail, and if\n           the client is placing a sexual partner(s) or other persons at risk, a service provider may\n           disclose that person's HIV status to their sex partner(s) or other people at risk.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2417, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "391e091f-c15c-4c9a-aa30-31aeebc95b76": {"__data__": {"id_": "391e091f-c15c-4c9a-aa30-31aeebc95b76", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "38"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "63ea3d6e-79bd-4be6-8772-2f712e8f113b", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "38"}, "hash": "eb809c195fdf69416349e2eedbe926fddf057b16082e6133a7dd72571acd72ea", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "78538c2a-21c1-4485-ada3-26b84cc54f53", "node_type": "1", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "38"}, "hash": "4854352bcf2ce435326644efa19dac0e5c201f101ff064933eb52884c2f173d1", "class_name": "RelatedNodeInfo"}}, "text": "However,\n           persons must be given a reasonable opportunity to disclose their HIV status to the sexual\n           partner(s) on their own before the service provider intervenes.\n       \u00a7   In some situations, a provider may disclose a client's HIV-positive results to another\n           medical provider involved in the client's care, to ensure the client receives appropriate\n           medical care. Such disclosure should respect the client's right to privacy and\n           confidentiality.\n   2.7 Linkage of HTS to care andART\n   Following an HIV diagnosis, a package of support interventions should be offered to ensure\n   timely linkage to care for all PLHIV. The following interventions should be used in improving\n   linkage to care:\n       \u00a7    Enhanced linkage with case management\n       \u00a7    Support for HIV disclosure\n       \u00a7    Patient tracking for those who failed to enroll in care\n       \u00a7    Training staff to provide multiple services\n       \u00a7    Streamlined services to accelerate time to initiation\n              NATIONAL GUIDELINES FOR HIV PREVENTION TREATMENT AND CARE 2020              16", "mimetype": "text/plain", "start_char_idx": 2418, "end_char_idx": 3539, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "940814c5-8250-4d0a-826c-117acba7eae2": {"__data__": {"id_": "940814c5-8250-4d0a-826c-117acba7eae2", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "39"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "92bf2e05-3654-4dcf-899e-375b80e8a29d", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "39"}, "hash": "0fa0d586e53c38d683d6b03748b51520162b04734f8c0dd7a614297b2c18966e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "908902d5-d79d-407e-817c-23f5ca168827", "node_type": "1", "metadata": {}, "hash": "2c4486d9ca40fdb204039adbdd06e0972a4729e2c23811776430864a15beaa94", "class_name": "RelatedNodeInfo"}}, "text": "\u00a7   Peer support and navigation approaches for linkage and\n    \u00a7   Quality improvement approaches using data to improve linkage\n2.8 Laboratory Diagnosis of HIV Infection\nLaboratory diagnosis of HIV infection is based on the demonstration of antibodies in plasma or\nserum (indirect testing) or of the viral nucleic acid in the blood (direct testing). With the\ntechnology that is available at present, HIV antibodies are usually detectable within four to six\nweeks of infection, and within 24 weeks in virtually all infected individuals. The virus can be\ndemonstrated in the blood with nucleic acid-based tests (PCR for proviral HIV DNA and RT-\nPCR for plasma viral RNA) and viral culture.\n2.8.1AntibodyAssays\nAntibody testing is performed with serial or parallel testing algorithms using rapid test kits\n(RTK). Screening tests include Enzyme-linked ImmunosorbentAssay (ELISA), which is mainly\nused in blood banks.\nHIV Rapid TestingAlgorithm\nSerial and parallel testing algorithms are the two HIV testing algorithms. The algorithm\nrecommended for routine HIV testing is the serial HIV testing algorithm. Rapid test kits (RTKs)\nrecommended for use under this algorithm include Determine, Unigold, Stat-Pak, Double-check\nGold, Sure-Check, and HIV Quick Check among others. HIV serological assays adopted for use\nshould have a minimum sensitivity of 99% and specificity of 98%. All test kits meeting these\nconditions should be approved by the Honorable Minister of Health following formal evaluation\nby appropriate government agencies. All groups and organizations wishing to procure test kits\nfor use in the country should adhere to the approved RTKs. Similarly, all newly procured batches\nof RTKs should undergo Post-Market Validation (PMV) duly endorsed by the national and State\nHIV Program.\n    \u00a7   Serial testing: This is the use of 2 different screening tests employed sequentially to test\n        for HIV antibody. If the initial screening is negative, no further testing is required. If the\n        initial test is positive, it is followed by a second test.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2061, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "908902d5-d79d-407e-817c-23f5ca168827": {"__data__": {"id_": "908902d5-d79d-407e-817c-23f5ca168827", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "39"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "92bf2e05-3654-4dcf-899e-375b80e8a29d", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "39"}, "hash": "0fa0d586e53c38d683d6b03748b51520162b04734f8c0dd7a614297b2c18966e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "940814c5-8250-4d0a-826c-117acba7eae2", "node_type": "1", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "39"}, "hash": "e42ad8cfea5fe8d16482e252cb2f5e28472cdd8ea95771881e84c2f3c18fcb2e", "class_name": "RelatedNodeInfo"}}, "text": "If the initial screening is negative, no further testing is required. If the\n        initial test is positive, it is followed by a second test. The first test should be the most\n        sensitive test and the second test should be very specific and based on an antigen source\n        different from that of the first test. Samples that produce discordant results in the two\n        tests are subjected to a third test called a tiebreaker. The main advantage of the serial over\n        parallel testing is the cost-savings in testing.\n          NATIONAL GUIDELINES FOR HIV PREVENTION TREATMENT AND CARE 2020              17", "mimetype": "text/plain", "start_char_idx": 1918, "end_char_idx": 2540, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8188bafd-ffbb-4990-83d2-378eac86c42f": {"__data__": {"id_": "8188bafd-ffbb-4990-83d2-378eac86c42f", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "40"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "6343b313-1d0c-430a-ba16-ee3cda232e1c", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "40"}, "hash": "ecf1805d00aba853d9b0cc3def4c8d828f5762de351c2be35deef5bfaea718d0", "class_name": "RelatedNodeInfo"}}, "text": "Figure 2.2 Serial Testing Algorithm\nKey:\nTest 1: Screening\nTest 2: Confirmatory\nTest 3: Tie Breaker\n2.8.2 Enzyme-Linked Immunosorbent Assay (ELISA) or Enzyme Immunoassay (EIA) for\nBlood Screening\nThis test detects HIV antibodies, which the body starts producing between 2-12 weeks after\nbecoming infected with HIV. Current HIV antibody test can detect antibodies as early as 3 weeks\nafter exposure. ELISA test system is grouped into 1st to 4th generation. While all can detect HIV\nantibody as early as 3 weeks, the 4th generation can detect both IgG and IgM antibodies, HIV-\n          NATIONAL GUIDELINES FOR HIV PREVENTION TREATMENT AND CARE 2020           18", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 660, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3d0d4905-7317-4170-8da8-4e01851fbaac": {"__data__": {"id_": "3d0d4905-7317-4170-8da8-4e01851fbaac", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "41"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "5fe73d90-810c-4f11-b0be-32f5ba5bf25e", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "41"}, "hash": "8d2e6548c97f0a5e4add4f3d01aa7b3b78b6d6cc78cb30972715393f07b6b907", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "016e2b9f-6077-4929-8b98-ff7c6ffcd3eb", "node_type": "1", "metadata": {}, "hash": "f9b16409ea86b0ad85ded8ccb5153ea3e89ea577c0c6176acb4ac58e249be367", "class_name": "RelatedNodeInfo"}}, "text": "1/HIV-2 antibodies and also p24 antigen. This makes the 4th generation more suitable for blood\ntransfusion screening for HIV.\n2.8.3 NucleicAcid-based Testing\nThis consists of DNA Polymerase Chain Reaction (DNA-PCR) and Reverse Transcriptase\nPolymerase Chain Reaction (RT-PCR). These tests are not routinely used for laboratory\ndiagnosis of HIV infection in adults and adolescents. Nucleic acid tests are virologic assays that\ndetect, confirm and measure the number of viral particles in the blood. It is recommended that\nvirologic assays used for clinical diagnostic testing (usually at birth, 6-8 weeks of age and below\n18 months of age) should have a sensitivity of >95% and a specificity of >98% under quality-\nassured, standardized and validated laboratory conditions.\n2.8.4 HIV DNAPolymerase Chain Reaction (PCR)\nThe HIV DNA-PCR test involves the amplification of specific DNA sequences in the proviral\nDNA that has been integrated into the host cell. This test is the preferred option for diagnosing or\nconfirming HIV infection in infants less than 18 months of age. However, false-positive results\nmay occur as a result of contamination or improper specimen handling. There is a need therefore\nto always ensure quality assurance and validation procedures in the laboratory.\n2.8.5 Viral LoadAssay- Reverse Transcriptase Polymerase Chain Reaction (RT-PCR)\nViral load RT-PCR test is used to detect and quantify the amount of HIV RNA in plasma, Dried\nBlood Spot (DBS) and plasma separation cards. The assay requires the conversion of viral RNA\nto DNA and amplification of specific sequences in the DNA produced by a process known as\nreverse transcriptase polymerase chain reaction (RT-PCR). Results are reported in copies/ml of\nplasma.\nSample Referral System: VL and EID samples are moved from areas without PCR laboratories\nto testing laboratories in the optimized networks and results returned by the National Integrated\nSample Referral Network (NISRN).", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1958, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "016e2b9f-6077-4929-8b98-ff7c6ffcd3eb": {"__data__": {"id_": "016e2b9f-6077-4929-8b98-ff7c6ffcd3eb", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "41"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "5fe73d90-810c-4f11-b0be-32f5ba5bf25e", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "41"}, "hash": "8d2e6548c97f0a5e4add4f3d01aa7b3b78b6d6cc78cb30972715393f07b6b907", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3d0d4905-7317-4170-8da8-4e01851fbaac", "node_type": "1", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "41"}, "hash": "12b9e5f6c2c3302ed9449ad6bea342d3c13bf90f26b3cfc87b5d1e819fcfb26a", "class_name": "RelatedNodeInfo"}}, "text": "Sample Referral System: VL and EID samples are moved from areas without PCR laboratories\nto testing laboratories in the optimized networks and results returned by the National Integrated\nSample Referral Network (NISRN). Clinical sample types have been expanded from the\ntraditional whole blood EDTA-plasma and DBS for VL to include Plasma Separation Card\n(PSC) and Plasma Preparation Tubes (PPT) to facilitate improved viral load quantification\ntesting, equitable viral load access for both clinic and community service-points across Nigeria\nthrough ease of handling, storage and transportation. All the standard of care PCR laboratories\nshould be linked to the National Laboratory Information Management Systems (LIMS) which is\nin turn linked to Nigeria Medical Records System (NMRS) and National Data Repository (NDR)\nfor real-time reporting of patients results into the health facility records and health repository.\nPoint of Care Testing (POCT) devices are being introduced into the HIV program to further\nensure equitable viral load access to key populations: paediatrics, pregnant/breastfeeding\nmothers, MSM, FSW, PWID; hard-to-reach communities, security challenged and other settings\nto bring testing closer to the clients, enhance effective viral load coverage and quick Turnaround\nTime (TAT) of results for clinical management of patients. Capacity development and Quality\nAssurance (QA) oversight will be provided quarterly by experts supporting the standard of care\nlaboratories. All the POCT devices for viral load will participate in National EQA supported by\nthe National Reference Laboratory/National External Quality Assurance Lab. This is to ensure\nquality assured results are produced from these devices and are useful for the management of\npatients.\n           NATIONAL GUIDELINES FOR HIV PREVENTION TREATMENT AND CARE 2020            19", "mimetype": "text/plain", "start_char_idx": 1739, "end_char_idx": 3596, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "610f6d17-09b3-4bd6-a083-272923bd4a27": {"__data__": {"id_": "610f6d17-09b3-4bd6-a083-272923bd4a27", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "42"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "7f69f97d-1b49-4ebe-b5b1-9df587747952", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "42"}, "hash": "e04f819675beb43ef809172b60877a3ff2d268337249e61eba7ecfe1cba1fd86", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d71c3e4f-9694-45fb-8f08-499f7bbe305a", "node_type": "1", "metadata": {}, "hash": "9907bc9710b10397fc96dd515ce72c9dfd875ad1141e0a99ac15b57f317cb842", "class_name": "RelatedNodeInfo"}}, "text": "2.9 Laboratory Diagnosis of HIV Infection in Children byAge Group\n   2.9.1 Children aged \u226418 months\n      Nucleic Acid Amplification Testing (NAAT) or Nucleic Amplification Testing (NAT) to detect\n DNA - can be used to detect HIV infection in neonates at birth, 6-8 weeks and 9 months. Testing\n   at birth will plug the gap of loss to follow up between birth and 6 months. Exposed infants are\nbrought into care as early as possible to reduce morbidity and mortality. NAAT has a specificity\nof 99.6% and sensitivity of 100% for infants infected during pregnancy or at least 4 weeks prior\n  to sample collection for testing. However, there is a need for follow-up testing at 6 weeks, 9\n months and 6 weeks after cessation of breastfeeding at a standard of care laboratory because of\n   the possibility of a false positive or negative result.\n         Polymerase Chain Reaction (PCR) should be used for the detection of HIV DNA in children\n       between the ages of 6 weeks to 18 months. Standard PCR laboratories available as referral\n network in the six geopolitical zones of Nigeria will support EID testing and return of results\n      back to facilities through the linkage of Laboratory Information Management Systems (LIMS)\n   to EMR platform.\n      \u00a7    All HIV\u2013 exposed infants should have initial DNAPCR testing at 0-3 days of age, then at\n           6-8 weeks of age (or earliest opportunity thereafter) and 6 weeks after complete\n           cessation of breastfeeding. DNAPCR test results should be provided to the clinic and\n           caregiver as soon as possible; latest within four weeks of specimen collection.\n      \u00a7    HIV- exposed children 9 -18 months of age may have circulating maternal antibodies\n           which could be from the child and/or the mother. In this case, DNA or RNA PCR is the\n           test of choice for a definitive diagnosis.\n      \u00a7    If a screening antibody test is negative, HIV-infection is excluded if the test has been\n           conducted at least 6 weeks after complete cessation of breastfeeding.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2050, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d71c3e4f-9694-45fb-8f08-499f7bbe305a": {"__data__": {"id_": "d71c3e4f-9694-45fb-8f08-499f7bbe305a", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "42"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "7f69f97d-1b49-4ebe-b5b1-9df587747952", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "42"}, "hash": "e04f819675beb43ef809172b60877a3ff2d268337249e61eba7ecfe1cba1fd86", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "610f6d17-09b3-4bd6-a083-272923bd4a27", "node_type": "1", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "42"}, "hash": "76f639631db6d4b2265599a9dcafbf3b5a8aaafeacec54aedfe82a30a1106cb0", "class_name": "RelatedNodeInfo"}}, "text": "\u00a7    If a screening antibody test is negative, HIV-infection is excluded if the test has been\n           conducted at least 6 weeks after complete cessation of breastfeeding.\n      \u00a7    For sick children <18 months in whom HIV infection is being considered, in the absence\n           of virological tests (DNA-PCR), HIV serological testing (RTKs) and use of the\n           algorithm (WHO clinical staging) for presumptive clinical diagnosis are recommended.\n      \u00a7    In a child <18 months with an initial positive virological test result, it is recommended\n           that ART should be started immediately, while a second specimen is collected to confirm\n           the result. It is not advised to deferART until the confirmation result is received.\n      \u00a7    HIV-exposed infants who are well should undergo HIV serological testing at 9 months of\n           age (or at the time of last immunization visit).\n      \u00a7    Infants who have reactive serological assays at 9 months should have     an immediate\n           virological test to confirm HIV infection and the need forART.\n      \u00a7    It is strongly recommended that children <18 months of age, with signs and symptoms\n           suggestive of HIV infection should undergo HIV serological testing in a setting where\n           DNA-PCR is not immediately available and if positive (reactive), do a DNA PCR test or\n           NAAT.\n      \u00a7    NAT technologies that are developed and validated for use at or near to the point of care\n           can be used for early infant HIV testing.\n             NATIONAL GUIDELINES FOR HIV PREVENTION TREATMENT AND CARE 2020             20", "mimetype": "text/plain", "start_char_idx": 1876, "end_char_idx": 3509, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bc6054f9-173a-4a32-9b2c-7445962c8cbd": {"__data__": {"id_": "bc6054f9-173a-4a32-9b2c-7445962c8cbd", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "43"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "aeb9eaa1-4ca4-458e-b00f-109d950c9113", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "43"}, "hash": "a40a1c8cd200d94ef0dea16d5f2c5a0429157eda7f05e0d038f1e67cdb8e5027", "class_name": "RelatedNodeInfo"}}, "text": "POSITIVE            NEGATIVE\n                   POSITIVE            NEGATIVE\n                               NEGATIVE\n                                                         POSITIVE        NEGATIVE\n                                           POSITIVE       NEGATIVE\n                                                                      POSITIVE      NEGATIVE\nFigure 2.3: Nigeria diagnostic testing protocol: HIV-exposed infants (< 18 months of age)\n          NATIONAL GUIDELINES FOR HIV PREVENTION TREATMENT AND CARE 2020                   21", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 542, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "eb7dcbd6-4b1c-400f-8613-186616908a45": {"__data__": {"id_": "eb7dcbd6-4b1c-400f-8613-186616908a45", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "44"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "6bfed05e-5bad-4e23-afc4-60b12f30e1b7", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "44"}, "hash": "ef29f069a51726ca6dabb665f73a0b6092f6c5411146b5318ffb0a456a08d7d3", "class_name": "RelatedNodeInfo"}}, "text": "2.9.2 Children aged \u226518 months\n    \u00a7   Antibody detection is reliable and recommended for children \u226518 months. The\n        exception is during the window period (6-8 weeks post-exposure) where antibodies may\n        not be present at a detectable level. For children testing negative, a repeat antibody\n        testing 3 months later is recommended if the window period is suspected.\n    \u00a7   From 18 months of life, an antibody test should be performed irrespective of whether a\n        child received breast milk or replacement feeds.\n    \u00a7   If the child is receiving breast milk after 18 months of age, repeat the test 12 weeks after\n        complete cessation of breastfeeding.\n    \u00a7   Methods such as DNA/RNAPCR could be used to resolve suspected false-negative\n        result.\n2.10 Clinical Diagnosis and Staging of HIV Infection\nThe WHO clinical staging of HIV for adults and adolescents that are HIV positive is as shown in\nTables 2.1 and 2.2. Staging is based on the patient's clinical presentation at the time of initial\nassessment with the healthcare provider. The most advanced symptoms at the time of evaluation\nrepresent the initial clinical stage of HIV infection.\nTable 2.1 WHO Clinical Classification of Established HIV Infection\n     HIV - Associated Symptomatology                      WHO Clinical Stage\n    Asymptomatic                                                     1\n    Mild Symptoms                                                    2\n    Advanced Symptoms                                                3\n    Severe Symptoms                                                  4\nThe staging systems include.\n    \u00b7   Presumptive clinical diagnoses that can be made in the absence of laboratory tests\n    \u00b7   Definitive clinical criteria that require confirmatory laboratory tests\n          NATIONAL GUIDELINES FOR HIV PREVENTION TREATMENT AND CARE 2020           22", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1893, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "dca62519-9b42-497e-ab14-ba6ce95bb0b3": {"__data__": {"id_": "dca62519-9b42-497e-ab14-ba6ce95bb0b3", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "45"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "c52b90a9-fcbe-4026-9ee1-adc00645fd88", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "45"}, "hash": "2a8b41b1adc419cda46b99be74c47b38caa88670e36102e11aea1daf31d044a1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "81e39c90-0469-4853-afdc-9bea3e11d3de", "node_type": "1", "metadata": {}, "hash": "b89bcead16ca32e3aacf6e0001bfdeda3d0e176a9fdeaf3d160cc072c6568a2d", "class_name": "RelatedNodeInfo"}}, "text": "Table 2.2 WHO Clinical Staging of HIV/AIDS for Adults and Adolescents with confirmed HIV Infection\nAdults and adolescentsa                             Children\n  Clinical stage 1\n \u2022  Asymptomatic                                    \u2022 Asymptomatic\n \u2022  Persistent generalized lymphadenopathy          \u2022 Persistent generalized lymphadenopathy\n  Clinical stage 2\n \u2022  Moderate unexplained weight loss (<10% of       \u2022 Unexplained persistent hepatosplenomegaly\n    presumed or measured body weight)               \u2022 Recurrent or chronic upper respiratory tract infections\n \u2022  Recurrent respiratory tract infections             (otitis media, otorrhoea, sinusitis, tonsillitis)\n    (sinusitis, tonsillitis, otitis media,          \u2022 Herpes zoster\n \u2022  pharyngitis)                                    \u2022 Lineal gingival erythema Recurrent oral ulceration\n    Herpes zoster Angular cheilitis                    Papular pruritic eruption Fungal nail infections\n \u2022  Recurrent oral ulceration Papular pruritic         Extensive wart virus infection\n    eruption Fungal nail infections Seborrhoeic     \u2022 Extensive molluscum contagiosum\n    dermatitis                                      \u2022 Unexplained persistent parotid enlargement\n  Clinical stage 3\n \u2022  Unexplained severe weight loss (>10% of         \u2022 Unexplained moderate malnutritionb not adequately\n    presumed or measured body weight)                  responding to standard therapy\n \u2022  Unexplained chronic diarrhoea for longer        \u2022 Unexplained persistent diarrhoea (14 days or more)\n    than 1 month                                    \u2022 Unexplained persistent fever (above 37.5\u00b0C,\n \u2022  Unexplained persistent fever (intermittent or      intermittent or constant, for longer than one 1 month)\n    constant for longer than 1 month)               \u2022  Persistent oral candidiasis (after first six weeks of\n \u2022  Persistent oral candidiasis Oral hairy             life) Oral hairy leukoplakia\n    leukoplakia Pulmonary tuberculosis              \u2022 Lymph node tuberculosis; pulmonary tuberculosis\n \u2022  Severe bacterial infections (such as               Severe recurrent bacterial pneumonia\n    pneumonia, empyema, pyomyositis, bone or        \u2022 Acute necrotizing ulcerative gingivitis or\n    joint infection, meningitis,", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2253, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "81e39c90-0469-4853-afdc-9bea3e11d3de": {"__data__": {"id_": "81e39c90-0469-4853-afdc-9bea3e11d3de", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "45"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "c52b90a9-fcbe-4026-9ee1-adc00645fd88", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "45"}, "hash": "2a8b41b1adc419cda46b99be74c47b38caa88670e36102e11aea1daf31d044a1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "dca62519-9b42-497e-ab14-ba6ce95bb0b3", "node_type": "1", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "45"}, "hash": "d5d234d0ff0d0330f085df992ce27001a2ff1d05133b939ba5259db0a83b6c79", "class_name": "RelatedNodeInfo"}}, "text": "empyema, pyomyositis, bone or        \u2022 Acute necrotizing ulcerative gingivitis or\n    joint infection, meningitis, bacteraemia)          periodontitis\n \u2022  Acute necrotizing ulcerative stomatitis,        \u2022 Unexplained anaemia (<8 g/dL), neutropaenia (<0.5\n    gingivitis or periodontitis                        \u00d7 109/L) or chronic thrombocytopaenia (<50 \u00d7\n \u2022  Unexplained anaemia (<8 g/dl),                     109/L)\n    neutropaenia (<0.5 \u00d7                            \u2022 Symptomatic lymphoid interstitial pneumonitis\n \u2022  109/L) and/or chronic thrombocytopaenia         \u2022 Chronic HIV-associated lung disease, including\n    (<50 \u00d7 109/L)                                      bronchiectasis\n  Clinical stage 4c\n            NATIONAL GUIDELINES FOR HIV PREVENTION TREATMENT AND CARE 2020                          23", "mimetype": "text/plain", "start_char_idx": 2139, "end_char_idx": 2949, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d0b0793e-88f9-4f4a-ac42-95fc26788971": {"__data__": {"id_": "d0b0793e-88f9-4f4a-ac42-95fc26788971", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "46"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "a3745c4c-2e2e-44ef-8290-168409046fc7", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "46"}, "hash": "15e9edb45e959d09bc8b1b3659890e78ccdb0e24be328aac05449566686570ca", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "19c763a1-eb5c-40b7-b2df-0cba459a44f6", "node_type": "1", "metadata": {}, "hash": "091779a57729ef82ec0f35b44a874a6ccfd12ff5e479ba374c3a71238415e827", "class_name": "RelatedNodeInfo"}}, "text": "\u2022  HIV wasting syndrome                       \u2022  Unexplained severe wasting, stunting or severe\n  \u2022  Pneumocystis (jirovecii) pneumonia            malnutritiond not responding to standard therapy\n     Recurrent severe bacterial pneumonia       \u2022  Pneumocystis (jirovecii) pneumonia\n  \u2022  Chronic herpes simplex infection           \u2022  Recurrent severe bacterial infections (such as empyema,\n     (orolabial, genital or anorectal of more      pyomyositis, bone or joint infection, meningitis, but\n     than one month in duration or visceral at     excluding pneumonia)\n     any site)                                  \u2022  Chronic herpes simplex infection (orolabial or cutaneous\n  \u2022  Oesophageal candidiasis (or candidiasis       of more than 1 month\u2019s duration or visceral at any site)\n     of trachea, bronchi or lungs)              \u2022  Oesophageal candidiasis (or candidiasis of trachea,\n  \u2022  Extrapulmonary tuberculosis Kaposi            bronchi or lungs)\n     sarcoma                                    \u2022  Extrapulmonary tuberculosis Kaposi sarcoma\n  \u2022  Cytomegalovirus infection (retinitis or    \u2022  Cytomegalovirus infection (retinitis or infection of other\n     infection of other organs)                    organs with onset at age older than one month)\n  \u2022  Central nervous system toxoplasmosis       \u2022  Central nervous system toxoplasmosis (after the neonatal\n     HIV encephalopathy                            period)\n  \u2022  Extrapulmonary cryptococcosis,             \u2022  HIV encephalopathy\n  \u2022  including meningitis                       \u2022  Extrapulmonary cryptococcosis,", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1574, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "19c763a1-eb5c-40b7-b2df-0cba459a44f6": {"__data__": {"id_": "19c763a1-eb5c-40b7-b2df-0cba459a44f6", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "46"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "a3745c4c-2e2e-44ef-8290-168409046fc7", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "46"}, "hash": "15e9edb45e959d09bc8b1b3659890e78ccdb0e24be328aac05449566686570ca", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d0b0793e-88f9-4f4a-ac42-95fc26788971", "node_type": "1", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "46"}, "hash": "54ae0d94310e2ca4c51c8e705f98d71ebf4312a3496342a8c85dcea9d582496e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a081cf28-ac17-41bd-939d-4e0f91718678", "node_type": "1", "metadata": {}, "hash": "6c60443b51a4bac252884882c659ace61e99f41e5902c02626a36eb0a7240f69", "class_name": "RelatedNodeInfo"}}, "text": "\u2022  HIV encephalopathy\n  \u2022  including meningitis                       \u2022  Extrapulmonary cryptococcosis, including meningitis\n     Disseminated nontuberculous                \u2022  Disseminated nontuberculous mycobacterial infection\n  \u2022  mycobacterial infection                    \u2022  Progressive multifocal leukoencephalopathy\n     Progressive multifocal                     \u2022  Chronic cryptosporidiosis (with diarrhoea) Chronic\n  \u2022  leukoencephalopathy                           isosporiasis\n     Chronic cryptosporidiosis Chronic          \u2022  Disseminated endemic mycosis (extrapulmonary\n  \u2022  isosporiasis                                  histoplasmosis, coccidioidomycosis, penicilliosis)\n     Disseminated mycosis (extrapulmonary       \u2022  Cerebral or B-cell non-Hodgkin lymphoma HIV-\n  \u2022  histoplasmosis, coccidioidomycosis)           associated nephropathy or cardiomyopathy\n     Lymphoma (cerebral or B-cell non-\n     Hodgkin)\n  \u2022  Symptomatic HIV-associated\n     nephropathy or cardiomyopathy\n  \u2022  Recurrent septicaemia (including\n     nontyphoidal\n  \u2022  Salmonella)\n  \u2022  Invasive cervical carcinoma Atypical\n     disseminated leishmaniasis\na In the development of this table, adolescents were defined as 15 years or older. For those younger than 15 years, the clinical staging for children\nshould be used.\nb For children younger than 5 years, moderate malnutrition is defined as weight-for-height < \u20132 z-score or mid-upper arm circumference 115\nmm to <125 mm.\nc Some additional specific conditions can be included in regional classifications, such as penicilliosis in Asia, HIV-associated rectovaginal\nfistula in southern Africa and reactivation of trypanosomiasis in Latin America.", "mimetype": "text/plain", "start_char_idx": 1471, "end_char_idx": 3154, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a081cf28-ac17-41bd-939d-4e0f91718678": {"__data__": {"id_": "a081cf28-ac17-41bd-939d-4e0f91718678", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "46"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "a3745c4c-2e2e-44ef-8290-168409046fc7", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "46"}, "hash": "15e9edb45e959d09bc8b1b3659890e78ccdb0e24be328aac05449566686570ca", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "19c763a1-eb5c-40b7-b2df-0cba459a44f6", "node_type": "1", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "46"}, "hash": "f6fc71d31158360e2a0219f5de08b65362a90e70d609c9565adb7c9566fdedab", "class_name": "RelatedNodeInfo"}}, "text": "c Some additional specific conditions can be included in regional classifications, such as penicilliosis in Asia, HIV-associated rectovaginal\nfistula in southern Africa and reactivation of trypanosomiasis in Latin America.\nd For children younger than five years of age, severe wasting is defined as weight-for-height < \u20133 z-score; stunting is defined as length-for-\nage/height-for-age < \u20132 z-score; and severe acute malnutrition is either weight for height < \u20133 z-score or mid-upper arm circumference <115\nmm or the presence of oedema.\nSource: Adapted from: WHO case definitions of HIV for surveillance and revised clinical staging and immunological classification of HIV-\nrelated disease in adults and children. Geneva, World Health Organization, 2007 (www.who.int/hiv/pub/guidelines/HIVstaging150307.pdf).\n             NATIONAL GUIDELINES FOR HIV PREVENTION TREATMENT AND CARE 2020                          24", "mimetype": "text/plain", "start_char_idx": 2932, "end_char_idx": 3843, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "351f0b12-1d68-4094-946a-f0e593fd0c1f": {"__data__": {"id_": "351f0b12-1d68-4094-946a-f0e593fd0c1f", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "47"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "f0aae6a7-1a78-4f55-9ce4-44e6e43fd70c", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "47"}, "hash": "57e8b10c981fa964ea2db27196c9368b1652610a572b144c0bdbe2e0bc1a09ce", "class_name": "RelatedNodeInfo"}}, "text": "List of Contributors                                                       Chapter 2\nMrs Grace Mfon Bassey                Assistant.Director, Head LAB NASCP\nMrs Ima-Dada John                    Assistant Director, Head HTS NASCP\nMrs Katherine Igbosofulu             Assistant Director, ACSM NASCP\nMr Envuladu Ovye                     Chief Science Lab. Technologist NASCP\nMrs Etubi Eruona                     ACMLS, Treatment, Care and Support NASCP\nOkorie Uche                          Senior Medical Laboratory Scientist NASCP\nSamson Omoighe                       Scientific officer 1 NASCP\nJames Yohanna                        Scientific Officer/PDA NASCP\nAgba Janet C                         AD MLS NTBS/FMOH\nDr Rex Mpazanje                      HIV Adviser WHO\nAdegoke Olufemi Dickson              Laboratory Systems Specialist CDC\nOkoye McPaul                         Laboratory Branch Chief/Project Officer CDC\nDr Jerry Gwamna                      Prevention Branch Chief CDC\nChidozie Meribe                      Senior Program Specialist HTS CDC\nDr Aminu Suleiman                    Lab Lead US DoD\nDr Yusuf Ahmed                       Prevention Team Lead US DoD\nAngela Agweye                        Project Management Specialist Testing and Linkages USAID\nKingston Omo-Emmanuel                Clinical Laboratory Manager USAID\nMrs Pamela Nenpanmwa Gado            HIV Testing Services Programme Manager USAID\nJibrin Kama                          Senior Program Manager CHAI\nAisha Ejigbo                         Senior Analyst CHAI\nObed Ikechukwu Nnamdi                Laboratory Quality Assurance/LMIS Specialist SFH\nChinelo Ekweremadu                   Senior Technical Specialist CRS\nChris Ogar                           MSH\nAbutu Abraham.E.                     Monitoring & Evaluation Officer NEPWHAN\nMr Mark Akhigbe                      Laboratory Advisor Heartland Alliance\nFortune Kailo                        National Coordinator APYIN\nDr Ali Onoja                         CEO African Health Project\nMr Manason Rubainu                   CEO Peak Medical Laboratories\n         NATIONAL GUIDELINES FOR HIV PREVENTION TREATMENT AND CARE 2020       25", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2164, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f98cd470-7b07-4ea9-90d4-2d6238c700d6": {"__data__": {"id_": "f98cd470-7b07-4ea9-90d4-2d6238c700d6", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "48"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "9462f033-4b95-46c4-9dd5-8b57c1cda3ec", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "48"}, "hash": "e1eccc0a02804de2a74194d71e057f3fc6a6bdfe762e75a3b2c1bbabbacbb881", "class_name": "RelatedNodeInfo"}}, "text": "3. ANTIRETROVIRAL\n                THERAPY\nWhat\u2019s Inside:\n 1.1 Objectives of the Guidelines\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026..\n3.1 Introduction\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026..\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026..\u202627\n 1.2 Epidemiology of HIV in Nigeria\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\n3.2 Classes of Antiretroviral Drugs\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026..\u2026\u202627\n 1.3 Natural History of HIV\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026.\u2026\u2026\n3.3. Preparation of Adults, Adolescents and\n     Children for ART\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026..\u2026\u2026\u2026\u2026\u2026\u2026....29\n3.4 Recommended ART Regimen for Adults,\n   Adolescents and Children\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026..\u2026\u2026\u2026\u202623\n3.5 Monitoring Patients on ART\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026..\u2026\u2026\u202634\n3.6 Management of HIV Treatment Failure\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026.37\n3.7 Third-line ART\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026..\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026.42\n3.8 Low-Level Viremia (LLV) \u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026..\u2026\u2026\u2026..43\n3.9 ART in Special Circumstances\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026..\u2026.....44", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 703, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "74088410-1373-49fc-b5a8-7ad1a5799bf4": {"__data__": {"id_": "74088410-1373-49fc-b5a8-7ad1a5799bf4", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "49"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "54019822-f97c-4b6b-8a63-f536088a96d5", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "49"}, "hash": "082f17a135c45a90549d341a06c5df0e1d3f1c84194d430db13f7932a57ece67", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "94d6ca21-e99d-4e2e-ad30-6d6925b1f369", "node_type": "1", "metadata": {}, "hash": "e73f686d4655481e85790af9902dcc7a56b5ce71a4e0babc41aa4cf1ea369daa", "class_name": "RelatedNodeInfo"}}, "text": "3.1 Introduction\nAntiretroviral therapy (ART) is the treatment of HIV infection using a combination of\nantiretroviral drugs (ARVs). All HIV infected persons irrespective of clinical stage and CD4+\ncell count without contraindications should be initiated the same day or within 7 days of HIV\ndiagnosis if possible. Pregnant and breastfeeding women, infants and children under 5 years, and\npatients with advanced HIV disease (AHD) should be prioritized for rapid initiation of ART.\nAntiretroviral therapy (ART) should be offered in a comprehensive manner that includes access\nto on-going adherence counselling, baseline and periodic clinical and laboratory monitoring,\nprevention and management of opportunistic infection (OIs), treatment monitoring and follow-\nup.\nThe goal of ART includes achievement of sustained virologic, immunologic, clinical, and\nepidemiologic control of HIV. Sustained viral suppression is necessary to prevent the\ndevelopment of ARV drug resistance, reduce morbidity from OIs and improve the quality of life\nof HIV infected individuals. In children, ART will promote and restore normal growth and\ndevelopment.\n3.2 Classes ofAntiretroviral Drugs\nAntiretroviral drugs (ARVs) are classified according to their modes of action. Each class targets\na different step in the viral life cycle. The classes of antiretroviral drugs are:\nNucleoside/Nucleotide Reverse Transcriptase Inhibitors (NRTIs):These compete with host\nnucleotides to serve as the substrate for reverse transcriptase chain elongation. Absence of 3'OH\ngroup on sugar moiety prevents the addition of another nucleotide, resulting in chain\ntermination, abortion of viral DNAchain elongation and cessation of viral replication.\nNon-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs):                Inhibit HIV reverse\ntranscriptase by binding a hydrophobic pocket close to the active site thereby locking the site in\nan inactive conformation.\nProtease Inhibitors (PI): Inhibit HIV protease by binding to its active site, preventing the\ncleavage of gag and gag-pol precursor. Virions are produced but they are incomplete and non-\ninfectious.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2123, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "94d6ca21-e99d-4e2e-ad30-6d6925b1f369": {"__data__": {"id_": "94d6ca21-e99d-4e2e-ad30-6d6925b1f369", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "49"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "54019822-f97c-4b6b-8a63-f536088a96d5", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "49"}, "hash": "082f17a135c45a90549d341a06c5df0e1d3f1c84194d430db13f7932a57ece67", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "74088410-1373-49fc-b5a8-7ad1a5799bf4", "node_type": "1", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "49"}, "hash": "9da49c3a7df733f85bc25989e24fefa4f6c04da54049a14de0bc5ebdc56e04c2", "class_name": "RelatedNodeInfo"}}, "text": "Protease Inhibitors (PI): Inhibit HIV protease by binding to its active site, preventing the\ncleavage of gag and gag-pol precursor. Virions are produced but they are incomplete and non-\ninfectious.\nEntry Inhibitors: Block the mechanisms by which HIV gains access into the cytoplasm of\nCD4+ cell molecule bearing cell. There are 3 classes:\n   (a) Attachment inhibitors: These agents complex with glycoprotein 120 and prevent it from\n         interacting with the CD4+ molecule thus, the attachment of the virus to the cell is\n       blocked.\n   (b)  Fusion inhibitors: These are agents designed to complex with the viral GP41. GP41 is\n         the viral protein that is capable of fusing with cellular membrane molecules called\n       chemokine receptors. The interaction of fusion inhibitors with GP41 blocks the fusion\n       of viral membrane with cellular membrane.\n   (c)      Chemokine Receptor Antagonists: These are agents that complex with cell membrane\n       receptors that serve as fusion proteins i.e. CXCR4, CCR5.\n          NATIONAL GUIDELINES FOR HIV PREVENTION TREATMENT AND CARE 2020            27", "mimetype": "text/plain", "start_char_idx": 1926, "end_char_idx": 3039, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d92d1a3c-a38b-4943-8082-0655295b6a3b": {"__data__": {"id_": "d92d1a3c-a38b-4943-8082-0655295b6a3b", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "50"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "92fee59f-3be9-445a-97ee-b7879139f00b", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "50"}, "hash": "e2f75aa09a76f087d432636c35981d832358626d4ee475f49bbb63f857bf6f86", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "de62119d-d3e6-4a79-ba85-20927bf33dfc", "node_type": "1", "metadata": {}, "hash": "36d825da3cf5e7bd463bd07266cf8762d9f946c4f4ec80efb869c75aae811089", "class_name": "RelatedNodeInfo"}}, "text": "HIV Integrase Inhibitors:Also known as Integrase Strand Transfer Inhibitors (INSTI). These\ninhibit DNA strand transfer into the host-cell genome and thus prevent viral integration.\nIntegrase Inhibitors do not confer resistance to otherART classes.\nPharmacokinetic enhancers/ PI boosters: These are drugs used in HIV treatment to increase\nthe effectiveness of certain classes of ARV drugs. The PIs are metabolized by cytochrome P450\n(CYP) 3A enzymes; and intentional inhibition of these enzymes' lead to higher drug exposure,\nlower pill burden and simplified dosing schedules (pharmacokinetic enhancement). In HIV\ntherapy, two pharmacokinetic enhancers or boosting agents are used: ritonavir and cobicistat.\nThese agents inhibit CYP3A4, with cobicistat being a more specific CYP inhibitor than\nritonavir. Unlike ritonavir, cobicistat does not have antiretroviral activity.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 871, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "de62119d-d3e6-4a79-ba85-20927bf33dfc": {"__data__": {"id_": "de62119d-d3e6-4a79-ba85-20927bf33dfc", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "50"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "92fee59f-3be9-445a-97ee-b7879139f00b", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "50"}, "hash": "e2f75aa09a76f087d432636c35981d832358626d4ee475f49bbb63f857bf6f86", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d92d1a3c-a38b-4943-8082-0655295b6a3b", "node_type": "1", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "50"}, "hash": "e14ff1e58b8575250335d1ca1dd2be470cef67d2d2f23f05c564be7ec1c78d45", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e43e550c-7c64-424d-a5d0-7418e7244f14", "node_type": "1", "metadata": {}, "hash": "001382477359ae5e69c02731863637ddbbce7d9ace71692540bd89e3a4fa9938", "class_name": "RelatedNodeInfo"}}, "text": "These agents inhibit CYP3A4, with cobicistat being a more specific CYP inhibitor than\nritonavir. Unlike ritonavir, cobicistat does not have antiretroviral activity.\nTable 3.1 Classes of Antiretroviral Drugs\n Class                                 Drugs\n Nucleoside/Nucleotide Reverse         Abacavir (ABC); Emtricitabine (FTC); Lamivudine (3TC);\n Transcriptase Inhibitors (NRTIs       Tenofovir Disoproxil fumarate (TDF); Tenofovir\n                                       Alafenamide (TAF); Zidovudine (AZT, ZDV); Didanosine\n                                           *\n                                       (ddI) ; Stavudine (d4T)\n Non-Nucleoside Reverse                Efavirenz (EFV); Etravirine (ETR); Nevirapine (NVP);\n Transcriptase Inhibitors (NNRTIs)     Rilpivirine (RPV)\n Protease Inhibitors (PI)              Atazanavir (ATV); Darunavir (DRV); Lopinavir (LPV);\n                                       Fosamprenavir (FPV); Indinavir (IDV); Nelfinavir\n                                       (NFV); Saqu inavir (SQV); Tipranavir (TPV)\n Protease Inhibitors (PIs) boosters    Ritonavir (RTV); Cobicistat (COBI)\n Integrase Strand Transfer Inhibitors  Dolutegravir (DTG); Elvitegravir (EVG); Raltegravir\n (INSTIs)                              (RAL); Cabotegravir (CAB)\n Attachment Inhibitors                 Fostemsavir; Ibalizumab; Anti CD4 adnectin\n Fusion Inhibitors                     Enfuvirtide; Anti-GP41 Adnectin; Combinectin\n Chemokine receptor antagonists        Maraviroc; Vicroviroc; Cenicriviroc\nAntiretroviral Drug Combination for HIV Treatment: It is recommended that combinations\nof a minimum of three drugs from at least two different classes of ARVs be used for ART.", "mimetype": "text/plain", "start_char_idx": 707, "end_char_idx": 2395, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e43e550c-7c64-424d-a5d0-7418e7244f14": {"__data__": {"id_": "e43e550c-7c64-424d-a5d0-7418e7244f14", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "50"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "92fee59f-3be9-445a-97ee-b7879139f00b", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "50"}, "hash": "e2f75aa09a76f087d432636c35981d832358626d4ee475f49bbb63f857bf6f86", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "de62119d-d3e6-4a79-ba85-20927bf33dfc", "node_type": "1", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "50"}, "hash": "6e09f69a728adb724efa35ad54a0d7ca55953e69ea51824e4b697697c1dcbc26", "class_name": "RelatedNodeInfo"}}, "text": "These\nARVs are expected to act at different points of the HIV life cycle. Typically, a backbone of 2\nNRTIs combined with an Integrase inhibitor, an NNRTI or a PI is used. Monotherapy or dual\nARV therapy for HIV infection is not recommended for treatment because of the increased risk\nof development of drug resistance.\n          NATIONAL GUIDELINES FOR HIV PREVENTION TREATMENT AND CARE 2020             28", "mimetype": "text/plain", "start_char_idx": 2396, "end_char_idx": 2802, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "95c9e048-42ce-4e47-86a2-3a7f232d5347": {"__data__": {"id_": "95c9e048-42ce-4e47-86a2-3a7f232d5347", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "51"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "c11c9312-bd47-4e2a-abe0-d66cf1405f29", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "51"}, "hash": "325d109f0141182362a0c5d622701860efcd787d98a3047ccbe527732af26b26", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bf4125f4-d8f1-4b70-a7ff-0c64ed1a5fde", "node_type": "1", "metadata": {}, "hash": "f2b945dcbf8514305ee9d9ef9bc4f3e58d3784925ba0bedb8d1073746cb596d7", "class_name": "RelatedNodeInfo"}}, "text": "3.3. Preparation ofAdults,Adolescents and Children forART\n      3.3.1 BaselineAssessment forART\n      The baseline assessment and preparation of patients forART should include:\n         \u00a7    Re-testing for HIV to verify HIV positive status\n         \u00a7    Acomprehensive history and clinical examination\n         \u00a7    Assessment of patient's readiness for initiation of ART (regimen, dosage, scheduling,\n              benefits, adverse effects, follow up, monitoring visits and age-appropriate disclosure)\n         \u00a7    Development of patient-centred adherence strategy\n         \u00a7    Baseline laboratory assessment\n         It is noteworthy that the first few months of therapy are important especially as certain\n       occurrences during the period can influence the outcome of treatment. These include Adverse\n              drug reactions, immune reconstitution inflammatory syndrome (IRIS) and opportunistic\n          infections following commencement of treatment. These may confuse healthcare workers and\n     patients leading to poor adherence and treatment failure. Patients should be warned to expect\nthese complications but reassured that they are usually transient and would abate in the course of\n         treatment. The importance of adherence for positive treatment outcomes must be emphasized\n    and health care workers are encouraged to develop individualized treatment adherence plans for\n   each patient. Patients should be advised that poor adherence to treatment at any time following\n initiation of ART is associated with treatment failure, rapid development of drug resistance, ill\n   health and possibly death. HIV positive adolescents and adults who are not willing and ready to\n      startART should receive on-going counselling and education to promote retention in care.\n      3.3.2 Further BaselineAssessment\n      Further baseline assessment includes:\n         1.   Complete history and physical examination: Anthropometric assessment (weight,\n              height/length, OFC, chest & mid-upper arm circumference). History of comorbidities\n              (renal, cardiovascular disease), pregnancy, anaemia, STI, prior ART use - including\n              single-dose Nevirapine, prescribed medications, drug misuse (heroin, alcohol), should\n              be documented. Social and sexual history should also be determined especially for\n              adolescents.\n         2.   Screening for TB and Hepatitis (B and C) should be done.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2460, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bf4125f4-d8f1-4b70-a7ff-0c64ed1a5fde": {"__data__": {"id_": "bf4125f4-d8f1-4b70-a7ff-0c64ed1a5fde", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "51"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "c11c9312-bd47-4e2a-abe0-d66cf1405f29", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "51"}, "hash": "325d109f0141182362a0c5d622701860efcd787d98a3047ccbe527732af26b26", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "95c9e048-42ce-4e47-86a2-3a7f232d5347", "node_type": "1", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "51"}, "hash": "e95db0f23c11e051462f82b331551856d991c701ec3711471846d0e9769ba7ff", "class_name": "RelatedNodeInfo"}}, "text": "Social and sexual history should also be determined especially for\n              adolescents.\n         2.   Screening for TB and Hepatitis (B and C) should be done. Xpert MTB/RIF assay should\n              be used for cases of presumptive TB. Where GeneXpert equipment is not accessible or\n              specimen not available for Xpert MTB/RIF assay, PLHIV with CD4+ cell count <200\n              cells/mm3 or severely ill irrespective of CD4+ cell count should receive a urine LF -\n              LAM assay for TB diagnosis.\n         3.   Determination of nutritional, psychosocial, growth and immunization status of patient\n              (including determination of BMI for adults)\n         4.   Rectal and vaginal examination (including cervical cancer screening)\n         5.   Screen for mental health issues and substance abuse\n         6.   Screen for Non-Communicable diseases\n         7.   Determination of WHO clinical stage for HIV/AIDS\n         8.   Pregnancy assessment, family planning and counselling services, where required\n         9.   Conducting baseline laboratory assessments\n      This assessment should not delay the commencement ofART.\n                NATIONAL GUIDELINES FOR HIV PREVENTION TREATMENT AND CARE 2020             29", "mimetype": "text/plain", "start_char_idx": 2296, "end_char_idx": 3549, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "50a5a480-ae11-485e-ad7e-47aa19d95039": {"__data__": {"id_": "50a5a480-ae11-485e-ad7e-47aa19d95039", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "52"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "e9dc1e80-2ec4-4a1f-8b91-02fc9fe5501d", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "52"}, "hash": "44e21d6c894ebb34d8b187132c483a0550892a5b4b58fbb2b8cc28af36f21d65", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "257cae56-1a2c-47f2-b656-ad36404a5070", "node_type": "1", "metadata": {}, "hash": "eb6a4cc7baacebfebe3526dc6675723dca6cab2122e3717e29feb7418bb6d692", "class_name": "RelatedNodeInfo"}}, "text": "3.3.3 InitiatingART inAdults\nART should be initiated in all adults living with HIV without contraindications, regardless of\nWHO clinical stage and CD4+ cell count. Initiating ART early in PLHIV is associated with\nreduced mortality and ill health. Untreated HIV infection may be associated with the\ndevelopment of serious co-morbidities such as cardiovascular, kidney and liver diseases, cancers\nand mental illness. Early initiation of ART serves the useful purpose of preventing the\noccurrence of these diseases. An additional advantage of early initiation of ART is that it\nsubstantially reduces the risk of sexual transmission to HIV-negative partners.\n3.3.4 InitiatingART inAdolescents (10-19 years of age)\nImplementation considerations\nTo ensure that adolescents (10-19 years) achieve the goals of ART, it will require developing\nadolescent-friendly health services, appropriate provider training and implementing\nprogrammes that emphasize support for age-appropriate disclosure, adherence and retention in\ncare, including peer to peer support.\nHealthcare providers are advised to leverage the influence that parents and caregivers exercise\non their adolescents to improve adherence to ART. Hence, parents and caregivers should be\ninvolved in developing a treatment adherence plan for their wards.\nRecommendations forART initiation in adolescents (10-19 years)\n    \u00b7         It is recommended that the implementation of early ART in adolescents should be\n        prioritized to ensure that effective and age-appropriate counselling approaches are a\n        prominent component of theART package for this age group.\n    \u00b7  ART should be initiated in all adolescents living with HIV, regardless of WHO clinical\n        stage and at any CD4+ cell count.\n    \u00b7         Use of DTG with NRTI backbone as the preferred 1st line regimen for adolescents\n                 including women of childbearing age (TDF + 3TC (or FTC) + DTG). Women should\n        however be given all necessary information to enable them make informed choices.\n    \u00b7    Adolescents with severe or advanced HIV clinical disease (WHO clinical stage 3 or 4)\n        and a CD4+ cell count of <200 cells/mm3 should be given priority forART initiation.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2217, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "257cae56-1a2c-47f2-b656-ad36404a5070": {"__data__": {"id_": "257cae56-1a2c-47f2-b656-ad36404a5070", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "52"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "e9dc1e80-2ec4-4a1f-8b91-02fc9fe5501d", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "52"}, "hash": "44e21d6c894ebb34d8b187132c483a0550892a5b4b58fbb2b8cc28af36f21d65", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "50a5a480-ae11-485e-ad7e-47aa19d95039", "node_type": "1", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "52"}, "hash": "6575a4612adb53ef227909cddd27fe1a94c25e347809e283d65f4dbde952a1e8", "class_name": "RelatedNodeInfo"}}, "text": "\u00b7    Adolescents with severe or advanced HIV clinical disease (WHO clinical stage 3 or 4)\n        and a CD4+ cell count of <200 cells/mm3 should be given priority forART initiation.\n3.3.5 Initiation ofART in infants and children younger than 10 years of age\nART should be initiated in all children with HIV, regardless of WHO clinical stage, or at any\nCD4+ cell count. Infants and young children living with HIV are more likely to die within the\nfirst two years of life from the disease in the absence of any intervention. As they grow older the\nrisk of disease progression and mortality, in the absence of treatment, falls to rates similar to\nthose of young adults.\nAside from preventing illness and death in very young children, earlier initiation of ART can\nmitigate the negative effects of HIV infection on growth, pubertal and nervous system\ndevelopment.\n3.3.6 Recommendations for Use ofART in TB/HIV Co-infection\nThere is strong evidence that initiation of ART within two weeks of TB treatment is associated\nwith a marked reduction in overall TB-related morbidity and mortality. ART should be started in\n           NATIONAL GUIDELINES FOR HIV PREVENTION TREATMENT AND CARE 2020            30", "mimetype": "text/plain", "start_char_idx": 2036, "end_char_idx": 3233, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a6dccf91-e425-482e-a821-de5ddc407696": {"__data__": {"id_": "a6dccf91-e425-482e-a821-de5ddc407696", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "53"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "f3f07b7b-a491-40bb-9c9d-4f66d4441eb6", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "53"}, "hash": "d823fb85c0e7c9d7971b9ad6376276f1aac302343674d307052fc0865446b741", "class_name": "RelatedNodeInfo"}}, "text": "all TB patients (adults, adolescents and children) living with HIV, regardless of CD4+ cell count.\nTB treatment should be initiated first, followed by ART as soon as possible within the first 2\nweeks of treatment. This strategy will:\n   \u00a7   Simplify patient management\n   \u00a7   Improve adherence\n   \u00a7   Avoid ARV and TB drug interactions\n   \u00a7   Avoid overlapping toxicities\n   \u00a7   Minimize the risk of immune reconstitution inflammatory syndrome (IRIS)\n   \u00a7   Reduces the confusion over which drug (ARV orAnti-TB) to take first\n3.3.7 Key considerations when treating PLHIV with TB:\n   a.  Patients onART who develop TB should have theARVs reviewed to accommodate the\n       use of Rifampicin in the anti-TB regimen.\n   b.  For patients on a PI-based initial or subsequentART regimen, rifabutin should be\n       substituted for rifampicin.\n   c.  Rifampicin significantly lowers the plasma concentration of DTG therefore a double\n       dose of DTG should be used (Give DTG 50 mg twice daily if rifampicin is being used as\n       the anti-TB regimen).\n   d.  Efavirenz cannot be used with Bedaquiline (BDQ) among PLHIV with drug-resistant\n       TB (DR-TB), as it decreases the concentration of BDQ. Nevirapine or DTG is\n       considered the best option for treatment of DR-TB with BDQ - based regimen.\n   e.  In the treatment of DR-TB, Delamanid is generally considered safe to be administered\n       with allARVs.\n          NATIONAL GUIDELINES FOR HIV PREVENTION TREATMENT AND CARE 2020             31", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1501, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "02b91b62-c8a9-46bc-9b76-f85dea6889ab": {"__data__": {"id_": "02b91b62-c8a9-46bc-9b76-f85dea6889ab", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "54"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "d94e24f1-4e7a-4adb-af4c-589947368d23", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "54"}, "hash": "e3b9a7493048233ec5a97e53793e3c3f90892ca13fc58fe9d35069073e9ee76f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "862c25f6-832b-44cb-8b26-18036d960898", "node_type": "1", "metadata": {}, "hash": "30e703bebf92ee29ffb80ac38bf34e2f8cb726aa52471c10d7a2ffdd193f9542", "class_name": "RelatedNodeInfo"}}, "text": "Table 3.2: Scenarios for the management of TB/HIV co-infected patients\n                Scenario            Action\n  Newly registered TB patients      \u00b7  Start TB treatment regimen immediately\n  diagnosed with HIV                \u00b7  Commence ART within 2 weeks of anti TB (irrespective\n                                       of the CD4+ cell count)\n                                    \u00b7  Initiate CPT\n  PLHIV on ART who develop TB       \u00b7  Continue ART  (Substitute N VP with E FV, if on DTG then\n                                       administer twice daily)\n                                    \u00b7  Start TB treatment immediately\n                                    \u00b7  Continue/initiate CPT\n                                    \u00b7  Reassess for HIV treatment failure\n  PLHIV on second  -line ART who    \u00b7  Reassess for HIV treatment failure\n  develop active TB                 \u00b7  Continue ART\n                                    \u00b7  Start TB treatment immediately, change anti-TB to single\n                                       drugs with rifabutin-containing regimen if on protease\n                                       inhibitors\n  Pregnant PLHIV on ART who         \u00b7  Continue ART\n  develop TB                               o   EFV not contraindicated\n                                           o   Double -dose DTG\n                                    \u00b7  Start TB treatment immediately\n                                    \u00b7  Continue/Initiate CPT (avoid CPT in 1sttrimester)\n                                    \u00b7  Reassess for HIV treatment failure\n3.3.8 Recommendations for use ofART in HIV/Hepatitis Co-infection\nAntiretroviral therapy (ART) should be initiated in all HIV/Hepatitis co-infected individuals\nregardless of CD4+ cell count and stage of liver disease.\n    \u00a7   HIV/HBV Coinfection: The recommendedART for HIV/HBV coinfected PLHIV is\n        TDF + 3TC (or FTC) + DTG. This is because TDF and 3TC are active against HBV.\n    \u00a7   HIV/HCV Coinfection:Antiretroviral therapy should be initiated first in HIV/HCV co-\n        infected patients before commencing DirectActingAntivirals (DAAs) for HCV\n        treatment. Drug-drug interactions (DDIs) should be carefully considered and the\n        appropriateARV or hepatitis drug substitutions/dose adjustments made before\n        commencing treatment.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2308, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "862c25f6-832b-44cb-8b26-18036d960898": {"__data__": {"id_": "862c25f6-832b-44cb-8b26-18036d960898", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "54"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "d94e24f1-4e7a-4adb-af4c-589947368d23", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "54"}, "hash": "e3b9a7493048233ec5a97e53793e3c3f90892ca13fc58fe9d35069073e9ee76f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "02b91b62-c8a9-46bc-9b76-f85dea6889ab", "node_type": "1", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "54"}, "hash": "c618fb9f186e0a2b5faf8da72ed85dc0c8e99fcbfdec24c10517a4c318dcca90", "class_name": "RelatedNodeInfo"}}, "text": "Drug-drug interactions (DDIs) should be carefully considered and the\n        appropriateARV or hepatitis drug substitutions/dose adjustments made before\n        commencing treatment.\n           NATIONAL GUIDELINES FOR HIV PREVENTION TREATMENT AND CARE 2020            32", "mimetype": "text/plain", "start_char_idx": 2126, "end_char_idx": 2396, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "03948ff2-e987-4066-8693-093b8855f380": {"__data__": {"id_": "03948ff2-e987-4066-8693-093b8855f380", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "55"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "ed66a7fd-1c76-455d-a419-0dc3f4f0e288", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "55"}, "hash": "b1dbf68e40c38a4e39e869150e07f6d7285516116d909bc6588fe8874d4ddeb7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2f7e4304-4ba9-4d8c-96f6-b4a2bab3a670", "node_type": "1", "metadata": {}, "hash": "4ecadf9c01ee63574bd4eef24ee3ffc341a15e1056a8f1aa22bfdb2942f03670", "class_name": "RelatedNodeInfo"}}, "text": "Healthcare workers need to note that there is a risk of IRIS associated with early initiation ofART\nin HIV/hepatitis coinfection, referred to as 'hepatitis flare' which usually occurs within the first 6\nto 12 weeks afterART initiation. (see section 8.1.8).\n3.4 RecommendedART Regimen forAdults,Adolescents and Children\nThe following are the recommendedART regimens for the management of HIV in Nigeria.\n3.4.1 First-lineART regimens for adults and adolescents\nTable 3.3 Recommended first-line ART regimens for adults, adolescents, pregnant, breastfeeding women and\nchildren\n First -line ART    Preferred first-line    Alternative first-  Special Circumstances\n                    regimen                 line regimens\n Adults and         TDF + 3TC (or FTC) +    TDF + 3TC (or FTC)  TAF + 3TC (or FTC) + DTG\n Adolescent s       DTG                     + EFV 400           ABC + 3TC + DTG\n                                                                AZT + 3TC + EFV 400\n 3.4.2 First-line ART for children\nTable 3.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1013, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2f7e4304-4ba9-4d8c-96f6-b4a2bab3a670": {"__data__": {"id_": "2f7e4304-4ba9-4d8c-96f6-b4a2bab3a670", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "55"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "ed66a7fd-1c76-455d-a419-0dc3f4f0e288", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "55"}, "hash": "b1dbf68e40c38a4e39e869150e07f6d7285516116d909bc6588fe8874d4ddeb7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "03948ff2-e987-4066-8693-093b8855f380", "node_type": "1", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "55"}, "hash": "50d1aa7ee96c3b484343245e6f5eb3e6112c62731165fb96d315944c65b9acf1", "class_name": "RelatedNodeInfo"}}, "text": "4.2 First-line ART for children\nTable 3.4 Recommended First-line ART regimen for Children\n  Weight       Age (years)   Preferred First Line  Alternative First Line  Special\n  (Kg)                       Regimen               Regimen                 Circumstances\n  Neonates\n  < 3kg        < 1 month     AZT + 3TC + DTG*      AZT + 3TC + LPV/r**     AZT+3TC+NVP\n                             or RAL\n  Infants & Children\n  < 20kg       < 6years      ABC +3TC + DTG        ABC+3TC +LPV/r          ABC + 3TC\n                                                   AZT + 3TC +LPV/r        +EFV*\u207a(or\n                                                   ABC (or AZT) +3TC+      NVP)\n                                                   RAL**+                  AZT + 3TC +\n                                                                           EFV (or NVP)\n  20 \u2013 30kg    6-10years     ABC+3TC+DTG           ABC+3TC +LPV/r          AZT + 3TC +\n                             Or                    ABC +3TC + RAL          LPV/r (or RAL)\n                             TDF***(TAF)****\n                             + 3TC +DTG\nNote:\n*DTG 5mg and 10mg (scored/dispersible) formulations are available for use in children from 4weeks of age and weighing at least 3kg to children\n<20kg\n**LPV/r pellets or granules can be used if starting after two weeks of age\n***TDF is used for children aged 6-10 years weighing >30kg\n****TAF is used for children with weight >25kg\n*+EFV is used for children above 3years (>15kg)\n**+The use of this INSTI could be considered where available in instances of poor tolerability or administration challenges with LPV/r,\nparticularly in settings where the rapid expansion of maternal treatment could lead to infants and children at very high risk of carrying an NNRTI\nresistance virus.\n          NATIONAL GUIDELINES FOR HIV PREVENTION TREATMENT AND CARE 2020           33", "mimetype": "text/plain", "start_char_idx": 973, "end_char_idx": 2847, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "404fe7e3-0a0e-4372-bf99-1f517afe7297": {"__data__": {"id_": "404fe7e3-0a0e-4372-bf99-1f517afe7297", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "56"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "7599d2fd-8a00-492c-8a43-54bc8ab6a02d", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "56"}, "hash": "f6593b4db1e081a45646c25b00cf7388cd40d44c2ad3e0625805df1f4c6eacd3", "class_name": "RelatedNodeInfo"}}, "text": "3.4.3 Programming Transitioning to DTG - based regimen\nThe transitioning of non-DTG based first-line regimens to DTG-based regimens should be done\nin virally suppressed and stable patients. Patients failing on a non-DTG based first-line regimen\nshould be switched to the preferred second-line regimen.\n3.5 Monitoring Patients onART\n3.5.1  Monitoring and Follow-up inAdults\nOnce a patient is initiated onART, assessment should look out for:\n    \u00a7   Any persisting or new signs/symptoms of HIV related conditions\n    \u00a7   Potential drug toxicities\n    \u00a7   OptimalAdherence\n    \u00a7   Response to therapy (Clinical, Immunological and Virological).\n    \u00a7   Weight changes, growth and development including height in children\n    \u00a7   Abnormal Laboratory parameters\nTable 3.5 Recommended Schedule for Monitoring Adults on ART: Clinical Assessments\n                         Pre-            Month           Every six       Every\n                         Treatment       three           months          Scheduled\n                         (Baseline)                                      Clinical\n                                                                         Consultation\n  Physical exam          X               X               X               X\n  * Adherence            X               X               X               X\n   counselling\n  * Clinical             X               X               X               X\n   Screening for TB\n  Clinical screening     X               X               X               X\n  for chronic care\n  & PHDP Services\n*Adherence counselling and clinical screening for TB should be done at every clinical or drug pick up visit\n          NATIONAL GUIDELINES FOR HIV PREVENTION TREATMENT AND CARE 2020           34", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1733, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "990fb0a7-6f29-4823-a0c8-081929a22106": {"__data__": {"id_": "990fb0a7-6f29-4823-a0c8-081929a22106", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "57"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "b6d1f9e0-3fd2-4e04-a803-9e696a2a0b6f", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "57"}, "hash": "96967fea69b41bf27d6c540bca08a2b106970a8e2428cb7c80257326ef08f563", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "af76fee2-df75-4ba9-8988-8b5f6ad734b7", "node_type": "1", "metadata": {}, "hash": "ca1d2fc82796b28ba9e72507461728542b1786af67d8357c251216e3892bf6be", "class_name": "RelatedNodeInfo"}}, "text": "Table 3.6 Recommended Schedule for Monitoring Adults on ART: Laboratory Tests\n                                          Pre-            Month on ART     Every 6  Every 12\n                                          Treatment    1st  3rd    6th 12th Months  Months\n                                          (Baseline)                                (Annual)\n HIV-1 RNA (VL)                                                    X\u2021 X\u2021                X\n      *\n CD4+                                          X\n *Cryptococcal antigen test (CrAg) and  3      X\n TB LAM if CD4+ cell count < 200 cells/mm\n Hb/PCV                                        X        X1   X                X\n WBC, Platelets                           As clinically indicated  As clinically indicated\n ALT                                                X              As clinically indicated\n Serum Creatinine (Calculate eGFR)             X             X                X\n HBsAg and HCV                                 X\n Urinalysis                                    X            X3                X3\n Syphilis test                            As clinically\n                                          indicated\n Cervical cancer screening (VIA/Pap                 X               Every 3 years if a screening\n Smear/HPV screen)                                                  test is negative\n AST, ALP, FBS, Amylase, Pregnancy test,                  As clinically indicated\n Lipid profile, U/E, Xpert MTB/RIF test,\n Chest X-Ray s\nX Essential\n1For patients on AZT; 2 Patients on NVP;  3 patients on TDF.\n\u2021We recommend that all adult clients on ART should have a VL test at 6 months after ART initiation; If <1000 copies/ml, then repeat testing 6\nmonths later, then repeat at least every 12 months if remains <1000 copies/ml. If the VL is \u22651000copies/ml, the patient should receive enhanced\nadherence counselling (EAC) and have a repeat VL only after three months of GOOD adherence. A repeat VL test result of \u22651000 cp/ml following\nEAC is indicative of virologic failure. Clients with persistent virologic failure despite EAC interventions may need to have their drug regimen\nswitched to second-line ART if they have been on a DTG-based regimen (e.g., TLD) for at least 1 year.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2238, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "af76fee2-df75-4ba9-8988-8b5f6ad734b7": {"__data__": {"id_": "af76fee2-df75-4ba9-8988-8b5f6ad734b7", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "57"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "b6d1f9e0-3fd2-4e04-a803-9e696a2a0b6f", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "57"}, "hash": "96967fea69b41bf27d6c540bca08a2b106970a8e2428cb7c80257326ef08f563", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "990fb0a7-6f29-4823-a0c8-081929a22106", "node_type": "1", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "57"}, "hash": "810560deee81e56ea7aeda946c8fbf7c8f8c367b540ee394e66589d7ab0f005c", "class_name": "RelatedNodeInfo"}}, "text": "Clients with persistent virologic failure despite EAC interventions may need to have their drug regimen\nswitched to second-line ART if they have been on a DTG-based regimen (e.g., TLD) for at least 1 year.\n* urine LF-LAM assay and CrAg tests should be done automatically by the laboratory on all CD4+ counts < 200 cells/mm . (CD4 test is\n                                                                                    3\nrecommended every 6 months until two consecutive values over 200 cells/mm ).\n                                                 3\nsLaboratory monitoring tests may differ according to the level of the health care facility and should be done according to the above schedule.\n3.5.2 Monitoring Children andAdolescents onART\nClinical and laboratory monitoring are essential parts of HIV and AIDS care in children and\nadolescents. However, laboratory results do not have to be available on the same day following\nHIV diagnosis to initiateART, provided there is no evidence of TB, meningitis or renal disease.\n          NATIONAL GUIDELINES FOR HIV PREVENTION TREATMENT AND CARE 2020              35", "mimetype": "text/plain", "start_char_idx": 2033, "end_char_idx": 3146, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "14e49c6e-ff3d-4de0-8a0c-01aeb1f6f3c6": {"__data__": {"id_": "14e49c6e-ff3d-4de0-8a0c-01aeb1f6f3c6", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "58"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "bbff61b3-7661-40d1-bc36-bb958fddf2e0", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "58"}, "hash": "ded0d08cbe936ca353ff1ed6db54c65b419d0b90b7567d1cabf425b9a0efb2d4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "35e5cfc5-20cc-4915-9e24-f348cfc1719b", "node_type": "1", "metadata": {}, "hash": "d3fb600c795549b915960b5cadc97ba23823eb28e394ee47f4055dd7d4a527bd", "class_name": "RelatedNodeInfo"}}, "text": "Table 3.7 Recommended Schedule for Monitoring Children and Adolescents on ART: Clinical Assessments\n                                              Pre-treatment          nd Week on ART    Every\n                                              (Baseline)      2      4th   8th   12th         +\n                                                                                       3months\n  History and Physical Exam                          X         X     X     X      X        X\n  AnthropometricMeasurements (Wt, Ht, Length,        X         X     X     X      X        X\n  OFC, MUAC*,Chest circumference, BMI**)\n  Nutrition (Feeding, diet)                          X         X     X     X      X        X\n                   ***\n  Immunization status                                X\n                           ****\n  HPV Vaccination Assessment                         X\n  Adherence monitoring                               X         X     X     X      X        X\n                       *****\n  Psychosocialassessment                             X         X     X     X      X        X\n  Clinical Screening for TB, Meningitis, and other   X                    As indicated\n  OIs (assessment INH and CTX Prophylaxis) and\n  other infectious diseases\n*Most appropriate for children aged 1 \u2013 5 years\u2019**BMI in kg/m for adolescents, +/- grading for obesity\u2019;***Ascertain completion of\n                                            2\nroutine immunization, otherwise refer accordingly;****For female children and adolescents between ages 9-18 years;*****Most\nappropriate for adolescents;+More frequent clinic visits and examination may be required for unstable patients\nTable 3.8 Recommended Schedule for Monitoring Children and Adolescents on ART: Laboratory Tests\n            Investigations           Pre-Treatment       Month on ART      Every 6  Every 12\n                                     (Baseline)        1\u02e2\u1d57  3\u02b3\u1d48 6\u1d57\u02b0  12\u1d57\u02b0  Months   Months\n                                                                                    (Annual)\n  HIV-1 RNA (viral load estimation)                   All Children and Adolescent should have a VL test\n                                                      every 6-months\n  CD4+ Cell count/CD4%*                                          X    X       X\n  Hb/PCV                                   X           As clinically indicated\n  WBC + differentials,", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2385, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "35e5cfc5-20cc-4915-9e24-f348cfc1719b": {"__data__": {"id_": "35e5cfc5-20cc-4915-9e24-f348cfc1719b", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "58"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "bbff61b3-7661-40d1-bc36-bb958fddf2e0", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "58"}, "hash": "ded0d08cbe936ca353ff1ed6db54c65b419d0b90b7567d1cabf425b9a0efb2d4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "14e49c6e-ff3d-4de0-8a0c-01aeb1f6f3c6", "node_type": "1", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "58"}, "hash": "460ee4ec335dff188c5717af76790aa6637b95d70b21d570fc4830ca3f218065", "class_name": "RelatedNodeInfo"}}, "text": "Platelets     As clinically indicated\n  ALT                                                 As clinically indicated\n  U/E/Creatinine (Calc CrCl)         As clinically indicated\n  HbsAg and HCV                      As clinically indicated\n  Urinalysis                                X         As clinically indicated\n  GeneXpert, Chest X-ray             As clinically indicated\n  Cervical Cancer Screening**               X         Every 3 years if screening test is negative\n  CrAg Test                                 X         For adolescents 10 \u201319 years only (Not\n                                                      recommended for children < 10yesars)\n  AST, ALP, FBS, Amylase, Pregnancy  As clinically indicated\n  test*, LF- LAM test for TB infection\nX Essential;1 For patients on AZT; 2 Patients on NVP;3 patients on TDF;*Most appropriate for adolescents especially where pregnancy is suspected;**\nOlder or sexually active adolescents;\u2021 Desirable: Baseline viral load can be performed especially for those with prior exposure to ARVs but is not routinely\nrecommended. We recommend that all children and Adolescents initiating ART should have viral load determined 6 months following initiation of therapy and\nevery 6 months thereafter. If the VL is \u22651000copies/ml, the patient should receive enhanced adherence counselling (EAC) and have a repeat VL only after three\nmonths of GOOD adherence. A viral load test result of >1000copies/ml following reinforced adherence counselling and support is indicative of virologic failure.\nClients with persistent virologic failure despite adherence interventions should have their drug regimen switched to second-line ART regimen.\n           NATIONAL GUIDELINES FOR HIV PREVENTION TREATMENT AND CARE 2020                36", "mimetype": "text/plain", "start_char_idx": 2386, "end_char_idx": 4155, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "28682727-e7f5-4fcb-a694-320ce7a127ca": {"__data__": {"id_": "28682727-e7f5-4fcb-a694-320ce7a127ca", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "59"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "62dd9a70-96cc-4c16-bd47-a2673523fa79", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "59"}, "hash": "7b6a3e89fb1184544f64b18e6c66b253b9998bf44995216cd028f5627950aa13", "class_name": "RelatedNodeInfo"}}, "text": "3.6     Management of HIV Treatment Failure\n3.6.1 Definition of HIV Treatment Failure\nHIV treatment failure may be defined as sub-optimal treatment outcomes following the initiation\nof ART. Although HIV treatment failure can be classified as either virologic, immunologic or\nclinical failure (see table 3.9); virologic treatment failure is the best measurement of treatment\nfailure.\nVirologic failure is defined as a VL above 1000 copies/ml based on two consecutive VL\nmeasurements 3 months apart, and after an adherence intervention Non-suppressed VL (VL \u2265\n1000copies/ml) and its management. Critical to the goal of viral suppression is the return of\nresults to the clinical staff and patient, and actions for non-suppressed VL. A VL \u2265\n1000copies/ml should be considered a critical lab value and communicated to the clinical staff\nand the patient in an expedited fashion. All patients with non-suppressed VL results should\nundergo EnhancedAdherence Counseling (EAC) sessions, which involves:\n  Step 1        A structured assessment of ART adherence\n  Step 2        Exploration of specific barriers contributing to poor adherence (as well as the\n                possibility of drug interactions, intercurrent infections, incorrect dosage in children)\n  Step 3        Identification of potential solutions to address barriers\n  Step 4        Joint development of an individualized adherence intervention plan and the follow\n                up of patients for improved adherence\nAVL test should be repeated in 3 months after EAC. Review patients for ART regimen switch if\nVL is still unsuppressed. In particular, it is important to ensure that effective laboratory\ninformation management systems are in place for the prompt identification and notification of\nthe sites, HCWs and unsuppressed patients for timely management.      All VL results must be\nreturned to the patient in addition to their charts.\n          NATIONAL GUIDELINES FOR HIV PREVENTION TREATMENT AND CARE 2020              37", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1991, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "49df9570-f175-446b-ba5a-0ba18f2e11eb": {"__data__": {"id_": "49df9570-f175-446b-ba5a-0ba18f2e11eb", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "60"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "9403a91f-f25b-4218-9f1f-847bc2c98097", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "60"}, "hash": "ceda1afce3f058743e612dedcb619feb2ec1505df789e6ec7795941d7234af61", "class_name": "RelatedNodeInfo"}}, "text": "Table 3.9 Classification of HIV Treatment Failure\n Failure             Definition                                        Comments\n                     Adults and adolescents                            The condition must be\n                     New or recurrent clinical event indicating        differentiated from IRIS\n                     severe immunodeficiency (WHO clinical             occurring after initiating ART\n                     stage 4 condition) after 6 months of effective\n                     treatment.                                        For adults, certain WHO clinical\n Clinical Failure    Children                                          stage 3 conditions (pulmonary\n                     New or recurrent clinical event indicating        TB and severe bacterial\n                     advanced or severe immunodeficiency               infections) may also indicate\n                     (WHO clinical stage 3 and 4 clinical              treatment failure\n                     condition with exception of TB) after 6\n                     months of effective treatment\n                     Adults and adolescents                            Without concomitant or\n Immunological       CD4+ cell count falls to the baseline (or below)  recent infection to cause a\n failure                                  Or                           transient decline in the CD4+\n                     Persistent CD4+ cell count below 100 cells/mm3    cell counts.\n                                          Or\n                     50% decline from on-therapy CD4+ cell count\n                     peak level\n                     Children\n                     Younger than 5 years\n                     Persistent CD4+ cell count below 200\n                     cells/mm or <10%\n                     Older than 5 years\n                     Persistent CD4+ cell count below 100 cells/mm\u00b3\n Virological         Plasma viral load \u2265 1000 copies/ml 6 months       An individual must be taking\n Failure             after starting ART on consecutive VL              ART for at least 12 months\n                     measurements                                      before it can be determined\n                                                                       that a regimen has failed\n           NATIONAL GUIDELINES FOR HIV PREVENTION TREATMENT AND CARE 2020                    38", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2376, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "49e813e7-8203-4b2a-8b34-a64c9e350c25": {"__data__": {"id_": "49e813e7-8203-4b2a-8b34-a64c9e350c25", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "61"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "de1db3f9-977c-460c-9185-896896b0292f", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "61"}, "hash": "f8085e55cf25bc6f2f5388711bb791281c11bc0978781970e66824e09f34d647", "class_name": "RelatedNodeInfo"}}, "text": "Figure 3.1: Algorithm for Treatment Failure Evaluation in Adults, Adolescents and Children\n3.6.2 Causes of HIV Treatment Failure\n   1.  Viral factors\n        \u00a7   Acquired drug resistance: Patients may develop drug-resistant mutations while on\n            ART if maximal adherence (\u226595%) is not maintained.\n        \u00a7   Transmitted drug resistance: Patients may be infected with drug-resistant virus\n            during their initial exposure or be re-infected with drug-resistant virus while on\n            ART.\n   2.  Non-viral Factors\n       HIV Treatment failure may result whenARV plasma drug levels do not reach therapeutic\n       concentration. This may be due to:\n        \u00a7   Host factors: poor adherence toART, malnutrition and malabsorption of drugs\n        \u00a7   Choice of initial ART regimen, poor potency or improper dosing\n        \u00a7   Drug-drug interactions\n3.6.3 Substitution and switch ofARV drugs\nSubstitution is the replacement of one or two ARV drugs in a regimen with another drug of the\nsame class usually because of the following;\n          NATIONAL GUIDELINES FOR HIV PREVENTION TREATMENT AND CARE 2020             39", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1135, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d135f1e3-90b4-40af-9dd9-b100b60510bd": {"__data__": {"id_": "d135f1e3-90b4-40af-9dd9-b100b60510bd", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "62"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "45531ce7-4604-45b4-b34d-c37333dd6245", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "62"}, "hash": "10062629ca10f04ebd98c3c06b0a60a796fa7c4b30cc65ed07e3e77de3cd0304", "class_name": "RelatedNodeInfo"}}, "text": "1.  Toxicity/ adverse drug reactions\n    2.  Co-morbidity\n    3.  Pregnancy\n    4.  Drug interaction\nSwitching is the replacement of two or more ARV drugs in a regimen with other drugs, including\ndrugs of a class due to treatment failure. Switching can also be referred to as changing a patient\nfrom a first-line regimen to a second-line regimen or from a second-line regimen to third-line or\nsalvage regimen.\nWhen to Switch to Second Line:\nThe longer an individual is maintained on a failing regimen, the longer there is ongoing viral\nreplication. This will lead to a worse clinical outcome, greater opportunity for drug resistance\nand increased risk of transmission.\nIn some patients with repeat VL >1,000 copies/ml it may be useful to consider the extent of viral\nload reduction by log scale. A reduction of >1 log per month with good adherence may suggest\nviral load suppression is achievable on the current regimen with additional time. Such patients\nshould continue the current regimen and repeat viral load in another few months to see if it has\ngone below 1,000 copies/ml.\nBefore switching to a second-line regimen, improved ART adherence should be reported and\ndetected, and treatment failure should be confirmed (repeat VL>1,000 copies/ml). Health\nfacilities should constitute a multidisciplinary Switch committee to review, track, and make\ndecisions about switching to second-line.\nIdeally, the committee should consist of a healthcare worker (medical doctor) and a nurse who\nknows the client and is conversant with his/her ART treatment history, and the adherence\ncounsellor who has provided EAC to the client and is aware of his/her barriers to adherence.\n3.6.4 Second-lineART Regimens\nProtease inhibitor-based regimen is recommended as the preferred ARV drug for second-line\nART among adults, adolescents and children. However, DTG may be used as an alternative\nsecond-line regimen if an individual is intolerant of LPV/r or has a contraindication to ATV/r or\nif the first-line regimen does not contain DTG.\n           NATIONAL GUIDELINES FOR HIV PREVENTION TREATMENT AND CARE 2020               40", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2112, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "344c5fdf-074e-435f-bbbc-859254826ae8": {"__data__": {"id_": "344c5fdf-074e-435f-bbbc-859254826ae8", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "63"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "6bdec29f-42fa-4b0a-8391-2b1523ad2eef", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "63"}, "hash": "e3a81ff5c05efb9553e0b6fd8bd7420f837db5eed62d0a9c9471e57e58424e2c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "01bf3547-2eee-403a-b3aa-d84a3afa4178", "node_type": "1", "metadata": {}, "hash": "c9f6325f4609a012013eb7d3e5a4b9303eb5c32b392fb971d3cd4f0c27c20228", "class_name": "RelatedNodeInfo"}}, "text": "Table 3.10 Preferred and Alternative Second-line ART regimens for Adult and Adolescents including Pregnant\n and Breastfeeding Women\n  Target Population  Failing First -line  Preferred Second -line  Alternative Second -line\n                     Regimen              Regimen                 Regimens\n  Adults and         TDF+3TC (or          AZT+3TC (or FTC)        AZT+3TC (or FTC)\n  Adolescents        FTC) +DTG            +ATV/r or LPV/r         +DRV/r\n                     TDF+3TC (or          AZT+3TC (or FTC)        AZT+3TC (or FTC) +DTG\n                     FTC) +EFV            +ATV/r or LPV/r\n                     AZT+3TC (or          TDF+3TC (or FTC)        TDF+3TC (or FTC) +DTG\n                     FTC) +EFV            +ATV/r or LPV/r\n  TB/HIV Co -        Same regimens as recommended above for adults and adolescents; however,\n  infection          DTG should be administered at 50 mg twice daily with first -line anti -TB\n                     medicines and rifabutin substituted for rifampicin in patients receiving\n                     protease inhibitors.Alternatively, double-dose LPV/r (that is, LPV/r 800\n                     mg/200 mg twice daily) is recommended for TB/HIV co-infected patients on\n                     first -line anti -TB medicines.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1268, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "01bf3547-2eee-403a-b3aa-d84a3afa4178": {"__data__": {"id_": "01bf3547-2eee-403a-b3aa-d84a3afa4178", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "63"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "6bdec29f-42fa-4b0a-8391-2b1523ad2eef", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "63"}, "hash": "e3a81ff5c05efb9553e0b6fd8bd7420f837db5eed62d0a9c9471e57e58424e2c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "344c5fdf-074e-435f-bbbc-859254826ae8", "node_type": "1", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "63"}, "hash": "1dfcca8ba5addeb777cbf6755b41f9da1db7b606e18f8112d0ec54fdc6a52259", "class_name": "RelatedNodeInfo"}}, "text": "TB/HBV Co -        TDF + 3TC (OR FTC) + ATV/r or LPV/r\n  infection\nTable 3.11: Recommended Second-line ART Regimen for Neonates, Infants, and Children\n  Weight (Kg)    Age (years)  Failing First Line          Preferred 2 ndLine Regimen\n                              Regimen\n  Neonates\n  < 3 kg         < 1 month    AZT + 3TC + DTG or RAL      AZT + 3TC + LPV/r\n  Infants & Children\n  < 20kg         < 6years     ABC +3TC + DTG              AZT+ 3TC + LPV/r or ATV/r  ***\n                                                          ABC+3TC +LPV/r\n                                                          ABC (or AZT) +3TC+ RAL\n  20 - <30kg     6 \u2013 10years  ABC+3TC+DTG                 AZT + 3TC + LPV/r  or ATV/r or\n                              OR                          DRV/r +\n                              TDF* (TAF**) + 3TC (or      ABC +3TC + LPV/r or ATV/r   or\n                              FTC) + *DTG                 DRV/r +\n  TB/HIV Co -    Same recommendations as for adults and adolescents. However, RAL dose\n  infection      should be doubled and administered twice daily with first -line anti -TB\n                 medicines\n *TDF is used for children aged 6-10 years weighing >30kg\n **TAF is used for children weighing > 25kg\n ***ATV/r can be used as an alternative to LPV/r for children older than 3months, but limited availability of suitable formulations for children\n younger than 6years\n + Should not be used for children < 3years and combine with appropriate dosing of ritonavir\n          NATIONAL GUIDELINES FOR HIV PREVENTION TREATMENT AND CARE 2020           41", "mimetype": "text/plain", "start_char_idx": 1271, "end_char_idx": 2856, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e38e56ba-7633-4a53-9545-eec6eb530778": {"__data__": {"id_": "e38e56ba-7633-4a53-9545-eec6eb530778", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "64"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "a651d5d3-ac2c-4a3c-aa9a-e71665b1505e", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "64"}, "hash": "4860b9480375eb25c708ac1e0aa8efa47937ca6a833a2fba77288c98f4a36ffe", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e361b83e-9c4c-4727-bea9-7d3d48e3ffa4", "node_type": "1", "metadata": {}, "hash": "26e52ab0cb004c8a451c59a5c40fef36875a838d099f148a144b966300feb7b6", "class_name": "RelatedNodeInfo"}}, "text": "3.7 Third-lineART\nThird-line therapy refers to the ART offered to PLHIV in response to the failure of second-line\ntreatment. Efforts should be made to assess and optimize adherence and rule out any significant\ndrug interactions. It is recommended that switch to third-line therapy be left in the hands of HIV\nspecialists with requisite experience and expertise in the management of treatment-experienced\nHIV patients. The choice of third-line therapy is more difficult in the absence of HIV drug\nresistance.\nThird-line regimens should include new drugs with minimal risk of cross-resistance to\npreviously used regimens, such as INSTIs and second or third-generation NNRTIs and PIs. The\nWHO has recommended that National ART programmes in resource-limited settings develop\npolicies for access to third-line ART, containing ritonavir-boosted darunavir, integrase\ninhibitors, and etravirine. These agents have been shown to be effective in highly treatment-\nexperienced patients in trial settings.\nThe FMOH has set up a third-line ART Committee to oversee the implementation of third-line\nART in Nigeria; and designated some sites spread across the six geo-political zones of the\ncountry as third-lineART sites.Also, it has developed and disseminated the criteria for the switch\nand operational guidance for third-lineART.\n3.7.1 Criteria for Switch to Third-LineART\nIn the event of suspected treatment failure on second-line ART, the following criteria should be\nmet before a switch to third-lineART:\n   1.   The patient should be confirmed to have failed on first-line and second-lineART\n   2.   The patient should have a viral load result suggestive of treatment failure\n        (>1000copies/ml) after at least 6 months on an effective second-lineART regimen\n   3.   The patient must undergo adherence assessment, followed by 3 months of documented\n        EAC; the EAC must assess and optimize adherence and rule out any significant drug\n        interactions.\n   4.   The patient's repeat viral load at the completion of EAC must be >1000copies/ml.\n   5.   The patient's adherence during and following EAC must be >95%.\n   6.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2125, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e361b83e-9c4c-4727-bea9-7d3d48e3ffa4": {"__data__": {"id_": "e361b83e-9c4c-4727-bea9-7d3d48e3ffa4", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "64"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "a651d5d3-ac2c-4a3c-aa9a-e71665b1505e", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "64"}, "hash": "4860b9480375eb25c708ac1e0aa8efa47937ca6a833a2fba77288c98f4a36ffe", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e38e56ba-7633-4a53-9545-eec6eb530778", "node_type": "1", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "64"}, "hash": "9a20166a34e27d1d722200e29b2f070826202eccf7fad2bfcc7d4729ab91c0a5", "class_name": "RelatedNodeInfo"}}, "text": "4.   The patient's repeat viral load at the completion of EAC must be >1000copies/ml.\n   5.   The patient's adherence during and following EAC must be >95%.\n   6.   HIV drug resistance testing (genotype or phenotype) should be done to determine the\n        ARVs that are still active.\n3.7.2 Operational Guidance for Third-LineART\n   1.   Patients that meet the criteria stated above for switch to third-lineART should be referred\n        to the third-line site closest to the referring facility with a filled third-LineART eligibility\n        form, a recent HIV viral load result (done within the last 6 months) and a result of HIV\n        drug resistance testing.\n   2.   The third-lineART site will review the third-lineART eligibility form and forward the\n        completed forms to the National third-line Committee through the\n        email: nationalthirdline@gmail.com\n   3.   Upon approval by the National third-line Committee, the patient will commence\n        treatment at the third-line site.\n   4.   Patients commenced on third-lineART should have a viral load test done 3 months after\n        the commencement of therapy.\n           NATIONAL GUIDELINES FOR HIV PREVENTION TREATMENT AND CARE 2020               42", "mimetype": "text/plain", "start_char_idx": 1963, "end_char_idx": 3187, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3e0159c2-cb80-4326-9ab9-ceee85fae64a": {"__data__": {"id_": "3e0159c2-cb80-4326-9ab9-ceee85fae64a", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "65"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "b0259191-7df7-40bc-bfc4-929bf92e09be", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "65"}, "hash": "e44cf1f5e43fb5c92946c4b5bf7b13f7158ec9c5751d95c6314a3fe813605026", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ac7a54a0-1e58-42d5-bb71-2496aa62934f", "node_type": "1", "metadata": {}, "hash": "a007c8b8ded6a00acba8aae728be1c68febbfef5b7b0c6f730aabccfe3b33689", "class_name": "RelatedNodeInfo"}}, "text": "The following table shows the sequence of switching ART from first-line to third-line regimens:\nTable 3.12 Sequence of Switching ART from first-Line to third-Line regimens\n Target Population       First-line         Second -line         Third-line Regimens\n                         Regimens           Regimens\n Adults and Adolescents  TDF + 3TC (or      AZT + 3TC (or FTC)   TDF + 3TC (or FTC) +\n                         FTC) + DTG         + ATV/r or LPV/r or  DRV/r + DTG +/ - ETV\n                                            DRV/r\n                         TDF + 3TC (or      AZT + 3TC (or FTC)   AZT+3TC (or FTC) +\n                         FTC) + EFV 400mg   + ATV/r or LPV/r or  DRV/r \u00b1 ETV +/ - DTG\n                                            DTG or DRV/r\n Children and infants    ABC + 3TC + DTG    AZT + 3TC + LPV/r    RAL or DTG + DRV/r\n                                            (or ATV/r)           (children >3years) + ABC\n                                            AZT + 3TC + DRV/r    or AZT + 3TC\n                                            (children > 3years)\n                         ABC (or AZT) +     AZT (or ABC) + 3TC\n                         3TC + LPV/r        + DTG\n                                            AZT (or ABC) + 3TC\n                                            + RAL\n                         ABC (or AZT) +     AZT (or ABC) + 3TC\n                         3TC + EFV          + DTG\n                                            AZT (or ABC) + 3TC\n                                            + LPV/r (or ATV/r)\n3.8 Low-Level Viremia (LLV)\nThe WHO recommends routine VL for individuals on ART as the preferred monitoring approach\nto confirmART success, and defines treatment failure as a \u201cpersistently detectable VL exceeding\n1000 copies/mL after at least 6 months of starting a new ART regimen\u201d. This VL threshold,\nhowever, misclassifies PLHIV who harbour drug-resistant viruses.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1908, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ac7a54a0-1e58-42d5-bb71-2496aa62934f": {"__data__": {"id_": "ac7a54a0-1e58-42d5-bb71-2496aa62934f", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "65"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "b0259191-7df7-40bc-bfc4-929bf92e09be", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "65"}, "hash": "e44cf1f5e43fb5c92946c4b5bf7b13f7158ec9c5751d95c6314a3fe813605026", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3e0159c2-cb80-4326-9ab9-ceee85fae64a", "node_type": "1", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "65"}, "hash": "6db191499bbe5dc143083e9249cb6b4ce5dd836d9bb622468673a1e771c64b7c", "class_name": "RelatedNodeInfo"}}, "text": "This VL threshold,\nhowever, misclassifies PLHIV who harbour drug-resistant viruses. Data have shown that low-\nlevel viremia (LLV), defined variably as an intermittent or persistent VL between 200 - 999\ncopies/ml is associated with drug resistance mutations (DRMs) and/or treatment failure, with an\nincidence of virologic failure (VF) among PLHIV with persistent LLV <500 copies/mL\nestimated to be about 4-8%. Persistent higher-range LLV (e.g. \u2265400 copies/ml) is associated\nwith clinical disease progression and/or mortality.\n3.8.1 Management of Low-level viremia (LLV)\n    \u00a7   All clients with low-level viremia (VL 200 - 999 copies/ml) should undergo a thorough\n        assessment of the cause of the elevated VL and specifically consider the possibility of\n        (ABCDE):\n        \u2022   Adherence problems\n        \u2022   Bugs (Intercurrent infections)\n        \u2022   In-CorrectART dosage\n        \u2022   Drug Interactions\n        \u2022   REsistance.\n    \u00a7   Implement interventions to re-suppress the VL, including EAC (1-3)\n          NATIONAL GUIDELINES FOR HIV PREVENTION TREATMENT AND CARE 2020           43", "mimetype": "text/plain", "start_char_idx": 1825, "end_char_idx": 2922, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6911d3be-94c5-471d-b258-0353043a2eec": {"__data__": {"id_": "6911d3be-94c5-471d-b258-0353043a2eec", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "66"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "97606e30-6cb6-4638-bd4f-44d732959551", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "66"}, "hash": "634e1157c544779ab1a02a1c8cc327c1d346238fdd51b594bbbaf09927cdc62c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "28a66f32-6740-4c9a-ad58-215e23206741", "node_type": "1", "metadata": {}, "hash": "c1f353a21be60d3fdd798c49b44cbaa9297cecf2a6a9744874e3c63f799ff03b", "class_name": "RelatedNodeInfo"}}, "text": "\u00a7   Repeat VL after three months of GOODADHERENCE\n    \u00a7   If the current regimen is TLE or TDF/3TC/NVP, switch to TLD.\n3.9ART in Special Circumstances\nA number of non-communicable diseases (NCDs) adversely affect the outcome of ART in\nPLHIV. These NCDs must be taken into consideration as dose adjustment helps significantly to\nlimit the complications of ART in these settings. The most common NCD in HIV infection is\nkidney impairment. Many patients also have drug-induced or disease-related cardio-myopathy.\nOsteoporosis is also becoming a common complication being reported among older women on\nTDF-containingART.\n3.9.1 Kidney impairment\nExperience from Nigeria has shown that 23.8% [2] of newly diagnosed HIV infected patients\npresent with evidence of kidney impairment. Long term follow-up of about 5,000 patients on\nTDF containing regimen in another study from Jos, Nigeria [3] showed that 10% of patients\nwithout baseline evidence of kidney impairment develop laboratory features of kidney\nimpairment by week 24 of follow up. This proportion increased to 45% by week 144. The\nauthors concluded that ART regimens in Nigeria need to be reviewed concerning the use of TDF.\nThey suggested an alternative regimen such as ABC or TAF. There is also the need to dose adjust\n3TC as this drug is 80 - 90% eliminated by the kidney.\n3.9.2 Cardiomyopathy\nThere is no current published national data regarding HIV and ARV related cardiomyopathy.\nHowever, anecdotal reports from high volume sites in Nigeria suggest that a significant number\nof HIV infected Nigerians are now developing hypertension and electrocardiographic and\nechocardiographic features of cardiomyopathy. Research is ongoing in Nigeria to study and\nreport this phenomenon. While awaiting this report, present knowledge suggests that\ncardiomyopathy is more associated with the use of ABC. Other studies have established a\nrelationship between ABC and increased hyperactivity of platelets. The platelet endothelial cell\ninteraction is suggested to be a major factor predisposing to cardiovascular diseases in HIV\ninfected population.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2093, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "28a66f32-6740-4c9a-ad58-215e23206741": {"__data__": {"id_": "28a66f32-6740-4c9a-ad58-215e23206741", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "66"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "97606e30-6cb6-4638-bd4f-44d732959551", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "66"}, "hash": "634e1157c544779ab1a02a1c8cc327c1d346238fdd51b594bbbaf09927cdc62c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6911d3be-94c5-471d-b258-0353043a2eec", "node_type": "1", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "66"}, "hash": "2ec6353d18f2841d2cb7ed6b2b5b2014d794fe8da2bae8ccf6cf8f27eb6e9946", "class_name": "RelatedNodeInfo"}}, "text": "Other studies have established a\nrelationship between ABC and increased hyperactivity of platelets. The platelet endothelial cell\ninteraction is suggested to be a major factor predisposing to cardiovascular diseases in HIV\ninfected population.\n3.9.3 Osteoporosis\nDecreased bone mineral density has been reported as a long-term complication of TDF. This is\nthe reason why paediatricians do not recommend the use of TDF in children in order not to limit\ngrowth potential. In adults, however, particularly post-menopausal females, decreased bone\nmineral density associated with post-menopausal age may become complicated with long term\nuse of TDF. Presently, we do not have in-country data to support the magnitude of this problem.\n          NATIONAL GUIDELINES FOR HIV PREVENTION TREATMENT AND CARE 2020          44", "mimetype": "text/plain", "start_char_idx": 1850, "end_char_idx": 2663, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "67062cb8-d337-4168-bb10-2cdad0cf2913": {"__data__": {"id_": "67062cb8-d337-4168-bb10-2cdad0cf2913", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "67"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "314ee1c2-8961-40f3-8fc6-b023dde21d3e", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "67"}, "hash": "df023426f8b9afb1f61c158d2c75573d20b432e8cf11f5f18600b1e457f9eaa7", "class_name": "RelatedNodeInfo"}}, "text": "Table 3.13. Recommendations for ART in special circumstances\n     Special circumstance       Problems              Recommendations\n     Kidney impairment          TDF toxicity      Replace TDF 300mg with ABC\n                                                  600mg*\n                                                  OR replace with TAF 25mg\n                                3TC toxicity      Dose adjustment based on eGFR\n                                                  eGFR>50, no adjustment, 300mg\n                                                  daily\n                                                  eGFR 30    \u2013  49ml/min, 150mg\n                                                  daily\n                                                  eGFR 15-29ml/min, 75mg daily\n                                                  eGFR <15ml/min or dialysis\n                                                  dependent, 75mg alternate days\n     Cardiomyopathy             ABC toxicity      Refer the patient for cardiology\n                                                  review and HIV specialist\n                                                  opinion\n     Osteoporosis               TDF toxicity       Replace with TAF\n*eGFR >50ml/min, recommended regimen is ABC+3TC+DTG, 600/300/50mg daily\neGFR 30-49ml/min, recommended regimen is ABC/3TC/DTG, 600/150/50mg daily\neGFR 15-29ml/min, recommended regimen is ABC/3TC/DTG, 600/75/50mg daily\neGFR <15ml/min or on renal dialysis, recommended regimen is ABC/3TC/DTG, 600 daily, 75mg alternate days (or 37.5mg daily), 50mg daily\nCreatinine Clearance (eGFR) can be calculated using Cockcroft -Gault equation below\n(140-age(yrs) x weight(kg)/Plasma Creatinine (mg/dl) x72\nFor Females, the result should be multiplied by 8\n         NATIONAL GUIDELINES FOR HIV PREVENTION TREATMENT AND CARE 2020        45", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1837, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b6c7efa0-7f7b-479e-9247-5bc871cb4a40": {"__data__": {"id_": "b6c7efa0-7f7b-479e-9247-5bc871cb4a40", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "68"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "98ef12a0-1d70-4570-94fb-44fa17d8cc52", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "68"}, "hash": "4c222d5d63e363d01cef426674265b7f81b890f2d03ace72acfd426ced7560be", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "be7725eb-ee1d-40ce-a5e2-e8b0be237353", "node_type": "1", "metadata": {}, "hash": "e98ae5520b616c24e5d417cd6d6988d90be1938e29ef06e8edb8785b1c080237", "class_name": "RelatedNodeInfo"}}, "text": "List of Contributors                                                         Chapter 3\nDr Bilikisu Jibrin                      Assistant Director, Head Treatment, Care and Support\n                                        NASCP\nDr Etiobhio Ehimen                      Senior Medical Officer, Treatment, Care and Support\n                                        NASCP\nDr. Urhioke Ochuko                      Assistant Director, Childhood TB - NTBLCP\nChika-Onyiah Ogechukwu                  Senior Scientific Officer I NASCP\nProf. Oche Agbaji                       Member NTTA / Physician JUTH Jos\nProf. Augustine Omoigberale             Member NTTA / Paediatrician UBTH Benin\nProf.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 677, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "be7725eb-ee1d-40ce-a5e2-e8b0be237353": {"__data__": {"id_": "be7725eb-ee1d-40ce-a5e2-e8b0be237353", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "68"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "98ef12a0-1d70-4570-94fb-44fa17d8cc52", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "68"}, "hash": "4c222d5d63e363d01cef426674265b7f81b890f2d03ace72acfd426ced7560be", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b6c7efa0-7f7b-479e-9247-5bc871cb4a40", "node_type": "1", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "68"}, "hash": "30695b26739ff8b9e717188eddd81112e20819510f613eb15c4ffd092d78d7af", "class_name": "RelatedNodeInfo"}}, "text": "Oche Agbaji                       Member NTTA / Physician JUTH Jos\nProf. Augustine Omoigberale             Member NTTA / Paediatrician UBTH Benin\nProf. Stephen Oguche                    Member NTTA / Paediatrician JUTH Jos\nDr Sunny Ochigbo                        Member NTTA / Paediatrician UCTH Calabar\nDr Abiola Davies                        Health Manager UNICEF\nDr Omoniyi Amos Fadare                  National Professional Officer TB/HIV WHO\nDr Andrew Abutu                         ART Program Manager CDC\nDr Fagbamigbe Omodele Johnson           Senior Program Specialist, HIV Care and Treatment CDC\nAdemola Oladapo                         Senior Progam specialist SI CDC\nDr Adegbenga Olarinoye                  Senior Program Specialist - Pediatric Treatment US DoD\nDr Ismail Lawal                         Lead for HIV Care and Treatment US DoD\nDr Chux Anago                           Program Manager CHAI\nDr Nere Otubu                           Program Manager CHAI\nDr Iboro Nta                            Associate CHAI\nDr Emerenini Franklin Chime             Paediatrics PMTCT Lead ICAP\nDr Olanrewaju Olaiya                    Project Director, Pro-Health International\nMrs Aisha Nantim Dadi                   Project Manager SFH\nDr Rosemary Adu                         Head of Programmes (GF HIV) SFH\nDr Plang Jwanle                         Associate Director APIN\nDr Echey Ijezie                         Country Program Director AHF\nIkechukwu Ezekpeazu                     APIN\nDr Austin Azihaiwe-Justine              Senior Technical Advisor FHI360\nDr Pius Nwaokoro                        Deputy Director Technical FHI360\nDr Felicia Mairiga                      FHI360\nPrince Gambo                            Deputy Coordinator NEPWHAN\nEmmanuel Clifford                       NEPWHAN\nDr Ugwuike, Joseph Eze                  Treatment Advisor Heartland Alliance\n                                        Access Manager, Johnson & Johnson Global Public\nChike Anyachor                          Health\n                                        Medical Affairs Manager, Johnson & Johnson Global\nDr Valentine Uche                       Public Health\n          NATIONAL GUIDELINES FOR HIV PREVENTION TREATMENT AND CARE 2020         46", "mimetype": "text/plain", "start_char_idx": 526, "end_char_idx": 2761, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "907fb015-c204-4da5-aad2-4bfb7a82757f": {"__data__": {"id_": "907fb015-c204-4da5-aad2-4bfb7a82757f", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "69"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "fd21b16e-df81-40d5-bed7-6c2fe358c691", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "69"}, "hash": "4b3c26b6681e07e2008683ac453ae849bbc81187cff616108dd7871e85d0337f", "class_name": "RelatedNodeInfo"}}, "text": "4. PHARMACOVIGILANCE\n              IN ANTIRETROVIRAL\n                   THERAPY\nWhat\u2019s Inside:\n  1.1 Objectives of the Guidelines\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026..\n4.1 Introduction\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026..\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026..\u202648\n 1.2 Epidemiology of HIV in Nigeria\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\n4.2 Pregnancy Monitoring for Patients on ARVs\u2026\u2026\u2026\u2026\u2026\u2026.....48\n 1.3 Natural History of HIV\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026.\u2026\u2026\n4.3 HIV Drug Resistance (HIVDR)\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026..\u2026...49\n4.4 Adverse drug reactions (ADRs)\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026..\u2026...49\n4.5 Drug toxicity\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026..\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026....46\n4.6 Steps to Recognize ADRs\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026..\u2026\u2026\u2026....54\n4.7 Who is to Report ADRs?\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026..\u2026\u2026\u2026\u2026..54\n4.8 What ADRs Should be Reported\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026........54\n4.9 Pharmacovigilance Data Collection\n and Reporting Process \u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026..\u2026\u2026\u2026\u2026.....55\n4.10 Principles of Management of Adverse\n        Drug Reactions \u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026..\u2026\u2026\u2026\u2026\u2026..\u2026\u202655\n4.11 Prevention of Adverse Drug Reactions \u2026\u2026\u2026\u2026\u2026\u2026...........61\n4.12 ARV Drug Interactions\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026..\u2026\u2026...........62", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 914, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cdbb6fc1-c11d-4cd9-9ed0-39209b9d3d44": {"__data__": {"id_": "cdbb6fc1-c11d-4cd9-9ed0-39209b9d3d44", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "70"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "02b5bbd0-2b23-427f-be27-6102fb479af6", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "70"}, "hash": "ef87d4b60d694f4aeb5eb29c53fa2b41dfb2595beb636722b422a6403e62bba1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "653f7390-dba3-451b-b1c9-4376f61ae1c3", "node_type": "1", "metadata": {}, "hash": "a383abfa891cf2e92f73ba0e9cef4e18f922c540546252a978b037b93d691175", "class_name": "RelatedNodeInfo"}}, "text": "4.1 Introduction\nPharmacovigilance (PV) is defined as the science and activities relating to the detection,\nassessment, understanding, and prevention of adverse effects or any other drug-related problem\nincluding medication errors, drug misuse, and abuse. Pharmacovigilance is an arm of patient\ncare that aims at making the best use of medicines for the treatment or prevention of disease.\nGood pharmacovigilance practise will identify the risks and the risk factors in the shortest\npossible time so that harm can be avoided or minimized.\nThere are two methods of pharmacovigilance:\n    \u00a7   Active pharmacovigilance\n    \u00a7   Passive pharmacovigilance\nMonitoring and reporting of drug therapy problems including adverse drug reactions (ADRs)\nand medication errors should be an integral part of clinical practice for ensuring patient safety\nand optimal treatment outcomes. All healthcare providers (doctors, pharmacists, nurses, and\ncounsellors, etc.) at various service delivery points should, therefore, assess patients for ADRs at\nevery encounter and report all suspected adverse events using the NAFDAC ADR form (Yellow\nform). All facilities should establish a functional hospital-based pharmacovigilance committee\nin all ART/PMTCT centres to coordinate ARV clinical pharmacovigilance. This committee is\nvery vital to the success of pharmacovigilance and management ofADRs in a clinical setting.\n4.1.1Active Pharmacovigilance\nActive (or proactive) safety surveillance means that active measures are taken to detect adverse\nevents. This is managed by active follow-up after treatment and the events may be detected by\nasking patients directly or screening patient records. It is based on structured procedures to\nobtain detailed information about patient populations, thereby allowing consideration of\nmodifying factors such as polypharmacy, comorbidity, and socio-demographic characteristics.\nIn addition, it enables targeted monitoring of specific drugs and adverse reactions to optimize the\nquality and quantity of reports as well as quantifying the frequency and severity of both expected\nand unanticipated adverse drug reactions. This surveillance is best done prospectively. Active\npharmacovigilance is sometimes descriptively referred to as hot 'pursuit'.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2262, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "653f7390-dba3-451b-b1c9-4376f61ae1c3": {"__data__": {"id_": "653f7390-dba3-451b-b1c9-4376f61ae1c3", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "70"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "02b5bbd0-2b23-427f-be27-6102fb479af6", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "70"}, "hash": "ef87d4b60d694f4aeb5eb29c53fa2b41dfb2595beb636722b422a6403e62bba1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cdbb6fc1-c11d-4cd9-9ed0-39209b9d3d44", "node_type": "1", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "70"}, "hash": "ac3dcd955275e59454e586c4b1af7ffd99abec513e7da7c841e12e953f4538e7", "class_name": "RelatedNodeInfo"}}, "text": "This surveillance is best done prospectively. Active\npharmacovigilance is sometimes descriptively referred to as hot 'pursuit'. The most\ncomprehensive method of active pharmacovigilance is Cohort Event Monitoring (CEM). It is an\nadaptable and powerful method of getting good comprehensive data. Other methods of active\nmonitoring include the use of registers, record linkage and screening of laboratory results in\nmedical laboratories.\nActive pharmacovigilance is compulsory for all new drugs imported or manufactured for use\nwithin the country. It may be initiated, managed or financed by the Market Authorization\nHolder/PHP voluntarily or pursuant to an obligation imposed by the National Agency for Foods\nand Drugs Administration and Control (NAFDAC). In any case, the process must be done in\ncollaboration with NAFDAC.\n4.2 Pregnancy Monitoring for Patients onARVs\nIt is strongly recommended that all women who are known to be pregnant on ART should be\nfollowed up to find out the outcome of the pregnancy and the health status of the infant. Health\ncare providers should collect data on all ARV drug exposure during pregnancy using an\nappropriate data collection tool. Data collected should include:\n           NATIONAL GUIDELINES FOR HIV PREVENTION TREATMENT AND CARE 2020           48", "mimetype": "text/plain", "start_char_idx": 2135, "end_char_idx": 3425, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f9813d9a-9cb7-41b7-9cca-e9ef07f488ad": {"__data__": {"id_": "f9813d9a-9cb7-41b7-9cca-e9ef07f488ad", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "71"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "33befe0e-2f00-4148-a7ae-f887c8c49d53", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "71"}, "hash": "4b924381904a740dbf44f586f417982007b999e7e9c0f925314379f9e55b9cdd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ade98854-ef0a-4f0c-ba3b-2f057c5bf8be", "node_type": "1", "metadata": {}, "hash": "bb484365ba3744b5effbbbdc42bebc63d876311962fd350da4ff8adbe5b8e9e0", "class_name": "RelatedNodeInfo"}}, "text": "\u00a7    Baseline information on the pregnancy; WhatARV is the woman on?, Did the woman\n        get pregnant while onART?, or WasART initiated during pregnancy?\n   \u00a7    Details on any pregnancy-related problems in the woman, foetal death and or\n        abnormalities observed when the infant is examined at birth or postnatally\n4.3 HIV Drug Resistance (HIVDR)\nThe global risk of further increases in HIVDR is heightened by the implementation of WHO\nguidelines recommending \"Treat All\" and pre-exposure prophylaxis, and many more people\ninitiating HIV treatment. While concerns about resistance should not stop the provision of\nantiretroviral therapy (ART) to all in need, the long-term implications of earlier initiation on\nadherence and drug resistance need to be closely monitored and responded to.\nIf not properly controlled, HIVDR can reduce the durability of the current first-line regimen for a\nsignificant proportion of patients. These patients would have to be switched to more expensive\nsecond-line or even third-line regimens. With higher levels of HIVDR, more resources would be\nneeded to treat the same number of patients, or more likely, fewer patients could be treated with\nthe same resources.\nTherefore, surveillance of HIVDR and implementation of effective responses are key to\npreserving the effectiveness of first-lineART which is the goal of anyART programme.\n4.4Adverse drug reactions (ADRs)\nAn adverse drug reaction (ADR) is defined by WHO as \u201ca response to a drug which is noxious\nand unintended, and which occurs at doses normally used in man for the prophylaxis, diagnosis,\nor therapy of disease, or the modification of physiological function.\u201d Side Effect refers to the\nunintended effect of a health product occurring at doses normally used in man which is related to\nthe pharmacological properties of the drug.\nThe therapeutic benefits of ARV use far outweigh the risk, thus despite the ADRs and toxicities\nencountered with ARV use, they are still essential inpatient management. ARVs resulting in\nADRs that pose a serious threat to the health and well-being should be discontinued without\ndelay and necessary consultations made regarding the next line of actions.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2186, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ade98854-ef0a-4f0c-ba3b-2f057c5bf8be": {"__data__": {"id_": "ade98854-ef0a-4f0c-ba3b-2f057c5bf8be", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "71"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "33befe0e-2f00-4148-a7ae-f887c8c49d53", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "71"}, "hash": "4b924381904a740dbf44f586f417982007b999e7e9c0f925314379f9e55b9cdd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f9813d9a-9cb7-41b7-9cca-e9ef07f488ad", "node_type": "1", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "71"}, "hash": "c289fd6ba5282d64e05344a37386022ab2a1fd989bb83bb8f6a2f6df6ae7d691", "class_name": "RelatedNodeInfo"}}, "text": "ARVs resulting in\nADRs that pose a serious threat to the health and well-being should be discontinued without\ndelay and necessary consultations made regarding the next line of actions.\n4.4.1 Classification ofAdverse Drug Reactions (ADRs)\nThe WHO classifies ADRs into four categories based on severity. Severity is a subjective\nassessment made by the healthcare provider and/or patients. Despite being subjective, it is useful\nin identifying adverse reactions that may affect adherence or further harm that needs prompt\nintervention.\n          NATIONAL GUIDELINES FOR HIV PREVENTION TREATMENT AND CARE 2020              49", "mimetype": "text/plain", "start_char_idx": 2002, "end_char_idx": 2623, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "425114d5-9e8f-44f0-9cc8-873317c3cbe1": {"__data__": {"id_": "425114d5-9e8f-44f0-9cc8-873317c3cbe1", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "72"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "236b607b-3370-4cb2-85db-8115efc9f614", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "72"}, "hash": "03cdf0c5e4108391d7571c4deec9e8126be97f963eb857ee383d3b95e4853661", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e9973750-2a6d-418e-8a75-870c6ebc8b90", "node_type": "1", "metadata": {}, "hash": "92a32860d2c51db0875b1ee20878b843fea5fdecd6fe79fd88940f616485e444", "class_name": "RelatedNodeInfo"}}, "text": "Table 4.1: WHO Severity Grading of ADR\n  Severity Grade                           Characteristics\n  1 \u2013 Mild ADR                         \u00b7   Transient or mild discomfort (<48 hours)\n                                       \u00b7   No limitation of activity\n                                       \u00b7   No medical intervention or therapy required\n  2 \u2013 Moderate ADR                     \u00b7   Mild to moderate limitation of activity\n                                       \u00b7   Some assistance may be needed\n                                       \u00b7   No or minimal medical intervention required\n  3 \u2013 Severe ADR                       \u00b7   Marked limitation of activity\n                                       \u00b7   Some assistance usually required\n                                       \u00b7   Medical intervention or therapy required\n                                       \u00b7   Hospitalization possible\n  4 \u2013 Life-Threatening ADR             \u00b7   Extreme limitation of activity\n                                       \u00b7   Significant assistance required\n                                       \u00b7   Significant medical intervention or therapy required\n                                       \u00b7   Hospitalization or hospice care probable.\n In the event of severe/life-threatening ADRs, the offending drug(s) must be discontinued and\n changed to another drug from within its class.\n 4.5 Drug toxicity\n This is the unwanted effect of drugs resulting from administration in excess of the required\n therapeutic dose, or accumulation of drugs in the body due to inefficient absorption, distribution,\n metabolism, or excretion. Some clinical conditions e.g. renal impairment and chronic liver\n disease may also predispose patients to drug toxicity. Drug toxicity can be detected clinically\n (history and clinical examination) and/or through laboratory testing (table 4.2).\n In the event of drug toxicity, dose adjustment is recommended where feasible; otherwise, the\n offending drug should be discontinued and changed to another drug from within its class.\n 4.5.1 Laboratory monitoring of toxicity:\n Laboratory monitoring of patients receiving ARVs for either HIV treatment or prophylaxis is\n very important for early detection and prevention of some ADRs. Abnormal laboratory values\n may be early warning signals preceding the clinical manifestations of some ADRs in patients\n receiving antiretroviral drugs. Symptom-related monitoring is useful and there are also several\n laboratory tests (but not routinely required) for assessing the safety and toxicity of ART,\n especially in high-risk clients.\n The table below shows the ARV drug class, clinical abnormality, and the laboratory test that\n could be used for its monitoring.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2696, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e9973750-2a6d-418e-8a75-870c6ebc8b90": {"__data__": {"id_": "e9973750-2a6d-418e-8a75-870c6ebc8b90", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "72"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "236b607b-3370-4cb2-85db-8115efc9f614", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "72"}, "hash": "03cdf0c5e4108391d7571c4deec9e8126be97f963eb857ee383d3b95e4853661", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "425114d5-9e8f-44f0-9cc8-873317c3cbe1", "node_type": "1", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "72"}, "hash": "aa159b2ba3ca739749606c08259ed2d0f734d9d0507c1b8e490bc56df1d70208", "class_name": "RelatedNodeInfo"}}, "text": "The table below shows the ARV drug class, clinical abnormality, and the laboratory test that\n could be used for its monitoring.\n           NATIONAL GUIDELINES FOR HIV PREVENTION TREATMENT AND CARE 2020             50", "mimetype": "text/plain", "start_char_idx": 2569, "end_char_idx": 2785, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8fda0991-4276-4ad7-8bae-b923347ceb0f": {"__data__": {"id_": "8fda0991-4276-4ad7-8bae-b923347ceb0f", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "73"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "b294b949-7894-4967-9bf7-a108adea1a9b", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "73"}, "hash": "1c4770a114f22552526abd3a79a609a166fcdaba12e2868268841577b8437fff", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e739ef30-79aa-4070-91e5-f441bf447b73", "node_type": "1", "metadata": {}, "hash": "331220d64cc0cbcb4f455878ec757d568ddc132b0c9669dadbfc3dd3e89daba0", "class_name": "RelatedNodeInfo"}}, "text": "Table 4.2 Common ADRs associated with ARV drugs and necessary laboratory tests\n Drug class Drug             Common ADRs              Riskfactors                Laboratory Tests\n NRTI        Abacavir        Hypersensitivity         Presence of HLA-B*5701     CPK,\n             (ABC)           Hepatotoxicity           gene                       Liver enzymes\n             Emtricitabine   Hepatotoxicity                                      Liver enzymes\n             (FTC)\n             Lamivudine      Cough, diarrhoea, fatigue,                          Non-specific\n             (3TC)           malaria, headache,\n                             lethargy, Nausea,\n                             vomiting and pancreatitis\n                             (in children\n             Tenofovir       Renal Toxicity           Underlying renal disease;  Creatinine,\n             Disoproxil                               Age >50 years old;         Urinalysis\n             Fumarate                                 BMI <18.5 or low body\n             (TDF)                                    weight (<50 kg), diabetes,\n                                                      hypertension Concomitant\n                                                      use of nephrotoxic drugs\n                                                      or a boosted PI\n                             Decreases in bone        History of osteomalacia\n                             mineral density          (in adults) and rickets (in\n                                                      children) and pathological\n                                                      fracture Risk factors for\n                                                      osteoporosis or bone\n                                                      mineral density loss,\n                                                      Vitamin D deficiency\n             Zidovudine      Anaemia, leukopenia,     Baseline anaemia or        Full blood count\n             (AZT)           neutropenia,             neutropenia CD4+ cell      E/U/Cr\n                                                      count of \u2264200 cells/mm\u00b3    CPK\n                             Lactic acidosis, severe  BMI >25 (or bodyweight\n                             hepatomegaly with        >75 kg) Prolonged\n                             Myopathy                 exposure to NRTIs\n NNRTI       Efavirenz       CNS manifestations       Depression or other mental\n             (EFV)                                    disorder (previous or at   Liver enzymes\n                                                      baseline), Daytime dosing  Serum cholesterol\n                             Hepatotoxicity           Underlying HBV and HCV\n                                                      co-infection,", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2786, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e739ef30-79aa-4070-91e5-f441bf447b73": {"__data__": {"id_": "e739ef30-79aa-4070-91e5-f441bf447b73", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "73"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "b294b949-7894-4967-9bf7-a108adea1a9b", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "73"}, "hash": "1c4770a114f22552526abd3a79a609a166fcdaba12e2868268841577b8437fff", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8fda0991-4276-4ad7-8bae-b923347ceb0f", "node_type": "1", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "73"}, "hash": "931c54cd30cfe7b95e07c7522557c30fc1847aefbc54a582d55c843b702285cd", "class_name": "RelatedNodeInfo"}}, "text": "Daytime dosing  Serum cholesterol\n                             Hepatotoxicity           Underlying HBV and HCV\n                                                      co-infection, Concomitant\n                                                      use of hepatotoxic drugs\n                             Hypercholesterolemia     Risk factor(s) unknown\n           NATIONAL GUIDELINES FOR HIV PREVENTION TREATMENT AND CARE 2020                    51", "mimetype": "text/plain", "start_char_idx": 2608, "end_char_idx": 3050, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "36bdbc73-3ef1-4335-8e05-f818fd151e83": {"__data__": {"id_": "36bdbc73-3ef1-4335-8e05-f818fd151e83", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "74"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "9bc5d05e-bdf4-480d-9d17-94e59543ab04", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "74"}, "hash": "b61a216bc88819f6354b4a237853d377d50c8e7868d622cd66e5ee5872a57aa4", "class_name": "RelatedNodeInfo"}}, "text": "Drug class Drug              Common ADRs                 Riskfactors           Laboratory Tests\n                             Gynaecomastia               Riskfactor(s) unknown\n            Nevirapine       Hepatotoxicity              Underlying hepatic disease  Liver enzymes\n            (NVP)                                        HBV and HCV co-infection\n                             Severe skin rash and        High baseline CD4+ cell\n                             hypersensitivity reaction,  count\n                             including Stevens-\n                             Johnson syndrome\nPI          Atazanavir/rito  Electrocardiographic        Pre-existing conduction     ECG\n            navir(ATV/r)     abnormalities (PR and       system disease\n                             QRS interval                Concomitant use of drugs\n                             prolongation)               which may prolong the PR\n                                                         or QRS intervals\n                                                         Congenital long QT\n                                                         syndrome\n                             Indirect                    Presence of UDP\n                             hyperbilirubinemia     Glucuronyl transferase\n                             (clinical jaundice)         1A1*28 (UGT1A1*28)\n                                                         gene\n                             Nephrolithiasis             Previous history\n            Darunavir/riton  Hepatotoxicity              Underlying hepatic          Liver enzymes\n            avir(DRV/r)                                  disease, Concomitant use\n                                                         of hepatotoxic drugs\n                             Severe skin and\n                             hypersensitivity reactions\n            Lopinavir        Hepatotoxicity         Underlying hepatic disease       Liver enzymes\n            /ritonavir                              HBV and HCV co-infection Serum amylase\n            (LPV/r)                                 Concomitant use of               ECG\n                                                    hepatotoxic drugs\n                             Pancreatitis                Advanced HIV disease,       Lipid profile\n                                                         alcohol\n                             Arrhythmias                 People with pre-existing\n                                                         conduction system disease\n                             Dyslipidaemia               Cardiovascular risk factors\n                                                         as obesity and diabetes\n          NATIONAL GUIDELINES FOR HIV PREVENTION TREATMENT AND CARE 2020                   52", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2792, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e81417f3-5945-449a-ad1c-b33e540a7799": {"__data__": {"id_": "e81417f3-5945-449a-ad1c-b33e540a7799", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "75"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "2c254d85-2947-4aaa-a7c6-77bc40f88383", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "75"}, "hash": "d760cfe7c89f9034c8396d922540be2919e7b395bd9b192183f52c728c090189", "class_name": "RelatedNodeInfo"}}, "text": "Drug class Drug            Common ADRs                 Riskfactors            Laboratory Tests\n                            Diarrhoea                   Riskfactor(s) unknown\n             Ritonavir      Hepatotoxicity              Underlying hepatic disease  Liver enzymes\n             (RTV)          Hyperglycaemia              HBV and HCV co-infection Urinalysis, BSL-\n                            Hyperlipidemia                                          blood sugar level\n                                                                                    Serum lipids\n                                                                                    CPK, Uric acid\n Integrase   Dolutegravir   Hepatotoxicity              Underlying hepatic          Liver enzymes\n inhibitors  (DTG)                                      disease, Concomitant use\n                                                        of hepatotoxic drugs\n                            Hypersensitivity reactions  Risk factor(s) unknown\n                            Insomnia                    Risk factor(s) unknown\n                            IRIS, Neural Tube           PLHIV with AHD\n                            Defects (NTDs)\n             Raltegravir    Rhabdomyolysis,             Concomitant use of other    CPK\n             (RAL)          myopathy, myalgia.          drugs that increase the risk\n                                                        of myopathy and             Liver enzymes\n                                                        rhabdomyolysis, including.\n                                                        statin\n                            Hepatotoxicity,             Risk factor(s) unknown\n                            Severe skin rash and\n                            hypersensitivity reaction\nTable 4.3: Common ADRs associated with drugs used in the management of Ois\n Drug                 Common ADRs                                                    Laboratory\n                                                                                     Tests\n Cotrimoxazole        Hypersensitivity, Steven Johnson\u2019s Syndrome, Anaemia and       CBC and Liver\n                      Liver problems                                                 function test\n Isoniazid            Liver problems, Musculoskeletal symptoms and GI symptoms       LFT\n Fluconazole          CNS and GI symptoms\n Amphotericin B       Injection site reactions, hypersensitivity reactions, GI       E/U/Cr\n                      symptoms, musculoskeletal symptoms, respiratory symptoms,\n                      CNS symptoms, vision changes, low potassium, and dysuria\n Flucytosine          Hypersensitivity, Hepatic disorders, Haematological,           LFT, E/U/Cr,\n                      Respiratory, Renal, GI and CNS disorders                       CBC & RBS\n           NATIONAL GUIDELINES FOR HIV PREVENTION TREATMENT AND CARE 2020                  53", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2922, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1b13e3c3-36d0-46f1-92cc-f4e5b7ef1335": {"__data__": {"id_": "1b13e3c3-36d0-46f1-92cc-f4e5b7ef1335", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "76"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "7508808c-84cc-4266-9c85-28a0b2536be8", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "76"}, "hash": "5ebe158a640d0e447e3e00db80bf36ada308d29d7b7db2d6bbb13ca088cc60ad", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9886289b-cf8b-47f7-9a31-9579e6be0afd", "node_type": "1", "metadata": {}, "hash": "22e5a0fa7160bb0a72cb2ffb5822b68b8b9b182df36458993d5d5452164328e1", "class_name": "RelatedNodeInfo"}}, "text": "The severity grading of laboratory test abnormalities may guide prompt intervention and\nprevent the negative consequences ofADR.\n4.6 Steps to RecognizeADRs\n    1.  Take adequate history and do a thorough physical examination of the patient\n    2.  Establish time relationships, between start of therapy to the time of onset of the\n        suspected reaction.\n    3.  Carry out appropriate laboratory investigations, where indicated\n    4.  Check the pharmacological properties of the suspected drugs if required\n4.7 Who is to ReportADRs?\nAdverse drug reactions (ADRs) should be reported by Physicians, Pharmacists, Nurses,\nMedical laboratory scientists, other health and community health care workers, caregivers, and\npatients. The original copy should be sent to NAFDAC by the facility pharmacovigilance focal\nstaff, while the duplicate copy should remain in the patient's folder. The third copy should\nremain in the booklet at the Service Delivery Point. All completed booklets should be sent to the\npharmacovigilance focal staff for safekeeping.\n Table 4.4: Reporting Timelines\n  Type of ADR Report                                                      Time frame for Reporting\n  Serious (expected and unexpected)                                       15 days\n  Non-serious(unexpected)                                                 15 days\n  Non-serious (expected)                                                  Within 90 days\n  Foreign report (Spontaneous/published/study)                            Within 90 days\n  Notification of change in nature, severity or frequency or risk factor  15 days\n  New information impacting on benefits \u2013 risk profile of product         3 days\n  including international regulatory decisions\n4.8 What ADRs Should be Reported\n    1.   All serious reactions (expected or unexpected) that one suspects for established or\n         well-known drugs\n    2.   All suspected reactions, including minor ones for new drugs\n    3.   If an increased frequency of a given reaction is observed\n    4.   All suspected adverse reactions associated with drug-drug, drug-food, or drug-food\n         supplement interactions and drug-disease interactions.\n    5.   ADRs during pregnancy and lactation\n    6.   ADRs occurring from an overdose or medication error\n    7.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2288, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9886289b-cf8b-47f7-9a31-9579e6be0afd": {"__data__": {"id_": "9886289b-cf8b-47f7-9a31-9579e6be0afd", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "76"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "7508808c-84cc-4266-9c85-28a0b2536be8", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "76"}, "hash": "5ebe158a640d0e447e3e00db80bf36ada308d29d7b7db2d6bbb13ca088cc60ad", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1b13e3c3-36d0-46f1-92cc-f4e5b7ef1335", "node_type": "1", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "76"}, "hash": "9fa4a36d9bbef997772935e2fed41fdda5a12e96bb79acc850e1b4c8be6cdaef", "class_name": "RelatedNodeInfo"}}, "text": "5.   ADRs during pregnancy and lactation\n    6.   ADRs occurring from an overdose or medication error\n    7.   Lack of efficacy of a medication, or when suspected pharmaceutical defects are\n         observed\n    8.   Reactions suspected of causing death, danger to life, admission to hospital,\n         prolongation of hospitalization, or birth defects.\n    9.   When in doubt whether the suspected adverse event/reaction is an ADR or not, you\n         must report to the National Pharmacovigilance Centre.\n           NATIONAL GUIDELINES FOR HIV PREVENTION TREATMENT AND CARE 2020               54", "mimetype": "text/plain", "start_char_idx": 2180, "end_char_idx": 2777, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fb593958-d6e2-4ed2-ba8e-54f915e7ff14": {"__data__": {"id_": "fb593958-d6e2-4ed2-ba8e-54f915e7ff14", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "77"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "b9aa4c94-93b3-4fac-9ab0-efd44e9534d0", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "77"}, "hash": "7967a314225082ab9cb0107e4da2eb23dadd5ac50d6c565d07ee4089d33dddd8", "class_name": "RelatedNodeInfo"}}, "text": "4.9 Pharmacovigilance Data Collection and Reporting Process\nAll ADRs should be reported to the National Pharmacovigilance Centre using the NAFDAC\nADR form (yellow form). The following steps should be taken:\nFigure 4.1 Pharmacovigilance Reporting\n Refer to the NAFDAC website for all reportedADRs (https://www.nafdac.gov.ng/)\n 4.10 Principles of Management ofAdverse Drug Reactions\n Ensure strict adherence to the standard procedures outlined below for detecting, evaluating and\n reportingADRs inART/PMTCT Clinical Settings\n          NATIONAL GUIDELINES FOR HIV PREVENTION TREATMENT AND CARE 2020          55", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 607, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9880e4c1-0f71-4712-96e8-86c722c0d1ed": {"__data__": {"id_": "9880e4c1-0f71-4712-96e8-86c722c0d1ed", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "78"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "0d56cc63-58fe-4e1f-bad2-40a348fc10f6", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "78"}, "hash": "9ce95539d2ccba94840471e39c0559297c32701a16c21186e7cf37b2703abb94", "class_name": "RelatedNodeInfo"}}, "text": "Figure 4.2: Management of Adverse Drug Reactions\n            NATIONAL GUIDELINES FOR HIV PREVENTION TREATMENT AND CARE 2020                     56", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 146, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ccddd486-4eb8-403f-922c-e012811b9025": {"__data__": {"id_": "ccddd486-4eb8-403f-922c-e012811b9025", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "79"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "f7fb7d50-71b5-4197-9b2e-afa11903fc62", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "79"}, "hash": "641ab8de8c3c249faab57b725ba674886db19932027447f5bc76753dbe3d7f85", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b4631fe8-16eb-4e21-ae23-0750d18ca60b", "node_type": "1", "metadata": {}, "hash": "18d9b05811a45d363ac408e70761315da4700ea053e681b582c629bb8c469e0e", "class_name": "RelatedNodeInfo"}}, "text": "4.10.1 Management of SpecificARVAdverse Drug Reactions\n      Adverse reactions associated with ARV drugs usually have a class similarity; however certain\n   drugs in each of the classes present more severe forms of adverse reactions than others. In the\n       management of adverse events, special attention should, therefore, be paid to drug-specific\n         adverse reactions. For example, Zidovudine is implicated in ARV-induced anaemia more than\n  any other ARV in the same class, just as Efavirenz is more likely to cause CNS toxicity than the\n     otherARV drugs in the same class.\n         a)          Nucleoside Reverse Transcriptase Inhibitors (NRTIs): All NRTIs are capable of\n                          inhibiting mitochondria DNA (mtDNA) gamma polymerase enzyme resulting in\n             mitochondrial toxicity.    As NRTIs inhibit DNA polymerase, all tissues that have DNA\n              can be affected. The manifestation of NRTI adverse drug reaction is dependent on the\n                organ involved; there can be myopathy presenting with muscle weakness, bone marrow\n               disorders causing depression of haemopoiesis and leading to anaemia, leucopenia and\n                  thrombocytopenia; lipolysis resulting in fat atrophy (lipoatrophy). It can cause\n               myelotoxicity and neuropathy when it affects peripheral neurons, thus precipitating\n                      peripheral neuropathy. Though rare, prolonged usage of NRTIs may also affect\n         myocardial cells resulting in cardiomyopathy. Others include hepatitis, pancreatitis, and\n             lactic acidosis.\n         b)            Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs): They increase the\n                incidence of severe hepatotoxicity in women with CD4+ cell count > 250cells/mm and\n                                                                                            3\n                 men with CD4+ cell count > 400cells/mm . Other common reactions include skin rash\n                                                      3\n             and CNS disorders.\n         c)       Protease Inhibitors (Pis): PIs are potent CYP3A4 inhibitors hence many drug-drug\n              interactions can occur on co-administration with other drugs. ADRs due to PIs can be\n          severe.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2303, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b4631fe8-16eb-4e21-ae23-0750d18ca60b": {"__data__": {"id_": "b4631fe8-16eb-4e21-ae23-0750d18ca60b", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "79"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "f7fb7d50-71b5-4197-9b2e-afa11903fc62", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "79"}, "hash": "641ab8de8c3c249faab57b725ba674886db19932027447f5bc76753dbe3d7f85", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ccddd486-4eb8-403f-922c-e012811b9025", "node_type": "1", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "79"}, "hash": "55b78387471a884d91f983fa3a51c6bca75a61378a001d5428a8d25bde7c5d9e", "class_name": "RelatedNodeInfo"}}, "text": "ADRs due to PIs can be\n          severe. These include acute effects of diarrhoea, vomiting and hepatotoxicity; and long-\n               term toxicity which includes peripheral loss of subcutaneous fat (lipoatrophy), fat\n                     accumulation within the abdominal cavity (protease paunch or crix-belly), fat\n               accumulation in the upper back (dorsocervical pad or buffalo hump), gynecomastia in\n             males, fat accumulation in the breast in females and fat accumulation in subcutaneous\n                tissue (peripheral lipomatosis). Management of acute ADRs includes reassurance and\n             symptomatic treatment as it clears within 4-6 weeks of therapy.\n         d)       Integrase Inhibitors: Neuropsychiatric (NP) symptoms have been reported with all\n       INSTIs, and their onset is usually described during the first few weeks after introduction.\n              Symptoms include headaches, reduced concentration, anxiety, irritability, dizziness,\n                   insomnia, altered dreams, depression, unexplained pain, and more recently, mood\n             changes.\nAll INSTIs have been associated with mild increases in creatinine levels, usually without clinical\n      significance, but caution is needed in patients with low eGFR (<30mls/min), when using other\n     nephrotoxic drugs, such as TDF. There is also a potential risk of weight gain associated with\n     DTG. Some of the following approaches may be helpful for patients on DTG:\n        \u00a7    Clinicians should avoid DTG for patients with a history of severe Neuro-Psychiatric\n             symptoms.\n        \u00a7    DTG should also not be given at the same time as supplements containing\n             Magnesium (Mg), or Zinc (Zn). These may be in multivitamins, certain laxatives,\n             or antacids, it is therefore important to know what other tablets your patients are taking\n                NATIONAL GUIDELINES FOR HIV PREVENTION TREATMENT AND CARE 2020           57", "mimetype": "text/plain", "start_char_idx": 2263, "end_char_idx": 4244, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9516df09-b3f9-4f97-9de2-01056e6a8dfe": {"__data__": {"id_": "9516df09-b3f9-4f97-9de2-01056e6a8dfe", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "80"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "c521f649-596f-42d1-9176-ca2684d23122", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "80"}, "hash": "115f4b234e746c086b45c876752c10af40f1a4288eeca7b04104c08f735ce564", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "eeaec2c2-1720-4b81-9c45-a8ab1b8cd1ce", "node_type": "1", "metadata": {}, "hash": "3352af02d911b768d5d705582ea5c013be2fe5ae3a92849af48147c1b118b846", "class_name": "RelatedNodeInfo"}}, "text": "\u2022    If your patients are taking any of these, advise them to take theirARVs at least 2\n             hours before or at least 6 hours afterwards\n    \u00a7   DTG may be given with calcium (Ca) or Iron (Fe) supplements if taken with food\n    \u00a7   Clinicians should monitor the body weight and BMI of patients.\nTable 4.3  Adverse drug reactions associated with the use of specific ARV drugs and their management\n Antiretrovira   Primary toxicities                  Minor           Monitoring/Management\n l Drug                                              toxicities\n Zidovudine      Anaemia, neutropenia, myopathy,     Blue to black   For anaemia:\n (AZT)           lipoatrophy or lipodystrophy [Risk  discolouration  \u00b7  Change to TDF and/or transfuse\n                 factors include -Baseline anaemia   of nails, nausea,\n                 or neutropenia; CD4+ cell count     and headache    \u00b7  Do not use AZT if Hb < 8.0 g/dl\n                 \u2264200 cells/mm3]                                        (PCV <24%)\n                 Lactic acidosis or severe                           For myopathy, discontinue if CPK\n                 hepatomegaly with steatosis [Risk                   rises. If AZT is being used in first-\n                 factors include -BMI >25 (or                        line ART, substitute with TDF or\n                 bodyweight >75 kg); Prolonged                       ABC. If AZT is being used in\n                 exposure to nucleoside analogues\n                                               ]                     second-line ART, substitute with\n                                                                     ABC\n Lamivudine      Pancreatitis, Liver toxicity        Skin rash,      Discontinue if serum amylase\n (3TC)           Mild peripheral neuropathy          headache        elevated.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1812, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "eeaec2c2-1720-4b81-9c45-a8ab1b8cd1ce": {"__data__": {"id_": "eeaec2c2-1720-4b81-9c45-a8ab1b8cd1ce", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "80"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "c521f649-596f-42d1-9176-ca2684d23122", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "80"}, "hash": "115f4b234e746c086b45c876752c10af40f1a4288eeca7b04104c08f735ce564", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9516df09-b3f9-4f97-9de2-01056e6a8dfe", "node_type": "1", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "80"}, "hash": "12932f69ff5ac24ef5063621a2ed103f9ebd4b90b848cf2d393dcc177d41c4d4", "class_name": "RelatedNodeInfo"}}, "text": "Restart when resolved or\n                                                                     change to ABC\n Emitricitabine  Similar to lamivudine               Occasional\n (FTC)                                               hyperpigmentat\n                                                     ion of skin\n                                                     (palms/ soles)\n Tenofovir       Tubular renal dysfunction,          Occasional GI   If creatinine clearance declines,\n Disoproxil      Fanconi syndrome [Risk factors:     intolerance     substitute with non-nephrotoxic\n Fumarate        Underlying renal disease; Older                     drugs such as ABC or adjust the\n (TDF)           age; BMI <18.5 (or bodyweight                       dosage. (See section on co-\n                 <50 kg); Untreated diabetes                         morbidities)\n                 mellitus; Untreated hypertension;                   If TDF is being used in first-line\n                 Concomitant use of nephrotoxic                      ART, substitute with AZT or ABC.\n                 drugs or a boosted PI]                              If TDF is being used in second-line\n                 Decreases in bone mineral                           ART (after AZT use in first-line\n                 Density [Risk factors: History of                   ART), substitute with ABC.\n                 osteomalacia and pathological\n                 fracture; risk factors for\n                 osteoporosis or bone loss]\n            NATIONAL GUIDELINES FOR HIV PREVENTION TREATMENT AND CARE 2020                    58", "mimetype": "text/plain", "start_char_idx": 1813, "end_char_idx": 3410, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0be6665f-bf00-4ebe-ade1-a55286506a3a": {"__data__": {"id_": "0be6665f-bf00-4ebe-ade1-a55286506a3a", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "81"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "2327ed29-f55d-475e-a76e-ff446fbcace1", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "81"}, "hash": "754edccb4ee402ddf0f33284cd15fd452d5aeb2c82afcba126207ef90cc43a16", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9ff7cb3d-bffc-43d4-9af3-09d92160e8a4", "node_type": "1", "metadata": {}, "hash": "8eeec01da3d0cbd354011386c98867867ffb2d9ced94c45080ef1e9584cb3f2c", "class_name": "RelatedNodeInfo"}}, "text": "Lactic acidosis or severe\n                hepatomegaly with steatosis [Risk\n                factors: Prolonged exposure to\n                nucleoside analogues; Obesity]\n                Exacerbation of hepatitis B\n                (hepatic flares) [Risk factors:                     Use an alternative drug for hepatitis\n                Discontinuation of TDF due to                       B treatment.\n                toxicity]\n  Abacavir      Life-threatening hypersensitivity                   Discontinue therapy if\n  (ABC)         reaction may occur in 3-9% of                       hypersensitivity develops. Abacavir\n                patients [Risk factors\n                                    - the presence                  should never be used in that\n                of HLA-B*5701 Gene]                                 individual again.\n                Lactic acidosis may also occur                      If ABC is being used in first-line\n                with/without hepatic steatosis                      ART, substitute with TDF or AZT.\n                                                                    If ABC is being used in second-line\n                                                                    ART, substitute w\n                                                                                    ith TDF\nNevirapine      Life-threatening skin rash and                      Low dose over first 2 weeks\n(NVP)           hypersensitivity reaction(Stevens-                  minimizes rashoccurrence. If mild\n                Johnson syndrome) which occurs                      or moderate (Grade 1/2) continue\n                in less than 5% of patients and                     cautiously or substitute with EFV.\n                usually within 8 weeks of treatment                 If severe discontinue NVP and\n                DRESS syndrome (drug rash,                          permanently if hepatitis confirmed.\n                eosinophilia, and systemic\n                symptoms) manifesting as fever,                     Change to EFV.If the person cannot\n                arthralgia, etc.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2112, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9ff7cb3d-bffc-43d4-9af3-09d92160e8a4": {"__data__": {"id_": "9ff7cb3d-bffc-43d4-9af3-09d92160e8a4", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "81"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "2327ed29-f55d-475e-a76e-ff446fbcace1", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "81"}, "hash": "754edccb4ee402ddf0f33284cd15fd452d5aeb2c82afcba126207ef90cc43a16", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0be6665f-bf00-4ebe-ade1-a55286506a3a", "node_type": "1", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "81"}, "hash": "c51b3841796ce320f2560dad47fe0961a41845e892b1bbec09d4c9ce17dec99b", "class_name": "RelatedNodeInfo"}}, "text": "eosinophilia, and systemic\n                symptoms) manifesting as fever,                     Change to EFV.If the person cannot\n                arthralgia, etc.                                    tolerate either NNRTI, use boosted\n                Hepatotoxicity [Risk factors:                       PIs\n                Underlying hepatic disease; HBV\n                and HCV co-infection;\n                Concomitant use of hepatotoxic\n                drugs; CD4 + cell count>250\n                cells/mm3 in women; CD4+ cell\n                                   3\n                count>400 cells/mmfor men; First\n                month oftherapy (if lead\n                not used)              -in dose is\n Efavirenz     Persistent central nervous system   Dizziness        Rash i n 10% but rarely severe in\n (EFV)         toxicity (such as abnormal dreams,                   <1%; CNS symptoms often resolve\n               hallucination, insomnia, amnesia,                    2-4 weeks.\n               depression or mental confusion).                     EFV is contraindicated in patients\n               CNS side effects occur in about                      who already have psychiatric\n               50% of pati  ents (usually self-                     manifestations.\n               limiting) [Risk factors: Depression                  Change to NVP. If the person\n               or other mental disorder (previous\n               or at baseline); Daytime dosing]                     cannot tolerate either NNRTI, use\n               Hepatotoxicity [Risk factors:                        boosted PIs\n               Underlying hepatic disease- HBV\n               and HCV co-infection,\n               Concomitant use of hepatotoxic\n               drug]\n          NATIONAL GUIDELINES FOR HIV PREVENTION TREATMENT AND CARE 2020                      59", "mimetype": "text/plain", "start_char_idx": 1950, "end_char_idx": 3797, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "81085bbb-3bed-4285-bb79-6fbc9c5bc201": {"__data__": {"id_": "81085bbb-3bed-4285-bb79-6fbc9c5bc201", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "82"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "9a65b5e3-fc9b-47fb-a3a9-ed87d4d6e5b7", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "82"}, "hash": "982e5b8293c5d61dcfa26a10c3c45aaf9b1f7e219f1a1375f99c4e7a878f9800", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "933f5aea-ed26-4cdc-99d2-acee32956713", "node_type": "1", "metadata": {}, "hash": "4502951c0fe73a0fac5976506247d44a826bde39e07875c0fdd65296fe00562b", "class_name": "RelatedNodeInfo"}}, "text": "Convulsions[Risk factor: History\n                of seizure]\n                Hypersensitivity reaction, Stevens-\n                Johnson syndrome. Mobiliform\n                rash may appear but usually not\n                life-threatening\n                Potential risk of neural tube birth\n                defects (very low risk in humans)\n                Male gynecomastia.\nEtravirine      Severe skin rash; hypersensitivity   GI Intolerance,  Monitor liver enzymes and lipids.\n(ETR)           reactions (Stevens-Johnson           rash             Rarely discontinue (<2%) due to\n                syndrome), Erythema multiforme,                       adversereaction.\n                hepatotoxicity, lipid abnormality                     Limitedoptions are available\n                and psychiatric disorders\nAtazanavir/     Electrocardiographic abnormalities   Nausea and    Clinical jaundice is cosmetic and\nritonavir       (PR interval prolongation) [Risk     diarrhoea, skin  not related to hepatitis or liver\n(ATV/r)         factors: Pre-existing conduction     rash             damage. Substitute only if\n                disease; Concomitant use of other                     adherence is compromised\n                drugs that may prolong the PR                         Monitor liver enzymes\n                interval]                                             Change to LPV/r or DRV/r. If\n                Indirect hyperbilirubinaemia                          boosted PIs are contraindicated\n                (clinical jaundice) [Risk factors:                    and NNRTIs have failed in\n                Underlying hepatic disease HBV                        first-line ART, consider integrase\n                and HCV co-infection;                                 inhibitors\n                Concomitant use of hepatotoxic\n                drugs]\n                Nephrolithiasis and risk of\n                prematurity [Risk factor unknown]\nLopinavir/rito  Electrocardiographic                 Headache,        Diarrhoea is rarely severe should\nnavir (LPV/r)   abnormalities (PR and                weakness,        be managed with antispasmodics-\n                QT interval prolongation,            nausea,          usually resolves after weeks to\n                torsades de pointes) [Risk factors:  vomiting,        months of therapy.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2342, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "933f5aea-ed26-4cdc-99d2-acee32956713": {"__data__": {"id_": "933f5aea-ed26-4cdc-99d2-acee32956713", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "82"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "9a65b5e3-fc9b-47fb-a3a9-ed87d4d6e5b7", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "82"}, "hash": "982e5b8293c5d61dcfa26a10c3c45aaf9b1f7e219f1a1375f99c4e7a878f9800", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "81085bbb-3bed-4285-bb79-6fbc9c5bc201", "node_type": "1", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "82"}, "hash": "3b85943dc5a4ae7f36c72b9aea2f09cdbcaeab3cb875800ff8b79a76b0b4322c", "class_name": "RelatedNodeInfo"}}, "text": "People with pre-existing             diarrhoea and\n                conduction system disease;           skin rash        If LPV/r isused in first-line ART\n                Concomitant use of other drugs                        for children, use an age-\n                that may prolong the PR interval]                     appropriate NNRTI (NVP for\n                QT interval prolongation [Risk                        children younger than 3 years and\n                factors: Congenital long QT                           EFV for children 3 years and\n                syndrome; Hypokalaemia;                               older). ATV can be used for\n                Concomitant use of drugs that                         children older than 6 years\n                may prolong the QT interval]                          If LPV/r is used in second-line\n                Hepatotoxicity [Risk factors:                         ART for adults, use ATV/r or\n                Underlying hepatic disease;                           DRV/r. If boosted PIs are\n                HBV and HCV co-infection;                             contraindicated and the person\n                Concomitant use of hepatotoxic                        has failed on treatment with\n                drugs]                                                NNRTI in first-line ART,\n                                                                      consider integrase inhibitors\n                Pancreatitis [Risk factors:\n                Advanced HIV disease]\n           NATIONAL GUIDELINES FOR HIV PREVENTION TREATMENT AND CARE 2020                    60", "mimetype": "text/plain", "start_char_idx": 2359, "end_char_idx": 3975, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f1bde30e-5d24-4dfe-95b4-4d384b944501": {"__data__": {"id_": "f1bde30e-5d24-4dfe-95b4-4d384b944501", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "83"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "df65d194-a6d8-462a-8b37-109606ec933f", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "83"}, "hash": "645f4d73d9858cbb4b0c4b1dfb36e9d9aee9d43a4eee5b2b7747adaf2ec64d56", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6610dd6a-a931-429b-9665-cb862404fd49", "node_type": "1", "metadata": {}, "hash": "c569acceae5bdbd59c782d9c3d3cec6c3e5e6634890e8dd61705895d758782c9", "class_name": "RelatedNodeInfo"}}, "text": "Risk of prematurity, lipoatrophy or\n                 metabolic syndrome,\n                 dyslipidaemia or severe diarrhoea\n                 [Risk factors unknown]\n Darunavir/rito  Hepatotoxicity [Risk factors:                    If DRV/r is being used in second-\n navir (DRV/r)   Underlying hepatic disease HBV                   line ART, substituting with ATV/r\n                 and HCV co-infection,                            or LPV/r can be considered.\n                 Concomitant use of hepatotoxic                   When it is used in third-line ART,\n                 drugs]                                           limited options are available\n Darunavir/rito  Hepatotoxicity [Risk factors:                    If DRV/r is being used in second-\n navir (DRV/r)   Underlying hepatic disease HBV                   line ART, substituting with ATV/r\n                 and HCV co-infection,                            or LPV/r can be considered.\n                 Concomitant use of hepatotoxic                   When it is used in third-line ART,\n                 drugs]                                           limited options are available\n                 Severe skin and hypersensitivity\n                 reactions [Risk factors:\n                 Sulfonamide allergy]\n Raltegravir     Rare, -hypersensitivity, acute   Myopathy,       Limited options are available\n (RAL)           renal failure                    myalgia, mild\n                                                  to moderate\n                                                  nausea,\n                                                  headache and\n                                                  diarrhoea\n Dolutegravir    Hepatotoxicity                   Insomnia,       Monitor liver function and toxicity\n (DTG)           Severe allergic reactions        headache        may worsen with existing hepatitis\n                 (hypersensitivity)                               B or C\n                                                                  Patient should be advised to take\n                                                                  drugs in the morning\n4.11 Prevention ofAdverse Drug Reactions\nApplying the principles of rational use of medicines can prevent most ADRs, some of the\nprinciples include the following:\n    \u00a7   Use of few drugs, whenever possible\n    \u00a7   Use drugs that you are familiar with\n    \u00a7   Do not change therapy from known drugs to unfamiliar ones without good reason\n    \u00a7   All patients commencingARV should be properly counselled on theADRs related to the\n        medications, preventive measures, where applicable, and what to do when it occurs or is\n        suspected.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2685, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6610dd6a-a931-429b-9665-cb862404fd49": {"__data__": {"id_": "6610dd6a-a931-429b-9665-cb862404fd49", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "83"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "df65d194-a6d8-462a-8b37-109606ec933f", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "83"}, "hash": "645f4d73d9858cbb4b0c4b1dfb36e9d9aee9d43a4eee5b2b7747adaf2ec64d56", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f1bde30e-5d24-4dfe-95b4-4d384b944501", "node_type": "1", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "83"}, "hash": "af0dec759f1995903051e2d434ae8770f812b6978205097a010c91f426415119", "class_name": "RelatedNodeInfo"}}, "text": "The healthcare provider should be very knowledgeable about this\n    \u00a7   Be vigilant and look out for these adverse effects when initiating therapy and during\n        follow-up.\n    \u00a7   Encourage patients to be actively involved inADR reporting.ADR monitoring tools can\n        be made available for patients to documentADRs they are experiencing while onART;\n        and this can be validated by the HCW during clinic visits.\n           NATIONAL GUIDELINES FOR HIV PREVENTION TREATMENT AND CARE 2020                   61", "mimetype": "text/plain", "start_char_idx": 2686, "end_char_idx": 3206, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ebbc39e7-5985-434d-9f11-ad53441d5f88": {"__data__": {"id_": "ebbc39e7-5985-434d-9f11-ad53441d5f88", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "84"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "d71d5fff-6c3c-4de5-a173-2cbb192590ed", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "84"}, "hash": "79cb45022051b1e3ebc6f9ed282bc53d89f10d43ed5d19f4b3974aca089cd388", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "08a32125-94ff-423d-8f1a-f1cfb9cc8f27", "node_type": "1", "metadata": {}, "hash": "9d69cde83df19c9190b3bafad8ca271be7279279b81d58914cf4ac4371c5b699", "class_name": "RelatedNodeInfo"}}, "text": "4.12ARV Drug Interactions\nDrug interaction refers to the modification of the action of one drug by another, and can be\nuseful, of no consequence, or harmful. Multiple drug use (polypharmacy) is extremely common\nin ART/PMTCT settings, so the potential for drug interaction is enormous. Adverse interactions\nmay be catastrophic but are often avoidable. Patients receiving care for HIV infection have the\nlikelihood of experiencing various drug interactions because of the drugs in ART combinations,\nco-administered drugs for OIs, and co-administered drugs for other concurrent ailments. There\nare two major groups ofARV drug interactions:\n   \u00a7    Non-ARV vs.ARV Drug Interactions\n   \u00a7    ARV vs.ARV Drug Interactions\nAs a rule of thumb, most ARV drugs are metabolized by the Cytochrome P450 3A4 isoenzyme\nin the liver. Many other drugs are also metabolized by this enzyme and ARV drugs will either\nraise or lower these other drug levels and either be increased or decreased themselves by these\ninteractions. All PIs, as well as all current clinically used NNRTIs, are metabolized by CYP 450\nenzyme cascade (particularly CYP 3A4) which can be induced and/or inhibited by several drugs\nthus the possibilities of many drug/drug interactions.\nTable 4.4 Important ARV drug interactions\n Drug         Interaction                     Action\n EFV; NVP     Decreased level of Atazanavir   Avoid the combination or consider increase LPV/r\n              and LPV/r significantly occur   dose to 533mg/133mg twice daily in PI-experienced\n              when used concomitantly with    patients.\n              EFV or NVP\n TDF          Concomitant use with ATV:       Dose: ATV/r (300/100 mg) daily co-administered\n              TDF level is increased by 24%-  with TDF 300 mg daily. Avoid concomitant use\n              37% and Atazanavir level is     without RTV. If using TDF and H2 receptor\n              decreased by 25%                antagonist in ART-experienced patients, use ATV/r\n                                              (400 mg/100 mg) daily.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2040, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "08a32125-94ff-423d-8f1a-f1cfb9cc8f27": {"__data__": {"id_": "08a32125-94ff-423d-8f1a-f1cfb9cc8f27", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "84"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "d71d5fff-6c3c-4de5-a173-2cbb192590ed", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "84"}, "hash": "79cb45022051b1e3ebc6f9ed282bc53d89f10d43ed5d19f4b3974aca089cd388", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ebbc39e7-5985-434d-9f11-ad53441d5f88", "node_type": "1", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "84"}, "hash": "847aa73c0f3f8f09af17899a25ed338e12a95435f62e25199e372ff4186ee341", "class_name": "RelatedNodeInfo"}}, "text": "If using TDF and H2 receptor\n              decreased by 25%                antagonist in ART-experienced patients, use ATV/r\n                                              (400 mg/100 mg) daily. Monitor for TDF-associated\n                                              toxicity.\nAbacavir (ABC) is not currently associated with any clinically significant pharmacokinetic drug\ninteractions. However, a large dose of ethanol (>0.7g/kg body weight) increases ABC plasma\nAUC by 41% as well as prolongs ABC elimination half-life by 26%. Patients must therefore be\ncautioned on alcohol use duringABC therapy.\n4.12.1 Interactions Between Contraceptives andAntiretroviral Drugs\nIn line with standard recommendations, ALHIV can use all available contraceptive methods,\nincluding hormonal contraceptives, implantable devices, intrauterine devices, the transdermal\npatch, and vaginal ring.\nMany PIs and NNRTIs alter the metabolism of oral contraceptives and may reduce the efficacy\nof oral contraceptive agents or increase the risk of estrogen \u2013 or progestin \u2013 related adverse\neffects. Integrase strand transfer inhibitors (specifically raltegravir) appear to have no\ninteraction with estrogen-based contraceptives. Dolutegravir (DTG) has been found safe and\n          NATIONAL GUIDELINES FOR HIV PREVENTION TREATMENT AND CARE 2020              62", "mimetype": "text/plain", "start_char_idx": 1847, "end_char_idx": 3180, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1b149e22-88c1-40ae-a614-4203fadfb63f": {"__data__": {"id_": "1b149e22-88c1-40ae-a614-4203fadfb63f", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "85"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "285426ad-b2f5-4d2d-a184-ce62d5d57bb7", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "85"}, "hash": "c8e2ba2f606e891a9b28d20b2adcc291b201b41d5b5be23d89ce7a3e36b44720", "class_name": "RelatedNodeInfo"}}, "text": "effective to use with hormonal contraceptives among women living with HIV.Unless there is\nclinical evidence or concern of bone fragility, providers may use depot medroxyprogesterone\nacetate (DMPA) with or without ART (specifically TDF), as an effective long-term\ncontraceptive.\nAdditional resources for other possible drug interactions can be found in the following sites:\nwww.hiv-druginteractions.org\nwww.hiv-interactionslite.org\n          NATIONAL GUIDELINES FOR HIV PREVENTION TREATMENT AND CARE 2020            63", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 517, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "459d3501-41f7-4244-89fd-49ce1c6219d9": {"__data__": {"id_": "459d3501-41f7-4244-89fd-49ce1c6219d9", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "86"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "d5ed7fa2-a099-4b27-b63f-5bbb5f196355", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "86"}, "hash": "2c84923870e087551c4393e2ba2438a378a59cf067181caf25596a2d04a07897", "class_name": "RelatedNodeInfo"}}, "text": "List of Contributors                                                       Chapter 4\nPharm. Ologun Taiye Joseph          Director, Logistics Unit NASCP\nPharm. Atu Uzoma                    Assistant Director, Logistics Unit NASCP\nPharm. Chidi OKorie                 Principal Pharmacist NASCP\nTuraki Abdul                        Principal Pharmacist Technician NASCP\nMr Ogbeke Geoffrey Ighowho          Senior Scientific Officer NASCP\nDr Fatimah Jajere                   ACRO NAFDAC\nProf. Ebun Adejuyigbe               Member NTTA / Paediatrician OAUTH, Ile Ife\nDr Hadiza Khamofu                   Chief of Party FHI360\nOluwakemi Sowale                    Senior Analyst CHAI\nDr Opeyemi Abudiore                 Senior Analyst CHAI\nPharm Anthonia Ibeme                Forecasting & Supply Planning Manager GHSC-PSM\nNkiru Anonyuo                       Plan and Source Director GHSC-PSM\nMr Batholomew Igwe                  Health System Strengthening and Logistics Specialist FHI360\nTimothy Yakubu                      Senior Laboratory Advisor ICAP\nPharm. Adebanjo Adeyemi Olowu       Supply Chain Lead JHPIEGO\nDr Kenneth Anene Agu                Associate Director, Howard University Pace Center\nOmeh Idoko Onuche                   Associate Director, Howard University Pace Center\nPharm. (Dr) Peter Agada             State Program Manager, Howard University Pace Center\nPharm. Agboola Oguntonade           Pharmacy Advisor Heartland Alliance\nPharm Usman Ismail                  Intern NAFDAC\nNkem Chukwuemeka                    South-South Deputy ASWHAN\n         NATIONAL GUIDELINES FOR HIV PREVENTION TREATMENT AND CARE 2020        64", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1635, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "890eb3ab-daf8-4785-adab-7cfc8927df36": {"__data__": {"id_": "890eb3ab-daf8-4785-adab-7cfc8927df36", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "87"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "175729ba-5bfe-4cac-9c51-acea1c635f08", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "87"}, "hash": "974238522d0d95ecefe5b976007e2641001611a5ed75856aa7f5bd417e68b445", "class_name": "RelatedNodeInfo"}}, "text": "5. ADHERENCE TO\n      ANTIRETROVIRAL\n              THERAPY\nWhat\u2019s Inside:\n 1.1 Objectives of the Guidelines\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026..\n5.1 Introduction\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u202666\n 1.2 Epidemiology of HIV in Nigeria\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\n5.2 Adherence Preparation for ART\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026..\u2026...66\n 1.3 Natural History of HIV\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026.\u2026\u2026\n5.3 On-going adherence for clients on ART\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026.67\n5.4 Monitoring of Adherence\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026..\u2026\u2026\u2026\u2026.67", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 399, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3f7cde92-6a49-4b67-afdb-367c4e1ef04b": {"__data__": {"id_": "3f7cde92-6a49-4b67-afdb-367c4e1ef04b", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "88"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "336bcbda-4e8e-4cc0-b232-eabf5c245c69", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "88"}, "hash": "3bc72c75be22301bffff70a8765c3a63f1ce8181b47eb27afc8229f674446337", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3d21ce87-7b06-4751-bab5-544574ec7e15", "node_type": "1", "metadata": {}, "hash": "7ee49aaacf61a3ddfa3b4490799b500605a918fba6fe874d3c004eba65e62466", "class_name": "RelatedNodeInfo"}}, "text": "5.1 Introduction\nAdherence is the patients' behaviour of taking drugs correctly based on mutual agreement\nbetween the patient and health care provider. It is the act of taking the right drugs, at the right\ndose, at the right frequency, and at the right time.\nAdherence to ART is necessary for achieving sustained suppression, delaying the onset of drug\nresistance, enhancing immune recovery, and improving the overall health and quality of life of\nthe individual. Poor or non-adherence toART results in suboptimal viral suppression which may\nlead to the emergence of drug resistance and loss of future treatment options.\nAll persons onART should receive adherence support which could be face-to-face and/or virtual.\nFace-to-face and virtual adherence support may be provided by health workers, family, friends,\ntreatment partners, and support groups. Adherence support IEC materials in the form of posters\nand patient information leaflets are also essential.\n5.2Adherence Preparation forART\nAdherence counselling and support has become even more important with the advent of the test\nand treat policy. This is because we have asymptomatic persons initiated on ART. It is\nrecommended that patients should undergo adherence preparation before they commence ART.\nIt is also recommended that adherence preparation should be implemented as an ongoing\nmultidisciplinary task that involves as many relevant health workers as possible that are involved\nin the care of the patient including the doctor, pharmacists, laboratory scientists, nurses, and the\nofficer officially designated as adherence counsellor.\nHealth workers should note that the success of any adherence strategy adopted depends on:\n    \u00b7  Information and education provided to clients before the initiation ofART\n    \u00b7  Assessing their understanding of the information provided\n    \u00b7  Willingness and readiness for the client to commence treatment\n    \u00b7  Assessing and addressing barriers to initiatingART\nAdherence counselling is central to any adherence strategy and should:\n    \u00b7  Provide basic information on HIV and its manifestations.\n    \u00b7  Provide information onARV medication which should include dosing, frequency,\n       duration, and adverse effects ofARV medications including how the medications should\n       be taken and what to do in case of missed dose.\n    \u00b7  Provide information onART and the benefits of early initiation.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2401, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3d21ce87-7b06-4751-bab5-544574ec7e15": {"__data__": {"id_": "3d21ce87-7b06-4751-bab5-544574ec7e15", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "88"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "336bcbda-4e8e-4cc0-b232-eabf5c245c69", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "88"}, "hash": "3bc72c75be22301bffff70a8765c3a63f1ce8181b47eb27afc8229f674446337", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3f7cde92-6a49-4b67-afdb-367c4e1ef04b", "node_type": "1", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "88"}, "hash": "03f1520dbe234b5916a7f57741fef81635acbba018b0af3d6516ef4646ceb7c1", "class_name": "RelatedNodeInfo"}}, "text": "\u00b7  Provide information onART and the benefits of early initiation.\n    \u00b7  Highlight the importance of 100% adherence, which implies not missing any dose.\n       Emphasize that non-adherence is the single most important factor that can lead to the\n       development of drug resistance.\n    \u00b7  Provide information to the patient in whomART initiation will be delayed due toAHD\n       (e.g. information on the increased risk of mortality when patients withAHD are\n       commenced on certainARVs such as DTG etc.).\n          NATIONAL GUIDELINES FOR HIV PREVENTION TREATMENT AND CARE 2020             66", "mimetype": "text/plain", "start_char_idx": 2335, "end_char_idx": 2935, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ddfb8ce9-5131-4d0a-8a10-22acc669941e": {"__data__": {"id_": "ddfb8ce9-5131-4d0a-8a10-22acc669941e", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "89"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "69858e8f-8380-4ea3-9501-b98ec47b5945", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "89"}, "hash": "bdd50e145dc4f65f6cf7581ff057c48d883378ba0e80732ee447ee192193e64f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "95a8a6a6-0dff-42e1-9f3f-a12b9b038600", "node_type": "1", "metadata": {}, "hash": "95b9951061ea3bdfd09a96154d071d6d6124836774d54969897525f89c817251", "class_name": "RelatedNodeInfo"}}, "text": "5.3 On-going adherence for clients onART\nContinuous adherence counselling is essential in ART and should be accessible to every patient\non ART. This should include adherence assessments and documentation at every clinic visit;\nemphasis should be on the importance of continued adherence, good nutrition, and involvement\nof support systems (relatives, friends, peers and/or community support personnel). Ongoing\nadherence support should be face-face or virtual. When provided by health workers, the checklist\nmust be used to document the interaction, and this should be filed in the client's folder. Barriers\nto adherence should also be assessed and addressed.\n5.4 Monitoring ofAdherence\nSustained viral suppression is dependent on adherence to ARVs. Adherence monitoring provides\nan opportunity to reinforce the positive behaviour of the adherent patient, and to flag patients that\nrequire support to improve adherence. Adherence in many studies is measured by expressing the\nnumber of doses taken as a percentage of the number of doses prescribed. For example, if 20\ndoses are prescribed and 19 doses are taken, adherence is 95%. This translates to missing one\ndose in ten days on a twice-daily regimen.\nEffective monitoring of adherence involves a combination of approaches based on resource\ncapacity (human/ financial), acceptability by client and providers, and comprehension of the\nlocal context. These include:\n   a.  Viral load monitoring: This is considered the gold standard for monitoring adherence\n       and treatment success. Where the viral load is not effectively suppressed an adherence\n       intervention should precede a repeat viral load test. Viral load monitoring has a high\n        likelihood to motivate adherence by engaging clients in the process of monitoring their\n       own results and understanding the meaning of their results.\n   b.  Pharmacy refill records: These records document the dates a client collected their\n       ARVs. Irregular collection may indicate adherence challenges.As with other adherence\n       assessment methods, pharmacy refill records may over-estimate adherence, as\n       collectingARVs does not guarantee that they are being taken or taken correctly. This is\n       however an acceptable proxy.\n   c.  Self-reporting:   This is a quick and inexpensive approach to adherence monitoring.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2346, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "95a8a6a6-0dff-42e1-9f3f-a12b9b038600": {"__data__": {"id_": "95a8a6a6-0dff-42e1-9f3f-a12b9b038600", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "89"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "69858e8f-8380-4ea3-9501-b98ec47b5945", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "89"}, "hash": "bdd50e145dc4f65f6cf7581ff057c48d883378ba0e80732ee447ee192193e64f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ddfb8ce9-5131-4d0a-8a10-22acc669941e", "node_type": "1", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "89"}, "hash": "a53643bbc5b71c953295332a650374e74d20bd6adb7b7a3858ae4266173fb4cb", "class_name": "RelatedNodeInfo"}}, "text": "This is\n       however an acceptable proxy.\n   c.  Self-reporting:   This is a quick and inexpensive approach to adherence monitoring. It is\n       easily carried out in clinical settings and frequently used in routine care; however, it is\n       subject to recall bias.\n   d.  Pill counts: This involves a physical count of the remaining pills at each pharmacy refill\n       visit. It is used to compare the actual to the expected consumption ofARVs for a given\n       period. The effectiveness of pill counting is limited by the fact that some clients may\n       discard tablets not taken before their routine clinic visits leading to over-estimated\n       adherence.Additionally, the time required by health providers to conduct pill counts may\n       not be available, especially in resource-limited settings. Other approaches may include\n       electronic methods e.g. Medication Event Monitoring System (MEMSCap). This\n       involves the use of an electronic device that monitors the dates and time the pill bottle is\n       opened. The bottle opening represents medicine intake.Another method that can be used\n       is the quantification of drug levels in body fluids (plasma, urine, saliva) of clients.\n          NATIONAL GUIDELINES FOR HIV PREVENTION TREATMENT AND CARE 2020                 67", "mimetype": "text/plain", "start_char_idx": 2212, "end_char_idx": 3516, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "55025c85-3d8b-4487-afba-06cbd342b823": {"__data__": {"id_": "55025c85-3d8b-4487-afba-06cbd342b823", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "90"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "b5d68a78-a203-45b8-b224-334c0d39b6e8", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "90"}, "hash": "9d96620506c26b6709135e71c7bbf1535dc6c6be6e57e83827d3519c7761fede", "class_name": "RelatedNodeInfo"}}, "text": "5.4.1 Factors known to improve adherence\nThe following factors have been associated with high adherence rates:\n     \u00a7    Increased access toART.\n     \u00a7    Individual patients, family, peers, and friends, community members, or treatment-\n          supporter engagement in adherence education and support.\n     \u00a7    Family-centred care when more than one family member is infected with HIV\n     \u00a7    Continuous and effective adherence counselling, which includes knowledge and\n          understanding of HIV infection, course of treatment, and expected adverse reactions and\n          what to do in the event of an adverse reaction occurring.\n     \u00a7    Drug regimen simplicity e.g. Fixed Drug Combination (low pill burden)\n     \u00a7    The use of drugs with fewer adverse effects.\n5.4.2 Factors associated with poor adherence\n              Patient factors                    Treatment Factors                     Patient-Provider\n           Self-efficacy (belief in             Drug toxicity                            Relationship\n           one\u2019s ability to succeed)            High pill burden                      Poor patient-caregiver\n           regarding adherence.                 Long duration of                      relationship\n           Substance abuse e.g.                 treatment                             Lack of trust\n           Active drug or alcohol               Complexity of the                     Poor conception of\n           use                                  treatment                             maintenance of client\u2019s\n           Lack of social support               Medication side effects               confidentiality\n           Incarceration                                                              Lack of empathy/\n           Pregnancy-related                                                          warmth\n           conditions                           Clinical Environment                  Poor communication\n           Inability of patients to             Distance to facility                  skills\n           identify their medications           Poor quality of adherence             Stigma and\n           Lack of patient                      counselling                           discrimination\n           education.                           Clinic staff attitude                 Lack of client\u2019s\n           Forgetfulness                         Cost of treatment                    openness/ cooperation\n           Stressful life events                Perceived benefits versus\n           Self-stigmatization                  barriers e.g.\n           Health status e.g. severe            discrimination and\n           illness, dementia, mental            stigmatization\n           health                               Perceived lack of\n                                                confidentiality\n                                                Unpleasant past\n                                                experiences\n                                                Long waiting time\nFigure 5.1: Factors associated with poor Adherence\n             NATIONAL GUIDELINES FOR HIV PREVENTION TREATMENT AND CARE 2020                                68", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 3201, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c55d5288-2b53-47f6-be5b-96ff143cf8c5": {"__data__": {"id_": "c55d5288-2b53-47f6-be5b-96ff143cf8c5", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "91"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "ef5dba80-8512-42ce-93af-7717b93dc385", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "91"}, "hash": "0351a751cbc70ff6a329117c2034d1886ac5a03b1b5fd49b0a8b401a54f37768", "class_name": "RelatedNodeInfo"}}, "text": "5.4.3 Adherence in Specific Populations\nWhile stigma, discrimination and health facility challenges are cross-cutting issues affecting\nadherence, some factors are peculiar to specific populations:\nTable 5.1: Adherence in specific populations\n Population              Factors affecting adherence\n Infants and young       \u00b7  Poor taste and large volumes of liquid formulations\n children                \u00b7  Large pill size, pill burden, and difficulty in swallowing pills.\n                         \u00b7  Changing dosage requirement in relation to weight gain\n                         \u00b7  Inadequate nutrition\n                         \u00b7  Identification of responsible caregivers and a family-centred approach\n                            would improve adherence   .\n Adolescents             \u00b7  Psychosocial factors such as peer pressure\n                         \u00b7  Limited adolescent-friendly health services including skilled health\n                            workforce\n                         \u00b7  The transition from paediatric to adolescent care\n                         \u00b7  Limited adolescent-tailored treatment literacy and adherence training tools\n                         \u00b7  Disclosure issues\n Pregnant and            \u00b7  Nausea and vomiting\n postpartum women        \u00b7  Post-partum depression\n                         \u00b7  Non-disclosure to significant persons\n                         \u00b7  Inadequate awareness and knowledge of HIV and PMTCT\n People with             \u00b7  Use of alcohol and substances abuse can lead to forgetfulness\n substance use and       \u00b7  Poor comprehension of treatment plans\n mental health           \u00b7  Drug interaction and ADRs\n conditions\n Key populations         \u00b7  Stigma and discrimination\n including prisoners     \u00b7  Poor access to health services\n                         \u00b7  Absence of health care which targets their specific needs\n                         \u00b7  Risk of drug-drug interaction\n Persons with            \u00b7  Poor access to health facilities\n disability              \u00b7  Lack of appropriate patient education channels (e.g. for visually and\n                            hearing impaired)\nHealth workers are required to take note of the adherence challenges peculiar to each of the\ngroups and design for each patient an individualized adherence plan that adjusts for their\nlifestyle, work, and social environment.\n           NATIONAL GUIDELINES FOR HIV PREVENTION TREATMENT AND CARE 2020              69", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2433, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2ef850d9-43c4-4b85-9985-5bc24867e47c": {"__data__": {"id_": "2ef850d9-43c4-4b85-9985-5bc24867e47c", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "92"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "f385409c-f9d7-4fce-84d6-2e5bab74d88f", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "92"}, "hash": "39f3e5f0a1372ab01a71a975ef5ac19a3b08efa5b895c4a02f8c05b232cc4bb5", "class_name": "RelatedNodeInfo"}}, "text": "5.4.4 Recommendations for improving adherence\nThe following can be useful to improve patient adherence toART:\n    \u00a7   Treatment education for patients and treatment supporters\n    \u00a7   Treatment-supporter involvement\n    \u00a7   Peer health education/peer counsellors\n    \u00a7   Routine assessment and reinforcement of adherence during follow up\n    \u00a7   The use of Fixed-Dose Combination (FDC) and drugs with lower dosing frequency\n    \u00a7   Reminders and patient engagement tools (e.g. a cell phone, SMS text messages, alarm\n        clock, calendars, social media platforms etc.)\n    \u00a7   ConvenientARV packs\n    \u00a7   Follow up visits beforeARV supplies are exhausted\n    \u00a7   Positive feedback on health improvements\n    \u00a7   Nutritional assessment, care, and support\n    \u00a7   Prevent and/or adequately manageADR\n    \u00a7   Address lifestyle factors e.g. alcohol abuse\n    \u00a7   Adapting therapy to the client's lifestyl\n    \u00a7   Minimizing out-of-pocket payments at the point of care as much as possible\n    \u00a7   Encourage participation in support groups\n    \u00a7   Improved social support\n    \u00a7   Directly Observed Therapy \u2013where possible\n    \u00a7   Cognitive-behavioral therapy and behavioral skill training\n          NATIONAL GUIDELINES FOR HIV PREVENTION TREATMENT AND CARE 2020           70", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1270, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f40c7f39-5b2c-41b6-b773-f1c7e362396c": {"__data__": {"id_": "f40c7f39-5b2c-41b6-b773-f1c7e362396c", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "93"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "dc9b56b9-0ada-4d10-ae9c-5c82e13a80e1", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "93"}, "hash": "603eb058e66529164356b35765e4fee2db246410728ff00480eca7211c8cd0fe", "class_name": "RelatedNodeInfo"}}, "text": "List of Contributors                                                       Chapter 5\nPharm. Ologun Taiye Joseph          Director, Logistics Unit NASCP\nPharm. Atu Uzoma                    Assistant Director, Logistics Unit NASCP\nPharm. Chidi OKorie                 Principal Pharmacist NASCP\nTuraki Abdul                        Principal Pharmacist Technician NASCP\nMr Ogbeke Geoffrey Ighowho          Senior Scientific Officer NASCP\nDr Fatimah Jajere                   ACRO NAFDAC\nProf. Ebun Adejuyigbe               Member NTTA / Paediatrician OAUTH, Ile Ife\nDr Hadiza Khamofu                   Chief of Party FHI360\nOluwakemi Sowale                    Senior Analyst CHAI\nDr Opeyemi Abudiore                 Senior Analyst CHAI\nPharm Anthonia Ibeme                Forecasting & Supply Planning Manager GHSC-PSM\nNkiru Anonyuo                       Plan and Source Director GHSC-PSM\nMr Batholomew Igwe                  Health System Strengthening and Logistics Specialist FHI360\nTimothy Yakubu                      Senior Laboratory Advisor ICAP\nPharm. Adebanjo Adeyemi Olowu       Supply Chain Lead JHPIEGO\nDr Kenneth Anene Agu                Associate Director, Howard University Pace Center\nOmeh Idoko Onuche                   Associate Director, Howard University Pace Center\nPharm. (Dr) Peter Agada             State Program Manager, Howard University Pace Center\nPharm. Agboola Oguntonade           Pharmacy Advisor Heartland Alliance\nPharm Usman Ismail                  Intern NAFDAC\nNkem Chukwuemeka                    South-South Deputy ASWHAN\n         NATIONAL GUIDELINES FOR HIV PREVENTION TREATMENT AND CARE 2020        71", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1635, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f668eb49-3429-4155-b401-0953bf83f07e": {"__data__": {"id_": "f668eb49-3429-4155-b401-0953bf83f07e", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "94"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "110ab407-9f8b-4ff1-a9dc-2020f75b7b9a", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "94"}, "hash": "8d5afbca8b16b9560a68ed072d9a74b6f682054c24d0a892c2db24791c798cb1", "class_name": "RelatedNodeInfo"}}, "text": "6. PREVENTION OF MOTHER\n               TO CHILD TRANSMISSION\n                  OF HIV INFECTION\nWhat\u2019s Inside:\n 1.1 Objectives of the Guidelines\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026..\n6.1 Introduction \u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026...73\n 1.2 Epidemiology of HIV in Nigeria\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\n6.2 Mother-to-Child Transmission of HIV\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026...73\n 1.3 Natural History of HIV\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026.\u2026\u2026\n6.3 Pre-ART Care for HIV-positive pregnant women\u2026\u2026\u2026\u2026\u2026.78\n6.4 Use of Antiretroviral Therapy for PMTCT\u2026\u2026\u2026\u2026\u2026\u2026\u2026....80\n6.5 Management of HIV positive women in labour,\n   delivery and within 72 hours of delivery\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026...82\n6.6 PMTCT/TB integration services\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026......84\n6.7 Care and Support of the HIV-Exposed Infant\u2026\u2026\u2026\u2026\u2026\u2026....86\n6.8 Special Considerations for Adolescent and\n   Young Women in PMTCT\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026..\u2026\u2026.......90\n6.9 Linkage of PMTCT with comprehensive\n   HIV Treatment, Care and Support Services\n   for Mothers and Infants\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026..\u2026\u2026\u2026\u2026....91", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 896, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4d738674-2fd4-4072-9aa2-54580af97f98": {"__data__": {"id_": "4d738674-2fd4-4072-9aa2-54580af97f98", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "95"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "52925b67-350f-4134-8ccd-5643edf2e960", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "95"}, "hash": "8c31ce3d46c6bbe74c4d0b4916af7897f560143efb942472546327035c99d100", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9c1d259f-f6d8-47c7-89a9-617b790232fe", "node_type": "1", "metadata": {}, "hash": "d40d08db4427b8765784f9a9123ea3aa4ab56b8720949c894f9a5522beb2a0fc", "class_name": "RelatedNodeInfo"}}, "text": "6.1 Introduction\nHIV can be transmitted from an infected mother to her child during pregnancy and delivery, and\nsubsequently through breastfeeding. This mother-to-child transmission of HIV (MTCT) is also\nreferred to as vertical transmission while measures to prevent its occurrence are the Prevention\nof Mother-to-Child Transmission (PMTCT). Given the successes recorded in the PMTCT, the\nglobal community is moving towards the elimination of Mother to Child Transmission of HIV\n(eMTCT).\n6.2 Mother-to-Child Transmission of HIV\nIn the absence of any preventive measures, the rate of occurrence of MTCT is about 25-40%\n(Figure 6.1). This mode of HIV transmission is responsible for most HIV infections in children.\nThe following factors have been associated with increased risk of MTCT in any population, high\nprevalence of HIV among women of reproductive age and their partners, low contraceptive use\nresulting in unintended pregnancies among HIV positive women. Increased risk of MTCT in a\nHIV positive woman during pregnancy, labour, delivery and breastfeeding has been associated\nwith high maternal viral load (from new or re-infection, advanced disease or treatment failure);\nwide range of infections, including STIs and those of the genital tract and maternal malnutrition.\nObstetric factors such as antepartum haemorrhage, external cephalic version, early rupture of\nmembrane exceeding four hours before delivery, chorioamnionitis, prolonged labour, invasive\ndelivery procedures including use of forceps and episiotomy have also been observed to\nincrease MTCT of HIV. Other risk factors include; preterm birth, first infant in multiple births,\nbreastfeeding and extended duration of breastfeeding, early mixed feeding, breast abscesses,\nnipple fissure, mastitis, and oral disease in the infant.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1800, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9c1d259f-f6d8-47c7-89a9-617b790232fe": {"__data__": {"id_": "9c1d259f-f6d8-47c7-89a9-617b790232fe", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "95"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "52925b67-350f-4134-8ccd-5643edf2e960", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "95"}, "hash": "8c31ce3d46c6bbe74c4d0b4916af7897f560143efb942472546327035c99d100", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4d738674-2fd4-4072-9aa2-54580af97f98", "node_type": "1", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "95"}, "hash": "0307d767db3bce72101772d9d9ea74c38306740c1081f2a842fff66f4c1a86af", "class_name": "RelatedNodeInfo"}}, "text": "Other risk factors include; preterm birth, first infant in multiple births,\nbreastfeeding and extended duration of breastfeeding, early mixed feeding, breast abscesses,\nnipple fissure, mastitis, and oral disease in the infant.\n       100 infants born to HIV infected women who breastfeed           60 to 75 infants will not\n   without any interventions                                           be HIV-infected\n           5-10 infants                     About 15                    5-15infants\n             infected                       infants                       infected\n              during                        infected                       during\n            pregnancy                    during labour                 breastfeeding\n                                          aud delivery\n                                 25-40 infants will be HIV-infected\nFigure 6.1: The Pattern of Mother-to-Child Transmission of HIV (MTCT) during Pregnancy, Delivery and\nBreastfeeding in Untreated Women Living with HIV.\nAlthough the current HIV prevalence of 1.4% in Nigerian adults and 0.2% among children\n(NAIIS 2018) suggest a low MTCT, two findings in the report have an ominous outcome;\n   a)  Women (1.3%) have almost 4 times the prevalence of men (0.4%) in the same age group.\n   b)  This gender disparity was greatest among females of age 20-24 years, the age when most\n       Nigerian women bear children.\n          NATIONAL GUIDELINES FOR HIV PREVENTION TREATMENT AND CARE 2020                73", "mimetype": "text/plain", "start_char_idx": 1574, "end_char_idx": 3078, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8c49a53c-7299-430d-9281-42a5cb3c8b92": {"__data__": {"id_": "8c49a53c-7299-430d-9281-42a5cb3c8b92", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "96"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "b3e663b1-ec07-4f4e-83c3-f9bd9517de5e", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "96"}, "hash": "7e71e1ce94ca1944e2bfccdb176c14df1ecca823a90b55097172ca667c5f0060", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e183dd11-bf0f-4dce-a760-be066f89246b", "node_type": "1", "metadata": {}, "hash": "63f2b14fb23370c789c6316985567356d6d06093e3011de6165eb8883189a55d", "class_name": "RelatedNodeInfo"}}, "text": "35.0\n    30.0    28.6     26.3     25.6\n    25.0                               19.7     16.9    18.0              19.4     20.6     21.0\n    20.0                                                         16.5\n    15.0    14.4     13.2     12.5     8.8      7.5     9.1      8.8      10.3     11.2     11.4\n    10.0\n     5,0\n     0.0\n            2010     2011     2012    2013     2014     2015     2016     2017     2018     2019\n                                    At six weeks     At final transmission\nFigure 6.2: Trends in Estimated Pattern of MTCT in Nigeria\n6.2.1 Prevention of MTCT\nTo stop the vertical transmission of HIV, WHO introduced a set of interrelated public health\ninterventions designed to prevent transmission of the virus from an HIV positive mother to her\nchild during the period of pregnancy, delivery and breastfeeding. Prevention of MTCT is the\npackage of care given to pregnant women, their families and communities, aimed at preventing\ntransmission of HIV from infected mothers to their babies (vertical transmission). It operates on\n4 pillars:\n Pillar 1        Primary prevention of HIV infection in women of reproductive age (WRA)\n                 & their partners\n Pillar 2        Prevention of unintended pregnancy among HIV- positive women\n Pillar 3        Prevention of HIV transmission from HIV positive mothers to their infants\n Pillar 4        Provision of appropriate treatment, care and support to HIV Positive mothers,\n                 their infants & families\nPillar 1:\nPrimary prevention of HIV infection in women of reproductive age and their partners include the\nfollowing:\n    \u00a7   Use of the \u201cABC\u201d approach to enhance safer and responsible sexual behaviour and\n        practices.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1720, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e183dd11-bf0f-4dce-a760-be066f89246b": {"__data__": {"id_": "e183dd11-bf0f-4dce-a760-be066f89246b", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "96"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "b3e663b1-ec07-4f4e-83c3-f9bd9517de5e", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "96"}, "hash": "7e71e1ce94ca1944e2bfccdb176c14df1ecca823a90b55097172ca667c5f0060", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8c49a53c-7299-430d-9281-42a5cb3c8b92", "node_type": "1", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "96"}, "hash": "4b2822123cec2e7ef70c43c157f38c0e59607da442c6397ff57e7ef912248306", "class_name": "RelatedNodeInfo"}}, "text": "This involves:\n        \u2022  A=Abstinence from having sexual intercourse\n        \u2022  B = Be faithful to a faithful partner\n        \u2022  C = Condom use correctly and consistently\n    \u00a7   Safe and responsible sexual practices include:\n        \u2022  Delaying the onset of sexual activity until marriage\n           NATIONAL GUIDELINES FOR HIV PREVENTION TREATMENT AND CARE 2020                 74", "mimetype": "text/plain", "start_char_idx": 1721, "end_char_idx": 2104, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6a00cb70-0ef9-45aa-be55-e1e23d81ff8a": {"__data__": {"id_": "6a00cb70-0ef9-45aa-be55-e1e23d81ff8a", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "97"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "accb8201-6bcf-4a12-b369-e1c7699808e9", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "97"}, "hash": "2f07f7f2c0b86e040c805292cea2c9bce113e2d03eb651812b3135cd0a7aa93f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "615d31b8-ebb0-45e8-8125-cafee6eda8cf", "node_type": "1", "metadata": {}, "hash": "93972871ba2cb8219c6dfee4d85959369587410711b44f61039d02e1d516b6a4", "class_name": "RelatedNodeInfo"}}, "text": "\u2022  Reducing the number of sexual partners\n       \u2022  Consistent and correct use of condoms.\n   \u00a7    Provision of early diagnosis and treatment of STIs: The early diagnosis and treatment of\n        STIs can reduce the incidence of HIV in the general population by about 40%.\n        Comprehensive STI treatment services present an opportunity to provide information on\n        HIV infection, MTCT and referral to HIV testing services (HTS). Making HIV testing\n        services widely available especially to women attending antenatal clinic ensures that\n        they know their HIV status. All HIV pregnant women should be linked to PMTCT\n        services on-site or by referral.\n   \u00a7    Provision of appropriate counselling for women who are HIV negative: Counselling\n        provides an opportunity for a woman who is HIV negative to better understand how to\n        protect herself and her infant from HIV infection. It also serves as motivation to adopt\n        safer sex, family planning practices and encourages partner testing.\nPillar 2:\nPrevention of unintended pregnancy among HIV positive women improves the lives of these\nwomen and their children and is essential for eliminating mother-to-child transmission of HIV.\nNigeria has an unmet need for family planning of 19% (NDHS 2018). The unintended pregnancy\nrate among women living with HIV reaches an estimated 51-90% in some settings, accounting\nfor 27% of maternal death, which can be prevented by meeting the unmet need for family\nplanning.\nIt is the responsibility of health services to provide HIV positive women and their partners with\ncomprehensive information and education about the risks associated with childbearing as part of\nroutine public information about HIV and AIDS. This is to ensure that HIV positive women and\ntheir partners have informed choices of action and to respect and support the decisions they reach\nas this is their sexual and reproductive rights. This implies:\n   \u00a7    Providing good quality, user-friendly, and easily accessible family planning services to\n        HIV positive women that can prevent unwanted pregnancy.\n   \u00a7    Providing and promoting consistent condom (male/female) use combined with a more\n        effective method of contraception (dual method) for dual protection from HIV and other\n        STIs and from unplanned pregnancies.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2342, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "615d31b8-ebb0-45e8-8125-cafee6eda8cf": {"__data__": {"id_": "615d31b8-ebb0-45e8-8125-cafee6eda8cf", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "97"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "accb8201-6bcf-4a12-b369-e1c7699808e9", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "97"}, "hash": "2f07f7f2c0b86e040c805292cea2c9bce113e2d03eb651812b3135cd0a7aa93f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6a00cb70-0ef9-45aa-be55-e1e23d81ff8a", "node_type": "1", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "97"}, "hash": "e250c06a218b755f0452eadeee4baeb8a1811ec1c64a1c0bd17bbe1ec6106fa3", "class_name": "RelatedNodeInfo"}}, "text": "\u00a7    Providing and promoting consistent condom (male/female) use combined with a more\n        effective method of contraception (dual method) for dual protection from HIV and other\n        STIs and from unplanned pregnancies.\n   \u00a7    Integrating dual protection messages into family planning counselling services\n   \u00a7    Offering contraception including emergency contraception to all HIV positive mothers\n        in the immediate postpartum period to prevent unintended pregnancy. Lactational\n        amenorrhoea does not guarantee adequate contraception even in women who\n        exclusively breastfeed. (Refer to medical eligibility criteria for contraceptive use in HIV\n        positive women).\nPillar 3:\nPrevention of HIV transmission from HIV Positive mothers to their infants includes;\n   \u00a7    HIV testing services\n   \u00a7    HIV and Infant feeding counselling\n   \u00a7    Modification of obstetric practices\n   \u00a7    Administration ofART to all HIV positive pregnant women irrespective of their WHO\n        clinical stage and CD4+ cell count\n   \u00a7    Administration of single or dualARV prophylaxis to all infants delivered to HIV\n        positive women.\n          NATIONAL GUIDELINES FOR HIV PREVENTION TREATMENT AND CARE 2020             75", "mimetype": "text/plain", "start_char_idx": 2117, "end_char_idx": 3358, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3e94feea-128f-4b9a-a395-47dfb1e906e0": {"__data__": {"id_": "3e94feea-128f-4b9a-a395-47dfb1e906e0", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "98"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "6607394e-4a4e-404c-b0f8-9e2ae5ba31b6", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "98"}, "hash": "8d49b2cf560e27c47eee49d29ceafb0b17dec13f943f6ab1e26fb0546e15276a", "class_name": "RelatedNodeInfo"}}, "text": "Pillar 4:\nProvision of appropriate treatment, care and support to HIV Positive mothers, their infants and family\n  Package of services for mothers            Package of services for HIV exposed children\n  \u00a7  ART for all HIV positive women          \u00a7   ARV prophylaxis\n  \u00a7  Cotrimoxazole prophylaxis               \u00a7   Routine immunization and growth monitoring\n  \u00a7  TB screening, prophylaxis and treatment     and support\n  \u00a7  Continued infant feeding counselling    \u00a7   Cotrimoxazole prophylaxis starting at 6 weeks\n     and support                                 HIV diagnostic testing using DBS for DNA-PCR\n  \u00a7  Nutritional counselling and support         or NAT at birth (when available), 6 to 8 weeks\n  \u00a7  Sexual and reproductive health              of age and 6 weeks after breastfeeding has ended.\n     services including family planning          HIV antibody test can be used for HIV screening\n                                                 for children older than 9 months where virologic\n  \u00a7  Cervical cancer screening                   test is not available. HIV antibody test is the\n  \u00a7  Psychosocial support.                       recommended diagnostic testing for children\n  \u00a7  Partner counselling and testing         \u00a7   older than 18 months.\n  \u00a7  Pre-Exposure Prophylaxis (PrEP) for         HIV antibody tests should primarily be used fo\n     serodiscordant couples                      screening of infants and children less than 18 of age\n                                                 months, so as to establish exposure status where\n                                                 the mother has not herself been tested for HIV or\n                                                 is not willing to be tested\n                                             \u00a7   Ongoing infant feeding counselling and support\n                                             \u00a7   Screening and management of tuberculosis\n                                             \u00a7   Prevention and treatment of malaria\n                                             \u00a7   Nutritional care and support\n                                             \u00a7   Psychosocial care and support\n                                             \u00a7   Antiretroviral therapy for all HIV infected\n                                                 children (see Chapter 3)\n                                             \u00a7   Symptom management and palliative care if needed\n To achieve effective PMTCT across Nigeria, the following challenges should be addressed\n (Table 6.1)\n           NATIONAL GUIDELINES FOR HIV PREVENTION TREATMENT AND CARE 2020                    76", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2624, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "08e2f4da-d706-4557-bef6-6bc49295cb8e": {"__data__": {"id_": "08e2f4da-d706-4557-bef6-6bc49295cb8e", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "99"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "9bc417ff-188d-4bcb-91f5-d132ae4d6104", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "99"}, "hash": "eabe4160d97e61f1404e600074bb832f2f357311a77694fe2501e3a89247514c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ef291609-ad4f-46ad-9d5c-f8a5a95177a1", "node_type": "1", "metadata": {}, "hash": "b3e8e7e6af46ba2768972868495cc875a10ed8aa257b8a3975704ae8ba1d10f7", "class_name": "RelatedNodeInfo"}}, "text": "Table 6.2 Challenges and Strategies to achieve effective PMTCT in Nigeria\n                      Challenges                         Strategies to Achieve Effective PMTCT\n  Only 46% WRA (45% of Males) have comprehensive       Primary prevention of HIV in WRA &\n  knowledge of HIV Transmission & Prevention*          Partners\n  Only 57% WRA (52% Males) know MTCT*\n  1% WRA (13% Males) have 2= sexual partners*\n  Only 12% of married women use modern contraceptive*  Prevention of unintended pregnancy in PLHIV\n  High PMTCT Cascade gaps & MTCT of 5% at 2months      Prevention of MTCT in pregnant PLHIV\n  (NASCP)\n  Dwindling funding for supporting PMTCT programmes    Treatment, care & support to HIV Positive\n  High out-of-pocket expenses for PLHIV                mothers, children & families\n*NDHS 2018\n6.2.2 Benefit of PMTCT\nThe benefits of PMTCT is not limited to the baby alone, a successful PMTCT intervention\nbenefits the mother, the family, community and health system as outlined in table 6.2\n Table 6.2 Challenges and Strategies to achieve effective PMTCT in Nigeria\n                                       Benefits of PMTCT\n                         \u00b7  Identification of HIV positive mothers for targeted interventions to\n                            reduce risk of transmission of infection to their infants and to access\n                            treatment,", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1364, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ef291609-ad4f-46ad-9d5c-f8a5a95177a1": {"__data__": {"id_": "ef291609-ad4f-46ad-9d5c-f8a5a95177a1", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "99"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "9bc417ff-188d-4bcb-91f5-d132ae4d6104", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "99"}, "hash": "eabe4160d97e61f1404e600074bb832f2f357311a77694fe2501e3a89247514c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "08e2f4da-d706-4557-bef6-6bc49295cb8e", "node_type": "1", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "99"}, "hash": "4a656dd798cc570fb00fbe14fc9913412af06c8dbe0b6fd22a031d182d1a4354", "class_name": "RelatedNodeInfo"}}, "text": "2 Challenges and Strategies to achieve effective PMTCT in Nigeria\n                                       Benefits of PMTCT\n                         \u00b7  Identification of HIV positive mothers for targeted interventions to\n                            reduce risk of transmission of infection to their infants and to access\n                            treatment, care and support services\n                         \u00b7  Promotion of positive behaviour change and reduction in risk of HIV\n  Mother                    transmission\n                         \u00b7  Increase the use of dual protection methods of family planning and STI\n                            prevention\n                         \u00b7  Promotion of optimal infant feeding practices and support\n                         \u00b7  Promotion of access to early preventive and medical care\n                         \u00b7  Prevention of HIV transmission to infants\n  Infant                 \u00b7  Promotion of early diagnosis and intervention for the HIV exposed\n                            infants including linkage to care for HIV positive infants\n                         \u00b7  Improvement of child health and survival\n                         \u00b7  Promotion of communication between couples and testing of both\n                            partners\n                         \u00b7  Reduction in the risk of sexual transmission to sero-discordant partners\n  Family                 \u00b7  Provision of opportunity for testing other family members\n                         \u00b7  Access to reproductive health services\n                         \u00b7  Contribution to reduction of stigma and discrimination\n                         \u00b7  Provision of infant feeding support.\n           NATIONAL GUIDELINES FOR HIV PREVENTION TREATMENT AND CARE 2020                77", "mimetype": "text/plain", "start_char_idx": 1006, "end_char_idx": 2778, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0a19e4b3-3161-4d1b-bb9a-db12b68e96f5": {"__data__": {"id_": "0a19e4b3-3161-4d1b-bb9a-db12b68e96f5", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "100"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "2a6933f1-51ac-4477-aa0d-a434b4efa411", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "100"}, "hash": "abf6f48030a1d73cde77f172ed6548b37bffd63a7fd716cf182f349509ceb882", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f19d0076-d34d-4fb9-8e59-1cac0215e2aa", "node_type": "1", "metadata": {}, "hash": "c7e4b432185d857362b02882f81c0c9c8ae8ed2cfee7745dd04c103d823297a8", "class_name": "RelatedNodeInfo"}}, "text": "\u00b7  Promotion of the understanding of the HIV and AIDS epidemic among\n                          those living with HIV and AIDS within the community thereby\n                          strengthening community support structures\n Community             \u00b7  Promotion of uptake of risk reduction practices\n                       \u00b7  Promotion of acceptance and uptake of HIV testing services\n                       \u00b7  Contribution to reduction of stigma and discrimination\n                       \u00b7  Provision of infant feeding support\n Health System         \u00b7  Provision of opportunity to strengthen the health system\n6.3 Pre-ART Care for HIV-positive pregnant women\n6.3.1 Initial evaluation of HIV pregnant women\nAll HIV- positive pregnant women should have a full physical examination.    In addition to\nroutine antenatal services, special focus should be placed on HIV-related illnesses including\nsymptoms and signs of opportunistic infections (OIs) especially tuberculosis. Special attention\nshould also be paid to the following:\n    \u00a7   Anaemia\n    \u00a7   Persistent diarrhoea\n    \u00a7   Respiratory infections: TB and other bacterial respiratory infections are common OIs in\n        HIV positive women\n    \u00a7   Oral and vaginal candidiasis\n    \u00a7   Lymphadenopathy\n    \u00a7   Herpes zoster (chronic/recurrent) is a common presenting sign of HIV infection,\n        occurring early in the disease, often before there is much immune suppression\n    \u00a7   Other skin conditions such as candidiasis, vaginal wart, and others\n    \u00a7   Other sexually transmitted infections\n    \u00a7   Weight gain or loss\nFurthermore, pregnant women found to have Advanced HIV Disease (AHD) should be managed\naccordingly (see chapter 8).\n6.3.2 Initial Clinical Examination of HIV Positive Pregnant Women\nThe initial examination of the HIV positive pregnant woman is done to identify possible\nproblems and complications that might be present. This examination should be done in a way\nthat respects clients' privacy and rights. All pregnant women should be counselled and told why\nit is important to conduct clinical examinations. A complete physical examination should be\nperformed and care taken to maintain all safety precautions. The examination should be holistic.\nHowever, special attention should be paid to HIV related\nsigns of OIs;\n    \u00a7   Palor: anaemia is common in pregnancy and can also occur as a result ofARV related\n        side effect (AZT) and OIs.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2420, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f19d0076-d34d-4fb9-8e59-1cac0215e2aa": {"__data__": {"id_": "f19d0076-d34d-4fb9-8e59-1cac0215e2aa", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "100"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "2a6933f1-51ac-4477-aa0d-a434b4efa411", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "100"}, "hash": "abf6f48030a1d73cde77f172ed6548b37bffd63a7fd716cf182f349509ceb882", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0a19e4b3-3161-4d1b-bb9a-db12b68e96f5", "node_type": "1", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "100"}, "hash": "df8b08c4b5d4bf0a08b8ffe64eb3f4446dae1ecec7a8ca061fd84c9fef174f1f", "class_name": "RelatedNodeInfo"}}, "text": "\u00a7   Dehydration: this could occur as a result of persistent diarrhoea.\n    \u00a7   Abnormal chest finding: respiratory infections, especially TB, are common OIs among\n        HIV positive women.\n    \u00a7   Oral, oesophagal and vaginal candidiasis: candidiasis is common and may be recurrent\n          NATIONAL GUIDELINES FOR HIV PREVENTION TREATMENT AND CARE 2020           78", "mimetype": "text/plain", "start_char_idx": 2425, "end_char_idx": 2794, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8f327443-6e71-4a86-8140-14cedf761502": {"__data__": {"id_": "8f327443-6e71-4a86-8140-14cedf761502", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "101"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "c95aea0f-0245-4a66-b665-cf14b3ac5bae", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "101"}, "hash": "e217673e965a788376e8218b546084ea4083c98123fd13ca6d4a5430f06a1510", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a61a696d-293a-4aa2-894a-633aa51d6743", "node_type": "1", "metadata": {}, "hash": "f2d6dbc98020f51d0c9ce8dd969771f991ca173f4e38c809a696cace0af656ce", "class_name": "RelatedNodeInfo"}}, "text": "\u00a7   Other skin conditions: such as pityriasis versicolor, vaginal warts, Kaposi sarcoma,\n        herpes zoster etc may also be found. It is therefore important to look out for these skin\n        conditions.\n    \u00a7   Signs of other STIs: HIV positive women may have other STIs. It is therefore important\n        to look out for these signs (see the section on STIs).\n6.3.3 Laboratory Investigation of HIV Positive Pregnant Women\nHIV positive pregnant women should have all routine laboratory investigations conducted for\npregnant women.               They should have additional tests performed to monitor the progression of\ntheir clinical condition. They should have haemoglobin or hematocrit estimation at least four\ntimes during the pregnancy and urinalysis done at every clinic visit. The following investigations\nare recommended. (See table 6.3 for appropriate laboratory investigation).\nTable 6.3 Recommended laboratory investigation of HIV positive pregnant women\n   Laboratory Investigations  At Booking/    2nd visit (26- 3rd visit (30-32 4thvisit (34-36\n                              Presentation     28 weeks)       weeks)             weeks)\n  Routine for all pregnant women\n  PCV or FBC where available       X               X              X                 X\n  Blood Group                      X\n  Haemoglobin Genotype             X\n  Cervical Cancer Screening        X         This screening should be done at least once during\n                                             pregnancy\n  HBsAg and HCV                    X\n  Syphilis test                    X\n  Urinalysis                       X               X              X               X\n  MP                          As clinically indicated\n  Specific for HIV positive\n  CD4+                              X                                               X\n  Viral load                  At 3months after the commencement of ART              X\n  LFT                         As clinically indicated\n  E/U/Cr                      As recommended by chapter 3\n  Lipid Profile               As clinically indicated\n*Hepatitis B at booking; If negative, she should be offered HBV vaccination. When positive, ART regimen containing TDF+ 3TC or FTC should\nbe used.\n**Newly diagnosed HIV positive women enrolled into care, should have at least one viral load test at a gestational age of 32 to 36 weeks.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2357, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a61a696d-293a-4aa2-894a-633aa51d6743": {"__data__": {"id_": "a61a696d-293a-4aa2-894a-633aa51d6743", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "101"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "c95aea0f-0245-4a66-b665-cf14b3ac5bae", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "101"}, "hash": "e217673e965a788376e8218b546084ea4083c98123fd13ca6d4a5430f06a1510", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8f327443-6e71-4a86-8140-14cedf761502", "node_type": "1", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "101"}, "hash": "8ccd8d4362cc8f751f9a9ed4167b232d1b2bac614068c45c36669b7dc6944cfc", "class_name": "RelatedNodeInfo"}}, "text": "**Newly diagnosed HIV positive women enrolled into care, should have at least one viral load test at a gestational age of 32 to 36 weeks.\n           NATIONAL GUIDELINES FOR HIV PREVENTION TREATMENT AND CARE 2020            79", "mimetype": "text/plain", "start_char_idx": 2220, "end_char_idx": 2445, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f800b041-4b81-428e-89e4-52c881825422": {"__data__": {"id_": "f800b041-4b81-428e-89e4-52c881825422", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "102"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "27f17e90-1ae4-418e-8389-213079cfecab", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "102"}, "hash": "a01466eb271546cf1442ac0f1cd10f62a7174107c1756f00e39a98debd5e2c76", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8783871d-64e3-4d1e-b12a-29ad298454f1", "node_type": "1", "metadata": {}, "hash": "baf77af50a72c039b0f2aa5544ff446082a7ec40e2573ce6093dbbf9bb38ceb9", "class_name": "RelatedNodeInfo"}}, "text": "6.3.4 Syphilis testing for pregnant women\nSyphilis has devastating effects on the unborn baby and mother. Untreated syphilis increases the\nrisk of spontaneous miscarriage and congenital infection which has lifelong impact. Syphilis is\nan opportunistic infection whose presence if not treated increases the risk of MTCT of HIV\nduring pregnancy. The spirochete has been documented to bore through the placental barrier\nthereby promoting MTCT of HIV. All pregnant women should be screened for syphilis using\navailable Treponema pallidum- based test.\n6.4 Use ofAntiretroviral Therapy for PMTCT\nPregnancy in HIV positive women is an absolute indication for ART. ART should be initiated in\nall HIV pregnant and breast-feeding women regardless of gestational age, WHO clinical stage\nand at any CD4+ cell count and continued for life.\nART should be initiated urgently in all pregnant and breastfeeding women, even if they are\nidentified late in pregnancy or postpartum. This is the most effective way to prevent MTCT of\nHIV through the reduction of maternal viral load. Same day initiation of ART is preferred except\nin patients withAHD (see chapter 8).\n6.4.1 Recommended first-line regimen for pregnant and breastfeeding women\nIn line with National recommendations, DTG- based regimen is the preferred first-line ART for\nHIV positive pregnant women.\nTable 6.4 Recommended first-line ART Regimen in Pregnant and Breast-Feeding Women\n Target Population      Preferred first-line        Alternative first-line regimens\n                        regimens\n Pregnant or            TDF + 3TC + DTG             TDF + 3TC (or FTC) + EFV\u2084\u2080\u2080\n breastfeeding women                                AZT + 3TC + EFV\n                                                                     400\n                                                    TDF + 3TC (or FTC) + EFV\n                                                                              400\n                                                    AZT + 3TC + NVP\n                                                    TDF + 3TC (or FTC) + NVP\n                                                    ABC + 3TC + DTG.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2135, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8783871d-64e3-4d1e-b12a-29ad298454f1": {"__data__": {"id_": "8783871d-64e3-4d1e-b12a-29ad298454f1", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "102"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "27f17e90-1ae4-418e-8389-213079cfecab", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "102"}, "hash": "a01466eb271546cf1442ac0f1cd10f62a7174107c1756f00e39a98debd5e2c76", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f800b041-4b81-428e-89e4-52c881825422", "node_type": "1", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "102"}, "hash": "016ef3bc50928617ccb48704f253760175da0a2ea27f5c501e97c5d11bf557e3", "class_name": "RelatedNodeInfo"}}, "text": "In order to serve this preferred 1\u02e2\u1d57 line regimen, all women of reproductive age who can\npotentially be on DTG-  based regimen during the 1\u02e2\u1d57 trimester of pregnancy should receive\nintensive counselling on the benefits and potential risks. This includes those already on the\nDTG-based regimen and those newly diagnosed.\n6.4.2ARV prophylaxis for the HIV exposed infant\nAll HIV exposed infants should receive ARV prophylaxis. Infants at low risk of acquiring HIV\nfrom their mothers should receive NVP only once daily for 6 weeks. While infants born to\nmothers with HIV who are at high risk of acquiring HIV should receive dual prophylaxis with\nAZT (twice daily) and NVP (once daily) for the first 12 weeks of life, whether they are breastfed\nor formula-fed.Antiretroviral prophylaxis should commence within 72 hours of birth.\n          NATIONAL GUIDELINES FOR HIV PREVENTION TREATMENT AND CARE 2020           80", "mimetype": "text/plain", "start_char_idx": 2136, "end_char_idx": 3044, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "57a7494d-489e-47c9-be03-c1a90f9e1e55": {"__data__": {"id_": "57a7494d-489e-47c9-be03-c1a90f9e1e55", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "103"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "7cef6422-89b7-4a55-8c3c-eee960af7db3", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "103"}, "hash": "f74fd6c77acc20443db8fc6dcbe6d2bf3f02f46acae5e327711db92735952a0b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "07d4de22-1af3-4b3c-8750-403b68b3d8a3", "node_type": "1", "metadata": {}, "hash": "ff9ea06fda08d77a39f4ac8fe181a4244d9ae85d0b7ac83695651354cc5ca56e", "class_name": "RelatedNodeInfo"}}, "text": "Table 6.5 ARV Prophylaxis for Low-Risk Infants with NVP\n  Infant Age                                     Daily Dosing\n  Birth to 6 weeks:\n  Birth weight <2.5kg                            10 mg (1 ml) once daily\n  Birth weight =2.5kg                            15 mg (1.5 ml) once daily\nARV prophylaxis for high-risk Infants\nHigh-risk infants are defined as those:\n    \u00a7   Born to women with established HIV infection who have received less than four weeks\n        ofART at the time of delivery\n                                              OR\n    \u00a7   Born to women with established HIV infection with viral load >1000 copies/mL in the\n        four weeks before delivery;\n                                              OR\n    \u00a7   Born to women with incident HIV infection during pregnancy (this includes women\n        diagnosed in labour) or breastfeeding;\n                                              OR\n    \u00a7   Identified for the first time during the postpartum period, with or without a negative HIV\n        test prenatally.\nTable 6.6 ARV prophylaxis for High-risk Infants with NVP and AZT\n  Infant Age                            Nevirapine daily dosing     Zidovudine daily dosing\n   Birth to 6 weeks (dual prophylaxis):\n   Birth weight <2.5kg                 10mg (1ml) once daily       10mg (1ml) twice daily\n   Birth weight >2.5kg                 15mg (1.5ml) once daily     15mg (1.5ml) twice daily\n   6 weeks to 12 weeks                 20mg (2ml) once daily        60 mg (6ml) twice daily\n6.4.3 Cotrimoxazole Prophylaxis for HIV exposed infants\nCotrimoxazole prophylaxis is recommended for HIV-exposed infants from 6 weeks of age and\nshould be continued until HIV infection has been excluded by an age-appropriate HIV test 8-12\nweeks after complete cessation of breastfeeding.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1786, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "07d4de22-1af3-4b3c-8750-403b68b3d8a3": {"__data__": {"id_": "07d4de22-1af3-4b3c-8750-403b68b3d8a3", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "103"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "7cef6422-89b7-4a55-8c3c-eee960af7db3", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "103"}, "hash": "f74fd6c77acc20443db8fc6dcbe6d2bf3f02f46acae5e327711db92735952a0b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "57a7494d-489e-47c9-be03-c1a90f9e1e55", "node_type": "1", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "103"}, "hash": "545a2fa23dfc27a379bd1e0f2f25d34e7b3f979f8b5e587e2ff3392761895279", "class_name": "RelatedNodeInfo"}}, "text": "Table 6.7 Dosing for Cotrimoxazole Prophylaxis in HIV-Exposed Infants and HIV-Infected Children\n  SN     Infant Age / Weight                                    Dosage\n  1       For infants below 6 months or < 5 kg                  120mg daily\n  2       For children 6 months - 5 years or 5 -15 kg           240 mg daily\n           NATIONAL GUIDELINES FOR HIV PREVENTION TREATMENT AND CARE 2020              81", "mimetype": "text/plain", "start_char_idx": 1787, "end_char_idx": 2196, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a2878915-96f6-4299-9a8a-3399462b2db2": {"__data__": {"id_": "a2878915-96f6-4299-9a8a-3399462b2db2", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "104"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "cd65c9aa-e7d5-4407-b32b-142314582741", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "104"}, "hash": "15bb58a969bae645340b5c69cd42e6a3baeef6a487cc3a708428a70b91d7ad45", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "393fb0f8-5997-437a-8af2-a13d371d1514", "node_type": "1", "metadata": {}, "hash": "453646672d583ed880e7d9098658aa2069a032b5443de3f33087576cb5d59a7c", "class_name": "RelatedNodeInfo"}}, "text": "6.4.4Antenatal Care for HIV positive pregnant women\nWhen a woman is known to be HIV positive or is diagnosed as HIV positive during pregnancy,\nher obstetric and medical care will need to be strengthened and modified. Post-test counselling\nfor HIV positive pregnant women should include information on the following:\n   \u00a7   Disclosure, partner notification and testing\n   \u00a7   Benefits of PMTCT intervention\n   \u00a7   ART\n   \u00a7   Nutrition\n   \u00a7   Delivery\n   \u00a7   Infant feeding and infant testing\n   \u00a7   Importance of testing other children and benefits of paediatricART\n   \u00a7   The need for follow-up and adherence\n   \u00a7   Continuous screening for active TB infections and TB Preventive Therapy (TPT) for\n       those who do not have the infection (see NTBLCP guidelines)\nAll HIV positive pregnant women should be given optimal health care to ensure their safe\ndelivery*. In a situation where the life of the woman is being threatened by the continuation of\nthe pregnancy, consideration of termination of pregnancy should be in accordance with the\nprovisions of the law. (see National Guidelines on the termination of pregnancy for legal\nindications 2018).\n6.5 Management of HIV positive women in labour, delivery and within 72 hours of delivery\nThe current use of very efficacious ARVs, such as DTG assures that most women should be\nvirologically suppressed by the time their delivery is due. Nonetheless, viral load estimation is\nrecommended between 32-36 weeks of gestation to confirm this and enhance the preference of\nvaginal delivery. The management of Labour should therefore follow standard obstetric practice\n(see National obstetric protocol). Analgesia should be given in labour if required and epidural\nanalgesia is not contraindicated (See Table 6.8 Interventions for safe vaginal delivery).\nHIV positive women should not be isolated or treated differently from other women in labour.\nSupportive measures, empathy and caring attitudes by the health care provider are important for\nall women, particularly for HIV positive women who are concerned about their condition and\nrisks of HIV transmission to their children. HIV positive pregnant women should not be\nstigmatized nor discriminated against by medical staff including those who may not have\ndisclosed their status to their partner or family members.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2310, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "393fb0f8-5997-437a-8af2-a13d371d1514": {"__data__": {"id_": "393fb0f8-5997-437a-8af2-a13d371d1514", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "104"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "cd65c9aa-e7d5-4407-b32b-142314582741", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "104"}, "hash": "15bb58a969bae645340b5c69cd42e6a3baeef6a487cc3a708428a70b91d7ad45", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a2878915-96f6-4299-9a8a-3399462b2db2", "node_type": "1", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "104"}, "hash": "c83ff77324ba7678457abcf0f58022285db6b19d01e9849cf81f9fb2f9e04610", "class_name": "RelatedNodeInfo"}}, "text": "HIV positive pregnant women should not be\nstigmatized nor discriminated against by medical staff including those who may not have\ndisclosed their status to their partner or family members.\nWhenever possible, during labour, HIV positive women should have the option to have a\ncompanion of their choice who can provide supportive companionship. Where this is not\npossible, labour ward staff must be sensitive to the fears and concerns of the HIV positive\nmother.\n*Note\n   \u00a7   Avoid invasive procedures such as chorionic villous sampling, amniocentesis or cordocentesis\n   \u00a7   External cephalic version (ECV) may carry a risk of HIV transmission to the foetus and should therefore be avoided\n          NATIONAL GUIDELINES FOR HIV PREVENTION TREATMENT AND CARE 2020           82", "mimetype": "text/plain", "start_char_idx": 2122, "end_char_idx": 2896, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c4f1831f-ddee-49d4-a198-4d1f057639a3": {"__data__": {"id_": "c4f1831f-ddee-49d4-a198-4d1f057639a3", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "105"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "52cc1d62-e826-45ea-9a7c-e2c54ab0531f", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "105"}, "hash": "4b4f5008da1beefc2b0d2a7cb9fd9ab7ea58cb2fcc1617138f2dcd191c541a7c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e15ce5fe-49ab-446c-8c62-1354ae71504c", "node_type": "1", "metadata": {}, "hash": "85b2ac9b851a27b494ea9877ecba108c5bcc0ca7ba8050309c4f3bb2f253b577", "class_name": "RelatedNodeInfo"}}, "text": "Table 6.8 Intervention for Safe Vaginal Delivery and Baby Care at Delivery\n Interventions during labour/delivery                Care of the baby at delivery\n \u00a7   Perform vaginal cleansing with warm (0.25%)     \u00a7  Wipe baby\u2019s mouth and nostrils with gauze at\n     chlorhexidine solution to prevent genital          the delivery of the head.\n     infections                                      \u00a7  Handle all babies with gloves regardless of the\n \u00a7   Avoid the following:                               mother\u2019s HIV status until blood and secretions\n     -   Frequent vaginal examinations                  are washed off\n     -   Episiotomies (unless absolutely necessary)  \u00a7  Keep all babies warm soon after delivery\n     -   Instrumental delivery (unless               \u00a7  Where suctioning is indicated, a mechanical\n         when necessary)                                suction unit (at a pressure below\n                                                        100mmHg) or bulb suction should be used;\n     -   Milking the cord before clamping               mouth operated suction should be avoided\n     -   Clamp cord immediately after the baby is    \u00a7  Place the baby on the mother\u2019s body for\n         delivered and cut, under cover of wrapped      skin-to-skin contact soon after delivery\n         gauze swab to avoid blood spurting.\n6.5.1 Induction of Labour\nAs prolonged rupture of membranes is associated with increased risk of MTCT, careful\nassessment of the desirability of Caesarean Section (CS) rather than induction of labour is\nnecessary. The use of prostaglandins or its analogues (misoprostol) can be considered.\n6.5.2 Conduct of Delivery\nDelivery should be conducted using standard practices and aseptic techniques while avoiding\nunnecessary trauma or prolongation of the second stage.\n6.5.3 Vaginal Delivery\nHIV positive women who are on ART should be allowed to deliver vaginally where there is no\nobstetric contraindication. Vaginal delivery remains the primary delivery mode of choice.\n6.5.4 Caesarean Section (CS)\nHIV infection on its own is not an indication for CS. Available evidence shows that elective CS\nfor women on ART who have achieved viral suppression has no added advantage over vaginal\ndelivery. Every pregnant woman including adolescents should be monitored closely.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2300, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e15ce5fe-49ab-446c-8c62-1354ae71504c": {"__data__": {"id_": "e15ce5fe-49ab-446c-8c62-1354ae71504c", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "105"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "52cc1d62-e826-45ea-9a7c-e2c54ab0531f", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "105"}, "hash": "4b4f5008da1beefc2b0d2a7cb9fd9ab7ea58cb2fcc1617138f2dcd191c541a7c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c4f1831f-ddee-49d4-a198-4d1f057639a3", "node_type": "1", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "105"}, "hash": "7d663a28c3ab4989457bd1ca0c59893752812398f68d34c1892fd83de6b7fa44", "class_name": "RelatedNodeInfo"}}, "text": "Available evidence shows that elective CS\nfor women on ART who have achieved viral suppression has no added advantage over vaginal\ndelivery. Every pregnant woman including adolescents should be monitored closely.\nElective CS can be considered for HIV positive women before the onset of labour or rupture of\nmembranes in cases where the woman is not on ART and/or where the maternal viral load is\nknown to be high (> 1000copies/ml). Available evidence shows that when elective CS is\nperformed before the onset of labour or rupture of membranes, it reduces the risk of MTCT by\ngreater than 50% as compared to vaginal delivery among women not on ART or with high viral\nload. These guidelines, however, do not recommend routine offer of elective CS for any group of\nHIV positive pregnant women.\n           NATIONAL GUIDELINES FOR HIV PREVENTION TREATMENT AND CARE 2020                  83", "mimetype": "text/plain", "start_char_idx": 2088, "end_char_idx": 2972, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "31fbc137-d1b3-40f8-9e4b-075acee83947": {"__data__": {"id_": "31fbc137-d1b3-40f8-9e4b-075acee83947", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "106"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "c78852ad-f8b2-4549-9514-06188dbd5c64", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "106"}, "hash": "46fc750346b9bf686cd5c18f4efcf8179d8176136dea078bb908cb8071a06a05", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a4af114e-4913-40e1-9aeb-9b630bdeffa5", "node_type": "1", "metadata": {}, "hash": "a7a9b3aac6dcf497d1a3674328553e50891743ab3fffe3c36c405e254b3022a4", "class_name": "RelatedNodeInfo"}}, "text": "Where CS is performed (elective or emergency) in HIV positive women, they should receive\nprophylactic antibiotics. If CS is performed after prolonged labour or prolonged rupture of\nmembranes a longer course of antibiotics is recommended.\n6.5.5  Specific Modification of Obstetric Care for HIV Positive Women\n    \u00a7   Care should be individualized in special circumstances such as premature rupture of\n        membranes (preterm and term) and ante-partum haemorrhage\n    \u00a7   Use of the partograph: proper and consistent use of the partograph in monitoring the\n        progress of labour will improve the management and reduce the risk of prolonged labour\n        in all women\n    \u00a7   Artificial rupture of membranes (ARM) is practised routinely in many settings although\n        it should be reserved for women with abnormal progress of labour. Rupture of\n        membranes of more than four (4) hours duration is associated with an increased risk of\n        HIV transmission. Therefore, earlyARM should be reserved for those with foetal\n        distress or abnormal progress.ARM can be done if cervical dilatation is 7 cm or more.\n    \u00a7   Instrumental delivery: forceps and vacuum delivery should be avoided as they have been\n        shown to be associated with increased risk of MTCT. If it has to be done, vacuum with\n        silastic cup is preferred\n    \u00a7   Vaginal cleansing with chlorhexidine (0.25% solution) reduces the risk of puerperal and\n        neonatal sepsis. It may also have some effect on HIV transmission where membranes are\n        ruptured for more than 4 hours. The number of vaginal examinations should be kept to a\n        minimum.\n    \u00a7   Routine episiotomy has been shown to have no obstetric benefit; it should be used only\n        for specific obstetric indications\n6.6  PMTCT/TB integration services\n6.6.1 Pregnant women with TB and HIV co-infection\nNigeria has the highest TB burden in Africa and the sixth highest in the world . TB causes one in\nthree deaths among PLHIV, and co-morbidity of TB and HIV in pregnancy causes up to 40%\nmortality.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2073, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a4af114e-4913-40e1-9aeb-9b630bdeffa5": {"__data__": {"id_": "a4af114e-4913-40e1-9aeb-9b630bdeffa5", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "106"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "c78852ad-f8b2-4549-9514-06188dbd5c64", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "106"}, "hash": "46fc750346b9bf686cd5c18f4efcf8179d8176136dea078bb908cb8071a06a05", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "31fbc137-d1b3-40f8-9e4b-075acee83947", "node_type": "1", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "106"}, "hash": "b0985288209067b58c807f484b597cb8b06813bcfa00189d4eb1be2fa7ea2b97", "class_name": "RelatedNodeInfo"}}, "text": "TB causes one in\nthree deaths among PLHIV, and co-morbidity of TB and HIV in pregnancy causes up to 40%\nmortality. These are the reasons why continuous screening of HIV positive pregnant women\nshould be conducted throughout pregnancy to identify women who have active TB disease.\nThose with the disease should be given immediate access to TB treatment according to the\nNTBLCP Guidelines. Those without the disease should be placed on TB Preventive Therapy\n(TPT) irrespective of the duration of pregnancy.\nEvery ANC provider should be prepared and equipped to screen every pregnant woman for TB\ndisease at each clinic visit, whether they are HIV positive or not. The screening of those who are\nHIV positive is even more important because not detecting the co-infection of HIV and TB in\npregnancy is a leading cause of death among them.\nAt every ANC visit, the HIV positive pregnant woman should be asked if she has any of the\nmajor symptoms of TB; cough, fever, weight loss or night sweats (especially drenching type).\nRefer to Appendix 7 for Algorithm for Screening Adults and Adolescents Living with HIV for\nTPT.\n           NATIONAL GUIDELINES FOR HIV PREVENTION TREATMENT AND CARE 2020           84", "mimetype": "text/plain", "start_char_idx": 1959, "end_char_idx": 3159, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b785705a-cb2f-4329-a651-b6c07b8d139e": {"__data__": {"id_": "b785705a-cb2f-4329-a651-b6c07b8d139e", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "107"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "59d553bf-b93e-40e1-856a-b1537b00c5bf", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "107"}, "hash": "eba133b2ee812ffab92dd10f36a94d7471e4f33cfe5bbc40b42ca019e4bf6267", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a7f50a94-2c8a-4d32-a83e-a521949008aa", "node_type": "1", "metadata": {}, "hash": "65674ee371e308f0cdf68046a92eb70dbe9f2ea028a3df8d1f09c26babacc96e", "class_name": "RelatedNodeInfo"}}, "text": "At each visit, the pregnant or breastfeeding HIV positive woman should be identified to belong to\nany of the following three categories:\n    1)   Has no cough but has other symptoms of TB \u2013 the patient should be referred to the\n         medical officer to exclude TB (according to NTBLCP Guidelines); or\n    2)   Has cough with other symptoms of TB \u2013 the patient is likely to have TB disease that\n         requires confirmation with Xpert MTB/RIF assay, and subsequent management\n         according to NTBLCP Guidelines; or\n    3)   Has none of the four symptoms \u2013 the patient should be counselled and started on TPT\n         irrespective of the gestational age of the pregnancy.\nTuberculosis Preventive Therapy (TPT) involves the administration of medicines (e.g. Isoniazid\n300mg daily) for a minimum period of six months to a pregnant/breastfeeding PLHIV who does\nnot have active TB disease. It is purposed to protect her from developing active TB disease.\n   Triple pill combination of Isoniazid + Cotrimoxazole + Pyridoxine is available and a good option for\n   TPT among pregnant and postpartum women with HIV.\n Management of Newborn of a Mother/ Household contacts with active TB\n Infants born to mothers with active TB disease may become infected with TB. When infected,\n the infant may be asymptomatic or present with acute symptoms that are often non-specific.\n Management depends on the peculiar situation, but evaluation should be at a referral centre\n Some possible scenarios regarding infant born to mothers with TB include:\n    i.   If a mother is diagnosed with TB before the third trimester of pregnancy and taking TB\n         medications with good adherence and is improving:\n         \u00a7  Examine the new born\n            o   If symptoms and signs of TB are not present administer BCG\n            o   If symptoms and signs of TB are present, evaluate further for TB disease\n            o   If symptoms and signs suggest other disease(s), manage/refer as appropriate\n         \u00a7  Perform maternal HIV screening (if not done inANC)\n         \u00a7  Refer all other household contacts for TB evaluation\n    ii.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2117, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a7f50a94-2c8a-4d32-a83e-a521949008aa": {"__data__": {"id_": "a7f50a94-2c8a-4d32-a83e-a521949008aa", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "107"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "59d553bf-b93e-40e1-856a-b1537b00c5bf", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "107"}, "hash": "eba133b2ee812ffab92dd10f36a94d7471e4f33cfe5bbc40b42ca019e4bf6267", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b785705a-cb2f-4329-a651-b6c07b8d139e", "node_type": "1", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "107"}, "hash": "33ca5ca742b92bff521dc0421c7ba774342c68e266b6c9f5716fd815250ff28e", "class_name": "RelatedNodeInfo"}}, "text": "If a mother is diagnosed with TB in the third trimester or shortly after delivery:\n         \u00a7  Evaluate for maternal PTB or EPTB disease including uterine TB\n         \u00a7  Perform maternal HIV screening (if not done inANC)\n         \u00a7  Defer BCG vaccine administration for the newborn\n         \u00a7  Evaluate infant for congenital TB if the newborn is symptomatic or where mother is\n            AFB positive or has untreated disseminated or partially treated TB/poor adherence.\n         \u00a7  Evaluate infant if mother is diagnosed with endometrial TB regardless of treatment\n            status with:\n            o   CXR\n            o   Gastric aspirates for Xpert MTB/Rif and culture of 3 consecutive samples\n            o   Abdominal ultrasound\n         \u00a7  Lumbar puncture for CSF Xpert MTB/Rif, LPAand cultures.\n         \u00a7  If TB disease is confirmed in the newborn, initiate TB therapy promptly in\n            consultation with a paediatrician where available.\n           NATIONAL GUIDELINES FOR HIV PREVENTION TREATMENT AND CARE 2020           85", "mimetype": "text/plain", "start_char_idx": 2119, "end_char_idx": 3161, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9431bc2d-e08e-46a3-bc80-d27cbaf386c4": {"__data__": {"id_": "9431bc2d-e08e-46a3-bc80-d27cbaf386c4", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "108"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "459cb1ea-e0d6-4719-9c4d-00514e5ace41", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "108"}, "hash": "629d03b0df50355792d03dba4a1b66418463d7637d42a75fc8679e9c0c7791db", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "04d66de4-a4f3-4c7d-9833-ded920821f2a", "node_type": "1", "metadata": {}, "hash": "9bdcb9d419438a5a1c03c657ba5bb7546df8fce58530278be706d797790c6d5f", "class_name": "RelatedNodeInfo"}}, "text": "\u00a7   If congenital TB is excluded, administer TPT for LTBI until age of 6 months\n       Perform Mantoux or IGRAtest and if positive, reassess for active TB\n   \u00a7   If active disease is ruled out, give TPT for LTBI\n   \u00a7   If the Mantoux/IGRAis negative and TB disease is ruled out and mother/household\n       contact becomes smear-negative, stop INH and administer BCG vaccine two weeks\n       after stopping TPT\n   \u00a7   Follow-up infant monthly.\n   \u00a7   Refer all other household contacts for TB evaluation\n6.6.2 Infection Control\n   \u00a7   Separate the newborn from any active TB case in the household including the mother\n       during the evaluation period\n   \u00a7   Newborn should receive expressed breastmilk during period of isolation\n   \u00a7   Mother/adult contact should wear a facemask while handling the baby\n   \u00a7   Follow isolation precautions\n   \u00a7   Once the baby is on INH and the mother or adult source is on continuation phase of\n       treatment, no need to separate the baby, and the mother can again breastfeed the baby\n6.6.3 Management of Newborn of a Mother/ Household contacts with LTBI\nIn a newborn whose mother or other household contact has LTBI:\n   \u00a7   Treat the mother or household contact for LTBI (if mother or household contact are\n       contacts of an infectious TB index case)\n   \u00a7   Perform maternal HIV screening (if not done inANC)\n   \u00a7   Since a positive Mantoux/IGRAresult is a marker for an unrecognised case of active TB\n       in the household, evaluate all other household members for TB disease/LTBI.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1529, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "04d66de4-a4f3-4c7d-9833-ded920821f2a": {"__data__": {"id_": "04d66de4-a4f3-4c7d-9833-ded920821f2a", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "108"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "459cb1ea-e0d6-4719-9c4d-00514e5ace41", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "108"}, "hash": "629d03b0df50355792d03dba4a1b66418463d7637d42a75fc8679e9c0c7791db", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9431bc2d-e08e-46a3-bc80-d27cbaf386c4", "node_type": "1", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "108"}, "hash": "3c028332a1cdabf91d1a878626fdbf56df32d17e0a8dfd6126eee3921e706b85", "class_name": "RelatedNodeInfo"}}, "text": "\u00a7   The newborn needs no special evaluation\n   \u00a7   Administer BCG vaccine if no active case of TB is detected in the household\n6.7 Care and Support of the HIV-Exposed Infant\n6.7.1 Immediate and on-going care of the new-born of HIV positive women\nThe immediate care of the new-born follows standard practice regardless of the mothers' HIV\nstatus.At delivery all newborns should:\n   \u00a7   Be handled with latex gloves until maternal blood and secretions are washed off\n   \u00a7   Have their mouths and nostrils wiped with sterile gauze after delivery of the head\n   \u00a7   Have the cord clamped immediately after the baby is delivered and avoid milking the\n       cord\n   \u00a7   Have the cord cut under cover of a lightly wrapped gauze swab to avoid blood spurting\n   \u00a7   Be kept warm\n   \u00a7   Be suctioned if indicated using a mechanical/electrical suction unit at a pressure below\n       100mmHg or bulb suction. Mouth operated suction is contraindicated\n   \u00a7   Be cleaned with warm chlorhexidine solution or wiped dry with a towel or surgical cloth\n       to remove maternal body fluids\n   \u00a7   Place the baby on the mother's chest for skin to skin contact soon after delivery. In this\n       position, the baby will latch on to one of the mother's breasts to initiate feeding unless the\n       mother opted for an alternative feeding method\n   \u00a7   Have vitamin K administered, ensuring injection safety\n          NATIONAL GUIDELINES FOR HIV PREVENTION TREATMENT AND CARE 2020            86", "mimetype": "text/plain", "start_char_idx": 1533, "end_char_idx": 3009, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8720dfe8-db22-4d69-9a8d-0579e28b18f1": {"__data__": {"id_": "8720dfe8-db22-4d69-9a8d-0579e28b18f1", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "109"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "af71b0c5-2326-4403-8d40-6e6bf9ccee93", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "109"}, "hash": "2ae68b793986e491b21f80a0f952c0fcab218a8052594639af38a5b4d365741c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ee17b38a-ca3c-42a3-8e16-b9a7bad1487d", "node_type": "1", "metadata": {}, "hash": "ac35d023e76fcd586dae77c1ff8cd1d8468871e09c38f4feffed0ef9d03e4807", "class_name": "RelatedNodeInfo"}}, "text": "6.7.2 Infant feeding in the context of HIV\nAppropriate infant feeding is critical to child survival because the natural food for infants is\nbreast milk. In the context of maternal HIV infection, infant feeding can become complex. HIV\ninfection may be transmitted through breast milk from mother to child and this risk approaches\n5%-15% in the absence of any intervention. Breast milk substitute has the benefit of zero HIV\ntransmission but carries with it the risk of increased morbidity and mortality from malnutrition,\ndiarrhoea and pneumonia.\n   \u00a7   It is recommended that mothers of HIV exposed infants breastfeed their babies\n       exclusively for the first six (6) months of life.\n   \u00a7   Adequate complementary feeds should be introduced at 6 months in addition to breast\n       milk\n   \u00a7   Breastfeeding complemented by adequate complementary and household foods should\n       be continued till 12 months of age.\nMothers who breastfeed should be aware that:\n   \u00a7   Mixed feeding (breast milk plus substitutes or foods) increases the risk of MTCT of\n       HIV.\n   \u00a7   ARV provided during labour and to the mother/infant pair throughout breastfeeding\n       protects the infant from MTCT of HIV\n   \u00a7   The risk of transmitting HIV to her infant during breastfeeding is higher in certain\n       conditions such as:\n       o   When the woman is severely ill (by clinical or laboratory measures)\n       o   When she has mastitis, breast abscess, or other similar conditions\n       o   When the child has ulcers in the mouth\n       o   When breastfeeding is prolonged beyond 12 months of age\nBreast milk substitute:Breast milk substitute means feeding infants who are receiving no\nbreast milk with correctly prepared commercial infant formula that provides most of the\nnutrients' infants need until the age at which they can be fully fed on family foods. Unlike\nbreastfeeding, it does not protect against infections. During the first 6 months of life, breast milk\nsubstitutes should be with a suitable commercial infant formula prepared hygienically. After 6\nmonths the suitable commercial formula should be complemented with other foods.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2141, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ee17b38a-ca3c-42a3-8e16-b9a7bad1487d": {"__data__": {"id_": "ee17b38a-ca3c-42a3-8e16-b9a7bad1487d", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "109"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "af71b0c5-2326-4403-8d40-6e6bf9ccee93", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "109"}, "hash": "2ae68b793986e491b21f80a0f952c0fcab218a8052594639af38a5b4d365741c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8720dfe8-db22-4d69-9a8d-0579e28b18f1", "node_type": "1", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "109"}, "hash": "2b7389225ea8e7167b31539f25d4c0f636b39f7bee89df1a43bf3ec6554657c4", "class_name": "RelatedNodeInfo"}}, "text": "During the first 6 months of life, breast milk\nsubstitutes should be with a suitable commercial infant formula prepared hygienically. After 6\nmonths the suitable commercial formula should be complemented with other foods.\n6.7.3 Early Infant Diagnosis (EID)\nAll HIV-exposed infants should have DNA PCR testing or NAT at birth, 6 \u2013 8 weeks of age, 9\nmonths and 8-12 weeks after complete cessation of breastfeeding. If the baby is not being\nbreastfed, DNAPCR testing should be done at birth and 6 weeks [ Refer to figure 2.3].\n6.7.4 Childhood Immunizations in the Context of HIV\nHIV-exposed infants, children and adolescents with HIV should receive all vaccines under\nroutine vaccination according to recommended national immunization schedule (NPI) as shown\non Table 6.9. The WHO recommends that the certain situations require special considerations\nfor HIV exposed and infected neonates, infants and children as outlined below.\n6.7.4.1 Considerations for BCG vaccine\n   \u00a7   Neonates born to women of unknown HIV status should be vaccinated as the benefits of\n       BCG vaccination outweigh the risks\n          NATIONAL GUIDELINES FOR HIV PREVENTION TREATMENT AND CARE 2020           87", "mimetype": "text/plain", "start_char_idx": 1920, "end_char_idx": 3105, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bb84cb96-5271-4879-87c2-19adda414bda": {"__data__": {"id_": "bb84cb96-5271-4879-87c2-19adda414bda", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "110"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "74f5de9b-e37d-47b2-9a9b-48ced6817969", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "110"}, "hash": "038c4e758846a57129bcb191c42ec8690f6dd588c893f168db8b87e190f4f06e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c11bd6d3-2248-4bc3-bd24-25bca91ce9b4", "node_type": "1", "metadata": {}, "hash": "38eb2ccb00b877fe89ea80627d788a2714b4c87f6900d7d941be1ec84bdeed29", "class_name": "RelatedNodeInfo"}}, "text": "\u00a7   Neonates of unknown HIV status born to HIV infected women should be vaccinated if\n       they have no clinical evidence suggestive of HIV disease, regardless of whether the\n       mother is receivingART\n   \u00a7   Neonates with HIV infection confirmed by early virological testing, BCG vaccination\n       should be delayed untilART has been started and the infant confirmed to be\n       immunologically stable (CD4>25%)\n   \u00a7   HIV-infected children onART, those clinically and immunologically stable (Cd4%\n       >25% for <5 years or CD4 count \u2265200 for >5 years) should be vaccinated with BCG.\n6.7.4.2 Considerations for Pneumococcal vaccines\n   \u00a7   HIV-positive infants and pre-term neonates who have received their 3 primary vaccine\n       doses before 12 months of age may benefit from a booster dose in the second year of life.\n   \u00a7   Unvaccinated children aged 1\u20135 years at high risk for pneumococcal infection due to\n       underlying conditions, such as HIV infection or sickle-cell disease, should receive at\n       least 2 doses separated by at least 8 weeks.\n6.7.4.3 Considerations for Measles vaccines\nIn the following situations, a supplementary dose of MCV should be given to infants from 6\nmonths of  age:\n   \u00a7   Measles vaccine should be routinely administered to potentially susceptible,\n       asymptomatic HIV infected children and adults, given the severe course of measles in\n       patients with advanced HIV disease (AHD).\n   \u00a7   Vaccination may be considered for those with symptomatic HIV infection if they are not\n       severely immunosuppressed.\n   \u00a7   Where there is a high incidence of both HIV infection and measles, an initial dose of\n       Measles vaccine may be offered as early as age 6 months (recorded as MCV0).\n   \u00a7   The 2 routine doses of Measles vaccines (MCV1 and MCV2) should then be\n       administered to these children according to NPI schedule.\n   \u00a7   An additional dose of Measles vaccine should be administered to HIV-infected children\n       receiving HAART following immune reconstitution.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2040, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c11bd6d3-2248-4bc3-bd24-25bca91ce9b4": {"__data__": {"id_": "c11bd6d3-2248-4bc3-bd24-25bca91ce9b4", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "110"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "74f5de9b-e37d-47b2-9a9b-48ced6817969", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "110"}, "hash": "038c4e758846a57129bcb191c42ec8690f6dd588c893f168db8b87e190f4f06e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bb84cb96-5271-4879-87c2-19adda414bda", "node_type": "1", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "110"}, "hash": "b44c8660f16b60cf215846613d637140a824350a445154b9faa7341f3bbf4140", "class_name": "RelatedNodeInfo"}}, "text": "\u00a7   An additional dose of Measles vaccine should be administered to HIV-infected children\n       receiving HAART following immune reconstitution.\n   \u00a7   If CD4+ counts are monitored, an additional dose of MCV should be administered when\n       immune reconstitution has been achieved, e.g. when the CD4+ count reaches 20\u201325%.\n   \u00a7   Where CD4+ monitoring is not available, children should receive an additional dose at\n       6\u201312 months after initiation of HAART.\n   \u00a7   Asupplementary dose (recorded as MCV0) should be considered for infants known to\n       be exposed (i.e. born to an HIV-infected woman) or soon after diagnosis of HIV\n       infection in children older than 6 months who are not receiving HAART and for whom\n       the risk of measles is high, with the aim of providing partial protection until they are\n       revaccinated after immune reconstitution with HAART.\n6.7.4.4 Considerations for Human Papillomavirus vaccine\n   \u00a7   A3-dose schedule (0, 1-2, 6 months) should be used for all vaccinations initiated \u226515\n       years of age, including in girls <15 years known to be immunocompromised and/or HIV\n       infected (regardless of whether they on HAART or not.\n   \u00a7   It is not necessary to screen for HPV infection or HIV infection prior to HPV\n       vaccination.\n          NATIONAL GUIDELINES FOR HIV PREVENTION TREATMENT AND CARE 2020           88", "mimetype": "text/plain", "start_char_idx": 1895, "end_char_idx": 3271, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a760fef5-7e49-4468-9b03-668367d9fd52": {"__data__": {"id_": "a760fef5-7e49-4468-9b03-668367d9fd52", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "111"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "3fdba418-b989-4825-85f9-f6ad8d977382", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "111"}, "hash": "e01c90ffe0da29aa88c987d2fdcdfc25fae50ed97d207c041eb725e55a3d21aa", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "81305aad-4c02-4ca2-bc2a-5bb3626115ad", "node_type": "1", "metadata": {}, "hash": "8826591495dc2665585e22c40df6d76cc0d52f0cb9f29b54e4304d25aafd2692", "class_name": "RelatedNodeInfo"}}, "text": "Table 6.9 National Routine Immunization Schedule\n Minimum        Vaccine              Dosage     Route of         Site of administration\n Target age                                     delivery\n At Birth       BCG                  0.05ml     Intradermal      Left upper arm\n                OPV0                 2 drops    Oral             Mouth\n                Hep B                0.5ml      Intramuscular    Right thigh (antero-lateral\n                                                                 aspect)\n 6 Weeks        Pentavalent (DPT,    0.5ml      Intramuscular    Left thigh (antero-lateral\n                Hep B, Hib) 1                                    aspect)\n                Pneumococcal                                     Left thigh (antero-lateral\n                Conjugate Vaccine    0.5ml      Intramuscular    aspect)\n                (PCV) 1\n                OPV1                 2 drops    Oral             Mouth\n                Rota 1               1ml        Oral             Mouth\n 10 Weeks       Pentavalent (DPT,    0.5ml      Intramuscular    Left thigh (antero-lateral\n                Hep B, Hib) 2                                    aspect)\n                Pneumococcal                                     Right thigh (antero-lateral\n                Conjugate Vaccine    0.5ml      Intramuscular    aspect)\n                (PCV) 2\n                OPV2                 2 drops    Oral             Mouth\n                Rota 2               1ml        Oral             Mouth\n 14 Weeks       Pentavalent (DPT,    0.5ml      Intramuscular    Left thigh (antero-lateral aspect)\n                Hep B, Hib) 3\n                Pneumococcal\n                Conjugate Vaccine    0.5ml      Intramuscular    Right thigh (antero-lateral aspect)\n                (PCV) 3\n                OPV3                 2 drops    Oral             Mouth\n                IPV                  0.5ml      Intramuscular    -Right thigh (anterolateral aspect,\n                                                                 25cm away from PCV3 site)\n 6 Months       Vitamin A            100,000    Oral             Mouth\n                                     IU\n 9 Months       Measles (MCV0)       0.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2201, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "81305aad-4c02-4ca2-bc2a-5bb3626115ad": {"__data__": {"id_": "81305aad-4c02-4ca2-bc2a-5bb3626115ad", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "111"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "3fdba418-b989-4825-85f9-f6ad8d977382", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "111"}, "hash": "e01c90ffe0da29aa88c987d2fdcdfc25fae50ed97d207c041eb725e55a3d21aa", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a760fef5-7e49-4468-9b03-668367d9fd52", "node_type": "1", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "111"}, "hash": "6ea826d6e64edc8f5ae2af0f3f882f8e8eea817b085c6ecb9824c1b0053ce202", "class_name": "RelatedNodeInfo"}}, "text": "25cm away from PCV3 site)\n 6 Months       Vitamin A            100,000    Oral             Mouth\n                                     IU\n 9 Months       Measles (MCV0)       0.5ml      Subcutaneous     Left upper arm\n                Yellow fever         0.5ml      Subcutaneous     Right upper arm\n                Meningitis           0.5ml      Intramuscular    Left thigh (antero-lateral aspect)\n 15 Months      Vitamin A            100,000    Oral             Mouth\n                                     IU\n                Measles (MCV1)       0.5ml      Subcutaneous     Left upper arm\n           NATIONAL GUIDELINES FOR HIV PREVENTION TREATMENT AND CARE 2020              89", "mimetype": "text/plain", "start_char_idx": 2025, "end_char_idx": 2703, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e6693d07-cbac-48fb-9574-a290228c7622": {"__data__": {"id_": "e6693d07-cbac-48fb-9574-a290228c7622", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "112"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "253c8ce6-0eb9-4343-92b9-80d3c99cb62a", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "112"}, "hash": "6b6ad8e99bc0b7a5ab83d800cac738f344bdb4b7bd51920ee96e5a2befaed14d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b61696f7-ae28-4cde-9704-70c5e0c7b1d1", "node_type": "1", "metadata": {}, "hash": "681f486059a2d76e0d888fee49c0f501689ece285c20751a5ecd0bdad664851b", "class_name": "RelatedNodeInfo"}}, "text": "6.8 Special Considerations forAdolescent and Young Women in PMTCT\nIn Nigeria, an estimated 23% of women aged 15-19 years begun childbearing, of which 17%\nhave had their first child and 5% are pregnant for their first child [4].\nTo achieve eMTCT in Nigeria, it is therefore very important to pay special attention to any\nadolescent girl presenting with pregnancy in a health facility. Efforts should be made to seek out\nthe many pregnant adolescents in the community that do not present to health facilities for ANC\nand delivery. The needs of Adolescent Girls and Young Women (AGYW) in eMTCT are like\nthose of an adult woman, the major difference is the fact that their vulnerabilities are heightened\nphysiologically, emotionally and socially. Service delivery thus needs to be responsive to their\nneeds across the 4 pillars of PMTCT as below:\nPillar 1:\nKey concerns forAGYW include:\n    \u00a7   Low knowledge of HIV transmission\n    \u00a7   Low-risk perception\n    \u00a7   Lack of awareness of prevention options/methods to reduce risks and/or skills to use\n        them\n    \u00a7   Late start ofANC\nPMTCT programmes should make provision for integration of HIV prevention\nmessages/information targeting AGYW at the community level and through women groups,\nmobile services, social media platforms, peer-groups, youth centres etc. Provider-facilitated\nscreening, lay or peer counsellor, self-assessment (considering sexual risk, risky relationships,\nlifestyle risk and situational risk) are additional considerations required.\nPillar 2:\nConsidering the high rates of unintended pregnancies in AGYW, unsafe abortion among\nadolescents contributes to maternal mortality for this age group. The specific challenges faced\nby pregnant AGYW living with HIV include lack of knowledge of contraceptive options, life\nskills and self-efficacy, inaccessible and non-friendly services, lack of support for dual\nprotection and limited access to contraceptives beyond condoms.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1945, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b61696f7-ae28-4cde-9704-70c5e0c7b1d1": {"__data__": {"id_": "b61696f7-ae28-4cde-9704-70c5e0c7b1d1", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "112"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "253c8ce6-0eb9-4343-92b9-80d3c99cb62a", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "112"}, "hash": "6b6ad8e99bc0b7a5ab83d800cac738f344bdb4b7bd51920ee96e5a2befaed14d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e6693d07-cbac-48fb-9574-a290228c7622", "node_type": "1", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "112"}, "hash": "7e3fc241f07fdb15273c798fbf521a0e776d551577294faed8c45ca7a7272006", "class_name": "RelatedNodeInfo"}}, "text": "Specific considerations required include:\n    \u00a7   FP/SRH information and life skills tailored forAdolescents living with HIV (ALHIV)\n    \u00a7   Contraception and dual protection tailored to their needs integrated within HIV care,\n        safe conception and pregnancy planning\n    \u00a7   Support group-based approaches\n    \u00a7   Community-based distribution and activities to optimize contraceptive options\n        available toALHIV\nPillar 3:\nThe major risk factors associated with vertical transmission in pregnant AGYW living with HIV\nare late start of ANC, delayed HIV testing and treatment initiation leading to suboptimal\ntreatment outcomes.\nSpecial considerations to be offered toAGYW include;\n    \u00a7   Tailored approaches to case finding, earlier pregnancy testing, and early initiation on\n        treatment for young mothers\n           NATIONAL GUIDELINES FOR HIV PREVENTION TREATMENT AND CARE 2020           90", "mimetype": "text/plain", "start_char_idx": 1946, "end_char_idx": 2856, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "16048e6f-cdd1-402f-8bd4-2835626318da": {"__data__": {"id_": "16048e6f-cdd1-402f-8bd4-2835626318da", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "113"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "19c43fe0-1cfd-4d53-852a-aed8dad99770", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "113"}, "hash": "03ae8537ad2c355754c0c3578ce168d1b6f750f13f4946c4310e53655ffaf0fc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "210754d4-5635-4563-81ce-37a73043cd62", "node_type": "1", "metadata": {}, "hash": "cc9c0bb9f58283d75d4d7fa75cf866f763c1d1f7f979bced479a1d4250c0463f", "class_name": "RelatedNodeInfo"}}, "text": "\u00a7   Active (facilitated) treatment referrals\n   \u00a7   Facility and out-of-facility based models specifically serving young mothers\nPillar 4:\nThe major concern for AGYW living with HIV postpartum (post EID) is treatment continuity.\nOther concerns include SRH needs, age of young mother and spacing of children. The PMTCT\nprogram should ensure young mothers living with HIV receive:\n   \u00a7   Longer-term care and support focused on retaining young mothers and children in care\n   \u00a7   Integrated delivery ofARV, SRHR, FP\n   \u00a7   Care involving men\n   \u00a7   Family-based care\n   \u00a7   Mental health screening and intervention approaches in the context of HIV care\n   \u00a7   Integrated case management systems\n6.9 Linkage of PMTCT with comprehensive HIV Treatment, Care and Support Services\nfor Mothers and Infants\nThe follow-up treatment, care and support for HIV-positive mothers after delivery, the care of\ntheir HIV exposed infant and other children is important as part of the continuum of care\npackage. A family-focused care should be the standard, this is designed to identify, engage and\ncare for all HIV-positive family members, prevent new infections among family members at\nrisk, raise family support and awareness within the HIV department at a health facility\ndepending on the PMTCT service model.\nPMTCT services can be offered in both public and private health facilities. Mother-infant pairs\nfrom health facilities with no capacity for comprehensive HIV care should be referred to\ncomprehensive health services that provide HIV treatment, care and support by 6 weeks after\ndelivery or at the earliest possible time thereafter. This is because it is important that treatment\nand care extend beyond the prevention of MTCT for women, infants, and family members at risk\nfor or infected with HIV.\n6.9.1 Engagement of Non-Formal Health Actors (NFHA) in the (referral and Linkage) of\nPMTCT services\nThere are human resource gaps in the health sector in Nigeria, while the implementation of the\ntask shifting policy is ongoing, there is a need for a medium-term intervention in the form of\nengagement of the non-formal health actors in the delivery of PMTCT services in Nigeria.\nNon-formal health actors play a critical role in maternal and child health care response.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2259, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "210754d4-5635-4563-81ce-37a73043cd62": {"__data__": {"id_": "210754d4-5635-4563-81ce-37a73043cd62", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "113"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "19c43fe0-1cfd-4d53-852a-aed8dad99770", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "113"}, "hash": "03ae8537ad2c355754c0c3578ce168d1b6f750f13f4946c4310e53655ffaf0fc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "16048e6f-cdd1-402f-8bd4-2835626318da", "node_type": "1", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "113"}, "hash": "ef5a7cf7765e2e177c7561338d2b722bbe52efaffd70d61c2144f552e4911402", "class_name": "RelatedNodeInfo"}}, "text": "Non-formal health actors play a critical role in maternal and child health care response. Their\nrole in PMTCT will include the following:\n   1.  Community sensitization and awareness creation\n   2.  Community mobilization\n   3.  HIV case identification\n   4.  Peer influence for PMTCT service uptake\n   5.  Referral and linkage including EID and immunization services\n   6.  Tracking and contact tracing\n   7.  Non-clinical care and support\n          NATIONAL GUIDELINES FOR HIV PREVENTION TREATMENT AND CARE 2020            91", "mimetype": "text/plain", "start_char_idx": 2170, "end_char_idx": 2697, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f4750933-4805-426e-802b-cb796833d767": {"__data__": {"id_": "f4750933-4805-426e-802b-cb796833d767", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "114"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "f6dffcce-0d98-40c0-99de-73a85289bf80", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "114"}, "hash": "1aa5e3a85b92dc7c3288632abafa9da9bd65eb0e870c97a8e018430c74df65fa", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7625cd1f-1d8d-475a-aa15-a82a2b923a5d", "node_type": "1", "metadata": {}, "hash": "d3164510c77805c06214426022f1acf1cea0c2506dc72427743d64f4ad9205ef", "class_name": "RelatedNodeInfo"}}, "text": "List of Contributors                                                         Chapter 6\nDr Adesigbin Clement           Deputy Director, Head of Prevention NASCP\nDr Ijaodola Olugbenga          Assistant Director, National Officer PMTCT NASCP\nTaiwo Olakunle                 Chief Scientific Officer NASCP\nZainab E. Abdullahi            Population Programme Officer I NASCP\nDr Adeyinka Adewemimo          Senior Medical Officer I NASCP\nDr Benson Udu                  SASPC, FCT\nMrs. Hidayat Bukola Yahaya     Programme Officer Health Sector Response Support NACA\nDr Gideon Sorochi Okorie       Assistant Chief program officer/ PMTCT/HTS Focal Officer NACA\nProf. Oladapo Shittu           Chairman, PMTCT Task Team / OBY/GYNAE ABUTH Zaria\nProf. Solomon Sagay            Member PMTCT Task team / OBY/GYNAE JUTH Jos\nProf Anteinette Ofili          Public Health Physician, UBTH Benin\nProf. Oliver Ezechi            Director of Research, NIMR Lagos\nDr Idowu Adebara               Consultant OBY/GYN, FTH Ido Ekiti\nDr Stephen B. Bature           Member PMTCT Task Team / OBY/GYN, BDTH/KASU Kaduna\nDr Chinyere Ukamaka Onubogu    Paediatrician, NAUTH, Nnewi\nDr Benjamin Aiwondagbon        WHO\nDr Ochola-Odonga Dorothy       Health & HIV Section UNICEF\nDr Victoria Isiramen           Health Manager UNICEF\nDr Idayat Uthman               National Program Officer UNAIDS\nDr.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1358, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7625cd1f-1d8d-475a-aa15-a82a2b923a5d": {"__data__": {"id_": "7625cd1f-1d8d-475a-aa15-a82a2b923a5d", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "114"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "f6dffcce-0d98-40c0-99de-73a85289bf80", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "114"}, "hash": "1aa5e3a85b92dc7c3288632abafa9da9bd65eb0e870c97a8e018430c74df65fa", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f4750933-4805-426e-802b-cb796833d767", "node_type": "1", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "114"}, "hash": "3689fb7005b86e8c398dff27e3d2c15f83d8454887c774f9f6ed593d6f94b657", "class_name": "RelatedNodeInfo"}}, "text": "Efuntoye Adeola Tim        Senior Specialist PMTCT, CDC\nBennett Okechukwu Urama        Forecasting and Supply Planning Advisor GHSC-PSM\nDr Chris Obanubi               Programme Manager USAID\nLilian Anomnachi               Deputy Program Director CHAI\nDr Andrew Etsetsowaghan        Technical Director FHI360\nDr Omoregie Godpower           Head/Practice Lead, HIV and TB SFH\nDr Amalachukwu Ukaere          Program Director SFH\nHalima Ibrahim                 Program Manager SFH\nMrs Ehi Adejo-Ogiri            Gender Officer/POC JHPIEGO\nOgochukwu Ginigeme             ICAP\nDr Helen Omuh                  Deputy Director IHVN\nRuth Dauda Akolo               Welfare - Deputy ASWHAN\nChinwe Aganekwu                Coordinator, FGI CISHAN\nAbang Roger                    Director of Programs Heartland Alliance\nMwoltu Nanribet Gabriel        Mental Health Technical Advisor Heartland Alliance\nAkanji Michael O               Key Populations Advisor Heartland Alliance\n          NATIONAL GUIDELINES FOR HIV PREVENTION TREATMENT AND CARE 2020        92", "mimetype": "text/plain", "start_char_idx": 1359, "end_char_idx": 2401, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2246a2be-d002-48ac-8b2c-8afde8a192ba": {"__data__": {"id_": "2246a2be-d002-48ac-8b2c-8afde8a192ba", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "115"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "a94b168c-0793-4138-934a-9034fa792009", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "115"}, "hash": "58389a3c2b9aeebc1acd09680bef7e0005a58a6a86ac4f645c82903ff5da528b", "class_name": "RelatedNodeInfo"}}, "text": "7. PREVENTIVE\n        MANAGEMENT IN HIV\nWhat\u2019s Inside:\n 1.1 Objectives of the Guidelines\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026..\n7.1 Introduction\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026..\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026......94\n 1.2 Epidemiology of HIV in Nigeria\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\n7.2 Pre-Exposure Prophylaxis\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026.\u2026\u2026\u2026.....95\n 1.3 Natural History of HIV\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026.\u2026\u2026\n7.3 Post-Exposure Prophylaxis\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026.\u2026\u2026\u2026...99\n7.4 Post-Sexual Assault Exposure Prophylaxis\u2026\u2026\u2026\u2026\u2026\u2026\u2026.102\n7.5 Interventions for Key Populations\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026...104\n7.6 Condom availability and promotion for\n  HIV programme\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026.\u2026\u2026\u2026\u2026\u2026\u2026......105\n7.7 Gender-Based Violence\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026.\u2026\u2026\u2026.......106\n7.8 Management of Sexually\n  Transmitted Infections (STIs)\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026.\u2026....108\n7.9 Prevention for Adolescent and Young\n  Persons (AYPs)\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026.\u2026\u2026\u2026..\u2026\u2026.........109", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 741, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8c95c435-ecae-458f-b93b-2a8e3e355ad5": {"__data__": {"id_": "8c95c435-ecae-458f-b93b-2a8e3e355ad5", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "116"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "22135a79-2828-4b0e-a1bf-3f86d8e82561", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "116"}, "hash": "79fb1c13859bd9f1efef5ac4526b28318bd5d344ef077d05ab4487ada98985be", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d258e18e-5dad-4b58-8cfb-1b6d4369fb47", "node_type": "1", "metadata": {}, "hash": "b549521fb7fa1653a5e593f36dfa6b5816f27d3385372fd46f7cee5b854a23fe", "class_name": "RelatedNodeInfo"}}, "text": "7.1 Introduction\nPreventive management of HIV is a broad term for different interventions that protect\nindividuals from contracting/transmitting HIV infection. It also includes interventions that\nprotect the HIV positive individual from common opportunistic infections (OIs) including\ntuberculosis. It is recommended that all persons who come in contact with health services should\nbe allowed access to any combination of HIV prevention interventions most suitable to their\nneeds. The necessity for the simultaneous employment of different approaches and intervention\ntypes for the prevention of HIV infection has led to the concept of combination prevention.\n7.1.1 Combination prevention / Minimum Prevention Package Intervention (MPPI)\nThe National Prevention Plan (NPP) 2010-2012 introduced the combination prevention\napproach, locally called the \u201cMinimum Prevention Package Intervention\u201d (MPPI), which are\ndefined prevention intervention packages that address the drivers of the epidemic. The package\nemphasized dosage and intensity and promoted ownership and sustainability. The MPPI is\ndefined as, \u201cthe strategic, simultaneous use of different classes of prevention activities\n(biomedical, behavioural, structural) that operate on multiple levels (individual, community and\nstructural), to respond to the specific needs of particular audiences and modes of HIV\ntransmission, and to make efficient use of resources through prioritization, partnership, and\nengagement of affected communities\u201d (UNAIDS Prevention Reference Group Definition).\nBehavioural interventions include a range of behaviour change communication activities\ndesigned to promote HIV risk-reducing and protective behaviours. These activities span, and\noften combine, mass media, community mobilization, advocacy and interpersonal\ncommunication (IPC) such as one-to-one or one-to-group educational activities. Social media\nand mobile technology are important tools that should be integrated into HIV prevention\nprogrammes and is particularly critical in informing about and providing prevention services to\nkey populations.\nBiomedical interventions include several medical interventions that can prevent HIV infection,\nreduce transmission, and/or reduce the risk of infection. These are interventions that directly\ninfluence the biological systems through which the virus infects a new host, such as preventing\ninfection (e.g., male and female condoms), reducing transmission (e.g., ART as prevention), or\nreducing acquisition/infection risk.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2513, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d258e18e-5dad-4b58-8cfb-1b6d4369fb47": {"__data__": {"id_": "d258e18e-5dad-4b58-8cfb-1b6d4369fb47", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "116"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "22135a79-2828-4b0e-a1bf-3f86d8e82561", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "116"}, "hash": "79fb1c13859bd9f1efef5ac4526b28318bd5d344ef077d05ab4487ada98985be", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8c95c435-ecae-458f-b93b-2a8e3e355ad5", "node_type": "1", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "116"}, "hash": "0b6133c3c3053150db928aba1236caf3e7b368d2e26695cda6320d2071454447", "class_name": "RelatedNodeInfo"}}, "text": "These interventions include correct and consistent use of\nmale and female condoms and lubricants, HIV testing and counselling, PMTCT, STI diagnosis\nand treatment,ARV for PrEP and PEP, microbicides, and vaccines.\nStructural interventions are strategies recommended for change in social, legal, political and\neconomic factors that increase vulnerability to HIV. These interventions address stigma and\ndiscrimination, legal and human rights violations, gender-based violence and inequality. They\nare also designed to support income-generating activities, promote the integration referral,\nadherence and retention in health services.\nEffective implementation of combination prevention in the country will require political\ncommitment and leadership, programme coordination and management, partnerships and\ncollaboration, adequate HR, advocacy, community and social mobilization, functional\ncommodity supply management systems, M&E and research.\n           NATIONAL GUIDELINES FOR HIV PREVENTION TREATMENT AND CARE 2020           94", "mimetype": "text/plain", "start_char_idx": 2514, "end_char_idx": 3541, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ad334e33-ebbf-4993-9877-5ad41b3db1cb": {"__data__": {"id_": "ad334e33-ebbf-4993-9877-5ad41b3db1cb", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "117"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "3fa149b1-5966-4c8b-a44a-c6d042800518", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "117"}, "hash": "0b84588e9a46a2df0c3171efeb6db8777f7dc1b9a06b7ca4ad213712f91bbfa4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f7b89b43-017c-4efc-b877-380025035b56", "node_type": "1", "metadata": {}, "hash": "f828a546a64133a567efd5132accc75f90627cb79ca21a7fe5a8f91c64d16e32", "class_name": "RelatedNodeInfo"}}, "text": "7.2 Pre-Exposure Prophylaxis\nPre-exposure prophylaxis (PrEP) is the pre-emptive use of ARVs to reduce the probability of\nHIV negative individuals acquiring HIV infection, especially in persons who are deemed at\nsubstantial risk.\nRationale: A systematic review and meta-analysis of oral PrEP trials using TDF-based ARV\ndrug combinations demonstrated that daily oral PrEP is effective in reducing the risk of acquiring\nHIV infection. The level of protection did not differ by age, sex, mode of acquiring HIV (rectal,\npenile or vaginal exposure).\n7.2.1 Criteria for PrEPinitiation\nThe criteria for PrEP initiation are as follow:\n    \u00a7   HIV seronegative\n    \u00a7   No suspicion of acute HIV infection\n    \u00a7   Asubstantial risk of HIV infection\n    \u00a7   Urinalysis to rule out proteinuria\n    \u00a7   Willingness to use PrEP as prescribed\n7.2.2 PrEPminimum package\nThe PrEP minimum package of services includes:\n    1.  HIV testing and counselling, including index testing, self-testing and couple testing\n    2.  eGFR* and monitoring of kidney function\n    3.  Hepatitis screening\n    4.  Comprehensive HIV prevention including risk-reduction counselling and\n        condom/lubricant distribution\n    5.  Assessment of need for contraceptives and/or pregnancy testing\n    6.  Sexually Transmitted Infection screening, diagnosis and treatment\n    7.  Screening for NCDs, such as diabetes mellitus and hypertension\n    8.  Referral for services for gender-based violence, legal aid services, or mental health\n        issues identified during counselling\n    9.  Adherence assessment and counselling, help identify possible barriers to good\n        adherence\n7.2.3 PrEPeffectiveness\nWhen used as directed, PrEP can reduce the risk of HIV among at-risk individuals by more than\n90%. PrEP can be more effective if it is combined with other HIV prevention mechanisms such\nas condom use, drug abuse treatment and harm reduction services for people living with HIV.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1946, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f7b89b43-017c-4efc-b877-380025035b56": {"__data__": {"id_": "f7b89b43-017c-4efc-b877-380025035b56", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "117"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "3fa149b1-5966-4c8b-a44a-c6d042800518", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "117"}, "hash": "0b84588e9a46a2df0c3171efeb6db8777f7dc1b9a06b7ca4ad213712f91bbfa4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ad334e33-ebbf-4993-9877-5ad41b3db1cb", "node_type": "1", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "117"}, "hash": "b5692b8f6738160bd794f25c855343b5f62e54bdd1b09f9debdfc17764471bbb", "class_name": "RelatedNodeInfo"}}, "text": "PrEP can be more effective if it is combined with other HIV prevention mechanisms such\nas condom use, drug abuse treatment and harm reduction services for people living with HIV.\n7.2.4Approved drugs for PrEP\nThe preferred drug regimen for PrEP is the combination of daily TDF + FTC / TDF + 3TC. The\nalternate regimen for PrEP is a daily dose of TDF.\n* Urinalysis should be offered as baseline screening when eGFR results are delayed, or when eGFR is not available in the health care facility.\nWaiting for eGFR result should not delay initiation of PrEP. However, if urinalysis is not normal, PrEP initiation should be delayed until\ncreatinine results come back. eGFR should be performed at 6 months, followed by annual screening.\n           NATIONAL GUIDELINES FOR HIV PREVENTION TREATMENT AND CARE 2020              95", "mimetype": "text/plain", "start_char_idx": 1768, "end_char_idx": 2587, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0e6b8c23-d409-4e25-921a-b6696859794f": {"__data__": {"id_": "0e6b8c23-d409-4e25-921a-b6696859794f", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "118"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "31b9b619-a63b-4330-96dc-4acb6d789f23", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "118"}, "hash": "83442ba062374e9575c5ec05131d76846a0527a9b08ed7a103d86a4fa5d06fc3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f1a51a60-1f60-4511-9e5f-e2edaed13c49", "node_type": "1", "metadata": {}, "hash": "ba94ff24c009eb0acb7cdea4d9c48317fbc8aa026cdf7b93e022c6d1904ca9c8", "class_name": "RelatedNodeInfo"}}, "text": "7.2.5 PrEPadministration guidance\nPrEP must be prescribed by a healthcare professional who has completed training on the\nNational Guidelines for the use of ARVs for PrEP. Daily PrEP should be used during periods of\nsubstantial risk of HIV acquisition and can be stopped during periods of low or no risk. The\ncategory of individuals prioritized for PrEP are listed below;\n   1.    Sero-discordant couples/partners\n   2.    Sex workers\n   3.    People who inject drugs (PWID)\n   4.    Individuals who engage in anal sex on a prolonged and regular basis\n   5.    Sexually exposed adolescents and young people\n7.2.6 Daily PrEPand Event-Driven PrEP\nThere are two options for the dosing frequency of PrEP: daily dosing and event-driven dosing.\nDaily dosing is recommended for men, women and transgender people. Event driven PrEP is\nONLY recommended for MSM.\nDaily dosing is the provision of PrEP given as 1 tablet daily. People must take their PrEP for 7\nconsecutive days before drug levels are high enough to prevent HIV infection. Daily dosing with\na single pill should be sustained throughout the period of HIV risk for as long as substantial risk is\nongoing. Those wanting to stop PrEP should continue taking the single pill daily dose for 28 days\nafter the last HIV exposureas\nEvent-driven PrEP (ED-PrEP) is only recommended for men who have with men. The first dose\nof 2 pills (TDF/FTC or TDF/3TC), called the loading dose, should be taken between 2 and 24\nhours prior to exposure. The second dose (after sex) is a single pill taken 24 hours after the first\ndose. The third dose is a single pill taken 24 hours after the second dose. ED-PrEP has been\ndescribed as \u201c2+1+1\u201d dosing. This 2+1+1 dosing is the only ED-PrEP regimen that has been\ndemonstrated to be effective. The 2+1+1 dosing describes ED-PrEP when an isolated act of sex is\ninvolved.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1845, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f1a51a60-1f60-4511-9e5f-e2edaed13c49": {"__data__": {"id_": "f1a51a60-1f60-4511-9e5f-e2edaed13c49", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "118"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "31b9b619-a63b-4330-96dc-4acb6d789f23", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "118"}, "hash": "83442ba062374e9575c5ec05131d76846a0527a9b08ed7a103d86a4fa5d06fc3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0e6b8c23-d409-4e25-921a-b6696859794f", "node_type": "1", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "118"}, "hash": "0d521de0ecbb91c88cb20166b38058fa69c0717c89c0d89f89232b2cb8a50b81", "class_name": "RelatedNodeInfo"}}, "text": "The 2+1+1 dosing describes ED-PrEP when an isolated act of sex is\ninvolved. If more sex acts take place over the following days, a single PrEP pill can be continued\ndaily for as long as sex continues, with a single daily pill taken for the next two days after the last\nsex act.\n7.2.7 PrEPfor Serodiscordant Couples\nHIV transmission occurs among sero-discordant couples. Where additional HIV prevention\nchoices are needed for sero-discordant couples, daily oral PrEP may be considered as a possible\nadditional intervention for the uninfected partner. PrEP can be discontinued by the uninfected\npartner when the infected partner has achieved viral load suppression and are adhering to their\nARVs.\n7.2.8 Settings Where PrEPcan beAccessed\nPrEP implementation can be integrated into any setting that meets the conditions for initial\nevaluation and initiation including:\n    \u00a7   One-Stop-Shop (OSS) for KPs (including community and facility settings)\n    \u00a7   HIV clinics\n    \u00a7   ANC/MNCH/RH and STI clinics\n    \u00a7   Community settings meeting the criteria for initial client assessment and evaluation e.g.\n        integrated prevention centres\n    \u00a7   Adolescent and youth-friendly outlets.\n          NATIONAL GUIDELINES FOR HIV PREVENTION TREATMENT AND CARE 2020             96", "mimetype": "text/plain", "start_char_idx": 1770, "end_char_idx": 3041, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6d91b42b-6348-47a1-94a9-51cbd00386c9": {"__data__": {"id_": "6d91b42b-6348-47a1-94a9-51cbd00386c9", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "119"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "6a0b6008-5a87-4a22-b09b-f557910361b3", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "119"}, "hash": "4e952d806eb61bf1e9509bdff11c96063a051cce77fbf284265a89994a2d6822", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cbb0087f-08a9-4dd6-b133-1cfd8d04bbf0", "node_type": "1", "metadata": {}, "hash": "15037002631471d2d4d97742afdcac32926fe2f44bb1a778193cb2adae7c49cf", "class_name": "RelatedNodeInfo"}}, "text": "Table 7.1: Services provided by cadre\n    Human resource cadre                 Services Provided\n  Doctors                                 Risk screening, clinical eligibility assessment, counselling,\n                                          initiation, prescriptions and follow up reviews\n  Nurses                                 Counselling and refills\n  Pharmacists                             Dispensing PrEP drugs, counselling on adherence and side effects\n  Laboratory Scientists/Technicians      Conducting laboratory tests and providing results\n  HTS Counsellors                        Counselling and risk screening, laboratory samples (if trained as a\n                                          phlebotomist)\n  Community and facility support          Demand creation, health education, counselling and risk\n  cadres (i.e. expert clients, Outreach  screening, appointment reminders and follow up\n  Workers, peer educators)\n 7.2.9 Contraindications for PrEP\n PrEP should NOT be provided to people with:\n    \u00a7    HIV positive test on the day of PrEP initiation using   Box 7.1. Sign and symptoms of AHI\n         the Nigeria national HIV testing algorithm\n    \u00a7    Known exposure to HIV in the past 72 hours                 Fever 38.38C or 101 F\n         (requires PEP)                                             Swollen lymph glands\n    \u00a7    Signs ofAcute HIV Infection (AHI) (Box 7.1)                Fatigue/Malaise\n         (Defer PrEP and consider PEP counselling for               Skin rash\n         clients with a history of high-risk unprotected sex in     Headache\n         the past three days, even in the absence of symptoms       Sore throat\n         ofAHI).                                                    Muscle or joint pains\n    \u00a7    Aclient unable to commit to PrEP adherence, and to         Nausea or vomiting\n         attend scheduled PrEP visits                               Diarrhoea\n    \u00a7    Drug allergy to TDF or FTC                                 Sweats\n    \u00a7    eGFR < 60 ml/min\n    \u00a7    Concurrent nephrotoxic medication\n 7.2.10 Client follow-up\n Once on PrEP, clients should return after one month to assess and confirm HIV-negative test\n status, assess for early side effects, discuss any difficulties with medication adherence, and any\n other client concerns. Follow-up should be every 3 months from the initiation visit.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2362, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cbb0087f-08a9-4dd6-b133-1cfd8d04bbf0": {"__data__": {"id_": "cbb0087f-08a9-4dd6-b133-1cfd8d04bbf0", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "119"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "6a0b6008-5a87-4a22-b09b-f557910361b3", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "119"}, "hash": "4e952d806eb61bf1e9509bdff11c96063a051cce77fbf284265a89994a2d6822", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6d91b42b-6348-47a1-94a9-51cbd00386c9", "node_type": "1", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "119"}, "hash": "cac5c3f01a3c1516bda0a12c8292574f742151a0632b9a9aae07700dc58eac5a", "class_name": "RelatedNodeInfo"}}, "text": "Follow-up should be every 3 months from the initiation visit. Table 7.2\n outlines the procedures for each of the follow-up visits.\n           NATIONAL GUIDELINES FOR HIV PREVENTION TREATMENT AND CARE 2020                 97", "mimetype": "text/plain", "start_char_idx": 2301, "end_char_idx": 2524, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0b169dee-4f40-401a-8764-416dbcb435ba": {"__data__": {"id_": "0b169dee-4f40-401a-8764-416dbcb435ba", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "120"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "502ad679-242f-4d03-8e19-4e1083741658", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "120"}, "hash": "674a122fd035417d09664a2726c5a17f4d0919460508d75694e31ae8d44012af", "class_name": "RelatedNodeInfo"}}, "text": "Table 7.2. Follow-up visits procedures\n           Visit                                         Procedure\n Visit 2 (Month 1)          \u00b7   Safety monitoring clinical assessment\n Counsellor/Clinician       \u00b7   HIV testing and counselling\n Visit                      \u00b7   Adherence and risk reduction counselling\n                            \u00b7   Offer HBV vaccination if available and HBsA gnegative (follow\n                                HBV vaccination schedule complete series)\n Visits for Months 3, 9,   \u00b7   HIV testing and counselling\n 15                        \u00b7   HIV risk assessment for PrEP continuation\n                           \u00b7   Adherence and risk reduction counselling\n                           \u00b7   Assess for adverse drug reactions\n Visits for  Months 6,     \u00b7   HIV testing and counselling\n 12, 18, 24, 36            \u00b7   Creatinine and eGFR *\n                           \u00b7   HIV risk review and assessment for PrEP continuation\n                           \u00b7   Adherence and risk reduction counselling\n                           \u00b7   Assess for adverse drug reactions\n Unscheduled visits: as    \u00b7   Determine if the reason for the visit is PrEP related or not e.g adverse\n per need.                     events\n                           \u00b7   Assess and manage the reason for the unscheduled visit according to\n                               national guidelines e.g. acute or chronicillnesses, worsening existing\n                               conditions\n                           \u00b7   Provide HIV risk reduction and PrEP adherence counselling\n                           \u00b7   Agree on follow up schedule\n During every visit\n Remind PrEP users on the dosage of PrEP needed to achieve adequate levels of the ARVs in tissues to be\n effective and importance of adherence. During these window periods, safer sex practices should be\n encouraged (including abstinence and condoms).\n Management of clients with inconclusive HIV test result during follow-up visits\n For non-pregnant or lactating clients:\n     \u00b7   Discontinue PrEP\n     \u00b7   Follow the national HIV testing algorithm for clients with an inconclusive result.\n     \u00b7   Only after a confirmed HIV negative result, can the client continuewith PrEP\n     \u00b7   Offer risk reduction counselling and strongly emphasize the importance of condom use during the\n         period with inconclusive HIV test results (e.g. new infection is highly infectious)\n*creatinine clearance should be performed at 6 months, followed by annual screening.\n           NATIONAL GUIDELINES FOR HIV PREVENTION TREATMENT AND CARE 2020                    98", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2586, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "100320dd-6521-475e-a469-ea2de2f092d9": {"__data__": {"id_": "100320dd-6521-475e-a469-ea2de2f092d9", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "121"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "1da58ef8-8c2e-4a86-885f-06ad61b0456e", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "121"}, "hash": "1ffce136df5f8562bec65f20c67e6c17a6ed7ecbda3e9d92a49535135e6b9cd0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0eb0f91e-fca4-41cb-bfbc-e734507d1697", "node_type": "1", "metadata": {}, "hash": "964703c3204d72f734b6ad316e9099655333af5dfccaf1c1be226ead28618cca", "class_name": "RelatedNodeInfo"}}, "text": "7.2.11 PrEPdiscontinuation\nIdeally, clients should inform their service provider when they want to discontinue PrEP. Health\ncare workers should discuss the options of when to discontinue PrEP with their clients. PrEP can\nbe stopped for the following reasons:\n    \u00a7   Client request\n    \u00a7   Positive HIV test (clients who seroconvert while on PrEP should be linked to care and\n        initiated onART in line with national guidelines)\n    \u00a7   Safety concerns, such as eGFR <60mls/min\n    \u00a7   No longer at substantial risk\n    \u00a7   Persistent side effects\nDocumentation for persons on PrEP should be as rigorous as for person who are on ART. Upon\ndiscontinuation of PrEP, the following information should be documented:\n    \u00a7   HIV status at the time of discontinuation\n    \u00a7   Reasons for discontinuation\n7.3 Post-Exposure Prophylaxis\nPost-Exposure Prophylaxis (PEP) is the short-term use of ARVs to prevent HIV infection in\npersons accidentally exposed to a potential risk of acquiring HIV infection. This applies usually\nto accidental exposure to HIV either in the course of legitimate work as could occur among\nhealth workers who are vulnerable to needle stick injuries or contact with infectious body fluids.\nIt also applies to sexual assault victims especially in cases where the HIV status of the perpetrator\ncannot be readily determined.\nIt is recommended that PEP for HIV infection should be offered and initiated as early as possible\nin all individuals with an exposure that has the potential for HIV transmission, as soon as\npossible within 72 hours.\n7.3.1 Post-Exposure Prophylaxis for Occupational HIV exposure\nNeedlestick injuries are major risks for HIV transmission in the workplace. The risk of\ntransmission is greatly increased if associated with deep injury, visible blood on the sharp\ninstrument, procedures involving a needle placed in the source patient's blood vessel, virally\nunsuppressed patients and terminal illness in the source patient.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1962, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0eb0f91e-fca4-41cb-bfbc-e734507d1697": {"__data__": {"id_": "0eb0f91e-fca4-41cb-bfbc-e734507d1697", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "121"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "1da58ef8-8c2e-4a86-885f-06ad61b0456e", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "121"}, "hash": "1ffce136df5f8562bec65f20c67e6c17a6ed7ecbda3e9d92a49535135e6b9cd0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "100320dd-6521-475e-a469-ea2de2f092d9", "node_type": "1", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "121"}, "hash": "d7e3955d3432032f0ae9a5d2dd510638d4fb128a985e164148d2fa870ad17622", "class_name": "RelatedNodeInfo"}}, "text": "The following types of exposures may pose the risk of HIV transmission for health workers and\nshould be considered for PEP:\n    \u00a7   Needlestick injury or injury with a sharp object that has been used on an HIV positive\n        patient\n    \u00a7   Mucosal exposure of the mouth, eye, or nose by splashing infectious body fluids\n    \u00a7   Broken skin exposed to blood, blood stained body fluids, or other infectious body fluids\n        (breast milk, genital secretions, cerebrospinal, amniotic, peritoneal, synovial,\n        pericardial and pleural fluids).\nSteps to take following a needle-stick injury or mucosal exposure:\nIn the event of an injury with a sharp object such as a needle or scalpel that has been used on a\npatient or in the event of a mucous surface being in contact with blood or secretions from a\npatient, the following steps should be followed:\n    \u00a7   Do not squeeze, suck or rub the injury site\n          NATIONAL GUIDELINES FOR HIV PREVENTION TREATMENT AND CARE 2020              99", "mimetype": "text/plain", "start_char_idx": 1963, "end_char_idx": 2960, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "35776140-6314-4d8a-9b73-2df8ab54bb72": {"__data__": {"id_": "35776140-6314-4d8a-9b73-2df8ab54bb72", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "122"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "97a17099-6991-4c98-81f7-99105971fe95", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "122"}, "hash": "4142d0dc0c84435d95624132ddfcc6c3df90f5425a5fcbb547eccbe7b892372a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e0c98463-de1e-400d-8f18-cd4a8cec5f31", "node_type": "1", "metadata": {}, "hash": "1ee125afb467973032e00bdda4a472c35d43d55f4876f793e6c34428565703f0", "class_name": "RelatedNodeInfo"}}, "text": "\u00a7    Allow blood or secretion to flow freely\n   \u00a7   Wash exposed area well immediately with soap and running water or antiseptic solutions\n       such as 2% polyhexidine or 70% glutaryladehyde.\n   \u00a7   After a splash to the eye or any other mucous surface, irrigate/rinse the exposed area\n       immediately with water (preferably running water) or normal saline\n   \u00a7   Report the exposure to a senior member of staff, supervisor or the PEP officer\n   \u00a7   If eligible, giveARV drugs recommended for PEP immediately possibly within 1 hour\n       and at the latest within 72 hours of the exposure (persons presenting after 72 hours of the\n       exposure should also be considered for PEP).\n7.3.2 Evaluation for Post-Exposure Prophylaxis\nEvaluating exposed person's eligibility for HIV PEP involves assessing the following:\n   \u00a7   Timing of the potential exposure\n   \u00a7   HIV status of exposed person\n   \u00a7   The nature and risk of the exposure\n   \u00a7   HIV status of the source of the potential exposure\n7.3.4 Determination of Risk andARV drugs for PEP\nThe exposure should be classified as \u201clow risk\u201d or \u201chigh risk\u201d for HIV infection as below:\n Low Risk:                                       High Risk:\n \u00a7   Solid needle or superficial exposure on     \u00a7  Large bore needle, deep injury, visible blood\n     intact skin                                    on device, needle in patient artery/vein\n \u00a7   Small volume (drops of blood) on mucous     \u00a7  Large volume (major blood splash on mucous\n     membrane or non -intact skin exposures         membrane or non -intact skin exposures)\n \u00a7   Source is asymptomatic or viral load <1000  \u00a7  Source patient is symptomatic, in acute\n     copies/ml                                      seroconversion and has high viral load (>\n                                                    1000 copies/ml)\n7.3.5 Recommendations for PEP\n   \u00a7   Immediately after exposure to HIV, all exposed individuals should take a 3drugARV\n       combination for PEP.\n   \u00a7   The chosen regimen should be continued for 28 days or until the result of the HIV test for\n       the source patient is known to be negative.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2125, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e0c98463-de1e-400d-8f18-cd4a8cec5f31": {"__data__": {"id_": "e0c98463-de1e-400d-8f18-cd4a8cec5f31", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "122"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "97a17099-6991-4c98-81f7-99105971fe95", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "122"}, "hash": "4142d0dc0c84435d95624132ddfcc6c3df90f5425a5fcbb547eccbe7b892372a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "35776140-6314-4d8a-9b73-2df8ab54bb72", "node_type": "1", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "122"}, "hash": "298ffe5e9d1952a0ec2d02c561a5a30a79e05d69262803c73b4c3b8d92c5aadf", "class_name": "RelatedNodeInfo"}}, "text": "\u00a7   The chosen regimen should be continued for 28 days or until the result of the HIV test for\n       the source patient is known to be negative.\n   \u00a7   Enhanced adherence counselling and support (psychosocial, mental, etc.) should be\n       provided for PEP users\n   \u00a7   If the preferred regimen is not available, it is better to administer an alternative regimen\n       than to wait.\n          NATIONAL GUIDELINES FOR HIV PREVENTION TREATMENT AND CARE 2020              100", "mimetype": "text/plain", "start_char_idx": 1980, "end_char_idx": 2455, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4e1cd198-b704-460e-8d0d-7631ac8bc072": {"__data__": {"id_": "4e1cd198-b704-460e-8d0d-7631ac8bc072", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "123"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "de82a231-70c6-4856-96d5-2a1fd1de9e0a", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "123"}, "hash": "3693f35430f8e4200bb77e12df650ee628d92a31e3ba1c7e949dd74303241a4e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2b03485e-3474-4fb1-9f1f-59598bd9b704", "node_type": "1", "metadata": {}, "hash": "a8fbe6fc1a33adae770426e72d98516c3d2f8c318b6e5c7ac8236886c46d0593", "class_name": "RelatedNodeInfo"}}, "text": "Table 7.3 Recommended actions following HIV testing in PEP\n  If the source person is HIV negative      \u00a7 No PEP is necessary for the exposed health worker\n                                              unless there is suspicion that the source is newly infected\n                                              and in the window period.\n  If the exposed health worker is HIV       \u00a7 No PEP is necessary\n  positive\n                                            \u00a7 The health worker should be referred for further\n                                              counselling and initiation of ART/ long - term management\n  If the health worker is HIV negative      \u00a7 Give ARV drugs for four weeks;\n  and the source patient is HIV positive    \u00a7 Repeat health worker\u2019s HIV test at 3 and 6 months after\n                                              the initial test.\n                                            \u00a7 Should the health worker seroconvert during this period,\n                                              provide appropriate care and counselling; refer for expert\n                                              opinion and long-term management.\n  If it is not possible to determine the    \u00a7 Assume that the source patient is positive and proceed\n  HIV status of the source patient            according to the guidelines above\n 7.3.6 Recommended Drug Combinations for PEP\n It is recommended that a three-drug ARV regimen should be used for PEP. TDF + 3TC (or FTC)\n is recommended as the preferred backbone regimen for HIV PEP for adults and adolescents.\n DTG or EFV are recommended as the preferred third drug for HIV PEP for adults and\n adolescents. However, where available, LPV/r, RAL, or DRV/r, can be considered as alternative\n options. If the source person is known to be on a second-line regimen or has failed first-line\n regimen, the preferred prophylaxis regimen should be \u201ca second-line regimen\u201d. If the source\n person on the second-line regimen has a detectable viral load, the prophylaxis should be a third-\n line regimen Children above 30kg should receive TDF/3TC/DTG or EFV. In children <10 years\n or less than 30kg, AZT + 3TC is recommended as the preferred backbone regimen for HIV PEP.\n Alternative backbone regimen for this age category will include ABC + 3TC or TDF + 3TC (or\n FTC). DTG is recommended as the preferred third drug for HIV PEP for children < 10 years.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2379, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2b03485e-3474-4fb1-9f1f-59598bd9b704": {"__data__": {"id_": "2b03485e-3474-4fb1-9f1f-59598bd9b704", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "123"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "de82a231-70c6-4856-96d5-2a1fd1de9e0a", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "123"}, "hash": "3693f35430f8e4200bb77e12df650ee628d92a31e3ba1c7e949dd74303241a4e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4e1cd198-b704-460e-8d0d-7631ac8bc072", "node_type": "1", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "123"}, "hash": "9df329f32a9eaecbce9d2be4f7d2a145815b10401ee3d51c7cdf7cf2fa25a17a", "class_name": "RelatedNodeInfo"}}, "text": "Alternative backbone regimen for this age category will include ABC + 3TC or TDF + 3TC (or\n FTC). DTG is recommended as the preferred third drug for HIV PEP for children < 10 years. An\n age-appropriate alternative regimen can be identified from LPV/r,ATV/r, RAL, DRV/r.\nTable 7.4 Recommended Drug Combinations for Post-Exposure Prophylaxis\n  Recommended 3-Drug ARV Combinations\n     1.  TDF/3TC/DTG (Preferred)\n     2.  TDF/3TC/EFV orAZT/3TC + EFV\n  Nevirapine should never be used for PEP as the risk of fatal hepatotoxicity outweighs the risk of HIV\n  infection.\n  Where DTG and EFV is contraindicated, either of the 2drug combinations may be combined with LPV/r,\n  RAL, or DRV/r\n Note:\n \u0178  NVP should not be used in children above the age of 2 years.\n \u0178  A 28-day prescription of antiretroviral drugs should be provided for HIV PEP following initial risk assessment.\n \u0178  Enhanced adherence counselling is suggested for individuals initiating HIV PEP\n            NATIONAL GUIDELINES FOR HIV PREVENTION TREATMENT AND CARE 2020                    101", "mimetype": "text/plain", "start_char_idx": 2198, "end_char_idx": 3248, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "35ccca7c-99bd-44db-a0d2-bcc050c6a42f": {"__data__": {"id_": "35ccca7c-99bd-44db-a0d2-bcc050c6a42f", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "124"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "1d02fefb-abe3-4ed3-86e7-26a4e79e7fbf", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "124"}, "hash": "a7882afdb569dbce5eddd7e2d4db15ea9624f7c52c7a2f54251b09d4ceb49107", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "76cc1574-73b8-4371-af21-5ff13d0074f9", "node_type": "1", "metadata": {}, "hash": "fe95f8d351619622e66a67f2490f4ce696b91e555341374b842203863cd4710e", "class_name": "RelatedNodeInfo"}}, "text": "In areas of high HIV incidence, a significant number of HIV positive individuals may be in the\n'window period' of acute infection and test antibody negative. A high level of suspicion for acute\nHIV infection should therefore be maintained and PEP continued if there is suspicion that the\nsource patient has recently been infected with HIV.\nGuidance should be given on risk reduction measures until the exposed person is known to be\nHIV negative. It is important to consider the risk of exposure to viral hepatitis when evaluating\npersons for post-exposure management.\nTable 7.5 Recommended schedules of investigations following HIV exposure\n Period                          Recommended Investigations\n Baseline                          HIV, HBV, HCV screening, FBC, LFT, Renal function test\n Two weeks                         FBC, Liver function test, Renal function test\n Six weeks                         HIV screening\n 3 months                          HIV screening\n 6 months                          HIV screening\n7.4 Post-SexualAssault Exposure Prophylaxis\nThe possibility of HIV exposure from sexual assault should be assessed at the time of the post-\nassault examination. The benefit of PEP in the prevention of HIV infection should be discussed\nwith the assault survivors if the risk of HIV exposure exists. The likelihood of the assailant being\nHIV infected, the time that elapsed after the event and any exposure characteristics that might\nincrease the risk for HIV transmission will impact the medical recommendation for PEP and the\nassault survivor's acceptance of the recommendation.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1597, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "76cc1574-73b8-4371-af21-5ff13d0074f9": {"__data__": {"id_": "76cc1574-73b8-4371-af21-5ff13d0074f9", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "124"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "1d02fefb-abe3-4ed3-86e7-26a4e79e7fbf", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "124"}, "hash": "a7882afdb569dbce5eddd7e2d4db15ea9624f7c52c7a2f54251b09d4ceb49107", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "35ccca7c-99bd-44db-a0d2-bcc050c6a42f", "node_type": "1", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "124"}, "hash": "706fa39a70e5b69f00fc201a24dcda015e346fcf36467795003f0d31f706f4bf", "class_name": "RelatedNodeInfo"}}, "text": "When an assailant's HIV status is\nunknown, the following factors should be considered in evaluating the level of risk:\n   \u00a7    Occurrence of vaginal or anal penetration\n   \u00a7    Occurrence of ejaculation on mucous membranes\n   \u00a7    Involvement of multiple assailants\n   \u00a7    Presence of mucosal lesions on the assailant or survivor\n   \u00a7    Other characteristics of the assault, survivor, or assailant that might increase the risk for\n        HIV transmission\nIf PEP is offered, the following should be discussed with the patient:\n   \u00a7    Benefits and known toxicities ofARV;\n   \u00a7    Follow-up that will be necessary\n   \u00a7    Benefit of adherence to recommendedARV dosing\n   \u00a7    Early initiation of PEP to optimize potential benefits (as soon as possible after and\n        preferably within 72 hours after the assault)\n           NATIONAL GUIDELINES FOR HIV PREVENTION TREATMENT AND CARE 2020              102", "mimetype": "text/plain", "start_char_idx": 1598, "end_char_idx": 2505, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "58afbb21-29e3-440a-a8fc-5c7191edd5fb": {"__data__": {"id_": "58afbb21-29e3-440a-a8fc-5c7191edd5fb", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "125"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "bb5420f3-411a-464d-baf1-7d0df539fd05", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "125"}, "hash": "c80ed346e99a86f9e5b839c006d2919b99c2404dbec33367730d249995c5cfcb", "class_name": "RelatedNodeInfo"}}, "text": "7.4.1 Recommendations\n   \u00a7   Athree-drugARV regimen should be used for post-sexual exposure PEP (seeART\n       Section)\n   \u00a7   As with all cases of sexual assault, it is important to arrange for continuous counselling\n       and support (psychosocial, mental and legal, etc.) for the survivor\n   \u00a7   Emergency contraception should also be provided if indicated\n7.4.2 Clinical considerations\n   \u00a7   Assessment of HBV infection status should not be a precondition for offering TDF-,\n       3TC- or FTC- based PEP, but people with established chronic HBV infection should be\n\u0178      monitored for hepatic flare after PEP discontinuation.Among people with unknown\n       HBV status and where HBV testing is readily available, people started on TDF-, 3TC- or\n       FTC-based PEP should be tested for HBV to detect active HBV infection and the need\n       for ongoing HBV therapy after discontinuing PEP\n   \u00a7   NVP should not be used for PEP among adults, adolescents and older children because of\n       the risk of life-threatening adverse events associated with HIV-negative adults using this\n       drug\n   \u00a7   DTG or EFV is widely available as a third agent, as this drug is used as part of the\n       preferred first-lineART regimen. EFV is well tolerated for treatment but has limited\n       acceptability for use as PEP, as there are concerns about giving a drug associated with\n       early neuropsychiatric adverse events to HIV-negative people who may have anxiety\n       related to HIV exposure\n   \u00a7   NVP has been widely used to prevent the transmission of HIV from mothers to HIV\n       uninfected infants and should be used for preterm babies or infants younger than two\n       weeks of age where LPV/r oral liquid cannot be used. However, because the NV\n       toxicity profile beyond infancy remains unclear, its use should be avoided in children\n       older than 2 years of age\n   \u00a7   Flow chart for the provision of care for a sexually assaulted child is shown in figure 7.1\n          NATIONAL GUIDELINES FOR HIV PREVENTION TREATMENT AND CARE 2020             103", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2077, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ac099cdb-d5ad-4961-a31a-eb8200eea9c1": {"__data__": {"id_": "ac099cdb-d5ad-4961-a31a-eb8200eea9c1", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "126"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "2f762054-3671-4809-a64e-4a4decb703a2", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "126"}, "hash": "e953ac1b60f2e67ef33289b4ea1b2c55588e3a42ede18ce1f4b521fee0f3ade0", "class_name": "RelatedNodeInfo"}}, "text": "Figure7.1. Algorithm for screening of sexual assault in children\n7.5 Interventions for Key Populations\nKey Populations (KPs) are defined groups who, due to specific high-risk behaviours, are at\nincreased risk of HIV irrespective of the epidemic type or local context. Also, they often have\nlegal and psycho-social issues related to their behaviours that increase their vulnerability to HIV.\nThe KPs are important to the dynamics of HIV transmission. In Nigeria, the various KPs makeup\nonly 3.4% of the population, yet account for around 32% of new HIV infections. Without\naddressing the needs of key populations, a sustainable response to HIV will not be achieved.\n7.5.1 Recommended comprehensive prevention package of Interventions for key\npopulations\nA combination of interventions is required to respond effectively to HIV among KPs. The\nfollowing comprehensive package of interventions is recommended to assist programming for\nHIV prevention among KPs.\n    1.  HIV prevention\n        \u00a7   Provision of condom for correct and consistent use with compatible lubricants.\n        \u00a7   PrEP should be offered as an additional prevention choice (see PrEP section for\n            guidance).\n        \u00a7   PEP should be available to all eligible people (see PEP section for guidance).\n          NATIONAL GUIDELINES FOR HIV PREVENTION TREATMENT AND CARE 2020           104", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1363, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "eab98260-9f90-49bf-9064-b8f1223f5342": {"__data__": {"id_": "eab98260-9f90-49bf-9064-b8f1223f5342", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "127"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "934015e6-7e39-400c-a5cc-9622a395898a", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "127"}, "hash": "1f9bef5ac93a52e60cd7eba9443c9b0ad5f24a955c35a037fb2b79ba452103c0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e6416993-0972-46c8-9e79-afd0df3c23c8", "node_type": "1", "metadata": {}, "hash": "82c20104a7190aa8f142d91bb61ad72d7ceb4b52ab45ab07857e9715e8e1deec", "class_name": "RelatedNodeInfo"}}, "text": "2.   HIV Testing Services\n         \u00a7   HTS including HIVST and index testing should be routinely offered to all Kps.\n    3.   Treatment as Prevention\n         \u00a7   Key populations living with HIV should have the same access to antiretroviral\n             therapy (ART) as achieving viral suppression is also key to HIV prevention.\n         \u00a7   All pregnant women from KPs should have access to PMTCT services (see PMTCT\n             section for guidance)\n    4.   Prevention, diagnoses and treatment of TB, viral hepatitis, cervical cancer screening,\n         STIs etc. (see the relevant sections for guidance)\n    5.  Routine screening and management of mental health disorders should be provided to\n         KPs\n    6.  Harm reduction for PWID: These include;\n         \u00a7   Improving access to sterile injecting equipment through needle and syringe\n             programme\n         \u00a7   Ensuring that KPs dependent on opioids should be offered and have access to\n             Opioid Substitution Therapy (OST)\n         \u00a7   Community distribution of Naloxone for overdoes management\n         \u00a7   Ensuring that KPs using harmful alcohol or other substance should have access to\n             evidence-based interventions\n7.6 Condom availability and promotion for HIV programme\nUniversally, condoms are pivotal in stemming the tide of the spread of HIV and STIs among any\npopulation. This is because they are the only known device that protects against STIs including\nHIV. Condom programming for key and general populations with latex condoms, compatible\nwith lubricants, substantially reduces the risk of HIV infection by 94% provided the condoms are\nused correctly and consistently. Condoms have in addition, contraceptive benefits hence their\npopularity as a product for dual protection (against unintended pregnancies and STIs including\nHIV).\nHowever, challenges with affordability, accessibility, availability, acceptability, perception\nincluding breakage and consistent and correct usage, have created a gap between the number of\ncondoms distributed and the amount needed for populations to protect themselves from HIV and\nSTIs. Improved condom programming can help close the gap in condom supply and use to\nreduce the spread of HIV and other STIs.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2248, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e6416993-0972-46c8-9e79-afd0df3c23c8": {"__data__": {"id_": "e6416993-0972-46c8-9e79-afd0df3c23c8", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "127"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "934015e6-7e39-400c-a5cc-9622a395898a", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "127"}, "hash": "1f9bef5ac93a52e60cd7eba9443c9b0ad5f24a955c35a037fb2b79ba452103c0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "eab98260-9f90-49bf-9064-b8f1223f5342", "node_type": "1", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "127"}, "hash": "109abd4f7f5e5598e5a75a23cdf12cf3a361bc487ab08c1c47deec0949a72796", "class_name": "RelatedNodeInfo"}}, "text": "Improved condom programming can help close the gap in condom supply and use to\nreduce the spread of HIV and other STIs.\n7.6.1 Elements of Condom Programing\nCondom programming is a strategic approach to ensure that sexually active persons at risk of\nHIV and STIs are motivated to use condoms, have access to quality condoms, and can use them\nconsistently and correctly. Thus, condom programming must address both the supply of and\ndemand (see figure 7.2) for good quality condoms as well as the environment, which is the\ncritical operating framework through which access to and use of condoms is ensured.\n           NATIONAL GUIDELINES FOR HIV PREVENTION TREATMENT AND CARE 2020            105", "mimetype": "text/plain", "start_char_idx": 2129, "end_char_idx": 2821, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6d06b256-ae19-4bed-b0fe-054b899505da": {"__data__": {"id_": "6d06b256-ae19-4bed-b0fe-054b899505da", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "128"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "ec8c0caa-a2ea-4e19-8641-274336c246d9", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "128"}, "hash": "1c2185252abc185294db03c749e1a51785e11448e39f613ab73b62f8a2f6eae4", "class_name": "RelatedNodeInfo"}}, "text": "DEMAND                             SUPPLY\n                        Target specific client groups.       Select products that appeal\n                                                             to clients and meet their needs:\n                    Identify barriers to access   CONDOM       Forecast condom needs.\n                     and use.                        USE        Procure high-quality condoms\n                    Use counselling and                         Manage inventory and use\n                    educational materials to                    accepted standards to store\n                    promote condoms at                          and transport condoms:\n                    distribution points.\n                         Build community , social;           Distribute condoms through\n                         and political support for           multiple channels\n                                                             and outlets\n                           condom use.\n Figure 7.2. Elements of condom programming\n 7.6.2 Key Steps in Condom Programing\n The goal of condom programming is to ensure that the sexually active persons at risk of STIs are\n motivated to use condoms, have easy access to quality condoms and can use them consistently\n and correctly. It addresses the supply of and demand for condoms as well as the political, socio-\n cultural, and economic environment. (see figure 7.3 below for the key steps)\n                                       141111111111\n                                         Understand condom clients\n                                          and the environment\n                            Monitor programme progress  2Assess programme\n                              and evaluate outcomes.      andcreateaction\n                                                          plan:\n                        6  Promote condoms at the community;  3procurehigh-quality condoms and\n                             district; and nationalevels_    manage the pipeline_\n                                   5   Promote condoms at\n                                       distribution points:  Expand distribution systems.\nFigure 7.3. Seven steps for condom programming for HIV prevention\n7.7 Gender-Based Violence\nGender-Based Violence (GBV), is a problem throughout the world, occurring in every society,\ncountry and region. When individuals or groups do not \u201cfit\u201d established gender\nexpectations/norms they often face stigma, discriminatory practices or social exclusion \u2013 all of\nwhich adversely affect health and increase vulnerability to HIV.\n            NATIONAL GUIDELINES FOR HIV PREVENTION TREATMENT AND CARE 2020                       106", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2685, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "09aed8ba-78be-4c77-83af-a76ef42e8df8": {"__data__": {"id_": "09aed8ba-78be-4c77-83af-a76ef42e8df8", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "129"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "28974f4c-43ba-4540-ac54-4a9fbcef2018", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "129"}, "hash": "83a1f00de221b477a6cf9db2da0c48d1a12c7b7ec1cee0492c0707197946333e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a7fc5a51-1c4c-47ed-a613-8ce989fee01f", "node_type": "1", "metadata": {}, "hash": "a697706b173fe4fd701f1e59dcbb1fc4d7118882b06cb2656456a0c68278f3b2", "class_name": "RelatedNodeInfo"}}, "text": "Ignoring gender-related barriers and its integration into HIV programs can negatively affect\nprevention efforts, service utilization, adherence and health outcomes for everyone. In line with\nthis, all health care service providers should ensure the following is implemented in health care\nsettings:\n7.7.1 GBV Prevention\n    \u00a7  Prevent risk before it begins by using evidence-based and age-appropriate approaches to\n       prevent sexual violence and any form of coercive/forced/non-consensual sex, prevent\n       early sexual debut, and support for healthy choices.\n    \u00a7  Implement activities to prevent Intimate Partner Violence (IPV), sexual violence, and\n       provide training of HCWs to deliver evidence-based violence prevention and how to\n       respond should participants in GBV prevention activities disclose an experience of\n       violence.\n7.7.2 GBV Case Identification and First-line Support Recommendations\nConduct routine clinical inquiry to actively identify cases of GBV in the following settings:\n    \u00a7  Care & Treatment,\n    \u00a7  ANC/PMTCT,\n    \u00a7  Adolescent friendly services\n    \u00a7  PrEP and PEP services\n    \u00a7  HTS\n7.7.3 GBV Clinical Response Recommendations\nProvide comprehensive and age-appropriate clinical post-GBV care that meets the expressed\nneed of survivors. Clinical care should include the following:\n    \u00a7  Providers identify survivors via routine and/or clinical enquiry duringART initiation and\n       routine clinical care.\n    \u00a7  Survivors offered support and provided with or referred to GBV clinical care\n       interventions that help improve the mental health and psychosocial functioning of\n       survivors.\n    \u00a7  Ensure that all sites delivering post-violence clinical care services provide the full\n       minimum package of post-violence care, including:\n       o    Treatment of injuries\n       o    Rapid HIV testing and counselling with linkage to treatment as needed\n       o    STI testing/screening and treatment\n       o    Post-exposure prophylaxis (PEP)\n       o    Emergency contraception\n       o    Counselling (first-line support)\n       o    Referral to non-clinical GBV response services, such as longer-term psychosocial\n            support, child protection, police, legal aid, shelter, economic empowerment, etc.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2278, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a7fc5a51-1c4c-47ed-a613-8ce989fee01f": {"__data__": {"id_": "a7fc5a51-1c4c-47ed-a613-8ce989fee01f", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "129"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "28974f4c-43ba-4540-ac54-4a9fbcef2018", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "129"}, "hash": "83a1f00de221b477a6cf9db2da0c48d1a12c7b7ec1cee0492c0707197946333e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "09aed8ba-78be-4c77-83af-a76ef42e8df8", "node_type": "1", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "129"}, "hash": "a0420a3869921abe3359a9bb28ddc5ced18e7d2a568214714497372523a5163c", "class_name": "RelatedNodeInfo"}}, "text": "\u00a7  Improve the quality of post-violence clinical care services in care and treatment sites by\n       strengthening HIV/GBV health systems and service delivery\nGBV considerations:     Providers only ask about violence in a private setting, ensuring\nconfidentiality, which requires space, thus an audio-visual private room/space should be\nconsidered and provided accordingly.\n          NATIONAL GUIDELINES FOR HIV PREVENTION TREATMENT AND CARE 2020            107", "mimetype": "text/plain", "start_char_idx": 2283, "end_char_idx": 2744, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a9520765-1317-40b9-b4c3-2e7cd628e848": {"__data__": {"id_": "a9520765-1317-40b9-b4c3-2e7cd628e848", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "130"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "78d61185-2e8c-4671-bb6e-c82de66a8652", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "130"}, "hash": "05dea75982e2659c136366d49a875daa7b436bb196c50cb5e5d246406bbc0a8b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2d14fd67-49a8-4f94-bf81-2d4bcaef52ee", "node_type": "1", "metadata": {}, "hash": "b0f3ac8b015897f2988c7f84c1944f1140efa6adcf62db9fac02713531afd640", "class_name": "RelatedNodeInfo"}}, "text": "7.8 Management of Sexually Transmitted Infections (STIs)\nGlobally, STIs / Reproductive Tract Infections (RTIs) remain a very important public health\nchallenge, and with the emergence of the HIV pandemic, it has become imperative for a more\ncoordinated approach to reduce its burden.\nA syndromic approach to the management of STIs/RTIs makes treatment accessible and\naffordable to a majority of the population because trained workers at all levels can use it as this\napproach does not require the use of sophisticated equipment, but a flow chart of symptoms\npresented by the patient and signs elicited by the health care provider is used for treatment.\nThe goal of STIs/RTIs syndromic management is not only to cure the patient but also to break the\nchain of transmission, avoid complications, patient education, partner treatment, provision of\ncondoms, diagnosis and prescription.\n7.8.1 Objectives of STIs/RTIs management\n    \u00a7   To make a correct diagnosis based on appropriate clinical assessment\n    \u00a7   To provide proper antimicrobial therapy, obtain cure, decrease infectivity and avoid\n        complications.\n    \u00a7   To reduce and prevent future high-risk behaviour\n    \u00a7   To treat sexual partners in order to break the transmission chain.\n7.8.2 Components of syndromic management\n    \u00a7   Building the capacity of the health care provider\n    \u00a7   Provision of counselling for STIs/RTIs\n    \u00a7   Identifying /treating all STIs/RTIs syndromes\n    \u00a7   Conducting risk assessment\n    \u00a7   Specific antimicrobial therapy\n    \u00a7   Partner notification\n    \u00a7   Prevention of ophthalmia neonatorum\n    \u00a7   Prevention of mother-to-child transmission of HIV\n    \u00a7   Referral to secondary/tertiary Healthcare levels for further management.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1732, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2d14fd67-49a8-4f94-bf81-2d4bcaef52ee": {"__data__": {"id_": "2d14fd67-49a8-4f94-bf81-2d4bcaef52ee", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "130"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "78d61185-2e8c-4671-bb6e-c82de66a8652", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "130"}, "hash": "05dea75982e2659c136366d49a875daa7b436bb196c50cb5e5d246406bbc0a8b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a9520765-1317-40b9-b4c3-2e7cd628e848", "node_type": "1", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "130"}, "hash": "423cac78a9f35a61886c5d4ecaff88177b1d1b5ef2bc4c8c2a8ad63a57c834fe", "class_name": "RelatedNodeInfo"}}, "text": "\u00a7   Data collection/management\n7.8.3 Prevention of STIs/RTIs\nSexually transmitted infections (STIs) and RTIs can be prevented by the following measures:\n    \u00a7   Primary preventive measures: abstinence, faithful sexual relationships, correct and\n        consistent use of condoms and vaccination\n    \u00a7   Secondary preventive measures: encouraging STI care-seeking behaviour, rapid and\n        effective treatment and case finding\n    \u00a7   Tertiary preventive measures: limitation of disability and rehabilitation including\n        psychosocial support\nThere is the risk assessment for all patients presenting with symptoms of STIs and anyone who\nfalls into two or more of the categories listed in the assessment is considered to be \u201crisk\nassessment positive\u201d and is assessed based on the flow charts that fits his/her symptoms. Below\nare flow charts that describe the steps to be taken in managing a patient with STI using the\nsyndromic approach.\n          NATIONAL GUIDELINES FOR HIV PREVENTION TREATMENT AND CARE 2020           108", "mimetype": "text/plain", "start_char_idx": 1737, "end_char_idx": 2768, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b3bea509-671c-44a5-aaf2-736887b0a21e": {"__data__": {"id_": "b3bea509-671c-44a5-aaf2-736887b0a21e", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "131"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "8f408e3c-4df0-4b5f-b86a-caacf1d2b6b6", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "131"}, "hash": "fdc9f9e1540ac4f4fb4251e63363a5b3ac373e0857a20c10b876338b3f0e29b2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1a9836bc-e4f9-4152-befd-9fbd1c51cac4", "node_type": "1", "metadata": {}, "hash": "dae43547baf689b4563a6bbdb8ac2fad4593f03593c41089b21df038bbd62cb1", "class_name": "RelatedNodeInfo"}}, "text": "7.9 Prevention forAdolescent and Young Persons (AYPs)\nAdolescents and young people are persons between 10 and 24 years of age. This age is\ncharacterized by rapid physical growth and development as well as sexual maturation. It is a\nperiod that can be marked by the need to try out new things such as sex, experiment with\ninjectable drugs as well as other drug types. As a result of engaging in these high-risk behaviours,\nthere has been an upsurge in the prevalence of HIV and other STIs in AYPs. The low social and\neconomic status of mostAYPs complicates the situation.\nAYPs make up 31% of the entire population of Nigeria. Data from the Nigeria AIDS Control\nAgency (NACA) put the prevalence of HIV at 4.2% for young people aged 15 to 24.      Forty\npercent of all reported new cases of HIV occur in young persons aged 15 to 24 which is the\nhighest when compared to other age groups.\nIn Nigeria, there are social and contextual factors that make AYP vulnerable to HIV infection.\nIdentification of the prevailing sociocultural factors in a particular community and designing\ninterventions to address them is key to success. The drivers of the epidemic pertinent to Nigerian\nAYP include multiple and concurrent sexual partnerships, intergenerational sex, sexual\ncoercion, low-risk perception, and transactional sex. Married adolescents and young women\nmay also be exposed to increased risk of HIV infections from their husbands. Exacerbating high-\nrisk behaviours are socioeconomic conditions like pervasive gender inequalities and gender-\nbased violence, poverty, unemployment or underemployment, and widespread HIV-related\nstigma and discrimination. There are also a number of traditional, religious, and cultural factors\nthat increase the risk of HIV infection and other sexual and reproductive health (SRH)\nmorbidities among young women and girls such as child and forced marriage, female genital\nmutilation, and widow inheritance. In addition, ineffective STI programming, poor integration\nof HIV and SRH services are other factors [5].", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2040, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1a9836bc-e4f9-4152-befd-9fbd1c51cac4": {"__data__": {"id_": "1a9836bc-e4f9-4152-befd-9fbd1c51cac4", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "131"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "8f408e3c-4df0-4b5f-b86a-caacf1d2b6b6", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "131"}, "hash": "fdc9f9e1540ac4f4fb4251e63363a5b3ac373e0857a20c10b876338b3f0e29b2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b3bea509-671c-44a5-aaf2-736887b0a21e", "node_type": "1", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "131"}, "hash": "a6a43b929591368f5db4a9e747f7088f83175e520ae83b79229128275c10f47d", "class_name": "RelatedNodeInfo"}}, "text": "In addition, ineffective STI programming, poor integration\nof HIV and SRH services are other factors [5].\nHIV program for AYPs in Nigeria has a goal to reduce new HIV infections and should be\ndelivered as a package of interventions for AYP in line with Minimum Prevention Package\nIntervention (MPPI).\n7.9.1 Harm Reduction program\nHarm Reduction (HR) is a range of public health policies and practices that are designed to lessen\nthe negative psychosocial and/or physical consequences associated with various human\nbehaviours, both legal and illegal. As relates to HIV, drug-related harms include overdose, drug-\nrelated deaths, blood-borne infections such as HIV, HCV, HBV and bacteremia/sepsis. HR\nprogramming in Nigeria include services such as:\n    \u00a7   Needle and syringe programmes (NSPs).\n    \u00a7   Opioid substitution therapy (OST) and other evidence-based drug dependence\n        prevention services\n    \u00a7   Use of own snorting straws and crack pipes\n    \u00a7   Peer interventions to reduce the incidence of viral hepatitis and HIV\n    \u00a7   Use of motivational techniques to increase behavioural change\n    \u00a7   Distribution of condoms and lubricants\n    \u00a7   IEC materials for PWID\n    \u00a7   Testing and management of STI, HIV, HCV, HBV\n          NATIONAL GUIDELINES FOR HIV PREVENTION TREATMENT AND CARE 2020           109", "mimetype": "text/plain", "start_char_idx": 1935, "end_char_idx": 3256, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "27c77f31-1d9b-4a23-8719-f9bcb569bf57": {"__data__": {"id_": "27c77f31-1d9b-4a23-8719-f9bcb569bf57", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "132"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "91d1cd86-050c-4a0e-bb08-d3a7c5b1f98e", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "132"}, "hash": "e774dec00ada8c2828e0d96eaf41696e456dd3f852dadd12678ef6b4d1ea426a", "class_name": "RelatedNodeInfo"}}, "text": "\u00a7   Vaccination, diagnosis and treatment of viral hepatitis\n    \u00a7   Prevention, diagnosis and treatment of other opportunistic infections (including HIV\n        and tuberculosis).\nIf scaled -up, these evidence-based harm reduction-oriented practices are known to reduce\ntransmission of blood-borne illnesses and injection related infections among PLHIV, as well as\nprevent fatal drug-related overdose and other harm associated with risky behaviours.\n7.9.2 Cervical Cancer Prevention\nCervical cancer is preventable and curable if diagnosed and treated early. The most effective\nstrategy available for primary prevention of cervical cancer is the vaccination against the HPV\naetiologic agent of cervical cancer. HPV vaccines are indicated for pre-pubertal girls and offer\nmost hope to effectively stop cervical cancer epidemic in Nigeria. HIV positive children can also\nreceive HPV vaccination because available evidence has shown that they develop sufficient\nimmune response.\nWomen living with HIV (WLHIV) have a higher risk of pre-cancer and invasive cervical cancer.\nThe risk and persistence of HPV infection increases with low CD4+ cell count and high HIV viral\nload. Cervical cancer screening leads to early detection of precancerous and cancerous cervical\nlesions that will prevent serious morbidity and mortality. WLHIV should be screened every three\nyears for evidence of precancerous changes in the cervix, regardless of whether they are taking\nART or their CD4+ cell count or viral load. All WLHIV should be screened for cervical cancer\nregardless of age.  Immediate management for precancerous and cancerous lesions should be\nprovided. For further detail, refer to the National Cervical Cancer Prevention and Control Policy.\n           NATIONAL GUIDELINES FOR HIV PREVENTION TREATMENT AND CARE 2020              110", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1824, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2bd0463f-4929-45e4-bb73-2ea09d711740": {"__data__": {"id_": "2bd0463f-4929-45e4-bb73-2ea09d711740", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "133"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "74d66383-bdab-4939-bb9c-9276fe620f20", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "133"}, "hash": "3f43c59902e53b83439a5fe9e57a2f3d9495ad6f198b77e533c9118922ad1c7b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "817a4c73-6152-4ab4-814a-e2bea8ff171d", "node_type": "1", "metadata": {}, "hash": "e60668a6d0168809884f0d67466da344e9f0b17074383578ede8ea8ee95ceead", "class_name": "RelatedNodeInfo"}}, "text": "List of Contributors                                                         Chapter 7\nDr Adesigbin Clement           Deputy Director, Head of Prevention NASCP\nDr Ijaodola Olugbenga          Assistant Director, National Officer PMTCT NASCP\nTaiwo Olakunle                 Chief Scientific Officer NASCP\nZainab E. Abdullahi            Population Programme Officer I NASCP\nDr Adeyinka Adewemimo          Senior Medical Officer I NASCP\nDr Benson Udu                  SASPC, FCT\nMrs. Hidayat Bukola Yahaya     Programme Officer Health Sector Response Support NACA\nDr Gideon Sorochi Okorie       Assistant Chief program officer/ PMTCT/HTS Focal Officer NACA\nProf. Oladapo Shittu           Chairman, PMTCT Task Team / OBY/GYNAE ABUTH Zaria\nProf. Solomon Sagay            Member PMTCT Task team / OBY/GYNAE JUTH Jos\nProf Anteinette Ofili          Public Health Physician, UBTH Benin\nProf. Oliver Ezechi            Director of Research, NIMR Lagos\nDr Idowu Adebara               Consultant OBY/GYN, FTH Ido Ekiti\nDr Stephen B. Bature           Member PMTCT Task Team / OBY/GYN, BDTH/KASU Kaduna\nDr Chinyere Ukamaka Onubogu    Paediatrician, NAUTH, Nnewi\nDr Benjamin Aiwondagbon        WHO\nDr Ochola-Odonga Dorothy       Health & HIV Section UNICEF\nDr Victoria Isiramen           Health Manager UNICEF\nDr Idayat Uthman               National Program Officer UNAIDS\nDr.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1358, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "817a4c73-6152-4ab4-814a-e2bea8ff171d": {"__data__": {"id_": "817a4c73-6152-4ab4-814a-e2bea8ff171d", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "133"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "74d66383-bdab-4939-bb9c-9276fe620f20", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "133"}, "hash": "3f43c59902e53b83439a5fe9e57a2f3d9495ad6f198b77e533c9118922ad1c7b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2bd0463f-4929-45e4-bb73-2ea09d711740", "node_type": "1", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "133"}, "hash": "50438991164fc9e49625b604d1fb1caab6f34a9de6257833b4e7886a77c65457", "class_name": "RelatedNodeInfo"}}, "text": "Efuntoye Adeola Tim        Senior Specialist PMTCT, CDC\nBennett Okechukwu Urama        Forecasting and Supply Planning Advisor GHSC-PSM\nDr Chris Obanubi               Programme Manager USAID\nLilian Anomnachi               Deputy Program Director CHAI\nDr Andrew Etsetsowaghan        Technical Director FHI360\nDr Omoregie Godpower           Head/Practice Lead, HIV and TB SFH\nDr Amalachukwu Ukaere          Program Director SFH\nHalima Ibrahim                 Program Manager  SFH\nMrs Ehi Adejo-Ogiri            Gender Officer/POC JHPIEGO\nOgochukwu Ginigeme             ICAP\nDr Helen Omuh                  Deputy Director IHVN\nRuth Dauda Akolo               Welfare - Deputy ASWHAN\nChinwe Aganekwu                Coordinator, FGI CISHAN\nAbang Roger                    Director of Programs Heartland Alliance\nMwoltu Nanribet Gabriel        Mental Health Technical Advisor Heartland Alliance\nAkanji Michael O               Key Populations Advisor Heartland Alliance\n          NATIONAL GUIDELINES FOR HIV PREVENTION TREATMENT AND CARE 2020        111", "mimetype": "text/plain", "start_char_idx": 1359, "end_char_idx": 2403, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "193ea219-1c85-4ea2-8795-0a0200488a2f": {"__data__": {"id_": "193ea219-1c85-4ea2-8795-0a0200488a2f", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "134"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "e3cd6429-e1a9-47eb-8027-38fae61e9fde", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "134"}, "hash": "25ba88765624a5b94520ab121ad97635019f0af19a0e0ce0a0d52caef85d6ed6", "class_name": "RelatedNodeInfo"}}, "text": "8. ADVANCED HIV DISEASE,\n         OPPORTUNISTIC INFECTIONS,\n             AND CO-MORBIDITIES\nWhat\u2019s Inside:\n 1.1 Objectives of the Guidelines\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026..\n8.1 Advanced HIV Disease\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026.\u2026\u2026\u2026.......113\n 1.2 Epidemiology of HIV in Nigeria\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\n8.2 Other Opportunistic Infections (OIs)\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026.......126\n 1.3 Natural History of HIV\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026.\u2026\u2026\n8.3 Preventing Opportunistic Infections (OIs)\u2026\u2026\u2026\u2026\u2026\u2026.......126\n8.4 HIV-Related Co-Morbidities\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026.\u2026.......146\n8.5 Mental Health and HIV\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026.\u2026\u2026\u2026.......146", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 513, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "02a635bd-e16b-4539-9a16-f2e3ecad7227": {"__data__": {"id_": "02a635bd-e16b-4539-9a16-f2e3ecad7227", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "135"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "3fe57bf8-6506-48ed-8f46-0045f2fff9e7", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "135"}, "hash": "1e0c015b4efa8137bbb01a51f343782f63d00d06e9beffceff7ea5b8789ff8bb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a6d380fd-9039-4be3-9e27-33d6fa885998", "node_type": "1", "metadata": {}, "hash": "d32d3b430426821a94a56117e5c6d26bd304c03c7f5f5f3fd395054531f00c6a", "class_name": "RelatedNodeInfo"}}, "text": "8.1Advanced HIV Disease\n8.1.1 Introduction\nThe morbidity and mortality associated with HIV infection have decreased over the past decade\nas access to ART has increased. Worldwide, AIDS-related deaths rose to 1.7 million in 2004 but\nhave been on a steady decline to 770,000 as at 2018 [6]. In Nigeria, there were 94,000AIDS death\nin 2003, but declined to 53,000 in 2018 [6]. Notwithstanding this progress, the decline in AIDS-\nrelated deaths appears to have plateaued in recent years. This is largely due to the persistent\nchallenge of Advanced HIV Disease (AHD) [8]. Globally, the proportion of people presenting\nwith AHD has remained largely unchanged during the past five years although the number of\npeople receiving ART in low- and middle-income countries (LMIC) has more than doubled over\nthis period. Recent estimates suggest that about 30\u201340% of people living with HIV starting ART\nin LMIC have a CD4+ cell count of < 200 cells/mm and 20% have a CD4+ cell count <100\n                                                    3\ncells/mm [9]. In some settings, up to 50% of people present to care with advanced HIV disease\n         3\n[9]. In Nigeria, 32% of patients that commenced ART in 2018 presented with advanced HIV\ndisease [9]. Similarly, data from six high volume ART sites in the country suggests that the\nburden ofAHD ranges from 16% - 50% [11].\nHIV infects the CD4+ cells leading to their destruction. The resultant immunosuppression\npredisposes the individual to severe opportunistic infections. These opportunistic infections\ninclude Tuberculosis, Cryptococcal meningitis, Oro-esophageal candidiasis, Toxoplasmosis,\nPneumocystis jiroveci pneumonia, histoplasmosis and septicemia [9]. Nigeria has the first and\nsixth highest TB burden in Africa and globally respectively [4].", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1786, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a6d380fd-9039-4be3-9e27-33d6fa885998": {"__data__": {"id_": "a6d380fd-9039-4be3-9e27-33d6fa885998", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "135"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "3fe57bf8-6506-48ed-8f46-0045f2fff9e7", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "135"}, "hash": "1e0c015b4efa8137bbb01a51f343782f63d00d06e9beffceff7ea5b8789ff8bb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "02a635bd-e16b-4539-9a16-f2e3ecad7227", "node_type": "1", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "135"}, "hash": "bbde7ac688f8b53f8b2cb4fb8b6ac5ab8d1b3a99d028626ee009937b08aba871", "class_name": "RelatedNodeInfo"}}, "text": "Nigeria has the first and\nsixth highest TB burden in Africa and globally respectively [4]. Cryptococcus and\nHistoplasmosis, initially thought not to be prevalent, are now becoming increasingly endemic in\nNigeria with more than 25,000 cases of Cryptococcus reported annually [9] and about 124 cases\nof Histoplasmosis also reported in Nigeria. These infections account for significant morbidity\nand mortality in the AHD population. Thus, the Nigerian government is committed to focusing\nefforts to ensure that those infected with HIV achieve virological suppression, minimize the risk\nof HIV transmission, prevent and treat co-morbidities, improve survival rate and ultimately\nmove Nigeria closer to ending the HIV epidemic.\nDifferentiated service delivery (DSD) is an approach that simplifies and adapts HIV services to\nbetter serve the needs of PLHIV and reduce unnecessary burdens on the health system. Under a\nDSD approach, people who are stable on treatment would have a reduced frequency of clinical\nconsultations and drug refills three monthly and in exceptional circumstances six monthly. This\nallows health service resources to focus on care for patients who are ill and need intensive\nclinical follow-up. Management of AHD is one of the DSD models which the country has now\nadopted to control the HIV epidemic.\nThe 2017 WHO guidelines on the management of AHD recommend a package of care for\nscreening, prophylaxis, rapid ART initiation and intensified adherence interventions. These are\noffered to everyone living with HIV presenting with advanced disease. The guidelines include\nan algorithm to support decision making for providing care for people with AHD. Even though\nthe 2016 Nigeria treatment guidelines also highlighted the need to provide a differentiated\npackage of care for OIs, the entityAHD was not clearly defined.\n          NATIONAL GUIDELINES FOR HIV PREVENTION TREATMENT AND CARE 2020             113", "mimetype": "text/plain", "start_char_idx": 1696, "end_char_idx": 3621, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fed4779b-e013-466c-83f5-04d6f8faabfe": {"__data__": {"id_": "fed4779b-e013-466c-83f5-04d6f8faabfe", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "136"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "3ec60722-2882-47ca-be3f-bc3755bd7a84", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "136"}, "hash": "d56b8b8e7a7ffffd51bd3f24d32d122db1c50e509ef41c6d0905e7d533c4927b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1e0954d4-5eae-4c7e-a501-83d7dda2d8c5", "node_type": "1", "metadata": {}, "hash": "17867cf575628dab06932b05249f3c65a299854ae466e921553474def9a34205", "class_name": "RelatedNodeInfo"}}, "text": "8.1.2 Definition of advanced HIV disease\n   WHO defines AHD in adults, adolescents and children older than five years as CD4+ cell count\n   <200cells/mm or WHO stage 3 or 4 event. All children younger than five years of age with HIV\n                3\nare considered as having AHD. The appearance of OIs is directly related to the extent of immune\n  deficiency; the lower the CD4+ cell count, the higher the likelihood of the appearance of OIs\n  [12]. The common OIs associated withAHD include the following:\n      \u00a7        Tuberculosis: Tuberculosis is the leading cause of morbidity and mortality among\n           PLHIV, accounting for one-third of the estimated 1.1 million people dying from AIDS-\n          related causes one-third of the estimated 1.1  million people dying from AIDS-related\n        causesglobally in 2015 [9]. Most of these TB-associated deaths (200,000 cases) occurred\n          among men [9]. TB also remains a leading cause of HIV-associated      hospitalization\n              among adults and children living with HIV worldwide. In 2017, the number of AIDS-\n           related deaths reported in Nigeria was 51,000, and 35,000 (68%) were associated with\n          TB [6]. Furthermore, 11% (12,521) out of the diagnosed 120,266 TB cases in Nigeria in\n        2019 were co-infected with HIV [13]. Factors responsible for the persistent high burden\n               of TB among PLHIV include lowART coverage, low uptake of Tuberculosis Preventive\n          Therapy (TPT) and sub-optimal diagnosis of active TB.\n      \u00a7   Cryptococcal meningitis: the incidence of cryptococcal meningitis remains substantial\n             despite the scale-up of ART [9]. A recent review estimated that there were 223,100\n        incident cryptococcal meningitis cases globally in 2014, with73% of the cases occurring\n              in sub-Saharan Africa; the annual global deaths from cryptococcal meningitis were\n         estimated to be 181,100.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1949, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1e0954d4-5eae-4c7e-a501-83d7dda2d8c5": {"__data__": {"id_": "1e0954d4-5eae-4c7e-a501-83d7dda2d8c5", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "136"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "3ec60722-2882-47ca-be3f-bc3755bd7a84", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "136"}, "hash": "d56b8b8e7a7ffffd51bd3f24d32d122db1c50e509ef41c6d0905e7d533c4927b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fed4779b-e013-466c-83f5-04d6f8faabfe", "node_type": "1", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "136"}, "hash": "89bc6e70e16f24057911f38235b9bff0f7260ff4bb6f0388880081dc1ac30dfa", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c83e71c1-7f1f-41c9-bcac-b33037dc8ed1", "node_type": "1", "metadata": {}, "hash": "5c0e86951c0ab349d339c42b96084b27011826267287a26896064da5278cff0d", "class_name": "RelatedNodeInfo"}}, "text": "Cryptococcal meningitis is a leading cause of mortality among\n         hospitalized adults living with HIV, accounting for 15\u201320% of adult deaths but is less\n                     common among children living with HIV [14]. An average global cryptococcal\n             antigenemia of 6% is reported among people with CD4+ cell count of < 100 cells/mm\u00b3\n           [14]. In Nigeria, there is an estimated 25,000 cases of Cryptococcosis annually [9].\n              Several studies from Nigeria have revealed rates of 2% 12.9% of Cryptococcus with\n           geographical variations [15]. An earlier study on cryptococcal meningitis revealed a\n            36% hospital-based frequency amongst patients presenting with neurological symptoms\n            at Jos University Teaching Hospital [16]. The 2018 WHO guidelines on the diagnosis,\n        prevention and treatment of cryptococcal disease among adults, adolescents and children\n                  summarizes the recommendations for the prevention, diagnosis and treatment of\n          cryptococcal meningitis. Pre-emptive therapy for cryptococcal antigen-positive\n          asymptomatic people is a key strategy to prevent cryptococcal meningitis.\n      \u00a7   Toxoplasmosis:          Cerebral toxoplasmosis is the most frequent cause of meningo-\n          encephalitis among adults living with HIV not receiving co-trimoxazole. Toxoplasmosis\n                   is a common protozoan infection among people with HIV. The prevalence of co-\n         infection is especially high in sub-Saharan Africa (45%), Latin America, the Caribbean\n            (49%), North Africa and the Middle East (61%) [9]. People with latent toxoplasmosis\n          infection are at risk of developing cerebral toxoplasmosis when their CD4+ cell count\n               <200 cells/mm . About 15% of hospitalized adults living with HIV died from AIDS-\n                        3\n            related illnesses were associated with cerebral toxoplasmosis [9]. The diagnosis of\n                cerebral toxoplasmosis requires imaging techniques, such as computed tomography\n               scans.", "mimetype": "text/plain", "start_char_idx": 1950, "end_char_idx": 4056, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c83e71c1-7f1f-41c9-bcac-b33037dc8ed1": {"__data__": {"id_": "c83e71c1-7f1f-41c9-bcac-b33037dc8ed1", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "136"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "3ec60722-2882-47ca-be3f-bc3755bd7a84", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "136"}, "hash": "d56b8b8e7a7ffffd51bd3f24d32d122db1c50e509ef41c6d0905e7d533c4927b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1e0954d4-5eae-4c7e-a501-83d7dda2d8c5", "node_type": "1", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "136"}, "hash": "64f11df79c5adca6a083c85001d85787ebf171bb6b33eb381abf2ff798b58467", "class_name": "RelatedNodeInfo"}}, "text": "The diagnosis of\n                cerebral toxoplasmosis requires imaging techniques, such as computed tomography\n               scans. In 2005, a study from JUTH revealed 32% prevalence of Toxoplasmosis among\n            NATIONAL GUIDELINES FOR HIV PREVENTION TREATMENT AND CARE 2020           114", "mimetype": "text/plain", "start_char_idx": 3922, "end_char_idx": 4219, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2da84c07-4ebe-4211-b5b0-fd21486d6b5a": {"__data__": {"id_": "2da84c07-4ebe-4211-b5b0-fd21486d6b5a", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "137"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "3b0b0a59-f43b-4fa0-87b7-22f81aa21f02", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "137"}, "hash": "3024771616060064bc5021a7ccbc48b9b6035e5d8eb0f999a6a514703144cf13", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5a30d31b-5559-4389-8785-720cd5dd7b54", "node_type": "1", "metadata": {}, "hash": "6d3f49f866f69c3d117b6d74945a39013533ae1a1231fbd08b2ec0c5dcdf26dc", "class_name": "RelatedNodeInfo"}}, "text": "HIV infected patients [17]. However, diagnosis was made using serological\n        technique.\n    \u00a7   Pneumocystis jiroveci pneumonia: Pneumocystis jiroveci pneumonia (PJP) is a\n        leading cause of mortality among hospitalized adults (13%) and children (29%) living\n        with HIV [18]. However, the global burden of morbidity and mortality attributable to PJP\n        is poorly characterized because appropriate diagnostic facilities are lacking in most\n        LMIC. This highlights the need for more accurate and feasible diagnostic approaches\n        and improved access to co-trimoxazole and ART. A study from Calabar revealed a 7.4%\n        prevalence of PJP among 272 known symptomatic HIV infected patients [19].\n    \u00a7   Histoplasmosis: Histoplasmosis is an AIDS-defining infection that is endemic and\n        commonly misdiagnosed as TB. The condition has been severally reported in Africa and\n        particularly in Nigeria. A recent review article revealed 470 documented cases in Africa.\n        HIV infected patients accounted for 38% of  the cases and Nigeria accounted for the\n        highest number of reported cases (124) [20]. However, most cases from Nigeria were\n        among HIV negative patient with only 4 documented cases in HIV positive Nigerian-\n        emigrant in Europe. A recent multicenter skin sensitivity screening revealed a 4.4%\n        prevalence rate of prior subclinical histoplasmosis with wide geographical variations\n    \u00a7   Severe bacterial infections:       People with AHD frequently have severe bacterial\n        infections in the bloodstream, respiratory, central nervous and gastrointestinal\n        systems.The burden of mortality and morbidity attributable to severe bacterial infections\n        is poorly characterized largely because appropriate diagnostic facilities are limited.\n        Severe bacterial infections are estimated to cause more than one-third of\n        hospitalizations among adults and children living with HIV worldwide.   It has been\n        reported that there is a 12.9% prevalence of bacterial bloodstream infection among\n        PLHIV with coagulase negative staphylococcus accounting for 58% of the patients [22].", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2198, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5a30d31b-5559-4389-8785-720cd5dd7b54": {"__data__": {"id_": "5a30d31b-5559-4389-8785-720cd5dd7b54", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "137"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "3b0b0a59-f43b-4fa0-87b7-22f81aa21f02", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "137"}, "hash": "3024771616060064bc5021a7ccbc48b9b6035e5d8eb0f999a6a514703144cf13", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2da84c07-4ebe-4211-b5b0-fd21486d6b5a", "node_type": "1", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "137"}, "hash": "029f75f96a09ad36c2aab5b6d680b5b25e890817035e8dc190ec9b8215ae4bbd", "class_name": "RelatedNodeInfo"}}, "text": "It has been\n        reported that there is a 12.9% prevalence of bacterial bloodstream infection among\n        PLHIV with coagulase negative staphylococcus accounting for 58% of the patients [22].\n        Another study from Lagos revealed 33% of bacterial bloodstream infections in HIV\n        infected population with non-typhoidal salmonella species accounting for 45.5%\n        followed by coagulase negative staphylococcus [23]. Co-trimoxazole prophylaxis\n        provides protection against some but not all severe bacterial infections.\n8.1.3 Components ofAHD package of care\n    1.  Diagnostics forAHD and associated OIs\n    2.  Prophylaxis against associated OIs withAHD\n    3.  Pre-emptive treatment for OIs associated withAHD\n    4.  Treatment of confirmed OIs associated withAHD\n    5.  ART initiation in the setting ofAHD\n    6.  Intensive adherence counselling and monitoring\n    7.  Vaccination\n8.1.4 Diagnostics forAHD and associated OIs\nThese include CD4+ cell count test required to diagnose AHD and specific tests to diagnose the\ncountry definedAHD associated OIs.\n8.1.4.1 Role of CD4+ cell count testing in the diagnosis ofAHD\nThe 2016 National treatment guidelines recommended starting ART regardless of CD4+ cell\ncount and that it should be done at baseline and every six months in addition to routine VL\n          NATIONAL GUIDELINES FOR HIV PREVENTION TREATMENT AND CARE 2020           115", "mimetype": "text/plain", "start_char_idx": 2002, "end_char_idx": 3413, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4eca5a85-55fa-4496-8876-ddee5fbf1f20": {"__data__": {"id_": "4eca5a85-55fa-4496-8876-ddee5fbf1f20", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "138"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "e6880aff-f18b-416d-a983-308d199f0a6f", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "138"}, "hash": "a0e372fac2b8c75953b7ff7a402596812b969aee5fe712b56d2888189eabd902", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5eb7decb-77d0-43b0-bec9-fa685b72edd1", "node_type": "1", "metadata": {}, "hash": "a778ef1f1e4feb5e4cd56c0bed7b300918cc9623edac3b4fda0adfe919668c55", "class_name": "RelatedNodeInfo"}}, "text": "monitoring. Relying on clinical staging alone risks missing substantial numbers of PLHIV with\n severe immunosuppression [24] . In a study from Zimbabwe, Uganda, Kenya and Malawi, close\n to half the people with CD4+ cell count <100 cells/mm were classified as having WHO clinical\n                                                     3\n stage 1 or 2 disease [24]. A five year (2005- 2010) retrospective cohort study involving over\n 14,000 patients revealed that 63% of PLHIV presented withAHD in Nigeria [25]. Despite the\n implementation of the 'test and treat' strategy, data from the national treatment program revealed\n that 32% of PLHIV presented with AHD in 2018. Consequently, it is imperative that all newly\n diagnosed PLHIV and those returning to care should have a baseline CD4+ cell count and same-\n day results obtained.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 829, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5eb7decb-77d0-43b0-bec9-fa685b72edd1": {"__data__": {"id_": "5eb7decb-77d0-43b0-bec9-fa685b72edd1", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "138"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "e6880aff-f18b-416d-a983-308d199f0a6f", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "138"}, "hash": "a0e372fac2b8c75953b7ff7a402596812b969aee5fe712b56d2888189eabd902", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4eca5a85-55fa-4496-8876-ddee5fbf1f20", "node_type": "1", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "138"}, "hash": "defe7aafa79c01e61c34f83725677194d0269aaa5d73b4dab723ca3dbb212624", "class_name": "RelatedNodeInfo"}}, "text": "Consequently, it is imperative that all newly\n diagnosed PLHIV and those returning to care should have a baseline CD4+ cell count and same-\n day results obtained.\nTable 8.1: Diagnostics for associated opportunistic infections in AHD\n  Associated OIs   Screening &           Required Sample     CD4+ Cell  Adults &  Children\n                   diagnosis                                 Count      Adolescents\n  Tuberculosis     Xpert MTB/RIF         Sputum              Any        Yes       Yes\n                   assay as the first test\n                   for TB diagnosis in\n                   symptomatic patients\n                   AFB, Xpert            Sputum/non                     Yes       Yes\n                   MTB/RIF assay         sputum (stool, CSF\n                                         and Cold Abscess)\n                   LF-LAM                Urine               Urine LF-  Yes       Yes*\n                                                             LAM assay for\n                                                             patients with\n                                                             CD4+ cell\n                                                             count <200\n                                                             cells/mm\u00b3\n  Cryptococcosis   Cryptococcal antigen  Serum, plasma or    <200  3    Yes       No\n                   (CrAg) screening      whole blood         cells/mm\n  Histoplasmosis   Histoplasma urinary   Urine               <200       Yes       Yes\n                   antigen screening                         cells/mm\u00b3\n  Pneumocystis     Giemsa stain,         Bronchial aspirate  <200       Yes       Yes\n  jiroveci         Grocott Methenamine                       cells/mm\u00b3\n  pneumonia (PJP)  Silver stain\n Adapted from WHO advanced HIV disease package of care 2018\n * Limited data available for children\n           NATIONAL GUIDELINES FOR HIV PREVENTION TREATMENT AND CARE 2020           116", "mimetype": "text/plain", "start_char_idx": 667, "end_char_idx": 2626, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cb2286b8-6bfc-42e7-ba49-82f29232984f": {"__data__": {"id_": "cb2286b8-6bfc-42e7-ba49-82f29232984f", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "139"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "57f0c827-e783-4bf9-bfb8-bbefc04b1f3a", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "139"}, "hash": "de2df93e0405162f342ae66e3a7ed64d91b3bfbe410498f0ece4e92799588352", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6ffdfbf1-737c-40c4-9de9-6b2b8482aaad", "node_type": "1", "metadata": {}, "hash": "0afa436bb1c2d7234bd3d53f1a132c6d9ecaa15d6cdb0b370fb236be307387b0", "class_name": "RelatedNodeInfo"}}, "text": "Table 8.2: Prophylaxis for AHD associated OIs\n Disease        Prophylactic    Pre-emptive        Criteria for Prophylaxis &  Target\n                Intervention    Treatment          Pre-emptive Treatment       Population\n Tuberculosis   Yes (TPT)       No                 Any CD4+ cell count value.  Adult and children\n Pneumocystis   Yes             No                 \u00b7  CD4+ cell count \u2264500     Adult and children\n jiroveci                                                     3\n pneumonia      (CPT)                                 cells/mm or WHO\n (PJP)                                             \u00b7  clinical stage 3 or 4 event.\n                                                       Any CD4+ cell count\n                                                       value in settings with\n                                                       high prevalence of\n                                                       malaria and/or severe\n                                                       bacterial infections\n Cryptococcal   No              Yes (Fluconazole   AHD                         Adult and\n Meningitis                     pre-emptive                                    adolescent\n                                therapy for CrAg\n                                positive patients\n                                without evidence of\n                                meningitis)\n8.1.5 Management of opportunistic infections inAHD\n8.1.5.1 Tuberculosis\nDiagnosis\n    \u00a7   Xpert MTB/RIF assay and TB-LF LAM are the recommended diagnostic tests for\n        PLHIV presenting with AHD\n    \u00a7   Where the above tests are not available,AFB microscopy can be used, or representative\n        samples referred to sites where Xpert MTB/RIF assay or TB-LF LAM is available\nWHO strongly recommends the use of LF-LAM to assist in diagnosing active TB among\nchildren and Adolescent living with HIV,\n    \u00a7   with signs and symptoms of TB (pulmonary and/or extrapulmonary)\n    \u00a7   with advanced HIV disease or who are seriously ill, regardless of signs and symptoms of\n        TB and with a CD4+ count <200 cells/ mm ;\n                                                   3\nProphylaxis & Treatment\n    \u00a7   Manage as in the national TB guidelines.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2234, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6ffdfbf1-737c-40c4-9de9-6b2b8482aaad": {"__data__": {"id_": "6ffdfbf1-737c-40c4-9de9-6b2b8482aaad", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "139"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "57f0c827-e783-4bf9-bfb8-bbefc04b1f3a", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "139"}, "hash": "de2df93e0405162f342ae66e3a7ed64d91b3bfbe410498f0ece4e92799588352", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cb2286b8-6bfc-42e7-ba49-82f29232984f", "node_type": "1", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "139"}, "hash": "21d3aca99f2b94c7fd91f563d8a5f719496a9d3e8d53ffac29cd8f29dadf4633", "class_name": "RelatedNodeInfo"}}, "text": "ART Initiation\n    \u00a7   ImmediateART initiation is not recommended for adults, adolescents and children\n        living with HIV who have TB, because of the risk of increased mortality and should be\n        deferred by 2 weeks (if CD4+ cell count is < 50), or 4 weeks (if CD4+ cell count is > 50\n        cells/mm ) after the initiation of anti-TB drugs.\n                  3\n8.1.5.2 Cryptococcal Meningitis\nDiagnosis\nFor adults, adolescents and children living with HIV suspected of having a first episode of\ncryptococcal meningitis, prompt lumbar puncture with measurement of cerebrospinal fluid\n(CSF) opening pressure and rapid cryptococcal antigen assay is recommended as the preferred\ndiagnostic approach.\n           NATIONAL GUIDELINES FOR HIV PREVENTION TREATMENT AND CARE 2020               117", "mimetype": "text/plain", "start_char_idx": 2235, "end_char_idx": 3033, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3cceab0d-8bbb-44a1-a2dc-f57c31632e82": {"__data__": {"id_": "3cceab0d-8bbb-44a1-a2dc-f57c31632e82", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "140"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "a1a5c8d4-bbb4-40e6-adaa-3915caccfb58", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "140"}, "hash": "840d2134ac41347790c24cff6cc80aea479fe6c03f8910a85bf45e28e3be9561", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e91cfa5d-4214-4b71-9ca7-7fa32303ccac", "node_type": "1", "metadata": {}, "hash": "e10dab37a8f9829958ead09ff0b5351daf6c81ae2ba2004d4db821ed62fbd198", "class_name": "RelatedNodeInfo"}}, "text": "The following diagnostic approaches are recommended, according to the context:\n                   a.  In settings with ready access to and no contraindication for lumbar puncture:\n                       i.                                   If both access to a cryptococcal antigen assay (either lateral flow assay or latex\n                                                                agglutination assay) and rapid results (<24 hours) are available, proceed with\n                                                              Lumbar puncture (LP) for a rapid CSF cryptococcal antigen assay as the preferred\n                           diagnostic approach\n                       ii.                             If access to a cryptococcal antigen assay is not available and/or rapid results are not\n                           available, proceed                                      with LP with CSF India ink test as the preferred diagnostic\n                           approach\n                   b.  In settings without immediate access to LP or when LP is clinically contraindicated\u1d43\n                       i.                              If both access to a cryptococcal antigen assay and rapid results are available within <\n                           24 hours, proceed with rapid serum, plasma or whole-blood cryptococcal antigen\n                           assays as the preferred diagnostic approaches\n                       ii.                              If a cryptococcal antigen assay is not available and/or rapid access to results is not\n                           ensured, prompt referral for further investigation and treatment is required\n               Prophylaxis\n               Screening for cryptococcal antigen\u1d47                                            followed by pre-emptive antifungal therapy among\n                                                      cryptococcal antigen-positive people to prevent the development of invasive cryptococcal\n                                                disease is recommended before initiating or reinitiating ART for adults and adolescents living\n               with HIV who have a CD4+ cell count < 200 cells/mm.\n                                                           Fluconazole 800 mg/day for two weeks, then 400 mg/day for eight weeks and continued\n               maintenance with fluconazole 200 mg/day is recommended for pre-emptive antifungal therapy.\n                                                  When cryptococcal antigen screening is not available, fluconazole primary prophylaxis should\n                                                be given to adults and adolescents living with HIV who have a CD4+ cell count < 200 cells/mm .\n                                                                                                            3\n                                                     Fluconazole 100mg daily for 8 weeks is recommended. Screening and primary prophylaxis are\n                                                  not recommended for children, given the low incidence of cryptococcal meningitis in this age\n               group.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 3130, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e91cfa5d-4214-4b71-9ca7-7fa32303ccac": {"__data__": {"id_": "e91cfa5d-4214-4b71-9ca7-7fa32303ccac", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "140"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "a1a5c8d4-bbb4-40e6-adaa-3915caccfb58", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "140"}, "hash": "840d2134ac41347790c24cff6cc80aea479fe6c03f8910a85bf45e28e3be9561", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3cceab0d-8bbb-44a1-a2dc-f57c31632e82", "node_type": "1", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "140"}, "hash": "911d2199e1405d80fd7d9002c670fd51b25dcf5b5219944a7c7546d3e4cd7496", "class_name": "RelatedNodeInfo"}}, "text": "Screening and primary prophylaxis are\n                                                  not recommended for children, given the low incidence of cryptococcal meningitis in this age\n               group.\n               Induction\n                   \u00a7                                              The following is recommended as the preferred induction regimen: For adults,\n                                                          adolescents and children, a short-course (one-week) induction regimen with liposomal\n                                                        amphotericin B (3.0 mg/kg/day) and flucytosine (100 mg/kg/day, divided into four doses\n                                                          per day), followed by 1 week of fluconazole (1200mg/day for adults, 12 mg/kg/day for\n                       children and adolescents, up to a maximum dose of 800mg daily)\n               The following induction regimens are recommended as alternative options depending on drug\n               availability:\n               aContraindications include significant coagulopathy or suspected space-occupying lesion based on focal nervous system signs (excluding\n    cranial nerve VI palsy) or recurrent seizures and, where possible, confirmed by computed tomography. Raised intracranial pressure does not\n  contraindicate LP in (suspected) cryptococcal meningitis. Other contraindications include major spinal deformity and patient refusal despite\n               adequate counselling.\n      bGood practice principle: All PLHIV with a positive cryptococcal antigen result on screening should be carefully evaluated for signs and\nsymptoms of meningitis and undergo an LP if feasible with CSF examination and cryptococcal antigen assay (or India ink if cryptococcal antigen\n               assay is not available) to exclude active cryptococcal disease.\n                         NATIONAL GUIDELINES FOR HIV PREVENTION TREATMENT AND CARE 2020              118", "mimetype": "text/plain", "start_char_idx": 2928, "end_char_idx": 4890, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "15416557-c23e-419e-abc9-9578e14ab17a": {"__data__": {"id_": "15416557-c23e-419e-abc9-9578e14ab17a", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "141"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "d679af73-ea2d-4874-818b-94158008bfe6", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "141"}, "hash": "986c0b60a17a9909e3f095be3870a32162d50d8b92a1caf8840d9c7f9d804204", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f0bb644a-08b3-49eb-ac06-673962ac0baa", "node_type": "1", "metadata": {}, "hash": "debbc5ebd20225f8d25e94a3e75286f23caa17354577094f4ca2d270467c455b", "class_name": "RelatedNodeInfo"}}, "text": "\u00a7   Two weeks of fluconazole (1200 mg daily for adults, 12 mg/kg/day for children and\n       adolescents) + flucytosine (100 mg/kg/day, divided into four doses per day)\n   \u00a7   Two weeks of amphotericin B deoxycholate (1.0 mg/kg/day) + fluconazole (1200 mg\n       daily for adults, 12 mg/kg/day for children and adolescents up to a maximum of 800 mg\n       daily).\nConsolidation\n   \u00a7   Fluconazole (800 mg daily for adults, 6\u201312 mg/kg/day for children and adolescents up to\n       a maximum of 800 mg daily) is recommended for the consolidation phase (for eight\n       weeks following the induction phase)\nMaintenance\n   \u00a7   Fluconazole (200 mg daily for adults, 6mg/kg/day for adolescents and children) is\n       recommended for the maintenance phase\n   \u00a7   Discontinuation of maintenance therapy should be done when the patient is stable on and\n       adherent to ART and has had antifungal maintenance treatment for at least one year and\n       has a CD4+ cell count \u2265200 cells/mm and a fully suppressed VL\n                                            3\nTherapeutic Lumbar Puncture\nUsing drugs (mannitol, acetazolamide, furosemide or steroids) for managing raised intracranial\npressure is not being recommended because there is no evidence that these drugs improve\n   \u00a7   Outcomes in managing cryptococcal meningitis\u2013associated raised intracranial pressure;\n       and available evidence suggests their utilization may be harmful [3]\n   \u00a7   Initial measurement of intracranial pressure and management of raised intracranial\n       pressure is an essential part of cryptococcal meningitis management to prevent death and\n       serious nervous system complications\n   \u00a7   Reduction of raised CSF pressure is associated with clinical improvement and survival\n       benefit, regardless of initial opening pressure.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1813, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f0bb644a-08b3-49eb-ac06-673962ac0baa": {"__data__": {"id_": "f0bb644a-08b3-49eb-ac06-673962ac0baa", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "141"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "d679af73-ea2d-4874-818b-94158008bfe6", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "141"}, "hash": "986c0b60a17a9909e3f095be3870a32162d50d8b92a1caf8840d9c7f9d804204", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "15416557-c23e-419e-abc9-9578e14ab17a", "node_type": "1", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "141"}, "hash": "e16c08fe5dca08de41530597076b70350caf024eda9c0fa98d8e03c8231cba48", "class_name": "RelatedNodeInfo"}}, "text": "Conversely, failure to reduce CSF\n       pressure is associated with poor nervous system outcome and increased mortality\n   \u00a7   Pressure should be relieved by draining a volume sufficient to reduce the CSF pressure to\n       < 20cm H20 or halving the baseline pressure if extremely high**\n   \u00a7   For people with initial intracranial pressure of 20cmH 0 or more or subsequent\n                                                                 2\n       development or recurrence of symptoms or signs of raised intracranial pressure, repeat\n       therapeutic LP should be carried out\nART Initiation\nImmediateART initiation is not recommended for PLHIV who have cryptococcal meningitis\nbecause of the risk of increased mortality and should be deferred by 4\u20136 weeks from the\ninitiation of antifungal\ntreatment.\nNote: A minimum package of pre-emptive hydration, electrolyte replacement, toxicity monitoring and management should be provided to\nminimize toxicity related to amphotericin B and flucytosine.\n** Ensure manometers are available\n          NATIONAL GUIDELINES FOR HIV PREVENTION TREATMENT AND CARE 2020             119", "mimetype": "text/plain", "start_char_idx": 1814, "end_char_idx": 2935, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "118fd178-faa9-4705-beb9-69682dd25e69": {"__data__": {"id_": "118fd178-faa9-4705-beb9-69682dd25e69", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "142"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "44714a06-f7fb-4eac-8510-fbeca8a3e72d", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "142"}, "hash": "c2fae8c56823f097c13ea7c2a7b2e03264cda6f30bb8834f076fdce9bbdaef18", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "08c58623-d8a7-4551-8c94-ab7c16eb9e58", "node_type": "1", "metadata": {}, "hash": "1bde1bff82ea0d50c997e7edba3cb13c570f4be3355180a4e57ceca83db4cd6c", "class_name": "RelatedNodeInfo"}}, "text": "8.1.5.3 Oro-oesophagal candidiasis\nDiagnosis\n    \u00a7   Clinically diagnosed by retrosternal chest pain (heartburn), pain or discomfort on\n        swallowing and features of candidiasis (pseudo membranous, erythematous lesions and\n        angular cheilitis) in the mouth or throat\n    \u00a7   Laboratory: Wet mount microscopy using KOH preparation\n    \u00a7   Endoscopy should be conducted for the patient if no response to antifungal therapy and\n        collect a representative sample for testing.\nTreatment\nAdult:\n    \u00a7   Fluconazole \u2013 oral 200mg on day 1, then 100 mg daily; doses up to 400 mg/day may be\n        used based on patient's response. Treat for a minimum of 3 weeks and at least 2 weeks\n        after resolution of symptoms\n                                            or\n    \u00a7   Itraconazole \u2013 oral 200mg daily for at least 2 weeks after resolution of symptoms\n                                            or\n    \u00a7   Oral Nystatin 400,000 \u2013 600,000 IU qds for at least 2 weeks after resolution of\n        symptoms\nPaediatric:\n    \u00a7   Fluconazole \u2013 oral, 6mg/kg stat on day 1, then 3mg/kg/day for 14-21 days.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1111, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "08c58623-d8a7-4551-8c94-ab7c16eb9e58": {"__data__": {"id_": "08c58623-d8a7-4551-8c94-ab7c16eb9e58", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "142"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "44714a06-f7fb-4eac-8510-fbeca8a3e72d", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "142"}, "hash": "c2fae8c56823f097c13ea7c2a7b2e03264cda6f30bb8834f076fdce9bbdaef18", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "118fd178-faa9-4705-beb9-69682dd25e69", "node_type": "1", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "142"}, "hash": "344dd936d1f9696d390c81f734135e00e2e45236421f853409d901ddb5e54716", "class_name": "RelatedNodeInfo"}}, "text": "or\n    \u00a7   Oral Nystatin 100,000 \u2013 200,000 IU qds for at least 2 weeks after resolution of symptoms\n8.1.5.4 Toxoplasmosis\nDiagnosis\n    \u00a7   Symptoms include fever, reduced alertness, headache, focal neurological deficits,\n        seizures, chorio-retinitis\n    \u00a7   The following diagnostic tool can be used on CSF sample: Dye test, indirect fluorescent\n        antibody test (IFA), enzyme immunoassays (ELISA, immunoblots), agglutination test,\n        avidity test\nProphylaxis\n    \u00a7   Cotrimoxazole until CD4+ cell levels increase to more than 200 cell/mm for more than 3\n                                                                           3\n        months\n    \u00a7   Alternatively, dapsone \u2013 pyrimethamine plus leucovorin\nTreatment\n    \u00a7   Pyrimethamine 100mg stat and 50mg daily with folinic acid 10-25mg daily plus\n        clindamycin 300mg given qds for 6 weeks followed by life-long suppressive therapy\n        until full immunological recovery.\n                                            or\n    \u00a7   Cotrimoxazole (Trimethoprim 10mg/kg/day + Sulphamethoxazole 50mg/kg/day) for 4\n        weeks if there is clinical and radiological improvement. Longer therapy may be\n        necessary if a response is incomplete at 6 weeks\n          NATIONAL GUIDELINES FOR HIV PREVENTION TREATMENT AND CARE 2020           120", "mimetype": "text/plain", "start_char_idx": 1156, "end_char_idx": 2475, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "08fa4b6c-9807-4b4a-b5a6-c04319932126": {"__data__": {"id_": "08fa4b6c-9807-4b4a-b5a6-c04319932126", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "143"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "a81e2521-1bbc-44a6-b7c2-b67efef91218", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "143"}, "hash": "be9694c061b490153749e483e65d43242e25c5965fa6d6856443843f4112ea1d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c5c145a4-29af-4775-9b3c-5ba827f4ba90", "node_type": "1", "metadata": {}, "hash": "66ab3f23ceda3424a2e27e30bb20890bc7d4d1e566095b401f190c9fb2abaf1a", "class_name": "RelatedNodeInfo"}}, "text": "8.1.5.5 Pneumocystis jiroveci pneumonia (PJP)\nDiagnosis\n    \u00a7   Acute/sub-acute nonproductive cough with difficulty in breathing. Oxygen saturation of\n        <92% at rest on room air\n    \u00a7   Sample types: bronchoalveolar lavage (BAL), induced and expectorated sputum,\n        nasopharyngeal aspirates and oral washing\n    \u00a7   Giemsa stain or GMS stain can be used for identification\nProphylaxis\n    \u00a7   Cotrimoxazole in adult and children (Children 6-8mg/kg/day PO,Adults 960mg daily)\n    \u00a7   Alternatively, Dapsone (100mg daily) or Dapsone plus pyrimethamine (50mg) plus\n        folinic acid 10mg weekly can be used.\nTreatment\n    \u00a7   For Moderate to severe PJP: IV Cotrimoxazole (TMP 15\u2013 20 mg and SMX 75\u2013 100 mg) /\n        kg/ day given qds or tds (switch to PO after clinical improvement for 21 days).", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 806, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c5c145a4-29af-4775-9b3c-5ba827f4ba90": {"__data__": {"id_": "c5c145a4-29af-4775-9b3c-5ba827f4ba90", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "143"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "a81e2521-1bbc-44a6-b7c2-b67efef91218", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "143"}, "hash": "be9694c061b490153749e483e65d43242e25c5965fa6d6856443843f4112ea1d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "08fa4b6c-9807-4b4a-b5a6-c04319932126", "node_type": "1", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "143"}, "hash": "6e0d3922401a780c6ac36ed7c465113c80bdbdabb96156e046bf0e0fce30db78", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5c5879bd-0e34-4ed1-9321-8e3a54ab2d9b", "node_type": "1", "metadata": {}, "hash": "47dbd017083b503a00a2124418b802073ce27e8764ffce1c5508a04f69635cbf", "class_name": "RelatedNodeInfo"}}, "text": "\u00a7   For Mild PJP: Cotrimoxazole: (TMP 15\u2013 20 mg/ kg/ day and SMX 75\u2013 100 mg/ kg/ day),\n        given PO in 3 divided doses for 21 days\nAlternative:\n    \u00a7   Moderate to Severe PJP: Primaquine 30 mg (base) PO once daily + clindamycin [IV 600\n        qds or 900 mg tds] or [PO 300 mg q6h or 450 mg q8h], Or Pentamidine 4 mg/ kg IV once\n        daily infused over at least 60 minutes, may reduce the dose to 3mg/kg IV once daily\n        because of toxicities\n    \u00a7   For Mild PJP: Dapsone 100 mg PO daily + TMP 15 mg/kg/day PO (3 divided doses),\n        OR Primaquine 30 mg (base) PO daily + clindamycin PO (300 mg q6h or 450 mg q8h)\n8.1.5.6 Histoplasmosis\nDiagnosis\n    \u00a7   Symptoms are non-specific mimicking TB (pulmonary or extrapulmonary)\n    \u00a7   Histoplasma urinary antigen screening\n    \u00a7   Tissue diagnosis will require histology of representative sample\nTreatment\n    \u00a7   Liposomal amphotericin B (3.0 \u2013 5.0 mg/kg daily intravenously for 1 -2 weeks) followed\n        by itraconazole (200mg 3 times daily for 3 days and then 200mg twice daily, for a total\n        of 12 weeks) is the preferred therapy for disseminated Histoplasmosis\n    \u00a7   For mild to moderate disease, itraconazole (200mg 3 times daily for 3 days and then\n        twice daily for at least 12 months is recommended).\n8.1.6ART Initiation and IntensiveAdherence Support for Patients withAHD\nThese Guidelines recommend that;\n    \u00a7   People who have no clinical signs and symptoms of TB or other OIs and whose CrAg test\n        is negative should initiate ART the same day in combination with their package of\n        prophylaxis outlined above.", "mimetype": "text/plain", "start_char_idx": 811, "end_char_idx": 2425, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5c5879bd-0e34-4ed1-9321-8e3a54ab2d9b": {"__data__": {"id_": "5c5879bd-0e34-4ed1-9321-8e3a54ab2d9b", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "143"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "a81e2521-1bbc-44a6-b7c2-b67efef91218", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "143"}, "hash": "be9694c061b490153749e483e65d43242e25c5965fa6d6856443843f4112ea1d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c5c145a4-29af-4775-9b3c-5ba827f4ba90", "node_type": "1", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "143"}, "hash": "d92aa193f15c5243933fc828a2495928dd3e68bc2281f01a2f88c2ecd57dcbfc", "class_name": "RelatedNodeInfo"}}, "text": "\u00a7   In settings where CrAg testing is not available; ART should be initiated, and fluconazole\n        prophylaxis may be considered for people with AHD and be monitored with CD4+ cell\n        count test until immunological recovery is achieved.\n          NATIONAL GUIDELINES FOR HIV PREVENTION TREATMENT AND CARE 2020           121", "mimetype": "text/plain", "start_char_idx": 2430, "end_char_idx": 2761, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0f06aedb-3f5e-44a2-ba9a-3d74ab1890a8": {"__data__": {"id_": "0f06aedb-3f5e-44a2-ba9a-3d74ab1890a8", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "144"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "2e2ec4da-b5d0-4cfd-8f70-a85395e5e2c9", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "144"}, "hash": "e5f0665a58fd789ffe973efe218358dee218373e8ccd6b4b6f41c352c24ad9e0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "238252a7-bb98-43f8-9227-994c3a9c6d19", "node_type": "1", "metadata": {}, "hash": "8bdc5204cafab09fde970f647e2fcda8c258c1c69318e5ec8802a6db0acba7c4", "class_name": "RelatedNodeInfo"}}, "text": "8.1.6.1 Intensive Follow-Up for Patients withAHD\n People withAHD require closer follow-up during the initial period of receivingART to monitor\n the response toART and to identify signs and symptoms of possible IRIS. The guidelines\n recommend that;\n    \u00a7   Weekly telephone calls or home visits be provided during the first month onART.\n    \u00a7   Intensive follow-up may be required after discharge forAHD.\n    \u00a7    People missing appointments should also be actively tracked by phone or through home\n        visits.\n    \u00a7          Where face-to-face contact is not feasible; distance contact through telephone\n     consultation, mHealth, text messaging or other mobile interventions, or visits through a\n               community health worker or home-based caregiver should be considered, with the\n        consent of the client.\n 8.1.6.2 InitiatingART in Patients withAHD\n People presenting for the first time or those returning to care should undergo history and clinical\n examination to evaluate for significant OIs (such as signs and symptoms of TB and signs and\n symptoms suggesting meningitis) before rapid ART initiation is offered. Baseline CD4+ cell\n count testing should be performed to determine whether the patient has AHD before initiating on\n ART.\n People who have no clinical signs and symptoms of TB or other OIs and whose cryptococcal\n antigen test is negative may initiate ART the same day in combination with their package of\n prophylaxis outlined in Chapter 3. For people with CD4+ cell count <100 cells/mm in settings\n                                                                                  3\n where cryptococcal antigen testing result is not available on the same day, consideration could be\n given to starting fluconazole prophylaxis and discontinuing if a cryptococcal antigen screening\n result is negative.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1837, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "238252a7-bb98-43f8-9227-994c3a9c6d19": {"__data__": {"id_": "238252a7-bb98-43f8-9227-994c3a9c6d19", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "144"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "2e2ec4da-b5d0-4cfd-8f70-a85395e5e2c9", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "144"}, "hash": "e5f0665a58fd789ffe973efe218358dee218373e8ccd6b4b6f41c352c24ad9e0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0f06aedb-3f5e-44a2-ba9a-3d74ab1890a8", "node_type": "1", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "144"}, "hash": "2324c0b68e940afa95a9ec224efe67e3e9f957d6e01610927acd9f1284465603", "class_name": "RelatedNodeInfo"}}, "text": "Table 8.3: ART Initiation and Intensive Adherence Support for Patients with AHD\n  Package     Intervention                                CD4+ cell   Adults and   Children\n                                                          count       adolescents\n  ART         Rapid ART initiation                        Any         Yes          Yes\n  initiation\n              Defer ART initiation if clinical signs and  Any         Yes          Yes\n              symptoms are suggestive of TB or\n              cryptococcal meningitis\n  Intensive   Tailored counselling to ensure optimal      < 200       Yes          Yes\n  adherence   adherence to advance disease care package,  cells/mm\u00b3\n  support     including home visits if feasible.\n 8.1.7 Vaccination for People withAHD\n Providing vaccinations to PLHIV does not appear to accelerate HIV disease progression and is\n recommended as an important part of the HIV care package. However, people with severe\n immunosuppression may be at higher risk of complications from some live attenuated vaccines,\n and the response to other inactivated vaccines may be less effective because of the degree of\n immunosuppression. Additional doses or revaccination after immune reconstitution on ART\n may therefore be required.\n           NATIONAL GUIDELINES FOR HIV PREVENTION TREATMENT AND CARE 2020            122", "mimetype": "text/plain", "start_char_idx": 1838, "end_char_idx": 3181, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bf83d6e8-4170-442a-8f94-2868e8b8cbd0": {"__data__": {"id_": "bf83d6e8-4170-442a-8f94-2868e8b8cbd0", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "145"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "41649b7d-774e-4dce-b744-e9bb756fa947", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "145"}, "hash": "d7222f6c9e370a9996c0c3cc03c724952de750e6e20260cad5538c72209e0f08", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "99a3500a-4731-4286-9977-eb78277a1871", "node_type": "1", "metadata": {}, "hash": "e94d8dca5cf27bea2bf9b9ee95cbb1ca0c830334ab77fb7bf6afbecdd8536c90", "class_name": "RelatedNodeInfo"}}, "text": "\u00a7   Human papillomavirus:Due to increased risk of cervical cancer, vaccine schedule for\n        HPV as recommended by National Cervical Cancer Prevention and Control Policy\n        o   Athree-dose schedule (0, 1\u20132 and 6 months) should be used if HPV vaccination is\n            initiated between the ages of 9 to 13 year and up to 26 years if not sexually exposed\n    \u00a7   Measles:\n        o   Children and adults with HIV infection are at increased risk of measles. However,\n            live vaccine should not be used for those with severe immunosuppression (CD4+\n            cell count <50 cells/mm )\n                                   3\n        o   Vaccination should be routinely administered to potentially susceptible,\n            asymptomatic children and adults living with HIV and should be considered for\n            those with symptomatic HIV infection if they are not severely immunosuppressed\n    \u00a7   Meningococcal vaccination:\n        o   Meningococcal vaccination should be offered to everyone with\n            immunodeficiency, including those patients with AHD\n    \u00a7   Polio vaccine: Polio vaccine is live attenuated and its use in patients with AHD\n        should be in line with WHO recommendation as indicated below.\n        o   Inactivated polio vaccine or bivalent OPV may be administered safely to\n            asymptomatic infants living with HIV. HIV testing is not a prerequisite for\n            vaccination.\n        o   Bivalent OPV is contraindicated among severely immunocompromised people\n            with known underlying conditions such as primary immunodeficiencies, thymus\n            disorders, symptomatic HIV infection or low CD4+ cell count; these populations\n            can safely receive inactivated polio vaccine Vaccines not currently recommended\n            for people with AHD include BCG, Rotavirus, Yellow Fever. This is because the\n            safety and immunogenicity of these vaccines in individuals with CD4+ cell count\n            less than 200 cell/mm ; is not certain.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2021, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "99a3500a-4731-4286-9977-eb78277a1871": {"__data__": {"id_": "99a3500a-4731-4286-9977-eb78277a1871", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "145"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "41649b7d-774e-4dce-b744-e9bb756fa947", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "145"}, "hash": "d7222f6c9e370a9996c0c3cc03c724952de750e6e20260cad5538c72209e0f08", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bf83d6e8-4170-442a-8f94-2868e8b8cbd0", "node_type": "1", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "145"}, "hash": "4766b94c5a73d1b007ae1a850321a3dbcc8e32de577f24f4e2629e45cd5d7594", "class_name": "RelatedNodeInfo"}}, "text": "This is because the\n            safety and immunogenicity of these vaccines in individuals with CD4+ cell count\n            less than 200 cell/mm ; is not certain.\n                                 3\n8.1.8 Immune Reconstitution Inflammatory syndrome (IRIS)\nAHD package of care is designed to ensure that early initiation of ART in severely\nimmunocompromised individuals does not precipitate immune reconstitution inflammatory\nsyndrome (IRIS) particularly in the setting of the use of highly potent DTG based first-line\nregimens. The package of care recommends that individuals with AHD initiate ART\nimmediately if the AHD defining OIs have been excluded. Despite this recommendation, other\nOIs that are associated with IRIS but whose management are not included in the package of care\nfor AHD may still occur when severely immunocompromised individuals initiate ART.\nConsequently, clinicians should be familiar with the risk factors associated with the\ndevelopment of IRIS, its diagnosis and management.\nThe risk factors for IRIS include:\n    \u00a7   High baseline viral load (>100,000 copies/ml)\n    \u00a7   Low CD4+ cell count (\u2264200 cells/mm ) atART initiation\n                                           3\n    \u00a7   Disseminated OIs or malignancies\n    \u00a7   Shorter duration of therapy for OIs beforeART initiation\n    \u00a7   ApotentART regimen e.g TDF/3TC/DTG\nThe management of IRIS involves prompt and effective treatment of any co-infections,\nreassurance of the patient to prevent discontinuation or poor adherence and supportive\nmanagement. The prevention of IRIS includes:\n          NATIONAL GUIDELINES FOR HIV PREVENTION TREATMENT AND CARE 2020           123", "mimetype": "text/plain", "start_char_idx": 1858, "end_char_idx": 3509, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6222af72-5045-43a4-9230-8d13e6560624": {"__data__": {"id_": "6222af72-5045-43a4-9230-8d13e6560624", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "146"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "15e9446d-bc1c-4bfc-9b0d-755d73d2f052", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "146"}, "hash": "f96dafd76b4165748abd992a88cdd42be3361b8d09f494388cfd4b58dd775118", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7174b84c-0bdd-4b90-b345-279a11a53946", "node_type": "1", "metadata": {}, "hash": "386e0534202c3c56297d0a55e6f0c7c30928f006bb25a979e6e7b5bf0969cc1d", "class_name": "RelatedNodeInfo"}}, "text": "\u00a7   Appropriate screening and treatment of OIs before initiation ofART; with the exception\n           of TB and cryptococcal meningitis, outcomes are improved with earlyART in patients\n           with OIs.\n           o   TB: StartART 2 weeks after initiating TB treatment. However, if the patient has TB\n               Meningitis,ART initiation should be started after 4 weeks of starting TB treatment.\n           o   Cryptococcal meningitis (CCM): StartART 4 - 6 weeks after initiating CCM\n               treatment\n    It is important for healthcare workers to exercise a high index of suspicion for IRIS in PLHIV\n    commencingART.\n    8.1.9 Management ofAHD among Children less than ten years\n All children less than 5 years are considered to have AHD. This is based on the rationale that\n                   most children younger than five years usually present for care with advanced\n          immunosuppression, younger children have an increased risk of disease progression and\n   mortality regardless of clinical and immune condition. Thus, varying age dependent CD4+ cell\n        count definitions for advanced immunosuppression among children younger than five years\n       make definitions based on CD4+ cell count difficult to implement. Children under 5 years\n      diagnosed with HIV should immediately be offered the requisite screening tests, and where\napplicable, provided with prophylaxis, treatment and vaccination for the major OIs based on the\noutcome of the screening. For children between 5 and 9 years of age, a positive HIV test should\n  be followed with a CD4+ test and clinical evaluation. If diagnosed with AHD, the child should\nreceive the applicable package of care that involves screening, prevention and treatment of OIs\n    and comorbid conditions, and optimized care.\n       \u00a7  Screen: In addition to clinical screening using signs and symptoms of common OIs, HIV\n        positive children with AHD less than 10 years should be screened for TB using available\n            laboratory tools such as urine LF-LAM assay, Xpert MTB/RIF, andAFB Microscopy.\n       \u00a7   Treat: The major OIs and co-morbidity associated with AHD in children <10 years are;\n         TB, severe pneumonia, severe bacterial infections and malnutrition.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2256, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7174b84c-0bdd-4b90-b345-279a11a53946": {"__data__": {"id_": "7174b84c-0bdd-4b90-b345-279a11a53946", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "146"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "15e9446d-bc1c-4bfc-9b0d-755d73d2f052", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "146"}, "hash": "f96dafd76b4165748abd992a88cdd42be3361b8d09f494388cfd4b58dd775118", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6222af72-5045-43a4-9230-8d13e6560624", "node_type": "1", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "146"}, "hash": "f08936e6d5d7c018bd8f8c93611c15447cc3cb5b2755f7e5e8ade86bbcc4e581", "class_name": "RelatedNodeInfo"}}, "text": "\u00a7   Treat: The major OIs and co-morbidity associated with AHD in children <10 years are;\n         TB, severe pneumonia, severe bacterial infections and malnutrition. Refer to table 8.4\n           and the section on management of OIs for the recommended treatment options for these\n            conditions.\n       \u00a7   Prevent:           The care package for children on AHD should include; TPT and CPT.\n               Screening and primary prophylaxis of cryptococcal meningitis are not recommended\n         for children younger than 10 years, given the low incidence of cryptococcal meningitis\n            in this age group.\n           Live vaccines should be avoided in children with advanced HIV disease, however,\n         vaccination is recommended for some of the OIs as the benefits outweigh the risk. Some\n                   of the vaccines include BCG, measles, catch up pneumococcal vaccine, and HPV\n             (mainly for adolescent female). Neonates with confirmed HIV infection should delay\n             BCG vaccination until ART has started and they are confirmed to be immunologically\n          stable (CD4% >25%). See table 8.4 for details on the screening, diagnosis, prevention\n               and treatment components of the AHD package of care for children under 10 years.\n            Recommendations for adolescents are similar to what obtains for adults.\n       \u00a7   Optimize: Although rapid ART initiation within seven days of diagnosis is a priority,\n          children with AHD who present with severe acute malnutrition or TB or other illnesses\n           that require hospitalization need to be stabilized first. However, initiating ART is\n         encouraged as part of the child's hospital admission to minimize loss to follow-up and\n              NATIONAL GUIDELINES FOR HIV PREVENTION TREATMENT AND CARE 2020            124", "mimetype": "text/plain", "start_char_idx": 2091, "end_char_idx": 3942, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cb944b09-95de-43bb-a556-7ab7d3775625": {"__data__": {"id_": "cb944b09-95de-43bb-a556-7ab7d3775625", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "147"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "0d440eb1-c44a-48a5-b7f9-05e70d8fd695", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "147"}, "hash": "391c0e949dca556b9d8c27cf85a578611e11dac1ad258e1d24cc4f5a9d36b643", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "aeb8da2f-379e-4b51-bcc9-61d9630b8d98", "node_type": "1", "metadata": {}, "hash": "728250f987e7a505b2fbcadf843be7fa59338f4b1f655695f437696a17a34d9a", "class_name": "RelatedNodeInfo"}}, "text": "failure to initiate ART after discharge. Similarly, ensuring linkage to the facility\n        where the child will receive ongoing HIV care upon discharge is critical. In addition,\n        intensive counselling and follow up should be provided to caregivers of children with\n        AHD.\nTable 8.4: Components of the Package of Care for Children with AHD\n Intervention Component                                                  < 5 years   5 \u2013 9 years\n               Screen for TB using clinical algorithm followed by X-ray  Yes         Yes\n               when indicated and if available\n Screening     Xpert\u00ae MTB/RIF or Xpert\u00ae Ultra assay as the first test\n and           (Induced or expectorated) sputum, gastric aspirate, stool or\n diagnosis     nasopharyngeal aspirate or other extrapulmonary specimens\n               LF-LAM assay                                              Yes         Yes\n               Cryptococcal antigen screening using serum, plasma, or    Noa         Noa\n               whole blood specimen\n               Pneumococcal conjugate vaccine (catch-up)                 Yes         No\n               Human Papilloma Vaccine (HPV)b                            No          No\n               Measles                                                   Yes         Noc\n               BCG           d                                           Yes         No\n Prevention,   Co-trimoxazole         e                                  Yes         Yes\n prophylaxis   TB preventive treatment                                   Yes         Yes\n and pre    -  TPT options include\n emptive       \u00b7  INH for 6 months\n treatment     \u00b7  Daily rifampicin and isoniazid for three months (3HR)\n               \u00b7  Weekly rifapentine and isoniazid for three months (3HP)\n                  could beused from two years of age\n               Fluconazole pre-emptive therapy for cryptococcal antigen  Not         Not\n               positive without evidence of meningitise                  Applicable  Applicable\n               Tuberculosis                                              Yes         Yes\n               \u00b7  based on current TB guidelines\n               Severe Pneumonia (if diagnosed)                           Yes         Yes\n               \u00b7  for children less than one, empirical treatment with\n                  Cotrimoxazole\n Treatment     \u00b7  for children between one and five,", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2387, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "aeb8da2f-379e-4b51-bcc9-61d9630b8d98": {"__data__": {"id_": "aeb8da2f-379e-4b51-bcc9-61d9630b8d98", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "147"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "0d440eb1-c44a-48a5-b7f9-05e70d8fd695", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "147"}, "hash": "391c0e949dca556b9d8c27cf85a578611e11dac1ad258e1d24cc4f5a9d36b643", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cb944b09-95de-43bb-a556-7ab7d3775625", "node_type": "1", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "147"}, "hash": "607a8676645ba9884106e6d5806fbc06d649fcc7ca0270baf01df55272a27117", "class_name": "RelatedNodeInfo"}}, "text": "empirical treatment with\n                  Cotrimoxazole\n Treatment     \u00b7  for children between one and five, treat according to\n                  laboratory findings\n               Severe bacterial infection                                Yes         Yes\n               \u00b7  treat according tothe confirmed organism\n               Malnutrition treatment                                    Yes         Yes\naScreening and primary prophylaxis of cryptococcal meningitis are not recommended for children younger than 10 years given the low incidence\nof cryptococcal meningitis in this age group; although this guideline does not recommend routine screening of children with AHD for\ncryptococcal infection because of the rarity of this condition in children, studies are appearing in literature reporting cases among children. As\nsuch, clinicians are encouraged to use their clinical judgement and screen their pediatric patients for cryptococcal infections and cryptococcal\nmeningitis when clinical features are suggestive.\nbEvidence indicates that adolescent females living with perinatally-acquired HIV have a higher prevalence of high-risk HPV and abnormal\ncervical cytology than uninfected adolescents. WHO recommends a three-dose series (0, 1\u20132 and 6 months) for females older than nine years\nliving with HIV rather than the standard two-dose series;\nconly if the child missed birth and early childhood dose;\ndTo be discontinued when CD4+ cell count >350 and viral load suppressed for at least 6 months;\neTB preventive treatment is currently not recommended for infants living with HIV younger than 12 months of age unless they have a household\ncontact of a TB case;\n          NATIONAL GUIDELINES FOR HIV PREVENTION TREATMENT AND CARE 2020              125", "mimetype": "text/plain", "start_char_idx": 2278, "end_char_idx": 4034, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "683e059a-6fe7-48a2-b28f-028fc3e289cf": {"__data__": {"id_": "683e059a-6fe7-48a2-b28f-028fc3e289cf", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "148"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "72248ba5-43b6-4b20-b425-2625127f975d", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "148"}, "hash": "819e891ab742fccbafec54a9dc34580124c9db7b4d2d0a55ab8186948346ad74", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "011bee2b-28a8-49b6-86af-6aac23188582", "node_type": "1", "metadata": {}, "hash": "35230606bfaee6c6886f66830f0e70d1ac1adf8b86e02e1f8fbf58b4771d8b22", "class_name": "RelatedNodeInfo"}}, "text": "8.2 Other Opportunistic Infections (OIs)\nPersons living with HIV (PLHIV) are more prone to developing infections than persons not\ninfected with the virus largely because of the immune system damage associated with HIV\ninfection. Most of the infections that occur in PLHIVs are called OIs because they depend on a\ncompromised immune system. The appearance of OIs in PLHIV is directly related to the extent\nof immune deficiency that is the degree of depletion of CD4+cells. The lower the CD4+ cell\ncount, the higher the likelihood of the appearance of OIs. Most OIs in PLHIV begin to appear at\nCD4+ cell counts of <350cells/mm ; and many of the OIs are useful for staging the severity of\n                                 3\nHIV disease.\nOpportunistic infections (OIs) associated with HIV fall into four broad categories namely,\nbacterial, viral, fungal and protozoal infections. The infections affect all major systems of the\nbody including the; nervous, gastrointestinal, respiratory, skin, musculoskeletal, eyes, ear, nose\nand throat. When OIs occur among PLHIV they should be treated immediately since they can\ncause considerable damage to the immune system and lead to a rapid increase in viral replication\nand disease progression and death.\nXpert MTB/RIF has enhanced the diagnosis of TB in HIV positive patients and its widespread\nuse in the country should improve health outcomes for HIV/TB co-infected patients.\nChronic non-communicable diseases (NCDs), including cardiovascular disease (CVD),\nhypertension, diabetes, chronic obstructive pulmonary disease (COPD), kidney disease and\nmental health illnesses present important considerations in adults and adolescents living with\nHIV and requires early assessment and management. Pre-disposing factors such as lack of\nphysical activities, smoking, and unhealthy dietary habits should be addressed.\nEarly initiation of ART, appropriate treatment of identified OIs and comorbidities, lead to a\nreversal of immune system damage with reconstitution and prevention ofAIDS-related death.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2034, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "011bee2b-28a8-49b6-86af-6aac23188582": {"__data__": {"id_": "011bee2b-28a8-49b6-86af-6aac23188582", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "148"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "72248ba5-43b6-4b20-b425-2625127f975d", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "148"}, "hash": "819e891ab742fccbafec54a9dc34580124c9db7b4d2d0a55ab8186948346ad74", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "683e059a-6fe7-48a2-b28f-028fc3e289cf", "node_type": "1", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "148"}, "hash": "35f3e744b5e167390e4e0dd6db66823e9bcee895c4132c19038be48375125c39", "class_name": "RelatedNodeInfo"}}, "text": "Early initiation of ART, appropriate treatment of identified OIs and comorbidities, lead to a\nreversal of immune system damage with reconstitution and prevention ofAIDS-related death.\n8.3 Preventing Opportunistic Infections (OIs)\nThe relationship between HIV and OIs is bi-directional; HIV depresses the immunity of an\nindividual thereby increasing predisposition to OIs, while OIs and other similar infections may\nlead to an acceleration of HIV disease progression.\nIt is therefore important that health workers have a good understanding of the role of\nchemotherapy in the prevention and treatment of OIs because while chemoprophylaxis directly\nprevent pathogen-specific morbidity and mortality, they also contribute to a reduced rate of\nprogression of HIV disease.\nFor instance, there is evidence that chemoprophylaxis with trimethoprim-sulfamethoxazole can\nboth decrease OI-related morbidity and improve survival. The reduced progression of HIV\ninfection would reduce the risk of subsequent OIs.\nThere are currently two main strategies for the prevention of OIs; CPT, which provides\nprotection to a wide range of bacterial infections and TPT, which is useful for treating latent\ntuberculosis.\n          NATIONAL GUIDELINES FOR HIV PREVENTION TREATMENT AND CARE 2020             126", "mimetype": "text/plain", "start_char_idx": 1851, "end_char_idx": 3135, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "46f99a4b-76b1-426d-bd37-df3db3460903": {"__data__": {"id_": "46f99a4b-76b1-426d-bd37-df3db3460903", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "149"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "9091ab65-582d-470f-8f37-50f989e629eb", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "149"}, "hash": "fde431901fba2bf0449fa1081281fc425da192240e126c77316e6c144078b976", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "86eaf194-7fba-4bce-8ae6-b04714c08f02", "node_type": "1", "metadata": {}, "hash": "5a630e27666c804c43f4939f38c90bdbcdbe618f72bda04a4ce9ddd5d897b540", "class_name": "RelatedNodeInfo"}}, "text": "8.3.1 Cotrimoxazole Preventive Therapy (CPT)\n         Cotrimoxazole Preventive Therapy (CPT) is a fixed-dose combination of two antimicrobial\n      agents (sulfamethoxazole and trimethoprim) used for the prevention of some AIDS-associated\n        OIs (Pneumocystis jirovecii pneumonia [PCP] and toxoplasmosis) and the reduction of HIV-\nassociated mortality in people with low CD4+ cell counts. CPT is also used to treat a variety of\n      bacterial, fungal and protozoan infections.\n      8.3.1.1 Cotrimoxazole prophylaxis for adults\n       Cotrimoxazole (CTX) prophylaxis is recommended for adults (including pregnant women) with\n   severe or advanced HIV clinical disease (WHO stage 3 or 4) and/or with a CD4+ cell count \u2264500\n      cells/mm ;.\n               3\n          \u00a7   Due to the high prevalence of malaria and severe bacterial infections in Nigeria,\n              Cotrimoxazole prophylaxis should be initiated regardless of CD4+ cell count or WHO\n              stage. Priority should be given to adults (including pregnant women) with severe or\n              advanced HIV clinical disease (WHO stage 3 or 4) and/or with a CD4+ cell count <500\n              cells/mm\u00b3\n          \u00a7   Routine cotrimoxazole prophylaxis should be given to all HIV-infected patients with\n              active TB disease regardless of CD4+ cell count\n          \u00a7   Cotrimoxazole prophylaxis may be discontinued in adults (including pregnant women)\n              with HIV who are clinically stable on ART, with evidence of immune recovery and\n              virological suppression\n            8.3.1.2 Cotrimoxazole prophylaxis for HIV-infected infants, children and Adolescents\n      Cotrimoxazole prophylaxis is recommended\n          \u00a7   For infants, children and adolescents with HIV, irrespective of clinical and immune\n              conditions.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1832, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "86eaf194-7fba-4bce-8ae6-b04714c08f02": {"__data__": {"id_": "86eaf194-7fba-4bce-8ae6-b04714c08f02", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "149"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "9091ab65-582d-470f-8f37-50f989e629eb", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "149"}, "hash": "fde431901fba2bf0449fa1081281fc425da192240e126c77316e6c144078b976", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "46f99a4b-76b1-426d-bd37-df3db3460903", "node_type": "1", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "149"}, "hash": "05f4ee4ecfe29d24e25bf68ebefedc6c03f55e7a4e84088592f1a114ab1d9c53", "class_name": "RelatedNodeInfo"}}, "text": "Priority should be given to all children younger than 5 years old regardless of\n              CD4+ cell count or clinical stage, and children with severe or advanced HIV clinical\n              disease (WHO clinical stage 3 or 4) and/or those with a CD4+ cell count \u2264500 cells/mm\u00b3\n          \u00a7   Should be continued until adulthood, irrespective of whetherART is provided\n          \u00a7   For HIV-exposed infants 6 weeks of age and should be continued until HIV infection has\n              been excluded by an age-appropriate HIV test to establish a final diagnosis after\n              complete cessation of breastfeeding\n          \u00a7   In all persons with active TB regardless of CD4+ cell count and continued until criteria\n              for discontinuation in adults and children is met\n      In HIV positive individuals who have ADR to cotrimoxazole, options for prophylaxis of PJP\n      include dapsone, dapsone plus pyrimethamine plus folinic acid and atovaquone. For those who\n      will be started on dapsone, do a G6PD deficiency test. Dapsone should be avoided in individuals\n      with G6PD deficiency.\n      8.3.1.3 Starting Patients on CPT\n      Before commencing a client on CPT the health worker should undertake the following actions:\n          \u00a7   Verify HIV status\n          \u00a7   Take medical history\n          \u00a7   Conduct physical examination\n          \u00a7   Counsel on OIs in HIV infection\n          \u00a7   Treat pre-existing OIs\n                NATIONAL GUIDELINES FOR HIV PREVENTION TREATMENT AND CARE 2020           127", "mimetype": "text/plain", "start_char_idx": 1833, "end_char_idx": 3363, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a7c6a127-f30a-4862-b0bb-8c9958a9159b": {"__data__": {"id_": "a7c6a127-f30a-4862-b0bb-8c9958a9159b", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "150"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "50bbf825-0710-4a08-9782-b7ccb27c929c", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "150"}, "hash": "aaed12e5e5d7d9687a71e72ca1afc1843b71a2076a1ccd7c38695a9edfabf22e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1356d135-6985-4aa5-ae4e-6a6150f6b73b", "node_type": "1", "metadata": {}, "hash": "31af677e8f693f611d1566fdb7d66d5b6f99e9604937e2cf9f19f36c5f4bbf54", "class_name": "RelatedNodeInfo"}}, "text": "\u00a7     Screen for contraindications to CPT: e.g. known allergy to Sulphur-containing drugs,\n         first trimester pregnancy, kidney or liver disease\nIn addition, the patient should be counselled for drug adherence and given detailed information\nof the likely side effects of cotrimoxazole and action to take in the event of the occurrence of\nany. Common side effects associated with CPT include skin eruptions, which may be severe\n(Stevens Johnson syndrome), nephritis, hepatitis, anaemia and hyperkalaemia.\nTable 8.5: Dosage of Cotrimoxazole for CPT\n Adult                               Children\n \u2265 14 years or >30 kg: 960 mg daily  Infants <6 months or < 5 kg: 120mg daily\n                                     Children 6 months \u20135 years or 5 -15 kg: 240 mg daily\n                                     Children 6 \u201314 years old or 15 \u201330 kg: 480 mg daily\n8.3.2 Tuberculosis Preventive Treatment (TPT)\nTuberculosis Preventive Treatment (TPT), previously referred to as Isoniazid preventive\ntherapy (IPT) is the treatment offered to individuals who are considered to be at risk of\ndeveloping TB disease, in order to reduce that risk. It is also referred to as the treatment of TB\ninfection or LTBI treatment. TB is a disease that is driven by HIIV and so it is frequently\nassociated with HIV and a common cause of illness and death among PLHIV.\nTPT is effective in preventing the development of active TB in HIV positive individuals.\nHowever, it is not a treatment for active TB, therefore this should be excluded before\ncommencing a patient on TPT.\nFor a patient to benefit from TPT, he/she must:\n   1.    Be HIV positive\n   2.    Not have active TB\n   3.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1655, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1356d135-6985-4aa5-ae4e-6a6150f6b73b": {"__data__": {"id_": "1356d135-6985-4aa5-ae4e-6a6150f6b73b", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "150"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "50bbf825-0710-4a08-9782-b7ccb27c929c", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "150"}, "hash": "aaed12e5e5d7d9687a71e72ca1afc1843b71a2076a1ccd7c38695a9edfabf22e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a7c6a127-f30a-4862-b0bb-8c9958a9159b", "node_type": "1", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "150"}, "hash": "4f783439dcf7c9a3ec458a282bd917e7a4d9f13455a33771b4e2ce05eea97ac7", "class_name": "RelatedNodeInfo"}}, "text": "For a patient to benefit from TPT, he/she must:\n   1.    Be HIV positive\n   2.    Not have active TB\n   3.    Be counselled and motivated to adhere to treatment\n8.3.2.1 Recommendations for TPT\n   \u00a7    Adults and adolescents living with HIV\n        o   Adults and adolescents living with HIV should be screened with a clinical\n            algorithm; those who do not report any one of the symptoms of current cough, fever,\n            weight loss or night sweats are unlikely to have active TB and should be offered TPT\n        o   Adults and adolescents living with HIV who are unlikely to have active TB or in\n            whom active TB has been safely ruled out should receive TPT as part of a\n            comprehensive package of HIV care. TPT should be given to such individuals\n            regardless of the degree of immunosuppression, and also to those onART, those who\n            have previously been treated for TB and pregnant women\n   \u00a7    Children\n        o   Children living with HIV who do not have poor weight gain, fever or current cough\n            are unlikely to have active TB. Children living with HIV who have poor weight gain,\n            fever or current cough or contact history with a TB case may have TB and should be\n          NATIONAL GUIDELINES FOR HIV PREVENTION TREATMENT AND CARE 2020              128", "mimetype": "text/plain", "start_char_idx": 1549, "end_char_idx": 2884, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "019ba598-c8d0-4900-a5e1-4e344c4216fb": {"__data__": {"id_": "019ba598-c8d0-4900-a5e1-4e344c4216fb", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "151"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "cd642cb9-c157-4153-81a0-94bf149586c4", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "151"}, "hash": "72484d040c27724b813a47a2c7c0bce155985fae837ceff53c1bf07d3277a21c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "73bb99a6-98dc-4f93-8bac-c593c5f770a3", "node_type": "1", "metadata": {}, "hash": "7bc7d46a9117e544178d3d539ff712847b7bbaaacf42245b7e430a37b5c40937", "class_name": "RelatedNodeInfo"}}, "text": "evaluated for TB and other conditions. If the evaluation shows no TB, they should be\n            offered TPT regardless of their age\n        o   Children living with HIV who are \u2265 12 months of age and who are unlikely to have\n            active TB on symptom-based screening and have no contact with a TB case should\n            receive six months of TPT (Isoniazid 10 mg/kg/day) but not more than 300mg/day as\n            part of a comprehensive package of HIV prevention and care if they live in a setting\n            with high TB transmission, regardless of contact with TB\n        o   In children living with HIV who are < 12 months of age, only those who have contact\n            with a TB case and who are evaluated for TB (using standard lab investigations)\n            should receive 6 months of TPT if the evaluation shows no TB disease\n        o   All children living with HIV, after successful completion of treatment for TB, should\n            receive TPT for an additional 6 months\n        o   Children aged < 5 years who are household contacts of people with confirmed\n            pulmonary TB and who are found not to have active TB on an appropriate clinical\n            evaluation or according to national guidelines should be given TPT even if LTBI\n            testing is unavailable\n        o   Children aged \u2265 5 years, adolescents and adults who are household contacts of\n            people with confirmed pulmonary TB who are found not to have active TB by an\n            appropriate clinical evaluation or according to national guidelines may be given\n            TPT\n8.3.2.2 Commencing TPT\nIt is recommended that health workers should undertake the following actions before initiating\npatients on TPT;\n    1.  Verify/Confirm HIV Status\n    2.  Counsel clients on TB/HIV interactions\n    3.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1812, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "73bb99a6-98dc-4f93-8bac-c593c5f770a3": {"__data__": {"id_": "73bb99a6-98dc-4f93-8bac-c593c5f770a3", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "151"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "cd642cb9-c157-4153-81a0-94bf149586c4", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "151"}, "hash": "72484d040c27724b813a47a2c7c0bce155985fae837ceff53c1bf07d3277a21c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "019ba598-c8d0-4900-a5e1-4e344c4216fb", "node_type": "1", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "151"}, "hash": "58ed5c431904eec4e0cebbc1de8082d0389cb9420490dda9893baab719a1eb60", "class_name": "RelatedNodeInfo"}}, "text": "Verify/Confirm HIV Status\n    2.  Counsel clients on TB/HIV interactions\n    3.  Exclude active TB by asking the client about:\n        a.  Ask the patients about cough, weight loss, fever and night sweats\n        b.  Check for lymph node enlargement\n        c.  For patients who answer no to (a) and (b) above, assess for contraindications to TPT,\n            counsel on adherence, and commence TPT\n        d.  For those with symptoms/signs in (a) and (b) above:\n            \u00b7  Xpert MTB/RIF should be done\n            \u00b7  If positive refer/commence short-course chemotherapy for TB (DOTS,\n               preferably)\n            \u00b7  Those with negative results should be referred to medical officers for\n               confirmation of diagnosis.\n            \u00b7  If signs and symptoms are absent, do a chest x-ray\n            \u00b7  If no active TB is confirmed, assess for contraindications to TPT, counsel on\n               adherence, and commence TPT.\n    4. Counsel patient/caregiver on:\n        a.  Importance of Treatment adherence\n        b.  Side effects of INH: peripheral neuropathy, jaundice, rash and what is expected in\n            such circumstances\n        c.  Immediate recognition and reporting of signs and symptoms of active TB If a patient\n             develops active TB during the course of TPT, discontinue TPT and refer/\n             commence anti-TB treatment (DOTS)\n           NATIONAL GUIDELINES FOR HIV PREVENTION TREATMENT AND CARE 2020              129", "mimetype": "text/plain", "start_char_idx": 1733, "end_char_idx": 3207, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "49528269-375f-4e87-9db1-521d9fff269d": {"__data__": {"id_": "49528269-375f-4e87-9db1-521d9fff269d", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "152"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "ebd0eb68-51d8-421e-89d1-c6503aa22a20", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "152"}, "hash": "ffbe44f8f06448bbbbfef150a8c921f74608fd56f2d639eebff6b317ad659560", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2f486d73-d2bb-4a5d-aa81-682dea6eaa29", "node_type": "1", "metadata": {}, "hash": "e6493e02e251df769bcbb7305c3869d28a8017a608aff1171bd8b81e5a4c59fa", "class_name": "RelatedNodeInfo"}}, "text": "5.  During the monthly visit, monitor the patients for:\n        a.   Signs and symptoms of active TB\n        b.   Side effects. The most common side effect is peripheral neuropathy\n             (numbness/tingling sensation of extremities). In addition, allergic skin eruptions\n            and jaundice can occur. Since INH is co formulated with Pyridoxine,\n            Complications such as numbness/tingling/burning sensation are not expected.\n            However, if jaundice develops, discontinue TPT and refer to the clinician for\n            assessment\n8.3.2.3 TPT options\nThe following options are recommended for the treatment of LTBI regardless of HIV status:\n    \u00a7   6 or 9 months of daily isoniazid\n    \u00a7   3-month regimen of weekly rifapentine plus isoniazid (3HP)\n    \u00a7   3-month regimen of daily isoniazid plus rifampicin. (3HR)\n    \u00a7   1-month of daily Isoniazid and Rifapentine (1HP)\nHarmonize dispensing schedule with that of ARVs and emphasize the importance of adherence\nat each visit. Complete necessary INH prophylaxis register and INH appointment card.\n8.3.2.4 Dosages of the Different TPT Regimens\nThe recommended dosages of medicines used for treatment of LTBI is as shown in Table 8.6\nbelow.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1215, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2f486d73-d2bb-4a5d-aa81-682dea6eaa29": {"__data__": {"id_": "2f486d73-d2bb-4a5d-aa81-682dea6eaa29", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "152"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "ebd0eb68-51d8-421e-89d1-c6503aa22a20", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "152"}, "hash": "ffbe44f8f06448bbbbfef150a8c921f74608fd56f2d639eebff6b317ad659560", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "49528269-375f-4e87-9db1-521d9fff269d", "node_type": "1", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "152"}, "hash": "185420f82502543ef60516943ff886d3a9da62ee6bfe9328f0a2132ab3dede87", "class_name": "RelatedNodeInfo"}}, "text": "8.3.2.4 Dosages of the Different TPT Regimens\nThe recommended dosages of medicines used for treatment of LTBI is as shown in Table 8.6\nbelow.\nTable 8.6: Recommended Dosages of Medicines used for Treatment of LTBI\n  TPT regimen                Dose per kg body weight in children          Maximum dose\n  Isoniazid alone daily for  10mg (range:7-15mg)                          300mg\n  6 months (6H)\n  Weekly Rifapentine plus    Isoniazid:                                   Isoniazid - 900mg\n  Isoniazid for 3 months-    Individuals aged \u2265 12 years -15mg            Rifapentine - 900mg\n  12 doses (3HP)             Individuals aged 2 -11 years -25mg\n                             Rifapentine:\n                             10.0 - 14.0 kg = 300mg\n                             14.1 - 25.0 kg = 450mg\n                             25.1 - 32.0 kg = 600mg\n                             32.1 -50.0 kg = 750mg\n                             > 50 kg = 900mg\n  Daily Isoniazid plus       Rifampicin:                                  Rifampicin - 600mg\n  Rifampicin for 3 months    Age < 10 years = 15mg (range: 10\u201320mg)       Isoniazid - 300mg\n  (3HR)                      Age \u2265 10 years = 10mg\n                             Isoniazid:\n                             Age < 10 years = 10mg (range: 7\u201315mg)\n                             Age \u2265 10 years = 5mg\n  Daily Isoniazid and        Age \u2265 13 years (regardless of weight band)   Isoniazid \u2013300mg\n  Rifapentine for 1 month    Isoniazid 300 mg/day                         Rifapentine - 600mg\n                             Rifapentine 600 mg/day\n           NATIONAL GUIDELINES FOR HIV PREVENTION TREATMENT AND CARE 2020                130", "mimetype": "text/plain", "start_char_idx": 1074, "end_char_idx": 2736, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d9aff44c-ac66-4082-9c24-f99af3add0c2": {"__data__": {"id_": "d9aff44c-ac66-4082-9c24-f99af3add0c2", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "153"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "53227f03-0b6b-4205-b7b5-b4329d0d70df", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "153"}, "hash": "464d4ff6c2467d653601a33d67f1b23d2a652c5e0a9880eac050a80ba0761ebc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f66ace3e-f075-43e3-b9a2-9fa29f751571", "node_type": "1", "metadata": {}, "hash": "4efefc0af2cbad7109edb2e1be5019a89dbd5eee2c1289eb74d16ec9a698eca6", "class_name": "RelatedNodeInfo"}}, "text": "Dosage of INH for TPT\n    i.   Dosage of INH for TPT in children: INH is administered daily for TPT in children for a\n         total duration of 6 months as stated in Table 8.7 below\n    ii.  The dosage of INH for TPT in adults is 300mg daily for 6 months.\n          Table 8.7: Dosage of INH for TPT in Children\n          Weight in kg      INH dosages in mg/day                 INH in Tablet/day\n              <2.5                    25                         \u00bc of 100mg tablet\n           2.5 - 5.9                  50                         \u00bd of 100mg tablet\n      6.0 - 10.9                     100                         1 of 100mg tablet\n          11.0 - 25.0                150                          1\u00bd of 100mg tablet\n Dosage of 3HPfor TPT\n   i.     Dosages of 3HP in children: The Dosages of 3HP in children.is as stated in Table 8.8\n          below.\nTable 8.8: TPT Dosage of 3HP for Children Aged 2 - 14 years*\n            Weight     Rifapentine** (150mg tablets)         Isoniazid (100mg tablets)\n                           Dose           Tablets             Dose             Tablets\n          10 - 15 kg      300mg              2               300mg                3\n          16 - 23 kg      450mg              3               500mg                5\n          24 - 30kg       600mg              4               600mg                6\n          > 31kg          750mg              5               700mg                7\n *Patient aged 15 years and older should receive adult dosing\n**Rifapentine has a bitter taste. For young children who cannot swallow, crush the tablet and mix with small amount of multivitamin syrup\n   ii.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1641, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f66ace3e-f075-43e3-b9a2-9fa29f751571": {"__data__": {"id_": "f66ace3e-f075-43e3-b9a2-9fa29f751571", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "153"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "53227f03-0b6b-4205-b7b5-b4329d0d70df", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "153"}, "hash": "464d4ff6c2467d653601a33d67f1b23d2a652c5e0a9880eac050a80ba0761ebc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d9aff44c-ac66-4082-9c24-f99af3add0c2", "node_type": "1", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "153"}, "hash": "7440a4eaaaacdbdfd5b562ec5c67946184ede85b5ab1edc55bcafe227e42a0dd", "class_name": "RelatedNodeInfo"}}, "text": "For young children who cannot swallow, crush the tablet and mix with small amount of multivitamin syrup\n   ii.    Dosages of 3HP in adults: The Dosages of 3HP in adults is as stated in Table 8.9 below\nTable 8.9: TPT Dosage of 3HP for greater than 14 years old\n    Medicine        Formulation     30 - 35kg Weight bands for patients >14 years\n                                               36 - 45kg  46 - 55kg  56 - 70kg   > 70kg\n   Isoniazid           300mg            3         3          3           3            3\n   Rifapentine         150mg            6         6          6           6            6\n Dosage of 3HR for TPT\n The dosage of fixed dose combination of 3HR for TPT in both children and adults is as stated in\n Table 8.10\nNote: A triple pill combination containing isoniazid 300 mg + pyridoxine 25 mg + sulfamethoxazole 800 mg + trimethoprim 160 mg (scored) is\navailable (1 pill daily for adults, half pill for children 5 years and older of age and quarter for children < 5 years of age).\n                       NATIONAL GUIDELINES FOR HIV PREVENTION TREATMENT AND CARE 2020 131", "mimetype": "text/plain", "start_char_idx": 1531, "end_char_idx": 2625, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "159d520b-bf8a-4d50-9e34-5cb865d66d45": {"__data__": {"id_": "159d520b-bf8a-4d50-9e34-5cb865d66d45", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "154"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "e024498a-153c-4b79-8074-2ab668ee5fed", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "154"}, "hash": "66661ee4323de62dafc753c2389f92fd8ac3d6f85ae9ec2de62b9d0741e4aa1b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "957ead0c-9e4e-4833-a99e-2d1f16bff36c", "node_type": "1", "metadata": {}, "hash": "bebea0dcbf7a58e2f92671e0694a0f7dc81cfce9f4271471fc92ad3d0532c595", "class_name": "RelatedNodeInfo"}}, "text": "Table 8.10: Dosage of Fixed Dose Combination of 3HR for TPT\n                Children                                         Adult\n       Strength: RH\n                     * 75mg/50mg FDC*\n                                    *                Strength: RH 150mg/75mg FDC\n      Weight Band           RH Tablets           Weight Band             RH Tablets\n       4 - 7 kg                  1                25 - 37 kg                  2\n       8 - 11kg                  2\n        12 - 15kg                3\n        16 - 24kg                4                38 - 54 kg                  3\n          \u2265 25           Use adult Regimen           \u2265 55                     4\n *INH and 3HR are available in child - friendly and dispersible forms\n **FDC \u2013 Fixed Dose Combination\n8.3.2.5 General Contraindications to TPT\n    \u00a7   Active hepatitis (acute or chronic)\n    \u00a7   Active TB\n    \u00a7   Regular and heavy alcohol consumption\n    \u00a7   Symptoms of peripheral neuropathy\n    \u00a7   Allergy to TPT medicines.\n8.3.2.6 Contraindications to the use of Rifapentine plus INH\n    \u00a7   Individuals taking medications that may have drug interactions that are difficult to\n        manage with the regimen (e.g. PLHIV on Protease Inhibitors and NVP)\n    \u00a7   Persons presumed infected with MTB resistant to INH and RIF\n    \u00a7   Pregnant women or women planning to become pregnant during treatment.\n    \u00a7   Individuals who have had prior adverse events or hypersensitivity to INH or Rifapentine\n    \u00a7   Known pre-existing liver damage\n    \u00a7   Children under two years (no dosing for children < 2 years)[26]\n   \u00a7   In patients with severe malaria (impaired consciousness, low blood glucose, jaundice,\n       kidney failure, anaemia and parasitaemia >10%), stop 3HP, treat malaria urgently.\n       Restart 3HP once the episode of Malaria is resolved, to avoid drug - drug interactions\n   \u00a7   Supplement with Pyridoxine 25mg daily for six months if available when INH is given\n       for 6 months.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1962, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "957ead0c-9e4e-4833-a99e-2d1f16bff36c": {"__data__": {"id_": "957ead0c-9e4e-4833-a99e-2d1f16bff36c", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "154"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "e024498a-153c-4b79-8074-2ab668ee5fed", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "154"}, "hash": "66661ee4323de62dafc753c2389f92fd8ac3d6f85ae9ec2de62b9d0741e4aa1b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "159d520b-bf8a-4d50-9e34-5cb865d66d45", "node_type": "1", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "154"}, "hash": "b2fd8795628efa91711bd6384197e6e3f65959f1cfdc89e2c92e5f82488a60ee", "class_name": "RelatedNodeInfo"}}, "text": "However, lack of pyridoxine should not become a barrier to commencing\n       TPT.\n   \u00a7   3HP is recommended for PLHIV on ART that have acceptable drug-drug interactions\n       with Rifapentine such as efavirenz as well as DTG and RAL in adults. 3HP is NOT\n       recommended for PLHIVs on PI or NVP based ART. In cases where 3HP is\n       contraindicated or cannot be administered, use Isoniazid for 6 months.\n   \u00a7   INH is the preferred regimen in HIV positive children on LPV/r, NVP, DTG or RAL\n       [27]\n   \u00a7   In view of test and treat policy as well as significant virological suppression from DTG\n       containing  regimens,  repeat TPT   after 2  years  of completion   is no  longer\n       recommended\n          NATIONAL GUIDELINES FOR HIV PREVENTION TREATMENT AND CARE 2020           132", "mimetype": "text/plain", "start_char_idx": 1963, "end_char_idx": 2762, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1f2d5787-aef0-4b9a-8238-f2365e362766": {"__data__": {"id_": "1f2d5787-aef0-4b9a-8238-f2365e362766", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "155"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "bbc6cd0e-eb61-4539-9c9c-62c1d548f002", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "155"}, "hash": "472d9c4c532d61d9aba7bfe0159a7d9a0ce9a3e68b53dc96cbd6480a70fc9a9e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "80db4039-569d-4360-8bda-55eec2f6d612", "node_type": "1", "metadata": {}, "hash": "2628f857c5c6ab1a43421d5e48029f4b069eb981b8223e917eef9421d9651cec", "class_name": "RelatedNodeInfo"}}, "text": "8.3.2.6 Monitoring of Patients on TPT\nDuring monthly drug refills, monitor patient for:\n   \u00a7    Development of active TB (clinical assessment of signs and symptoms of active TB).\n   \u00a7    Development of side-effects; e.g. peripheral neuropathy (numbness/tingling sensation\n        of extremities). If present give Pyridoxine 50 - 75 mg daily.\n   \u00a7    Check for jaundice (yellowish eyes), abdominal pain, nausea, vomiting and yellowish\n        urine. If present, stop TPT and refer to medical officer to rule out active liver disease.\n   \u00a7    Check for allergic skin eruptions. If present stop treatment and refer to the medical\n        officer.\n   \u00a7    Evaluate adherence and counsel appropriately.\n   \u00a7    Any client who did not come a week after his/her TPT appointment day should be\n        tracked and managed appropriately.\nIf patient develops symptoms suggestive of active TB during the course of TPT:\n   \u00a7    Discontinue TPT\n   \u00a7    Assess for active TB\n   \u00a7    Commence DOTS if confirmed or refer to medical officer\n   \u00a7    Assess forART/re-assess forART failure\n8.3.2.7 Management of children and adults whose TPT is interrupted\nInterrupted treatment or incomplete TB preventive treatment is defined as the loss of at least one-\nthird of the intended LTBI treatment regimen (a lapse in treatment that lasted at least 1 or 2\nmonths consecutively depending on the TPT regimen employed).\nFor any client who misses appointment:\n   \u00a7    Trace the client/care giver\n   \u00a7    Find out the reason for missed appointment and address as appropriate\n   \u00a7    Offer adherence counseling\n   \u00a7    Evaluate to rule out active TB disease\n   \u00a7    Prolong treatment to compensate for the missed doses\nRefer to Table 8.11 below on management of IPT interruption\n   Table 8.11: Management of interruption of TPT\n     TPT         Length of                              Next Step\n   Regimen      Interruption\n  3HR, 6H       Less than     a.  Resume preventive treatment immediately upon return\n                2 weeks       b.  Add the number of days of missed doses to the total treatment\n                                  duration.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2118, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "80db4039-569d-4360-8bda-55eec2f6d612": {"__data__": {"id_": "80db4039-569d-4360-8bda-55eec2f6d612", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "155"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "bbc6cd0e-eb61-4539-9c9c-62c1d548f002", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "155"}, "hash": "472d9c4c532d61d9aba7bfe0159a7d9a0ce9a3e68b53dc96cbd6480a70fc9a9e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1f2d5787-aef0-4b9a-8238-f2365e362766", "node_type": "1", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "155"}, "hash": "a3bf2a2b2564cb348aa7984b5673ae6098f5a746706c36305819b0d9c1479a83", "class_name": "RelatedNodeInfo"}}, "text": "More than     a.  If treatment interruption occurred after more than 80% of doses\n                2 weeks           expected in the regimen were taken\n                                \u00b7  No action is required.\n                                \u00b7  Continue and complete the remaining treatment as per-original\n                                   plan.\n          NATIONAL GUIDELINES FOR HIV PREVENTION TREATMENT AND CARE 2020              133", "mimetype": "text/plain", "start_char_idx": 2135, "end_char_idx": 2571, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "65d10243-f15d-4bce-bbc2-e106f3533b61": {"__data__": {"id_": "65d10243-f15d-4bce-bbc2-e106f3533b61", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "156"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "7cea03c8-4dc6-44ce-961c-9038ff779864", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "156"}, "hash": "f63a6dba6d6714e5aafc264eb3c0b6f922cf3af6ed240d66063f37900760851d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9970512e-3eb7-47ad-9a30-c12d3b878f48", "node_type": "1", "metadata": {}, "hash": "e594c48fa2d49efd18d269dac8ae3fe034ffd8b878bfc2e1848104a4c7a31419", "class_name": "RelatedNodeInfo"}}, "text": "TPT         Length of                                  Next Step\n Regimen      Interruption\n3HR, 6H       More than       b.   If less than 80% of doses expected in the regimen were taken, and\n              2 weeks              the treatment course can still be completed within the expected time\n                                   for completion, i.e. treatment duration + 33% additional time.\n                                \u00b7 No action is required.\n                                \u00b7 Continue and complete the remaining treatment as per original plan.\n                              c.   If less than 80% of doses expected in the regimen were taken, and\n                                   the treatment course cannot be completed within the expected time\n                                   for completion\n                                \u00b7 Restart the full TPT course.\n3HP           Weekly          a.  If the missed dose is remembered within the next 2 days\n              schedule of       \u00b7 Take the dose immediately.\n              one dose          \u00b7 Continue the schedule as originally planned\n              missed\n                              b.  If the missed dose is remembered more than 2 days later.\n                                \u00b7 Take the missed dose immediately and change the schedule for\n                                   weekly intake to the day the missed dose was taken until treatment\n                                   completion.\n              More than       a.  If between 1-3 weekly doses are missed.\n              1 weekly         \u00b7    Treatment is continued until all 12 doses are taken, thus prolonging\n              doses of 3HP          the treatment duration to a maximum of 16 weeks\n              missed          b.  If 4 or more weekly doses are missed, restart the full TPT course.\n1HP           Less than 1     a.  If more than 80% (23) of doses expected in the regimen were taken.\n              week             \u00b7    No action is required, complete the remaining doses\n                              b. If less than 80% (23) of doses expected in the regimen were taken.\n                               \u00b7 Resume treatment immediately upon return\n                               \u00b7 Add the missed doses to the total treatment duration to complete the\n                                  course within a maximum of 6 weeks.\n              More than       a.   If more than 7 consecutive doses were missed.\n              1 week            \u00b7   Consider restarting the complete course of 1HP regimen.\n                              b.   If more than 7 doses were missed intermittently.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2609, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9970512e-3eb7-47ad-9a30-c12d3b878f48": {"__data__": {"id_": "9970512e-3eb7-47ad-9a30-c12d3b878f48", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "156"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "7cea03c8-4dc6-44ce-961c-9038ff779864", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "156"}, "hash": "f63a6dba6d6714e5aafc264eb3c0b6f922cf3af6ed240d66063f37900760851d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "65d10243-f15d-4bce-bbc2-e106f3533b61", "node_type": "1", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "156"}, "hash": "8e18c8c956eaf9aa6d0781ef49dd24769110444685a4b9ed109f62a22af2f54c", "class_name": "RelatedNodeInfo"}}, "text": "More than       a.   If more than 7 consecutive doses were missed.\n              1 week            \u00b7   Consider restarting the complete course of 1HP regimen.\n                              b.   If more than 7 doses were missed intermittently.\n                                \u00b7   Resume preventive treatment immediately upon return\n                                \u00b7   Add the missed doses to the total treatment duration to complete the\n                                    course within a maximum of 8 weeks\n                              c.   If adherence to 1HP is not possible\n                                \u00b7   consider discontinuing it and offering an alternative daily regimen\n                                    or 3HP\n* If attempt to complete LTBI treatment fails after 3 attempts, no further effort should be made.\n        NATIONAL GUIDELINES FOR HIV PREVENTION TREATMENT AND CARE 2020                    134", "mimetype": "text/plain", "start_char_idx": 2367, "end_char_idx": 3283, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "93da8cc7-87d3-490b-8951-60141efad62c": {"__data__": {"id_": "93da8cc7-87d3-490b-8951-60141efad62c", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "157"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "aa3dca8a-5e60-45ce-8aac-012c7dd140e2", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "157"}, "hash": "40abcf225c240f94f401246ee622d1f5f6a5c7ed635392b50117a0e2b046a9ef", "class_name": "RelatedNodeInfo"}}, "text": "8.3.2.8 Outcomes of TPT\nHealth care workers (HCW) should ensure that all children started on TPT are evaluated after\ncompleting their treatment and assigned a treatment outcome which should be documented in\nthe recording and reporting tools. The following are the possible treatment outcomes:\n   1.  Completed treatment\n   2.  Loss to follow-up\n   3.  Not evaluated\n   4.  Died\n   5.  Developed active TB\nRefer to appendix 7 for algorithms on screening and diagnosing children and adults living with\nHIV for TB.\nFor further information on TPT, refer to the National TB Guidelines and the National Guidelines\non Programmatic Management of Latent TB Infection in Nigeria.\n          NATIONAL GUIDELINES FOR HIV PREVENTION TREATMENT AND CARE 2020             135", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 758, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "44c6acb1-b760-4408-b3fd-6a197204891c": {"__data__": {"id_": "44c6acb1-b760-4408-b3fd-6a197204891c", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "158"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "a7a21d13-887b-49f3-913a-8812bc22837a", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "158"}, "hash": "6010f9aadfdc1be1f46651f220151c2b2579b171ddba91ca6d472793be55150f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a36f1734-219c-49a1-95c6-9f9f5832704e", "node_type": "1", "metadata": {}, "hash": "0677e5e1b032acd4adef37f8a7206473e24bea5bcc06388c15dd3cb16ec3e436", "class_name": "RelatedNodeInfo"}}, "text": "Table 8.12: Common HIV-Related Opportunistic Infections (OIs): Clinical Features, Treatment, and Prophylaxis\n                         -protein\n                                     -Interferon\n                                                                          Provide and\n                                                                            maintain\n                                                                                  nutrition\n                                                                                      E,U,Cr is useful\n                                                                                         to monitor renal\n                                                                               adequate    complications\n               HBsAg quantification if\n                 available\n                     Liver biopsy if necessary\n                         Baseline alpha feto\n                          (AFP) if possible\n               1.    2.  3.\n         Comments               complicated.\n                                     Some may require Peg\n                                       treatment\n                                           Baseline AFP if possible       Rehydrate\n                                                                            (SSS, ORS or\n                                                                                  required)\n                                                                                      Zinc\n                                                                                         supplement\n                                                                                           20mg daily for\n                              Refer for specialist care if                     Resomal as           patients\n                                                                                              10-14 days for\n                                                                                                 paediatric\n                          TDF and add\n                                                                                  Stool m/c/s\n                                                                                  -\n                                                                              Laboratory:\n         Treatment and Prophylaxis                                                    Serology\n                    TDF and 3TC, and where\n                      TDF is contraindicated,\n                          substitute for          (DAA);\n                                                         the pangenotypic regimen\n                                                            consisting ofSofosbuvir-\n                The regimen should include                                Clinical\n                           Entecavir            Direct-acting antiviral\n                                                        The Guideline Recommends\n                                                              Daclatasvir\n                                                                   Refer for specialist care for\n                                                                     complicated cases.\n                          HBsAg Anti HCV\n                                    HBV-DNAAnti HCV\n                                                  LFT\n                           Anti HBeAg               Abdominal ultrasound.\n                              Anti HBcAg\n                                      LFT\n                                          Abdominal ultrasound\n                                                       HCV RNA (Refer if\n                                                         positive)\n         Diagnosis  positive, screen for the\n                      following;\n                          1.    4.  5.        1.  2. 3.                   Frequent watery stools\n                Screen for HBsAg. If\n                           2. 3.      6.  7.           4.    5.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 4030, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a36f1734-219c-49a1-95c6-9f9f5832704e": {"__data__": {"id_": "a36f1734-219c-49a1-95c6-9f9f5832704e", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "158"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "a7a21d13-887b-49f3-913a-8812bc22837a", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "158"}, "hash": "6010f9aadfdc1be1f46651f220151c2b2579b171ddba91ca6d472793be55150f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "44c6acb1-b760-4408-b3fd-6a197204891c", "node_type": "1", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "158"}, "hash": "337b750effa5c9d74ea4a1b43b014fff9f355be36c63556a51cb2cd1809f9528", "class_name": "RelatedNodeInfo"}}, "text": "5.        1.  2. 3.                   Frequent watery stools\n                Screen for HBsAg. If\n                           2. 3.      6.  7.           4.    5. FBC\n                      except\n                                                                              Enterobacteriae\n                                                                                  E. Coli\n        Symptoms and                                                      Bacteria:\n                    signs and\n                      symptoms\n                          as in chronic liver     signs and\n                                                     symptoms except\n          signsThere may be no                          as in chronic liver           C. jejuni\n                           disease.             There may be no\n                                                           disease.       -   -   -\n                                                                              Rotavirus\n        Causative Virus                                                   Viruses: Enteroviruses\n          organisms                                                           -   -   Other viruses\n                Hepatitis B                         Hepatitis C\n                                                      Virus               -\n        Infection/                                                        Acute watery\n          Conditions\n                Hepatitis                                                   Diarrhoea\n       NATIONAL GUIDELINES FOR HIV PREVENTION TREATMENT AND CARE 2020                        136", "mimetype": "text/plain", "start_char_idx": 3869, "end_char_idx": 5481, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3e1a7525-f207-4824-98c0-bd1c44040906": {"__data__": {"id_": "3e1a7525-f207-4824-98c0-bd1c44040906", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "159"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "a80395d4-ee8c-42d0-82ff-8ba86116797e", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "159"}, "hash": "1637ee849d0facaa382f6c5a0d19f0d57343635b8a12b74f9ccc99f45576e2d3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "90849e80-dc64-43b4-b3a0-9a7a76d4c2d7", "node_type": "1", "metadata": {}, "hash": "020953e05916e3c3bda994aa0fabacad7c6dc33ad38463c169efd1490707eb10", "class_name": "RelatedNodeInfo"}}, "text": "Provide and\n           maintain\n             adequate\n                nutrition\n                    E, U.Creatinine\n                      is useful to\n                         monitor renal\n                            complications\n                     Ciprofloxacin   Albendazole\n                         Metronidazole\n Comments                   and CTX\n        Oral                     Strongyloidiasis:\n           rehydration\n               If antibiotics\n                 required:     For   -  Oral Zinc\n                                          therapyExtra caution for possible NVP\n                                                     interactions with ketoconazole\n                                                       (see the section on drug\n                                                          interactions)\n                                                             Internationally ketoconazole\n                                                               relativelycontraindicated since\n                                                                  2013 due to increased\n                                                                     idiosyncratic reactions\n                                                                          Secondary bacterial infection\n                     -   -                                                  may be common.\n                                                            2% Miconazole cream b.d\n                Stool m/c/s                                   to the skin for 3-5 weeks\n Treatment and Prophylaxis                           Whitfield\u2019s ointment applied\n        Clinical\n            Laboratory:\n                    Serology, e.g. Widal test     Topical application:\n                                                     -  b.d. for 3-5 weeks\n                                                                  Oral therapy: itraconazole/\n                                                                     fluconazole\n                                                                          Selenium sulphide shampoo,\n                                                                            or  Tar shampoo followed by\n                                                                                  sulphur salicylic acid cream\n                                                                                     or 1% hydrocortisone, or\n                -                                           -                            Ketoconazole cream\n Diagnosis\n        Frequent watery stools,\n           abdominal cramps bloody\n             stools, fever, nausea and\n                vomiting,dehydration              Clinical\n                                                     Laboratory: skin scrapings\n                                                        stained with KOHClinical\n            C. jejuni\n               Cyclospora\n                   Microsporidia\n                       C. albicans\n                           M. avium complex\n Symptoms and                 S. Stercoralis\n   signs                          Clostridium deficile\n                                                  Itchy circular\n                                                    lesions with raised\n                                                       edges, fine scaly\n                                                         area in the centre,\n                                                            loss of hair  Greasy scales over\n                                                                            scalp and redness\n                                                                               of cheek and\n            -      -   -   -  -                                                  flexural aspects\n        E. hystolitica\n            G. Lamblia\n                Isospora belli\n                    Cryptosporidia\n Causative              Salmonella spp.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 3949, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "90849e80-dc64-43b4-b3a0-9a7a76d4c2d7": {"__data__": {"id_": "90849e80-dc64-43b4-b3a0-9a7a76d4c2d7", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "159"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "a80395d4-ee8c-42d0-82ff-8ba86116797e", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "159"}, "hash": "1637ee849d0facaa382f6c5a0d19f0d57343635b8a12b74f9ccc99f45576e2d3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3e1a7525-f207-4824-98c0-bd1c44040906", "node_type": "1", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "159"}, "hash": "082fd19f73a30d6ec4ae3ad8d4e2e59885cc5d0334c59a6f1af7dbc39cfaf7ab", "class_name": "RelatedNodeInfo"}}, "text": "organisms               Shigella               Malassaezia\n                                                    furfur  Trichophyton\n                                                              rubrum      Allergicreaction\n                                                                            to yeast\n                                                                               infection\n        -   -   -   -   -                                                        (Pityrosporum)\n Infection/\n   Conditions\n        Dysentery                                 Tinea corporis\n                                                         Tinea capitis    Seborrhoeic\n                                                                            dermatitis\nNATIONAL GUIDELINES FOR HIV PREVENTION TREATMENT AND CARE 2020                     137", "mimetype": "text/plain", "start_char_idx": 3953, "end_char_idx": 4796, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c28bf029-c532-4154-9766-e090e7bc7136": {"__data__": {"id_": "c28bf029-c532-4154-9766-e090e7bc7136", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "160"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "28155c3f-7d1a-449a-8234-b22f335c8147", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "160"}, "hash": "000b8c9a02f026ce26facd722ffb6edfbfdab5e660999950dd7f6f356ce90757", "class_name": "RelatedNodeInfo"}}, "text": "Comments\n         Refer intractable cases for\n           specialist care.\n               Refer cases of herpes zoster\n                  involving the eye and ear for\n                    specialist care.\n                                 NSAIDS,                                 Tab Acyclovir\n                          10 mg/kg IV q8hr for 7\n                             days\n                                 Analgesics\u2013\n                                    carbamazepine,\n                                     amitriptyline\n                                         Local application of\n                                            calamine lotion;\n                                                Topical application of\n                                                  Acyclovir cream\n                                                      For painful vesicular\n                                                        unilateral lesions on face\n                                                           or trunk.\n                                                              Add gentian violet topical\n                                                                application, tab pregabalin\n                                                                   75mg BD (adult) 7 to 10\n         Adult:           -      -       -      -                    days,\n Treatment and Prophylaxis\n            Acyclovir: 800mg 5\n               times/day for 7 days\n                   + amitriptyline 25mg nocte\n                      OR                              -                  Paediatrics:\n                                                                           30mg/kg/day tds x 7 days\n                                                                                Acyclovir Tab 400mg tds\n                                                                                   for 7 \u201314 days\n                                                                                      OR 200mg 5 times daily\n                                                              -                          for 7 -14 days\n Diagnosis                                                                      Clinical\n         Clinical\n Symptoms and\n    signs Painful vesicular\n           lesions in a\n              dermatomal\n                distribution, on the\n                   face and trunk                                               Blisters or painful\n                                                                                   sores on or around\n                                                                                     the genitals,\n                                                                                        rectum\n Causative\n    organisms\n         Varicella zoster\n           virus                                                                Herpes simplex\n                                                                                   virus-(HSV)\n Infection/\n    Conditions\n         Herpes zoster\n           (Shingles)                                                           Herpes simplex\n                                                                                   Genitalis\nNATIONAL GUIDELINES FOR HIV PREVENTION TREATMENT AND CARE 2020                    138", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 3291, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e074bc41-cafe-4be4-b56f-588f9f15373a": {"__data__": {"id_": "e074bc41-cafe-4be4-b56f-588f9f15373a", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "161"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "eab121bf-01a6-4981-bb92-f0d6aa9ba3f7", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "161"}, "hash": "b0172d41cb28ae049a7c0d3cb918aab70df7d5da082a6427adf51f906b207094", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7c345bc1-163a-4ec7-bf34-7717e3ba570e", "node_type": "1", "metadata": {}, "hash": "aaa72f2803f547c29c2518b50d267026b46f23d361615883eb759e5cca7dc64e", "class_name": "RelatedNodeInfo"}}, "text": "Nausea, vomiting, diarrhoea,\n          headache, malaise, rash, seizures,\n             renal dysfunction                                   Highly contagious;\n                                                                    Refer Complications; Nutrition\n                                                                       support\n                                       Ophthalmological\nTreatment and Prophylaxis Comments\n       IV Acyclovir        Ganciclovir 5mg/kg IV bid x\n           Paediatrics: 20mg/kg tid x\n              21days\n                 Adult: 10-15 mg/kg IV q8hr\n                    for 14-21 days\n                              2-3 weeks;\n                                 Foscarnet IV 40-60mg/kg 8\n                                    hrly x 2-3 weeks\n                                       Retinitis\u2013\n                                          examination; same drug\n                                            therapy as above.    Supportive therapy\n                                                                    Antipyretics\n                                                                        Vitamin A, antibiotics as\n                                                                           indicated, adequate\n                                                                             hydration\nDiagnosis\n       Increased CSF: serum\n          HSV antibody ratio\n              Viral isolationClinical\n                               Laboratory:\n                                  Biopsy\n                                    (intracellular inclusions)\n                                        Serology\n                                            SkullX-ray\n                                               CT Scan\n                                                   CMV in CSF    Clinical\n                                     od;                                -\n                                                                   -\nSymptoms and\n   signsFever, altered\n          consciousness,\n             convulsions \u00b1 focal\n               neurological signs\n                           Enterocolitis:\n                              Fever, cramps,\n                                dysphagia,\n                                   odynophagia,\n                                     diarrhoea \u00b1 blo\n                                         CNS: Delirium,\n                                           lethargy, headache,\n                                             malaise\n                                                disorientation, neck\n                                                  stiffness,\n                                                     photophobia,\n                                                      cranial nerve palsy,\n                                                         blurred vision or\n                                                            \u201cfloaters\u201d\n                                                                 Fever, cough, red\n                                                                   eyes, kerato\n                                                                      conjunctivitis,\n                                                                        coryza, maculo\n                                                                           papular rash;\n                                                                              Complications:\n                                                                                 Pneumonia,\n                                                                                   diarrhoeal disease,\n                                                                                      malnutrition.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 3721, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7c345bc1-163a-4ec7-bf34-7717e3ba570e": {"__data__": {"id_": "7c345bc1-163a-4ec7-bf34-7717e3ba570e", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "161"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "eab121bf-01a6-4981-bb92-f0d6aa9ba3f7", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "161"}, "hash": "b0172d41cb28ae049a7c0d3cb918aab70df7d5da082a6427adf51f906b207094", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e074bc41-cafe-4be4-b56f-588f9f15373a", "node_type": "1", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "161"}, "hash": "bf3297249fffe37ba83c53a71bf7f1a747b85016f007c3ac039d5ba7f9d3e964", "class_name": "RelatedNodeInfo"}}, "text": "Causative\n   organisms\n       Herpes simplex\n          virus 1 and 2    Cytomegaloviru\n                              s (CMV)                            Measles virus\nInfection/\n   Conditions\n       Herpes virus\n          encephalitis     Cytomegaloviru\n                              s: Enteritis\n                                     Colitis\n                                         CNS\n                                           involvement           Measles\nNATIONAL GUIDELINES FOR HIV PREVENTION TREATMENT AND CARE 2020                  139", "mimetype": "text/plain", "start_char_idx": 3722, "end_char_idx": 4264, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6da50fab-5980-4c2c-84af-31918320c1d5": {"__data__": {"id_": "6da50fab-5980-4c2c-84af-31918320c1d5", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "162"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "45cd944d-2c5a-4ead-bbe8-70af481b85a6", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "162"}, "hash": "0dba443d25ba9ae65d30cdf4e1be05b9f1c39f8b65d49dfd57983571981b64ef", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4f7838a0-b176-4965-b8c0-685273a0447b", "node_type": "1", "metadata": {}, "hash": "29e7c2e703f40566e6a2060c88b984ff00d64b6e77d8241235baaa20ff22ae61", "class_name": "RelatedNodeInfo"}}, "text": "Nausea, vomiting, diarrhoea,\n           headache, malaise, rash, seizures,\n             renal dysfunction                                   Highly contagious;\n                                                                     Refer Complications; Nutrition\n                                                                        support\n                                        Ophthalmological\n Treatment and Prophylaxis Comments\n        IV Acyclovir\n            Paediatrics: 20mg/kg tid x\n              21days\n                  Adult: 10-15 mg/kg IV q8hr\n                    for 14-21 days\n                            Ganciclovir 5mg/kg IV bid x\n                              2-3 weeks;\n                                  Foscarnet IV 40-60mg/kg 8\n                                    hrly x 2-3 weeks\n                                        Retinitis\u2013\n                                          examination; same drug\n                                             therapy as above.   Supportive therapy\n                                                                     Antipyretics\n                                                                         Vitamin A, antibiotics as\n                                                                           indicated, adequate hydration\n                               Biopsy\n Diagnosis\n        Increased CSF: serum\n           HSV antibody ratio\n              Viral isolation Clinical\n                               Laboratory:\n                                  (intracellular inclusions)\n                                     Serology\n                                         SkullX-ray\n                                             CT Scan\n                                                CMV in CSF       Clinical\n                                      od;                                -\n                                                                    -\n Symptoms and\n   signs\n        Fever, altered\n           consciousness,\n             convulsions \u00b1 focal\n               neurological signs\n                            Enterocolitis:\n                              Fever, cramps,\n                                 dysphagia,\n                                   odynophagia,\n                                      diarrhoea \u00b1 blo\n                                         CNS: Delirium,\n                                           lethargy, headache,\n                                              malaise\n                                                 disorientation, neck\n                                                   stiffness,\n                                                     photophobia,\n                                                      cranial nerve palsy,\n                                                         blurred vision or\n                                                             \u201cfloaters\u201d\n                                                                 Fever, cough, red\n                                                                    eyes, kerato\n                                                                      conjunctivitis,\n                                                                         coryza, maculo\n                                                                           papular rash;\n                                                                               Complications:\n                                                                                 Pneumonia,\n                                                                                    diarrhoeal disease,\n                                                                                      malnutrition.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 3692, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4f7838a0-b176-4965-b8c0-685273a0447b": {"__data__": {"id_": "4f7838a0-b176-4965-b8c0-685273a0447b", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "162"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "45cd944d-2c5a-4ead-bbe8-70af481b85a6", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "162"}, "hash": "0dba443d25ba9ae65d30cdf4e1be05b9f1c39f8b65d49dfd57983571981b64ef", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6da50fab-5980-4c2c-84af-31918320c1d5", "node_type": "1", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "162"}, "hash": "57fe3bef651390aa5ff225e696f0212cd5c63362ce30a78ff634b876d72027ea", "class_name": "RelatedNodeInfo"}}, "text": "Causative\n   organisms\n        Herpes simplex\n           virus 1 and 2    Cytomegaloviru\n                              s (CMV)                            Measles virus\n Infection/\n   Conditions\n        Herpes virus\n           encephalitis     Cytomegaloviru\n                              s:  Enteritis\n                                     Colitis\n                                         CNS\n                                           involvement           Measles\nNATIONAL GUIDELINES FOR HIV PREVENTION TREATMENT AND CARE 2020                  140", "mimetype": "text/plain", "start_char_idx": 3694, "end_char_idx": 4242, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "47391560-6334-47d5-9e62-6686f17e4f06": {"__data__": {"id_": "47391560-6334-47d5-9e62-6686f17e4f06", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "163"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "e8a10dae-2516-45da-acd4-0ee1cf985fec", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "163"}, "hash": "3a514fff30dc3a538548d763f3ddaffac64fc32b130f26ada0f30310fda14104", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c347c70f-8257-4b7e-a6d8-3af905c52495", "node_type": "1", "metadata": {}, "hash": "bac4aed0758cf9a6545eca8369458bee552077ed4df4fe94d0363749e4b69c41", "class_name": "RelatedNodeInfo"}}, "text": "a 2nd line anti TB\n  Comments\n          For severe pneumonia in children\n             <12 months old treat PJP\n               presumptively with CTX.\n                    If facilities to exclude PJP\n                      infections are not available or ifa\n                         child on CPT develops bacterial\n                            pneumonia do not treat with CTX\n                               but refer.\n                                   Quinolones are\n                                      drug hence rule out TB before\n                                        using quinolones(levofloxacin)\n             requires only\n                                                 (Azithromycin or\n                                                    clarithromycin).\n                                                      Respiratory quinolones\n                                                         (levofloxacin) in adults.\n                        Out-patient therapy with\n                           CTX or         2nd and 3rd generation\n                                                 o    o\n  Treatment and Prophylaxis                  cephalosporin as 2nd line. 3rd and 4th generation\n          Viral pneumonia is self-\n             limiting \u2013\n               supportive care\n                    Bacterial: Amoxicillin or\n                                 Amoxicillin/clavulanic acid.\n                                      For in-patient therapy:  Amoxicillin or Amoxicillin/\n                                                                clavulanic acid.\n                                                                    2nd generation cephalosporin\n                                                                           cephalosporin, and\n                                                                              respiratory quinolones\n                        -                 -                                      (levofloxacin)\n              blood culture.\n                                                                      Throat swab for m/c/s\n          Clinical                                                    -\n              Laboratory:\n                  Chest x-ray\n                      -sputum examination                      Clinical\n  Diagnosis                                                      Laboratory:\n  Symptoms and\n    signs Fever, chills, cough\n             and pleuritic chest\n               pain, difficulty/ fast\n                  breathing.\n                      Crepitations,\n                         bronchial breath\n                            sounds                             Fever, cough,\n                                                                vomiting, refusal of\n                                                                   feeds, drooling of\n                                                                      saliva, inflamed\n                                                                         tonsils/ pharynx.\n                                                                         Strep.\n                                                                           pneumoniae\n                                                                                H. influenza\n                                                                                    Moxerella\n                                                                                      Catarhalis\n                                                                                           Klebs.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 3545, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c347c70f-8257-4b7e-a6d8-3af905c52495": {"__data__": {"id_": "c347c70f-8257-4b7e-a6d8-3af905c52495", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "163"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "e8a10dae-2516-45da-acd4-0ee1cf985fec", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "163"}, "hash": "3a514fff30dc3a538548d763f3ddaffac64fc32b130f26ada0f30310fda14104", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "47391560-6334-47d5-9e62-6686f17e4f06", "node_type": "1", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "163"}, "hash": "f74796feca17efc014cd6db0066c1d5a9dcefd499b325feae37fe6a18a7911b2", "class_name": "RelatedNodeInfo"}}, "text": "Strep.\n                                                                           pneumoniae\n                                                                                H. influenza\n                                                                                    Moxerella\n                                                                                      Catarhalis\n                                                                                           Klebs.\n  Causative                                                              -      -   -      -  pneumoniae\n    organisms\n          Respiratory\n             viruses\n                 Bacteria:\n                     S. pneumoniae\n                         H. influenza\n                             S. aureus\n                                 M. catarhalis\n                                      Kl. pneumonia\n                                          P. aeruginosa        Respiratory\n                                                                viruses\n                                                                    Bacteria:\n  Infection/\n    Conditions\n          Pneumonia                                            Acute\n                                                                Pharyngo\u2013\n                                                                   tonsillitis\nNATIONAL GUIDELINES FOR HIV PREVENTION TREATMENT AND CARE 2020                         141", "mimetype": "text/plain", "start_char_idx": 3071, "end_char_idx": 4511, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7da6e1b6-9f0b-43cf-8518-ac6ffc87ed63": {"__data__": {"id_": "7da6e1b6-9f0b-43cf-8518-ac6ffc87ed63", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "164"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "26e48ada-ab03-42ed-9bee-26a3123d7a5f", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "164"}, "hash": "6b82bddf5c86b68485ace02de7983d9c5f7f1a1a543494d2457381e47f12842a", "class_name": "RelatedNodeInfo"}}, "text": "Infection/      Causative        Symptoms and       Diagnosis                Treatment and Prophylaxis  Comments\n                                               Hearing loss is a complication\n            Amoxicillin or\n              Amoxicillin/ clavulanic\n                 acid\n                    2nd generation\n                      cephalosporin\n                         3rd and 4th generation\n                           cephalosporin, and\n                              respiratory quinolones\n                                (levofloxacin) Refer to ENT specialist\n                                                                   Clean sore with antiseptics\n                                                                      Drain pus if fluctuant\n                                                                          Ampicillin/cloxacillin\n                                                                             Cefuroxime, cefixime,\n                                                                               amoxicillin-clavulanic\n                                                                                  acid and flucloxacillin.\n                                                                                    Topical agents such as\n                                                                                       Mupirocin or Retapamulin\n                  Ear swab for m/c/s                  Ear swab for m/c/s\n                  -                                   -\n            Clinical\n               Laboratory:                     Clinical\n                                                  Laboratory:\n                                                        X-ray of mastoid\n                                                                   Clinical\n            Fever, vomiting,\n              cough, ear-\n                tugging;\n                    Hyperaemic\n                      tympanic\n                        membrane,\n                          purulent ear\n                            discharge          Ear discharge\n                                                 lasting >14 days  Skin pustules\n                                                                      crusts,\n       signs                                                            Fever (rarely)\n                    Strep.   Staph.\n                               Aureus\n                                  Moraxella\n                                     catarhalis\n                       pneumoniae       Klebs.\n                    -     H. influenza    pneumoniae\n                          -  -    -     -          H. influenza\n                                                      S. Aureus\n                                                         M. Catarhalis\n                                                               P. aeruginosa\n                                                                   Streptococcus\n                                                                      spp,\n                                                                         Staph. Aureus\n                                                            Kl. pneumoniae\n       organisms                               S. pneumoniae\n            Respiratory\n              viruses\n                 Bacteria:                     -   -  -  -  -  -   -     -\n            Acute otitis\n              media                            Chronic\n                                                 suppurative\n       Conditions                                  otitis media    Impetigo\n     NATIONAL GUIDELINES FOR HIV PREVENTION TREATMENT AND CARE 2020               142", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 3662, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "556f10bc-7d4e-458a-a0a0-f538ed644201": {"__data__": {"id_": "556f10bc-7d4e-458a-a0a0-f538ed644201", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "165"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "3aa86a31-973c-4fce-ab66-f4aa7bff5043", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "165"}, "hash": "cc0d11d1e4cd0f7c62d48160242d961e8f5fc467c115efd1f0f1d67e2734760f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bb94cf11-a258-4b70-81ac-9873bf3f873e", "node_type": "1", "metadata": {}, "hash": "47194218dad578455fc7d1ed8e86b0e3aade391ae96c176bb9ef9fbb335498b0", "class_name": "RelatedNodeInfo"}}, "text": "Refer to a higher-level\n         facility if complicated\n                      There is an increased risk of\n                         neutropenia with AZT and\n                           increased risk of hepatotoxicity\n                             with EFV.                 Refer to a tertiary facility i\n                                                         necessary\n                                                            If in shock, provide supportive\nComments                                                       therapy\n                     amodiaquine in\n                        patients taking\n                          zidovudine or EFV.\n                             Avoid ACT\n                                containing sulfado-\n                                  xine-pyrimethamine\n                                     combination if a\n                                       patient is on CPT.\n                                          Avoid Intermittent\n                                            Preventive Treatment\n                                              (IPT) for malaria in\n                                                pregnancy if the\n                   Avoid ACT containing            patient is on CPT.\n                             -            -\n                Injectable Artesunate\n                   -                                               acid + genticin\n                                                                          generatio  infection\n                                                            Penicillin + Gentamycin\n                                                                Amoxicillin/clavulanic\n                                                                      Metronidazole for\n                                                                       anaerobes 2nd or 3rd\n                                                                           cephalosporin and\n                                                                              amoxicillin-clavulanic acid\n                                                                                with/out other antibiotics\n                \u00b7                                                                 depending on the focus of\nTreatment and Prophylaxis                              While awaiting m/c/s\n      Uncomplicated:                                     results, either:\n          Artemisinin-based\n           Combination Therapy\n               Complicated:                                 -   -   -\n                                                                         -specific\n                                                              FBC\n                                                                  Blood culture\n                                                                      Urine culture\n                                                                         Organ\n                                                                          signs/focus of\n                                                                            infection determines\n                                                              -   -   -  -    theneeded test(s).\n       Clinical RDT.                                                              -\n          Laboratory: malaria\n            parasite in blood film                     Clinical assessment\nDiagnosis                                                 Laboratory:\n       Fever, chills and\n         rigour, headache,\n            nausea and\n              vomiting                                 Fever\nSymptoms and                                              Shock\n  signs\n                                                                          -negatives\n                                                       S. pneumoniae\n                                                          H. influenzae\n                                                              Salmonella\n                                                                   N. meningitides\n                                                                      Staph aureus\n                                                                          Gram\n                                                                          (e.g.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 4309, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bb94cf11-a258-4b70-81ac-9873bf3f873e": {"__data__": {"id_": "bb94cf11-a258-4b70-81ac-9873bf3f873e", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "165"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "3aa86a31-973c-4fce-ab66-f4aa7bff5043", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "165"}, "hash": "cc0d11d1e4cd0f7c62d48160242d961e8f5fc467c115efd1f0f1d67e2734760f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "556f10bc-7d4e-458a-a0a0-f538ed644201", "node_type": "1", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "165"}, "hash": "bb545e26ff5b64e7d09e48b9667c2ef1d920622e7dd9cd6105a7160e94df2358", "class_name": "RelatedNodeInfo"}}, "text": "E. coli)\n         falciparum                                                          Anaerobes\nCausative\n  organisms                                            -  -   -    -  -   -  -\n       Mainly P.\n       Malaria                                         Sepsis\nInfection/\n  Conditions\nNATIONAL GUIDELINES FOR HIV PREVENTION TREATMENT AND CARE 2020                143", "mimetype": "text/plain", "start_char_idx": 4310, "end_char_idx": 4679, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6415ca26-b722-4662-9a6a-d13e0d33aace": {"__data__": {"id_": "6415ca26-b722-4662-9a6a-d13e0d33aace", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "166"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "3cd572bc-021d-4450-807b-8020691904b4", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "166"}, "hash": "55a7d53c35753a4ffcce6dd8843bc38955eea253f82b9e45e799581f87983439", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5a8bee1d-c015-437f-9775-69993b402fb4", "node_type": "1", "metadata": {}, "hash": "65d1f443489ed2aaeb79e2bcd2d45e7b5ffb7a3842de8682525dbc97394ccf2e", "class_name": "RelatedNodeInfo"}}, "text": "Refer to a tertiary facility if\n                necessary                    Treat super -imposed bacterial\n                                                 infection with oral antibiotics\n                                                      Treat all household members even\n                                                         if asymptomatic\n                                                              Ivermectin is not recommended for\n                                                                  children below 15kg and pregnant\n  Comments                                                            or lactating women\n                                                                \u201314 hours.          -14 days +/ -\n                                                 neck down nocte\n            Penicillin & Chloramphenicol\n                or   3rd generation cephalosporin\n                        + Gentamycin\n                              Supportive treatment\n                                             25% Benzyl benzoate applied\n                                                 whole body,\n                                                    for 3 days OR\n                                                         Permethrin cream 5% applied\n                                                             whole body, neck down and\n                                                                washed off after 8\n                                                                    Repeat after 1 \u20132 weeks.\n                                                                                    If poor response to topical\n                                                                                        treatment then oral\n                                                                                    Ivermectin tablet 200mcg/kg\n                                                                                    stat, repeat after 7\n                                                                                       25% benzy l benzoate or\n                                                                                           Crotamiton.\n                                                                                                Was h and sun -dry/iron\n                                                                                                   clothings, beddings and\n  Treatment and Prophylaxis                                                                            fomites.\n                                                  copy\n                       FBC Blood culture\n            Clinical assessment  CSF analysis\n                 Laboratory:                 Clinical,\n                                                  Laboratory: Micros\n                                                      on KOH prep.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2861, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5a8bee1d-c015-437f-9775-69993b402fb4": {"__data__": {"id_": "5a8bee1d-c015-437f-9775-69993b402fb4", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "166"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "3cd572bc-021d-4450-807b-8020691904b4", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "166"}, "hash": "55a7d53c35753a4ffcce6dd8843bc38955eea253f82b9e45e799581f87983439", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6415ca26-b722-4662-9a6a-d13e0d33aace", "node_type": "1", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "166"}, "hash": "354a7c3436d8d3180d29075f34194d23c92bc704d2382a21f76ba1bd387f590e", "class_name": "RelatedNodeInfo"}}, "text": "copy\n                       FBC Blood culture\n            Clinical assessment  CSF analysis\n                 Laboratory:                 Clinical,\n                                                  Laboratory: Micros\n                                                      on KOH prep. of skin\n  Diagnosis            -    -    -                       scrapings\n            Fever, headache,\n                vomiting,\n                   irritability, altered\n                       sensorium,\n                          convulsions\n                               Nuchal rigidity,\n                                   bulging fontanelle\n                                      (in children)\n                                             Intense itchy\n                                                 lesions most\n                                                    prominent in inter-\n                                                       digital web, spaces\n                                                          of the fin gers,\n                                                               wrist, buttocks and\n                                                                  axillary area;\n                                                                       Papular rashes or\n                                                                           generalised\n                                                                              (Norwegian)\n                                                                                    Presentation could\n                                                                                       be more\n                                                                                          generalized in the\n                                                                                              context of\n  Symptoms and                                                                                   HIV/AIDS\n     signs\n            S. pneumoniae\n                 H. influenzae\n                       Salmonella\n                            N. meningitides\n                                  Staph aureusSarcoptes\n  Causative                                      scabei\n     organisms\n            -    -     -    -     -          -\n            Acute bacter ial\n  Infection/    Meningitis                   Scabies\n     Conditions\nNATIONAL GUIDELINES FOR HIV PREVENTION TREATMENT AND CARE 2020                                  144", "mimetype": "text/plain", "start_char_idx": 2579, "end_char_idx": 5067, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e59fd1cc-d0b5-4df0-86aa-31f92f58f2ca": {"__data__": {"id_": "e59fd1cc-d0b5-4df0-86aa-31f92f58f2ca", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "167"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "4e19f959-ebc1-4f57-8dd5-9234afd2eb1d", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "167"}, "hash": "75f729093f6c87945f813dd3d9decfbf201e3621631f394ad608a649cb95f43a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5765ea47-1c9b-4937-b3c7-c70726de1f69", "node_type": "1", "metadata": {}, "hash": "a6d6cfa02655dfe736082aaf09129a86bd0fce10b762239ac5b54111ab26dbcb", "class_name": "RelatedNodeInfo"}}, "text": "-\n        Nausea and vomiting\n                Optic neuritis may occur with\n                   ethambutol                               Complications of therapy with\n                                                              prednisolone include\n                                                                  Hypertension, gastritis, adrenal\n                                                                     insufficiency, seizures, pseudo\n                                                                       tumour cerebri, hypokalaemia,\nComments                                                                  fluid retention, glucose intolerance\n               + ethambutol 15 mg/kg daily\n            Clarithromycin 500 mg b.d.\n                 with or without rifabutin\n                    (300 mg daily).\n                       Azithromycin (500-600 mg\n                         daily) can be substituted for\n                            clarithromycin.\n                                    Clarithromycin\n                                      7.5mg/kg/dose b.d or\n                                         azithromycin 5-\n                                            20mg/kg/dose once daily\n                                              plus Ethambutol\n                                                 15mg/kg/day for 6 months.\n        Adult:                  Paediatrics:        Prophylaxis: guided by CD4+\n                                                      countSteroids (prednisolone\n                                                              2mg/kg/day x 6 weeks, taper\n                                                                 off) Oxygen\n                                                                         Bronchodilators (salbutamol)\n                                                                             Chest physiotherapy\n                                                                                Referral toa specialist\nTreatment and Prophylaxis                                                          (paediatricpulmonologist)\n            -          -            -\n                                                               ion.-\n        Clinical\n            Laboratory: Multiple\n               blood cultures;\n                   Lymph node biopsyfor\n                     intracellular inclusions               Clinical\n                                                               Diagnosis of exclus\n                                                                   Chest X-Ray: reticulo\n                                                                      nodular infiltrates,\n                                                                         bilateral hilar/mediastinal\nDiagnosis                                                                  lymphadenopathy;\n           recurrent fever,\n        Disseminated form\n           \u2013 chronic diarrhoea,\n                lymphadenopathy,\n                   weight loss/failure\n                     to thrive,\n                        abdominal pain,\n                           Respiratory\n                             symptoms may\n                                occur                       May initially be\n                                                              asymptomatic.\n                                                                  Recurrent Cough,\n                                                                     respiratory distress,\n                                                                       parotid\n                                                                          enlargement,\n                                                                             generalized\n                                                                               lymphadenopathy,\n                                                                                  hepatosplenomegal\n                                                                                     y, digital clubbing,\n                                                                                       and poor response\nSymptoms and                                                                              to TB therapy.\n   signs\n                                                              associated with\n                                                                 co-infection\n                                                                    with Epstein\n        M. Avium spp.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 4507, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5765ea47-1c9b-4937-b3c7-c70726de1f69": {"__data__": {"id_": "5765ea47-1c9b-4937-b3c7-c70726de1f69", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "167"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "4e19f959-ebc1-4f57-8dd5-9234afd2eb1d", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "167"}, "hash": "75f729093f6c87945f813dd3d9decfbf201e3621631f394ad608a649cb95f43a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e59fd1cc-d0b5-4df0-86aa-31f92f58f2ca", "node_type": "1", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "167"}, "hash": "6293bf5efd0cf26b2a9a9fe82c18529a5a268ac5624bed5e19a6b47da3b4cf0a", "class_name": "RelatedNodeInfo"}}, "text": "signs\n                                                              associated with\n                                                                 co-infection\n                                                                    with Epstein\n        M. Avium spp.                                                 Barr Virus\nCausative                                                   Unknown, but\n   organisms\n        Mycobacterium\n           Avium Complex                                    Lymphoid\n                                                              interstitial\n                                                                 pneumonitis\nInfection/                                                          (LIP)\n   Conditions\nNATIONAL GUIDELINES FOR HIV PREVENTION TREATMENT AND CARE 2020                     145", "mimetype": "text/plain", "start_char_idx": 4243, "end_char_idx": 5070, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b4ad81ae-1a81-4289-9433-0fc3740b1f32": {"__data__": {"id_": "b4ad81ae-1a81-4289-9433-0fc3740b1f32", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "168"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "8845ef23-bac5-4a94-83fe-864068ff0ae6", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "168"}, "hash": "e5c8d530f8eed1c5a44f176a6218864959daeb9f9fb92f655a9e0ec56b1707c7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b93f2ebe-a233-4c3b-8d25-2b11a2ba52c1", "node_type": "1", "metadata": {}, "hash": "cca846e0da40f0a7dc7d367428aa78b639e2b2215251491914a3a3c7bdf230b0", "class_name": "RelatedNodeInfo"}}, "text": "8.4 HIV-Related Co-Morbidities\nTable 8.13 Common HIV-Related Co-Morbidities\n Comorbidities      Example                                 Comment\n Cardiovascular     1.  Hypertension                        Asses all PLHIV for risk of CVD and\n                    2.  Heart failure                       implement risk reduction strategies.\n                    3.  Cardiomyopathy                      Treat uncomplicated hypertension\n                    4.  Arrhythmias                         and heart failure refer others for\n                    5.  Artheroclerosis/Ischaemic heart     specialist care\n                        diseases/Cerebrovascular diseases\n Others             Type 2 diabetes,                        Clients should be assessed and\n                    Asthma                                  managed for these diseases including\n                    Chronic obstructive pulmonary           referral for specialist care where\n                    disease(COPD)                           necessary.\n                    Breast and Cervical cancers             All women with HIV should be\n                                                            screened for cervical cancer\n                                                            regardless of age.\n8.5 Mental Health and HIV\nMental health problems can increase the risk of HIV acquisition both directly and indirectly. In\nsub-Saharan Africa (SSA) HIV constitutes a major burden on mental health-related challenges\n[28]. The prevalence of depressive illness amongst PLHIV on ART in SSA is estimated to range\nfrom 29 to 63.1% [28]. HIV neuro-inflammation occurs nearly in every person that is HIV\ninfected but may present with symptoms in only about 60% of patients [29] who are said to have\nHIV-associated neurocognitive disorder (HAND). Although the severity of HAND is said to\nreduce in the era of combination antiretroviral therapy the neuro-inflammation is a long-lasting\ninflammation that still manifests as symptoms even in some individuals on effective ARV giving\nrise to the notion that neurocognitive decline may be resistant to treatment in some patients [29].\nHIV-associated neurocognitive disorder (HAND) is not only a long-lasting disorder, it is\nassociated with a profound decrease in the quality of life. It complicates autonomy, may\nadversely modify ARV treatment adherence and can produce high-level vulnerability to wrong\njudgment and accidents. Therefore, this guideline recommends that every PLHIV should have a\nmental health assessment.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2527, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b93f2ebe-a233-4c3b-8d25-2b11a2ba52c1": {"__data__": {"id_": "b93f2ebe-a233-4c3b-8d25-2b11a2ba52c1", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "168"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "8845ef23-bac5-4a94-83fe-864068ff0ae6", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "168"}, "hash": "e5c8d530f8eed1c5a44f176a6218864959daeb9f9fb92f655a9e0ec56b1707c7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b4ad81ae-1a81-4289-9433-0fc3740b1f32", "node_type": "1", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "168"}, "hash": "ecb8a5751468fadb68d348008dee64efba54ace8a65209ced7cf3a9f6393e387", "class_name": "RelatedNodeInfo"}}, "text": "It complicates autonomy, may\nadversely modify ARV treatment adherence and can produce high-level vulnerability to wrong\njudgment and accidents. Therefore, this guideline recommends that every PLHIV should have a\nmental health assessment.\n8.5.1 Recommendations\n    1.  Conduct an assessment for HAND\n    2.  Manage HAND appropriately\n           NATIONAL GUIDELINES FOR HIV PREVENTION TREATMENT AND CARE 2020                146", "mimetype": "text/plain", "start_char_idx": 2290, "end_char_idx": 2715, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "382ab8aa-8fe1-4b7a-9fe9-093bdd4d20dd": {"__data__": {"id_": "382ab8aa-8fe1-4b7a-9fe9-093bdd4d20dd", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "169"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "4a3165f7-60ef-4165-acbf-6f9a419e6b54", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "169"}, "hash": "da0276d0a9a1af7f8fbb1117ebe061eeaaf059846e84f2172ba1d1c72a7d0e85", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6e3d678b-a98b-457e-974d-38fe4314ae20", "node_type": "1", "metadata": {}, "hash": "8c8a49ea654ec851ee6e54805af39a33156aca06e08f6e06d851c545ea1a1ebd", "class_name": "RelatedNodeInfo"}}, "text": "Table 8.14: Assessment for HAND as Proposed by the National Institute of Neurological Diseases and Stroke\n         Hand Type              Diagnostic Criteria\n                                \u00b7   Slight cognitive deficits in two or more neuropsychological\n                                    domains\n HIV-associated asymptomatic    \u00b7   Cognitive function impairment does not affect daily\n neurocognitive impairment      \u00b7   functioning\n (ANI)                              Neurocognitive disorders fail to meet the criteria for delirium\n                                    or dementia\n                                \u00b7   There is no evidence of pre -existing cause of ANI\n                                \u00b7   Mild or moderate cognitive function impairment in two or\n                                    more neuropsychological domains\n                                \u00b7   Cognitive disorders affect, at least to a mild extent, daily\n HIV-associated mild            \u00b7   functioning\n neurocognitive disorder            Cognitive disorders fail to meet the c riteria for delirium or\n (MND)                              dementia\n                                \u00b7   They are not conditioned by other concomitant diseases\n                                \u00b7   A patient may display mild concentration, attention or memory\n                                    disturbances (e.g. complaints about difficulty in reading)\n                                \u00b7   Moderate or severe cognitive function impairment in two or\n                                    more neuropsychologica l domains\n                                \u00b7   Considerable difficulty in performing daily functions\n                                    associated with intensification of cognitive disorders\n HIV-associated dementia        \u00b7   Cognitive disorders fail to meet the criteria for delirium\n (HAD)\n                                \u00b7   Cognitive disorders are not conditioned by comorbid diseases\n                                \u00b7   The patient may develop speech problems, emotional\n                                    shallowness, lack of spontaneity and social withdrawal\n8.5.2 Management Considerations\nThe key principle to management of HAND is to:\n    1   Exclude cerebral OIs which may mimic features of HAND or depression\n    2.  Implementation of treatment for depression among people with HIV may require task-\n        shifting, building health worker capacity, national adaptation of screening tools and\n        simplification of tools for use by nonspecialized primary Health care providers.\n    3.  The patient is placed on effectiveART with good central nervous system (CNS)\n        penetration capacity.\n    4.  The patient is appropriately referred for expert Neuropsychiatric assessment\nAnother Mental health screening tool for PLHIV according to the New York state department\nof HealthAIDS Institute is described in appendix 2.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2895, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6e3d678b-a98b-457e-974d-38fe4314ae20": {"__data__": {"id_": "6e3d678b-a98b-457e-974d-38fe4314ae20", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "169"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "4a3165f7-60ef-4165-acbf-6f9a419e6b54", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "169"}, "hash": "da0276d0a9a1af7f8fbb1117ebe061eeaaf059846e84f2172ba1d1c72a7d0e85", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "382ab8aa-8fe1-4b7a-9fe9-093bdd4d20dd", "node_type": "1", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "169"}, "hash": "da1e9470dd3557cacb2b0a420403b51432574587cbb0ee2463bf6d5f85709451", "class_name": "RelatedNodeInfo"}}, "text": "4.  The patient is appropriately referred for expert Neuropsychiatric assessment\nAnother Mental health screening tool for PLHIV according to the New York state department\nof HealthAIDS Institute is described in appendix 2.\n           NATIONAL GUIDELINES FOR HIV PREVENTION TREATMENT AND CARE 2020                147", "mimetype": "text/plain", "start_char_idx": 2673, "end_char_idx": 2988, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2c691738-dc4b-4cbc-8882-78121574e5e9": {"__data__": {"id_": "2c691738-dc4b-4cbc-8882-78121574e5e9", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "170"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "7251f124-7168-4ec5-807a-14a4ed7476ce", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "170"}, "hash": "2a5c8d2cd6887ab8a102da55f8db9b8ae001de62d3b02000a063819719598bc1", "class_name": "RelatedNodeInfo"}}, "text": "List of Contributors                                                   Chapter 8\nDr. Umo Mildred Ene-Obong    Head/Director, Public Health Department FMoH\nDr Akudo Ikpeazu             National Coordinator NASCP\nMr Araoye Segilola           Former, National Coordinator\nPharm Oloyede Yekini         Former, Director, Logistics Unit NASCP\nDr Akpan Nsebong             Deputy Director NASCP\nOmbudadu Obadiah A           Deputy Director NASCP\nDr Deborah Odoh              Deputy Director, NTTP & Performance Management NASCP\nMrs Semlek Rachael N         Chief Accountant NASCP\nDr Nwaokenneya Peter         Assistant Director, Adult ART/TB/HIV - NASCP\nDr Chioma Ukanwa             Senior Medical Officer 1, NTTP & Performance Management\n                             NASCP\nMs Rahila Agwom              Chief Scientific Officer NASCP\nDr Chinwendu Ndukwe          Deputy Director, Health Sector Response Support NACA\nProf. Sulaimon Akanmu        Chairman NTTA / Haematologist LUTH Lagos\nDr Damien Anweh              Member NTTA / Physician FMC, Markurdi\nDr Rita O. Oladele           Member NTTA / Microbiologist LUTH Lagos\nDr Charles Olomofe           Public Health Physician FETH Ido Ekiti\nDr Oluwafunke Ilesanmi       Technical Officer, HIV and Viral Hepatitis WHO\nDr Dennis Onotu              Branch Chief, Continuum of care & treatment CDC\nDr Obinna Ogbanufe           Senior Program Specialist, HIV care and treatment CDC\nDr Igboeline Onyeka Donald   Programme Manager, Treatment USAID\nDr Abiye Kalio               Programme Manager USAID\nFolu Lufadeju                Deputy Country Director CHAI\nPharm Willams Eigege         Associate CHAI\nDr Saswata Dutt              Senior Technical Advisor, HIV/TB/DR -TB IHVN\nDr Olufemi Oke               Technical Advisor CRS\nDr Olawale Fadare            Technical Director TMEC/RISE Program\nDr Olayiwola Lanre           Senior Technical Advisor CCFN\n         NATIONAL GUIDELINES FOR HIV PREVENTION TREATMENT AND CARE 2020     148", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1967, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0378a33e-7743-4673-9c1a-ad55dbf0810a": {"__data__": {"id_": "0378a33e-7743-4673-9c1a-ad55dbf0810a", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "171"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "d68cfc65-85b5-4234-88ae-0a3b989a0e69", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "171"}, "hash": "b16ed90ca1a994b72054a504eccae43597e1906c067712d9529b9afaa96d2ef2", "class_name": "RelatedNodeInfo"}}, "text": "9. SERVICE DELIVERY\nWhat\u2019s Inside:\n 1.1 Objectives of the Guidelines\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026..\n9.1 Introduction\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026.\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026.....150\n 1.2 Epidemiology of HIV in Nigeria\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\n9.2 Differentiated Service Delivery\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026..\u2026.150\n 1.3 Natural History of HIV\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026.\u2026\u2026\n9.2 Standards for Quality HIV Service Delivery\u2026\u2026\u2026\u2026\u2026.......163\n9.3 Nutrition\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026..\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026.167\n9.4 Service Delivery for Adolescents Living with HIV\u2026\u2026\u2026.....169", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 431, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "91f262c2-39ed-4662-bbd5-2ecec9c26b0b": {"__data__": {"id_": "91f262c2-39ed-4662-bbd5-2ecec9c26b0b", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "172"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "234056e2-413f-41f7-aa87-1a4b4a508d4e", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "172"}, "hash": "3e17f008c175f74f13c80cc41cf2acccdf0e99dc8c45b12b11ee0ce4e87f0fa2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c5d4e1fa-01d7-4b5a-9fb6-6466e430846f", "node_type": "1", "metadata": {}, "hash": "f577707616da7956feaca65c67b912091fcdd9e0cfe23b777788d7ff04272a6a", "class_name": "RelatedNodeInfo"}}, "text": "9.1 Introduction\nHealthcare service delivery in the context of HIV management provides the continuum of care to\nPLHIV that ensures access to HIV prevention, treatment and care aimed at promoting sustained\nvirological suppression and improved quality of life.\nResponsive HIV service delivery that meets the needs of various sub-populations is required to\nensure equitable, accessible, acceptable, appropriate and effective health services for PLHIV. In\nNigeria barriers to treatment access still exist. These include service-related, structural, policy\nand stage of life barriers. With the introduction of 'Test and Treat', as recommended by the 2016\nNational Guidelines for HIV Prevention Treatment and Care in Nigeria, the burden of HIV\nservice delivery on health facilities has increased.\nTo achieve the goal of virological suppression and ensure client-centred care, Nigeria must adopt\ninnovative strategies at both the health facility and community level. These strategies reduce the\nchallenges and barriers associated with accessing HIV services and enable healthcare workers to\nstrategically focus HIV investments and resources on clients with AHD and those who are not\nstable on treatment. As a nation, they are critical to enabling us to achieve the UNAIDS 95:95:95\ngoals. They must be targeted at and appropriate for the various sub populations of PLHIV to\nensure that no group is left behind.\n9.2 Differentiated Service Delivery\nDifferentiated service delivery (DSD), which is synonymous with differentiated care, is \u201can\napproach that simplifies and adapts HIV services to better serve the needs of PLHIV whilst\nreducing unnecessary burdens on the health system\u201d [30]. The concept of DSD is client-centred,\nfocusing on the needs and expectations of PLHIV, those vulnerable to acquiring HIV and how to\nmeet these needs. It seeks to improve access, quality and efficiency of health systems by re-\nexamining traditional service delivery approaches and building upon existing structures in both\nthe health facilities and the communities. Differentiated service delivery integrates task shifting,\ndecentralization, integration and simplification of care across the HIV care continuum. This\nservice delivery approach provides strategies tailored to specific patient populations.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2282, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c5d4e1fa-01d7-4b5a-9fb6-6466e430846f": {"__data__": {"id_": "c5d4e1fa-01d7-4b5a-9fb6-6466e430846f", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "172"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "234056e2-413f-41f7-aa87-1a4b4a508d4e", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "172"}, "hash": "3e17f008c175f74f13c80cc41cf2acccdf0e99dc8c45b12b11ee0ce4e87f0fa2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "91f262c2-39ed-4662-bbd5-2ecec9c26b0b", "node_type": "1", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "172"}, "hash": "35245671b1b598da4c6c4e4e5e27070aac96d1163373f56a8f1e3c720b550f27", "class_name": "RelatedNodeInfo"}}, "text": "Differentiated service delivery integrates task shifting,\ndecentralization, integration and simplification of care across the HIV care continuum. This\nservice delivery approach provides strategies tailored to specific patient populations. It is also\ntermed patient-centred or focused care and aims to efficiently deliver quality services that are\ndeemed satisfactory by the client, whilst also empowering the clients and their communities.\nThere are various types of DSD models which prioritize access and linkage to HTS, rapid ART\ninitiation, re-engagement in care, adherence and retention, all with the goal of achieving\nsustained virological suppression.\n                                     Differentiated Service Delivery\n                 __________________________________________________________________________\n                 I                                                            I\n                    95%                     95%                    95%\n                  Diagnosed                  On                    Virally\n                                         Treatment                Suppressed\n                                    __________________________________________\n                                           I                                 I\n                                                   Differentiated ART Delivery\n  Figure 9.1: Differentiated Care \u2013 Application across the HIV Care continuum\n           NATIONAL GUIDELINES FOR HIV PREVENTION TREATMENT AND CARE 2020               150", "mimetype": "text/plain", "start_char_idx": 2044, "end_char_idx": 3572, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "25a3054d-1c71-4bc8-aecb-4a27c9de691e": {"__data__": {"id_": "25a3054d-1c71-4bc8-aecb-4a27c9de691e", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "173"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "83ff9d67-084f-45e2-91bd-9542ba422b41", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "173"}, "hash": "e00c730c5e912bcaf65a3edd4201a1684b10116677d53a938959e8cb2cf21295", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b1eb4b3e-567e-4f17-877d-095f1809f230", "node_type": "1", "metadata": {}, "hash": "3cd9efc1f9b0fcbca3bfe1c606c53d0a5733463c2e58ed7c070de7cd685c5ef3", "class_name": "RelatedNodeInfo"}}, "text": "9.2.1 Differentiated HIV Testing Service Delivery\nHIV Testing Services (HTS) are the full range of services that should be provided together with\nHIV testing and the following components: counselling; linkage to appropriate HIV prevention,\ntreatment and care services; other support services and coordination with laboratory services to\nsupport quality assurance and the delivery of correct results.\nThis chapter will focus on Differentiated ART Service Delivery (Guidelines for Differentiated\nHIV Testing Services are addressed in Chapter Two).\n9.2.2 DifferentiatedART Service Delivery\nDifferentiated ART service delivery describes a series of management approaches that align with\nthe clinical status (clinically stable or unstable) of PLHIV and their needs and preferences [30].\nModels are broadly classified as facility-based or community-based.\n    \u00a7   Facility-based models are HIV treatment and care models where services are offered\n        within the existing health facilities\n    \u00a7   Community-based models are HIV treatment and care models where services are offered\n        outside the existing health facilities.\nThese models implement either one or a combination of the following approaches:\n    \u00a7   Differentiated patient flow: dedicated client pathways at sites for specific patient\n        populations based on patient needs e.g. new patients and those withAHD.\n    \u00a7   Differentiated schedules: adapting clinic flow or dedicating hours, days or appointments\n        for specific populations such as adolescents.\n    \u00a7   Differentiated locations: providing services to certain groups of clients such as stable\n        adults and adolescents within the community; and One Stop Shops for Key Populations.\nTable 9.1: Models of differentiated ART Service Delivery in the Country\n FACILITY - BASED                                   COMMUNITY - BASED\n Fast track (Individual or Group):  stable          Community drug distribution points : These\n clients pick their drugs from the facility         are designated points within the community\n pharmacy without going through the normal          where ARVs and other medications are\n clinic flow, including a doct or\u2019s review          dispensed to stable PLHIV\n Multi-month dispensing: Medication                 Community Pharmacy Refills\n dispensing interval of 3 months and above.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2342, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b1eb4b3e-567e-4f17-877d-095f1809f230": {"__data__": {"id_": "b1eb4b3e-567e-4f17-877d-095f1809f230", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "173"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "83ff9d67-084f-45e2-91bd-9542ba422b41", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "173"}, "hash": "e00c730c5e912bcaf65a3edd4201a1684b10116677d53a938959e8cb2cf21295", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "25a3054d-1c71-4bc8-aecb-4a27c9de691e", "node_type": "1", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "173"}, "hash": "e67c6b47fecf3da68328e01d0f9eda19cf0469c3efa630572acfe0748c143a28", "class_name": "RelatedNodeInfo"}}, "text": "Health Facility Based ART Group                    Community ART Group (CAG\n These are health facility -based groups formed     These are community -based groups formed\n voluntarily by support groups of persons living    voluntarily by persons living with HIV within a\n with HIV who are already meeting regularly at      community for ARVs and other medication\n the health facility for ARVs and other             refills. This can either be PLHIV led or\n medication refills. This can either be client-led  healthcare provider led.\n or Healthcare provider-led:                        These healthcare providers may include\n                                                    community health workers, case managers and\n                                                    other trained volunteers.\n           NATIONAL GUIDELINES FOR HIV PREVENTION TREATMENT AND CARE 2020                151", "mimetype": "text/plain", "start_char_idx": 2344, "end_char_idx": 3232, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "591fad25-4e6c-4337-868e-3d7a7279a2d9": {"__data__": {"id_": "591fad25-4e6c-4337-868e-3d7a7279a2d9", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "174"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "1dcaa35b-e0bb-4635-8503-e752f6878893", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "174"}, "hash": "ed75fa0edc3a356ddb49d94e4d2d77376948ebacd3d5e27fe907a1a35235c451", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d67ccacd-0a5d-46e8-8290-e85878cfd945", "node_type": "1", "metadata": {}, "hash": "ac006d1f5b6c780fcc31cb819f9d23702bf393de7f557ded49d1f4bd44fc4a1e", "class_name": "RelatedNodeInfo"}}, "text": "Decentralization : refers to the devolution of stable clients from la rger, centralized secondary and\n  tertiary facilities (hubs), to smaller more peripheral primary facilities (spokes). This can be either:\n  -   semi-autonomous model which restricts ART service delivery at PHCs to ARV and medication\n      refills only\n  -   autonomous model which allows for ART initiation at the PHC level and also ARV and\n      medication refills.\n  Adolescent clubs: Groups of adolescents and young people living with HIV for whom age-appropriate,\n  affordable, friendly health services are provided in an accessible and acceptable environment\n  Post Natal Clubs : Groups of women living with HIV who are supported in the postnatal period by\n  healthcare workers and other volunteers like mentor mothers to ensure improved maternal/child\n  health outcomes.\n  One-Stop Shops  and Mobile Clinics are community-based service delivery sites where multiple\n  services are offered and clients can access all their needs under one roof targeted specifically at\n  providing services for Key Populations\nThe choice of service delivery model for each client is individualized and should be made\nfollowing consultation and consent obtained from the client. All community-based models of\nservice delivery must be linked to approved facility-based sites.\nDifferentiating service delivery should be based on local assessment which is targeted to\nimprove patient satisfaction, quality of care offered and outcomes. Clients are offered packages\nof care based on four building blocks (delivery components) and three elements [30] .These\ncharacteristics can be applied across the entire HIV care continuum, for both stable and unstable\nPLHIV who are new to treatment or on long-term follow-up. The building blocks are:\n    \u00a7    WHERE services are provided (service location)\n    \u00a7    WHAT service packages are offered (service intensity)\n    \u00a7    WHO is the service provider (health worker cadre)\n    \u00a7    WHEN the recommended frequency of visits (service frequency)\nThe 3 elements to be considered in each assessment for differentiating service delivery are:\n    \u00a7    Clinical Characteristics \u2013 Patient stability and associated co-morbidities\n    \u00a7    Specific Populations \u2013 Children,Adolescents, Women (Pregnant and breastfeeding),\n         Men and Key Populations\n    \u00a7    Context \u2013 Urban or rural location, unstable context (e.g.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2405, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d67ccacd-0a5d-46e8-8290-e85878cfd945": {"__data__": {"id_": "d67ccacd-0a5d-46e8-8290-e85878cfd945", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "174"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "1dcaa35b-e0bb-4635-8503-e752f6878893", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "174"}, "hash": "ed75fa0edc3a356ddb49d94e4d2d77376948ebacd3d5e27fe907a1a35235c451", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "591fad25-4e6c-4337-868e-3d7a7279a2d9", "node_type": "1", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "174"}, "hash": "a9eb58872d1a1332fcdfd632c6681b1ceb698702853246fe9ee998bd24ca1ab1", "class_name": "RelatedNodeInfo"}}, "text": "conflict, high migration) and\n         epidemic/pandemic scenarios\n           NATIONAL GUIDELINES FOR HIV PREVENTION TREATMENT AND CARE 2020                152", "mimetype": "text/plain", "start_char_idx": 2406, "end_char_idx": 2565, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a776e386-3461-47e8-ab19-abb143d86fc6": {"__data__": {"id_": "a776e386-3461-47e8-ab19-abb143d86fc6", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "175"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "dc3784ad-deb5-4bbe-88fc-ae486253e4c8", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "175"}, "hash": "d6febbbcb4597cc5c3bd2d5877731bda2815a15f7d5bac2ad8caaca559282177", "class_name": "RelatedNodeInfo"}}, "text": "Monthly\n                                                                            Je6 months\n            clinical manitorlng\n            Adherence wunport\n            Lboratoty Icsta\n            Psychosoclal support     Servlce          Sorvice\n            Kenulls                 Intensity        frequency\n                                             Patient\n                                                                                  Phyticuun\n                                                         Hoalth workor            pharmaciet\n            HIV < Uncrhosptal       Servlce                  cadre\n            Commumlty               location\nFigure 9.2: Key factors in differentiated approaches to HIV care\n9.2.3 Differentiated Service Delivery Based on Clinical Characteristics\nNon- pregnant adult PLHIV can be categorized into four broad groups, each with distinct care\nneeds namely;\n    \u00a7    Newly diagnosed or re-engaging clients who are well\n    \u00a7    Clients who present withAHD\n    \u00a7    Clients who are onART and stable\n    \u00a7    Clients onART and unstable\nIt is recommended that each of these groups is offered care packages which address their\npeculiar needs.\nTable 9.2: Care Package Elements for Distinct Groups of PLHIV\n People living with HIV             Care package elements and focus of care\n Newly diagnosed, generally         Preparation for ART requires readiness and willingness to\n well at presentation, in WHO       initiate treatment. Adherence and retention in care are essential\n stage 1 and 2 with                 in committing to lifelong ART.\n high CD4+ cell counts              -   Adherence counselling\n (>200 cells/mm 3)                  -   ART Initiation\n                                    -   TPT\n                                    -   Retention support\n                                    -   TB screening\n Advanced HIV disease               Accelerated clinical response to prevent death and reduce illness\n (CD4+ cell count <200              with the following:\n           3\n cells/mm and /or WHO disease       -   Appropriately timed initiation of ART (taking the risk of IRIS\n stages 3 and 4)                        into consideration)\n                                    -    Screening and management of OIs and other care and support\n                                        services\n                                    -   TB screening, diagnosis and treatment\n                                    -   CPT and TPT\n                                    NATIONAL GUIDELINES FOR HIV PREVENTION TREATMENT AND CARE 2020  153", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2574, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4cdc837f-c000-49ad-b983-a17fcc373492": {"__data__": {"id_": "4cdc837f-c000-49ad-b983-a17fcc373492", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "176"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "597f6fd3-b13f-445a-a547-e86c0068b20b", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "176"}, "hash": "8aab61d50e72df47898e766f9ef3d54026beb08cd323ae04435ee375e3950ffd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1a125332-8d89-4302-927f-b116e893c6d5", "node_type": "1", "metadata": {}, "hash": "04931d73f59038b396ac43b90e3d857ec3c8d691fc87e8d370e1423ada3de264", "class_name": "RelatedNodeInfo"}}, "text": "People living with HIV             Care package elements and focus of care\n                                    -   Close monitoring for identification and management of\n                                        opportunistic infections\n Patients who are on ART and        -   Adherence monitoring\n are unstable                       -   Treatment literacy and retention support\n                                    -   Viral load testing\n                                    -   Switch to second- or third-line ART if indicated\n                                    -   TB screening, diagnosis and treatment\n                                    -   CPT and TPT\n                                    -   Monitoring for HIV drug resistance (HIVDR)\n                                    -   Other care and support services\n Patients who are on ART and        -   Reduced frequency of clinic visits\n are stable                         -   Community ART delivery models\nThese groupings are fluid with clients moving from one group to another whilst in care but\nenabling health systems to differentiate and target individuals requiring intense facility-based\nservices from those who require less frequent clinical consultations and could collect their ART\nfrom the community- based models of care.\nStability is defined based on duration on ART, age, clinical status, level of adherence and\ntreatment success. Children, men and non-pregnant/breastfeeding women living with HIV are\nstated to be stable or unstable based on the following criteria:\nTable 9.3: Stability Criteria for Children, Adult Men and Non-Pregnant Women\n Criteria       STABLE                                      UNSTABLE/COMPLEX\n Age            Adults, Adolescents and Children > 5yrs     Children < 5yrs\n Duration of    On ART for at least one year                -   ART na\u00efve patients\n ART                                                        -   On ART less than one year\n                                                            -   AHD (WHO clinical stages 3-4)\n Clinical       Clinically stable with no opportunistic     -   Co-morbidities e.g.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2108, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1a125332-8d89-4302-927f-b116e893c6d5": {"__data__": {"id_": "1a125332-8d89-4302-927f-b116e893c6d5", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "176"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "597f6fd3-b13f-445a-a547-e86c0068b20b", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "176"}, "hash": "8aab61d50e72df47898e766f9ef3d54026beb08cd323ae04435ee375e3950ffd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4cdc837f-c000-49ad-b983-a17fcc373492", "node_type": "1", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "176"}, "hash": "fbdf5a05b25480191fa0bfc45f23727916bb1752a1904c5f7d152557bd4ae8b7", "class_name": "RelatedNodeInfo"}}, "text": "diabetes\n status *       infections or current illnesses                 mellitus, heart, chronic liver, and\n                                                                chronic kidney diseases\n                -   Adherent with an optimal\n Adherence          understanding of lifelong treatment     -   Poor adherence\n                -   Age-appropriate disclosure desirable    -   Orphans and vulnerable children\n                    for children and adolescents\n                -   Evidence of treatment success - two     -   Unsuppressed viral load\n                    consecutive viral load measurements     -   On 2\u207f\u1d48 or 3\u02b3\u1d48 line regimen\n Treatment          < 1,000 copies/ul                       -   On recently changed regimen <\n                -   Has initiated/completed TPT                 6months\n                -   Has no adverse drug reactions that      -   Experiencing treatment failure\n                    require regular monitoring\n Monitoring     -   Does not require close monitoring at    -   Close monitoring necessary at the\n                    the facility level                          facility level\n                -   Regular CD4+ cell count monitoring      -   CD4+ cell count monitoring may be\n                    is unnecessary                              required\n*All mentally impaired or retarded PLHIV, including those with psychiatric manifestations should be classified as unstable, irrespective of the\nage, CD4+cell count or viral load ;Unstable clients require closer monitoring and should receive facility-based care. They should not be\ndevolved into any community model of differentiated ART delivery; Clients devolved to community- based models who become unstable should\nbe referred back to the mainstream facility for closer monitoring.\n           NATIONAL GUIDELINES FOR HIV PREVENTION TREATMENT AND CARE 2020                    154", "mimetype": "text/plain", "start_char_idx": 2109, "end_char_idx": 3991, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "932daae5-4796-4f35-88c8-040e867cb136": {"__data__": {"id_": "932daae5-4796-4f35-88c8-040e867cb136", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "177"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "450b659d-5a69-4bfe-b049-7a67a3a14eae", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "177"}, "hash": "68f62cd7e071704ac1e82f40bdead6a17a63d6c5850bab08be490d1feda63a49", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "955f6a4f-1e22-4141-b5c3-3a67c3a6f936", "node_type": "1", "metadata": {}, "hash": "cd36e0ffd21d52ed5b29426c941bd49d7cd963e346838a25b620b8f39dceb8aa", "class_name": "RelatedNodeInfo"}}, "text": "Stable clients can be offered packages of care at the community level that do not include\n   CD4+ cell count monitoring and also a reduction in the frequency of:\n       \u00b7   Clinical consultations to every 3-6 months\n       \u00b7   ARV drug refills and medication pickup to every 3 months\n9.2.4 Differentiated Service Delivery based on Sub-Populations\nThe various sub-populations of PLHIV considered for differentiated ART service delivery\ninclude :\n   \u00a7    Pregnant and breastfeeding women\n   \u00a7    Children\n   \u00a7    Adolescents and young people\n   \u00a7    Adult men and non-pregnant women\n   \u00a7    Key Populations (KPs)\n9.2.4.1 Differentiated Service Delivery for Pregnant and Breastfeeding Women\nThe facility-based DSD model of care is recommended for Pregnant and Breastfeeding women\nas it makes provision for safe delivery practices, promotes mother/baby pair, in addition to\nprevention of mother-to-child transmission and antiretroviral therapy.\nStability Criteria for Pregnant and Breastfeeding Women: The stability criteria for pregnant and\nbreastfeeding women differs from the criteria for non-pregnant adults and children and is based\non the viral load in the index pregnancy and previous PMTCT outcomes.\nA pregnant or breast-feeding woman is stated to be stable or unstable based on the criteria\noutlined in Table 9.4.\nTable 9.4: Stability Criteria for Pregnant and Breastfeeding Women\n STABLE                                          UNSTABLE\n Viral load < 1000copies/ml in index pregnancy   Viral load >1000copies/ml or unknown VL\n Has had a previous PMTCT experience and         -  Is a newly diagnosed PLHIV\n had a child with a HIV negative test result at  -  Is less than 20 years of age\n 18 months                                       -  Has an obstetric or medical condition\n                                                 -  First PMTCT experience irrespective of ART status\n                                                 -  Previous PMTCT experience witha negative outcome\nIt is recommended that pregnant and breastfeeding women be categorized into the following\ngroups. This categorization will assist in deciding the most appropriate DSD model especially if\na facility-based DSD model is not available in the environment.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2236, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "955f6a4f-1e22-4141-b5c3-3a67c3a6f936": {"__data__": {"id_": "955f6a4f-1e22-4141-b5c3-3a67c3a6f936", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "177"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "450b659d-5a69-4bfe-b049-7a67a3a14eae", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "177"}, "hash": "68f62cd7e071704ac1e82f40bdead6a17a63d6c5850bab08be490d1feda63a49", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "932daae5-4796-4f35-88c8-040e867cb136", "node_type": "1", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "177"}, "hash": "e4bf8e94562d17a67c1f0aba1bc6398fcef89fe1646ac646f4de2d1091ab2bcf", "class_name": "RelatedNodeInfo"}}, "text": "This categorization will assist in deciding the most appropriate DSD model especially if\na facility-based DSD model is not available in the environment.\n   \u00a7   It is recommended that stable pregnant and breastfeeding women should continue on\n       DSD as appropriate to their peculiar situation. TheirART and antenatal clinic visits\n       should be synchronized for those previously receiving care in a facility model of DSD.\n       However, if she had been devolved into a community model of DSD, she should be\n       linked to a health facility for antenatal services and to a health care provider-led group or\n       mentor mother-led group for her drug pick up.\n   \u00a7   The facility-based DSD model of care is recommended for all unstable pregnant and\n          NATIONAL GUIDELINES FOR HIV PREVENTION TREATMENT AND CARE 2020              155", "mimetype": "text/plain", "start_char_idx": 2084, "end_char_idx": 2930, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a1c4a550-3889-4009-9833-172b16e0566d": {"__data__": {"id_": "a1c4a550-3889-4009-9833-172b16e0566d", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "178"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "7a7b5fd3-fbd7-4001-9a24-3e9755b111f4", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "178"}, "hash": "f7bb8b9cda7b9c884324fdff96ed5a7030e373f8db0c92e5e88f06f4743cd9f3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a215e493-b820-46c6-8c21-c461ab40661b", "node_type": "1", "metadata": {}, "hash": "55ef981931a1b1e3f6ddff722b0e92dc9c2146f1ee8878a25fc5f1c6c19e9e80", "class_name": "RelatedNodeInfo"}}, "text": "breastfeeding women and children up to five years, at the secondary or tertiary facility\n       level, to ensure PMTCT and Safe delivery. Women on facility-based DSD models prior\n       to delivery may choose to maintain such but clinical consultation should be aligned with\n       Mother-Infant Pair (MIP) visits. It is recommended thatARV/medication refills should\n       not exceed 3 months.\n     \u00a7  It is recommended that all unstable pregnant women should be managed at\n        a facility model of DSD\n     \u00a7  Stable pregnant and breastfeeding women who were devolved to a community\n        model of DSD prior to pregnancy can continue to receive ARV/medication\n        refills at the community level but should be linked to a facility for ANC.\n     \u00a7  Alignment of clinical visits and ARV/medication refills for the mother-infant\n        pair is recommended\n     \u00a7  ARV/medication refills should NOT exceed 3 months\n9.2.4.2 Differentiated Service Delivery for Children\nChildren are peculiar and are often not adequately catered for in most health care programs.\nBased on this, it is recommended that the DSD model a child is devolved to should, as much as\npossible align with that of the mother or the caregiver (if also onART).\nChildren should be considered for enrollment into DSD from 5 years and above when they meet\nthe enrollment criteria. It is imperative that the time frame for children to be seen at the primary\ntreatment facilities should not be longer than 3 months in any case scenario. If, however, at any\npoint after enrollment the criteria for eligibility for DSD are not met, the child should be\npromptly referred back to the facility of primary treatment for review and continued\nmanagement.\nSpecial Scenarios: Incarcerated children, those in boarding schools and children whose parents\nare classified as KPs, should also be categorized as stable or unstable based on the criteria listed\nin table 9.3 above. Provision should also be made for their caregivers, lay providers, and school\nmatrons to pick up their ART drug refills. It is recommended that clinical consultations for those\nin boarding schools should be aligned as much as possible with school holidays.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2188, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a215e493-b820-46c6-8c21-c461ab40661b": {"__data__": {"id_": "a215e493-b820-46c6-8c21-c461ab40661b", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "178"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "7a7b5fd3-fbd7-4001-9a24-3e9755b111f4", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "178"}, "hash": "f7bb8b9cda7b9c884324fdff96ed5a7030e373f8db0c92e5e88f06f4743cd9f3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a1c4a550-3889-4009-9833-172b16e0566d", "node_type": "1", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "178"}, "hash": "8a723b65cdc6c94e5ca81cbd472ed3ce5f968e13534fb2bab385aece93ff6758", "class_name": "RelatedNodeInfo"}}, "text": "It is recommended that clinical consultations for those\nin boarding schools should be aligned as much as possible with school holidays.\n        It is recommended that all unstable children should be managed at a facility model of DSD.\n          Children (from 5 years), who are stable can be devolved into a community model of DSD,\n            however, ARV/medication refills should NOT be dispensed for more than 3 months and\n  clinical consultation visits should take place at the mainstream health facility every 3\n  months\n          NATIONAL GUIDELINES FOR HIV PREVENTION TREATMENT AND CARE 2020             156", "mimetype": "text/plain", "start_char_idx": 2053, "end_char_idx": 2668, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9fb267a4-f08d-4753-b774-f6847951b0b9": {"__data__": {"id_": "9fb267a4-f08d-4753-b774-f6847951b0b9", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "179"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "ec434ea7-d8fc-4be0-a63a-cd5d4fabfa06", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "179"}, "hash": "78af50f80958c136a044ef22ea21ade53563c9bf5bffa0f38ff90911badf5b93", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d5bc45e6-b9ca-4574-ad1a-191c0993c8d6", "node_type": "1", "metadata": {}, "hash": "79e1aea3a017bcec2c8b0faaca75fb89696a3a865bb0858b5e69fd6832ed7203", "class_name": "RelatedNodeInfo"}}, "text": "9.2.4.3 Differentiated Service Delivery forAdolescents and Young People (AYP)\nDifferentiated service delivery for AYP focuses on the preferences and expectations of this sub-\npopulation. It aims at offering fewer intensive services to those who are stable on ART.\nAdolescents and young people with AHD at initiation should be provided with a package of care\ntargeted to ensure stability within the first year of care. Stable clients on DSD who become\nunstable should be referred back to the mainstream facility for the continuum of care.\nIt is recommended that a family approach be adopted for stable AYP, whereby families receive\nsame-day appointments, same-length ART refills or allowing one family member (rotated) to\ncollectART refills for other stable family members.\nThe principles of DSD models forAYP living with HIV should include the following:\n     \u00a7   AYP- centred (friendly, accessible, acceptable, affordable and stigma/discrimination-\n         free)\n     \u00a7   Leverage on the existing adolescent support groups/clubs either at the facility or\n         community\n     \u00a7   Preferably peer-led, especially amongst the olderAYP\n     \u00a7   Adaptable (after school hours, weekends and holidays)\n     \u00a7   Pregnant adolescents should not be differentiated to community- based models\nDSD Modelling Approaches for AYP: These models outlined in Figures 9.3 and 9.4 below\nshould be implemented primarily for stable adolescents whose ART refill should be every three\nto six months with clinical reviews completed at each visit. ART refills can also take place at the\nadolescents' club or support group meetings or within community ART groups. Where feasible,\ncommunity volunteers should conduct monthly home visits to stable adolescents in community\nmodels. Unstable adolescents should have ART refills and clinical consultations conducted\nmore frequently (one to two-monthly basis) at the facility.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1898, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d5bc45e6-b9ca-4574-ad1a-191c0993c8d6": {"__data__": {"id_": "d5bc45e6-b9ca-4574-ad1a-191c0993c8d6", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "179"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "ec434ea7-d8fc-4be0-a63a-cd5d4fabfa06", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "179"}, "hash": "78af50f80958c136a044ef22ea21ade53563c9bf5bffa0f38ff90911badf5b93", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9fb267a4-f08d-4753-b774-f6847951b0b9", "node_type": "1", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "179"}, "hash": "aef195fed6669282f237d3e4314685265e562d6a2f00f3e710f5814eba23c2b3", "class_name": "RelatedNodeInfo"}}, "text": "Where feasible,\ncommunity volunteers should conduct monthly home visits to stable adolescents in community\nmodels. Unstable adolescents should have ART refills and clinical consultations conducted\nmore frequently (one to two-monthly basis) at the facility.\nFigure 9.3: Building Blocks for DSD in AYP 10 \u2013 19 years\n                                Receiving services                 Delivering services\n            WHO                 \u00a7  Young Adolescents               \u00a7   ART Clinician\n                                \u00a7  Caregivers and family           \u00a7   ART Nurse\n                                                                   \u00a7   Adherence officer\n                                                                   \u00a7   Laboratory officer\n                                                                   \u00a7   Pharmacist\n                               Facility-based                         Community -based\n                               \u00a7  Out-of school clinic hours managed  \u00a7  Community Pharmacies\n          WHERE                \u00a7  by HCWs                             \u00a7  Adolescent community ART\n                                  Weekend adolescent focused clinic      distribution groups\n                               \u00a7  Using adolescent support groups     \u00a7  School based clinics\n                               \u00a7  Adolescent clubs (peer-led)\n                                \u00a7  ART initiation/fill                \u00a7  Linkage of caregivers to\n           WHEN                 \u00a7  Laboratory tests                      household economic\n                                \u00a7  Clinical monitoring                   empowerment and\n                                \u00a7  Psychosocial support                  livelihood opportunities\n                                \u00a7  Treatment of OI\u2019s\n                                \u00a7  Adherence support\n*For already mapped-out schools with established clinics\n            NATIONAL GUIDELINES FOR HIV PREVENTION TREATMENT AND CARE 2020                      157", "mimetype": "text/plain", "start_char_idx": 1642, "end_char_idx": 3637, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7352ca8c-463a-4789-87cd-29007b9c57cd": {"__data__": {"id_": "7352ca8c-463a-4789-87cd-29007b9c57cd", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "180"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "f094c334-0898-440e-82dd-983151b82c98", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "180"}, "hash": "8833f58aa4d8ea7a92533311e81b266231278691d7d9c20c68542aa468d5bace", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5d936c1e-d077-4c5a-8b4f-0620578780ce", "node_type": "1", "metadata": {}, "hash": "33970df2c785a363fc16618f0e5d016d0628293f51d7124686d391b3e7c636fc", "class_name": "RelatedNodeInfo"}}, "text": "Figure 9.4: Building Blocks for DSD in AYP 20 \u2013 24 years\n                               Receiving services             Delivering services\n                               \u00a7  Young persons               \u00a7  ART Clinician\n           WHO                 \u00a7  Peers                       \u00a7  ART Nurse\n                                                              \u00a7  Adherence officer\n                                                              \u00a7  Laboratory officer\n                                                              \u00a7  Pharmacist\n                               Facility-based                Community -based\n         WHERE                 \u00a7   Support group              \u00a7  Community pharmacies\n                               \u00a7   Youth clubs                \u00a7  Adolescent community ART\n                                                                 distribution groups\n                                                              \u00a7  Higher institution-based clinics\n                               \u00a7  ART initiation/fill     \u00a7  Linkage of caregivers to household\n          WHEN                 \u00a7  Laboratory tests           economic empowerment and livelihood\n                               \u00a7  Clinical monitoring        opportunities\n                               \u00a7  Psychosocial support    \u00a7  Peer support\n                               \u00a7  Treatment of OI\u2019s       \u00a7  SMS adherence support\n                               \u00a7  Adherence support       \u00a7  Youth Whatsapp platforms\n*For already mapped-out institutions with established clinics\n 9.2.4.4 Differentiated Service Delivery for Men and Non- Pregnant Women\n It is recommended that adult men and non-pregnant women who are stable on ART be\n differentiated to models of care that offer less frequent clinical consultations (3-6 months) and\n drug refills (3-6 months).\n Recommendations made below for service delivery in adults will be divided into those\n recommended at baseline, for those presenting well or with AHD and also for those who are\n stable or unstable after at least 1 year onART.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2053, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5d936c1e-d077-4c5a-8b4f-0620578780ce": {"__data__": {"id_": "5d936c1e-d077-4c5a-8b4f-0620578780ce", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "180"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "f094c334-0898-440e-82dd-983151b82c98", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "180"}, "hash": "8833f58aa4d8ea7a92533311e81b266231278691d7d9c20c68542aa468d5bace", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7352ca8c-463a-4789-87cd-29007b9c57cd", "node_type": "1", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "180"}, "hash": "0df366a6d98203f66da26b60682e211be821e281c83232461902ab28ceb7896e", "class_name": "RelatedNodeInfo"}}, "text": "Recommendations made below for service delivery in adults will be divided into those\n recommended at baseline, for those presenting well or with AHD and also for those who are\n stable or unstable after at least 1 year onART.\nTable 9.5: Packages of Care for Newly Diagnosed, Re-engaging or AHD Clients\n  Baseline Package of Care        Client Presenting Well              Advanced HIV Disease\n  Who qualifies for the package   Client with WHO clinical stage 1    Client with WHO clinical stage 3\n  of care                         or 2 or CD4+ count > 200 cell/mm\u00b3   or 4 or CD4+ count <200 cell/mm\u00b3\n                                  Healthcare workers trained to       Healthcare workers trained to\n                                  provide ART services (Clinician,    provide ART services ( Clinician,\n  Who is the Service Provider     Nurse, adherence counsellor,        Nurse, adherence counsellor,\n                                  laboratory and pharmacy             laboratory and pharmacy\n                                  personnel) *                        personnel)\n  Service Location                Approved health facilities          Approved health facilities\n  Service Intensity (Packages Offered) and Service Frequency\n                                                                    ** Weekly/Bi-weekly in the first 1\n                                  **Monthly for the first 2 months,    month\n  Clinical consultations          thereafter 2-monthly for the first  Monthly for the first 2 months,\n                                  year.                               thereafter 2-monthly for the first\n                                                                      year\n           NATIONAL GUIDELINES FOR HIV PREVENTION TREATMENT AND CARE 2020                       158", "mimetype": "text/plain", "start_char_idx": 1829, "end_char_idx": 3624, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0db5d2a8-780d-4765-b3ad-1950e5680a6c": {"__data__": {"id_": "0db5d2a8-780d-4765-b3ad-1950e5680a6c", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "181"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "00bfb6e8-6eba-49f4-a85c-ec35a355053b", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "181"}, "hash": "ffb970c2305261523d192c986a2031b5604b1101b3abec2fca95039d6df71339", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3d6506b9-0da1-4512-95b7-362a8f768b48", "node_type": "1", "metadata": {}, "hash": "260845c97a31ae83dc4a9b0e40f31baf7e5767d7a0b884126fd28e78e696c30b", "class_name": "RelatedNodeInfo"}}, "text": "Baseline Package of Care          Client Presenting Well                Advanced HIV Disease\n                                    **Monthly for the first 2 months,     **Monthly for the first 2 months,\n  ART Refill Visits                 thereafter 2 -monthly for the first   thereafter 2 -monthly for the first\n                                    year.                                 year\n                                                                          Laboratory monitoring tests may\n                                    Laboratory monitoring tests may       differ according to the level of the\n                                    differ according to the level of the  health care facility and should be\n                                    health care facility and should be    done according to the schedule\n                                    done according to the schedule        approved in the National\n  Monitoring                        approved in the National              Guidelines. Additional tests may\n                                    Guidelines                            be indicated based on\n                                                                          diagnosed OIs\n  Ancillary services: psycho-                                             Every week for the first 1 month\n  social services, intensified      At every clinic contact               At every clinic contact\n  adherence support                                                       subsequen tly\n  chronic care/PHDP Services\n*Adherence counselling/support and clinical screening for TB should be done at every clinic contact.\n**The client should be informed to return to the health facility IMMEDIATELY if s/he develops adverse drug reaction(s) or has any complaints\n Table 9.6: Packages of Care for Clients who have been on ART for at least 1 year\n  Package of Care                   Stable Client                    Unstable Client\n  Service Location                  Community models of DSD          Approved health facilities\n                                    and Approved health facilities   No devolvement till stable\n  Service Intensity (Packages Offered) and Service Frequency\n  Clinical consultations            Less frequent \u2013 3 to 6           Frequent - Monthly for 3 months or as\n                                    monthly                          indicated; subsequently as indicated.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2408, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3d6506b9-0da1-4512-95b7-362a8f768b48": {"__data__": {"id_": "3d6506b9-0da1-4512-95b7-362a8f768b48", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "181"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "00bfb6e8-6eba-49f4-a85c-ec35a355053b", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "181"}, "hash": "ffb970c2305261523d192c986a2031b5604b1101b3abec2fca95039d6df71339", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0db5d2a8-780d-4765-b3ad-1950e5680a6c", "node_type": "1", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "181"}, "hash": "99a5255349dfdd3162a7f8910641fe2a4c86009cfb904e5ff5af693f9a47952d", "class_name": "RelatedNodeInfo"}}, "text": "ART Refill Visits                 Less frequent \u2013 3 to 6           Frequent - monthly for 3 months;\n                                    monthly                          subsequently 2 monthly or as indicated\n                                    VL monitoring annually           VL monitoring at the end of 3 months\n  Monitoring                        Cessation of CD4+ count          after EAC for unsuppressed patients;\n                                    monitoring if viral load         subsequently according to National\n                                    testing is available             guidelines\n  Ancillary services: psycho-\n  social services intensified       Aligned with clinic visit and    Monthly for 3 months or as indicated;\n  adherence support                 ART refill                       subsequently aligned with clinic visits\n  chronic care/PHDP Services\n             NATIONAL GUIDELINES FOR HIV PREVENTION TREATMENT AND CARE 2020                          159", "mimetype": "text/plain", "start_char_idx": 2411, "end_char_idx": 3394, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "46ac092f-0d3a-428b-b2f2-04c0e351f128": {"__data__": {"id_": "46ac092f-0d3a-428b-b2f2-04c0e351f128", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "182"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "40248634-2aee-4ecb-a90c-5605ca8a7cde", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "182"}, "hash": "6e737818bdd340257d4860e5e4113b2db656fa3a250e08666666a82ea1e6f820", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b9b98a4a-26e8-4818-971f-70b70c505552", "node_type": "1", "metadata": {}, "hash": "a45cc18353f643975005d2a22e79d8049949721734273aefb43e8bbe4602b3d2", "class_name": "RelatedNodeInfo"}}, "text": "9.2.4.5 Differentiated Service Delivery for Key Populations\n   Key populations (KPs) are defined as \u201cgroups who due to specific higher-risk behaviours, are at\n       increased risk of HIV irrespective of the epidemic type or local context\u201d [1].\n    Internally Displaced Persons (IDPs), people in closed settings, fishing communities, truckers,\n       marginalized or minority groups such as undocumented migrants, ethnic and sexual minorities\n       etc. are also categorized as vulnerable and hard-to-reach populations.\nThe stability criteria used in streamlining service delivery for PLHIV are not as suitable for KPs\n       due to the following reasons:\n          \u00a7   The health-seeking behaviour of KPs is geared towards alternative structures that are\n              community- based and not facility-based and this also means that identification of new\n              cases will be at these alternative community structures.\n          \u00a7   Key Populations are also highly mobile in nature.\n          \u00a7   There are ancillary services uniquely demanded by KPs which include legal aid\n              support, interventions for gender-based violence, Mental Health and Psychosocial\n              Services (MHPSS). These are not provided under one roof or in most health facilities\n              and this mitigates against KPs accessing and being retained in care at these health\n              facilities.\n          \u00a7   The fear of stigmatization, discrimination and a criminalizing legal environment is also\n              a huge challenge at the health facilities. An enabling environment (safe space) that\n              provides the full complement of services required by this group is pertinent.\n              Based on the above peculiarities the following models are advocated for service\n              delivery to key populations\n          \u00a7   One-Stop-Shop (OSS) strategy: This refers to the delivery of a comprehensive service\n              package, under one roof, which is non-discriminatory, non-stigmatizing, safe, friendly\n              and in a conducive environment.\n          \u00a7     Mobile ART teams (MART): These are trained healthcare service providers that often\n              compose of at least 3 members namely; a clinician, a pharmacist and a laboratory\n              scientist. These teams leverage on outreaches and designated hot spots to provide\n              services to KPs.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2399, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b9b98a4a-26e8-4818-971f-70b70c505552": {"__data__": {"id_": "b9b98a4a-26e8-4818-971f-70b70c505552", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "182"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "40248634-2aee-4ecb-a90c-5605ca8a7cde", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "182"}, "hash": "6e737818bdd340257d4860e5e4113b2db656fa3a250e08666666a82ea1e6f820", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "46ac092f-0d3a-428b-b2f2-04c0e351f128", "node_type": "1", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "182"}, "hash": "aaff73382c3d3a68153be97b5ec6916f1485dd0029c809cb81c569b911dd4603", "class_name": "RelatedNodeInfo"}}, "text": "These teams leverage on outreaches and designated hot spots to provide\n              services to KPs.\n          \u00a7   Community Pharmacy (CP): These are pharmacies within the community used for ARV\n              refills to maintain good adherence toARVs and retention onART.\n          \u00a7   Focal Service Providers (FSP): These are trained personnel who reside within the\n              community and can easily be called upon to provide tailored services to KPs within their\n              environment.\n          \u00a7   Peer-led support group meetings: This is a confidential platform where meetings are\n              routinely held during which ART refills, adherence education/reinforcement and\n              general social support are provided basically to strengthen retention in care. Guidance is\n              also provided by experts during such meetings.\n          \u00a7   Key Population Friendly Health Facility: These facilities provide comprehensive\n              services for KPs in a friendly and conducive environment. They ensure that all\n              community-level DSD models for KPs are provided with a strong linkage to the Health\n              facilities.\n                 NATIONAL GUIDELINES FOR HIV PREVENTION TREATMENT AND CARE 2020            160", "mimetype": "text/plain", "start_char_idx": 2298, "end_char_idx": 3558, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2abde0a5-fc07-42ae-966b-cf476439c776": {"__data__": {"id_": "2abde0a5-fc07-42ae-966b-cf476439c776", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "183"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "edf9a86c-f9de-497d-b30e-68957387335b", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "183"}, "hash": "0886a83ba072e3e40cce981c554f7c6a1cccd3214f3afdca378b48ea313686e4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "dff543c0-112b-4bfc-9ea6-02d098c47924", "node_type": "1", "metadata": {}, "hash": "f7e6efe97fa7917bdff2fff3f2ef7faf6b9e8c6347bc1896861114b2d0a0be93", "class_name": "RelatedNodeInfo"}}, "text": "Table 9.7: Service Package and Level of Provision\n Where service is delivered  Community Level             Facility\n                                                         Level\n Service Delivery Model      OSS     MART FSP  CP  Peer  HCP\n                                                   Support\n                                                   Group\n HTS                                 \u00fc  \u00fc  \u00fc  \u00fc           \u00fc\n ART enrolment/Initiation            \u00fc  \u00fc  \u00fc              \u00fc\n ARV refills (3,6 MMD)               \u00fc  \u00fc  \u00fc  \u00fc     \u00fc     \u00fc\n STI screening /diagnosis            \u00fc  \u00fc  \u00fc  \u00fc     \u00fc     \u00fc\n TPT/CPT                             \u00fc  \u00fc  \u00fc  \u00fc     \u00fc     \u00fc\n GBV intervention                    \u00fc  \u00fc                 \u00fc\n Legal support services              \u00fc              \u00fc\n Harm reduction (NSP, Overdose       \u00fc  \u00fc  \u00fc  \u00fc     \u00fc     \u00fc\n &wound management)\n Harm Reduction (OST)                                     \u00fc\n Hepatitis screening                 \u00fc                    \u00fc\n TB screening (five questions using  \u00fc  \u00fc  \u00fc  \u00fc     \u00fc     \u00fc\n screening tool)\n Cervical cancer screening           \u00fc                    \u00fc\n PMTCT (ANC/ART)                                          \u00fc\n HIV exposed infant prophylaxis/     \u00fc                    \u00fc\n EID\n9.2.5 Differentiated Service Delivery Based on Context\nThe context in which HIV services are offered takes into consideration the prevalence rates of\nHIV in these areas (high or low), whether the epidemic is concentrated, generalized or mixed and\nalso the location (urban or rural), where services are offered. Unstable, challenging settings such\nas conflict regions, high migration areas and border towns also require specifically tailored\ninterventions to ensure that affected populations can access quality HIV services within these\nchallenging scenarios. Linkages to and sustained care may be hindered by distance, terrain,\nsafety concerns, transportation costs and few, over-burdened health facilities with long waiting\ntimes. It is recommended that differentiated service delivery models take into consideration the\ncontext in which services are required in such communities and be tailored to the specific needs\nof these individuals.\nPandemics associated with other infectious diseases lead to scenarios where there may be\ncompeting needs for human, infrastructural and financial resources.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2329, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "dff543c0-112b-4bfc-9ea6-02d098c47924": {"__data__": {"id_": "dff543c0-112b-4bfc-9ea6-02d098c47924", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "183"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "edf9a86c-f9de-497d-b30e-68957387335b", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "183"}, "hash": "0886a83ba072e3e40cce981c554f7c6a1cccd3214f3afdca378b48ea313686e4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2abde0a5-fc07-42ae-966b-cf476439c776", "node_type": "1", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "183"}, "hash": "654e768c59b19a948885451bdfddbfcf0300a3940bbb13577263c660cceb8232", "class_name": "RelatedNodeInfo"}}, "text": "Pandemics associated with other infectious diseases lead to scenarios where there may be\ncompeting needs for human, infrastructural and financial resources. When these scenarios also\ninvolve nationwide or regional lockdowns, physical and social distancing, the challenges to\nhealthcare service delivery are increased. These scenarios such as with the COVID-19 pandemic\nrequire innovative approaches to service delivery to ensure continuity of services, retention in\ncare of clients and sustained viral load suppression. Refer to the guidelines on providing ART\nservices in the presence of a complex emergency.\n9.2.6 Integration of Service Delivery\nIt is recommended that facility and community- based sites leverage on differentiated service\ndelivery models for ART and integrate other services. This is cost-effective in terms of human\n       NATIONAL GUIDELINES FOR HIV PREVENTION TREATMENT AND CARE 2020  161", "mimetype": "text/plain", "start_char_idx": 2173, "end_char_idx": 3084, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b3419208-47cd-46f4-a0b6-d58583ac57a3": {"__data__": {"id_": "b3419208-47cd-46f4-a0b6-d58583ac57a3", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "184"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "b92f8adb-2957-4154-9167-8e0db018db41", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "184"}, "hash": "c1b74fbb614b496407b4269f3d36e5f6654f81ee7d73d476c7d5037fe897edee", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5bd3588c-954f-474b-a367-59c6221bb051", "node_type": "1", "metadata": {}, "hash": "78c81f66456c7e3bb3961edf9d1b642f44d419a34ba633f84d95bf287c7940fc", "class_name": "RelatedNodeInfo"}}, "text": "and financial resources and will also improve the scale-up of these services. The following can\nbe integrated into differentiated care models for ART service delivery:\n    \u00a7   Tuberculosis Preventive Therapy (TPT)\n    \u00a7   Sexual and Reproductive Health Services (SRHS)\n    \u00a7   Viral hepatitis\n    \u00a7   Sexually transmitted Infections\n    \u00a7   Mental health services\n    \u00a7   Men's health\n    \u00a7   Substance use/abuse services\n    \u00a7   Non-communicable disease services\n    \u00a7   Food and nutrition support\nSelf- care is defined as \u201cthe ability of individuals, families and communities to promote health,\nmaintain health, prevent disease and to cope with illness and disability, with or without the\nsupport of a healthcare provider\u201d[30]. It empowers individuals, families and communities for\ninformed health decision-making, improved access, ensure health equity and improved\nefficiency of health systems. Community-based DSD with its pre-established linkages to health\nfacilities provides an enabling environment for the implementation of self-care interventions\nwhilst ensuring the availability of hospital/specialist care, where necessary. Self-care\ninterventions share common elements across health programs for SRHS, communicable and\nnon-communicable diseases. The recommended interventions for self-care in PLHIV include\nthe following:\n    \u00a7   Self-testing/monitoring: HIV self\u2013testing, hepatitis B and C testing, blood pressure and\n        blood sugar monitoring\n    \u00a7   HPV self-sampling\n    \u00a7   Prevention transmission interventions - to combat STIs and promote sexual health\n        o   PrEP and PEP\n        o   safer sexual and injection drug use practices (including over the counter condoms,\n            oral contraceptive pills and provision of safe injection packs)\n        o   eliminating unsafe abortion\n    \u00a7   Healthy lifestyle routines \u2013 nutrition, physical exercise, sleep patterns, water/sanitation\n        hygiene and stress management\n9.2.7 Family-Centred Differentiated Service Delivery\nFamily-centred DSD in the context of HIV services provides integrated services for family\nmembers at the same time (when), by the same healthcare provider (who) at the same venue\n(where). Family-centred care, though not new have had limited applicability.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2259, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5bd3588c-954f-474b-a367-59c6221bb051": {"__data__": {"id_": "5bd3588c-954f-474b-a367-59c6221bb051", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "184"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "b92f8adb-2957-4154-9167-8e0db018db41", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "184"}, "hash": "c1b74fbb614b496407b4269f3d36e5f6654f81ee7d73d476c7d5037fe897edee", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b3419208-47cd-46f4-a0b6-d58583ac57a3", "node_type": "1", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "184"}, "hash": "7176ce158300aaef19907cf14f2b0f1450e772c5bdadd5ed63258ea2c83aa52c", "class_name": "RelatedNodeInfo"}}, "text": "Family-centred care, though not new have had limited applicability. These\ninterventions seek to align visits at facility or community level for family members, including\nchildren and adolescents to further improve efficiency, adherence, retention in care and\nvirological suppression of patients. It also reduces the multiplicity of healthcare workers\noffering one family services, thereby reducing the frequency and intensity of contact with\nhealthcare providers. It is recommended that implementation of DSD models provide an avenue\nto implement and scale-up family-centred interventions which have benefits for not only the\npatients and affected caregivers, but also the healthcare system itself.\n          NATIONAL GUIDELINES FOR HIV PREVENTION TREATMENT AND CARE 2020           162", "mimetype": "text/plain", "start_char_idx": 2192, "end_char_idx": 2977, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8216c642-67e0-460d-bf97-d50d6802b845": {"__data__": {"id_": "8216c642-67e0-460d-bf97-d50d6802b845", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "185"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "44dfdbb7-31d7-44e0-8d98-8ed3836bc2e3", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "185"}, "hash": "4bcf35c944ca52591bda586067558c75489f06add72ab06da16eae9376d93fb3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f0dce1ea-755c-418e-966e-01bc4708ff3e", "node_type": "1", "metadata": {}, "hash": "344dd5ab24693ae73eaa3a6841aed6cd84865679034fad05a0197cf239b900b6", "class_name": "RelatedNodeInfo"}}, "text": "\u00a7  Differentiated ART service delivery models are broadly classified as facility-based\n     or community-based and all community-based models of service delivery should\n     be linked to an approved facility.\n  \u00a7  It is recommended that all unstable PLHIV be managed at a facility model of DSD\n  \u00a7  Stable clients can be offered and devolved to packages of care at the community\n     level with a reduction in the frequency of clinical consultations and ARV/medication\n     drug refills\n  \u00a7  Alignment of consultation and refill visits for family members and integration of\n     other services into differentiated ART service delivery models is recommended\n9.3 Standards for Quality HIV Service Delivery\nQuality is defined as the totality of features and characteristics of an entity that bears on its ability\nto satisfy a stated or implied need. The perception of the healthcare needs of a client or\ncommunity will vary based on the views and perspectives of the client, service provider, society\nand the social, political and economic environment. Standards are seen as expectations of\nperformance and help organizations understand how they can meet the diverse treatment needs\nof a variety of populations and thus are patient-centred.\nThe standards for quality HIV service delivery in Nigeria spans the entire care continuum from\nprevention, testing, care and treatment across both public and private health facilities as well as\nat the community level. The need for streamlined standards for HIV service delivery across all\nstrata of health care cannot be over-emphasized, bearing in mind the differences in unmet need\nacross the various sub-populations of PLHIV.\nThe best quality system may not function if there is no commitment on the part of the people\ninvolved to implement it. On the other hand, the simplest of systems can work very effectively if\nthere is motivation and commitment on the part of those involved to improve the quality of care.\nContinuous quality improvement can therefore be achieved by encouraging a quality culture that\nis based on a common vision, purpose, understanding, values and principles.\n9.3.1 Standards of Care\nThe standard care continuum for HIV extends from testing and counselling to care, treatment,\nand monitoring.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2259, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f0dce1ea-755c-418e-966e-01bc4708ff3e": {"__data__": {"id_": "f0dce1ea-755c-418e-966e-01bc4708ff3e", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "185"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "44dfdbb7-31d7-44e0-8d98-8ed3836bc2e3", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "185"}, "hash": "4bcf35c944ca52591bda586067558c75489f06add72ab06da16eae9376d93fb3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8216c642-67e0-460d-bf97-d50d6802b845", "node_type": "1", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "185"}, "hash": "3674389388036d3ea97bfea13c8fe7e6e95f3d9a2ec2a475d7176df79e52b3a1", "class_name": "RelatedNodeInfo"}}, "text": "9.3.1 Standards of Care\nThe standard care continuum for HIV extends from testing and counselling to care, treatment,\nand monitoring. The care continuum is not a \u201cone size fits all\u201d rather there are peculiarities for\nthe various sub-populations, such as children, adolescents, key populations and\npregnant/breastfeeding women. With more than 1.14 million (at 2019) PLHIV enrolled in care,\nit is important to employ strategies that strengthen linkages to care, retention in care and\nadherence to therapy to ensure that at least 95% of each of the various sub-populations of PLHIV\nachieve and sustain virological suppression.\nCertain strategies have been shown to strengthen/optimize the indices necessary to cater to the\nunmet need in HIV service delivery, key among them are:\nImproving Quality of Health Service Delivery\nQuality of care emphasizes that services should be effective in achieving desired health\noutcomes and that health care practices should be people-centred and safe. Efficient and\neffective HIV service delivery in Nigeria requires the following:\n          NATIONAL GUIDELINES FOR HIV PREVENTION TREATMENT AND CARE 2020             163", "mimetype": "text/plain", "start_char_idx": 2127, "end_char_idx": 3279, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "45bb6def-f19b-49b0-a0c4-1adacee31023": {"__data__": {"id_": "45bb6def-f19b-49b0-a0c4-1adacee31023", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "186"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "0f587ed7-3674-457c-af4c-c28acb21276e", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "186"}, "hash": "8030f0aa5035557ae15b7481c008d3f66d06641c5ddc7a2705206beea872c765", "class_name": "RelatedNodeInfo"}}, "text": "\u00a7   Health system strengthening and well-coordinated systemic linkages across primary,\n        secondary and tertiary health facilities as well as with community-based facilities, social\n        support services and support groups.\n    \u00a7   National quality evaluation and accreditation processes for health facilities and health\n        providers at both the facility and the community level aimed at:\n        o   creating new service delivery sites at both facility and community levels\n        o   reviewing existing facilities for potential designation as service delivery site\n        o   assessing community capacity and identifying interventions to train and coordinate\n            public education\n        o   allocating new resources or reallocating existing scarce resources to HIV care\n        o   overseeing national treatment programmes\n    \u00a7   Capacity building for healthcare providers at both the facility and community level and\n        also of PLHIV for effective service delivery and communication. Tasks must be clearly\n        delineated and performance expectations well defined.\n    \u00a7   Providing information and supporting clients to make informed decisions about their\n        health, their engagement with health care and management of their health\n    \u00a7   Strengthening existing patient appointment systems with acceptable frequency of clinic\n        and medication refill visits and an efficient system for identification and tracking of\n        PLHIV who default on their appointments\n    \u00a7   Adoption of differentiated service delivery models and quality improvement strategies\n        to reduce waiting and turnaround times in clinics, laboratories and drug refill centres\n    \u00a7   Integrating the delivery of other services into HIV service delivery platforms as\n        appropriate and relevant e.g. TB, hepatitis, STIs, mental health, substance abuse, NCDs,\n        nutrition and SRHS\n    \u00a7   Quality control for test kits, medications (includingARVs and OI drugs ) and diagnostic\n        equipment.\n    \u00a7   Data Management\nThe need to continually monitor and improve on perceived gaps in service delivery cannot be\nover-emphasized therefore continuous quality improvement should be integrated into routine\nservice delivery. The framework in use in Nigeria for quality improvement programs is the\nNigeriaQual.\n                  FMOH and\n                      IPs\n                                  State MP\n                               teams and IP\n                                  Ql teams\n                                                  Site and\n                                               Network Ql\n                                                   teams\nFigure 9.5: NigeriaQual Implementation Structure\n          NATIONAL GUIDELINES FOR HIV PREVENTION TREATMENT AND CARE 2020           164", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2834, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c12d2cdd-8f46-4487-831a-88c5a9012017": {"__data__": {"id_": "c12d2cdd-8f46-4487-831a-88c5a9012017", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "187"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "e90314e1-14f1-4c1f-a8be-453d26509f50", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "187"}, "hash": "a78654486c8d1e4d8695baededda17359ded0021c9952436c86ec913387c0bd0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bad0abb5-aca4-4329-a0af-102a03b07d23", "node_type": "1", "metadata": {}, "hash": "652559fc3c985619b496d4c4fd51c851a482c7bb35e9d3ceece9b05bd2df507b", "class_name": "RelatedNodeInfo"}}, "text": "NigeriaQual builds upon the HealthQual framework and has the following components:\n    \u00a7     Performance measurement\n          o  Indicator development, data collection, analysis and reporting\n    \u00a7     Quality management structure\n          o  Quality improvement teams at sites\n          o  Multidisciplinary management teams at facility, local government, state and federal\n             government level.\n    \u00a7     Quality improvement\n          o  Problem identification, prioritization, implementation of tests of change\n          o  Plan, Do, Study,Act (PDSA) cycle guides sustainable ongoing change\n         Review the findings of your quality                          Identify yourgoalsand baseline\n        management system                                             Assemble internal resources\n        Re-evaluate both the processes\n        and the product           ACT            PLAN                 Determine quality standards and the\n         Begin the quality management                                 requirements t0 meet those standards\n         process again                                                Determine what procedures will be used\n                                                                       ensure criteria is being met\n   Control; measure and monitor your outputs  CHECK DO                Organize supporting documentation (ISO\n   to ensure they meet expected criteria                              documentation; policies, procedures\n   Identify areas where there is opportunity                          training materials; work instructions; etc;)\n   for improvement                                                      documentmanagement system\n                                                                      Train employees on new process(es)\n                                                                      Deploy the quality management system\nFigure 9.6: The Four Main Components of Quality Control Management\nHuman Resource for Health\nThe inadequacy of the right number and mix of health workers to deliver quality ART services is\na major obstacle to the achievement of universal access to quality HIV prevention, treatment and\ncare. Evidence-based interventions should be implemented to boost human resource for HIV\nservice delivery. There is also the need to minimize staff attrition/incessant transfer of trained\nART service providers. There is also a need for government and responsible agencies to\nconsistently employ competent healthcare providers for the provision ofART services.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2550, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bad0abb5-aca4-4329-a0af-102a03b07d23": {"__data__": {"id_": "bad0abb5-aca4-4329-a0af-102a03b07d23", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "187"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "e90314e1-14f1-4c1f-a8be-453d26509f50", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "187"}, "hash": "a78654486c8d1e4d8695baededda17359ded0021c9952436c86ec913387c0bd0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c12d2cdd-8f46-4487-831a-88c5a9012017", "node_type": "1", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "187"}, "hash": "d81c9c1a9cd545e8b1124b64188a0d53d6139c26d9d3378e27ba888ba8a1617c", "class_name": "RelatedNodeInfo"}}, "text": "There is also the need to minimize staff attrition/incessant transfer of trained\nART service providers. There is also a need for government and responsible agencies to\nconsistently employ competent healthcare providers for the provision ofART services.\nTraining of Health Workers\nIt is recommended that:\n    \u00a7     All health workers and lay providers involved in the provision of HIV treatment and care\n          should receive training prior to offering services and periodic re-training thereafter\n    \u00a7     Training of health workers and lay providers should conform with globally accepted\n          standards for high-quality training\n    \u00a7     Training of health workers and lay providers should be conducted using nationally\n          approved training curricula and manuals\n    \u00a7     Training curricula for the different cadres of healthcare providers, lay providers, peer\n          educators, mentor mothers etc should be age and context appropriate\n           NATIONAL GUIDELINES FOR HIV PREVENTION TREATMENT AND CARE 2020               165", "mimetype": "text/plain", "start_char_idx": 2298, "end_char_idx": 3347, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8cd0fb02-f656-4cd2-afe5-6f73df309dcf": {"__data__": {"id_": "8cd0fb02-f656-4cd2-afe5-6f73df309dcf", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "188"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "4646dc06-b860-46aa-abb1-e1bdd7506144", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "188"}, "hash": "f9546f8e7365404867194820be72b3be20d417de96a7ac5a1f458fd36e52434c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8e6622eb-c28c-4495-a3e1-38132d7a632d", "node_type": "1", "metadata": {}, "hash": "bf31252c08a09c6bfa9e7b3fb6bde024e7cf7f9fd9ffc447de16b7333871b1cd", "class_name": "RelatedNodeInfo"}}, "text": "Task shifting and Task sharing\nTask shifting and task sharing involve the redistribution of tasks within health workforce teams\nthat allows specialized health workers more time to focus on advanced clinical conditions while\nnon-physician providers attend to more stable patients. It also makes it possible for lay providers\nto offer certain non-specialized services especially in community models of HIV service\ndelivery. Task shifting and task sharing has enhanced linkage to care, addressed the high patient-\nto-doctor ratio, helped reduce the high default rates among patients already on ART, improved\ntreatment adherence, patient satisfaction and also strengthened community systems. Task\nshifting and sharing must be implemented with clear cut clarification of roles and assignments. It\nalso requires mentorship and supportive supervision to ensure continuous quality improvement.\nThe National Policy on Task Shifting provides guidelines and recommendations on task shifting\nand service provision and should be referred to for support in ensuring consistent quality of\nservice delivery.\n9.3.2 Standard Precautions\nThese are general guidelines to safeguard the various individuals involved in HIV service\ndelivery, including healthcare workers, lay providers, clients and the community at large. In the\nday to day delivery of HIV services, there are safety measures that must be considered if optimal\nservices are to be sustained; these include:\nInfection Prevention and Control (IPC) Measures\nThese are measures/protocols put in place to ensure protection from infectious agents either as a\nresult of nosocomial exposure or wide-spread infection at the community level. It is necessary to\nput in place protocols which will provide guidance in cases of infections of public health\nconcern. In the case of HIV, it is necessary to prevent accidental infections, occupational\ninfections and any widespread infection within a vulnerable sub population due to harmful\npractices or low level of awareness. There should be an established IPC policy in all health\nfacilities in the private and public sectors to ensure the prevention of accidental/occupational\nexposure to blood, body fluids and airborne pathogens that may result in infection with HIV or\nany other infectious disease.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2281, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8e6622eb-c28c-4495-a3e1-38132d7a632d": {"__data__": {"id_": "8e6622eb-c28c-4495-a3e1-38132d7a632d", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "188"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "4646dc06-b860-46aa-abb1-e1bdd7506144", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "188"}, "hash": "f9546f8e7365404867194820be72b3be20d417de96a7ac5a1f458fd36e52434c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8cd0fb02-f656-4cd2-afe5-6f73df309dcf", "node_type": "1", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "188"}, "hash": "542b4dafe5fdae267eb2f6b5a827032de81a5b5c5acd2d6bb336b2ad96bc6a02", "class_name": "RelatedNodeInfo"}}, "text": "Standard Precautions\nThese are minimum infection prevention practices that should be observed by ALL health\nworkers/lay providers in the provision of HIV services, regardless of suspected or confirmed\ninfection status and include:\n   \u00a7    Hand Hygiene - Routine hand washing with soap and water before and after contact with\n        each patient, regardless of the HIV status\n   \u00a7    Respiratory hygiene/cough etiquette\n   \u00a7    Use of barrier precautions including Personal Protective Equipment (PPE) such as\n        gloves, gowns and masks etc.\n   \u00a7    Sharps Safety/Safe Injection Practices - Safe handling and disposal of sharp instruments\n        and equipment, including needles and syringes\n   \u00a7    Clean and disinfected work surfaces\nFor more details, refer to the National Guideline for Continuity of HIV service delivery in the\ncontext of complex emergencies It is recommended that ALL health facilities should provide the\nfollowing for their workers:\n          NATIONAL GUIDELINES FOR HIV PREVENTION TREATMENT AND CARE 2020             166", "mimetype": "text/plain", "start_char_idx": 2282, "end_char_idx": 3331, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c3b13267-f840-48de-ade5-ae96a746d135": {"__data__": {"id_": "c3b13267-f840-48de-ade5-ae96a746d135", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "189"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "12c6b0c9-86f8-48b8-a1db-018fee279d7e", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "189"}, "hash": "42799e64b64f09d883a92e73e156e8389bcabf80bf2921e4d1827e415cf9b2b7", "class_name": "RelatedNodeInfo"}}, "text": "\u00a7   Vaccinations against vaccine-preventable diseases such as Hepatitis B and tuberculosis\n    \u00a7   Post-Exposure Prophylaxis\n    \u00a7   Screening for HIV, TB, HBV, HCV, SARS\u2013Cov-2 and other infections\n    \u00a7   Asafe working environment. This includes the adaptation and dissemination of policies\n     and SOPs on universal safety precautions, IPC and workplace safety to ensure the safety\n        and health of the employees within the workplace\n9.4 Nutrition\nNutritional interventions, both food-based approaches and micronutrient supplementation, are\nan essential component of comprehensive HIV care. Infection with HIV affects the nutritional\nstatus of PLHIV by causing increased energy requirements, metabolic alterations, reduced\ndietary intake and nutrient malabsorption. These eventually lead to weight loss, malnutrition and\nwasting in PLHIV.         Malnutrition also affects the immune system in similar ways as HIV\ninfection itself with abnormal B-cell responses, suppression of delayed hypersensitivity and\ndecrease in CD4+ T-cells.\nGood nutrition contributes to an optimal nutritional status that enhances the wellbeing of the\nPLHIV at all stages of the disease and contributes to the prolongation of life. It requires the\nconsumption of adequate both macronutrients (proteins, carbohydrates and fats) and\nmicronutrients (vitamins and minerals).\nFigure 9.7: Relationship between nutrition and HIV\n9.4.1 Nutrition in HIV Positive Pregnant and Lactating Woman\nThe nutritional status of an HIV positive woman before, during and after pregnancy affects not\njust her health but also the outcome of the pregnancy and survival of the newborn. Anaemia may\nbe more severe in HIV positive pregnant women, and severe anaemia (Hb < 7g/dL) is associated\nwith poor pregnancy outcomes and increased maternal and perinatal mortality. Extra nutrients\nare required during pregnancy to support the growth and development of the baby in utero.\n9.4.2 Nutrition in Children Living with HIV\nSuccessfully treating a child requires the commitment and involvement of a responsible\ncaregiver. Parents and other family members of children living with HIV may themselves be\n           NATIONAL GUIDELINES FOR HIV PREVENTION TREATMENT AND CARE 2020            167", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2242, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "53557098-7254-4bc5-b4b5-094ee193e2b3": {"__data__": {"id_": "53557098-7254-4bc5-b4b5-094ee193e2b3", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "190"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "978a7020-a72d-43d7-b10a-ad804af6846a", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "190"}, "hash": "4f6c9f4e041d1605908140e49974b4a2726397148e147e303f2921bf574e316d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a201247f-3973-4ee6-be77-1836943fb055", "node_type": "1", "metadata": {}, "hash": "761541b16694d5b478a242ede57b84f0990bfa04b110d4ff2a5473cb6b28f69a", "class_name": "RelatedNodeInfo"}}, "text": "infected with HIV, and sub-optimal HIV care and treatment for family members could result in\nsub-optimal care for the child. Another challenge to optimal treatment is lack of nutritional\nsupport.\nThe nutritional needs of infants, young children, adolescents and adults alike should be\nadequately addressed during the initial evaluation, and it should be balanced with the need for\ntheir medication. It is important to ensure that nutritional counselling starts as soon as the\ndiagnosis of HIV is made and is re-emphasized at each subsequent contact with healthcare\nproviders at both the facility and the community level. All CLHIV should benefit from\nnutritional assessment, counselling and support (NACS).\nImproving the nutritional status of CLHIV should be based on scientific evidence, available\nlocal resources and expert opinion from clinical and programmatic experiences.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 877, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a201247f-3973-4ee6-be77-1836943fb055": {"__data__": {"id_": "a201247f-3973-4ee6-be77-1836943fb055", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "190"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "978a7020-a72d-43d7-b10a-ad804af6846a", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "190"}, "hash": "4f6c9f4e041d1605908140e49974b4a2726397148e147e303f2921bf574e316d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "53557098-7254-4bc5-b4b5-094ee193e2b3", "node_type": "1", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "190"}, "hash": "09ee571173f0ce16a53cadc002fede38060d8a1437a519fcc54efd0bb6a9e76e", "class_name": "RelatedNodeInfo"}}, "text": "All CLHIV should benefit from\nnutritional assessment, counselling and support (NACS).\nImproving the nutritional status of CLHIV should be based on scientific evidence, available\nlocal resources and expert opinion from clinical and programmatic experiences.\nNutritional counselling, care and support requires the following steps:\n   \u00a7   Assessment of the specific circumstances of each CLHIV\n       o   Present nutritional status and diet\n       o   Identification of factors mitigating against and facilitating adequate dietary intake\n   \u00a7   Nutritional counselling to address specific areas identified during assessment and\n       mutual agreements on the dietary plan based on available local resources\n   \u00a7   Monitoring and documentation of nutritional status\nTable 9.8: Strategies and Guides for Improving and Monitoring the Nutritional Status of PLHIV\n Diet and Lifestyle                                      Monitoring\n \u00a7   Eat a variety of foods that include proteins,       \u00a7  Clinical assessment\n     carbohydrates, and a little good fat (nuts, avocado,   -    History taking (intake, weight\n     fish, soybean)                                              changes and growth, GI symptoms,\n \u00a7   Eat a diet high in fresh fruits and vegetables              and functional capacity)\n \u00a7   Daily intake of lean, low-fat protein \u2013skinless     \u00a7  Physical examination\n     chicken, fish, extra-lean meat, beans, groundnuts,     -    Anthropometric measurements for\n     soya beans, eggs and low-fat dairy products                 growth monitoring in children\n     -  Use salt sparingly                                  -    Height, Weight, BMI for age and\n \u00a7   Ensure adequate water intake                                Sex MUAC,\n \u00a7   Avoid alcohol and cigarette smoking                 \u00a7  Bodyweight changes in adults (BMI in\n \u00a7   Limit simple sugars in sweets, soft drinks, cakes      kg/m 2)\n     and foods with added sugar                             -  underweight \u2264 18.5\n \u00a7   Hygienically prepared food, drinking water and         -  normal = 18.5 \u2013 24.9\n     bev erages                                             -  overweight = 25 \u2013 29.9\n \u00a7   Nutrition educ ation and counselling                \u00a7  -  obese \u2265 29.9\n \u00a7   Prompt treatment of OIs that interfere with         \u00a7  Waist -Hip Ratio\n     nutrition (mouth disorders, diarrhoea etc)             Biochemical measurements of\n \u00a7   Nutritional Support-macro/micronutrients               metabolic parameters, serum proteins,\n \u00a7   Regular exercise and physical activity                 and micronutrients\n \u00a7   Economic empowerment\n          NATIONAL GUIDELINES FOR HIV PREVENTION TREATMENT AND CARE 2020                168", "mimetype": "text/plain", "start_char_idx": 621, "end_char_idx": 3307, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ac759fc7-42df-41ee-8b71-e91a5cb10858": {"__data__": {"id_": "ac759fc7-42df-41ee-8b71-e91a5cb10858", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "191"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "65e287af-c1f1-4dd9-8695-737aa98e0b75", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "191"}, "hash": "df9c4517f7a88ae74db1310b3667413dc8f14ddfcebf241406393a4112db0604", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "256e7148-5d6f-415a-a224-9b8771243c10", "node_type": "1", "metadata": {}, "hash": "1d9869de5ead90df4d2b2a4af85c36b3a57d3d11d67e825bc0be7f207c7cf88d", "class_name": "RelatedNodeInfo"}}, "text": "9.4.3 Nutrition andAntiretroviral Therapy\nMetabolic complications associated with the use of some ART such as lactic acidosis, alterations\nin bone metabolism, derangement in blood glucose and lipid metabolism must be taken into\nconsideration whilst planning an adequate diet for all PLHIV. Co-morbidities such as diabetes\nmellitus, cardiovascular and renal diseases may also require additional dietary modifications.\nAn optimal nutritional status may enhance adherence to ART, its acceptability, effectiveness and\nultimately virological suppression.\n         Nutritional support is an essential component of comprehensive HIV care. It is\n   recommended     that  nutritional interventions,  both  food-based   approaches    and\n   micronutrient supplementation (where applicable), are included as part of the routine care\n   of infants, young children, adolescents and    adults living with HIV and their family\n   members\n9.5 Service Delivery forAdolescents Living with HIV\nThere are about 120,000 adolescents (10-19 years) living with HIV (ALHIV) in Nigeria, with\n70,000 (nearly 60%) being female [6]. Adolescents are a heterogenous group undergoing rapid\ndevelopmental, emotional and social changes. Unique changes that occur during adolescence\ninclude: emerging autonomy but limited access to resources; dramatic increase in number and\nvariety of social relations that could increase vulnerability; developing self and sexual identity,\nincluding capacity for self-direction; enhanced but evolving cognitive ability and greater\nimpulsivity; and a gap between biological maturity and assumption of adult roles. Adolescents,\ntherefore, have peculiar needs and challenges which have implications for their health and well-\nbeing.\nAddressing the distinct and diverse needs of adolescents living with HIV (ALHIV) to improve\ntheir HIV-related outcomes requires a comprehensive and integrated approach. Adolescent HIV\nservices in Nigeria (where available) often have limited integration with other adolescent health\nservices. Surveys and HIV program results have shown that over the years, adolescents living\nwith HIV in Nigeria have been underserved and have significantly worse access to HIV testing,\nlower ART coverage, and lower viral load suppression rates compared to adults.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2277, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "256e7148-5d6f-415a-a224-9b8771243c10": {"__data__": {"id_": "256e7148-5d6f-415a-a224-9b8771243c10", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "191"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "65e287af-c1f1-4dd9-8695-737aa98e0b75", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "191"}, "hash": "df9c4517f7a88ae74db1310b3667413dc8f14ddfcebf241406393a4112db0604", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ac759fc7-42df-41ee-8b71-e91a5cb10858", "node_type": "1", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "191"}, "hash": "bf24ae9034c118ee9e4b430f5bc49b50e8860f9cba568a64dca240ff7e7a90ff", "class_name": "RelatedNodeInfo"}}, "text": "Surveys and HIV program results have shown that over the years, adolescents living\nwith HIV in Nigeria have been underserved and have significantly worse access to HIV testing,\nlower ART coverage, and lower viral load suppression rates compared to adults. They are at\nhigher risk of loss to follow-up both before and after antiretroviral therapy initiation, with\npregnant adolescents living with HIV and adolescent key populations particularly vulnerable.\nIn 2014, the FMOH developed consensus guidelines to reconcile key ethical, legal and socio-\ncultural issues that pose serious challenges to the conduct of SRH research and access to HIV\nservices. Globally, specific interventions, service delivery models and approaches tailored to the\nspecific needs of adolescents have shown significant improvements in health outcomes for\nadolescents underscoring the need for the tailoring service delivery for adolescents living with\nHIV to their specific needs through what is now widely termed adolescent-friendly health\nservices (AFHS).\n9.5.1Adolescent Friendly Health Services\nAdolescent-friendly health services (AFHS) encompasses interventions, service delivery\nmodels and approaches tailored to the specific needs of adolescents. AFHS has the twin goals of\npromoting healthy development in adolescents, and the prevention and response to health\nproblems if and when they arise.\n           NATIONAL GUIDELINES FOR HIV PREVENTION TREATMENT AND CARE 2020           169", "mimetype": "text/plain", "start_char_idx": 2022, "end_char_idx": 3487, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cf4ebd45-e0be-4f3e-9abe-5e16d0746ea1": {"__data__": {"id_": "cf4ebd45-e0be-4f3e-9abe-5e16d0746ea1", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "192"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "782057ad-51ec-4afd-b252-97ed9f6ecc0f", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "192"}, "hash": "70d5431ce99da5b104044d443a525c5a95f6c142d7c3323f143009ee993d901e", "class_name": "RelatedNodeInfo"}}, "text": "Tomake HIV services adolescent-friendly, the principles below should be followed\n      \u00a7  Equitable: all adolescents, not just certain groups, are able to obtain the health\n         services they need\n      \u00a7  Accessible: adolescents are able to obtain the services that are provided\n      \u00a7  Acceptable: health services are provided in ways that meet the expectations of\n         adolescent clients\n      \u00a7  Appropriate: the right health services that adolescents need is provided\n      \u00a7  Effective: the right health services are provided in the right way and make a\n         positive contribution to the health of adolescents\n9.5.2 Package of services for adolescents living with HIV\nAdolescents living with HIV (ALHIV) need additional specific HIV-related services in addition\nto routine health services. Providing an appropriate package of services is one of the global\nstandards for high-quality health services for adolescents. The package of services for ALHIV\nshould be standardized and aligned with the principles of adolescent-friendly health services and\nthe global standards for quality health-care services for adolescents (Fig 9.8). To ensure high-\nquality HIV services for adolescents in Nigeria, a package of HIV services for ALHIV is here\ndefined and is recommended for implementation at health facilities and through referral links to\nother service delivery channels using a standardized approach.\n              Principle of                                    Global standards for\n              adolescent-friendly                             quality health care\n              health services                                 services for adolescent\n                                        High quality\n                                       HIV services for\n                                        adolescents\n                                       Standardized\n                                       package of services\n                                       for ALHIV\nFigure 9.8: Key elements for high-quality adolescent HIV service delivery\n9.5.3Age-appropriate disclosure support\nDisclosure of HIV status is the process of informing a child or adolescent of his/her HIV status. It\nalso refers to the adolescent sharing his/her HIV status with a family member, friend or\nsignificant other. Disclosure is not a one-time event, but rather a process that involves ongoing\ndiscussions about the disease as the child or adolescent matures cognitively, socially,\nemotionally, and sexually.\n          NATIONAL GUIDELINES FOR HIV PREVENTION TREATMENT AND CARE 2020              170", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2595, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c49e0122-9adb-4288-92f4-97d36142a55c": {"__data__": {"id_": "c49e0122-9adb-4288-92f4-97d36142a55c", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "193"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "b9681a79-d47a-462e-a0d4-6e58a4d91c40", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "193"}, "hash": "19102a936d8252b8b0c8c50f10af8c455211a1328bb93e76dd831e9cc61a54dc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d5c9a962-ce2d-4327-9bd8-18fff39d192a", "node_type": "1", "metadata": {}, "hash": "23b36693093519ceda02c5398075cdd1d7f896be365ea84519c32a5fc50aea4f", "class_name": "RelatedNodeInfo"}}, "text": "Phases of disclosure and age recommendations\n     No disclosure: There is no mention of any illness or HIV and no information is\n     provided about HIV diagnosis. This is recommended for children aged 0-4years.\n                                                            .\n     Partial Disclosure: Children are given some but not all information about their\n     illness. Information may be given on immunity and the need to take medicines in\n     order to keep illness at bay. There is no mention of HIV or AIDS.This is\n     recommended for children aged 5 -8 years.\n     Full Disclosure: Children are told the name of the illness (HIV and/or AIDS),\n     disease specific information (e.g., how the virus works, how it is transmitted),\n     and how they acquired the disease.\n     This is recommended for children/ adolescents aged 9 -12 years with the goal\n     of completing full disclosure by age 10-12 years.\n     Post-disclosure:Period following disclosure, commonly described as early\n     post-disclosure (first three to six months) and late post-disclosure (over six months)\n     periods. The objective of post-disclosure evaluation and follow-up is to identify\n     the feelings, perception, and degree of coping with the diagnosis and to prevent\n     any complications after disclosure.\nAccidental disclosure occurs when someone talks about the HIV status of a child or adolescent\nwithout knowing that he/she is not aware of it. The service provider should carry out at least a\npartial disclosure of an HIV status to the child or adolescent when this occurs, and a readiness\nassessment and discussions with the parents or caregiver should be undertaken as soon as\nfeasibly possible.\nDisclosure helps the child/adolescent to know the HIV diagnosis, infection, understand the\ndisease process and health changes that could occur; develop strategies to lead a healthy life; and\nunderstand his/her responsibilities thereby promoting adherence to care and treatment, which is\nvital to achieving viral suppression. It has a positive long-term psychological impact and may\nimprove social functioning and school performance. Both the health care team and caregivers\nshould be involved throughout the disclosure process. Disclosure service provision should\ninvolve facility-based health care providers\u2014such as doctors, psychologists, nurses\u2014as well as\nsocial workers and community health workers.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2398, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d5c9a962-ce2d-4327-9bd8-18fff39d192a": {"__data__": {"id_": "d5c9a962-ce2d-4327-9bd8-18fff39d192a", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "193"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "b9681a79-d47a-462e-a0d4-6e58a4d91c40", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "193"}, "hash": "19102a936d8252b8b0c8c50f10af8c455211a1328bb93e76dd831e9cc61a54dc", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c49e0122-9adb-4288-92f4-97d36142a55c", "node_type": "1", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "193"}, "hash": "448ff21735536867e78ae0fbee197c91dbc624471fa083f13ad85606826890de", "class_name": "RelatedNodeInfo"}}, "text": "Both the health care team and caregivers\nshould be involved throughout the disclosure process. Disclosure service provision should\ninvolve facility-based health care providers\u2014such as doctors, psychologists, nurses\u2014as well as\nsocial workers and community health workers.\nKey considerations for successful disclosure:\n    \u00a7   Service providers and healthcare workers should build up trust and establish rapport\n        with children and adolescents and their caregivers from the start of service delivery\n    \u00a7   The disclosure process should be aligned with recommended age guidance and should\n        take child's cognitive development into account, while remaining flexible and sensitive\n        to the family's feelings and needs as they evolve through the phases of disclosure\n    \u00a7   An individual plan for disclosure should be developed for each child/ adolescent and\n        documented using a disclosure checklist/ tracker as part of his/her medical records\n    \u00a7   The clinical team/care providers should provide intensive support and services to\n           NATIONAL GUIDELINES FOR HIV PREVENTION TREATMENT AND CARE 2020           171", "mimetype": "text/plain", "start_char_idx": 2128, "end_char_idx": 3271, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "534c08a5-1c4a-44e2-8145-6585465a9092": {"__data__": {"id_": "534c08a5-1c4a-44e2-8145-6585465a9092", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "194"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "9d8fed63-108a-4713-984b-4849a0c93d93", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "194"}, "hash": "5d18240b60ff1346f5b624d54e27f226d25fd838febdff4cd9ef1fb436b5be46", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "afbcfc94-bd07-4b97-9f1d-572cfcc31a4c", "node_type": "1", "metadata": {}, "hash": "44d3566e2e5cd0cc605e5db1baae9d76ffa2ee98656d349c54d59cb6fda402eb", "class_name": "RelatedNodeInfo"}}, "text": "caregivers who object to disclosing an adolescent's HIV diagnosis to address their\n        concerns\n    \u00a7   Beyond disclosure support by the healthcare team for informing an adolescent of his/her\n        HIV status, support for onward disclosure to others such as family members, friend and\n        significant other should be provided\n9.5.4 Psychosocial support for adolescents living with HIV\nHIV affects adolescents in various ways in addition to the peculiarities of adolescence. One of\nthe gaps in the delivery of paediatric and adolescent HIV care and treatment services is the\nprovision of psychosocial counselling to HIV infected/affected adolescents and their caregivers.\nPsychosocial support entails attendance to the emotional, psychological, social, spiritual, and\npractical needs of the adolescent within his/her current situation, family, environment and\nrelationships. It is important for health care workers to receive adequate knowledge and skills\nneeded to comfortably provide psychosocial counselling to HIV positive children/adolescents\nand their caregivers. There is also a need to provide on-going supportive counselling, to address\ncare and treatment adherence issues.\nRecommendations for addressing gaps in the provision of psychosocial support forALHIV:\n    \u00a7   Training of healthcare workers on the provision of psychosocial support to children and\n        adolescents and their caregivers using a standard curriculum.\n    \u00a7   Provision of child/adolescent centred counselling using appropriate SOPs and job aids.\n        Service providers should bear in mind that each adolescent is unique and so should not\n        generalize when providing support.\n    \u00a7   Provision of strength-based counselling for adolescents.\n    \u00a7   Psychosocial support should be available and accessible as part of the package of care at\n        ART refill visits\n    \u00a7   Counselling should be provided based on the needs of the adolescents.\n    \u00a7   There should be multidisciplinary team involvement when providing psychosocial\n        support to handle other issues like disclosure, nutritional support, mental health, caring\n        for a sick caregiver etc.\n    \u00a7   Availability of peer support through individual engagement, peer support groups, virtual\n        platforms etc. is important for adolescents.\n    \u00a7   Provision of access to basic education and literacy programs.\n    \u00a7   Provision of life skill coaching and empowerment which helps build their confidence\n        and self-sufficiency.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2506, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "afbcfc94-bd07-4b97-9f1d-572cfcc31a4c": {"__data__": {"id_": "afbcfc94-bd07-4b97-9f1d-572cfcc31a4c", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "194"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "9d8fed63-108a-4713-984b-4849a0c93d93", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "194"}, "hash": "5d18240b60ff1346f5b624d54e27f226d25fd838febdff4cd9ef1fb436b5be46", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "534c08a5-1c4a-44e2-8145-6585465a9092", "node_type": "1", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "194"}, "hash": "9ed6bea7d2a7df294a330619be4db3926c17b1452a48eccc9e5c8cb231a27949", "class_name": "RelatedNodeInfo"}}, "text": "is important for adolescents.\n    \u00a7   Provision of access to basic education and literacy programs.\n    \u00a7   Provision of life skill coaching and empowerment which helps build their confidence\n        and self-sufficiency.\nFor adherence support and SRH in adolescents, refer to the chapters on adherence and PMTCT\nrespectively.\n9.5.5 Transitioning to adult care\nTransitioning is a purposeful, planned process to facilitate and support the movement of\nadolescents and young people from child/adolescent care- to adult-centred healthcare. A\nnationwide study reported that most secondary and tertiary health facilities in Nigeria\ntransitioned adolescents to adult care at 15 or 18 years of age [31]. Less than 30% of facilities\nhad an adolescent-specific clinic or transition policy, and most care was provided in a family-\ncentred fashion.\n           NATIONAL GUIDELINES FOR HIV PREVENTION TREATMENT AND CARE 2020               172", "mimetype": "text/plain", "start_char_idx": 2285, "end_char_idx": 3213, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fe0b450f-7112-4e84-b0c0-d2e8b48fdd28": {"__data__": {"id_": "fe0b450f-7112-4e84-b0c0-d2e8b48fdd28", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "195"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "f38adb69-52e3-4bb4-8799-b8ccfdb7a069", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "195"}, "hash": "7460c3870ff8ecee90986fe79af66474901d82844a73a8be944fb1ad93712d31", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "55dc894b-318e-48e7-8a65-a946d6273230", "node_type": "1", "metadata": {}, "hash": "4187e8f26b482d768ee8381c3bcd9cebae6b77aa0b99504d7cfe551f4771bcf1", "class_name": "RelatedNodeInfo"}}, "text": "9.5.5.1 Organizing a Transition Plan\nTransition should involve a multidisciplinary team of paediatricians, adult physicians, nurses,\nsocial workers, adolescent peer mentors and mental health professionals where available. All\nhealthcare facilities and providers should have a written standard plan in place to transition\nadolescents to adult care. This plan should include a schedule for the transition process initiated\nfrom early adolescence and engaging both the adolescent and the parents/caregivers. The plan\nshould not be a \u201cone-size-fits-all,\u201d but should be flexible and tailored to clients' individual\ncapacities, readiness, and developmental age. Caregivers should be active stakeholders in the\ntransition process. Disclosure is important for successful transitioning and recommendations for\ndisclosure provided in this document should be implemented.\nDiscussions on the transition to adult care should be initiated latest by age 14 years and barriers\nto adherence, retention and viral suppression addressed. During the transition process,\nadolescents should be empowered to take full responsibility for their health and commit to\nachieving good treatment outcomes. Some services may not be available at all levels of care and\nmay require a referral.\n9.5.5.2 Key Considerations for the Transition Process\nTransitioning should be a continuous and seamless process rather than a \u201cone-off\u201d event that\noccurs with one meeting. Flexibility will ensure those involved in the process can recognize and\nrespond to the unique needs of ALHIV. Informed decision-making is the key to mature self-care\nand is the overall goal of successful transitioning.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1650, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "55dc894b-318e-48e7-8a65-a946d6273230": {"__data__": {"id_": "55dc894b-318e-48e7-8a65-a946d6273230", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "195"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "f38adb69-52e3-4bb4-8799-b8ccfdb7a069", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "195"}, "hash": "7460c3870ff8ecee90986fe79af66474901d82844a73a8be944fb1ad93712d31", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fe0b450f-7112-4e84-b0c0-d2e8b48fdd28", "node_type": "1", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "195"}, "hash": "343b8a38c152230a9e92ff38251eb451c00a7916955ed7a449745c0291755afa", "class_name": "RelatedNodeInfo"}}, "text": "Flexibility will ensure those involved in the process can recognize and\nrespond to the unique needs of ALHIV. Informed decision-making is the key to mature self-care\nand is the overall goal of successful transitioning. The following are key principles to guide the\ntransition process:\n    \u00a7   Individualize the approach for each child and adolescent based on their developmental\n        readiness\n    \u00a7   Identify HCWs to engage in the transition\n    \u00a7   Begin the process early, ensuring communication among the adolescent, caregivers, and\n        the HCWs in the adult health care setting, before, during, and after\n    \u00a7   Develop and follow an individualized transition plan for each adolescent; in addition to\n        developing an orientation plan in the adult health care setting;\n        o   Plans should be flexible to meet the adolescent's needs, and also should include\n            provisions for any regressions that an adolescent may have\n        o   Achecklist may be useful to develop such a plan\n    \u00a7   Use a multidisciplinary transition team including peers who are in the process of\n        transitioning or who have transitioned successfully\n    \u00a7   Address comprehensive care needs of each adolescent, as part of the transition,\n        including medical, psychosocial, and financial aspects of transitioning\n    \u00a7   Allow adolescents to express their opinions\n    \u00a7   Educate HIV care teams and staff about transitioning\n    \u00a7   Follow up transitioned adolescents in the adult clinic for 6 - 12 months to ensure\n        adherence and retention in care\nThere may be various barriers to seamless transitioning at the provider, adolescent and family\nlevels and these should be identified and addressed to minimize interruptions in care and\ntreatment. Poor communication among all stakeholders forms one of the largest barriers and\n           NATIONAL GUIDELINES FOR HIV PREVENTION TREATMENT AND CARE 2020              173", "mimetype": "text/plain", "start_char_idx": 1432, "end_char_idx": 3372, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "faa17b0f-4ca3-4367-9f5a-9d15003457d4": {"__data__": {"id_": "faa17b0f-4ca3-4367-9f5a-9d15003457d4", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "196"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "18e077a2-a4d9-4909-8c6b-35494d5ba0b2", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "196"}, "hash": "7ee6843ed93591c3a7a2fe6904ccf185c23564ae75108ad32b6afbc6f76a4b98", "class_name": "RelatedNodeInfo"}}, "text": "should be addressed. The transition should only occur when all parties have agreed that the child\nor adolescent has met the required criteria and is also mentally prepared.\n9.5.6 Peer-driven adolescent service delivery models\nMeaningful adolescent engagement is one of the standards for high-quality health services for\nadolescents. It entails intentionally involving adolescents in the planning, monitoring and\nevaluation of health services; inappropriate aspects of service provision; and in decisions\nregarding their care. It is essential that the meaningful participation and engagement of\nadolescent peers are encouraged and supported, and adolescents empowered and trained as\neffective peer educators, counsellors, trainers and advocates.\nWHO recently selected and profiled some adolescent peer-based models that are currently being\nimplemented in multiple countries across sub-Saharan Africa which have shown evidence of\nimprovement in linkage to care, adherence to antiretroviral therapy, retention in care, and viral\nsuppression. Some of these models are being tested in Nigeria but are yet to be harmonized and\nevaluated. They include:\n    \u00a7   ArielAdherence Clubs\n    \u00a7   Baylor College of Medicine International PediatricAids Initiative Teen Club\n        Programme\n    \u00a7   Operation Triple Zero (OTZ) Model\n    \u00a7   REACH (Re-engageAdolescents and Children with HIV) Programme\n    \u00a7   Zvandiri Model\n          NATIONAL GUIDELINES FOR HIV PREVENTION TREATMENT AND CARE 2020            174", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1498, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6d0b7261-7810-47f9-aac7-28b2efd64d3e": {"__data__": {"id_": "6d0b7261-7810-47f9-aac7-28b2efd64d3e", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "197"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "d1f797ff-1625-4757-8f13-f6f80526a9b3", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "197"}, "hash": "e0c9377214df5672fa3f6bac2311bcc3901266990f786ac33414c8c0220cbd5b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "517eefcf-7e93-4a38-a7e6-2a8874a70d0b", "node_type": "1", "metadata": {}, "hash": "9366a5aa1b3735740f8348363f80d2e9f86bfd8902535f45d3a4606fbd61334b", "class_name": "RelatedNodeInfo"}}, "text": "List of Contributors                                                         Chapter 9\nMs Bridget Onyebuchi             Assistant Chief Scientific Officer, NASCP\nMr Usman Mohammed                Senior Scientific Officer NASCP\nMr Sani Khalil A.                Senior Medical Laboratory Scientist NASCP\nMrs Sanni Kudirat                CNO NASCP\nProf. Lawal Umar                 Member NTTA / Paediatrician ABUTH, Zaria\nDr Eugenia Ofondu                Member NTTA / Dermatologist FMC Owerri\nDr Egejuru Ukabiala              Member NTTA / Paediatrician, Military Hospital, Lagos\nDr Olufunke Bolaji               Member NTTA / Paediatrician, FTH Ido Ekiti\nDr Richard Amenyah               Fast Track Advisor UNAIDS\nDr Olumuyiwa Ojo                 National Professional Officer (NPO) WHO\nDr Helen Sagay                   Technical Assistance- NTTP WHO\nOdelola Babatunji                Lead, Integrated Service Delivery Team/HIV/AIDS-TB USAID\nDr Uzoma Ene                     Senior Program Specialist HIV Care and Treatment CDC\nMs.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1029, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "517eefcf-7e93-4a38-a7e6-2a8874a70d0b": {"__data__": {"id_": "517eefcf-7e93-4a38-a7e6-2a8874a70d0b", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "197"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "d1f797ff-1625-4757-8f13-f6f80526a9b3", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "197"}, "hash": "e0c9377214df5672fa3f6bac2311bcc3901266990f786ac33414c8c0220cbd5b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6d0b7261-7810-47f9-aac7-28b2efd64d3e", "node_type": "1", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "197"}, "hash": "8171e157523176b4a6854bb004a37c9a549b016323fba55bbdf15b50be1d7098", "class_name": "RelatedNodeInfo"}}, "text": "Dolapo T. Ogundehin          Care and Treatment Lead (Acting) USAID\nDr Adamu Yakubu                  Deputy Director, Public Health Programs US DoD\nDr Ikechukwu Amamilo             Senior Technical Advisor CHAI\nChiedozie Nwafor                 Analyst CHAI\nDr Philip Imohi                  Associate Director - Prevention, Care and Treatment FHI360\nDr Majekodunmi Omololuoye        Senior Technical Officer FHI360\nDr Eluke Francis Blessing        Senior Technical Officer FHI360\nDr Onyekwelu Innocent            Technical Officer FHI360\nDr Otoyo Eskor Toyo              Associate Director FHI360\nDr Chidubem Oraelosi             Senior Technical Advisor, Prevention Care and Treatment FHI360\nDr Temi Omole                    Senior Technical Advisor APIN\nDr Honey D. Okpe                 Senior Technical Officer APIN\nDr Chinyerem Frances Immanuel    Care and Treatment Lead ICAP\nDr Emmanuel Nwabueze             Medical Director AHF\nDr Torbunde Nguavese             Senior Program Officer, Pediatric/Adolescent HIV IHVN\nDr Nadia Sam-Agudu               Senior Technical Advisor, Pediatric and Adolescent HIV IHVN\nDr Oladokun Oluwatosin           Clinical Service Manager Paediatrics and Adolescent CIHP\nDr Kemi Akagwu                   CSO PMTCT CIHP\nDr Winifred Ezeobi               Technical Advisor CCFN\nDr Chioma Helga Law-Maduka       Program Advisor Heartland Alliance\nDr Dominic Umoru                 Member NTTA/Paediatrician\n          NATIONAL GUIDELINES FOR HIV PREVENTION TREATMENT AND CARE 2020        175", "mimetype": "text/plain", "start_char_idx": 1030, "end_char_idx": 2548, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4c7d908f-b4a2-40da-87a5-3e19ff1bd043": {"__data__": {"id_": "4c7d908f-b4a2-40da-87a5-3e19ff1bd043", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "198"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "25bc5166-550b-4580-8e6d-dde3d6ba386c", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "198"}, "hash": "234141f474c3e9da94e764a635e0e05ba6cddbd52a7a44845a5f3c1333c9d0ae", "class_name": "RelatedNodeInfo"}}, "text": "10. MONITORING AND EVALUATION\n What\u2019s Inside:\n  1.1 Objectives of the Guidelines\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026..\n 10.1 Introduction \u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026.\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026..177\n  1.2 Epidemiology of HIV in Nigeria\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\n 10.2 Selection of Indicators\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026.\u2026\u2026\u2026\u2026...177\n  1.3 Natural History of HIV\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026.\u2026\u2026\n 10.3 Data Management\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026.\u2026\u2026\u2026\u2026\u2026.....182\n 10.4 HIV Data Dissemination and Use\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026..184\n 10.5 Human Resource for M&E\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026.\u2026.......184\n 10.6 HIV M&E Logistics\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026.\u2026\u2026\u2026\u2026\u2026..185\n 10.7 Additional Strategies in M&E\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026........185\n 10.8 HIV Research\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026.\u2026\u2026\u2026\u2026\u2026\u2026\u2026....185\n 10.9 Periodic monitoring of the implementation of\n    the guidelines and content update\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026...185", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 676, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4a1f28a9-be7f-478d-87a4-9ca78ee7b78a": {"__data__": {"id_": "4a1f28a9-be7f-478d-87a4-9ca78ee7b78a", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "199"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "bd086099-3f55-4263-8059-158420704be4", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "199"}, "hash": "f3b4f064ef1d9389088a1091b748dc66be831930501a1256d7c6566817757490", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6b44b1c5-16c8-4cb0-ad25-a33e49bf4f7b", "node_type": "1", "metadata": {}, "hash": "3ccff11d6f6411e9ffa024277ebb4421e96a057adbe953ca68d37053350ba992", "class_name": "RelatedNodeInfo"}}, "text": "10.1 Introduction\nMonitoring and evaluation of the HIV programme enables the country to measure the level of\neffectiveness of interventions and linkages between services. This will enable the country track\nprogress toward achieving its programme goals and set targets. It also provides data for informed\ndecision-making on the programme and allocation of resources.\nThe M&E objectives include:\n    1.  Monitoring programme performance across the domain of HIV prevention, treatment,\n        care and support.\n    2.  Improving data quality to inform decision making and programme planning.\n    3.  Strengthening capacity in data management across all levels of implementation.\n    4.  Improving data reporting from private, public and community level.\n    5.  Strengthening and utilizing HIV surveillance and research.\nNew strategies in the management of HIV and co-infections, along with changes in the\nimplementation environment call for a broadening of the M&E system in order to adequately\nmeasure and assess the impact of the interventions. In addition, routine monitoring shall be\ncomplemented by periodic systematic evaluations and programme reviews to assess the\nperformance and impact of HIV programmes. Data triangulation, modelling and other analytic\ntools will be utilized to improve the accuracy and usability of HIV data.\n10.2 Selection of Indicators\nIn 2017, the country adopted WHO global indicators for M&E reporting of the HIV programme.\nThe categories of national indicators relate to the following:\n    1.  HIV testing services\n    2.  Treatment and care for pregnant and breastfeeding women (prevention of mother-to-\n        child transmission (PMTCT)\n    3.  Paediatric, adolescent and adult HIV treatment and care\n    4.  Advanced HIV disease\n    5.  TB/HIV co-infection\n    6.  Other comorbidities and co-infections\n    7.  Post-exposure prophylaxis (PEP) and Pre-exposure prophylaxis (PrEP)\n    8.  Services for key populations\n    9.  Linkage, enrolment and retention in care\n    10. Toxicity monitoring\n    11. HIV drug resistance (HIV-DR)\n    12. Viral suppression and\n    13.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2104, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6b44b1c5-16c8-4cb0-ad25-a33e49bf4f7b": {"__data__": {"id_": "6b44b1c5-16c8-4cb0-ad25-a33e49bf4f7b", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "199"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "bd086099-3f55-4263-8059-158420704be4", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "199"}, "hash": "f3b4f064ef1d9389088a1091b748dc66be831930501a1256d7c6566817757490", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4a1f28a9-be7f-478d-87a4-9ca78ee7b78a", "node_type": "1", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "199"}, "hash": "e993307d2d8e5fcd936d99eac2433623fd6a72705711ce2f5b12edd815c22d49", "class_name": "RelatedNodeInfo"}}, "text": "Linkage, enrolment and retention in care\n    10. Toxicity monitoring\n    11. HIV drug resistance (HIV-DR)\n    12. Viral suppression and\n    13. Impact evaluation (mortality, prevalence and incidence)\n           NATIONAL GUIDELINES FOR HIV PREVENTION TREATMENT AND CARE 2020              177", "mimetype": "text/plain", "start_char_idx": 1961, "end_char_idx": 2251, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1756db42-47ab-49e4-b001-b3fe2212262f": {"__data__": {"id_": "1756db42-47ab-49e4-b001-b3fe2212262f", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "200"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "bdadc22a-0000-4cd1-a937-793a9afe85ed", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "200"}, "hash": "a5553ab5e75f6d8d3d3096dde8de42ce1870016bf49ef1e3647b5a144a2257fa", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ea70f1f9-da2a-47d7-b250-a502f31295bb", "node_type": "1", "metadata": {}, "hash": "2d0bf5a59875134623a78ab001ba2fda1853ba53b876d79e8661f3f2e749083f", "class_name": "RelatedNodeInfo"}}, "text": "Table 10.1: MONITORING AND EVALUATION FRAMEWORK\n INDICATORS                      DEFINITION                               Disaggregation     DATA         FREQUENCY        RESPONSIBLE\n                                 How is it calculated/measured?                              SOURCE       How often\n      Who will STATE/FMOH                                  STATE/FMOH\n        measure it?         STATE/FMOH     STATE/FMOH                    SMOH/ FMOH\n      will it   Annually                                   Annually\n        be measured?        Annually       Bi-annually                   Bi-annually\n                                                                                 Cohort Analysis\n                                             Data (PMM\n                                                & PM E           Tools).      & PME\n      How will it                                                                Tools).\n        be measured?\n                Programme\n                  Data.\n                     Spectrum.\n                            Spectrum.      Programme\n                                                  Tools).  Programme\n                                                            Data (PMM\n                                                              & PME      Programme\n                                                                           Data (PMM\n                1\u20134, 5\u20139,                                                     49, 50+\n                    49, 50+     49, 50+        49, 50+        49, 50+\n                    \u2013          \u2013               \u2013              \u2013               \u2013\n                      years); sex\n                             10-14, 15\u201319, 20\u2013\n                                24, 25       10-14, 15\u201319, 20\u2013\n                                                24, 25           years); sex  24, 25\n                Age (<1,                                                         years); sex\n                  10-14, 15\u201319, 20\u2013\n                    24, 25  Age (<1, 1\u20134, 5\u20139,\n                                  years); sex\n                                           Age (<1, 1\u20134, 5\u20139,\n                                                  years); sex\n                                                           Age (<1, 1\u20134, 5\u20139,\n                                                            10-14, 15\u201319, 20\u2013\n                                                              24, 25     Age (<1, 1\u20134, 5\u20139,\n                                                                           10-14, 15\u201319, 20 \u2013\n                                                   .\n                                                                                          6.)\n                                                    VL test result at 6 months of  year.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2781, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ea70f1f9-da2a-47d7-b250-a502f31295bb": {"__data__": {"id_": "ea70f1f9-da2a-47d7-b250-a502f31295bb", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "200"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "bdadc22a-0000-4cd1-a937-793a9afe85ed", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "200"}, "hash": "a5553ab5e75f6d8d3d3096dde8de42ce1870016bf49ef1e3647b5a144a2257fa", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1756db42-47ab-49e4-b001-b3fe2212262f", "node_type": "1", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "200"}, "hash": "e628e664c00eae6576c3f0516beed901e683c59d43accb41e3cff200ceaa5f9f", "class_name": "RelatedNodeInfo"}}, "text": "6.)\n                                                    VL test result at 6 months of  year. (This includes those who\n                            NA\n                                          Number of PLHIV who are virally       Number of PLHIV initiating ART up\n                                                                Number of PLHIV on ART that received\n                                                 Number of PLHIV on ART that\n                                                         Number of PLHIV who are virally\n                : Number of annual AIDS deaths among                    Number of PLHIV alive and on ART at 6\n                     : Estimated number of PLHIV.D:received a                   D:to 6 months before the beginning of the\n                N PLHIV.                                                           reporting\n                     D      N&D:          N:suppressed at 6 months of initiation\n                                               on ART.initiation on ART\n                                                         N:suppressed at 12 months of initiation\n                                                              on ART.\n                                                                D:a VL test result at 12 months of initiation\n                                                                     on ART.\n                                                                        N:months of ART initiation.\n                                                                                     have died since starting therapy, those who\n                                                                                        have stopped therapy and those lost to\n                                                                                          follow-up as of month\n                annual AIDS death among       suppressed at 6 months           initiation during the\n                                      OUTCOME INDICATORS\n           IMPACT INDICATORS                    during the reporting period.     reporting period.\n                % of\n                  PLHIV during the reporting\n                    period.Number of new infections\n                              averted      % PLHIV on ART who are\n                                              virally     % of PLHIV on ART who are\n                                                            virally suppressed at 12 months\n                                                              during the reporting period.\n                                                                         % of PLHIV on ART who are\n                                                                           retained on ART at 6 months\n                                                                               after\n      NATIONAL GUIDELINES FOR HIV PREVENTION TREATMENT AND CARE 2020                178", "mimetype": "text/plain", "start_char_idx": 2689, "end_char_idx": 5601, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c6754ee2-afe1-4935-9f64-bcdac692a0d4": {"__data__": {"id_": "c6754ee2-afe1-4935-9f64-bcdac692a0d4", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "201"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "4e180018-fbbf-43e8-a1ea-15cf6627a8f8", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "201"}, "hash": "a3d065355ed5a191152d2880c71926ecce8975a98bde81517fb5a35557189a8e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "616c5b36-980f-4fe4-88b4-5c783ec57e63", "node_type": "1", "metadata": {}, "hash": "3660bdb0c0525b00cdc9c209984795cd2e08f0bf48b1c5e4ee1c3482a6c5ab6c", "class_name": "RelatedNodeInfo"}}, "text": "% of PLHIV on ART who are           N: Number of PLHIV alive and on ART at 12      Age (<1, 1 \u20134, 5 \u20139,  Programme     Annually          SMOH/ FMOH\nretained on ART at 12 months of     months of ART initiation.                      10-14, 15 \u201319, 20 \u2013   Data (PMM\ninitiation during the reporting     D: Number of PLHIV initiating ART up to 12     24, 25 \u201349, 50+       & PME\n                                SMOH/ FMOHSMOH/ FMOH                           SMOH/ FMOH\n      Cohort Analysis           Bi-annually    Bi-annually                     Bi-annually\n      Tools).                   Programme\n                                   Data (PMM\n                                      & PME\n                                        Tools).\n                                              Programme\n                                                 Data (PMM\n                                                    & PME\n                                                       Tools).  Spectrum       Programme\n                                                                                  Data (PMM\n                                                                                     & PME\n                                                                                        Tools). Spectrum\n                                      49, 50+\n                                      \u2013\n      years); sex               Age (<1, 1 \u20134, 5 \u20139,\n                                   10-14, 15 \u201319, 20 \u2013\n                                      24, 25\n                                        years); sex\n                                                                    -\n                                                         :\n                                                                    Number of HIV             Number of HIV\n                                NA            Number of HIV- exposed infants who\n                                                                               No. of HIV Exposed babies who tested for\n                                                         Population-based denominatorEstimated number of HIV -positive pregnant\n        months before the beginning of the reporting\n                                year. (This includes those who have died since\n                                   starting therapy, those who have stopped\n                                therapy and those lost to follow-up as of month\n                    12)         N&D:          N: received EID/DNA-PCR test for HIV within\n                                                    two months of birth during the reporting period.\n                                                         D:  Estimated number of HIV-positive pregnant\n                                                                women during the r eporting period.\n                                                                    Facility-based denominator:\n                                                                       positive pregnant women.\n                                                                               N: HIV within 18 months of birth by Rapid Test.\n                                                                                      D: women during the reporting period.\n                                                                                              Facility-based denominator:\n                                                                                                 positive pregnant women\n                                                    birth\n      period.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 3580, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "616c5b36-980f-4fe4-88b4-5c783ec57e63": {"__data__": {"id_": "616c5b36-980f-4fe4-88b4-5c783ec57e63", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "201"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "4e180018-fbbf-43e8-a1ea-15cf6627a8f8", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "201"}, "hash": "a3d065355ed5a191152d2880c71926ecce8975a98bde81517fb5a35557189a8e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c6754ee2-afe1-4935-9f64-bcdac692a0d4", "node_type": "1", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "201"}, "hash": "68a8a2733e94d4e7f33189af1c35fd6de046cfd2cf460d4359555b21dc6dcce8", "class_name": "RelatedNodeInfo"}}, "text": "N: HIV within 18 months of birth by Rapid Test.\n                                                                                      D: women during the reporting period.\n                                                                                              Facility-based denominator:\n                                                                                                 positive pregnant women\n                                                    birth\n      period.                   OUTPUT INDICATORS\n                                Number counselled, tested for HIV\n                                   and received results during the\n                                      reporting period.\n                                              % of infants born to HIV -positive\n                                                 women receiving a DNA -PCR test\n                                                    for HIV within 2 months of\n                                                       during the reporting period.\n                                                                               % o f HIV Exposed babies who\n                                                                                  tested for HIV within 18 months of\n                                                                                     birth by Rapid Test during the\n                                                                                        reporting period.\n                                NATIONAL GUIDELINES FOR HIV PREVENTION TREATMENT AND CARE 2020  179", "mimetype": "text/plain", "start_char_idx": 3094, "end_char_idx": 4677, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cc8fb98b-60fe-4174-ab94-99396a846c30": {"__data__": {"id_": "cc8fb98b-60fe-4174-ab94-99396a846c30", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "202"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "b8539cb0-7426-419b-b170-de4567b073a3", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "202"}, "hash": "d4b2af51df49d23d2d2b0228a02df1660fda58a701412370c4c77c32ca0edccd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8290b52f-ce85-48f0-9acb-ac6d915d401f", "node_type": "1", "metadata": {}, "hash": "101c51a3ef96fa9b7f3c358b828fc082f428b5dc839c8fce7fe0e9b9147b6112", "class_name": "RelatedNodeInfo"}}, "text": "% of persons who test           N: Number of persons who test                               Programme    Annually        SMOH/ FMOH\nHIV-positive                    HIV-positive.                                               Data\nduring the reporting period.    D: Number of persons counselled tested                      (numerator)\n                                       .                                                    Spectrum\n          SMOH/ FMOH\n                      SMOH/ FMOH           SMOH/ FMOH\n                                                        SMOH/ FMOH\n                                                                     SMOH/ FMOH\n          Bi-annually  Bi-annually         Bi-annually  Bi-annually  Bi-annually\n          Programme\n              Data (PMM\n               & PME\n                Tools).\n                      Programme\n                         Data (PMM\n                           & PME\n                             Tools).       Programme\n                                             Data (PMM\n                                               & PME\n                                                  Tools).\n                                                        Programme\n                                                         Data (PMM\n                                                           & PME\n                                                             Tools).\n                                                                     Programme\n                                                                      Data (PMM\n                                                                       & PME\n                                                                         Tools).\n                           49, 50+             49, 50+     49, 50+     49, 50+\n                           \u2013                   \u2013           \u2013           \u2013\n                      Age (<1, 1\u20134, 5\u20139,\n                         10-14, 15\u201319, 20\u2013\n                           24, 25\n                             years); sex   Age (<1, 1\u20134, 5\u20139,\n                                             10-14, 15\u201319, 20\u2013\n                                               24, 25\n                                                  years); sex\n                                                        Age (<1, 1\u20134, 5\u20139,\n                                                         10-14, 15\u201319, 20\u2013\n                                                           24, 25\n                                                             years); sex\n                                                                     Age (<1, 1\u20134, 5\u20139,\n                                                                      10-14, 15\u201319, 20\u2013\n                                                                       24, 25\n                                                                         years); sex\n                                           N/A\n                                    Estimated number of PLHIV.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2977, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8290b52f-ce85-48f0-9acb-ac6d915d401f": {"__data__": {"id_": "8290b52f-ce85-48f0-9acb-ac6d915d401f", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "202"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "b8539cb0-7426-419b-b170-de4567b073a3", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "202"}, "hash": "d4b2af51df49d23d2d2b0228a02df1660fda58a701412370c4c77c32ca0edccd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cc8fb98b-60fe-4174-ab94-99396a846c30", "node_type": "1", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "202"}, "hash": "2d0330d44dca13bd56d8f08148bb4627f444adcb9b8bdfe163fedc844bdb032e", "class_name": "RelatedNodeInfo"}}, "text": "Estimated number of PLHIV\n                  Number of newly diagnosed PLHIV                       Total number of PLHIV currently\n          Number of newly diagnosed PLHIV\n                     Number of positive PLHIV who       Number of PLHIV currently\n     and received                                                    Number of PLHIV enrolled in HIV care\n          N:newly enrolled in clinical care during\n               the reporting period.\n                  D: N:received at least one of the following\n                          during the reporting period: clinical\n                             assessment (WHO staging) OR CD4+\n                               count OR viral load OR current\n                                  on treatment.\n                                    D:Facility-based denominator:\n                                           N & D:       N:receiving ART.\n                                                            D:       N:whose TB status was assessed and recorded\n                                                                      at their last visit during the reporting period.\n                                                                        D:receiving HIV care during the reporting\n                                                                             period.\n                                                                     PLHIV in care (including\n          Proportion of newly diagnosed                 ART coverage among PLHIV\n            HIV-positive PLHIV newly\n               enrolled in clinical care during\n                 the reporting period\n                      % of positive PLHIV who\n                         received clinical assessment\n                           (WHO staging) OR CD4+count\n                              OR viral load OR current on\n                                treatment during the reporting\n                                   period.               during the reporting period.\n                                                                     % of\n                                                                     PMTCT) who were clinically\n                                                                       screened for TB in HIV care and\n                                                                         treatment settin gs during the\n                                          Number of PLHIV newly            reporting period.\n                                             started on ART during the\n                                               reporting period.\n     NATIONAL GUIDELINES FOR HIV PREVENTION TREATMENT AND CARE 2020                180", "mimetype": "text/plain", "start_char_idx": 3038, "end_char_idx": 5705, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "083fd25e-254e-404b-bd4f-28ae3f7c4c07": {"__data__": {"id_": "083fd25e-254e-404b-bd4f-28ae3f7c4c07", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "203"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "8b2f744a-0bcd-4408-9b89-2e4762db91ce", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "203"}, "hash": "c2fd8f1e9baaa271eee147ed74d2df2969aebf594253e11e5882716853062d2a", "class_name": "RelatedNodeInfo"}}, "text": "% of PLHIV Enrolled in HIV Care    N:  Total number of PLHIV enrolled in care   Age (<1, 1 \u20134, 5\u20139,  Programme     Bi-annually      SMOH/ FMOH\nwho have Active TB Disease.        who have active TB disease during the        10-14, 15 \u201319, 20 \u2013  Data (PMM\n                                   reporting period.                            24, 25               & PME\n                                                                                years); sex          Tools).\n                  SMOH/ FMOH\n                  Bi-annually\n                  Programme\n                    Data (PMM\n                        & PME\n                          Tools).\n                       49, 50+\n                       \u2013\n                  Age (<1, 1 \u20134, 5\u20139,\n                    10-14, 15 \u201319, 20 \u2013\n                        24, 25\n                          years); sex\n       Total number of PLHIV currently in HIV\n                              Total number of H-positive new and\n                  Total number of HIV-positive new and\n                  N:relapsed TB PLHIV started on TB treatment\n                        during the reporting period who are already on\n       D:                 ART or started on ART during TB treatment.\n          care who were screened for TB during the\n            reporting period  D:relapsed TB PLHIV registered during the\n                                    reporting period\n                  ART coverage among\n                    HIV-Positive New and Relapsed\n                        TB PLHIVduring TB Treatment.\n      NATIONAL GUIDELINES FOR HIV PREVENTION TREATMENT AND CARE 2020                        181", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1633, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fea5705c-de9f-4a70-bfbc-527e61f089ef": {"__data__": {"id_": "fea5705c-de9f-4a70-bfbc-527e61f089ef", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "204"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "9163314a-af75-4fa5-9076-af39d6c9dd46", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "204"}, "hash": "672e5db484906bd94ea4af308fdf067a25b0ba880109cd027f79a4e8fefd4ce3", "class_name": "RelatedNodeInfo"}}, "text": "10.3 Data Management\nHIV data management is a process that includes the collection, collation, analysis, dissemination\nand use of HIV data for planning and implementing HIV services. The data is disaggregated by\nage, sex, location (LGA, state and national), breastfeeding and pregnancy status to improve\ndecision making.\n10.3.1 Data Collection\nRoutine HIV data is collected through both paper-based and electronic platforms. Efforts are to\nbe geared towards strengthening the platforms to improve the quality of data.\nPatients' information is collected using 2 types of tools;\n    1.  Patient Management and Monitoring (PMM) tools\n    2.  Programme Monitoring and Evaluation (PME) tools.\nPMM tools are used to collect data on individual patients and help in improving the management\nof PLHIV. The tools are available at every point of HIV service delivery. This information is\nmonitored over time and enables healthcare providers to assess a patient's response to treatment.\nPME tools are used to track the progress of services provided to PLHIV. The data can be used to\nroutinely monitor and evaluate the effectiveness, efficiency and acceptability of HIV service\nprovision at all levels of healthcare.\nHCWs at service delivery points should ensure proper documentation of all HIV services\nprovided. Facility M&E staff are responsible for the collection of data from all service delivery\npoints for monthly reporting.\nIn general, the emphasis will be on using the PMM/PME tools to continuously inform HIV\nprogramming. Process and outcome evaluations will be periodically conducted to assess\nprogramme performance for informed decisions.\nThe following are current tools used for M&E in the national HIV programme:\n          NATIONAL GUIDELINES FOR HIV PREVENTION TREATMENT AND CARE 2020             182", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1802, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7b9fe65d-10d0-4a0e-90c4-8efd765732d4": {"__data__": {"id_": "7b9fe65d-10d0-4a0e-90c4-8efd765732d4", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "205"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "f504e0ff-dfe9-4084-9e91-3537423ad842", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "205"}, "hash": "62a53fe333c3a2c22eeb2f949a7e20f5da78e60d43b7702db041a3298d957e1f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "91e26530-b151-488c-a65c-0dcd2608ef5f", "node_type": "1", "metadata": {}, "hash": "3f6a70c5e89321abf8b73a51568c0db7a3583feb6f3ea808721b8cf7a5c52163", "class_name": "RelatedNodeInfo"}}, "text": "Table 10.2: Tools used for M&E in the national HIV programme\n  HTS                           PMTCT                          ART\n  PMM                           PME                            PMM\n  -Client Intake form           - PMTCT Monthly Summary         - Care card\n  -Request & Result form         form                           - Adult Initial Clinical Evaluation\n  -Client Referral form         - General ANC Register          -form\n                                - PMTCT HTS Register             Paediatric Initial Clinical\n                                -Maternal Cohort Register       -Evaluation form\n  PME                           -Child Follow-up Register       - Lab Order & Results form\n  - HTS Register                                                - Pharmacy Order form\n  - Daily HIV & Syphilis Test   -Partner Register                HIV Care & Treatment transfer\n   Worksheet                    -PMTCT Delivery Register        - form\n  - Referral Register                                            Client Tracking & Termination\n                                                                 form\n  - HTS Monthly Summary                                        PME\n   form                                                         -Care card\n                                                                -Enrolment Register\n                                                                -ART Register\n                                                                -ART monthly summary form\n                                                                -Pharmacy Daily Worksheet\n                                                                -HIV Care & Treatment Client\n                                                                Tracking Register\n                                                                -Post Exposure Prophylaxis\n                                                                Register\n                                                                -Cohort analysis report\n10.3.2 Data Security, Collation & Reporting Flow\nHandling of PMM/PME tools requires confidentiality and efficiency to give the clients a sense of\nsecurity. A filing system for HIV programme records should be developed and followed within\neach facility. All records should be kept confidential and stored in a secure room with lockable\ncabinets. Backup records should be secured from damage or loss.\nAt the end of each month, routine HIV programme data should be validated for quality and\ncollated into monthly summary forms. Completed monthly summary forms should be forwarded\nto the Local Government Area (LGA), where data from all the HIV sites in the LGA are collated\nand transmitted to the State Ministry of Health and District Health Information System (DHIS).\nAt State M&E review meetings HIV data should be validated, collated and analysed by all\nrelevant HIV programme stakeholders. States should in turn forward to the NASCP of the\nFMOH.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2980, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "91e26530-b151-488c-a65c-0dcd2608ef5f": {"__data__": {"id_": "91e26530-b151-488c-a65c-0dcd2608ef5f", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "205"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "f504e0ff-dfe9-4084-9e91-3537423ad842", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "205"}, "hash": "62a53fe333c3a2c22eeb2f949a7e20f5da78e60d43b7702db041a3298d957e1f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7b9fe65d-10d0-4a0e-90c4-8efd765732d4", "node_type": "1", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "205"}, "hash": "e3ece19fe52dcb0224b632c47be8d30896d6954f9807b6eb81adbb38294251ca", "class_name": "RelatedNodeInfo"}}, "text": "At State M&E review meetings HIV data should be validated, collated and analysed by all\nrelevant HIV programme stakeholders. States should in turn forward to the NASCP of the\nFMOH.\nThe respective health authorities at the various levels will have responsibility for reporting to the\nHIV and AIDS coordinating authorities at the various levels (i.e. health facility to LGA to State\nMOH to FMOH).\nFacilities can now upload information on the monthly summary forms directly on the DHIS.\nValidation is conducted by the L.G.A. and the State. The information can be viewed at the local,\nstate and national level. With the electronic medical record (EMR) system, facilities upload\npatient-level data into the National Data Repository (NDR) which can be reviewed for quality at\nall levels and analysed by stakeholders. Electronic data record should be stored and secured in a\n           NATIONAL GUIDELINES FOR HIV PREVENTION TREATMENT AND CARE 2020               183", "mimetype": "text/plain", "start_char_idx": 2800, "end_char_idx": 3759, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9ef78b46-7267-4cd0-82c3-c98141f0529a": {"__data__": {"id_": "9ef78b46-7267-4cd0-82c3-c98141f0529a", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "206"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "2f63e83e-49c0-4f12-8f48-25806f25b43b", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "206"}, "hash": "b936acc5df280913280e0b88b1dba9049b4781c1d5512395e9629cd3e572627e", "class_name": "RelatedNodeInfo"}}, "text": "passworded device for authorised users and uploaded to secured networks and servers. It is\n recommended that health facilities should migrate to the EMR system.\n                            HIV Program Datd Flow Chart\n       Tational level                   Naticnal DAIS                  Naticnal Dara\n                                           Server                       Recosiony\n       State level\n                                            DAIS 2\n                                           catacase\n           LGAIvel\n      Paper Based Tools                Patrenlevel Data             Electronic Medical\n                                                                      Recoras (EMR)\n                                      Health Facilities\nFigure 10.1 \u2013 Data Flow Chart for HIV reporting\n 10.4 HIV Data Dissemination and Use\n The significance of data cannot be fully realized until it is disseminated to all relevant\n stakeholders for effective planning and decision making. The dissemination of HIV data and\n information products will be via regular fact sheets, bulletins, report and official social media\n platforms. Also validated data are shared with the states biannually as a way of feedback. Data\n use should be encouraged at all levels especially at the health facilities where these data are\n generated, to improve patient management and monitoring.\n 10.5 Human Resource for M&E\n The relevant human resource for monitoring and evaluation should be employed at all levels to\n support data management. The FMOH in collaboration with relevant stakeholders will ensure\n training and retraining of healthcare workers, local government and state officers on data\n management and use.\n           NATIONAL GUIDELINES FOR HIV PREVENTION TREATMENT AND CARE 2020            184", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1788, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6e540052-01f2-4f78-888e-792941510760": {"__data__": {"id_": "6e540052-01f2-4f78-888e-792941510760", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "207"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "3cc64a19-ea77-49da-a05f-ef6ac5e2ad80", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "207"}, "hash": "fccc83299465769e5b11963dee08dee768c40f800967e761a4a49fea5e9ee36f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3ff1aa4b-f786-4648-a832-ffa6fe2d5e38", "node_type": "1", "metadata": {}, "hash": "7000e59aa49c134048b68556c16d011648a3db35a264a6b18704f0c384f85553", "class_name": "RelatedNodeInfo"}}, "text": "10.6 HIV M&E Logistics\nNational M&E tools and infrastructure should be made available to all sites delivering HIV\nservices to facilitate service documentation and reporting of routine data. Indicator Reference\nSheets and User Guides should be made available to end-users to aid understanding of\nprogramme indicators and also help in the completion of M&E tools.\n10.7Additional Strategies in M&E\nAs the country makes progress towards epidemic control, the need to put in place innovative\nstrategies in monitoring and evaluating national HIV health sector response has become highly\nimperative. This enables evidence-based planning, resource allocation and decision making in\nline with innovations within the response. Some of the innovative strategies include the\nintroduction of case-based surveillance, mortality surveillance and recency surveillance.\n   \u00a7   The case-based surveillance allows a shift from aggregate reporting to focus on\n       individual follow up from the time of identification of a new case to retention in care and\n       even death. This longitudinal form of data collection is used to track clinical outcomes\n       and monitor the quality of linkage to care.\n   \u00a7   Recency surveillance provides insight into the timeline of an individual's HIV infection.\n       This information is important to public health because of the ability to use such data for\n       targeted interventions, programmatic shifts and to achieve epidemic control.\n   \u00a7   The mortality surveillance also determines the distribution, trends and patterns of\n       leading causes of death attributable to HIV among people receivingART in the program.\nAdditional M&E tools are being developed to capture data on Recency testing, Self-testing,\nPrEP,AHD and DSD.\n10.8 HIV Research\nThe National HIV research policy and agenda seeks to inform HIV implementation and\nformative research that provide evidence-based data to improve the effectiveness and efficiency\nof HIV programme management in Nigeria.\nResearch programmes will be prioritized to identify cost-effective mechanisms for HIV\ntreatment, care, and support. It should also prioritize research that promotes the reduction of\nHIV risk behaviours among key, vulnerable and general populations, enhance prevention\nprogrammes, strengthen basic and implementation research, clinical trials, social science\nresearch and systematic reviews.\n10.9 Periodic monitoring of the implementation of the guidelines and content update\nHIV medicine is a dynamic speciality with continuously emerging evidence and innovations that\noptimizes prevention, treatment and care of PLHIV.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2614, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3ff1aa4b-f786-4648-a832-ffa6fe2d5e38": {"__data__": {"id_": "3ff1aa4b-f786-4648-a832-ffa6fe2d5e38", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "207"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "3cc64a19-ea77-49da-a05f-ef6ac5e2ad80", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "207"}, "hash": "fccc83299465769e5b11963dee08dee768c40f800967e761a4a49fea5e9ee36f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6e540052-01f2-4f78-888e-792941510760", "node_type": "1", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "207"}, "hash": "83c63ab814587111e2236ae8f9b9cc113f0ccface079eaa8b60b671dfcfdd568", "class_name": "RelatedNodeInfo"}}, "text": "10.9 Periodic monitoring of the implementation of the guidelines and content update\nHIV medicine is a dynamic speciality with continuously emerging evidence and innovations that\noptimizes prevention, treatment and care of PLHIV. Consequently, this necessitates periodic\nupdates to these guidelines. In addition, there is also a need to monitor and evaluate the level of\nimplementation of these guidelines at service delivery points with the aim of re-strategizing for\neffective programme implementation. It is recommended that FMOH should take the lead with\nthe support of all stakeholders to ensure regular reviews and update of these guidelines.\n          NATIONAL GUIDELINES FOR HIV PREVENTION TREATMENT AND CARE 2020           185", "mimetype": "text/plain", "start_char_idx": 2386, "end_char_idx": 3120, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fbd8d84c-3423-4060-b7e3-67bf71aff80b": {"__data__": {"id_": "fbd8d84c-3423-4060-b7e3-67bf71aff80b", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "208"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "45d7e776-771a-46df-a08c-98b3fa4e8e31", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "208"}, "hash": "bd5bf804ad901bb12522d9453dfdbc696bec31e76c8c790dc08bca514dcc95b5", "class_name": "RelatedNodeInfo"}}, "text": "List of Contributors                                                      Chapter 10\nDr Uba Sabo                    Assistant Director, PREP/STI NASCP\nDr Onifade Bodunde             Senior Medical Officer II, HIV Data Manager NASCP\nMr Adebayo Adesina             Senior Scientific Officer, M&E NASCP\nDr Yewande Olaifa              Assistant Director NACA\nDr Tolulope Oladele            Assistant Director, Health Sector Response Support NACA\nProf. Musa Babashani           Member NTTA / Physician AKTH Kano\nDr Elon W. Isaac               Senior Lecturer Paediatrics / College of Medical Sciences,\n                               GSU Gombe\nChika Obiora-Okafo             Director Monitoring & Evaluation FHI360\nDr Augustine Idemudia          Associate Director; Monitoring & Evaluation FHI360\nDr Levy-Braide Boma            Senior Analyst CHAI\nOmaye Victoria Negedu          Senior Analyst CHAI\nDr Akanmu                      Analyst CHAI\nMuhammad-Mujtaba\nOlusegun Adewole               Technical Officer APIN\nDr Abiodun Hassan              Technical Director FHI360\nDr Chizoba Mbanefo             Technical Director CRS\nOyedokun Aliu Ope              Medical Officer II, NASCP\nNkechi Okoro                   M&E Officer NEPWHAN\nIjeoma Amazue                  US DoD\n          NATIONAL GUIDELINES FOR HIV PREVENTION TREATMENT AND CARE 2020       186", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1347, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3577ddd8-a3ff-46d9-a733-08405eacaa91": {"__data__": {"id_": "3577ddd8-a3ff-46d9-a733-08405eacaa91", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "209"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "77e7257b-3bb4-43d8-aea4-976a73f41c70", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "209"}, "hash": "04198b58fb140dc0de21d12c2aaa6d8670ae72c043040f690bf8ee17bc59fd40", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7dd51d13-583c-4a60-a6c2-d1a11c75027b", "node_type": "1", "metadata": {}, "hash": "01404cd061ff8bbce9b3140847f1bdeca8776968aebe7fff12f43967c625c416", "class_name": "RelatedNodeInfo"}}, "text": "REFERENCES\n[1]     World Health Organisation, \u201cConsolidated guidelines on the use of antiretroviral drugs\n        for treating and preventing HIV infection,\u201d WHO, 2016.\n[2]     O.Agbaji , P.Agaba , K. Falang ,A. Onu, M. Muazu and J. Idoko, \u201cPredictors of impaired\n        renal function among HIV infected patients commencing highly active antiretroviral\n        therapy in Jos, Nigeria.,\u201d Nigerian Medical Journal. 2011, 2011.\n[3]     O.Agbaji , P.Agaba,A. Ebonyi, Z. Gimba, E.Abene and S. Gomerep, \u201cLong term\n        exposure to tenofovir disoproxil fumarate-containing antiretroviral therapy is associated\n        with renal impairment in anAfrican cohort of HIV-infected adults,\u201d vol. 18, pp. 1-9,\n        2019.\n[4]     World Health Organisation, \u201cGLOBALTB REPORT,\u201d WHO, 2018.\n[5]     National Population Commission Nigeria, \u201cNigeria Demographic Health Survey,\u201d NPC,\n        2018.\n[6]     NationalAgency for the Control ofAIDS, \u201cNational HIV strategy for adolescents and\n        young people 2016-2020,\u201d NACA, 2016.\n[7]     UNAIDS, \u201c90-90-90An ambitious treatment target to help end theAIDS epidemic,\u201d\n        UNAIDS, 2014.\n[8]     Federal Ministry of Health Nigeria, \u201cNigeria HIV/AIDS Indicator and Impact Survey,\u201d\n        FMOH, 2018.\n[9]     NationalAgency for the Control ofAIDS, \u201cNATIONALAGENCY FOR THE Cnational\n        HIV and AIDS Strategic Framework 2017-2021,\u201d NACA, 2017.\n[10]    Eluwa G,Adebajo S, Eluwa T, Ogbanufe O, Ilesanmi O and Nzelu C, \u201cEluwa GIE,\n        Rising HIV prevalence among men who have sex with men in Nigeria:Atrend\n        analysis.,\u201d BMC Public Health, vol. 1, no. 19, pp. 1-10, 2019.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1620, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7dd51d13-583c-4a60-a6c2-d1a11c75027b": {"__data__": {"id_": "7dd51d13-583c-4a60-a6c2-d1a11c75027b", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "209"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "77e7257b-3bb4-43d8-aea4-976a73f41c70", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "209"}, "hash": "04198b58fb140dc0de21d12c2aaa6d8670ae72c043040f690bf8ee17bc59fd40", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3577ddd8-a3ff-46d9-a733-08405eacaa91", "node_type": "1", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "209"}, "hash": "16807d77fe8ff0b556e7d94bab00b44e0525a3cd95c896ad8146d12522761eb1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "aa8c86e2-fc29-4acd-80c7-8c479019d490", "node_type": "1", "metadata": {}, "hash": "4f35ba978c5279d9fef0d4644627684c17f4509cee2b76d46d05dad007fca093", "class_name": "RelatedNodeInfo"}}, "text": "1, no. 19, pp. 1-10, 2019.\n[11]    NationalAgency for the Control ofAIDS, \u201cNational HTS Guidelines,\u201d NACA, 2017.\n[12]    World Health Organisation, \u201cGuidelines for managing advanced HIV disease and rapid\n        initiation of antiretroviral therapy,\u201d WHO, 2017.\n[13]    Federal Ministry of Health, \u201cNational Tuberculosis and Leprosy Control Programme\n        report,\u201d NTBLCP, 2019.\n[14]    World Health Organisation, \u201cGuidelines for the diagnosis, prevention and management\n        of cryptococcal disease in HIV-infected adults, adolescents and children: supplement to\n        the 2016 consolidated guidelines on the use of antiretroviral drugs for treating and\n        preventing HIV infection.,\u201d WHO, 2018.\n[15]    Gomerep S, Idoko J and Ladep N, \u201cFrequency of cryptococcal meningitis in HIV-1\n        infected patients in north central Nigeria.,\u201d Nigerian Journal of Medicine. 2010; 19(4): ,\n        vol. 19, no. 4, p. 395\u2013399, 2010.\n[16]    Oladele R, JordanA,Akande P,Akanmu S,Akase I andAliyu S, \u201cTackling cryptococcal\n        meningitis in Nigeria, one-step at a time; the impact of training.,\u201d PLoS One, vol. 15, no.\n        7, 2020.\n[17]    Uneke C, Duhlinska D and Njoku M, \u201cSeroprevalence of acquired toxoplasmosis in\n        HIV- infected and apparently healthy individuals in Jos, Nigeria.,\u201d Parassitologia.\n        2005;47(2):233\u20136., vol. 47, no. 2, pp. 233-6, 2005.\n[18]    MorrisA, Lundgren J, Masur H, Walzer P, Hanson D, Frederick T, Huang L, Beard C and\n        Kaplan J,\u201cCurrent epidemiology of Pneumocystis pneumonia,\u201d Emerg Infect Dis., vol.\n        10, no. 10, pp.", "mimetype": "text/plain", "start_char_idx": 1594, "end_char_idx": 3182, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "aa8c86e2-fc29-4acd-80c7-8c479019d490": {"__data__": {"id_": "aa8c86e2-fc29-4acd-80c7-8c479019d490", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "209"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "77e7257b-3bb4-43d8-aea4-976a73f41c70", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "209"}, "hash": "04198b58fb140dc0de21d12c2aaa6d8670ae72c043040f690bf8ee17bc59fd40", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7dd51d13-583c-4a60-a6c2-d1a11c75027b", "node_type": "1", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "209"}, "hash": "48b85f99864b4bce55271a5e707f1fb60b9fcafb8ad9e5cd2b59310668aa0110", "class_name": "RelatedNodeInfo"}}, "text": "10, no. 10, pp. 1713-20, 2004.\n           NATIONAL GUIDELINES FOR HIV PREVENTION TREATMENT AND CARE 2020           187", "mimetype": "text/plain", "start_char_idx": 3167, "end_char_idx": 3285, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b43df622-c91e-408e-a646-f6febc686638": {"__data__": {"id_": "b43df622-c91e-408e-a646-f6febc686638", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "210"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "859d421e-5245-40b6-847a-6a62eb4cd6bd", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "210"}, "hash": "7cee5b03d3ebaad90862d16abc2fed30bce9bb9b5aa931b0183e96beb62fdff3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6cf5bb9c-2c90-444d-80ea-fcbe435c2053", "node_type": "1", "metadata": {}, "hash": "a326d7ff15be4aeabde3c761e5d4fa1d33fb72e48706516d52380ba12a37d787", "class_name": "RelatedNodeInfo"}}, "text": "[19]   Ogba, Ofonime,Abia-Bassey, Lydia, Epoke and James, \u201cThe relationship between\n       opportunistic pulmonary fungal infections and CD4 count levels among HIV\n       seropositive patients in Calabar, Nigeria,\u201d Royal Society of Tropical Medicine, 2013.\n[20]   Oladele R,Anyanlowo O, Richardson M and Denning D, \u201cHistoplasmosis inAfrica:An\n       emerging or a neglected disease? . 2018 Jan 18;12(1):e0006046. doi:,\u201d PLoS Negl Trop\n       Dis, vol. 12, no. 1, 2018.\n[21]   Oladele R, Toriello C, Ogunsola F,Ayanlowo O, Foden P and FayemiwoA, \u201cPrior\n       subclinical histoplasmosis revealed in Nigeria using histoplasmin skin testing,\u201d PLoS\n       ONE, vol. 13, no. 5, pp. 1-11, 2018.\n[22]   AdeyemiA, SulaimanA, Solomon B, Chinedu O and Victor I, \u201cBacterial bloodstream\n       infections in HIV-infected adults attending a Lagos teaching hospital,\u201d J Health Popul\n       Nutr, vol. 28, no. 4, pp. 318-26, 2010.\n[23]   Ogunsola F, Arewa D, Akinsete I, Oduyebo O, Akanmu A and Odugbemi T, \u201cAetiology\n       of bacteraemia among adultAIDS patients attending Lagos University Teaching\n       Hospital (LUTH), Lagos, Nigeria.,\u201d Niger Postgrad Med J, vol. 16, no. 3, pp. 186-92,\n       2009.\n[24]   Ford N et al, \u201cManagingAdvanced HIV Disease in a Public HealthApproach.,\u201d Clinical\n       Infectious Diseases, 2018.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1314, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6cf5bb9c-2c90-444d-80ea-fcbe435c2053": {"__data__": {"id_": "6cf5bb9c-2c90-444d-80ea-fcbe435c2053", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "210"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "859d421e-5245-40b6-847a-6a62eb4cd6bd", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "210"}, "hash": "7cee5b03d3ebaad90862d16abc2fed30bce9bb9b5aa931b0183e96beb62fdff3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b43df622-c91e-408e-a646-f6febc686638", "node_type": "1", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "210"}, "hash": "b6a00db05b01bcbef7c34f1ac1eddbaf4658ecd30f2953787a3e9089ec422261", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "56ef3328-76e1-4bca-87a9-bbda654cc6fb", "node_type": "1", "metadata": {}, "hash": "295bceeca5b717e3ea3db2bc20de3cbd5bcc037e24b5f39fa76fe92d8d495f1c", "class_name": "RelatedNodeInfo"}}, "text": "3, pp. 186-92,\n       2009.\n[24]   Ford N et al, \u201cManagingAdvanced HIV Disease in a Public HealthApproach.,\u201d Clinical\n       Infectious Diseases, 2018.\n[25]   Agaba P, Meloni S, Sule H,Agbaji O, Ekeh P, Job G, Nyango N, Ugoagwu P, Imade G,\n       Idoko J and Kanki P, Patients who present late to HIV care and associated risk factors in\n       Nigeria. HIV medicine, vol. 15, no. 7, pp. 396-405, 2014 .\n[26]   World Health Organisation, \u201cLatent TB Infection: Updated and consolidated guidelines\n       for programmatic management.,\u201d WHO, 2018.\n[27]   World Health Organisation, \u201cOperational handbook on tuberculosis: module 1:\n       prevention: tuberculosis preventive treatment,\u201d WHO, 2020.\n[28]   Nakimuli-Mpungu E, Wamala K, Okello J, Ndyanabangi S, Kanters S and Mojtabai R,\n       \u201cProcess Evaluation of a Randomized Controlled Trial of Group Support Psychotherapy\n       for Depression Treatment Among People with HIV/AIDS in Northern Uganda,\u201d\n       Community Ment Health J, vol. 58, no. 3, p.991\u20131004., 2017.\n[29]   Elbrit D, Mahlab-Guri K, Bezalel-Rosenberg S, Gill H,Attali M andAsher I, \u201cHIV-\n       associated neurocognitive disorders (HAND),\u201d Isr MedAssoc J., vol. 17, no. 1, pp. 54-9,\n       2015.\n[30]   World Health Organisation, \u201cConsultation on HIV differentiated service delivery models\n       for specific populations and settings: Pregnant and breastfeeding women, children,\n       adolescents and key populations,\u201d WHO, 2016.\n[31]   Badejo O, Menson W, Sam-Agudu N, Pharr J, Erekaha S and Bruno T, \u201cPediatric to adult\n       healthcare transitioning for adolescents living with HIV in Nigeria:Anational survey,\u201d\n       PLoS ONE, vol. 13, no.", "mimetype": "text/plain", "start_char_idx": 1163, "end_char_idx": 2827, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "56ef3328-76e1-4bca-87a9-bbda654cc6fb": {"__data__": {"id_": "56ef3328-76e1-4bca-87a9-bbda654cc6fb", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "210"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "859d421e-5245-40b6-847a-6a62eb4cd6bd", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "210"}, "hash": "7cee5b03d3ebaad90862d16abc2fed30bce9bb9b5aa931b0183e96beb62fdff3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6cf5bb9c-2c90-444d-80ea-fcbe435c2053", "node_type": "1", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "210"}, "hash": "aeaa5ac7789e35e70fd8267e56ef1fb380f99252cbd512f26aeee013c691be1e", "class_name": "RelatedNodeInfo"}}, "text": "13, no. 6, pp. 1-13, 2018.\n          NATIONAL GUIDELINES FOR HIV PREVENTION TREATMENT AND CARE 2020           188", "mimetype": "text/plain", "start_char_idx": 2820, "end_char_idx": 2933, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "011cd2dc-5daa-4099-ae52-c422ea93665c": {"__data__": {"id_": "011cd2dc-5daa-4099-ae52-c422ea93665c", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "211"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "400c0315-9b01-4364-a6d1-fbe4bfa116bb", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "211"}, "hash": "a343f06d92f3435bfa7f91ea02e94fdd883e563de68ea1a17f746f7502d5a35b", "class_name": "RelatedNodeInfo"}}, "text": "APPENDIX\n1.1 Objectives of the Guidelines\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026..\n1.2 Epidemiology of HIV in Nigeria\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\n1.3 Natural History of HIV\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026.\u2026\u2026", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 139, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "443480d9-8490-4c04-b8eb-608a5557f39a": {"__data__": {"id_": "443480d9-8490-4c04-b8eb-608a5557f39a", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "212"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "6a0fe561-167d-41d4-a792-6aa016cb2f89", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "212"}, "hash": "cfc9e98dfd85b32ae3faea55098bc20e795453f8ac47154efbf7068345c0057c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e65103d2-9d27-4d80-b330-a6f058f29760", "node_type": "1", "metadata": {}, "hash": "cbec080f90dce02dd27614896c323d81d5c669c9d3a1a537f83f902882e95671", "class_name": "RelatedNodeInfo"}}, "text": "Appendix 1: Commonly used Adult and Paediatric ARV Formulations and Dosage\nTable 1.1 Dosages of ARV drugs for adults and adolescents\n Generic name                                Dose\n Nucleoside reverse-transcriptase inhibitors (NRTIs)\n Abacavir (ABC)                              300 mg twice daily or 600 mg once daily\n Emtricitabine (FTC)                         200 mg once daily\n Lamivudine (3TC)                            150 mg twice daily or 300 mg once daily\n Zidovudine (AZT)                            300 mg twice daily\n Nucleotide reverse-transcriptase inhibitors (NtRTIs)\n Tenofovir disoproxil fumarate (TDF)         300 mg once daily\n Tenofovir alfenamide (TAF)                  10-25 mg once dailya\n Non-nucleoside reverse-transcriptase inhibitors (NNRTIs)\n Efavirenz (EFV)                             400\u2013600 mg once daily\n Etravirine (ETV)                            200 mg twice daily\n Nevirapine (NVP)                            200 mg once daily for 14 days followed by 200 mg twice\n                                             daily\n Proteases inhibitors (PIs)\n Atazanavir/ritonavir (ATV/r)                300 mg/100 mg once daily\n Darunavir + ritonavir (DRV/r)               800 mg + 100 mg once daily or 600 mg + 100 mg twice\n                                             daily\n Lopinavir/ritonavir (LPV/r)                 400 mg/100 mg twice daily\n                                             Considerations for individuals receiving TB therapy\n                                             In the presence of rifampicin, adjusted dose of LPV/r\n                                             (\u201cDoubledose\u201dLPV 800 mg/ +ritonavir 200mg twice\n                                             daily or \u201csuper boosted\u201d with LPV 400 mg/ + ritonavir\n                                             100 mg twice dailyplus additional doses ofRTV 300 mg\n                                             twice daily), withclose monitoring.Inthe presence of\n                                             rifabutin, nodose adjustment required. Rifapentine\n                                             shouldnot be used.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2116, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e65103d2-9d27-4d80-b330-a6f058f29760": {"__data__": {"id_": "e65103d2-9d27-4d80-b330-a6f058f29760", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "212"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "6a0fe561-167d-41d4-a792-6aa016cb2f89", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "212"}, "hash": "cfc9e98dfd85b32ae3faea55098bc20e795453f8ac47154efbf7068345c0057c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "443480d9-8490-4c04-b8eb-608a5557f39a", "node_type": "1", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "212"}, "hash": "ad200fa23f5586e676fce104c7578eb1510e6f7ea11f0109636fd33ca7df90a8", "class_name": "RelatedNodeInfo"}}, "text": "Rifapentine\n                                             shouldnot be used.\n Integrase strand transfer inhibitors (integrase inhibitors)\n Dolutegravir (DTG)                          50 mg once dailyb\n Raltegravir (RAL)                           400 mg twice daily\n                                             Considerations for individuals receiving TB therapy\n                                             In the presence of rifampicin, adjusted dose of DTG (50 mg\n                                             twice daily) and RAL (800 mg twice daily), with close\n                                             monitoring.In the presence of rifabutin or rifapentine, no dose\n                                             adjustmentis required.\naTAF 25 mg and TAF/FTC/DTG (TAF 25 mg, Emtricitabine 200 mg, Dolutegravir 50 mg fixed dose combination) can be used once daily in\nadolescents living with HIV weighing at least 25 kg.\nb DTG 50 mg and TLD (Tenofovir 300 mg, Lamivudine 300 mg, Dolutegravir 50 mg fixed dose combination) can be used once daily in\nadolescents living with HIV weighing at least 30 kg.\n           NATIONAL GUIDELINES FOR HIV PREVENTION TREATMENT AND CARE 2020                    190", "mimetype": "text/plain", "start_char_idx": 2041, "end_char_idx": 3241, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5e3a72d7-0c87-4911-bafe-e9b0cd48002d": {"__data__": {"id_": "5e3a72d7-0c87-4911-bafe-e9b0cd48002d", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "213"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "06a807af-a1bb-4e3c-a47b-b3b0499c8f31", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "213"}, "hash": "7189533155524662c56b9216053465bb0d502abf79dc0b0280df1b0aa4dca698", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8098cf99-80dd-4731-b554-d66d19f9e67e", "node_type": "1", "metadata": {}, "hash": "b1642bb57fc82689f80ea9b715a41792c1e6a6c94027e1ceaa5a4e0d37a0d1bd", "class_name": "RelatedNodeInfo"}}, "text": "Table 1.2: Dosing of optimal pediatric ARVs\nFormulation       3\u20135.9   6\u20139.9    10\u201314.9    15\u201319.9    20\u201324.9    25\u201329.9        \u226530 kg\n                    kg     kg        kg         kg         kg          kg\n               A    P   A     P    A    P     A    P     A    P    AM    PM    AM    PM\n               M    M   M     M    M    M     M    M     M     M\nABC/3TC                                                             1 adult        1 adult\n120/60mg                                                              tab          tab\nscored            1       1.5         2         2.5         3       (600/300       (600/300\ndispersible                                                           mg)          mg)\ntablet\nLPV/r 40/10\nmg pellets     2    2   3     3    4     4    5     5     6    6       -           -\n(capsules)\nLPV/r 40/10\nmg granules    2    2   3     3    4     4    5     5     6    6       -           -\n(sachets)\nLPV/r\n100/25 mg                          2     1    2     2     2    2    3     3     3     3\ntablets\n4-in-1\nABC/3TC/L\nPV/r           2    2    3    3    4     4    5     5     6    6       -           -\n30/60/40/10\nmg\n(capsules)\nDTG 5 mg\ndispersible       2        3       4     5    -     -     -    -    -     -     -     -\ntablets\nDTG 10 mg\nscored            0.5     1.5         2         2.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1335, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8098cf99-80dd-4731-b554-d66d19f9e67e": {"__data__": {"id_": "8098cf99-80dd-4731-b554-d66d19f9e67e", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "213"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "06a807af-a1bb-4e3c-a47b-b3b0499c8f31", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "213"}, "hash": "7189533155524662c56b9216053465bb0d502abf79dc0b0280df1b0aa4dca698", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5e3a72d7-0c87-4911-bafe-e9b0cd48002d", "node_type": "1", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "213"}, "hash": "997a800fda9eb850a9dccaf6ff69e6ee3edb627d4d7dd108c8534af16568f305", "class_name": "RelatedNodeInfo"}}, "text": "5     1.5         2         2.5       -    -    -     -     -     -\ndispersible\ntablet\nDTG 50 mg         -        -          -          -          1          1           1\ntablet\nTDF/3TC\n(or\nFTC)/DTG          -        -          -          -          -          -           1\n300/300 (or\n200)/50 mg\ntablet\n                              NATIONAL GUIDELINES FOR HIV PREVENTION TREATMENT AND CARE 2020  191", "mimetype": "text/plain", "start_char_idx": 1305, "end_char_idx": 1708, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7e3255d9-6fcf-4875-a214-1b2d44e89e21": {"__data__": {"id_": "7e3255d9-6fcf-4875-a214-1b2d44e89e21", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "214"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "340ea794-2988-449e-8d9c-cd76cac952dd", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "214"}, "hash": "a56ef0ae5df3cc7a61e7d7c9131a9aefcf2d3dd6a4a184b1415f99a9cf31af04", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1a83fd36-9000-493d-95ec-5fa53f439cd3", "node_type": "1", "metadata": {}, "hash": "66a4eb7c6af07499b4a57e0a888600d0263b1ad382c936d377c8c72c9c5ce284", "class_name": "RelatedNodeInfo"}}, "text": "Table 1.3 Simplified dosing of child-friendly fixed-dose solid formulations for twice-daily dosing in infants and children 4 weeks of age and older\u1d43\n  Drug              Strength of                Number of tablets by weight band morning and evening                    Strength of       Number of\n                      PM       1           1           0.5         0.5\ntablets by    25 \u201334.9 kg      1           1           0.5         0.5\n   weight band        AM\n                                 mg        mg/200 mg     mg          mg\nadult tablet                 300 mg/150300 mg/150     600 mg/300  600 mg/300\n                       PM      3           3           3           1.5\n              20 \u201324.9 kg      3           3           3           1.5\n                       AM\n                       PM      2.5         2.5         2.5         1.5\n              14 \u201319.9 kg      2.5         2.5         2.5         1\n                       AM\n                       PM      2           2           2           1\n              10 \u201313.9 kg      2           2           2           1\n                       AM\n                       PM      1.5         1.5         1.5         1\n              6\u20139.9 kg         1.5         1.5         1.5         0.5\n                       AM\n                       PM      1           1           1           0.5\n              3\u20135.9 kg         1           1           1           0.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1416, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1a83fd36-9000-493d-95ec-5fa53f439cd3": {"__data__": {"id_": "1a83fd36-9000-493d-95ec-5fa53f439cd3", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "214"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "340ea794-2988-449e-8d9c-cd76cac952dd", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "214"}, "hash": "a56ef0ae5df3cc7a61e7d7c9131a9aefcf2d3dd6a4a184b1415f99a9cf31af04", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7e3255d9-6fcf-4875-a214-1b2d44e89e21", "node_type": "1", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "214"}, "hash": "c0145b3bf141d9654eba67617d249ddcc2c23e9893188de076ff9ddbd7c189a1", "class_name": "RelatedNodeInfo"}}, "text": "5         0.5\n                       AM\n                       PM      1           1           1           0.5\n              3\u20135.9 kg         1           1           1           0.5\n                       AM\n                                                          c\n                            Tablet mg/30 mg         mg  Tablet  mg/30 mg 120/60 mg\n                                           60 mg/30 mg/50\n                               (dispersible) 60        (dispersible) 60\npaediatric tablets                         Tablet (dispersible)   Tablet (dispersible)\n                               C           NVP b\n                               AZT/3T                        ABC/3TC\n                                           AZT/3TC/                          For infants younger than 4 weeks of age refer to table 4 for more accurate dosing which is reduced due to the decreased ability to excrete and\n                                                                                          Please note that this regimen and formulation is no longer recommended and should only be used in special circumstances where other age\n                                                                                                 This formulation will be phased out of use over time and programs should transition to use of the 120 mg/ 60 mg dispersible scored tablets.\n                                                                                 metabolize medications. For infants who are at least 4 weeks of age but less than 3 kg, immaturity of renal and hepatic pathways of elimination\n                                                                                     are less of a concern but uncertainty still exists on the appropriate dosing of ARVs in preterm and low birth weight infants.\n                                                                           a            b    appropriate formulations are not available.\n                                                                                               c\nNATIONAL GUIDELINES FOR HIV PREVENTION TREATMENT AND CARE 2020                             192", "mimetype": "text/plain", "start_char_idx": 1236, "end_char_idx": 3369, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4c4a0768-1bca-4f74-8f15-0dc150963178": {"__data__": {"id_": "4c4a0768-1bca-4f74-8f15-0dc150963178", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "215"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "7e32cd2e-1b1e-4732-9193-7a0ef26b5447", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "215"}, "hash": "20a6f6c0440284346a63f8a11b1d67b8f1c15336bc47d0c1090a0ae030d384e4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8d36f64b-9514-4036-9d79-021772b5a77a", "node_type": "1", "metadata": {}, "hash": "abc05d57178cde0534e51f8c8e6653b16f6edfc17ebb4a06c5dbce80e57a1aa1", "class_name": "RelatedNodeInfo"}}, "text": "Table 1.4 Simplified dosing of child-friendly solid formulations for once-daily dosing in infants and children 4 weeks of age and older\u1d43\nDrug          Strength of             Number of tablets or capsules by weight band once daily Strength of  Number of t ablets\n                 2        1       1    1e       1       1   1\n            25\u201334.9 kg\n    or capsules by\n       weight band once\n         daily\n                 \u2013         mg     25 mg 300 mg  600 mg  100 mg 50 mg\n    adult tablet        600 mg/300\n                 1.5   6     3    \u2013  2   1  1    4  4    2  1\n            20\u201324.9 kg\n                 1.5   5     2.5  \u2013  2   1  1    4  4    2  \u2013\n            14\u201319.9 kg\n                 1     4     2    \u2013  2   1  \u2013    \u2013  \u2013    \u2013  \u2013\n            10\u201313.9 kg\n                 \u2013     3     1.5  \u2013  \u2013   \u2013  \u2013    \u2013  \u2013    \u2013  \u2013\n            6\u20139.9 kg\n                 \u2013     2     1    \u2013  \u2013   \u2013  \u2013    \u2013  \u2013    \u2013  \u2013\n            3\u20135.9 kg\n    paediatric tablet\n                Tablet (scored) 200\n                  mg  Tablet (dispersible)\n                       60/30 mg\n                               Tablet (dispersible)\n                               120/60 mg\n                                  Tablet 25 mg\n                                     Capsules 100 mg\n                                         Capsules 200 mg\n                                            Tablet 600 mg\n                                                 Tablet 150 mg\n                                                    Tablet 25 mg\n                                                         Tablet 50 mg\n                                                          Film -coated Tablet\n                                                            50 mg\n                b                 c   d      f      g     h\n                 EFV   ABC /3TC   TAF  ATV      DRV     RTV DTG\n                               ABC/3TC\n                                                               a See table 1.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1954, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8d36f64b-9514-4036-9d79-021772b5a77a": {"__data__": {"id_": "8d36f64b-9514-4036-9d79-021772b5a77a", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "215"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "7e32cd2e-1b1e-4732-9193-7a0ef26b5447", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "215"}, "hash": "20a6f6c0440284346a63f8a11b1d67b8f1c15336bc47d0c1090a0ae030d384e4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4c4a0768-1bca-4f74-8f15-0dc150963178", "node_type": "1", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "215"}, "hash": "c6a011df3d4aa9d6a93fd83dcd537b240e7a50955ee5b6b582bb64c56ff4002d", "class_name": "RelatedNodeInfo"}}, "text": "6 for dosing recommendations for infants younger than 4 weeks old. Doses for this age group are reduced to account for the decreased ability to excrete and metabolize medications. For infants\n                                                                  who are at least 4 weeks of age but less than 3 kg, immaturity of renal and hepatic pathways of elimination are less of a concern but uncertainty still exists on the appropriate dosing of ARVs in preterm and\n                                                                     low birth weight infants.\n                                                                        b EFV is not recommended for children younger than 3 years and weighing less than 10 kg.\n                                                                          c At the time of this update, TAF film coated tablets were approved for children above 6 years by FDA for use in un-boosted regimens such as with DTG. A fixed dose combination containing TAF/FTC/ DTG\n                                                                             (TAF 25 mg, Emtricitabine 200 mg, Dolutegravir 50 mg fixed dose combination) received tentative approval by US FDA and can be used once daily in children and adolescents living with HIV weighing at\n                                                                                least 25 kg.\n                                                                                   d ATV is only approved for use in children 3 months and older. ATV single strength capsules should be administered with RTV 100 mg for all weight bands 10 kg and above. ATV powder formulation has\n   NATIONAL GUIDELINES FOR HIV PREVENTION TREATMENT AND CARE 2020           193", "mimetype": "text/plain", "start_char_idx": 1954, "end_char_idx": 3676, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e17646bd-5731-4469-abcb-85375c4b587a": {"__data__": {"id_": "e17646bd-5731-4469-abcb-85375c4b587a", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "216"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "9569d721-8a91-43a0-854b-076916ad2334", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "216"}, "hash": "1def52bc4ea9625204ed01a64049255411e3b4fe702213b9d1c6b373deb7c1d8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f4cfbbeb-2eda-48d6-b788-084c74ed6ffe", "node_type": "1", "metadata": {}, "hash": "9c39fcc448289163eafb933b6ca70d510c4cbf3ed2cca0500eaa6994ceabd4dc", "class_name": "RelatedNodeInfo"}}, "text": "limited availability in LMIC, but enables administration of ATV to infants and children as young as 3 months. Infants and children 5-15 kg should be administered 200 mg of ATV powder (4 packets, 50 mg/\npacket) with 80 mg of RTV oral solution (1 ml).\nhttps://www.accessdata.fda.gov/drugsatfda_docs/label/2018/021567s042,206352s007lbl.pdf\ne A 300 mg dose for 25-29.9 kg is recommended on the basis of findings from the PRINCE-2 study8\n            f DRV in combination with RTV should be used, in children older than 3 years, once daily when this is used without previous exposure to PI. While approved dosing for 30-35kg is 675 mg, preliminary data\n                from adult studies suggest that even lower DRV doses may be effective, therefore use of 600 mg dose was extended to the entire 25-35 kg weight band.\n                     g RTV should only be use as a boosting agent in combination with ATV or DRV or to \u201csuper boost\u201d LPV/r when given with concomitant rifampicin for TB (see table 5).\n                         h At the time of this update, 10 mg and 25 mg DTG film coated tables were approved for children above 6 years by the FDA (35mg FCT for weight 30 to < 40kg, 50mg FCT for weight  40 kg)8 and by the EMA\n                             (20mg FTC 15 to < 20, 25mg FCT for 20 to < 30, and 35 FCT for 30 to < 40, 50mg FCT for weight  40 kg)7 based on data from the IMPAACT 1093 trial.9 Simplified weight band dosing which deviates from\n                                 current US FDA and EMA dosing recommendations is being investigated in the Odyssey trial5 which supports the use of DTG 50 mg FCT dose for all children  20 kg. In January 2019 the PAWG reviewed\n                                      and discussed unpublished data from the Odyssey trial investigating the use of 50 mg FCT in children weighting 20-25 kg10.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1834, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f4cfbbeb-2eda-48d6-b788-084c74ed6ffe": {"__data__": {"id_": "f4cfbbeb-2eda-48d6-b788-084c74ed6ffe", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "216"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "9569d721-8a91-43a0-854b-076916ad2334", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "216"}, "hash": "1def52bc4ea9625204ed01a64049255411e3b4fe702213b9d1c6b373deb7c1d8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e17646bd-5731-4469-abcb-85375c4b587a", "node_type": "1", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "216"}, "hash": "4370a722dc6dea4533b45fa1095e1933312e11444aefc0fa052e8441c1b16e9b", "class_name": "RelatedNodeInfo"}}, "text": "In January 2019 the PAWG reviewed\n                                      and discussed unpublished data from the Odyssey trial investigating the use of 50 mg FCT in children weighting 20-25 kg10. The PAWG members acknowledged the short follow up and limited clinical\n                                          experience, but had no major concerns and agreed with recommending the use of 50 mg FCT from 20 kg, as proposed here. Routine standard toxicity monitoring remains of critical importance in light of the\n                                              current limited experience with this dosing. All children over 20kg receiving 50mg FCT will continue to be followed up in ODYSSEY and toxicity data collected. For adolescents living with HIV weighting\n                                                  more than 30 Kg a fixed dose formulation of TDF 300mg/3TC 300mg/DTG 50mg (TLD) can be used and is preferred\n         NATIONAL GUIDELINES FOR HIV PREVENTION TREATMENT AND CARE 2020                                                   194", "mimetype": "text/plain", "start_char_idx": 1640, "end_char_idx": 2680, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ef47eb3c-026d-4787-a438-b549e01ceca0": {"__data__": {"id_": "ef47eb3c-026d-4787-a438-b549e01ceca0", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "217"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "1117452e-2b19-4868-9ff4-260052446b71", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "217"}, "hash": "c0e456d712de42ecb8cb5e85fd8d00ddf33be9267de92c9ae5b5b22ad09a0934", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "122a1120-c052-4d90-96d7-b8c1b3f16f8c", "node_type": "1", "metadata": {}, "hash": "40e8a6ac24189d6c92787056be32ddd4b08262decdecbd4b3baf5c11a544daab", "class_name": "RelatedNodeInfo"}}, "text": "Table 1.5: Simplified dosing of child-friendly solid and oral liquid formulations for twice-daily dosing in infants and children 4 weeks of age and older\u1d43\nDrug            Strength of paedaitric  Number of tablets or MLS by weight -band morning (AM) and evening  Strength of  Number of\n                    PM      1    1    1    3  \u2013  \u2013    1     1      1\n                25\u201334.9 kg  1    1    1    3  \u2013  \u2013    1     1      1\n        tablets by  AM\n          weight\n             band\n                            300 mg         \u2013  \u2013  \u2013          100 mg 400 mg\n                                 300 mg\n                                      200 mg          400 mg\n        adult\n          tablet\n                    PM      3    3    3    2  6  6    5  2   1  6   1.5\n                20\u201324.9 kg  3    3    3    2  6  6    5  2   1  6   1.5\n                    AM\n                    PM      2.5  2.5  2.5  2  5  5    5  2   1  4   1\n                14\u201319.9 kg  2.5  2.5  2.5  2  5  5    5  2   1  4   1\n                    AM\n                    PM      2    2    2    1  4  4    \u2013  \u2013   \u2013  3   \u2013\n                10\u201313.9 kg\n                    AM      2    2    2    2  4  4    \u2013  \u2013   \u2013  3   \u2013\n                    PM      1.5  1.5  1.5  \u2013  3  3    \u2013  \u2013   \u2013  2   \u2013\n                      Solid formulations\n                6\u20139.9 kg    1.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1325, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "122a1120-c052-4d90-96d7-b8c1b3f16f8c": {"__data__": {"id_": "122a1120-c052-4d90-96d7-b8c1b3f16f8c", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "217"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "1117452e-2b19-4868-9ff4-260052446b71", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "217"}, "hash": "c0e456d712de42ecb8cb5e85fd8d00ddf33be9267de92c9ae5b5b22ad09a0934", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ef47eb3c-026d-4787-a438-b549e01ceca0", "node_type": "1", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "217"}, "hash": "9216132e39a158ddd979970ed82eabb8ff6a3570ace416473808d78346604cbe", "class_name": "RelatedNodeInfo"}}, "text": "5  1.5  1.5  \u2013  3  3    \u2013  \u2013   \u2013  2   \u2013\n                      Solid formulations\n                6\u20139.9 kg    1.5  1.5  1.5  \u2013  3  3    \u2013  \u2013   \u2013  2   \u2013\n                    AM\n                            1    1    1    \u2013  2  2    \u2013  \u2013   \u2013  1   \u2013\n                    PM\n                3\u20135.9 kg    1    1    1    \u2013  2  2    \u2013  \u2013   \u2013  1   \u2013\n        (PM)        AM\n                               60\n        tablets or oral liquidTablet (dispersible) 60\n                            mgTablet (dispersible)\n                                 mgTablet (dispersible) 50\n                                       mg Tablet 100 mg/25 mg\n                                              Pellets 40 mg/10 mg\n                                                Granules 40 mg/10 mg\n                                                   sachet\n                                                      Tablet 75 mg\n                                                         Tablet 25 mg\n                                                             Tablet 50 mg\n                                                                Chewable tablets 25 mg\n                                                                    Chewable tablets 100 mg\n                           AZT ABC    NVPb    LPV/rc  DRVd\n                                                           RTVe   RALf\n     NATIONAL GUIDELINES FOR HIV PREVENTION TREATMENT AND CARE 2020           195", "mimetype": "text/plain", "start_char_idx": 1214, "end_char_idx": 2628, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f9935644-aebb-4a9a-92e7-bae20a49226d": {"__data__": {"id_": "f9935644-aebb-4a9a-92e7-bae20a49226d", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "218"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "9406704c-a3c5-4085-8d95-39644968bf9e", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "218"}, "hash": "7a922da029081bc416e10b303487e060a2e054ebb94bd13cef0c66a64040e7c2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "10a78eb7-9639-4842-8a00-a445a0ae2ad7", "node_type": "1", "metadata": {}, "hash": "a33d7e94d937ff83214e8a19f2dbb8fde772fb474bf32a20678d6878c11d4dcf", "class_name": "RelatedNodeInfo"}}, "text": "Liquid formulations\nAZT              10 mg/ml               6 ml   6 ml  9 ml   9 ml  12 ml 12 ml    \u2013     \u2013      \u2013      \u2013      \u2013           \u2013      \u2013\nABC              20 mg/ml               3 ml   3 ml  4 ml   4 ml   6 ml  6 ml    \u2013     \u2013      \u2013      \u2013      \u2013           \u2013      \u2013\n        \u2013   \u2013  \u2013   \u2013   \u2013    \u2013\n        \u2013   \u2013  \u2013   \u2013   \u2013    \u2013\n        \u2013   \u2013  \u2013   \u2013   \u2013    \u2013\n        \u2013   \u2013  3 ml\u2013   \u2013    \u2013\n        \u2013   \u2013  3 ml\u2013   \u2013    \u2013\n        \u2013   \u2013  2.5 ml      10 mL\n                   3.5 ml\n                       0.6 ml\n        \u2013   \u2013  2.5 ml      10 mL\n                   3.5 ml\n                       0.6 ml\n        6 ml   2 ml         8 mL\n            10 ml  2.5 ml\n                       0.5 ml\n        6 ml   2 ml         8 mL\n            10 ml  2.5 ml\n                       0.5 ml\n        4 ml8 ml   \u2013   \u2013    5 mL\n               1.5 ml\n        4 ml8 ml   \u2013   \u2013\n               1.5 ml       5 mL\n        3 ml5 ml1 ml\u2013  \u2013    3 mL\n        3 ml5 ml1 ml\u2013  \u2013    3 mL\n        10 mg/ml\n            10 mg/ml\n               80/20 mg/ml\n                   100 mg/ml\n                       80 mg/ml\n                          10 mg/mL (Oral granules\n                            for suspension: 100\n                               mg/sachet)\n                                                            See table 1.6 for dosing recommendations for infants younger than 4 weeks old. Doses for this age group are reduced to account for the decreased ability to excrete and metabolize medications. For\n                                                            NVP dose escalation with half dose for 2 weeks when initiating ART is still recommended to avoid toxicity from high initial NVP levels.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1680, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "10a78eb7-9639-4842-8a00-a445a0ae2ad7": {"__data__": {"id_": "10a78eb7-9639-4842-8a00-a445a0ae2ad7", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "218"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "9406704c-a3c5-4085-8d95-39644968bf9e", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "218"}, "hash": "7a922da029081bc416e10b303487e060a2e054ebb94bd13cef0c66a64040e7c2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f9935644-aebb-4a9a-92e7-bae20a49226d", "node_type": "1", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "218"}, "hash": "89e9fcd04f5f040797f64ae23cf65576c6ac533072aa1d1d4ebbec5cb4f44861", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8c262150-a2b3-435b-a71f-fd4e3b8f9a72", "node_type": "1", "metadata": {}, "hash": "91885e37e5899189aec766e7c7f9474f43fb7bd24a569f1b69c2d733a2ff9a2e", "class_name": "RelatedNodeInfo"}}, "text": "For\n                                                            NVP dose escalation with half dose for 2 weeks when initiating ART is still recommended to avoid toxicity from high initial NVP levels. However, secondary analysis from the (CHAPAS)-1 trial\n                                                                                                            DRV, DRV, to be used in children older than 3 years, must be administered with 0.5 ml of RTV 80 mg/mL oral suspension if less than 15 kg and with RTV 50mg (using 25mg or 50 mg solid\n                                                                          RTV should only be used at this dose as a boosting agent in combination with ATV or DRV.\n                                                            LPV/r liquid requires a cold chain during transport and storage. The LPV/r heat-stable tablet formulation must be swallowed whole and should not be split, chewed, dissolved or crushed. Adult\n        3TCNVPb                                                                                             RAL granules are approved from birth. Feasibility and acceptability of such formulations has not been widely investigated and concerns have been raised regarding administration in resource\n                LPV/rc\n                   DRVd\n                       RTV  RALf                            infants who are at least 4 weeks of age but less than 3 kg, immaturity of renal and hepatic pathways of elimination are less of a concern but uncertainty still exists on the dosing of ARVs in preterm\n                                      and low birth weight infants.\n                                                            suggested that younger children have a lower risk of toxicity, and consideration can be given to starting with a full dose11. Please note that this regimen is no longer recommended and should only\n                                                            be used in special circumstances where other age appropriate formulations are not available.\n                                                                                                            200/50 tablet could be used for patients 14-24.9kg (1 tab am and 1 tab pm) and for patients 25-34.9kg (2 tab am and 1 tab pm). LPVr pellets formulation should not be used in infants younger than 3\n                                                                                                            months. More details on the administration of LPVr pellets can be found at https://www.who.int/hiv/pub/toolkits/iatt-factsheet-lopinavir-ritonavir/en/ . This dosing schedule applies to equivalent solid\n                                                                                                            dosage forms such as LPVr granules which can be use from 2 weeks of age.", "mimetype": "text/plain", "start_char_idx": 1481, "end_char_idx": 4316, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8c262150-a2b3-435b-a71f-fd4e3b8f9a72": {"__data__": {"id_": "8c262150-a2b3-435b-a71f-fd4e3b8f9a72", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "218"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "9406704c-a3c5-4085-8d95-39644968bf9e", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "218"}, "hash": "7a922da029081bc416e10b303487e060a2e054ebb94bd13cef0c66a64040e7c2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "10a78eb7-9639-4842-8a00-a445a0ae2ad7", "node_type": "1", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "218"}, "hash": "6fe94191252caa67da79639cb802890ccceedaaf8f2b8a1d2b110e8b8e21565e", "class_name": "RelatedNodeInfo"}}, "text": "This dosing schedule applies to equivalent solid\n                                                                                                            dosage forms such as LPVr granules which can be use from 2 weeks of age. Since supply is currently constrained both pellets and granules should be discouraged for children above 14 kg who\n                                                              should receive LPVr 100/25mg tablets instead. Info on LPVr formulations for children available at: https://www.arvprocurementworkinggroup.org/lpv-r-supply\n                                                                                                            formulation) in children 15 to 30 kg. RTV 100 mg tablets can be used as booster if lower-strength RTV tablets are not available. This is based on limited experience suggesting good acceptability and\n                                                                       tolerability. But no efficacy data.\n                                                                                                            limited settings. Due to the administration challenges presented by the granule formulation the use of the 25 mg chewable tablets as dispersible has been endorsed by the PAWG for infants and\n                                                                                                            children older than 4 weeks and weighting at least 3 kg. This was largely based on in vitro data on solubility and bioequivalence between tablets and granules6 as well as considering the limited\n                                                                                                            availability of adequate alternatives for this age group. However, findings from a feasibility and acceptability assessment conducted in South Africa demonstrate that administration of RAL granules\n                                 a      b         c             d         e  f                                                                                   in rural settings is feasible as long as supported with adequate training and counselling.\n      NATIONAL GUIDELINES FOR HIV PREVENTION TREATMENT AND CARE 2020             196", "mimetype": "text/plain", "start_char_idx": 4087, "end_char_idx": 6307, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e7ca2172-90e8-4a47-892c-0c5a6f03e774": {"__data__": {"id_": "e7ca2172-90e8-4a47-892c-0c5a6f03e774", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "219"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "67038ab4-121a-43cd-a86b-f09cf60f4a09", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "219"}, "hash": "81bd8b1a17d6aeb140f1c792fb2f03012055e29d448c9d447168a634489d47f1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2ad63c89-a59c-46cb-bee0-fc9ba90434cd", "node_type": "1", "metadata": {}, "hash": "14c6fa2f8f842fd8edc4920ddd179fd4d4a58f29ee130eb7f1ee8bef740d54fe", "class_name": "RelatedNodeInfo"}}, "text": "Table 1.6 Drug dosing of liquid formulations in infants less than 4 weeks of age\u1d43\n Drug                   Strength of oral liquid                2-3 kg                    3-4 kg                    4-5 kg\n                                    C\n         PM   2 mL3 mL1 mL1 mL2            1.5 mL\n                                2    0.7 mL (once daily)\n         AM   2 mL3 mL1 mL1 mL             1.5 mL\n                                    C\n         PM                     2\n              1.5 mL       0.8 mL\n                  2 mL0.8 mL               1 mL\n              1.5 mL   0.8 mL   2    0.5 mL (once daily)\n         AM       2 mL     0.8 mL          1 mL\n                                    C\n         PM   1 mL1.5 mL        \u2013\n                       0.5 m L\n                           0.6 mL          0.8 mL\n         AM       1.5 mL        \u2013    0.4 mL (once daily)\n                       0.5 mL\n              1 mL         0.6 mL          0.8 mL\n                                    <1 week\n                                           >1 week\n              10 mg/mL\n                  10 mg/mL\n                       10 mg/mL\n                           80/20 mg/mL\n                              Granules 40 mg/10 mg sachet\n                                    10 mg/mL\n                                       (Oral granules for\n                                          suspension: 100\n                                             mg/sachet) C\n              AZT NVP3TC      LPV/r b   RAL        PK data in preterm infants are available only for AZT; there is limited data and considerable uncertainty of appropriate dosing for NVP, RAL and 3TC in preterm and low birth weight infants. In\n                                                                       RAL granules for oral suspension should use in neonates of at least 2 kg and be administered in once a day during the first week of life (http://www.merck.com/product/usa/pi_circulars/i/\n                                                           Do not use LPV/r solution in infants aged <2 weeks of age. LPVr pellets should not be used in infants younger than 3 months.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2126, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2ad63c89-a59c-46cb-bee0-fc9ba90434cd": {"__data__": {"id_": "2ad63c89-a59c-46cb-bee0-fc9ba90434cd", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "219"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "67038ab4-121a-43cd-a86b-f09cf60f4a09", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "219"}, "hash": "81bd8b1a17d6aeb140f1c792fb2f03012055e29d448c9d447168a634489d47f1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e7ca2172-90e8-4a47-892c-0c5a6f03e774", "node_type": "1", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "219"}, "hash": "0bc6ac9b73ed92f6e00019018f46171071db49702ffde349cd78cd3a191e533d", "class_name": "RelatedNodeInfo"}}, "text": "LPVr pellets should not be used in infants younger than 3 months. More details on the administration of LPVr pellets can be found at\n                                                     addition, LPV/r solution should not be given to preterm infants until they have reached 42 weeks gestational age, because of the risk of adverse effects that may occur in this population. This guidance\n                                                        will be updated when more evidence is available from ongoing trials.\n                                                              https://www.who.int/hiv/pub/toolkits/iatt-factsheet-lopinavir-ritonavir/en/. Due to lack of clinical data to fully inform the use of LPVr granules in neonates, these dosing recommendations were\n                                                                 developed on the basis of the current US FDA approval (supporting use of LPVr granules from 2 weeks) and considering the substantial uncertainty which exist particularly for neonates weighting 2-3\n                                                                    kg. Where no other formulation exist, 1 sachet twice a day could be considered for neonates above 2 weeks who are 2-3 kg in order to minimize the risk of potential toxicity with overdosing.\n                                                  a       b           c  isentress/isentress_pi.pdf) and twice a day afterwards.\n      NATIONAL GUIDELINES FOR HIV PREVENTION TREATMENT AND CARE 2020              197", "mimetype": "text/plain", "start_char_idx": 2061, "end_char_idx": 3564, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9fd7a2cc-ed16-4e88-aae6-6cb7107c4deb": {"__data__": {"id_": "9fd7a2cc-ed16-4e88-aae6-6cb7107c4deb", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "220"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "e3e28858-244d-4587-a781-7722c8e9b153", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "220"}, "hash": "46d8da1af1c4bf1d42f5aa7a843ec4aee82075f4759134571ed94b5dffc99cfd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c12fcee9-b5bb-4b2a-b4be-d72d46092a9d", "node_type": "1", "metadata": {}, "hash": "82bc2d12ed8f3c260a11384655b0a1cd8ba5a17b37a6bc8ff11b48ff4490d128", "class_name": "RelatedNodeInfo"}}, "text": "Appendix 2: Mental Health Screening\n  Mental Health Screening for HIV Infected Patients According to the New York state\n                            Department of Health AIDS Institute\nAll HIV-infected patients should receive baseline and ongoing assessment of the following:\n   \u00b7    Mental health disorders:\n        o   Depression (every visit)\n        o   Anxiety (at least annually)\n        o   Post-traumatic stress disorder (at least annually)\n   \u00b7    Cognitive function (at least annually)\n   \u00b7    Sleep habits and appetite (every visit)\n   \u00b7    Psychosocial status (at least annually)\n   \u00b7    Suicidal/violent ideation (every visit)\n   \u00b7    Alcohol and substance use (at least annually)\n   \u00b7    Screening Questions to Identify Depression in HIV infected patients\n        o   In the past year, were you ever on medication or antidepressants for depression or\n            nerve problems?\n        o   In the past year, was there ever a time when you felt sad, blue, ordepressed for more\n            than 2 weeks in a row?\n        o   In the past year, was there ever a time lasting more than 2 weeks when you lost interest\n            in most things like hobbies, work, or activities that usually give you pleasure n?\n   \u00b7    Screening Questions to IdentifyAnxiety in HIV infected patients\n        o   In the past year, did you ever have a period lasting more than 1 month when most of\n            the time you felt worried and anxious?\n        o   In the past year, did you have a spell or an attack when all of a sudden you felt\n            frightened, anxious, or very uneasy when most people would not be afraid or\n            anxious?\n        o   In the past year, did you ever have a spell or an attack when for no reason your heart\n            suddenly started to race, you felt faint, or you couldn't catch your breath?\n   \u00b7    Screening Questions to Identify Post Traumatic Stress Disorder in HIV infected patients\n        o   During your lifetime, as a child, or adult, have you experienced or witnessed\n            traumatic event(s) that involved harm to yourself or others?\n        o   If \u201cyes\u201d:\n   \u00a7    In the past year, have you been troubled by flashbacks, nightmares, or thoughts of the\n        trauma?", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2222, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c12fcee9-b5bb-4b2a-b4be-d72d46092a9d": {"__data__": {"id_": "c12fcee9-b5bb-4b2a-b4be-d72d46092a9d", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "220"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "e3e28858-244d-4587-a781-7722c8e9b153", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "220"}, "hash": "46d8da1af1c4bf1d42f5aa7a843ec4aee82075f4759134571ed94b5dffc99cfd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9fd7a2cc-ed16-4e88-aae6-6cb7107c4deb", "node_type": "1", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "220"}, "hash": "800dc5844c850baf4b9465f4969c18d4fab276c16d71d07c75517fe5cac382f9", "class_name": "RelatedNodeInfo"}}, "text": "o   If \u201cyes\u201d:\n   \u00a7    In the past year, have you been troubled by flashbacks, nightmares, or thoughts of the\n        trauma?\n        o   In the past 3 months, have you experienced any event(s) or received information that\n            was so upsetting it affected how you cope with everyday life?\n   \u00b7    Screening Questions to Identify Mania in HIV infected patients\n   \u00b7    In the past year, when not high or intoxicated, did you ever feel extremely energetic or\n        irritable and more talkative than usual?\n           NATIONAL GUIDELINES FOR HIV PREVENTION TREATMENT AND CARE 2020              198", "mimetype": "text/plain", "start_char_idx": 2098, "end_char_idx": 2701, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "73a7f409-b431-49e6-8c1c-68e230ffebb1": {"__data__": {"id_": "73a7f409-b431-49e6-8c1c-68e230ffebb1", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "221"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "cd162de7-556f-4dd8-8b33-28a367ef554b", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "221"}, "hash": "99f7eff9ce9a1a1d349b4333f56cafead90e25f6f833a230e8f081e6c6a67ce5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f0dce60d-5ad1-493d-801d-5d7e4cf8e44a", "node_type": "1", "metadata": {}, "hash": "62b3945b1d42139f32cab61f73abe747497d8f191acf06a91659000120aa0306", "class_name": "RelatedNodeInfo"}}, "text": "Appendix 3: Energy and Nutritional Recommendations for PLHIV\n                                         Energy and Nutritional Recommendations for PLHIV\nMACRONUTRIENT INTAKE\nNormal Energy Requirements for Health:\nCarbohydrates - 45% to 65% of total energy intake\nProtein        - 10% - 30% of total energy intake\nFat            - 20% to 35% of total energy intake\nChildren                         Adults                           Pregnant and Lactating Women\nA 10% increase in energy         A 10% increase in energy intake  The recommended energy intake\nintake is recommended to         is recommended to maintain       for HIV-infected adolescents and\nmaintain growth in               body weight and physical         pregnant and lactating women\nasymptomatic children.           activity in asymptomatic HIV-    should be the same as their HIV\n                                 infected adults                  negative counterparts\nA 50% - 100% increase in         A 20% - 30% increase in energy   Additional energy requirement\nenergy intake over established   intake is recommended during     during pregnancy and lactation:\nrequirements for healthy         symptomatic disease or           1st Trimester = 90kcal/day\nuninfected children is           opportunistic infections to      2nd Trimester = 300kcal/day\nrecommended in children who      maintain body weight             3rd Trimester = 450kcal/day\nhave weight loss                                                  Lactation = 500kcal/day\nMICRONUTRIENT INTAKE\nPeople LHIV require extra vitamins and minerals to help repair and heal damaged cells. Consumption of a\nhealthy diet may be insufficient to correct nutritional deficiencies in PLHIV and supplementation may be\nrequired.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1737, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f0dce60d-5ad1-493d-801d-5d7e4cf8e44a": {"__data__": {"id_": "f0dce60d-5ad1-493d-801d-5d7e4cf8e44a", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "221"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "cd162de7-556f-4dd8-8b33-28a367ef554b", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "221"}, "hash": "99f7eff9ce9a1a1d349b4333f56cafead90e25f6f833a230e8f081e6c6a67ce5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "73a7f409-b431-49e6-8c1c-68e230ffebb1", "node_type": "1", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "221"}, "hash": "a80d9645d9f207098e4bfa33bcc0502bd3e4d2d207b7e7c12ea8674914f5dc70", "class_name": "RelatedNodeInfo"}}, "text": "Consumption of a\nhealthy diet may be insufficient to correct nutritional deficiencies in PLHIV and supplementation may be\nrequired. The following vitamins can be found in the foods listed:\n \u00b7   Vitamin A and beta-carotene: dark green, yellow, orange, or red vegetables and fruit; liver; whole\n     eggs; milk\n \u00b7   Vitamins B: meat, fish, chicken, grains, nuts, white beans, avocados,broccoli, and green leafy\n     vegetables\n \u00b7   Vitamin C: citrus fruits\n \u00b7   Vitamin E: green leafy vegetables, peanuts, and vegetable oils\n \u00b7   Selenium: whole grains, nuts, poultry, fish, eggs, and peanut butter\n \u00b7   Zinc: meat, poultry, fish, beans, peanuts, milk and other dairy products\nChildren                           Pregnant and Lactating Women\nVitamin A Supplementation          Vitamin A Supplementation\nIn keeping with WHO                Daily vitamin A intake by HIV-infected women during pregnancy\nrecommendations,                   and lactation should not exceed the RDA.\n6 month to 60 month-old            In areas of endemic vitamin A deficiency, a\nexposed/infected children born to  single high-dose of vitamin A (200 000 IU) is recommended to be\nHIV-infected mothers living in     given to women as soon as possible after delivery, but no later than\nresource-limited settings should   six weeks after delivery.\nreceive periodic (every 4\u20136        Iron Folate Supplementation\nmonths)                            To prevent anaemia, WHO recommends daily iron-folate\nvitamin A supplements (100,000     supplementation (400 g of folate and 60 mg of iron) during six\nIU for infants 6 to 12 months and  months of pregnancy, and twice-daily supplements to treat severe\n200,000 IU for children >12        anaemia. Available data do not support a change in this\nmonths)                            recommendation for women living with HIV\n          NATIONAL GUIDELINES FOR HIV PREVENTION TREATMENT AND CARE 2020                     199", "mimetype": "text/plain", "start_char_idx": 1606, "end_char_idx": 3534, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5abbd6a7-21cd-43a2-9b78-f1dc99e43c32": {"__data__": {"id_": "5abbd6a7-21cd-43a2-9b78-f1dc99e43c32", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "222"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "80a41d94-9d28-4157-ba0a-fbf85f1c7d5c", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "222"}, "hash": "e1b71ae9b8e48172e5aa8d9af167042c5d507cce5fe6e922ab8a05659dab0c65", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "471e71e0-58c2-4646-93be-4b0d82358810", "node_type": "1", "metadata": {}, "hash": "f1c279f488bbd64d867ec4c8d318de840992c845b232a7b01a961da26e82a85d", "class_name": "RelatedNodeInfo"}}, "text": "Appendix 4: Recommended activities for adolescent HIV service delivery\n                         Recommended activities for adolescent HIV service delivery aligned with the global\n                                   standards for quality of health-care services for adolescents\nGlobal standard          Description                       Recommended activities\n1.  Adolescents\u2019         The health facility implements          Training of peer supporters and adolescents living with\n    health literacy      systems to ensure that                  HIV(ALHIV)in HIV prevention, sexual and\n                         adolescents are knowledgeable           reproductive health, mental health and life skills\n                         about their own health and they         Developing job aides on HIV testing, care and\n                         know where and when to obtain           treatment, viral load monitoring, adherence counselling\n                         health services                         and contraceptive information and provision specific to\n                                                                 adolescents\n                                                                 Peer supporters and treatment literacy staff address\n                                                                 HIV knowledge and adherence concerns of adolescents\n2. Community             The health facility implements          Facilities create strong linkages with bi-directional\n    support              systems to ensure that parents,         referral to community-based services such as orphans\n                         guardians and other                     and vulnerable children (OVC), gender-based violence\n                         community members and                   prevention and support, social and legal protection,\n                         community organizations                 vocational training etc. through partnerships\n                         recognize the value of providing        Facilities and relevant community-based organizations\n                         health services to adolescents          (CBOs) establish formalized relationships (e.g. through\n                         and support such provision and          memoranda of understanding) for shared implementation,\n                         the utilization of services by          monitoring and reporting whenever feasible\n                         adolescents\n                                                                 Facilities participate and support the training of\n                                                                 community service providers as appropriate\n                                                                 Provision of community -based support for both ALHIV\n                                                                 and their caregivers\n                                                                 Conducting sensitization sessions within schools to\n                                                                 eliminate stigma and promote testing, adherence and\n                                                                 retention by school attending ALHIV\n3.  Appropriate          The health facility provides a          Standard operating procedures and job aids developed\n    package of           package of information,                 and implementedto provide standard and simplified\n    services             counselling, diagnostic,                information on the package of services for adolescents\n                         treatment and care services             Constitute a multidisciplinary mentorship team on\n                         that fulfils the needs of all           capacity-building for the needs of the adolescents\n                         adolescents.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 3838, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "471e71e0-58c2-4646-93be-4b0d82358810": {"__data__": {"id_": "471e71e0-58c2-4646-93be-4b0d82358810", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "222"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "80a41d94-9d28-4157-ba0a-fbf85f1c7d5c", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "222"}, "hash": "e1b71ae9b8e48172e5aa8d9af167042c5d507cce5fe6e922ab8a05659dab0c65", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5abbd6a7-21cd-43a2-9b78-f1dc99e43c32", "node_type": "1", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "222"}, "hash": "1dd914f04015d014dd0f9b42ed853dea8d9b6cb75c7166e5a634234099ed7fcf", "class_name": "RelatedNodeInfo"}}, "text": "Services are\n                         provided in the facility and\n                         through referral links and\n                         outreach\n            NATIONAL GUIDELINES FOR HIV PREVENTION TREATMENT AND CARE 2020                                     200", "mimetype": "text/plain", "start_char_idx": 3839, "end_char_idx": 4106, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "433064f1-cefd-4348-9bb5-a75f55bf1dac": {"__data__": {"id_": "433064f1-cefd-4348-9bb5-a75f55bf1dac", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "223"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "732bce29-a7a6-4e8a-a71c-c4957199ae29", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "223"}, "hash": "2e63adf87f414aa9902d19708e449efb33c41094cadddbad6d4c3e4ec78c463f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a44a9e60-a785-46b9-b3d3-2b97573e2709", "node_type": "1", "metadata": {}, "hash": "dd739285ac749390e99f4d6f65800e8f42b7997c47acc8a87f8577ff201ee768", "class_name": "RelatedNodeInfo"}}, "text": "4.  Providers\u2019           Health-care providers                   Development of training curriculum for facility and\n    competencies         demonstrate the technical               community health care workers, training curriculum for\n                         competence required to provide          peer educators, and adolescent club guide\n                         effective health services to            Trainingofhealth-care workersat service delivery points\n                         adolescents. Health-care                on providing adolescent-friendly health services within\n                         providers and support staff             an integrated service package\n                         respect protect and fulfil\n                         adolescents\u2019 rights to                  Regular meetings, on-site support and mentorship, and\n                         information, privacy,                   refresher workshops\n                         confidentiality, non-\n                         discrimination, non-judgmental\n                         attitude and respect\n5.  Facility             The health facility has                 Age band clinic appointment and flexible opening hours\n    characteristics      convenient operating hours, a           outside regular clinic hours, such as evenings or\n                         welcoming and clean                     weekends or school holidays to facilitate convenience\n                         environment and maintains               A safe space for adolescent HIV care and psychosocial\n                         privacy and confidentiality. It has     support discussions, and peer interactions\n                         the equipment, medicines,\n                         supplies and technology needed          This could be designated spaces or multi-use spaces\n                         to ensure effective service             with time allotments\n                         provision to adolescents                Scheduling of multidisciplinary teams to provide\n                                                                 variousservices including counselling, antiretroviral\n                                                                 medicine refill, viral load testing\n                                                                 Development and adherence to infection prevention\n                                                                 and control policies\n6.  Equity and           The health facility provides            Services provided free of charge with no out-of-pocket\n    nondiscriminatio     high-quality services to all            expenses\n    n                    adolescents regardless of their         Client satisfactory survey done periodically to\n                         ability to pay, age, sex, marital       get feedback for improvement\n                         status, education level, ethnic\n                         origin, sexual orientation or           Involvement and collaboration by multi-layered\n                         other characteristics                   and multisectoral agencies, including social\n                                                                 protection services and government health\n                                                                 ministries/agencies at all levels\n7.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 3344, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a44a9e60-a785-46b9-b3d3-2b97573e2709": {"__data__": {"id_": "a44a9e60-a785-46b9-b3d3-2b97573e2709", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "223"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "732bce29-a7a6-4e8a-a71c-c4957199ae29", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "223"}, "hash": "2e63adf87f414aa9902d19708e449efb33c41094cadddbad6d4c3e4ec78c463f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "433064f1-cefd-4348-9bb5-a75f55bf1dac", "node_type": "1", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "223"}, "hash": "9ff77fa3eb182b7c310d2a9c965d5306e569709b90b849923e798c4ca2c0ab3d", "class_name": "RelatedNodeInfo"}}, "text": "Data and quality     The health facility collects,           Develop and implement standard data collection tools\n    improvement          analyses and uses data on               at the facility level and a reporting template that\n                         service utilization and quality         capture age, sex and outcomes\n                         of care, disaggregated by age           Establish quality improvement teams at health\n                         and sex, to support quality             facilities and build their capacity to use data\n                         improvement. Health facility\n                         personnel are supported in              Quality improvement teams to routinely review\n                         participating in continual              disaggregated data, identify, test and implement\n                         quality improvement                     appropriate solutions\n            NATIONAL GUIDELINES FOR HIV PREVENTION TREATMENT AND CARE 2020                                         201", "mimetype": "text/plain", "start_char_idx": 3346, "end_char_idx": 4380, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c6d55ce3-e8ce-4f3e-9fc8-6829d85c7473": {"__data__": {"id_": "c6d55ce3-e8ce-4f3e-9fc8-6829d85c7473", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "224"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "6d2af672-ac27-499b-a420-7a2683e65e86", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "224"}, "hash": "467feeaabfc7d6f6cccd47d216a654284b373dd63035eee1c646886807cc3af4", "class_name": "RelatedNodeInfo"}}, "text": "8.  Adolescents\u2019         Adolescents are involved in           Involvement of peer supporters/educators in relevant\n    participation        planning, monitoring and              facility health team activities and meetings such as\n                         evaluating health services and        case reviews and advocacy for adolescent-friendly\n                         in decisions regarding their          health services\n                         care and incertain appropriate        Training of peers to be self-healthmanagers, to\n                         aspects of service provision          motivate self and others and to be a source of positive\n                                                               peer pressure to others\n                                                               Developing viable and effective mechanisms for\n                                                               harnessing input and feedback from adolescents on the\n                                                               planning, implementation, monitoring and evaluation\n                                                               of services provided\n            NATIONAL GUIDELINES FOR HIV PREVENTION TREATMENT AND CARE 2020                                   202", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1279, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "13909637-aa38-493f-bc29-b03f285b950e": {"__data__": {"id_": "13909637-aa38-493f-bc29-b03f285b950e", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "225"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "87414f2f-a2e6-41b7-b89e-b0324101029c", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "225"}, "hash": "9bb44954e73e0a0e5edbba94a0924e87c1fed72b5f419da96634fa3c4013e76e", "class_name": "RelatedNodeInfo"}}, "text": "Appendix 5: Guide on Age Appropriate Disclosure for Children and Adolescents\n                 Guide on Age-Appropriate Disclosure for Children and Adolescents\nAge characteristics       Stage of        Provider Action\n                          Disclosure\n0 - 4 years               No              At this stage, no disclosure is done since the child is too young to understand\n                          disclosure      about HIV\n5 - 8 years               Partial         At this age , the child can understand a lot. Define the virus as a germ and\n                          disclosure      the CD4+ as the soldier in the body that keep fighting and one has to take\n                                          the drugs to strengthen the soldiers in the body\n                                          Full disclosure is important since most children at this stage a  re able to\n                                          understand more about HIV and would have heard about HIV as part of\n                                          formal education at school\n                                          Follow the following stages in the disclosure process\n                                          Stage 1\n                                          Assessing the child social support system to ensure    the availability of\n                                          sufficient support once disclosure is completed\n                                          Stage2\n                          Full            Assess the child's prior knowledge about HIV/ AIDS including information\n                          disclosure      given at school, any myths and misconceptions. Offer or reinforce accurate\n                                          information\n                                          Stage 3\n9 to 12 years                             Use an imaginary exercise or story to assess a child's reaction to disclosure\n                                          of HIV status\n                                          Stage4\n                                          Tell the child about their HIV status. Support parents to disclose to the child\n                                          and clarify the mode of infection.\n                                          Address immediate reaction and concerns a childmight have\n                          Post-           Find out from the parent/guardian if they have observed anything after\n                          disclosure      disclosure, e.g. behaviour change:\n                          (3-6 months         \u2022  Introduce the child to tell their story and emerge as a hero (a comic\n                          after full             book may be a useful aid)\n                          disclosure)         \u2022  Link the child to a support group or with an older child who has been\n                                                 disclosed to\n                                          NB: Find out how the child is doing at every visit after full disclosure\n            NATIONAL GUIDELINES FOR HIV PREVENTION TREATMENT AND CARE 2020                                  203", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 3106, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "53d10b46-b207-458c-ac52-7c6e3cf26a5a": {"__data__": {"id_": "53d10b46-b207-458c-ac52-7c6e3cf26a5a", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "226"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "888b838f-619a-42ca-b02b-e0aa05be92e9", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "226"}, "hash": "07abbaade02b0cb742f03219a0839515e64c0ff4555cd23ac5f39f0f9244f84a", "class_name": "RelatedNodeInfo"}}, "text": "Appendix 6: Self-management timeline for transitioning ALHIV\n                                                           Self-management timeline for transitioning ALHIV\nAge                  From 10-12 years            From 13-16 years          From 17-19 years       (Capacity to\n                     (Envisioning a future)      (Working towards          transition)\n                                                 responsibility)\nIndividual growth and environmental support: Encouraging healthy decisions\nPsycho-social           \u00b7   Link to relevant     \u00b7   Link to relevant      \u00b7   Link to relevant support groups\nsupport                     support groups and       support groups and        and programs\n                            programs                 programs              \u00b7   Support mentorship of younger\n                                                                               positive adolescents\nSexual and              \u00b7   Answer any           \u00b7   Link to an            \u00b7   Continue sexuality\nreproductive health,        questions that           adolescent-friendly       conversations, encourage\npositive health and         emerge honestly          reproductive health       questions about HIV, pregnancy,\nprevention                  and truthfully           provider and clinics,     and sexuality\n                                                     review sexuality      \u00b7   Refer for regular sexual health\n                                                     issues and safe sex       check-ups\n                                                     practices\n                                                 \u00b7   Refer for regular     \u00b7   Discuss HIV prevention methods\n                                                     sexual health check-\n                                                     ups\n                                                 \u00b7   Discuss HIV\n                                                     prevention methods\nSubstance use           \u00b7   Discuss substance    \u00b7   Discuss the links     \u00b7   Discuss the links between\n                            use and how it can       between sexually          sexually risky behaviours and\n                            impact health            risky behaviours,         substance abuse, and poor health\n                                                     substance abuse, and      outcomes; assess if using\n                                                     poor health               substances and what triggers use\n                                                     outcomes; assess if\n                                                     using substances and\n                                                     what triggers use\nFuture planning         \u00b7   Initiate             \u00b7   Promote peer          \u00b7   Connect ALHIV to job training,\n                            conversation about       education                 vocational training, and\n                            future goals (work,      opportunities             continued education\n                            school, etc.)        \u00b7   Connect ALHIV             opportunities\n                                                     with relevant NGOs\n            NATIONAL GUIDELINES FOR HIV PREVENTION TREATMENT AND CARE 2020                             204", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 3311, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a554d9fe-d6f7-407d-827f-6750409c9e23": {"__data__": {"id_": "a554d9fe-d6f7-407d-827f-6750409c9e23", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "227"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "540a07a9-1ac4-4b04-9d6a-3eaeb4aec50b", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "227"}, "hash": "7c24482f57506ec47d536026809cbd6c26cd55ff32d4d6d8ca85243cc31c85b1", "class_name": "RelatedNodeInfo"}}, "text": "Clinical support: Providing or facilitating referrals for needed services\nSelf-care               \u00b7   Support caregivers   \u00b7   Build a               \u00b7   Reinforce responsibility in\n                            to disclose to the       schedule/calendar         taking medications and keeping\n                            adolescent if not        with the adolescent       appointments\n                            already done             to strengthen\n                        \u00b7   Talk to the child to     adherence to\n                            start mapping out        treatment and\n                            the transition           retention\n                            timeline after       \u00b7   Discuss and address\n                            disclosure               transport barriers\n                                                     and other issues that\n                                                     hinder Clinic and\n                                                     ART adherence\nClinical                \u00b7   Talk about HIV       \u00b7   Talk to the           \u00b7   Help identify appropriate adult\nmanagement                  and prevention           adolescent about          providers/clinics\n                            measures                 diagnosis,            \u00b7   Solicit questions about care,\n                        \u00b7   Begin to explain         medications,              treatment, and potential future\n                            medications and          appointment keeping       changes in treatment\n                            reinforce adherence      and adherence         \u00b7   Link to counselling (including\n                            messages             \u00b7   Talk to adolescent        lay or peer) for any mental\n                        \u00b7   Talk about               about how to seek         health issues\n                            adherence issues         clinical care for\n                                                     symptoms or           \u00b7   . Ensure that viral load\n                        \u00b7   Link to counselling      emergencies               suppression (<1000 c\n                                                                                                   opies/ml) is\n                            (including lay or    \u00b7   Link to counselling       achieved within the last one year\n                            peer) for any            (including lay or         prior to completion of\n                            mental health            peer) for any mental      transitioning to adult care\n                            issues                   health issues         \u00b7   Follow up with transitioned\n                                                 \u00b7   Orient adolescent in      adolescents6 months to ensure\n                                                     adult clinic              adherence and retention in care\n            NATIONAL GUIDELINES FOR HIV PREVENTION TREATMENT AND CARE 2020                             205", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2984, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c6d3bb5a-db7f-4681-b4f9-e30793afffbe": {"__data__": {"id_": "c6d3bb5a-db7f-4681-b4f9-e30793afffbe", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "228"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "eaf52094-1c59-4fcf-a559-dfe9f9d0d1aa", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "228"}, "hash": "28e5e3b84e8dc0ddf0a810dff3437f49ee89302ffc626c61acc3564b21321a46", "class_name": "RelatedNodeInfo"}}, "text": "Appendix 7: Algorithm for Screening and Diagnosing TB in PLHIV\n                                       Figure 7.1: Algorithm for Screening Children aged \u2265 1 year living with HIV\n                                                                     for TB Preventive Therapy\n                                Children aged      \u2265 12 months\n                                living with HIV *\n               eline  Screen for TB with a         ny one of the following symptoms:\n                       eline   eline   eline            eline  eline  eline  eline  eline  elin\n                                       Weight loss or poor weight gain\n               eline   eline   eline   eline     Fever         eline         eline\n                                                        eline         eline         eline  eline\n                                           Current cough\n                                       History of contact with a person with TB\n                 No                                                                 Yes\n  Assess for contraindications to TPT                           Investigate for TB and other diseases\n       No                     Yes                 Other Diagnosis             Not TB              TB\n                                                  Give                        Follow up         Treat\n                           Defer TPT               eline        eline     eline      eline       eline\n   Administer              until                  Appropriate                 and               for TB\n   eline   eline           problem                Treatment                   consider\n       TPT                 eline    eline          eline        eline     eline      eline       eline\n                           resolved               and consider                TPT\n                                                  TPT\n                                                   Screen regularly for TB at each encounter with the patient\n                                       *All infants <1 year should only be given TPT if they have a history of household contact with a TB caseand do not have active TB after\nevaluation\n           NATIONAL GUIDELINES FOR HIV PREVENTION TREATMENT AND CARE 2020                          206", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2277, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "69aab10b-ffbc-4629-b7f5-fd11b30dad25": {"__data__": {"id_": "69aab10b-ffbc-4629-b7f5-fd11b30dad25", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "229"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "28f16f19-8eb6-4647-ba72-e7c9d32bbb99", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "229"}, "hash": "9d28ec62750ebc3cd0d8151656a1b66fe3f95adfa6315f579c2b270ee749d217", "class_name": "RelatedNodeInfo"}}, "text": "Figure 7.2: Algorithm for screening Adult and Adolescent Living with\n                                                 HIV(including pregnant PLHIV) for TB Preventive therapy\n                                    All Adults and\n                            Adolescents living with HIV\n                      Screen for TB with any one of the following symptoms:\n                                   Current cough\n                                        Fever\n            No                      Weight loss                     Yes\n                                    Night sweats\n            No                                                      Yes\n Assess for contraindications to TPT                Investigate for TB and other\n                                                    diseases\n    No                  Yes                    Other              No t TB            TB\n                                            Diagnosis\n                      Defer TPT            Give                 Follow up\n                      until                Appropriate          and               Treat\nAdminister            problem              Treatment            consider          for TB\n    TPT               resolved             and consider         TPT\n                                           TPT\n               Screen regularly for TB at each encounter with the patient\n         NATIONAL GUIDELINES FOR HIV PREVENTION TREATMENT AND CARE 2020                 207", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1460, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "53569573-9409-42e8-944c-90be55b06552": {"__data__": {"id_": "53569573-9409-42e8-944c-90be55b06552", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "230"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "216625c0-c0eb-4f4d-b50b-05ecd7970ef3", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "230"}, "hash": "119eb96bb3d28748448d1a7c2f0d37ae1a8a351cbac9435dd9a1323130f2a6cb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1ebfe15c-9949-4500-987b-323d16d35971", "node_type": "1", "metadata": {}, "hash": "63ec85e3eae1744069fa12afc19a60d3a6fb5d5a123889438ace278cdf6bb064", "class_name": "RelatedNodeInfo"}}, "text": "Figure 7.3: Algorithm for Diagnosing TB in Children and Adolescent\n    Presume TB in a child living with HIV if any of the following is present:\n     eine    eine     eine     eline    eline    eine      eine   eline      eine     eine     eine      eline\n    a. Current cough\n    b. Unexplained fever\n    c. Weight loss or failure to gain weight\n     eline   eline    eline    eline    eline    eline     eline  eline      eline    eline    eline     eline\n    d. History of contact with an adult TB\n    e. Features of Extra-pulmonary TB\n                                                        If specimen is available:\n                                                        \u2022 Collect appropriate specimen (e.g. sputum, stool,\n                                                         lymph node/gastric aspirate, cerebrospinal fluid,\n                                                         abscess/pus    and    other  body   fluids)  for  Xpert\n                                                         MTB/RIF       assay OR     collect sputum only for\n                                                         Truenat MTB/RIF test\n  If specimen is unavailable (e.g.                                               MTB                   MTB\n                                                              eline     eline  eline      eline         eline    eline\n  presumptive EPTB) or MTB not detected *                                        detected,             detected,\n  1. History of contact with TB patient or        :          MTB not             RIF                   RIF\n   eline    eline    eline    eline    eline    eline        detected            resistance            resistance\n      positive Mantoux test                                   eline     eline  eline      eline         eline    eline\n  2. Physical signs suggestive of TB                                             not detected          detected\n  3. TB suggestive imaging features (e.g.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 1967, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1ebfe15c-9949-4500-987b-323d16d35971": {"__data__": {"id_": "1ebfe15c-9949-4500-987b-323d16d35971", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "230"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "216625c0-c0eb-4f4d-b50b-05ecd7970ef3", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "230"}, "hash": "119eb96bb3d28748448d1a7c2f0d37ae1a8a351cbac9435dd9a1323130f2a6cb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "53569573-9409-42e8-944c-90be55b06552", "node_type": "1", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "230"}, "hash": "70a3abb9275a5e6c307dcfefdf96bb58298b2cf4f78b79cb913270c475ca0c6e", "class_name": "RelatedNodeInfo"}}, "text": "Physical signs suggestive of TB                                             not detected          detected\n  3. TB suggestive imaging features (e.g.\n   eline    eline    eline    eline    eline    eline\n      chest x -ray and computed tomography\n      scan)                                                                    Treat as Drug         Inform State\n                                                                                eline  eline          eline   eline\n                                                                               Susceptible           TB\n    If only one of three features             If two or more                   TB (DS-TB)            Programme\n                                                                **              eline  eline          eline   eline\n    present                                   features present                 if child is not       and LGA\n                                                                               a contact of          Supervisor\n                                                                               DR-TB case            to initiate\n                                                                                eline  eline          eline   eline\n    If child is ill:                  If child is well:                        ***                   DR-TB\n    Refer to Medical Officer          Review after 2 - 4 weeks                                       Treatment\n  Presume DR-TB ifin addition to symptoms of TB, the child has any of the under               -listed risk factors:\n    Close contact with confirmed DR -TB patients\n    Close contact with patient that died from TB, failed or is not adherent to TB treatment\n    History of previous TB treatment (in the past 6 - 12months)\n    Not improving after 2 months of DS-TB treatment\n*Clinical diagnosis is recommended if all effort at bacteriological c confirmation using\n  Xpert MTB/RIF assay/Truenat test (or Urine LF-LAM assay in PLHIV with advanced disease) is not possible\n**In settings where there is no doctor (e.g. hard to reach areas), the trained health care\n                               .\n   worker can make a diagnosis of TB and commence anti -TB treatment.\n***Treat as DR-TB if child is a contact of DR-TB case\n            NATIONAL GUIDELINES FOR HIV PREVENTION TREATMENT AND CARE 2020                                   208", "mimetype": "text/plain", "start_char_idx": 1819, "end_char_idx": 4222, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6294f098-a86c-49f1-bfd7-c36a1ea01dd5": {"__data__": {"id_": "6294f098-a86c-49f1-bfd7-c36a1ea01dd5", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "231"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "3f93b626-4976-4748-80b4-ba3cdecfad10", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "231"}, "hash": "2199a4fea9298fc50c8715aec2427c192c2e5e8fde6652332343bcf04c391135", "class_name": "RelatedNodeInfo"}}, "text": "Figure 7.4: Algorithm TB in Diagnosis in Adults\nNATIONAL GUIDELINES FOR HIV PREVENTION TREATMENT AND CARE 2020                          209", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 139, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9dd4b5f5-f9ea-4605-82b4-b27474df43f5": {"__data__": {"id_": "9dd4b5f5-f9ea-4605-82b4-b27474df43f5", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "232"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "8a74ce19-e71e-4c07-9d07-68c714416ef0", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "232"}, "hash": "5577680b297ac2c49b36c7c653ddbc661b5122af12793333a4bce83405803de9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c6d9a079-8b91-4b5f-9540-8777b0f01195", "node_type": "1", "metadata": {}, "hash": "e93972e549c3c646a97517a4dfdf9c9cdbed3288d1552c8ae6019c52164de259", "class_name": "RelatedNodeInfo"}}, "text": "Appendix 8: Global Standards for Quality Health-Care Services for Adolescents\nEight global standards define the required level of quality in the delivery of services as shown in\nthe table below. Each standard reflects an important facet of quality services, and to meet the\nneeds of adolescents all standards need to be met. This section presents each of these standards\nand its criteria, categorized as input, process and output criteria.\n  Adolescents\u2019          Standard 1-The health facility implements systems to ensure that\n  health literacy       adolescents are knowledgeable about their own health, and know where and\n                        when to obtain health services.\n  Community             Standard 2-The health facility implements systems to ensure that parents,\n  support               guardians and other community members and community organizations\n                        recognize the value of providing health services to adolescents and support\n                        such provision and the utilization of services by adolescents.\n  Appropriate           Standard 3-The health facility provides a package of information,\n  package of            counselling, diagnostic, treatment, and care services that fulfils the needs\n  services              of all adolescents. Services are provided in the facility and through referral\n                                             1\n                        linkages and outreach.\n  Providers\u2019            Standard 4-Health-care providers demonstrate the technical competence\n  competencies          required to provide effective health services to adolescents. Both healthcare\n                        providers and support staff respect, protect and fulfil adolescents\u2019 rights to\n                        information, privacy, confidentiality, non-discrimination, non-judgmental attitude,\n                        and respect.\n  Facility              Standard 5-The health facility has convenient operating hours, a\n  characteristics       welcoming and clean environment and maintains privacy and\n                        confidentiality. It has the equipment, medicines, supplies, and technology\n                        needed to ensure effective service provision to adolescents.\n  Equity   and non -    Standard 6-The health facility provides quality services to all adolescents\n  discrimination        irrespective of their ability to pay, age, sex, marital status, education level,\n                        ethnic origin, sexual orientation, or other characteristics.\n  Data and   quality    Standard 7- The health facility collects, analyses and uses data on service\n  improvement           utilization and quality of care, disaggregated by age and sex, to support\n                        quality improvement. Health facility staff is supported to participate in\n                        continuous quality improvement.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2885, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c6d9a079-8b91-4b5f-9540-8777b0f01195": {"__data__": {"id_": "c6d9a079-8b91-4b5f-9540-8777b0f01195", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "232"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "8a74ce19-e71e-4c07-9d07-68c714416ef0", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "232"}, "hash": "5577680b297ac2c49b36c7c653ddbc661b5122af12793333a4bce83405803de9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9dd4b5f5-f9ea-4605-82b4-b27474df43f5", "node_type": "1", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "232"}, "hash": "025363ade2c5294ec6f6555560049922fde3215824949e47d302afb253e82cab", "class_name": "RelatedNodeInfo"}}, "text": "Health facility staff is supported to participate in\n                        continuous quality improvement.\n  Adolescents\u2019          Standard 8-Adolescents are involved in the planning, monitoring, and\n  participation         evaluation of health services and in decisions regarding their own care, as\n                        well as in certain appropriate aspects of service provision.\n 1 Service provision in the facility should be linked, as relevant, with service provision in referral level health facilities, schools, and other\n community settings.\n            NATIONAL GUIDELINES FOR HIV PREVENTION TREATMENT AND CARE 2020                     210", "mimetype": "text/plain", "start_char_idx": 2777, "end_char_idx": 3430, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9f2ed756-fb5c-46d3-b4ce-a001dda1cd11": {"__data__": {"id_": "9f2ed756-fb5c-46d3-b4ce-a001dda1cd11", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "233"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "bd20100a-1245-4eca-8cd2-d504ac7ca099", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "233"}, "hash": "9e95ef255d165cb2d3dd31fd0f6c50cbd13d8264f7041f9e96cd19db745004c2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "17a8c567-2856-4c2a-b440-3e6a8d968a38", "node_type": "1", "metadata": {}, "hash": "d2454e0b0e58487e8ba2a15f12c3a544559cebd300ba75f23b5242173d5b0698", "class_name": "RelatedNodeInfo"}}, "text": "Appendix 9: Pharmacovigilance or Drug and Therapeutic Committees (PVC)\n                                    - Terms of Reference\nThere should be the existence of a functional Pharmacovigilance or drug and therapeutic\ncommittee at the facility level, which meets regularly to provide oversight, review all the\ndocumented/reported cases of ADRs and advise on the management of such patients. The\ncommittee should be comprised minimally of a clinician, Pharmacist, Nurse, Adherence\ncounselor, and a Lab scientist; may also include data/record officer, Mentor mother and other\nsupport staff where available.\nTerms of Reference of the PVC or DTC\nThe Pharmacovigilance or Drug and Therapeutic committee will hold regular meetings in\npursuant of their roles and responsibilities as stated below. If necessary, the committee will need\nto enforce mandatory attendance to accomplish the functions of the committee. Minutes and\nMOVs need to be prepared for each meeting and distributed to the appropriate departments.\nFinally, all goals, terms of reference, policies, decisions, and other actions of the PVC or DTC\nshould be documented, and the records kept.\nRoles and Responsibilities\nThe responsibilities of the PVC or DTC include but are not limited to \u2013\n   1.   Medication advisory role to the facility\n       \u2013    On VL optimization and results review, pharmacovigilance & management\n            activities, regimen switch and substitutions decisions etc.\n    2.  Identifying drug use problems and promoting rational drug use.\n        \u2013   Through examinations of reports such as Medication error reports; Drug-drug\n            interactions; VL reports for treatment failure (unsuppressed clients to be considered\n            for EAC and decision to switch);ADR reports, etc.\n    3.  Promoting interventions that improve drug use such as education program (e.g., CME,\n        bulletin publication, in-service training) and managerial program (such as conduct Drug\n        Use evaluation).\n    4.  Promoting pharmacovigilance activities by encouraging, monitoring, assessing,\n        reporting, and prevention ofADRs and other medication related problems:\n        \u2013   To review the availability and adequacy of tools (ADR Screening form, NAFDAC\n            yellow/ADR reporting form), and the skills of HCWs to monitor and reportADR at\n            the facility.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 2352, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "17a8c567-2856-4c2a-b440-3e6a8d968a38": {"__data__": {"id_": "17a8c567-2856-4c2a-b440-3e6a8d968a38", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "233"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "bd20100a-1245-4eca-8cd2-d504ac7ca099", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "233"}, "hash": "9e95ef255d165cb2d3dd31fd0f6c50cbd13d8264f7041f9e96cd19db745004c2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9f2ed756-fb5c-46d3-b4ce-a001dda1cd11", "node_type": "1", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "233"}, "hash": "c4014d6eda0a4bd54bf396e96e545e6aeafc7d392fd985443b8ce49b856f1c53", "class_name": "RelatedNodeInfo"}}, "text": "\u2013   Liaise with supporting Implementing Partners, state LMCU, or other partners to\n            address identified gaps in Pharmacovigilance monitoring and reporting at the\n            facility level.\n        \u2013   Ensure the documentation, collation, and routine reporting of identifiedADRs from\n            the facility to the National Pharmacovigilance Centre (NPC) managed by\n            NAFDAC.\n        \u2013   Provide guidance to community pharmacies and other out of facility DSD models, to\n            ensure that the capacity and tools are available to monitor and reportADRs among\n            the patients they serve.\n          NATIONAL GUIDELINES FOR HIV PREVENTION TREATMENT AND CARE 2020             211", "mimetype": "text/plain", "start_char_idx": 2361, "end_char_idx": 3070, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a2a474fe-1dd7-418b-aed3-dc0950d7c607": {"__data__": {"id_": "a2a474fe-1dd7-418b-aed3-dc0950d7c607", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "234"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "17c7bdc9-14b2-40bb-9ea8-85158057cd7c", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "234"}, "hash": "d303b79d0b5ed0867ad976f363577c8bc1e353f607906221713bf51d13a6cdc6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9c415600-8538-4b0c-aeb9-f263840c72b4", "node_type": "1", "metadata": {}, "hash": "10bec4e14ac13588ec0d919b64ef29b2a99a223f8ec79add04d2ca6a38170657", "class_name": "RelatedNodeInfo"}}, "text": "Appendix 10: NAFDAC ADR Form\n  ANNEXURE                                                PVPMS-003-01                                        SERIAL NO:          00024981\nNational Agency for Food andDrug                                                                                                NAFDAC USE ONLY\nAdministration   Control (NAFDAC);\n               and\n Corporate Headquarters; Way                                           MAFDAC\nPlot 2032 Olusegun Obasanjo                                            NAFDAC\nWuse Zone     Abuja\n                                                           National Pharmacovigilance Centre\n         PATIENT INFORMATION                                                                2. Indicatlons for Use (Diagnosis)\n  1 . Patient' $ Full Name or Initials (In Confidence                                       Dosage                        Frequency            Route ot Administration\n  2. Age                                 Sex                     Weight (kg)                Date Medicatlon Started (dd-mmm-yyYy)  Date Medication Stopped (dd-mmm-YyYY)\n                                          Female\n                                          Male\n  Or Date of Birth (eg: 03 May 1925)\n                                                                                        5. Reaction Stopped or Reduced                6. Reaction Reappeared After Drug\n                                                                                            After Drug Withdrawal?                       Reintroduction?\n  Hospital Treatment Centre                             Patient                                         Yes                                 Yes\n                                                        Record No                                                                           No\n                                                                                                         Doesn\"t                            Doesn't apply\n                                                                                                               apply\n  B.     ADVERSE EVENT                                                                      D. CONCOMITANT MEDICINES\n                                                                                            (All medicines taken within the last months; including herbal and self-medication)\n  1. Describe Event                                                                      Brand or Generic  Dosage      Route        Date       Date       Reason\n                                                                                         Name                                       Started    Stopped    for Use\n                                                                                            E: RELEVANT TESTS LABORATORY DATA WITH DATES\n  2. Seriousness of Adverse Event (Check all that apply)\n       Death  Include date (dd-mmm-yyyy)\n       Life threatening\n       Hospitalization\n              Initial                                                                       F.OTHER RELEVANT HISTORY\n              Prolonged\n       Disability or Permanent Damage                                                       Including Preexisting Medical Conditions:\n       Congenital Anomaly/Birth Defects                                                               Pregnancy                              Akcohol use\n       Required intervention to Prevent Permanent Impairment or Disability (Devices)                  Smoking                                Liver problems\n       Others (Specify)                                                                     Allergies Kidney Problems\n   3.", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 3714, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9c415600-8538-4b0c-aeb9-f263840c72b4": {"__data__": {"id_": "9c415600-8538-4b0c-aeb9-f263840c72b4", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "234"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "17c7bdc9-14b2-40bb-9ea8-85158057cd7c", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "234"}, "hash": "d303b79d0b5ed0867ad976f363577c8bc1e353f607906221713bf51d13a6cdc6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a2a474fe-1dd7-418b-aed3-dc0950d7c607", "node_type": "1", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "234"}, "hash": "b639e530b781c8cd4e387d68bf063af8374856661a2adb32a6c7f9fdbfbb0025", "class_name": "RelatedNodeInfo"}}, "text": "Outcomes                                                                           Others (Specify)\n               fully\n       Recovered\n       Recovering\n       Fatal\n       Unknown                                                                                 REPORTER\n       Others (Specify)\n              Onset Date of Event (dd-mmm-yyyY)  Stop Date of Event                         Name and Address\n                                                             (dd-m\n                                                                 mmm-YYYY)                  Last Name:                        First Name:\n                                                                                            Address:\n              SUSPECTED DRUG (Including Biologicals Traditional/Herbal                      City:                             State:\n  Medicines & Cosmetics)                                                                    Country:                         Date:\n  L Prduct Deteik Nameand other details;attach product label_product sample _if available)  Phone No:                        Email:\n  Brand Name                                           Batch No:                            2. Health Professional?\n  Generic Name:                                        NAFDAC No:                                     Yes\n  Nameand Address of Manufacturer:                     Expiry Date:\n                                                                                            3. Occupation:\n                   NATIONAL GUIDELINES FOR HIV PREVENTION TREATMENT AND CARE 2020                                                                          212", "mimetype": "text/plain", "start_char_idx": 3715, "end_char_idx": 5378, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "20c2254e-cedc-4b42-9fb4-739da40e1b96": {"__data__": {"id_": "20c2254e-cedc-4b42-9fb4-739da40e1b96", "embedding": null, "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "235"}, "excluded_embed_metadata_keys": [], "excluded_llm_metadata_keys": [], "relationships": {"1": {"node_id": "a8a09e86-3e26-4100-acdd-2b34deaae2cb", "node_type": "4", "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "235"}, "hash": "bb74403ca82fab0009e33844630df2515bcd2f0fafedcf1aec35ab0a877bf877", "class_name": "RelatedNodeInfo"}}, "text": "NO_CONTENT_HERE", "mimetype": "text/plain", "start_char_idx": 0, "end_char_idx": 15, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}}, "docstore/metadata": {"50518c17-70e0-49ab-acc9-52fc13113b17": {"doc_hash": "cff2b7939cbbc2d2c585c5f23a985ef7a646e9e7a402ceb342c74b578c6a63c4", "ref_doc_id": "f43c593e-89ed-466f-b6c5-bb24c6a815e1"}, "3f1d571b-2021-4509-a361-8c30df814751": {"doc_hash": "bb4493850a4bb8a14390ae3b7adf9e230dc281c1d246552369b10a5c8604cae6", "ref_doc_id": "33cfe3c1-14e1-49ff-b2f4-1204ec745a13"}, "81a53cc0-056c-42d5-98c2-b2045020e78a": {"doc_hash": "4ade35138f807af8f8a4f9e1b600d9f22398e65a2f3fc77f0b78416a64978ae7", "ref_doc_id": "5740e021-9ec2-4533-98b4-38e359f67d99"}, "992c25fa-a72a-402f-8d0e-ae9198581c3c": {"doc_hash": "c398eb8e1e802e53a698462b8a200823ad205747c87b27d897786df68f6df080", "ref_doc_id": "48a1d039-dad7-4de1-bba3-f1ab011f0d4f"}, "f8cb1ffc-b06c-45fe-b45a-6c0a00e293ef": {"doc_hash": "bbc141b15a82249d24e63a27f4902584b8c7962cbc1c1e7b0288bf08106836c0", "ref_doc_id": "2707617b-f4f3-4996-82a9-0713064cdaa6"}, "badb5fd5-d87b-4df8-884a-756d70136d49": {"doc_hash": "1977420b289b10b285ffa283e72861995f8d580bf0b8e07175d3278c9459145e", "ref_doc_id": "2707617b-f4f3-4996-82a9-0713064cdaa6"}, "1af01015-e8a9-4684-b600-d5aa1cb379b1": {"doc_hash": "1acc61b3dbd0360d3e75024ca9def0f21b9ce0f72fe8eab8c976900ec099cf4b", "ref_doc_id": "1a8f068a-802e-4756-bf9c-5fd772fccfe8"}, "9de5bb69-e271-4caa-80b0-2a2c5a21c2a2": {"doc_hash": "edda193ff2be919686a67ae789fa1725391540a4da09c3e559c6d918711616af", "ref_doc_id": "865919fb-e6b1-4c75-a31f-12c593829279"}, "dfc139a8-33c8-4e52-b414-59bbce40475d": {"doc_hash": "f44adafa3c318c92abbfd9d712b1e136c8e4a106c74ebf455b374350896cea77", "ref_doc_id": "900e7684-a187-4634-80a6-ea378566b7a2"}, "7e39e4d7-18f9-4c49-9455-2eb8ea80ef38": {"doc_hash": "185d641f56f2b9fbabe57b49b0d90b26de1ad6a68a3c34e3382e0f966011c694", "ref_doc_id": "900e7684-a187-4634-80a6-ea378566b7a2"}, "cdbcdf29-23ad-4f81-9580-eb1de933e417": {"doc_hash": "84a2ab863f2135fcbf5775797cd9bade2052b7597b9564797cab231717b12149", "ref_doc_id": "06f00cd4-3235-419c-8b97-af2b12125874"}, "8c0e79bf-c0fe-4664-9a1a-b79ca9785e06": {"doc_hash": "dbce0a3a39491895968ed713059f86837cdc4bf0964f48eda13081753cca11a7", "ref_doc_id": "0e4b47d9-a774-48bb-9b4c-12501018e172"}, "b46a55ab-92e7-4051-828e-fd5c56a53bf3": {"doc_hash": "01002e52491da08ae6222b68750247462edb5074f4b19d60264c859215ed3bac", "ref_doc_id": "48f508d2-1ddc-4317-9957-7fd98a03f7d0"}, "9d74f21b-eca2-49f3-a3f0-7ed25b0a43ca": {"doc_hash": "6c3192b1325a5aa8c03d4509c5247f266e4e23dfcbdd669265384ada626ea4d6", "ref_doc_id": "0c2fc187-a867-4749-bce5-de989b6f2d6f"}, "38ee5dcf-6976-4456-b42b-4dc6e1238147": {"doc_hash": "7302826d084341be20ed30ad6c5fdf8cc92833c2b591d71bf33784795cbfa2a1", "ref_doc_id": "9f98d8d1-8b4f-460b-b844-9900d87d592e"}, "0999f6fb-11e8-4b81-a703-8a9093115c4f": {"doc_hash": "bf4d24a369422db025ee6d3f72ee655546fb0aaca3330cb9c5f4310c4df577b2", "ref_doc_id": "a9e414c2-0ad2-4f86-b027-7d5464d9db35"}, "7c7167b9-515e-4057-8310-f175626727c5": {"doc_hash": "f42602de4a373f0342b2c8dc8aee9668b9d0bb8f5f0b0359e539f4bec524226c", "ref_doc_id": "38105d1e-ada4-4286-ba63-95302fd7a6cf"}, "b08f35ca-997b-4603-b100-a0d1c77b9a55": {"doc_hash": "14383ab2204c35a0e854d10b618379444d6c3db432a55dc0fa20c70a8aa21f64", "ref_doc_id": "43c55b8f-10fe-48ab-9054-bd2060453080"}, "e661668d-5cdd-4824-96b0-6b0890c63be1": {"doc_hash": "d21c0fd77156bbe7f3e7e01166da2f41710c9f2cb0c47408cb0e0f6edea095f6", "ref_doc_id": "4d0239dc-1a6b-4bf9-9057-795128282e1d"}, "cd046753-2159-428d-b8c9-725dba206a56": {"doc_hash": "eeb5ac606b50713dbf36562319165e824692f0a931e63bd36d52fa24a25022f8", "ref_doc_id": "4d0239dc-1a6b-4bf9-9057-795128282e1d"}, "1098ee4c-cc4a-4fa4-a61e-08ebb06f9859": {"doc_hash": "a4f33ce3efe0c4a7845a7d34c0121eef8121955e469150cbd736ee4b01eb23d8", "ref_doc_id": "85d58af4-3b02-4044-9918-549d94ae4597"}, "baddc56b-8c64-4068-b306-f88fcefa0ee5": {"doc_hash": "b608923e69b6a09fb04bd9392ba0ddb2da1d7f0fcd73d2ff757c38c3f80231ff", "ref_doc_id": "e4c46efc-0f35-4a29-86f1-65aef502d37c"}, "c91099d5-b81b-42c7-a721-8add5215bfb4": {"doc_hash": "b9ee00d89a1586b18f88555ffe08cc6ecb559ac98c8c764f00e21d99612edea9", "ref_doc_id": "e4c46efc-0f35-4a29-86f1-65aef502d37c"}, "369f0351-2c85-4b9b-9917-f7c937734690": {"doc_hash": "915c68692f0d5055158628ba235776ef9463c09247de03dc51e4a297f36ff73b", "ref_doc_id": "e6371965-5bfe-47d0-9767-59ab3816f25d"}, "88567eaf-e135-43b1-a9ac-99285c9b6d15": {"doc_hash": "3b87593cd2a352fcd00e2c3494f1f2f9c24c6402c1395bf34c27f650dda81dd2", "ref_doc_id": "8e172500-8da7-4265-b4fd-0e01a6b90194"}, "a6e38fcb-0a27-49d5-aab3-1efba5aa9376": {"doc_hash": "4f3dfab2b019df6b487992bf8cb9f82dd844dc3476a6dc6e17e2ab61b8f15822", "ref_doc_id": "363e1eb8-1ad6-4c2b-ab5b-d984c7e3ae18"}, "e3881d48-fff3-4801-81ba-04ef34258e2d": {"doc_hash": "891f48cd242f510501a81ce273de0b8d31795cb1df7eefef5a16501f21372480", "ref_doc_id": "483f9eee-bb1b-4dd6-a8b5-fc84080aa764"}, "4897978d-c7a1-4bd9-880c-db86c00e386e": {"doc_hash": "27f89b7448d6b8d7b835efdf11879753e10e6e30a24603dae1609f4ea8f4eca8", "ref_doc_id": "706c9d10-8f5f-40d7-bcd4-8d1954d74ccb"}, "d4fb2855-9795-4388-8c11-de2f72ff19ab": {"doc_hash": "cf47ab23941350781219ea9d79ff3db31af468d0207594a5cfd0fefb4ff0f124", "ref_doc_id": "534b29d7-3ad4-499d-8598-798ee3004ddb"}, "09d75f31-6eb3-4aff-8c9f-a78fbdabdf80": {"doc_hash": "e636ea679ef7a569c16ec2c96408d33088dcb5eb4f88a45c22374c4cda441197", "ref_doc_id": "6f0bb102-26dc-4d53-8118-ce7e5ec2e6fa"}, "497e6490-1ed1-4933-bb46-cefdbed3c66d": {"doc_hash": "00224703c80feb7cbc7b76ec1a85a39d730a19516ad1b120cbb8d86da9a94a80", "ref_doc_id": "b3b39082-bb34-46df-ab7c-515bebfd721c"}, "73965777-ae9f-4e50-a8bc-0996070aa62c": {"doc_hash": "873e5068f9d1750e616bd3455db5ce25c2c07596a1c4fa65317750ba10fd4ed4", "ref_doc_id": "5916f592-b89c-463d-aca3-16d46036741f"}, "51e1e2a1-84b4-4f0f-a244-f0b8c1dce220": {"doc_hash": "f2a338e059cc7eaf144c2cbeb21b447552e6d914e37edaa711344b8868efa569", "ref_doc_id": "9b5fa04d-bf79-4afe-b62d-d7a960e59f4e"}, "c91c3709-ca09-41d5-8cef-6a0622e55dcd": {"doc_hash": "4b8f3c6f5da13d26e2b5dc32c1da2b46d08e047f1812127ba53b67e5670795cc", "ref_doc_id": "e9466e68-19c6-4fb3-b354-f5472c997aa1"}, "f15b87a1-e498-44b4-a567-bf8b26c90bc3": {"doc_hash": "a19ea08ecf07f3c9d1ff8c5e3361dde651065bf7f37abaa900a4cd9c22d757fe", "ref_doc_id": "f3c32bbe-05d4-44cd-b05a-b02bd9d8068e"}, "fae5aab6-515f-4110-a0d2-e42bf3c11fb5": {"doc_hash": "192864d26715bc5979b7173318d5c03ce0e5d33f704056be83b6c012193c2ee0", "ref_doc_id": "93f21b34-a1a4-48c4-b494-3ac20cd1ef45"}, "79bf1dc7-78e7-4601-8dc4-5ffb469afcc3": {"doc_hash": "56ef1c219a2a1f8cfd96e9cb540fef26c73e96b569c1fc6a31fc7ff415029c7f", "ref_doc_id": "c0700c85-55a6-4343-9498-9140ce49596a"}, "2f1dfd95-94bd-4bcc-9aa0-880231d4d1e9": {"doc_hash": "7755220697242e657ed01c8a844d0452bb708cc6a83016508a06a7a733716551", "ref_doc_id": "aea93032-3dad-4e39-b175-da0f3b305434"}, "4e5a7826-a3ed-4947-9981-cc333bf0c006": {"doc_hash": "02816bdfafccfdc2232efc8533b7638e73c6da1627ec60254d2af7a7d5f2b1e5", "ref_doc_id": "a00b51d9-5ea3-448f-abf1-d7192d2d2d4b"}, "1b8de6c2-23aa-4c85-a86d-dfe7e74165f2": {"doc_hash": "3d0288751cf93bf3bbd0a9e425d6442df096a73f187c13bd4899f6e6064c73c0", "ref_doc_id": "d3247f64-6274-4438-bb74-0524b6af3641"}, "df532087-72ba-4d31-8414-073ec200d3c2": {"doc_hash": "7f406728dc2312a0943f31e80004c255a6dc24ea509a745efff2b065b8a24b68", "ref_doc_id": "ef06c418-da71-4fef-9f7c-f445ce54f8ee"}, "d7bc0c14-cd01-4d34-8cb2-a12bee562cae": {"doc_hash": "7fbb79e23290e33794b8b6d37f34e4b1a583401ca36cd9677ec0af94e3ceb124", "ref_doc_id": "a22575b0-6773-4ddb-ab69-b23a7c9af473"}, "8f27a5dc-bb16-4518-9706-835da560527b": {"doc_hash": "922b7cef5bafb40bc56598afa5615d91927defbd13ce01b6481ce164e3e13e22", "ref_doc_id": "98fe2058-5865-4ec4-a278-702605d64998"}, "eadc4862-6600-4062-87ab-3b9b7689db0a": {"doc_hash": "ff5169a9a70f543b64ba4a7c54f0a0bbc153380b588897ed31fc25e5e970c8ea", "ref_doc_id": "a8492db5-e2d5-48fa-833a-9063c0bb44bf"}, "d443a6b8-d505-4d96-910d-591bf60ab08c": {"doc_hash": "c272f092fbf4f1f3fb5ef51a638b469a749efb01f71c1fc0c6bba0454fbfe275", "ref_doc_id": "cc0e96c3-6274-43b2-a897-5247c8aad6ea"}, "8071ab23-00d2-4ed7-9c5e-a61f3f8185e8": {"doc_hash": "71d0bdcc9f43d6cafb92dd56124f1aad58e7a67383e90271d36d32917df06def", "ref_doc_id": "5a15611e-286d-4f94-a182-168bde4d2ea2"}, "ca62f555-e01e-40fe-9638-532092146784": {"doc_hash": "b5116a2df4f1190dbbc830e57c0758e96f4e4763ca33ba6bd11ee3fcfcbaf177", "ref_doc_id": "363389a7-cc41-4927-baa5-b90552a62131"}, "7a053b45-d71f-4aaa-bd21-68fba9936314": {"doc_hash": "f0fb01ceded354e5459e6f090d6089331dbbe48d1c9abe21293dce8ea18dbc81", "ref_doc_id": "655b9702-cad0-4212-8c9b-73559011b941"}, "ded2182e-77f9-4b4f-96a6-e0cea13c284e": {"doc_hash": "a4975fa1286d0b8649798b3afbe770aedcf101912ac1e2b6737cae88df816b99", "ref_doc_id": "33a76e83-b18f-4a99-b55d-322bb71774da"}, "aa0f495d-e9bc-42bb-a7d5-47ec2c2e8390": {"doc_hash": "31fa98c40d5c5881216f08b8c91e13e047fec933177b3716033604a52a0370bf", "ref_doc_id": "b8f0f2d0-0c91-43c4-8515-cfdec3f09737"}, "0c2c9a9b-e858-444e-a0a7-a0b112005eeb": {"doc_hash": "e30b3307c74009c7d041d2df069f002456b9ff84df36f8a618c9be352449931a", "ref_doc_id": "6c92f981-ed42-438a-bf4c-6bf56d956a1d"}, "ce5ea23f-709c-4be4-9e25-6b27bbb2a251": {"doc_hash": "c599068944a1a0075f94d74e3237c61489a796c8b5827a652ed43afba1938554", "ref_doc_id": "39dce267-57a0-4fb1-ac51-76f577721550"}, "db087328-49c9-4f57-9ee3-72c1e03ee1fc": {"doc_hash": "f7fb5bcd230b5c448209815bfbcc8e97a10731e3755b059d5dcc3b70599f3c19", "ref_doc_id": "b999b205-e144-4245-9107-181e5dc5abb6"}, "71fefab7-5f21-4cc5-b669-d5578ad0f891": {"doc_hash": "03afd913ac7f69fe5a05851a01cdf333387e19cc97489e808046897045e08af3", "ref_doc_id": "80ef6957-225f-4973-86c5-5f015bb439f3"}, "515cd16c-bd47-459f-b649-e1b6e319eb47": {"doc_hash": "b312c132a62df4a0ecf387db2512842e4d668ce5c882d0b856c46ec2dfc8addc", "ref_doc_id": "26f48a53-ead4-4644-b019-697d49cf85c8"}, "76587d14-cedf-4272-9cb2-aa93845f7861": {"doc_hash": "ae35f7b719a02babfbcd3e9277750e4106af3963b8d046e0be5b41a5ed5f7a42", "ref_doc_id": "abccca78-2ff9-4942-b9f3-b39cab0240ba"}, "0432597b-320d-4eab-84d1-8617b41c3bc0": {"doc_hash": "9420cbef63eacbc5c5947b5621ef8e43c14671116aedc9993ab4c4fac2c43367", "ref_doc_id": "7ae25cc6-5f07-4ef4-874a-95825f79171d"}, "a460504b-ff2a-4081-a0a2-fdadf046ca6b": {"doc_hash": "03e1cfafa33881b7662eebb5d16ac36be978993f682f382133725d1a16659879", "ref_doc_id": "1507bdbb-4cbc-493e-b123-8e16993523da"}, "65a4de50-405b-4c13-8f20-60112112a9a8": {"doc_hash": "89ba83cf2e49233a2da3bbf374cb2fced1d04fdf25b2eebe10edc1d85c74c1ec", "ref_doc_id": "fe6b3108-616a-43b0-9bd2-4596b175e8c1"}, "1d01d112-1e91-4b76-93cc-1837967f0166": {"doc_hash": "683714cb33fc9fef351a0f1eac7788feacd39f5ddc586ec48af523cd90264296", "ref_doc_id": "fb71b03f-5018-4516-bd78-44b5f932b6f4"}, "2e8bf8d5-9762-4752-b5c2-c6204a71a26e": {"doc_hash": "325d39e4e9deb53e132c913f27e316756e45b9c3e7e7d55c189d49ba49b05de1", "ref_doc_id": "fb71b03f-5018-4516-bd78-44b5f932b6f4"}, "714548f2-e984-486d-8294-c4c8847814e9": {"doc_hash": "f55238966d1acbcb00224ee59a9dc353b011a9c41d809c4a8502c96f56111b42", "ref_doc_id": "c02786c3-e1cb-46bc-9780-4a425a99c063"}, "6a31c926-9a66-4e21-b50a-096748e2e86a": {"doc_hash": "9cedfc9d17b361011b307307fc6f682b4fdc6dab6b60ea7e1f1ae9d353a8532e", "ref_doc_id": "c40f7665-4cd4-4afc-bfec-d6af3452c3cc"}, "8eb3c645-2a60-4047-b445-d26cd87ed486": {"doc_hash": "31dbe8c24f52064494316b48cbc0b900d718e59c9b157ab017f3f66c9d46dedb", "ref_doc_id": "c40f7665-4cd4-4afc-bfec-d6af3452c3cc"}, "5d625c9d-a782-43c7-8e7a-b50d1dd396af": {"doc_hash": "3573495763ab64a0072356225dc3556a379745cecda7d5f44d4d2bf5c2885930", "ref_doc_id": "fce8dc94-f1eb-4132-be4e-22cce801620e"}, "47b79629-7d7e-4d81-907d-f1058f199cc5": {"doc_hash": "815c67048675b025b86dbaa913b3c64a870b87d1437256cc39a4ffc313a5b56c", "ref_doc_id": "6fc149aa-c829-4482-b779-0f9aea27357b"}, "66cd5319-fa32-41da-a606-1844b15b8e67": {"doc_hash": "8975a2680112c1d60f64e29962348830a6643c91ba1e8e49a4c6baf31dfee2bb", "ref_doc_id": "ab0e4de8-321c-4733-af3a-5eae30cfe581"}, "075b3b31-93dd-460c-bf5f-6d6aa56bbda9": {"doc_hash": "35265aaac933dff93b8eb9ad014d908eace97afbd1358490aaaabd19e8730675", "ref_doc_id": "ab0e4de8-321c-4733-af3a-5eae30cfe581"}, "d68ecb37-d7a8-4b80-9569-3e9260496f62": {"doc_hash": "cdd13fd085dad0d7b51599d100b5696b95f852e365f85d267cfb01ec813dd6d4", "ref_doc_id": "3ae57e02-320a-452e-93c4-fdd7d303e773"}, "b1ce24d4-aa5f-4ebf-96a3-6a94fa983f2b": {"doc_hash": "1e1b30908e660bed78e504d829673bcaac1d0d7ab159c07bc664dcc96f024a6d", "ref_doc_id": "3ae57e02-320a-452e-93c4-fdd7d303e773"}, "e60d60ff-1cb0-476d-9251-c41b6a0016d7": {"doc_hash": "e2c5ee48e2e421c6c1fc902115fab16c1a1e6510ace3e3567f58ec73ecd45d9e", "ref_doc_id": "3ae57e02-320a-452e-93c4-fdd7d303e773"}, "dc913588-6fa4-4b63-82fe-638a6c62b661": {"doc_hash": "ceaad27286190c08457235c346c5903f8d3000ed646ab6c2cdb8bcf341e97283", "ref_doc_id": "3ae57e02-320a-452e-93c4-fdd7d303e773"}, "fabd3392-dc0a-430e-b01e-af8c62102ead": {"doc_hash": "a6e4d12cbded543885bcbc4381eb4fb91814145deb18c837c73466af990194d0", "ref_doc_id": "3940fa73-df36-4c12-ac50-d8eeb5b80b07"}, "71cde287-8a10-4ff9-a726-242eff8874a5": {"doc_hash": "9eaa1d21831014ed035446aed2f4600400bfcda3462013f369394a20ce451581", "ref_doc_id": "349a13db-2381-4ea4-b093-f882978006d5"}, "e17bbb93-259c-4fc1-8bb3-0c21fe858b69": {"doc_hash": "82537401d6005c4bff7bcacfa866bafd972f1dd076968caba4604c502a33e2c0", "ref_doc_id": "349a13db-2381-4ea4-b093-f882978006d5"}, "25f2c40a-3b24-4c47-83f8-d60f86e55a12": {"doc_hash": "1ac618971c9a01b78926fdd6b53804b0d1a9b8eeb284ba8d616c37f6df3bc0a5", "ref_doc_id": "d5b7f9bd-c988-4ad1-a3c2-0bf105a1c0ee"}, "d16f899c-3ca5-45a6-b8c2-019a8fa6580b": {"doc_hash": "f01b41f8be889520b0a8892720ec3e8d5f29f1c639fcb36e3a7ee1447cdef4af", "ref_doc_id": "d5b7f9bd-c988-4ad1-a3c2-0bf105a1c0ee"}, "f9f78d36-11b6-4d59-8693-eb1dc862091c": {"doc_hash": "09c2a65282b5650e481c1c308726ef064b56a28928789b603e05f6d2d710d595", "ref_doc_id": "035a0d1f-18d5-423e-a9b7-ee78ba2be488"}, "3fb203e3-7841-4564-ac7d-8e06dd9c751c": {"doc_hash": "ef0789f9f345431eac036e1ab4689d478f9e390af0ceec79da8ba12004522c5e", "ref_doc_id": "035a0d1f-18d5-423e-a9b7-ee78ba2be488"}, "a7265232-49b2-45de-af78-14a9bc213cf8": {"doc_hash": "76da35456e7a9dcc037cdd861c86e0b8a368614b4dbd1fc02e408a63e7e9bf38", "ref_doc_id": "8cdcef1e-40b7-41a6-b303-f17a8fd785e7"}, "df41fe27-1008-4cd7-ace6-39214a032696": {"doc_hash": "18d5cd610d1966b560dac40f54f35b10ae43bbc1cf8d555d2d67e59d9c99b0c7", "ref_doc_id": "6fa5849b-43eb-44b2-b32a-bb68edeaba16"}, "d5fe4d38-8210-4adc-aed5-7605e096ed9a": {"doc_hash": "112dd9e5a7d0fe515d267f9d7f4d8caa941ce81d069d56c66e12224becc4e7a3", "ref_doc_id": "c5816b76-96d2-4e10-8bf4-4e39d5b65e8f"}, "88de8c8f-9fbf-4dc7-a7f1-d6450bb818dd": {"doc_hash": "e8eaa1526569a59140cedb7e5418c6c006ced8856db1c3db431e31cff35c33ba", "ref_doc_id": "c5816b76-96d2-4e10-8bf4-4e39d5b65e8f"}, "88ccce6e-b750-42c6-8219-c1ca56019a96": {"doc_hash": "d103dc12088aefcfb87e9133a1cf8c07e1b807276707c8c93cdec268b4237c25", "ref_doc_id": "21922845-92f7-4b0b-9a68-565b4698a080"}, "a696c461-b9d5-4700-885f-7c0a261d29a4": {"doc_hash": "db64bf166afc08e4a92380906121b58b4721e6dc621e6d06fd55c67f0bdd9ad8", "ref_doc_id": "21922845-92f7-4b0b-9a68-565b4698a080"}, "1c48043f-2b2d-4c05-bf46-ecb25c7de621": {"doc_hash": "f7ef97d4621609f7d02b8c8e77bddde5051545623b4a8fe210c583fe77999c36", "ref_doc_id": "db116fb9-dbdf-4caf-a9e7-41830ec22cd7"}, "2a2c3453-2be4-4058-a91f-168c1e73e4a3": {"doc_hash": "778040d6170b74b548758f02b1d0b735a9a5fdf3da22f4cd64ef1b59a8bd59bb", "ref_doc_id": "db116fb9-dbdf-4caf-a9e7-41830ec22cd7"}, "1ec4f19e-06bf-4ae4-b452-0538f409061a": {"doc_hash": "eca35b03ee81f1db975f3ddd27e428cb8d1912a168231557d933ddd862a58267", "ref_doc_id": "5837ff70-24ca-44c6-8fe1-5781c60ab4a4"}, "1fdd53db-e9b6-484a-ab14-0a483d2cb0e3": {"doc_hash": "58e042cdc96828b51b69393701baa32b6a6f5a32b8629585c56b9ad25217591d", "ref_doc_id": "5837ff70-24ca-44c6-8fe1-5781c60ab4a4"}, "be259450-aec9-4e34-aa9a-2bbcb2bc03a5": {"doc_hash": "962f983c0138c554dee553c197ee4cef7c1d4a4a4809941e7289a11ad4724b3d", "ref_doc_id": "6408426f-40e8-4fbb-afcf-d90b4b419a1f"}, "47c01386-5879-48ed-a39b-70a263ea3222": {"doc_hash": "658e83a756a6cea052f35e347f16195e9c063c3e4274b3e7d67bc9bf418ea884", "ref_doc_id": "6408426f-40e8-4fbb-afcf-d90b4b419a1f"}, "973447f0-7edf-497d-80f4-27f6da1dbe8e": {"doc_hash": "3105931f460e06cfc618e55736e5746c2d18306ba9d531cb48384adf03cc9d54", "ref_doc_id": "1f5e5fb4-4ef3-40d3-beba-01b553677604"}, "0a58930e-29c2-474b-882a-283d5d830df4": {"doc_hash": "438eaa9f772d49f0484d7bbce1b7c4e99978e2a63efb71c20d80e75f55d78ff0", "ref_doc_id": "1f5e5fb4-4ef3-40d3-beba-01b553677604"}, "b6005d89-68ab-4eb2-8c65-493f7a2a7a32": {"doc_hash": "05d3ab26aaefde9b5a7dcf6f697fdb0f35171a91b8c05a3d49a57548f4e09ffa", "ref_doc_id": "56775138-d8d7-4bdc-9f96-5e87129bdbbd"}, "381a11a1-bb4b-4be4-b4a0-387a80331ac2": {"doc_hash": "80288e6ab561f8ea6c5406252a922aa868d20ee458cba2e74802c9ccb533daa8", "ref_doc_id": "eb34050c-8cda-444f-8acc-288aee6129cd"}, "3d024a8e-daca-444b-8d18-aec7dc7aee5e": {"doc_hash": "3873b6995665e5d05f566508cf9cedd35cdf85fc1b09dffc395701623aebbca3", "ref_doc_id": "fb8b7439-dcbd-44ea-95a6-2a3a1ac65cbf"}, "eb38e7a3-760b-48b5-babb-c6ccaf6cedea": {"doc_hash": "3facf427fcc524b838bea63085fcaf894d2ff0f330b835f800a6898b214dd433", "ref_doc_id": "fb8b7439-dcbd-44ea-95a6-2a3a1ac65cbf"}, "5937fddf-7c87-44dc-8461-353fa0d80c4c": {"doc_hash": "4746526c6f4c7278458352ff10537d215ae9d6dcba3cb96646d6805c1811aa42", "ref_doc_id": "cc99a405-53cf-4854-b5d1-80c3dc9ee1bc"}, "ab791cfd-3ce7-4422-a34f-5ec98bf49597": {"doc_hash": "679d05613c78efd92c993add3903ea36b2ec4c10ea78a9305f934dfa5ecff3df", "ref_doc_id": "cc99a405-53cf-4854-b5d1-80c3dc9ee1bc"}, "703118b6-256b-465b-9471-fc92def9d512": {"doc_hash": "d0430192bd6b7cb788253b49ef7fed57442c534cc4583f4993369eebd7596ed6", "ref_doc_id": "51259645-995b-4f02-8a10-e641385258e3"}, "fc6ef00f-e8df-4241-be1d-648eb49f53b3": {"doc_hash": "82355cbf8790e79bc9683850c3f40022968428703fe0679436955bef7edaa1cb", "ref_doc_id": "51259645-995b-4f02-8a10-e641385258e3"}, "728620d4-351f-4adb-879e-5949fe76f6f8": {"doc_hash": "77da86328661e660c896698c00b4e7345f3b1eb71c1b23d808a417bc9e4c064d", "ref_doc_id": "dfcc96b8-71bd-4664-9e94-dce152098c4a"}, "b0026f6a-75ba-4e8b-b580-bc88925d8551": {"doc_hash": "f63bee528f4949a048a3ba74483923ed53c4ae64a9a5cfe11efc28df4a916352", "ref_doc_id": "dfcc96b8-71bd-4664-9e94-dce152098c4a"}, "97ed69eb-4cd3-46f4-ad83-66fabbd6d505": {"doc_hash": "28dc5a5ca44628b589b0502c0f8c92c00937a5c8d56eb194cebec2b2f5311ad1", "ref_doc_id": "7fb21985-2a3c-41fa-9439-59933388b7ab"}, "6cff8427-ced7-41a3-aa0c-0400639c6612": {"doc_hash": "2d39c001bc4c7086b4ef6dfb834c54b90163a5d611ecfebdfc94115cf8e65be9", "ref_doc_id": "7fb21985-2a3c-41fa-9439-59933388b7ab"}, "5bd05fc3-ec6f-4f70-8aa2-45f1543036ff": {"doc_hash": "ce8c045fdb09fc722c9d59c219207bbf979a1dfcad85be2e0fd9b0233df6366f", "ref_doc_id": "f56d4435-5b05-4b84-b39b-5d9f48e61593"}, "2107cd9f-a41e-455d-9f68-83269e72e446": {"doc_hash": "6ffc551533cc1b410f79e22eee7fa3130512b12d9dc9f9e175864a7758aaa7e3", "ref_doc_id": "f56d4435-5b05-4b84-b39b-5d9f48e61593"}, "723dc5de-91b4-4edb-8a0b-f5a949c4587f": {"doc_hash": "ab265ea6e358e904cc402ed4088f92e837671fd4656deed839133fb290e67d2c", "ref_doc_id": "09b84246-9dd9-4beb-a27d-959ce1ff617b"}, "ed45b48b-5eb1-4ef0-97f8-14f42b9b2301": {"doc_hash": "120b35fe5faddbefb93fd8ebb5b2886dc3b76d076d3a9840b4f62a3c25c6c67a", "ref_doc_id": "5480768c-287f-4c19-86b8-b3787f4e8bdd"}, "fd729b2d-039a-411f-9fe2-62aa14c34989": {"doc_hash": "45dba05742b158e29dbeaf5dbfa6925907c9b475729067c392ebaa1ff6b00a65", "ref_doc_id": "2e614534-c2cb-4295-9518-283e94b93ab8"}, "4a398e6a-65f2-4989-93b4-cf17b1f6a18e": {"doc_hash": "ef8d419078dfce5bb53008682ef4eb4ea29104b03de786fc28b71c9177381081", "ref_doc_id": "768cdfe1-e04f-4f94-869b-289d45bcf568"}, "5ab1634d-f527-41cb-bd3c-e6aebac333e2": {"doc_hash": "fa7d07f20b4baac91fbf5586f9cf668f72bfc148e9e8a0f4f672a365cd7d2c84", "ref_doc_id": "768cdfe1-e04f-4f94-869b-289d45bcf568"}, "d601492b-411f-4d54-b637-5cf886d720c2": {"doc_hash": "166eaf34af7b8b62ee68f09633956848e0d7fdf326d9596026434003a8a3c087", "ref_doc_id": "b66dc964-d18a-475b-b8ae-e29a58bf9a44"}, "6ecadc27-9ad7-4d09-9484-cc2fc61be463": {"doc_hash": "e553e1db660dc3426cfac0cd9003a4e8b5afd1e43ffb985250fe7199005447d0", "ref_doc_id": "b66dc964-d18a-475b-b8ae-e29a58bf9a44"}, "c3dc768d-c408-432b-bdaf-cf5a60a936ca": {"doc_hash": "a1ef01f373d130dacfd46a28ecb9f87d7ebf314a70400aaaebfd3e829f0c0da9", "ref_doc_id": "8e4cc579-deef-4b4f-89a0-0d01946d0015"}, "983507b7-e8f3-4eca-8039-8e3f1376ebc8": {"doc_hash": "cd6a8bdaa219af2e215bd010415e80cf666c5815b776feabc68c65f9894333d8", "ref_doc_id": "8e4cc579-deef-4b4f-89a0-0d01946d0015"}, "20e6c4b6-392d-4344-b798-00ac774d1b48": {"doc_hash": "d8796651d071d1a5c4549efde1ee6b00e2c54c85fb6f8850078c6f5ad99d2ed1", "ref_doc_id": "3f20f726-b6b3-4128-a98d-ee247064acb1"}, "e033d6c5-dfef-45ed-8160-3550aa0c8c16": {"doc_hash": "9194ae94a3a5e71ec0e75730daf7bd8635c8472eb8aa5a9b7e2e9170ac471e47", "ref_doc_id": "3f20f726-b6b3-4128-a98d-ee247064acb1"}, "4a9166df-b4ee-4776-8277-37b1d4ccbe63": {"doc_hash": "e6cb47b9ac7bd20d5b156add6cc9afe608a02b5921e515eb83be170bb8c686e7", "ref_doc_id": "709e5466-b7a0-4723-bfcc-64330017e4b5"}, "3c8f7695-ed1f-4324-b36c-4c93079b0c82": {"doc_hash": "df4baf1666578957536915edc49e277884c9ebf52c250cbed2d8ff34f36c4854", "ref_doc_id": "709e5466-b7a0-4723-bfcc-64330017e4b5"}, "78538c2a-21c1-4485-ada3-26b84cc54f53": {"doc_hash": "4854352bcf2ce435326644efa19dac0e5c201f101ff064933eb52884c2f173d1", "ref_doc_id": "63ea3d6e-79bd-4be6-8772-2f712e8f113b"}, "391e091f-c15c-4c9a-aa30-31aeebc95b76": {"doc_hash": "ab8e302ff66ff7dfa0ac2c485cbfee5ad9f5966d590375639603210a5913ca94", "ref_doc_id": "63ea3d6e-79bd-4be6-8772-2f712e8f113b"}, "940814c5-8250-4d0a-826c-117acba7eae2": {"doc_hash": "e42ad8cfea5fe8d16482e252cb2f5e28472cdd8ea95771881e84c2f3c18fcb2e", "ref_doc_id": "92bf2e05-3654-4dcf-899e-375b80e8a29d"}, "908902d5-d79d-407e-817c-23f5ca168827": {"doc_hash": "3748f131c466a1a14391445839bc8dad87736a550763344d6e15437c0771495c", "ref_doc_id": "92bf2e05-3654-4dcf-899e-375b80e8a29d"}, "8188bafd-ffbb-4990-83d2-378eac86c42f": {"doc_hash": "ecf1805d00aba853d9b0cc3def4c8d828f5762de351c2be35deef5bfaea718d0", "ref_doc_id": "6343b313-1d0c-430a-ba16-ee3cda232e1c"}, "3d0d4905-7317-4170-8da8-4e01851fbaac": {"doc_hash": "12b9e5f6c2c3302ed9449ad6bea342d3c13bf90f26b3cfc87b5d1e819fcfb26a", "ref_doc_id": "5fe73d90-810c-4f11-b0be-32f5ba5bf25e"}, "016e2b9f-6077-4929-8b98-ff7c6ffcd3eb": {"doc_hash": "4bc0207e2426893613017db572f3b9660c7397da9c29df6f8d59b73d3a47c69c", "ref_doc_id": "5fe73d90-810c-4f11-b0be-32f5ba5bf25e"}, "610f6d17-09b3-4bd6-a083-272923bd4a27": {"doc_hash": "76f639631db6d4b2265599a9dcafbf3b5a8aaafeacec54aedfe82a30a1106cb0", "ref_doc_id": "7f69f97d-1b49-4ebe-b5b1-9df587747952"}, "d71c3e4f-9694-45fb-8f08-499f7bbe305a": {"doc_hash": "7c33b8fb4dbe6f7fa6edac01b1839c7c8719f4afdfaea7c092c7be76a99ab363", "ref_doc_id": "7f69f97d-1b49-4ebe-b5b1-9df587747952"}, "bc6054f9-173a-4a32-9b2c-7445962c8cbd": {"doc_hash": "a40a1c8cd200d94ef0dea16d5f2c5a0429157eda7f05e0d038f1e67cdb8e5027", "ref_doc_id": "aeb9eaa1-4ca4-458e-b00f-109d950c9113"}, "eb7dcbd6-4b1c-400f-8613-186616908a45": {"doc_hash": "ef29f069a51726ca6dabb665f73a0b6092f6c5411146b5318ffb0a456a08d7d3", "ref_doc_id": "6bfed05e-5bad-4e23-afc4-60b12f30e1b7"}, "dca62519-9b42-497e-ab14-ba6ce95bb0b3": {"doc_hash": "d5d234d0ff0d0330f085df992ce27001a2ff1d05133b939ba5259db0a83b6c79", "ref_doc_id": "c52b90a9-fcbe-4026-9ee1-adc00645fd88"}, "81e39c90-0469-4853-afdc-9bea3e11d3de": {"doc_hash": "ac28e580d3a4a1236269797709531bb83a893b5699e77506e706580e63ef1c90", "ref_doc_id": "c52b90a9-fcbe-4026-9ee1-adc00645fd88"}, "d0b0793e-88f9-4f4a-ac42-95fc26788971": {"doc_hash": "54ae0d94310e2ca4c51c8e705f98d71ebf4312a3496342a8c85dcea9d582496e", "ref_doc_id": "a3745c4c-2e2e-44ef-8290-168409046fc7"}, "19c763a1-eb5c-40b7-b2df-0cba459a44f6": {"doc_hash": "f6fc71d31158360e2a0219f5de08b65362a90e70d609c9565adb7c9566fdedab", "ref_doc_id": "a3745c4c-2e2e-44ef-8290-168409046fc7"}, "a081cf28-ac17-41bd-939d-4e0f91718678": {"doc_hash": "416bac9eb9ec1218b185ffde1162d5471f8f8e73eb737d7e2eac4a8c7a340c5f", "ref_doc_id": "a3745c4c-2e2e-44ef-8290-168409046fc7"}, "351f0b12-1d68-4094-946a-f0e593fd0c1f": {"doc_hash": "57e8b10c981fa964ea2db27196c9368b1652610a572b144c0bdbe2e0bc1a09ce", "ref_doc_id": "f0aae6a7-1a78-4f55-9ce4-44e6e43fd70c"}, "f98cd470-7b07-4ea9-90d4-2d6238c700d6": {"doc_hash": "e1eccc0a02804de2a74194d71e057f3fc6a6bdfe762e75a3b2c1bbabbacbb881", "ref_doc_id": "9462f033-4b95-46c4-9dd5-8b57c1cda3ec"}, "74088410-1373-49fc-b5a8-7ad1a5799bf4": {"doc_hash": "9da49c3a7df733f85bc25989e24fefa4f6c04da54049a14de0bc5ebdc56e04c2", "ref_doc_id": "54019822-f97c-4b6b-8a63-f536088a96d5"}, "94d6ca21-e99d-4e2e-ad30-6d6925b1f369": {"doc_hash": "03d7f2323b9f1bb72a6a538171efdf24424fb7bf2e246f3327999afc8d51c14e", "ref_doc_id": "54019822-f97c-4b6b-8a63-f536088a96d5"}, "d92d1a3c-a38b-4943-8082-0655295b6a3b": {"doc_hash": "e14ff1e58b8575250335d1ca1dd2be470cef67d2d2f23f05c564be7ec1c78d45", "ref_doc_id": "92fee59f-3be9-445a-97ee-b7879139f00b"}, "de62119d-d3e6-4a79-ba85-20927bf33dfc": {"doc_hash": "6e09f69a728adb724efa35ad54a0d7ca55953e69ea51824e4b697697c1dcbc26", "ref_doc_id": "92fee59f-3be9-445a-97ee-b7879139f00b"}, "e43e550c-7c64-424d-a5d0-7418e7244f14": {"doc_hash": "571599d67bfb38159a601eb6454f4cd44495f69bc30d0e8f04ecf547651c614f", "ref_doc_id": "92fee59f-3be9-445a-97ee-b7879139f00b"}, "95c9e048-42ce-4e47-86a2-3a7f232d5347": {"doc_hash": "e95db0f23c11e051462f82b331551856d991c701ec3711471846d0e9769ba7ff", "ref_doc_id": "c11c9312-bd47-4e2a-abe0-d66cf1405f29"}, "bf4125f4-d8f1-4b70-a7ff-0c64ed1a5fde": {"doc_hash": "0fe6efd85a4179fdf913a469446babed82f9de6a42dd69150c52b9f5c83a5875", "ref_doc_id": "c11c9312-bd47-4e2a-abe0-d66cf1405f29"}, "50a5a480-ae11-485e-ad7e-47aa19d95039": {"doc_hash": "6575a4612adb53ef227909cddd27fe1a94c25e347809e283d65f4dbde952a1e8", "ref_doc_id": "e9dc1e80-2ec4-4a1f-8b91-02fc9fe5501d"}, "257cae56-1a2c-47f2-b656-ad36404a5070": {"doc_hash": "be06ccd92652c34c6241ea0513ee1f0906a04b11233617e78a8491b52f7e6295", "ref_doc_id": "e9dc1e80-2ec4-4a1f-8b91-02fc9fe5501d"}, "a6dccf91-e425-482e-a821-de5ddc407696": {"doc_hash": "d823fb85c0e7c9d7971b9ad6376276f1aac302343674d307052fc0865446b741", "ref_doc_id": "f3f07b7b-a491-40bb-9c9d-4f66d4441eb6"}, "02b91b62-c8a9-46bc-9b76-f85dea6889ab": {"doc_hash": "c618fb9f186e0a2b5faf8da72ed85dc0c8e99fcbfdec24c10517a4c318dcca90", "ref_doc_id": "d94e24f1-4e7a-4adb-af4c-589947368d23"}, "862c25f6-832b-44cb-8b26-18036d960898": {"doc_hash": "ddad303de12ea29846e5567cef4081e50a9142d6016954e8d1c3666a67894df6", "ref_doc_id": "d94e24f1-4e7a-4adb-af4c-589947368d23"}, "03948ff2-e987-4066-8693-093b8855f380": {"doc_hash": "50d1aa7ee96c3b484343245e6f5eb3e6112c62731165fb96d315944c65b9acf1", "ref_doc_id": "ed66a7fd-1c76-455d-a419-0dc3f4f0e288"}, "2f7e4304-4ba9-4d8c-96f6-b4a2bab3a670": {"doc_hash": "f2e2fa4e94d251c2fe0811023ed05839710cab4f20813fa834baeb2f181465fe", "ref_doc_id": "ed66a7fd-1c76-455d-a419-0dc3f4f0e288"}, "404fe7e3-0a0e-4372-bf99-1f517afe7297": {"doc_hash": "f6593b4db1e081a45646c25b00cf7388cd40d44c2ad3e0625805df1f4c6eacd3", "ref_doc_id": "7599d2fd-8a00-492c-8a43-54bc8ab6a02d"}, "990fb0a7-6f29-4823-a0c8-081929a22106": {"doc_hash": "810560deee81e56ea7aeda946c8fbf7c8f8c367b540ee394e66589d7ab0f005c", "ref_doc_id": "b6d1f9e0-3fd2-4e04-a803-9e696a2a0b6f"}, "af76fee2-df75-4ba9-8988-8b5f6ad734b7": {"doc_hash": "ce826537f10355262d16177c839889edba032ed61f29ea15e495b4454d88460a", "ref_doc_id": "b6d1f9e0-3fd2-4e04-a803-9e696a2a0b6f"}, "14e49c6e-ff3d-4de0-8a0c-01aeb1f6f3c6": {"doc_hash": "460ee4ec335dff188c5717af76790aa6637b95d70b21d570fc4830ca3f218065", "ref_doc_id": "bbff61b3-7661-40d1-bc36-bb958fddf2e0"}, "35e5cfc5-20cc-4915-9e24-f348cfc1719b": {"doc_hash": "09019a6e4cf250b91c7327cbfa87bf7ef30cd4081f27c39fc0aeeaf4dffc938c", "ref_doc_id": "bbff61b3-7661-40d1-bc36-bb958fddf2e0"}, "28682727-e7f5-4fcb-a694-320ce7a127ca": {"doc_hash": "7b6a3e89fb1184544f64b18e6c66b253b9998bf44995216cd028f5627950aa13", "ref_doc_id": "62dd9a70-96cc-4c16-bd47-a2673523fa79"}, "49df9570-f175-446b-ba5a-0ba18f2e11eb": {"doc_hash": "ceda1afce3f058743e612dedcb619feb2ec1505df789e6ec7795941d7234af61", "ref_doc_id": "9403a91f-f25b-4218-9f1f-847bc2c98097"}, "49e813e7-8203-4b2a-8b34-a64c9e350c25": {"doc_hash": "f8085e55cf25bc6f2f5388711bb791281c11bc0978781970e66824e09f34d647", "ref_doc_id": "de1db3f9-977c-460c-9185-896896b0292f"}, "d135f1e3-90b4-40af-9dd9-b100b60510bd": {"doc_hash": "10062629ca10f04ebd98c3c06b0a60a796fa7c4b30cc65ed07e3e77de3cd0304", "ref_doc_id": "45531ce7-4604-45b4-b34d-c37333dd6245"}, "344c5fdf-074e-435f-bbbc-859254826ae8": {"doc_hash": "1dfcca8ba5addeb777cbf6755b41f9da1db7b606e18f8112d0ec54fdc6a52259", "ref_doc_id": "6bdec29f-42fa-4b0a-8391-2b1523ad2eef"}, "01bf3547-2eee-403a-b3aa-d84a3afa4178": {"doc_hash": "be00b565104bceba6441153b5e38e265d9a83bef3fe91d1e0c8af22e777dd652", "ref_doc_id": "6bdec29f-42fa-4b0a-8391-2b1523ad2eef"}, "e38e56ba-7633-4a53-9545-eec6eb530778": {"doc_hash": "9a20166a34e27d1d722200e29b2f070826202eccf7fad2bfcc7d4729ab91c0a5", "ref_doc_id": "a651d5d3-ac2c-4a3c-aa9a-e71665b1505e"}, "e361b83e-9c4c-4727-bea9-7d3d48e3ffa4": {"doc_hash": "ef0673336eb53a8d4fd6d9c2a769a55e035c6bc8431428dffb5c62b06e9c5fcd", "ref_doc_id": "a651d5d3-ac2c-4a3c-aa9a-e71665b1505e"}, "3e0159c2-cb80-4326-9ab9-ceee85fae64a": {"doc_hash": "6db191499bbe5dc143083e9249cb6b4ce5dd836d9bb622468673a1e771c64b7c", "ref_doc_id": "b0259191-7df7-40bc-bfc4-929bf92e09be"}, "ac7a54a0-1e58-42d5-bb71-2496aa62934f": {"doc_hash": "a391817e0b6ce37d0515c18e868b8ed3de09c059028986e2fe2548ec2f0b420c", "ref_doc_id": "b0259191-7df7-40bc-bfc4-929bf92e09be"}, "6911d3be-94c5-471d-b258-0353043a2eec": {"doc_hash": "2ec6353d18f2841d2cb7ed6b2b5b2014d794fe8da2bae8ccf6cf8f27eb6e9946", "ref_doc_id": "97606e30-6cb6-4638-bd4f-44d732959551"}, "28a66f32-6740-4c9a-ad58-215e23206741": {"doc_hash": "fefb514627b6777948ff7d2ed14376ff662c7ec1a4d338b3f620fb85c754f577", "ref_doc_id": "97606e30-6cb6-4638-bd4f-44d732959551"}, "67062cb8-d337-4168-bb10-2cdad0cf2913": {"doc_hash": "df023426f8b9afb1f61c158d2c75573d20b432e8cf11f5f18600b1e457f9eaa7", "ref_doc_id": "314ee1c2-8961-40f3-8fc6-b023dde21d3e"}, "b6c7efa0-7f7b-479e-9247-5bc871cb4a40": {"doc_hash": "30695b26739ff8b9e717188eddd81112e20819510f613eb15c4ffd092d78d7af", "ref_doc_id": "98ef12a0-1d70-4570-94fb-44fa17d8cc52"}, "be7725eb-ee1d-40ce-a5e2-e8b0be237353": {"doc_hash": "8cd2b7814dff20f9f0af7bd53b1776352129acc8d767b232d20b91e58072815b", "ref_doc_id": "98ef12a0-1d70-4570-94fb-44fa17d8cc52"}, "907fb015-c204-4da5-aad2-4bfb7a82757f": {"doc_hash": "4b3c26b6681e07e2008683ac453ae849bbc81187cff616108dd7871e85d0337f", "ref_doc_id": "fd21b16e-df81-40d5-bed7-6c2fe358c691"}, "cdbb6fc1-c11d-4cd9-9ed0-39209b9d3d44": {"doc_hash": "ac3dcd955275e59454e586c4b1af7ffd99abec513e7da7c841e12e953f4538e7", "ref_doc_id": "02b5bbd0-2b23-427f-be27-6102fb479af6"}, "653f7390-dba3-451b-b1c9-4376f61ae1c3": {"doc_hash": "5aa2ab37f583e39fce47082d7cdfec061171dd33f808870e3504731972cfbe2d", "ref_doc_id": "02b5bbd0-2b23-427f-be27-6102fb479af6"}, "f9813d9a-9cb7-41b7-9cca-e9ef07f488ad": {"doc_hash": "c289fd6ba5282d64e05344a37386022ab2a1fd989bb83bb8f6a2f6df6ae7d691", "ref_doc_id": "33befe0e-2f00-4148-a7ae-f887c8c49d53"}, "ade98854-ef0a-4f0c-ba3b-2f057c5bf8be": {"doc_hash": "6d5a3c2af76afbf9076ad4a6dc9e0187557167cdba4088e662e45182d96aaccb", "ref_doc_id": "33befe0e-2f00-4148-a7ae-f887c8c49d53"}, "425114d5-9e8f-44f0-9cc8-873317c3cbe1": {"doc_hash": "aa159b2ba3ca739749606c08259ed2d0f734d9d0507c1b8e490bc56df1d70208", "ref_doc_id": "236b607b-3370-4cb2-85db-8115efc9f614"}, "e9973750-2a6d-418e-8a75-870c6ebc8b90": {"doc_hash": "51f709a3be7f73b5bd4dd6f91d9f9ced073a8f1bf1f1fda2447831cbf822d2f0", "ref_doc_id": "236b607b-3370-4cb2-85db-8115efc9f614"}, "8fda0991-4276-4ad7-8bae-b923347ceb0f": {"doc_hash": "931c54cd30cfe7b95e07c7522557c30fc1847aefbc54a582d55c843b702285cd", "ref_doc_id": "b294b949-7894-4967-9bf7-a108adea1a9b"}, "e739ef30-79aa-4070-91e5-f441bf447b73": {"doc_hash": "e577e3bbe570755dc37e7e70cc7210cd50a752998016544f5aad88e65f6a4b91", "ref_doc_id": "b294b949-7894-4967-9bf7-a108adea1a9b"}, "36bdbc73-3ef1-4335-8e05-f818fd151e83": {"doc_hash": "b61a216bc88819f6354b4a237853d377d50c8e7868d622cd66e5ee5872a57aa4", "ref_doc_id": "9bc5d05e-bdf4-480d-9d17-94e59543ab04"}, "e81417f3-5945-449a-ad1c-b33e540a7799": {"doc_hash": "d760cfe7c89f9034c8396d922540be2919e7b395bd9b192183f52c728c090189", "ref_doc_id": "2c254d85-2947-4aaa-a7c6-77bc40f88383"}, "1b13e3c3-36d0-46f1-92cc-f4e5b7ef1335": {"doc_hash": "9fa4a36d9bbef997772935e2fed41fdda5a12e96bb79acc850e1b4c8be6cdaef", "ref_doc_id": "7508808c-84cc-4266-9c85-28a0b2536be8"}, "9886289b-cf8b-47f7-9a31-9579e6be0afd": {"doc_hash": "4e7499dd86e4a93562dc54d584c833929dc2b6850fe285bd5aa68461a93265ba", "ref_doc_id": "7508808c-84cc-4266-9c85-28a0b2536be8"}, "fb593958-d6e2-4ed2-ba8e-54f915e7ff14": {"doc_hash": "7967a314225082ab9cb0107e4da2eb23dadd5ac50d6c565d07ee4089d33dddd8", "ref_doc_id": "b9aa4c94-93b3-4fac-9ab0-efd44e9534d0"}, "9880e4c1-0f71-4712-96e8-86c722c0d1ed": {"doc_hash": "9ce95539d2ccba94840471e39c0559297c32701a16c21186e7cf37b2703abb94", "ref_doc_id": "0d56cc63-58fe-4e1f-bad2-40a348fc10f6"}, "ccddd486-4eb8-403f-922c-e012811b9025": {"doc_hash": "55b78387471a884d91f983fa3a51c6bca75a61378a001d5428a8d25bde7c5d9e", "ref_doc_id": "f7fb7d50-71b5-4197-9b2e-afa11903fc62"}, "b4631fe8-16eb-4e21-ae23-0750d18ca60b": {"doc_hash": "b1e521aab99edc6969909d879686633320ea07c4a569ae693db149f6e1ff74cf", "ref_doc_id": "f7fb7d50-71b5-4197-9b2e-afa11903fc62"}, "9516df09-b3f9-4f97-9de2-01056e6a8dfe": {"doc_hash": "12932f69ff5ac24ef5063621a2ed103f9ebd4b90b848cf2d393dcc177d41c4d4", "ref_doc_id": "c521f649-596f-42d1-9176-ca2684d23122"}, "eeaec2c2-1720-4b81-9c45-a8ab1b8cd1ce": {"doc_hash": "9547c8225e81f2273193dbd9cb6d2808ce00368a727186a01f7ef8fe5ee48d0c", "ref_doc_id": "c521f649-596f-42d1-9176-ca2684d23122"}, "0be6665f-bf00-4ebe-ade1-a55286506a3a": {"doc_hash": "c51b3841796ce320f2560dad47fe0961a41845e892b1bbec09d4c9ce17dec99b", "ref_doc_id": "2327ed29-f55d-475e-a76e-ff446fbcace1"}, "9ff7cb3d-bffc-43d4-9af3-09d92160e8a4": {"doc_hash": "51199a5db1f5329ec8f6e91d199b1603ceb56c6078eda7f267650dbb99e42630", "ref_doc_id": "2327ed29-f55d-475e-a76e-ff446fbcace1"}, "81085bbb-3bed-4285-bb79-6fbc9c5bc201": {"doc_hash": "3b85943dc5a4ae7f36c72b9aea2f09cdbcaeab3cb875800ff8b79a76b0b4322c", "ref_doc_id": "9a65b5e3-fc9b-47fb-a3a9-ed87d4d6e5b7"}, "933f5aea-ed26-4cdc-99d2-acee32956713": {"doc_hash": "461a242458ed48a5c426c07f20638333e284b401bcda8b5760ee89cddfeb45b8", "ref_doc_id": "9a65b5e3-fc9b-47fb-a3a9-ed87d4d6e5b7"}, "f1bde30e-5d24-4dfe-95b4-4d384b944501": {"doc_hash": "af0dec759f1995903051e2d434ae8770f812b6978205097a010c91f426415119", "ref_doc_id": "df65d194-a6d8-462a-8b37-109606ec933f"}, "6610dd6a-a931-429b-9665-cb862404fd49": {"doc_hash": "fa2eb00268912beac82409d62aa767612b670119d0d9742d5f0d88a428baea6c", "ref_doc_id": "df65d194-a6d8-462a-8b37-109606ec933f"}, "ebbc39e7-5985-434d-9f11-ad53441d5f88": {"doc_hash": "847aa73c0f3f8f09af17899a25ed338e12a95435f62e25199e372ff4186ee341", "ref_doc_id": "d71d5fff-6c3c-4de5-a173-2cbb192590ed"}, "08a32125-94ff-423d-8f1a-f1cfb9cc8f27": {"doc_hash": "8ad88878ba0c3a880edbe878772ddbe0acbda00998c27bc7bf382d11c0c45469", "ref_doc_id": "d71d5fff-6c3c-4de5-a173-2cbb192590ed"}, "1b149e22-88c1-40ae-a614-4203fadfb63f": {"doc_hash": "c8e2ba2f606e891a9b28d20b2adcc291b201b41d5b5be23d89ce7a3e36b44720", "ref_doc_id": "285426ad-b2f5-4d2d-a184-ce62d5d57bb7"}, "459d3501-41f7-4244-89fd-49ce1c6219d9": {"doc_hash": "2c84923870e087551c4393e2ba2438a378a59cf067181caf25596a2d04a07897", "ref_doc_id": "d5ed7fa2-a099-4b27-b63f-5bbb5f196355"}, "890eb3ab-daf8-4785-adab-7cfc8927df36": {"doc_hash": "974238522d0d95ecefe5b976007e2641001611a5ed75856aa7f5bd417e68b445", "ref_doc_id": "175729ba-5bfe-4cac-9c51-acea1c635f08"}, "3f7cde92-6a49-4b67-afdb-367c4e1ef04b": {"doc_hash": "03f1520dbe234b5916a7f57741fef81635acbba018b0af3d6516ef4646ceb7c1", "ref_doc_id": "336bcbda-4e8e-4cc0-b232-eabf5c245c69"}, "3d21ce87-7b06-4751-bab5-544574ec7e15": {"doc_hash": "4b3d48fd9f0e70611742fec9aa28b94c14fde0f4ef65bea66ad5ddf9f509fac8", "ref_doc_id": "336bcbda-4e8e-4cc0-b232-eabf5c245c69"}, "ddfb8ce9-5131-4d0a-8a10-22acc669941e": {"doc_hash": "a53643bbc5b71c953295332a650374e74d20bd6adb7b7a3858ae4266173fb4cb", "ref_doc_id": "69858e8f-8380-4ea3-9501-b98ec47b5945"}, "95a8a6a6-0dff-42e1-9f3f-a12b9b038600": {"doc_hash": "81cc90b701a85691019e47064699b3a99f0a8c1e9a15000749d1c83930808857", "ref_doc_id": "69858e8f-8380-4ea3-9501-b98ec47b5945"}, "55025c85-3d8b-4487-afba-06cbd342b823": {"doc_hash": "9d96620506c26b6709135e71c7bbf1535dc6c6be6e57e83827d3519c7761fede", "ref_doc_id": "b5d68a78-a203-45b8-b224-334c0d39b6e8"}, "c55d5288-2b53-47f6-be5b-96ff143cf8c5": {"doc_hash": "0351a751cbc70ff6a329117c2034d1886ac5a03b1b5fd49b0a8b401a54f37768", "ref_doc_id": "ef5dba80-8512-42ce-93af-7717b93dc385"}, "2ef850d9-43c4-4b85-9985-5bc24867e47c": {"doc_hash": "39f3e5f0a1372ab01a71a975ef5ac19a3b08efa5b895c4a02f8c05b232cc4bb5", "ref_doc_id": "f385409c-f9d7-4fce-84d6-2e5bab74d88f"}, "f40c7f39-5b2c-41b6-b773-f1c7e362396c": {"doc_hash": "603eb058e66529164356b35765e4fee2db246410728ff00480eca7211c8cd0fe", "ref_doc_id": "dc9b56b9-0ada-4d10-ae9c-5c82e13a80e1"}, "f668eb49-3429-4155-b401-0953bf83f07e": {"doc_hash": "8d5afbca8b16b9560a68ed072d9a74b6f682054c24d0a892c2db24791c798cb1", "ref_doc_id": "110ab407-9f8b-4ff1-a9dc-2020f75b7b9a"}, "4d738674-2fd4-4072-9aa2-54580af97f98": {"doc_hash": "0307d767db3bce72101772d9d9ea74c38306740c1081f2a842fff66f4c1a86af", "ref_doc_id": "52925b67-350f-4134-8ccd-5643edf2e960"}, "9c1d259f-f6d8-47c7-89a9-617b790232fe": {"doc_hash": "d68e46cfe6ce1dccb840812fcaab4dd9e1ed2919f4784fff3aed650728a3f002", "ref_doc_id": "52925b67-350f-4134-8ccd-5643edf2e960"}, "8c49a53c-7299-430d-9281-42a5cb3c8b92": {"doc_hash": "4b2822123cec2e7ef70c43c157f38c0e59607da442c6397ff57e7ef912248306", "ref_doc_id": "b3e663b1-ec07-4f4e-83c3-f9bd9517de5e"}, "e183dd11-bf0f-4dce-a760-be066f89246b": {"doc_hash": "7e338fce6db4091ccc59ff610a028478f99d31e5fa3aeb2db09ee935f6c18b1a", "ref_doc_id": "b3e663b1-ec07-4f4e-83c3-f9bd9517de5e"}, "6a00cb70-0ef9-45aa-be55-e1e23d81ff8a": {"doc_hash": "e250c06a218b755f0452eadeee4baeb8a1811ec1c64a1c0bd17bbe1ec6106fa3", "ref_doc_id": "accb8201-6bcf-4a12-b369-e1c7699808e9"}, "615d31b8-ebb0-45e8-8125-cafee6eda8cf": {"doc_hash": "4394ad932da14558923da9bacb57f998c62982cd7b1ff92f340f69a84c583f0f", "ref_doc_id": "accb8201-6bcf-4a12-b369-e1c7699808e9"}, "3e94feea-128f-4b9a-a395-47dfb1e906e0": {"doc_hash": "8d49b2cf560e27c47eee49d29ceafb0b17dec13f943f6ab1e26fb0546e15276a", "ref_doc_id": "6607394e-4a4e-404c-b0f8-9e2ae5ba31b6"}, "08e2f4da-d706-4557-bef6-6bc49295cb8e": {"doc_hash": "4a656dd798cc570fb00fbe14fc9913412af06c8dbe0b6fd22a031d182d1a4354", "ref_doc_id": "9bc417ff-188d-4bcb-91f5-d132ae4d6104"}, "ef291609-ad4f-46ad-9d5c-f8a5a95177a1": {"doc_hash": "bf40c3888e3d91bbdb5914f78813802cc47f617821e2f40b957edc0d160f253a", "ref_doc_id": "9bc417ff-188d-4bcb-91f5-d132ae4d6104"}, "0a19e4b3-3161-4d1b-bb9a-db12b68e96f5": {"doc_hash": "df8b08c4b5d4bf0a08b8ffe64eb3f4446dae1ecec7a8ca061fd84c9fef174f1f", "ref_doc_id": "2a6933f1-51ac-4477-aa0d-a434b4efa411"}, "f19d0076-d34d-4fb9-8e59-1cac0215e2aa": {"doc_hash": "99ae126487609aaa942e221fa385fb985928d92802ed3a0e8cab375cd4e591cf", "ref_doc_id": "2a6933f1-51ac-4477-aa0d-a434b4efa411"}, "8f327443-6e71-4a86-8140-14cedf761502": {"doc_hash": "8ccd8d4362cc8f751f9a9ed4167b232d1b2bac614068c45c36669b7dc6944cfc", "ref_doc_id": "c95aea0f-0245-4a66-b665-cf14b3ac5bae"}, "a61a696d-293a-4aa2-894a-633aa51d6743": {"doc_hash": "5ad3bb36b162ccb4dd153339dc709ace2e7b0659543ccdf56680452e04b5aff7", "ref_doc_id": "c95aea0f-0245-4a66-b665-cf14b3ac5bae"}, "f800b041-4b81-428e-89e4-52c881825422": {"doc_hash": "016ef3bc50928617ccb48704f253760175da0a2ea27f5c501e97c5d11bf557e3", "ref_doc_id": "27f17e90-1ae4-418e-8389-213079cfecab"}, "8783871d-64e3-4d1e-b12a-29ad298454f1": {"doc_hash": "42651589e621ca5eb5a442088b65d056f4d1d67ce45058744ce65e9f50e93df1", "ref_doc_id": "27f17e90-1ae4-418e-8389-213079cfecab"}, "57a7494d-489e-47c9-be03-c1a90f9e1e55": {"doc_hash": "545a2fa23dfc27a379bd1e0f2f25d34e7b3f979f8b5e587e2ff3392761895279", "ref_doc_id": "7cef6422-89b7-4a55-8c3c-eee960af7db3"}, "07d4de22-1af3-4b3c-8750-403b68b3d8a3": {"doc_hash": "bfaa24cf6c034eae13c82673b1a27b88afde4c22f81b362116128ee655ed34a1", "ref_doc_id": "7cef6422-89b7-4a55-8c3c-eee960af7db3"}, "a2878915-96f6-4299-9a8a-3399462b2db2": {"doc_hash": "c83ff77324ba7678457abcf0f58022285db6b19d01e9849cf81f9fb2f9e04610", "ref_doc_id": "cd65c9aa-e7d5-4407-b32b-142314582741"}, "393fb0f8-5997-437a-8af2-a13d371d1514": {"doc_hash": "d3f65bd4059de548adc3726cea77285e469ebc39f77c0c82f82fca586cf17ad7", "ref_doc_id": "cd65c9aa-e7d5-4407-b32b-142314582741"}, "c4f1831f-ddee-49d4-a198-4d1f057639a3": {"doc_hash": "7d663a28c3ab4989457bd1ca0c59893752812398f68d34c1892fd83de6b7fa44", "ref_doc_id": "52cc1d62-e826-45ea-9a7c-e2c54ab0531f"}, "e15ce5fe-49ab-446c-8c62-1354ae71504c": {"doc_hash": "ecb9bdde61417b425cda8a7d558443c33f614b7de712d96b3779682287a1a7cc", "ref_doc_id": "52cc1d62-e826-45ea-9a7c-e2c54ab0531f"}, "31fbc137-d1b3-40f8-9e4b-075acee83947": {"doc_hash": "b0985288209067b58c807f484b597cb8b06813bcfa00189d4eb1be2fa7ea2b97", "ref_doc_id": "c78852ad-f8b2-4549-9514-06188dbd5c64"}, "a4af114e-4913-40e1-9aeb-9b630bdeffa5": {"doc_hash": "c9eb8bc9475615cde3088097d406b7f4380408d6bbeb36a31ace072fea5cc384", "ref_doc_id": "c78852ad-f8b2-4549-9514-06188dbd5c64"}, "b785705a-cb2f-4329-a651-b6c07b8d139e": {"doc_hash": "33ca5ca742b92bff521dc0421c7ba774342c68e266b6c9f5716fd815250ff28e", "ref_doc_id": "59d553bf-b93e-40e1-856a-b1537b00c5bf"}, "a7f50a94-2c8a-4d32-a83e-a521949008aa": {"doc_hash": "b6cae14b8be7ec1951c307eda38b6c010bd4c58f9611b832f0faa5ec797c43ba", "ref_doc_id": "59d553bf-b93e-40e1-856a-b1537b00c5bf"}, "9431bc2d-e08e-46a3-bc80-d27cbaf386c4": {"doc_hash": "3c028332a1cdabf91d1a878626fdbf56df32d17e0a8dfd6126eee3921e706b85", "ref_doc_id": "459cb1ea-e0d6-4719-9c4d-00514e5ace41"}, "04d66de4-a4f3-4c7d-9833-ded920821f2a": {"doc_hash": "2a6bea41927291ec31c1e15e5023ac355b38a581abc41d09c4cc2219ddf0f60a", "ref_doc_id": "459cb1ea-e0d6-4719-9c4d-00514e5ace41"}, "8720dfe8-db22-4d69-9a8d-0579e28b18f1": {"doc_hash": "2b7389225ea8e7167b31539f25d4c0f636b39f7bee89df1a43bf3ec6554657c4", "ref_doc_id": "af71b0c5-2326-4403-8d40-6e6bf9ccee93"}, "ee17b38a-ca3c-42a3-8e16-b9a7bad1487d": {"doc_hash": "f1b0df5026e0f738a7ecdb3265890f3cce567e50c83f6d91fcf81c947e84d309", "ref_doc_id": "af71b0c5-2326-4403-8d40-6e6bf9ccee93"}, "bb84cb96-5271-4879-87c2-19adda414bda": {"doc_hash": "b44c8660f16b60cf215846613d637140a824350a445154b9faa7341f3bbf4140", "ref_doc_id": "74f5de9b-e37d-47b2-9a9b-48ced6817969"}, "c11bd6d3-2248-4bc3-bd24-25bca91ce9b4": {"doc_hash": "9c40f747906976a66d117a5d8ad6a370c30a9a21c2299242fdf7a8d938568bcc", "ref_doc_id": "74f5de9b-e37d-47b2-9a9b-48ced6817969"}, "a760fef5-7e49-4468-9b03-668367d9fd52": {"doc_hash": "6ea826d6e64edc8f5ae2af0f3f882f8e8eea817b085c6ecb9824c1b0053ce202", "ref_doc_id": "3fdba418-b989-4825-85f9-f6ad8d977382"}, "81305aad-4c02-4ca2-bc2a-5bb3626115ad": {"doc_hash": "efc5b4924a91f691459972e004fcf026b6f2dea43a284139eff0a68f08e273a3", "ref_doc_id": "3fdba418-b989-4825-85f9-f6ad8d977382"}, "e6693d07-cbac-48fb-9574-a290228c7622": {"doc_hash": "7e3fc241f07fdb15273c798fbf521a0e776d551577294faed8c45ca7a7272006", "ref_doc_id": "253c8ce6-0eb9-4343-92b9-80d3c99cb62a"}, "b61696f7-ae28-4cde-9704-70c5e0c7b1d1": {"doc_hash": "ee4b66b9cdca538f249b1b0feec4b664a5919370f8eecb3cbfd949ed845cc6e2", "ref_doc_id": "253c8ce6-0eb9-4343-92b9-80d3c99cb62a"}, "16048e6f-cdd1-402f-8bd4-2835626318da": {"doc_hash": "ef5a7cf7765e2e177c7561338d2b722bbe52efaffd70d61c2144f552e4911402", "ref_doc_id": "19c43fe0-1cfd-4d53-852a-aed8dad99770"}, "210754d4-5635-4563-81ce-37a73043cd62": {"doc_hash": "91b21ed104bcb9fc6445ea72f1ab49d679aaf6b4c2eaa3632092352e22b72407", "ref_doc_id": "19c43fe0-1cfd-4d53-852a-aed8dad99770"}, "f4750933-4805-426e-802b-cb796833d767": {"doc_hash": "3689fb7005b86e8c398dff27e3d2c15f83d8454887c774f9f6ed593d6f94b657", "ref_doc_id": "f6dffcce-0d98-40c0-99de-73a85289bf80"}, "7625cd1f-1d8d-475a-aa15-a82a2b923a5d": {"doc_hash": "a8c9d2a9de888bb761c37daa6b00ecfcf38b257fbbbcd3f1ed3b917aa0eadda2", "ref_doc_id": "f6dffcce-0d98-40c0-99de-73a85289bf80"}, "2246a2be-d002-48ac-8b2c-8afde8a192ba": {"doc_hash": "58389a3c2b9aeebc1acd09680bef7e0005a58a6a86ac4f645c82903ff5da528b", "ref_doc_id": "a94b168c-0793-4138-934a-9034fa792009"}, "8c95c435-ecae-458f-b93b-2a8e3e355ad5": {"doc_hash": "0b6133c3c3053150db928aba1236caf3e7b368d2e26695cda6320d2071454447", "ref_doc_id": "22135a79-2828-4b0e-a1bf-3f86d8e82561"}, "d258e18e-5dad-4b58-8cfb-1b6d4369fb47": {"doc_hash": "ba2e0a63ae9d0fbe299eb899e12e901a5999bc5c8a8c502f77ae0bb7f56dba04", "ref_doc_id": "22135a79-2828-4b0e-a1bf-3f86d8e82561"}, "ad334e33-ebbf-4993-9877-5ad41b3db1cb": {"doc_hash": "b5692b8f6738160bd794f25c855343b5f62e54bdd1b09f9debdfc17764471bbb", "ref_doc_id": "3fa149b1-5966-4c8b-a44a-c6d042800518"}, "f7b89b43-017c-4efc-b877-380025035b56": {"doc_hash": "aed9cd6766dc0f9d0e71531228bb69166c251e4ff53543ba9bb4490d22ab11d3", "ref_doc_id": "3fa149b1-5966-4c8b-a44a-c6d042800518"}, "0e6b8c23-d409-4e25-921a-b6696859794f": {"doc_hash": "0d521de0ecbb91c88cb20166b38058fa69c0717c89c0d89f89232b2cb8a50b81", "ref_doc_id": "31b9b619-a63b-4330-96dc-4acb6d789f23"}, "f1a51a60-1f60-4511-9e5f-e2edaed13c49": {"doc_hash": "27bccdfaea55327e4566bcd700a2e13049422377c9eae647e8be1bd930fed1c2", "ref_doc_id": "31b9b619-a63b-4330-96dc-4acb6d789f23"}, "6d91b42b-6348-47a1-94a9-51cbd00386c9": {"doc_hash": "cac5c3f01a3c1516bda0a12c8292574f742151a0632b9a9aae07700dc58eac5a", "ref_doc_id": "6a0b6008-5a87-4a22-b09b-f557910361b3"}, "cbb0087f-08a9-4dd6-b133-1cfd8d04bbf0": {"doc_hash": "2ff3e227e97b63bf0f2c27eeebca2ed398984c1bb923decc866938c4b483bac5", "ref_doc_id": "6a0b6008-5a87-4a22-b09b-f557910361b3"}, "0b169dee-4f40-401a-8764-416dbcb435ba": {"doc_hash": "674a122fd035417d09664a2726c5a17f4d0919460508d75694e31ae8d44012af", "ref_doc_id": "502ad679-242f-4d03-8e19-4e1083741658"}, "100320dd-6521-475e-a469-ea2de2f092d9": {"doc_hash": "d7e3955d3432032f0ae9a5d2dd510638d4fb128a985e164148d2fa870ad17622", "ref_doc_id": "1da58ef8-8c2e-4a86-885f-06ad61b0456e"}, "0eb0f91e-fca4-41cb-bfbc-e734507d1697": {"doc_hash": "b9a47af7c035eef6ef96b0c36b030217b080c64929a976363a779e56aeb03570", "ref_doc_id": "1da58ef8-8c2e-4a86-885f-06ad61b0456e"}, "35776140-6314-4d8a-9b73-2df8ab54bb72": {"doc_hash": "298ffe5e9d1952a0ec2d02c561a5a30a79e05d69262803c73b4c3b8d92c5aadf", "ref_doc_id": "97a17099-6991-4c98-81f7-99105971fe95"}, "e0c98463-de1e-400d-8f18-cd4a8cec5f31": {"doc_hash": "4465c4de00a11c542bf4f183cbd1f0aa393c19c0e71ad1df89414052c7991c1f", "ref_doc_id": "97a17099-6991-4c98-81f7-99105971fe95"}, "4e1cd198-b704-460e-8d0d-7631ac8bc072": {"doc_hash": "9df329f32a9eaecbce9d2be4f7d2a145815b10401ee3d51c7cdf7cf2fa25a17a", "ref_doc_id": "de82a231-70c6-4856-96d5-2a1fd1de9e0a"}, "2b03485e-3474-4fb1-9f1f-59598bd9b704": {"doc_hash": "0ae142116302e9e681fb4cee0a30dda44fa8e59f0df6631cc88190e990da503d", "ref_doc_id": "de82a231-70c6-4856-96d5-2a1fd1de9e0a"}, "35ccca7c-99bd-44db-a0d2-bcc050c6a42f": {"doc_hash": "706fa39a70e5b69f00fc201a24dcda015e346fcf36467795003f0d31f706f4bf", "ref_doc_id": "1d02fefb-abe3-4ed3-86e7-26a4e79e7fbf"}, "76cc1574-73b8-4371-af21-5ff13d0074f9": {"doc_hash": "1e2ca3cae749d49148defbb28cf2820bf437fa18472e048b2d91a9a71e9f7002", "ref_doc_id": "1d02fefb-abe3-4ed3-86e7-26a4e79e7fbf"}, "58afbb21-29e3-440a-a8fc-5c7191edd5fb": {"doc_hash": "c80ed346e99a86f9e5b839c006d2919b99c2404dbec33367730d249995c5cfcb", "ref_doc_id": "bb5420f3-411a-464d-baf1-7d0df539fd05"}, "ac099cdb-d5ad-4961-a31a-eb8200eea9c1": {"doc_hash": "e953ac1b60f2e67ef33289b4ea1b2c55588e3a42ede18ce1f4b521fee0f3ade0", "ref_doc_id": "2f762054-3671-4809-a64e-4a4decb703a2"}, "eab98260-9f90-49bf-9064-b8f1223f5342": {"doc_hash": "109abd4f7f5e5598e5a75a23cdf12cf3a361bc487ab08c1c47deec0949a72796", "ref_doc_id": "934015e6-7e39-400c-a5cc-9622a395898a"}, "e6416993-0972-46c8-9e79-afd0df3c23c8": {"doc_hash": "0fd57d59586ac7e8a5199111217e5e28e354e2e9438ff44ab9670471f9f92818", "ref_doc_id": "934015e6-7e39-400c-a5cc-9622a395898a"}, "6d06b256-ae19-4bed-b0fe-054b899505da": {"doc_hash": "1c2185252abc185294db03c749e1a51785e11448e39f613ab73b62f8a2f6eae4", "ref_doc_id": "ec8c0caa-a2ea-4e19-8641-274336c246d9"}, "09aed8ba-78be-4c77-83af-a76ef42e8df8": {"doc_hash": "a0420a3869921abe3359a9bb28ddc5ced18e7d2a568214714497372523a5163c", "ref_doc_id": "28974f4c-43ba-4540-ac54-4a9fbcef2018"}, "a7fc5a51-1c4c-47ed-a613-8ce989fee01f": {"doc_hash": "b357eaa4999d67af788486b7b4e57a16f6629bc4ced394afdc0a550b6ad40e60", "ref_doc_id": "28974f4c-43ba-4540-ac54-4a9fbcef2018"}, "a9520765-1317-40b9-b4c3-2e7cd628e848": {"doc_hash": "423cac78a9f35a61886c5d4ecaff88177b1d1b5ef2bc4c8c2a8ad63a57c834fe", "ref_doc_id": "78d61185-2e8c-4671-bb6e-c82de66a8652"}, "2d14fd67-49a8-4f94-bf81-2d4bcaef52ee": {"doc_hash": "96f26d902087172dbd6b869fab13baf38f69352cf6759268b9b0c9e782a586d9", "ref_doc_id": "78d61185-2e8c-4671-bb6e-c82de66a8652"}, "b3bea509-671c-44a5-aaf2-736887b0a21e": {"doc_hash": "a6a43b929591368f5db4a9e747f7088f83175e520ae83b79229128275c10f47d", "ref_doc_id": "8f408e3c-4df0-4b5f-b86a-caacf1d2b6b6"}, "1a9836bc-e4f9-4152-befd-9fbd1c51cac4": {"doc_hash": "db01fc674eb1950ff83d5691adc300d2749295172a440cb01bd64e5a59ba8959", "ref_doc_id": "8f408e3c-4df0-4b5f-b86a-caacf1d2b6b6"}, "27c77f31-1d9b-4a23-8719-f9bcb569bf57": {"doc_hash": "e774dec00ada8c2828e0d96eaf41696e456dd3f852dadd12678ef6b4d1ea426a", "ref_doc_id": "91d1cd86-050c-4a0e-bb08-d3a7c5b1f98e"}, "2bd0463f-4929-45e4-bb73-2ea09d711740": {"doc_hash": "50438991164fc9e49625b604d1fb1caab6f34a9de6257833b4e7886a77c65457", "ref_doc_id": "74d66383-bdab-4939-bb9c-9276fe620f20"}, "817a4c73-6152-4ab4-814a-e2bea8ff171d": {"doc_hash": "074bbe89bdc00cce0b197d07b6fb2cc7e62678d4adf8adf1fbfd11a21b3e7a53", "ref_doc_id": "74d66383-bdab-4939-bb9c-9276fe620f20"}, "193ea219-1c85-4ea2-8795-0a0200488a2f": {"doc_hash": "25ba88765624a5b94520ab121ad97635019f0af19a0e0ce0a0d52caef85d6ed6", "ref_doc_id": "e3cd6429-e1a9-47eb-8027-38fae61e9fde"}, "02a635bd-e16b-4539-9a16-f2e3ecad7227": {"doc_hash": "bbde7ac688f8b53f8b2cb4fb8b6ac5ab8d1b3a99d028626ee009937b08aba871", "ref_doc_id": "3fe57bf8-6506-48ed-8f46-0045f2fff9e7"}, "a6d380fd-9039-4be3-9e27-33d6fa885998": {"doc_hash": "b55ef608ec179b447b637a70e2bc1a98bd06c836af9d2663be7f61299e9c9a44", "ref_doc_id": "3fe57bf8-6506-48ed-8f46-0045f2fff9e7"}, "fed4779b-e013-466c-83f5-04d6f8faabfe": {"doc_hash": "89bc6e70e16f24057911f38235b9bff0f7260ff4bb6f0388880081dc1ac30dfa", "ref_doc_id": "3ec60722-2882-47ca-be3f-bc3755bd7a84"}, "1e0954d4-5eae-4c7e-a501-83d7dda2d8c5": {"doc_hash": "64f11df79c5adca6a083c85001d85787ebf171bb6b33eb381abf2ff798b58467", "ref_doc_id": "3ec60722-2882-47ca-be3f-bc3755bd7a84"}, "c83e71c1-7f1f-41c9-bcac-b33037dc8ed1": {"doc_hash": "a14ffcbe561baff1bbc01689d77cfd4a8d8642ccfd15c2b39841a103cd2d7e42", "ref_doc_id": "3ec60722-2882-47ca-be3f-bc3755bd7a84"}, "2da84c07-4ebe-4211-b5b0-fd21486d6b5a": {"doc_hash": "029f75f96a09ad36c2aab5b6d680b5b25e890817035e8dc190ec9b8215ae4bbd", "ref_doc_id": "3b0b0a59-f43b-4fa0-87b7-22f81aa21f02"}, "5a30d31b-5559-4389-8785-720cd5dd7b54": {"doc_hash": "6fcec6c6263962e257264e5918dc904c6e0a644e37f3f2bf4f9ee442125a3432", "ref_doc_id": "3b0b0a59-f43b-4fa0-87b7-22f81aa21f02"}, "4eca5a85-55fa-4496-8876-ddee5fbf1f20": {"doc_hash": "defe7aafa79c01e61c34f83725677194d0269aaa5d73b4dab723ca3dbb212624", "ref_doc_id": "e6880aff-f18b-416d-a983-308d199f0a6f"}, "5eb7decb-77d0-43b0-bec9-fa685b72edd1": {"doc_hash": "f4e25fa3aaf22f203a1c522c1db4e97d6938e6603de79b9df36c78fdd9f9d4f6", "ref_doc_id": "e6880aff-f18b-416d-a983-308d199f0a6f"}, "cb2286b8-6bfc-42e7-ba49-82f29232984f": {"doc_hash": "21d3aca99f2b94c7fd91f563d8a5f719496a9d3e8d53ffac29cd8f29dadf4633", "ref_doc_id": "57f0c827-e783-4bf9-bfb8-bbefc04b1f3a"}, "6ffdfbf1-737c-40c4-9de9-6b2b8482aaad": {"doc_hash": "e5cda590f9f484e2977aefdfadc66286095a90b42da6ace0b52544825594ff77", "ref_doc_id": "57f0c827-e783-4bf9-bfb8-bbefc04b1f3a"}, "3cceab0d-8bbb-44a1-a2dc-f57c31632e82": {"doc_hash": "911d2199e1405d80fd7d9002c670fd51b25dcf5b5219944a7c7546d3e4cd7496", "ref_doc_id": "a1a5c8d4-bbb4-40e6-adaa-3915caccfb58"}, "e91cfa5d-4214-4b71-9ca7-7fa32303ccac": {"doc_hash": "7e9b839cb7ecc46a45a9ab26ccb344f8d5d26df190b756c0cd498c2b28126efc", "ref_doc_id": "a1a5c8d4-bbb4-40e6-adaa-3915caccfb58"}, "15416557-c23e-419e-abc9-9578e14ab17a": {"doc_hash": "e16c08fe5dca08de41530597076b70350caf024eda9c0fa98d8e03c8231cba48", "ref_doc_id": "d679af73-ea2d-4874-818b-94158008bfe6"}, "f0bb644a-08b3-49eb-ac06-673962ac0baa": {"doc_hash": "88de3ece08d1fa9ae40fbfbc23d35ddf0e71ab90e7ed52f77c0c836501344685", "ref_doc_id": "d679af73-ea2d-4874-818b-94158008bfe6"}, "118fd178-faa9-4705-beb9-69682dd25e69": {"doc_hash": "344dd936d1f9696d390c81f734135e00e2e45236421f853409d901ddb5e54716", "ref_doc_id": "44714a06-f7fb-4eac-8510-fbeca8a3e72d"}, "08c58623-d8a7-4551-8c94-ab7c16eb9e58": {"doc_hash": "dcfc29fca41c86389c3eec3077aa159150e3f8cb46bb051f0bf4de538009f62a", "ref_doc_id": "44714a06-f7fb-4eac-8510-fbeca8a3e72d"}, "08fa4b6c-9807-4b4a-b5a6-c04319932126": {"doc_hash": "6e0d3922401a780c6ac36ed7c465113c80bdbdabb96156e046bf0e0fce30db78", "ref_doc_id": "a81e2521-1bbc-44a6-b7c2-b67efef91218"}, "c5c145a4-29af-4775-9b3c-5ba827f4ba90": {"doc_hash": "d92aa193f15c5243933fc828a2495928dd3e68bc2281f01a2f88c2ecd57dcbfc", "ref_doc_id": "a81e2521-1bbc-44a6-b7c2-b67efef91218"}, "5c5879bd-0e34-4ed1-9321-8e3a54ab2d9b": {"doc_hash": "54d532553cbb5f00aed96499c0dc20f5419de52198c08259894f3e14b7c79b7e", "ref_doc_id": "a81e2521-1bbc-44a6-b7c2-b67efef91218"}, "0f06aedb-3f5e-44a2-ba9a-3d74ab1890a8": {"doc_hash": "2324c0b68e940afa95a9ec224efe67e3e9f957d6e01610927acd9f1284465603", "ref_doc_id": "2e2ec4da-b5d0-4cfd-8f70-a85395e5e2c9"}, "238252a7-bb98-43f8-9227-994c3a9c6d19": {"doc_hash": "789d25991c5038f1cfede225cb8b0e10f4c08212decb25fff1cdf05ba57ffc05", "ref_doc_id": "2e2ec4da-b5d0-4cfd-8f70-a85395e5e2c9"}, "bf83d6e8-4170-442a-8f94-2868e8b8cbd0": {"doc_hash": "4766b94c5a73d1b007ae1a850321a3dbcc8e32de577f24f4e2629e45cd5d7594", "ref_doc_id": "41649b7d-774e-4dce-b744-e9bb756fa947"}, "99a3500a-4731-4286-9977-eb78277a1871": {"doc_hash": "336e965a430d083923484fb6055f171312ba8bc371094feccc8a3dec312dd8bc", "ref_doc_id": "41649b7d-774e-4dce-b744-e9bb756fa947"}, "6222af72-5045-43a4-9230-8d13e6560624": {"doc_hash": "f08936e6d5d7c018bd8f8c93611c15447cc3cb5b2755f7e5e8ade86bbcc4e581", "ref_doc_id": "15e9446d-bc1c-4bfc-9b0d-755d73d2f052"}, "7174b84c-0bdd-4b90-b345-279a11a53946": {"doc_hash": "9cb0e13f48a606173d5b592b998d07da0df2164a4829f5ae117a0b56dcf14e8d", "ref_doc_id": "15e9446d-bc1c-4bfc-9b0d-755d73d2f052"}, "cb944b09-95de-43bb-a556-7ab7d3775625": {"doc_hash": "607a8676645ba9884106e6d5806fbc06d649fcc7ca0270baf01df55272a27117", "ref_doc_id": "0d440eb1-c44a-48a5-b7f9-05e70d8fd695"}, "aeb8da2f-379e-4b51-bcc9-61d9630b8d98": {"doc_hash": "7283fe2eea66f2a1ebd15df80efbc269db6ed0e416dfb408e030e1d67eefdcde", "ref_doc_id": "0d440eb1-c44a-48a5-b7f9-05e70d8fd695"}, "683e059a-6fe7-48a2-b28f-028fc3e289cf": {"doc_hash": "35f3e744b5e167390e4e0dd6db66823e9bcee895c4132c19038be48375125c39", "ref_doc_id": "72248ba5-43b6-4b20-b425-2625127f975d"}, "011bee2b-28a8-49b6-86af-6aac23188582": {"doc_hash": "367c73265e8d2c8fb65ab8b46b71d2976827e3a8ea823d4482d3ef2a36600ee7", "ref_doc_id": "72248ba5-43b6-4b20-b425-2625127f975d"}, "46f99a4b-76b1-426d-bd37-df3db3460903": {"doc_hash": "05f4ee4ecfe29d24e25bf68ebefedc6c03f55e7a4e84088592f1a114ab1d9c53", "ref_doc_id": "9091ab65-582d-470f-8f37-50f989e629eb"}, "86eaf194-7fba-4bce-8ae6-b04714c08f02": {"doc_hash": "60ec1465185f0a1ee1bc9d91be7a716c17cb493fb2583931a9b910a39560a82c", "ref_doc_id": "9091ab65-582d-470f-8f37-50f989e629eb"}, "a7c6a127-f30a-4862-b0bb-8c9958a9159b": {"doc_hash": "4f783439dcf7c9a3ec458a282bd917e7a4d9f13455a33771b4e2ce05eea97ac7", "ref_doc_id": "50bbf825-0710-4a08-9782-b7ccb27c929c"}, "1356d135-6985-4aa5-ae4e-6a6150f6b73b": {"doc_hash": "a81fbf4d739e88fecdd6923f55bdf7be778adf29f8a03c1cb94d105e7ed9b67c", "ref_doc_id": "50bbf825-0710-4a08-9782-b7ccb27c929c"}, "019ba598-c8d0-4900-a5e1-4e344c4216fb": {"doc_hash": "58ed5c431904eec4e0cebbc1de8082d0389cb9420490dda9893baab719a1eb60", "ref_doc_id": "cd642cb9-c157-4153-81a0-94bf149586c4"}, "73bb99a6-98dc-4f93-8bac-c593c5f770a3": {"doc_hash": "d6479842caa2d6273fc92f1ebed75a89ffc9307dbda5b4711c389a9314183592", "ref_doc_id": "cd642cb9-c157-4153-81a0-94bf149586c4"}, "49528269-375f-4e87-9db1-521d9fff269d": {"doc_hash": "185420f82502543ef60516943ff886d3a9da62ee6bfe9328f0a2132ab3dede87", "ref_doc_id": "ebd0eb68-51d8-421e-89d1-c6503aa22a20"}, "2f486d73-d2bb-4a5d-aa81-682dea6eaa29": {"doc_hash": "639b0e603bb82100254052b17ce44de68bdbfa8cbfca6fd8c84bcbb173e28888", "ref_doc_id": "ebd0eb68-51d8-421e-89d1-c6503aa22a20"}, "d9aff44c-ac66-4082-9c24-f99af3add0c2": {"doc_hash": "7440a4eaaaacdbdfd5b562ec5c67946184ede85b5ab1edc55bcafe227e42a0dd", "ref_doc_id": "53227f03-0b6b-4205-b7b5-b4329d0d70df"}, "f66ace3e-f075-43e3-b9a2-9fa29f751571": {"doc_hash": "46183feca5e38e8cebe206fb74b45f0166c4c14a33527297b609a91aab8d442f", "ref_doc_id": "53227f03-0b6b-4205-b7b5-b4329d0d70df"}, "159d520b-bf8a-4d50-9e34-5cb865d66d45": {"doc_hash": "b2fd8795628efa91711bd6384197e6e3f65959f1cfdc89e2c92e5f82488a60ee", "ref_doc_id": "e024498a-153c-4b79-8074-2ab668ee5fed"}, "957ead0c-9e4e-4833-a99e-2d1f16bff36c": {"doc_hash": "2d86429f6aadf45ceaf206fccbe1d44e3e550e4d208821f1d6e5254421e96e01", "ref_doc_id": "e024498a-153c-4b79-8074-2ab668ee5fed"}, "1f2d5787-aef0-4b9a-8238-f2365e362766": {"doc_hash": "a3bf2a2b2564cb348aa7984b5673ae6098f5a746706c36305819b0d9c1479a83", "ref_doc_id": "bbc6cd0e-eb61-4539-9c9c-62c1d548f002"}, "80db4039-569d-4360-8bda-55eec2f6d612": {"doc_hash": "614a7826f0f7bf0ef0b5974acbb90756086b5e07356d8478514d3dfaa1fb3fe4", "ref_doc_id": "bbc6cd0e-eb61-4539-9c9c-62c1d548f002"}, "65d10243-f15d-4bce-bbc2-e106f3533b61": {"doc_hash": "8e18c8c956eaf9aa6d0781ef49dd24769110444685a4b9ed109f62a22af2f54c", "ref_doc_id": "7cea03c8-4dc6-44ce-961c-9038ff779864"}, "9970512e-3eb7-47ad-9a30-c12d3b878f48": {"doc_hash": "8f2e8c68db8d1ce260ad528b3fc3cc4e34e437c851c4b0b93330e873f227d82c", "ref_doc_id": "7cea03c8-4dc6-44ce-961c-9038ff779864"}, "93da8cc7-87d3-490b-8951-60141efad62c": {"doc_hash": "40abcf225c240f94f401246ee622d1f5f6a5c7ed635392b50117a0e2b046a9ef", "ref_doc_id": "aa3dca8a-5e60-45ce-8aac-012c7dd140e2"}, "44c6acb1-b760-4408-b3fd-6a197204891c": {"doc_hash": "337b750effa5c9d74ea4a1b43b014fff9f355be36c63556a51cb2cd1809f9528", "ref_doc_id": "a7a21d13-887b-49f3-913a-8812bc22837a"}, "a36f1734-219c-49a1-95c6-9f9f5832704e": {"doc_hash": "de19c43ab9c5fd2d3e42dcf20a703de2fe28670a10300e91c45daf1432ac9e3a", "ref_doc_id": "a7a21d13-887b-49f3-913a-8812bc22837a"}, "3e1a7525-f207-4824-98c0-bd1c44040906": {"doc_hash": "082fd19f73a30d6ec4ae3ad8d4e2e59885cc5d0334c59a6f1af7dbc39cfaf7ab", "ref_doc_id": "a80395d4-ee8c-42d0-82ff-8ba86116797e"}, "90849e80-dc64-43b4-b3a0-9a7a76d4c2d7": {"doc_hash": "233183613dcbc55e650133950db7313b28deee0dceafc0801c8400647ec70660", "ref_doc_id": "a80395d4-ee8c-42d0-82ff-8ba86116797e"}, "c28bf029-c532-4154-9766-e090e7bc7136": {"doc_hash": "000b8c9a02f026ce26facd722ffb6edfbfdab5e660999950dd7f6f356ce90757", "ref_doc_id": "28155c3f-7d1a-449a-8234-b22f335c8147"}, "e074bc41-cafe-4be4-b56f-588f9f15373a": {"doc_hash": "bf3297249fffe37ba83c53a71bf7f1a747b85016f007c3ac039d5ba7f9d3e964", "ref_doc_id": "eab121bf-01a6-4981-bb92-f0d6aa9ba3f7"}, "7c345bc1-163a-4ec7-bf34-7717e3ba570e": {"doc_hash": "ceb6cb96416bc6185e3e2635730f60c43dbeca9936517758232e47afa74f3dbd", "ref_doc_id": "eab121bf-01a6-4981-bb92-f0d6aa9ba3f7"}, "6da50fab-5980-4c2c-84af-31918320c1d5": {"doc_hash": "57fe3bef651390aa5ff225e696f0212cd5c63362ce30a78ff634b876d72027ea", "ref_doc_id": "45cd944d-2c5a-4ead-bbe8-70af481b85a6"}, "4f7838a0-b176-4965-b8c0-685273a0447b": {"doc_hash": "9f4ee9885833d76f67989d81968f216650a9d6c4694f17054c1a2cf3bf36b525", "ref_doc_id": "45cd944d-2c5a-4ead-bbe8-70af481b85a6"}, "47391560-6334-47d5-9e62-6686f17e4f06": {"doc_hash": "f74796feca17efc014cd6db0066c1d5a9dcefd499b325feae37fe6a18a7911b2", "ref_doc_id": "e8a10dae-2516-45da-acd4-0ee1cf985fec"}, "c347c70f-8257-4b7e-a6d8-3af905c52495": {"doc_hash": "c3e35b07c15d3b25507ce3be32be31356e99812996f52affcf621b5a0ad84ebc", "ref_doc_id": "e8a10dae-2516-45da-acd4-0ee1cf985fec"}, "7da6e1b6-9f0b-43cf-8518-ac6ffc87ed63": {"doc_hash": "6b82bddf5c86b68485ace02de7983d9c5f7f1a1a543494d2457381e47f12842a", "ref_doc_id": "26e48ada-ab03-42ed-9bee-26a3123d7a5f"}, "556f10bc-7d4e-458a-a0a0-f538ed644201": {"doc_hash": "bb545e26ff5b64e7d09e48b9667c2ef1d920622e7dd9cd6105a7160e94df2358", "ref_doc_id": "3aa86a31-973c-4fce-ab66-f4aa7bff5043"}, "bb94cf11-a258-4b70-81ac-9873bf3f873e": {"doc_hash": "f9c0c9bb48cfbe2a3153e0aa23d0b0042657ac684c6e4309420c113e89fd51af", "ref_doc_id": "3aa86a31-973c-4fce-ab66-f4aa7bff5043"}, "6415ca26-b722-4662-9a6a-d13e0d33aace": {"doc_hash": "354a7c3436d8d3180d29075f34194d23c92bc704d2382a21f76ba1bd387f590e", "ref_doc_id": "3cd572bc-021d-4450-807b-8020691904b4"}, "5a8bee1d-c015-437f-9775-69993b402fb4": {"doc_hash": "2d44f3b495ecf45321874a1f7c27e7a3eb5fa0cf54585485218f97dcd9f8df9b", "ref_doc_id": "3cd572bc-021d-4450-807b-8020691904b4"}, "e59fd1cc-d0b5-4df0-86aa-31f92f58f2ca": {"doc_hash": "6293bf5efd0cf26b2a9a9fe82c18529a5a268ac5624bed5e19a6b47da3b4cf0a", "ref_doc_id": "4e19f959-ebc1-4f57-8dd5-9234afd2eb1d"}, "5765ea47-1c9b-4937-b3c7-c70726de1f69": {"doc_hash": "d01b1cb9d77aa963cdeff7d1504684b68f1b49ee8f377856208cfd1406b2fe2d", "ref_doc_id": "4e19f959-ebc1-4f57-8dd5-9234afd2eb1d"}, "b4ad81ae-1a81-4289-9433-0fc3740b1f32": {"doc_hash": "ecb8a5751468fadb68d348008dee64efba54ace8a65209ced7cf3a9f6393e387", "ref_doc_id": "8845ef23-bac5-4a94-83fe-864068ff0ae6"}, "b93f2ebe-a233-4c3b-8d25-2b11a2ba52c1": {"doc_hash": "c4c55e07736b66ab44009b92d3d1fcfef202bd221d3d990f3c9061d4ed7d1357", "ref_doc_id": "8845ef23-bac5-4a94-83fe-864068ff0ae6"}, "382ab8aa-8fe1-4b7a-9fe9-093bdd4d20dd": {"doc_hash": "da1e9470dd3557cacb2b0a420403b51432574587cbb0ee2463bf6d5f85709451", "ref_doc_id": "4a3165f7-60ef-4165-acbf-6f9a419e6b54"}, "6e3d678b-a98b-457e-974d-38fe4314ae20": {"doc_hash": "59e9b82fbf4641a738657ec363e649f69c42366d42fb6a1935cdb1612730b24d", "ref_doc_id": "4a3165f7-60ef-4165-acbf-6f9a419e6b54"}, "2c691738-dc4b-4cbc-8882-78121574e5e9": {"doc_hash": "2a5c8d2cd6887ab8a102da55f8db9b8ae001de62d3b02000a063819719598bc1", "ref_doc_id": "7251f124-7168-4ec5-807a-14a4ed7476ce"}, "0378a33e-7743-4673-9c1a-ad55dbf0810a": {"doc_hash": "b16ed90ca1a994b72054a504eccae43597e1906c067712d9529b9afaa96d2ef2", "ref_doc_id": "d68cfc65-85b5-4234-88ae-0a3b989a0e69"}, "91f262c2-39ed-4662-bbd5-2ecec9c26b0b": {"doc_hash": "35245671b1b598da4c6c4e4e5e27070aac96d1163373f56a8f1e3c720b550f27", "ref_doc_id": "234056e2-413f-41f7-aa87-1a4b4a508d4e"}, "c5d4e1fa-01d7-4b5a-9fb6-6466e430846f": {"doc_hash": "5910558d972c02084bf13e43d835a147d83a085b5b5ab3fdbe97e0453fcc5d8a", "ref_doc_id": "234056e2-413f-41f7-aa87-1a4b4a508d4e"}, "25a3054d-1c71-4bc8-aecb-4a27c9de691e": {"doc_hash": "e67c6b47fecf3da68328e01d0f9eda19cf0469c3efa630572acfe0748c143a28", "ref_doc_id": "83ff9d67-084f-45e2-91bd-9542ba422b41"}, "b1eb4b3e-567e-4f17-877d-095f1809f230": {"doc_hash": "94b79709b5a1a44c95e8850ed151f8b85b94c6240c10a1bff36cfbc0fd967962", "ref_doc_id": "83ff9d67-084f-45e2-91bd-9542ba422b41"}, "591fad25-4e6c-4337-868e-3d7a7279a2d9": {"doc_hash": "a9eb58872d1a1332fcdfd632c6681b1ceb698702853246fe9ee998bd24ca1ab1", "ref_doc_id": "1dcaa35b-e0bb-4635-8503-e752f6878893"}, "d67ccacd-0a5d-46e8-8290-e85878cfd945": {"doc_hash": "8b68d0d3361b1bd7d28ac1fb4caf7f7668c2482f9e9091608e45620bdf592461", "ref_doc_id": "1dcaa35b-e0bb-4635-8503-e752f6878893"}, "a776e386-3461-47e8-ab19-abb143d86fc6": {"doc_hash": "d6febbbcb4597cc5c3bd2d5877731bda2815a15f7d5bac2ad8caaca559282177", "ref_doc_id": "dc3784ad-deb5-4bbe-88fc-ae486253e4c8"}, "4cdc837f-c000-49ad-b983-a17fcc373492": {"doc_hash": "fbdf5a05b25480191fa0bfc45f23727916bb1752a1904c5f7d152557bd4ae8b7", "ref_doc_id": "597f6fd3-b13f-445a-a547-e86c0068b20b"}, "1a125332-8d89-4302-927f-b116e893c6d5": {"doc_hash": "c0b8f3678ab2fd43b0a2c8f7b7ac28148ba29223c8c3fc2af215106d12920b18", "ref_doc_id": "597f6fd3-b13f-445a-a547-e86c0068b20b"}, "932daae5-4796-4f35-88c8-040e867cb136": {"doc_hash": "e4bf8e94562d17a67c1f0aba1bc6398fcef89fe1646ac646f4de2d1091ab2bcf", "ref_doc_id": "450b659d-5a69-4bfe-b049-7a67a3a14eae"}, "955f6a4f-1e22-4141-b5c3-3a67c3a6f936": {"doc_hash": "21a338acb772a6b5484bc6a5a4b9c37f1151e47ad9da5e91cfd61736186337ae", "ref_doc_id": "450b659d-5a69-4bfe-b049-7a67a3a14eae"}, "a1c4a550-3889-4009-9833-172b16e0566d": {"doc_hash": "8a723b65cdc6c94e5ca81cbd472ed3ce5f968e13534fb2bab385aece93ff6758", "ref_doc_id": "7a7b5fd3-fbd7-4001-9a24-3e9755b111f4"}, "a215e493-b820-46c6-8c21-c461ab40661b": {"doc_hash": "01d321f53b79bb848e3375a4bd0a9290e6ba43ff56b74010eee06ad4ede1c468", "ref_doc_id": "7a7b5fd3-fbd7-4001-9a24-3e9755b111f4"}, "9fb267a4-f08d-4753-b774-f6847951b0b9": {"doc_hash": "aef195fed6669282f237d3e4314685265e562d6a2f00f3e710f5814eba23c2b3", "ref_doc_id": "ec434ea7-d8fc-4be0-a63a-cd5d4fabfa06"}, "d5bc45e6-b9ca-4574-ad1a-191c0993c8d6": {"doc_hash": "0af54078ba35a8773d6110e6882e341ff99ddb95fd20edf7127469ce599398cf", "ref_doc_id": "ec434ea7-d8fc-4be0-a63a-cd5d4fabfa06"}, "7352ca8c-463a-4789-87cd-29007b9c57cd": {"doc_hash": "0df366a6d98203f66da26b60682e211be821e281c83232461902ab28ceb7896e", "ref_doc_id": "f094c334-0898-440e-82dd-983151b82c98"}, "5d936c1e-d077-4c5a-8b4f-0620578780ce": {"doc_hash": "5ed00ebe5b6f359e9d45d1d18fe71d75f401ff4ea62054efffbcfcca934ce95d", "ref_doc_id": "f094c334-0898-440e-82dd-983151b82c98"}, "0db5d2a8-780d-4765-b3ad-1950e5680a6c": {"doc_hash": "99a5255349dfdd3162a7f8910641fe2a4c86009cfb904e5ff5af693f9a47952d", "ref_doc_id": "00bfb6e8-6eba-49f4-a85c-ec35a355053b"}, "3d6506b9-0da1-4512-95b7-362a8f768b48": {"doc_hash": "7bff5891c365a5b604e1e96e3624b94cee57620411a18cde6d454bad54d6d35e", "ref_doc_id": "00bfb6e8-6eba-49f4-a85c-ec35a355053b"}, "46ac092f-0d3a-428b-b2f2-04c0e351f128": {"doc_hash": "aaff73382c3d3a68153be97b5ec6916f1485dd0029c809cb81c569b911dd4603", "ref_doc_id": "40248634-2aee-4ecb-a90c-5605ca8a7cde"}, "b9b98a4a-26e8-4818-971f-70b70c505552": {"doc_hash": "bf729c7614459b9d0dc7d4a11d9987c96927e4fd1d182875992e82f484432e1c", "ref_doc_id": "40248634-2aee-4ecb-a90c-5605ca8a7cde"}, "2abde0a5-fc07-42ae-966b-cf476439c776": {"doc_hash": "654e768c59b19a948885451bdfddbfcf0300a3940bbb13577263c660cceb8232", "ref_doc_id": "edf9a86c-f9de-497d-b30e-68957387335b"}, "dff543c0-112b-4bfc-9ea6-02d098c47924": {"doc_hash": "186d4a33f0d533c686eec36d59a14d95b53705b719c17324c1e0f7438819ba96", "ref_doc_id": "edf9a86c-f9de-497d-b30e-68957387335b"}, "b3419208-47cd-46f4-a0b6-d58583ac57a3": {"doc_hash": "7176ce158300aaef19907cf14f2b0f1450e772c5bdadd5ed63258ea2c83aa52c", "ref_doc_id": "b92f8adb-2957-4154-9167-8e0db018db41"}, "5bd3588c-954f-474b-a367-59c6221bb051": {"doc_hash": "74fd0a08a98677c8eea9868c1408e63b4309e93780f260f8afa5f3c2994b7fcc", "ref_doc_id": "b92f8adb-2957-4154-9167-8e0db018db41"}, "8216c642-67e0-460d-bf97-d50d6802b845": {"doc_hash": "3674389388036d3ea97bfea13c8fe7e6e95f3d9a2ec2a475d7176df79e52b3a1", "ref_doc_id": "44dfdbb7-31d7-44e0-8d98-8ed3836bc2e3"}, "f0dce1ea-755c-418e-966e-01bc4708ff3e": {"doc_hash": "e9df603385677bad623ec9f0e340b24cec228810b0c0d0a50cd8c6881677f193", "ref_doc_id": "44dfdbb7-31d7-44e0-8d98-8ed3836bc2e3"}, "45bb6def-f19b-49b0-a0c4-1adacee31023": {"doc_hash": "8030f0aa5035557ae15b7481c008d3f66d06641c5ddc7a2705206beea872c765", "ref_doc_id": "0f587ed7-3674-457c-af4c-c28acb21276e"}, "c12d2cdd-8f46-4487-831a-88c5a9012017": {"doc_hash": "d81c9c1a9cd545e8b1124b64188a0d53d6139c26d9d3378e27ba888ba8a1617c", "ref_doc_id": "e90314e1-14f1-4c1f-a8be-453d26509f50"}, "bad0abb5-aca4-4329-a0af-102a03b07d23": {"doc_hash": "525ac7aa04f953bf47c580356201d3b7d3ed7c731109076685c37e3c748b00e3", "ref_doc_id": "e90314e1-14f1-4c1f-a8be-453d26509f50"}, "8cd0fb02-f656-4cd2-afe5-6f73df309dcf": {"doc_hash": "542b4dafe5fdae267eb2f6b5a827032de81a5b5c5acd2d6bb336b2ad96bc6a02", "ref_doc_id": "4646dc06-b860-46aa-abb1-e1bdd7506144"}, "8e6622eb-c28c-4495-a3e1-38132d7a632d": {"doc_hash": "496fddb872a697277de727e8cbce3987fb32e6f0acc9864677b01c98282fa2ab", "ref_doc_id": "4646dc06-b860-46aa-abb1-e1bdd7506144"}, "c3b13267-f840-48de-ade5-ae96a746d135": {"doc_hash": "42799e64b64f09d883a92e73e156e8389bcabf80bf2921e4d1827e415cf9b2b7", "ref_doc_id": "12c6b0c9-86f8-48b8-a1db-018fee279d7e"}, "53557098-7254-4bc5-b4b5-094ee193e2b3": {"doc_hash": "09ee571173f0ce16a53cadc002fede38060d8a1437a519fcc54efd0bb6a9e76e", "ref_doc_id": "978a7020-a72d-43d7-b10a-ad804af6846a"}, "a201247f-3973-4ee6-be77-1836943fb055": {"doc_hash": "43e3d7d19c47e2aa7b457323a235bd5a8be310bf5fc081038f63d49a5a5c8716", "ref_doc_id": "978a7020-a72d-43d7-b10a-ad804af6846a"}, "ac759fc7-42df-41ee-8b71-e91a5cb10858": {"doc_hash": "bf24ae9034c118ee9e4b430f5bc49b50e8860f9cba568a64dca240ff7e7a90ff", "ref_doc_id": "65e287af-c1f1-4dd9-8695-737aa98e0b75"}, "256e7148-5d6f-415a-a224-9b8771243c10": {"doc_hash": "7c11e9eb8d2dec9dcf5c93062f8b09bc7fd081ffb375ed3f6cfa9eb0acd6ed6a", "ref_doc_id": "65e287af-c1f1-4dd9-8695-737aa98e0b75"}, "cf4ebd45-e0be-4f3e-9abe-5e16d0746ea1": {"doc_hash": "70d5431ce99da5b104044d443a525c5a95f6c142d7c3323f143009ee993d901e", "ref_doc_id": "782057ad-51ec-4afd-b252-97ed9f6ecc0f"}, "c49e0122-9adb-4288-92f4-97d36142a55c": {"doc_hash": "448ff21735536867e78ae0fbee197c91dbc624471fa083f13ad85606826890de", "ref_doc_id": "b9681a79-d47a-462e-a0d4-6e58a4d91c40"}, "d5c9a962-ce2d-4327-9bd8-18fff39d192a": {"doc_hash": "d72af8abbc6b0850e07f52b612d23e33d36308856246e93e54cd7eb7add3e93a", "ref_doc_id": "b9681a79-d47a-462e-a0d4-6e58a4d91c40"}, "534c08a5-1c4a-44e2-8145-6585465a9092": {"doc_hash": "9ed6bea7d2a7df294a330619be4db3926c17b1452a48eccc9e5c8cb231a27949", "ref_doc_id": "9d8fed63-108a-4713-984b-4849a0c93d93"}, "afbcfc94-bd07-4b97-9f1d-572cfcc31a4c": {"doc_hash": "29ce30e36094c22b81fb6bd56dd36850f40d6f3570879aaf920478c4aed72703", "ref_doc_id": "9d8fed63-108a-4713-984b-4849a0c93d93"}, "fe0b450f-7112-4e84-b0c0-d2e8b48fdd28": {"doc_hash": "343b8a38c152230a9e92ff38251eb451c00a7916955ed7a449745c0291755afa", "ref_doc_id": "f38adb69-52e3-4bb4-8799-b8ccfdb7a069"}, "55dc894b-318e-48e7-8a65-a946d6273230": {"doc_hash": "7c10c401ca3d1e1032d1b2915be7660f9a7f1982ede81fd7eb4d008ea0d5400d", "ref_doc_id": "f38adb69-52e3-4bb4-8799-b8ccfdb7a069"}, "faa17b0f-4ca3-4367-9f5a-9d15003457d4": {"doc_hash": "7ee6843ed93591c3a7a2fe6904ccf185c23564ae75108ad32b6afbc6f76a4b98", "ref_doc_id": "18e077a2-a4d9-4909-8c6b-35494d5ba0b2"}, "6d0b7261-7810-47f9-aac7-28b2efd64d3e": {"doc_hash": "8171e157523176b4a6854bb004a37c9a549b016323fba55bbdf15b50be1d7098", "ref_doc_id": "d1f797ff-1625-4757-8f13-f6f80526a9b3"}, "517eefcf-7e93-4a38-a7e6-2a8874a70d0b": {"doc_hash": "e66b3ac5471eb7817bb7ffedc2106ca0559424e682953714e65aed0d04f04ba2", "ref_doc_id": "d1f797ff-1625-4757-8f13-f6f80526a9b3"}, "4c7d908f-b4a2-40da-87a5-3e19ff1bd043": {"doc_hash": "234141f474c3e9da94e764a635e0e05ba6cddbd52a7a44845a5f3c1333c9d0ae", "ref_doc_id": "25bc5166-550b-4580-8e6d-dde3d6ba386c"}, "4a1f28a9-be7f-478d-87a4-9ca78ee7b78a": {"doc_hash": "e993307d2d8e5fcd936d99eac2433623fd6a72705711ce2f5b12edd815c22d49", "ref_doc_id": "bd086099-3f55-4263-8059-158420704be4"}, "6b44b1c5-16c8-4cb0-ad25-a33e49bf4f7b": {"doc_hash": "41caf013ccd7f4b8d8fa790768ac3ecf67d63a47ff8e2e8fa442484c99b81a8b", "ref_doc_id": "bd086099-3f55-4263-8059-158420704be4"}, "1756db42-47ab-49e4-b001-b3fe2212262f": {"doc_hash": "e628e664c00eae6576c3f0516beed901e683c59d43accb41e3cff200ceaa5f9f", "ref_doc_id": "bdadc22a-0000-4cd1-a937-793a9afe85ed"}, "ea70f1f9-da2a-47d7-b250-a502f31295bb": {"doc_hash": "d29442a0ff4ef73b3d328902bfcb570b43b41a4beffd8e7893a3e28debfde2c3", "ref_doc_id": "bdadc22a-0000-4cd1-a937-793a9afe85ed"}, "c6754ee2-afe1-4935-9f64-bcdac692a0d4": {"doc_hash": "68a8a2733e94d4e7f33189af1c35fd6de046cfd2cf460d4359555b21dc6dcce8", "ref_doc_id": "4e180018-fbbf-43e8-a1ea-15cf6627a8f8"}, "616c5b36-980f-4fe4-88b4-5c783ec57e63": {"doc_hash": "21321678d59199881779f72cc48772a4c5a31572fc03591f82e06c5ccb7c6d73", "ref_doc_id": "4e180018-fbbf-43e8-a1ea-15cf6627a8f8"}, "cc8fb98b-60fe-4174-ab94-99396a846c30": {"doc_hash": "2d0330d44dca13bd56d8f08148bb4627f444adcb9b8bdfe163fedc844bdb032e", "ref_doc_id": "b8539cb0-7426-419b-b170-de4567b073a3"}, "8290b52f-ce85-48f0-9acb-ac6d915d401f": {"doc_hash": "1715a2c1dbfea7c2243bab558133b64153e3c7a8d7abc6525285ecd4d8b04f36", "ref_doc_id": "b8539cb0-7426-419b-b170-de4567b073a3"}, "083fd25e-254e-404b-bd4f-28ae3f7c4c07": {"doc_hash": "c2fd8f1e9baaa271eee147ed74d2df2969aebf594253e11e5882716853062d2a", "ref_doc_id": "8b2f744a-0bcd-4408-9b89-2e4762db91ce"}, "fea5705c-de9f-4a70-bfbc-527e61f089ef": {"doc_hash": "672e5db484906bd94ea4af308fdf067a25b0ba880109cd027f79a4e8fefd4ce3", "ref_doc_id": "9163314a-af75-4fa5-9076-af39d6c9dd46"}, "7b9fe65d-10d0-4a0e-90c4-8efd765732d4": {"doc_hash": "e3ece19fe52dcb0224b632c47be8d30896d6954f9807b6eb81adbb38294251ca", "ref_doc_id": "f504e0ff-dfe9-4084-9e91-3537423ad842"}, "91e26530-b151-488c-a65c-0dcd2608ef5f": {"doc_hash": "8e1d36275d91c51cb3847b5e4e3ce56d8778b051569a0e27d1e1566c8a164134", "ref_doc_id": "f504e0ff-dfe9-4084-9e91-3537423ad842"}, "9ef78b46-7267-4cd0-82c3-c98141f0529a": {"doc_hash": "b936acc5df280913280e0b88b1dba9049b4781c1d5512395e9629cd3e572627e", "ref_doc_id": "2f63e83e-49c0-4f12-8f48-25806f25b43b"}, "6e540052-01f2-4f78-888e-792941510760": {"doc_hash": "83c63ab814587111e2236ae8f9b9cc113f0ccface079eaa8b60b671dfcfdd568", "ref_doc_id": "3cc64a19-ea77-49da-a05f-ef6ac5e2ad80"}, "3ff1aa4b-f786-4648-a832-ffa6fe2d5e38": {"doc_hash": "1056f43f11dae56ce35b3167c53587e05bf3d75b4a4f23976828d7aaa4e85847", "ref_doc_id": "3cc64a19-ea77-49da-a05f-ef6ac5e2ad80"}, "fbd8d84c-3423-4060-b7e3-67bf71aff80b": {"doc_hash": "bd5bf804ad901bb12522d9453dfdbc696bec31e76c8c790dc08bca514dcc95b5", "ref_doc_id": "45d7e776-771a-46df-a08c-98b3fa4e8e31"}, "3577ddd8-a3ff-46d9-a733-08405eacaa91": {"doc_hash": "16807d77fe8ff0b556e7d94bab00b44e0525a3cd95c896ad8146d12522761eb1", "ref_doc_id": "77e7257b-3bb4-43d8-aea4-976a73f41c70"}, "7dd51d13-583c-4a60-a6c2-d1a11c75027b": {"doc_hash": "48b85f99864b4bce55271a5e707f1fb60b9fcafb8ad9e5cd2b59310668aa0110", "ref_doc_id": "77e7257b-3bb4-43d8-aea4-976a73f41c70"}, "aa8c86e2-fc29-4acd-80c7-8c479019d490": {"doc_hash": "7e17b1e4876ee29e3fc2183726104f09c027dcb35234f4f5bf9967fda4dc20bc", "ref_doc_id": "77e7257b-3bb4-43d8-aea4-976a73f41c70"}, "b43df622-c91e-408e-a646-f6febc686638": {"doc_hash": "b6a00db05b01bcbef7c34f1ac1eddbaf4658ecd30f2953787a3e9089ec422261", "ref_doc_id": "859d421e-5245-40b6-847a-6a62eb4cd6bd"}, "6cf5bb9c-2c90-444d-80ea-fcbe435c2053": {"doc_hash": "aeaa5ac7789e35e70fd8267e56ef1fb380f99252cbd512f26aeee013c691be1e", "ref_doc_id": "859d421e-5245-40b6-847a-6a62eb4cd6bd"}, "56ef3328-76e1-4bca-87a9-bbda654cc6fb": {"doc_hash": "1e5345bc02e27921c9fb29cae48acb80aa4f7150483d77bd95355e035d57e50a", "ref_doc_id": "859d421e-5245-40b6-847a-6a62eb4cd6bd"}, "011cd2dc-5daa-4099-ae52-c422ea93665c": {"doc_hash": "a343f06d92f3435bfa7f91ea02e94fdd883e563de68ea1a17f746f7502d5a35b", "ref_doc_id": "400c0315-9b01-4364-a6d1-fbe4bfa116bb"}, "443480d9-8490-4c04-b8eb-608a5557f39a": {"doc_hash": "ad200fa23f5586e676fce104c7578eb1510e6f7ea11f0109636fd33ca7df90a8", "ref_doc_id": "6a0fe561-167d-41d4-a792-6aa016cb2f89"}, "e65103d2-9d27-4d80-b330-a6f058f29760": {"doc_hash": "3cd46b8aeda70c76616927b075eb684bcefa5a0b6d43367014235f298a743542", "ref_doc_id": "6a0fe561-167d-41d4-a792-6aa016cb2f89"}, "5e3a72d7-0c87-4911-bafe-e9b0cd48002d": {"doc_hash": "997a800fda9eb850a9dccaf6ff69e6ee3edb627d4d7dd108c8534af16568f305", "ref_doc_id": "06a807af-a1bb-4e3c-a47b-b3b0499c8f31"}, "8098cf99-80dd-4731-b554-d66d19f9e67e": {"doc_hash": "b4ff53ff1bdec5ab7bda5b816f7a73f463f7203c0a64bd1d868e61c3e64f7e20", "ref_doc_id": "06a807af-a1bb-4e3c-a47b-b3b0499c8f31"}, "7e3255d9-6fcf-4875-a214-1b2d44e89e21": {"doc_hash": "c0145b3bf141d9654eba67617d249ddcc2c23e9893188de076ff9ddbd7c189a1", "ref_doc_id": "340ea794-2988-449e-8d9c-cd76cac952dd"}, "1a83fd36-9000-493d-95ec-5fa53f439cd3": {"doc_hash": "1b9fe2b4a26f7580aa10d4deeb5bc6a9d60284c65d8347c4518baeb9cf0bddcf", "ref_doc_id": "340ea794-2988-449e-8d9c-cd76cac952dd"}, "4c4a0768-1bca-4f74-8f15-0dc150963178": {"doc_hash": "c6a011df3d4aa9d6a93fd83dcd537b240e7a50955ee5b6b582bb64c56ff4002d", "ref_doc_id": "7e32cd2e-1b1e-4732-9193-7a0ef26b5447"}, "8d36f64b-9514-4036-9d79-021772b5a77a": {"doc_hash": "25e1d457eebfb49c60b5b662c6a68662a27d9da8daba38a021b38ddf72c99eeb", "ref_doc_id": "7e32cd2e-1b1e-4732-9193-7a0ef26b5447"}, "e17646bd-5731-4469-abcb-85375c4b587a": {"doc_hash": "4370a722dc6dea4533b45fa1095e1933312e11444aefc0fa052e8441c1b16e9b", "ref_doc_id": "9569d721-8a91-43a0-854b-076916ad2334"}, "f4cfbbeb-2eda-48d6-b788-084c74ed6ffe": {"doc_hash": "85cc351d216931cb02e8dac7f7af3c2d04c2d2ef2a10354606135c91eef227f4", "ref_doc_id": "9569d721-8a91-43a0-854b-076916ad2334"}, "ef47eb3c-026d-4787-a438-b549e01ceca0": {"doc_hash": "9216132e39a158ddd979970ed82eabb8ff6a3570ace416473808d78346604cbe", "ref_doc_id": "1117452e-2b19-4868-9ff4-260052446b71"}, "122a1120-c052-4d90-96d7-b8c1b3f16f8c": {"doc_hash": "667d13fd42aa7af57d7f0b77853de61a45b49e66776324248d189f8be11a1319", "ref_doc_id": "1117452e-2b19-4868-9ff4-260052446b71"}, "f9935644-aebb-4a9a-92e7-bae20a49226d": {"doc_hash": "89e9fcd04f5f040797f64ae23cf65576c6ac533072aa1d1d4ebbec5cb4f44861", "ref_doc_id": "9406704c-a3c5-4085-8d95-39644968bf9e"}, "10a78eb7-9639-4842-8a00-a445a0ae2ad7": {"doc_hash": "6fe94191252caa67da79639cb802890ccceedaaf8f2b8a1d2b110e8b8e21565e", "ref_doc_id": "9406704c-a3c5-4085-8d95-39644968bf9e"}, "8c262150-a2b3-435b-a71f-fd4e3b8f9a72": {"doc_hash": "5e5f1a3fc26c920b4f3ce8063e76c44ab446e7e2862fdd6a45e0575e79dd14aa", "ref_doc_id": "9406704c-a3c5-4085-8d95-39644968bf9e"}, "e7ca2172-90e8-4a47-892c-0c5a6f03e774": {"doc_hash": "0bc6ac9b73ed92f6e00019018f46171071db49702ffde349cd78cd3a191e533d", "ref_doc_id": "67038ab4-121a-43cd-a86b-f09cf60f4a09"}, "2ad63c89-a59c-46cb-bee0-fc9ba90434cd": {"doc_hash": "d42b209bc64b359a078ff7bec66435967c3a9a44bf53e305c4a450991e974eec", "ref_doc_id": "67038ab4-121a-43cd-a86b-f09cf60f4a09"}, "9fd7a2cc-ed16-4e88-aae6-6cb7107c4deb": {"doc_hash": "800dc5844c850baf4b9465f4969c18d4fab276c16d71d07c75517fe5cac382f9", "ref_doc_id": "e3e28858-244d-4587-a781-7722c8e9b153"}, "c12fcee9-b5bb-4b2a-b4be-d72d46092a9d": {"doc_hash": "95170eece4976e69dfd91bc4a88ecbcbf8939b09f962710bc1d7df7cdbc91725", "ref_doc_id": "e3e28858-244d-4587-a781-7722c8e9b153"}, "73a7f409-b431-49e6-8c1c-68e230ffebb1": {"doc_hash": "a80d9645d9f207098e4bfa33bcc0502bd3e4d2d207b7e7c12ea8674914f5dc70", "ref_doc_id": "cd162de7-556f-4dd8-8b33-28a367ef554b"}, "f0dce60d-5ad1-493d-801d-5d7e4cf8e44a": {"doc_hash": "1579bfe4760c0ffdb29ba36fa63fc205fe560737cffd64270dae14f61ff59224", "ref_doc_id": "cd162de7-556f-4dd8-8b33-28a367ef554b"}, "5abbd6a7-21cd-43a2-9b78-f1dc99e43c32": {"doc_hash": "1dd914f04015d014dd0f9b42ed853dea8d9b6cb75c7166e5a634234099ed7fcf", "ref_doc_id": "80a41d94-9d28-4157-ba0a-fbf85f1c7d5c"}, "471e71e0-58c2-4646-93be-4b0d82358810": {"doc_hash": "ffc4d9f5cee69637557cc22f2387af96f23d5206884d0dbe3c6d8cbf7f9a825f", "ref_doc_id": "80a41d94-9d28-4157-ba0a-fbf85f1c7d5c"}, "433064f1-cefd-4348-9bb5-a75f55bf1dac": {"doc_hash": "9ff77fa3eb182b7c310d2a9c965d5306e569709b90b849923e798c4ca2c0ab3d", "ref_doc_id": "732bce29-a7a6-4e8a-a71c-c4957199ae29"}, "a44a9e60-a785-46b9-b3d3-2b97573e2709": {"doc_hash": "99b8bc8659f9a2c6d16296d7f315841c408931cab60eb9b28ff78503e5001393", "ref_doc_id": "732bce29-a7a6-4e8a-a71c-c4957199ae29"}, "c6d55ce3-e8ce-4f3e-9fc8-6829d85c7473": {"doc_hash": "467feeaabfc7d6f6cccd47d216a654284b373dd63035eee1c646886807cc3af4", "ref_doc_id": "6d2af672-ac27-499b-a420-7a2683e65e86"}, "13909637-aa38-493f-bc29-b03f285b950e": {"doc_hash": "9bb44954e73e0a0e5edbba94a0924e87c1fed72b5f419da96634fa3c4013e76e", "ref_doc_id": "87414f2f-a2e6-41b7-b89e-b0324101029c"}, "53d10b46-b207-458c-ac52-7c6e3cf26a5a": {"doc_hash": "07abbaade02b0cb742f03219a0839515e64c0ff4555cd23ac5f39f0f9244f84a", "ref_doc_id": "888b838f-619a-42ca-b02b-e0aa05be92e9"}, "a554d9fe-d6f7-407d-827f-6750409c9e23": {"doc_hash": "7c24482f57506ec47d536026809cbd6c26cd55ff32d4d6d8ca85243cc31c85b1", "ref_doc_id": "540a07a9-1ac4-4b04-9d6a-3eaeb4aec50b"}, "c6d3bb5a-db7f-4681-b4f9-e30793afffbe": {"doc_hash": "28e5e3b84e8dc0ddf0a810dff3437f49ee89302ffc626c61acc3564b21321a46", "ref_doc_id": "eaf52094-1c59-4fcf-a559-dfe9f9d0d1aa"}, "69aab10b-ffbc-4629-b7f5-fd11b30dad25": {"doc_hash": "9d28ec62750ebc3cd0d8151656a1b66fe3f95adfa6315f579c2b270ee749d217", "ref_doc_id": "28f16f19-8eb6-4647-ba72-e7c9d32bbb99"}, "53569573-9409-42e8-944c-90be55b06552": {"doc_hash": "70a3abb9275a5e6c307dcfefdf96bb58298b2cf4f78b79cb913270c475ca0c6e", "ref_doc_id": "216625c0-c0eb-4f4d-b50b-05ecd7970ef3"}, "1ebfe15c-9949-4500-987b-323d16d35971": {"doc_hash": "734697e713bac5886030314279a2f39b4b9b07b5cd2a91e8b990a3e0d53b02b7", "ref_doc_id": "216625c0-c0eb-4f4d-b50b-05ecd7970ef3"}, "6294f098-a86c-49f1-bfd7-c36a1ea01dd5": {"doc_hash": "2199a4fea9298fc50c8715aec2427c192c2e5e8fde6652332343bcf04c391135", "ref_doc_id": "3f93b626-4976-4748-80b4-ba3cdecfad10"}, "9dd4b5f5-f9ea-4605-82b4-b27474df43f5": {"doc_hash": "025363ade2c5294ec6f6555560049922fde3215824949e47d302afb253e82cab", "ref_doc_id": "8a74ce19-e71e-4c07-9d07-68c714416ef0"}, "c6d9a079-8b91-4b5f-9540-8777b0f01195": {"doc_hash": "5c4fe4424ebc1f66ae67111053b104666920d82d0fe0b07385030bffecb06554", "ref_doc_id": "8a74ce19-e71e-4c07-9d07-68c714416ef0"}, "9f2ed756-fb5c-46d3-b4ce-a001dda1cd11": {"doc_hash": "c4014d6eda0a4bd54bf396e96e545e6aeafc7d392fd985443b8ce49b856f1c53", "ref_doc_id": "bd20100a-1245-4eca-8cd2-d504ac7ca099"}, "17a8c567-2856-4c2a-b440-3e6a8d968a38": {"doc_hash": "3bcb7dbeaae0c3861986faddbec521b0807e43cc9aa80d97ada40f619a2af5c8", "ref_doc_id": "bd20100a-1245-4eca-8cd2-d504ac7ca099"}, "a2a474fe-1dd7-418b-aed3-dc0950d7c607": {"doc_hash": "b639e530b781c8cd4e387d68bf063af8374856661a2adb32a6c7f9fdbfbb0025", "ref_doc_id": "17c7bdc9-14b2-40bb-9ea8-85158057cd7c"}, "9c415600-8538-4b0c-aeb9-f263840c72b4": {"doc_hash": "d64e4cb87cf010bf1d75de1694cf350bd8715fd0970c86c16d86600f7cbbae56", "ref_doc_id": "17c7bdc9-14b2-40bb-9ea8-85158057cd7c"}, "20c2254e-cedc-4b42-9fb4-739da40e1b96": {"doc_hash": "bb74403ca82fab0009e33844630df2515bcd2f0fafedcf1aec35ab0a877bf877", "ref_doc_id": "a8a09e86-3e26-4100-acdd-2b34deaae2cb"}}, "docstore/ref_doc_info": {"f43c593e-89ed-466f-b6c5-bb24c6a815e1": {"node_ids": ["50518c17-70e0-49ab-acc9-52fc13113b17"], "metadata": {"source": "Data.FI Nigeria_LAMISPlus Mobile User Guide V.2_TL-24-11_KM revised.pdf", "page_label": "1"}}, "33cfe3c1-14e1-49ff-b2f4-1204ec745a13": {"node_ids": ["3f1d571b-2021-4509-a361-8c30df814751"], "metadata": {"source": "Data.FI Nigeria_LAMISPlus Mobile User Guide V.2_TL-24-11_KM revised.pdf", "page_label": "2"}}, "5740e021-9ec2-4533-98b4-38e359f67d99": {"node_ids": ["81a53cc0-056c-42d5-98c2-b2045020e78a"], "metadata": {"source": "Data.FI Nigeria_LAMISPlus Mobile User Guide V.2_TL-24-11_KM revised.pdf", "page_label": "3"}}, "48a1d039-dad7-4de1-bba3-f1ab011f0d4f": {"node_ids": ["992c25fa-a72a-402f-8d0e-ae9198581c3c"], "metadata": {"source": "Data.FI Nigeria_LAMISPlus Mobile User Guide V.2_TL-24-11_KM revised.pdf", "page_label": "4"}}, "2707617b-f4f3-4996-82a9-0713064cdaa6": {"node_ids": ["f8cb1ffc-b06c-45fe-b45a-6c0a00e293ef", "badb5fd5-d87b-4df8-884a-756d70136d49"], "metadata": {"source": "Data.FI Nigeria_LAMISPlus Mobile User Guide V.2_TL-24-11_KM revised.pdf", "page_label": "5"}}, "1a8f068a-802e-4756-bf9c-5fd772fccfe8": {"node_ids": ["1af01015-e8a9-4684-b600-d5aa1cb379b1"], "metadata": {"source": "Data.FI Nigeria_LAMISPlus Mobile User Guide V.2_TL-24-11_KM revised.pdf", "page_label": "6"}}, "865919fb-e6b1-4c75-a31f-12c593829279": {"node_ids": ["9de5bb69-e271-4caa-80b0-2a2c5a21c2a2"], "metadata": {"source": "Data.FI Nigeria_LAMISPlus Mobile User Guide V.2_TL-24-11_KM revised.pdf", "page_label": "7"}}, "900e7684-a187-4634-80a6-ea378566b7a2": {"node_ids": ["dfc139a8-33c8-4e52-b414-59bbce40475d", "7e39e4d7-18f9-4c49-9455-2eb8ea80ef38"], "metadata": {"source": "Data.FI Nigeria_LAMISPlus Mobile User Guide V.2_TL-24-11_KM revised.pdf", "page_label": "8"}}, "06f00cd4-3235-419c-8b97-af2b12125874": {"node_ids": ["cdbcdf29-23ad-4f81-9580-eb1de933e417"], "metadata": {"source": "Data.FI Nigeria_LAMISPlus Mobile User Guide V.2_TL-24-11_KM revised.pdf", "page_label": "9"}}, "0e4b47d9-a774-48bb-9b4c-12501018e172": {"node_ids": ["8c0e79bf-c0fe-4664-9a1a-b79ca9785e06"], "metadata": {"source": "Data.FI Nigeria_LAMISPlus Mobile User Guide V.2_TL-24-11_KM revised.pdf", "page_label": "10"}}, "48f508d2-1ddc-4317-9957-7fd98a03f7d0": {"node_ids": ["b46a55ab-92e7-4051-828e-fd5c56a53bf3"], "metadata": {"source": "Data.FI Nigeria_LAMISPlus Mobile User Guide V.2_TL-24-11_KM revised.pdf", "page_label": "11"}}, "0c2fc187-a867-4749-bce5-de989b6f2d6f": {"node_ids": ["9d74f21b-eca2-49f3-a3f0-7ed25b0a43ca"], "metadata": {"source": "Data.FI Nigeria_LAMISPlus Mobile User Guide V.2_TL-24-11_KM revised.pdf", "page_label": "12"}}, "9f98d8d1-8b4f-460b-b844-9900d87d592e": {"node_ids": ["38ee5dcf-6976-4456-b42b-4dc6e1238147"], "metadata": {"source": "Data.FI Nigeria_LAMISPlus Mobile User Guide V.2_TL-24-11_KM revised.pdf", "page_label": "13"}}, "a9e414c2-0ad2-4f86-b027-7d5464d9db35": {"node_ids": ["0999f6fb-11e8-4b81-a703-8a9093115c4f"], "metadata": {"source": "Data.FI Nigeria_LAMISPlus Mobile User Guide V.2_TL-24-11_KM revised.pdf", "page_label": "14"}}, "38105d1e-ada4-4286-ba63-95302fd7a6cf": {"node_ids": ["7c7167b9-515e-4057-8310-f175626727c5"], "metadata": {"source": "Data.FI Nigeria_LAMISPlus Mobile User Guide V.2_TL-24-11_KM revised.pdf", "page_label": "15"}}, "43c55b8f-10fe-48ab-9054-bd2060453080": {"node_ids": ["b08f35ca-997b-4603-b100-a0d1c77b9a55"], "metadata": {"source": "Data.FI Nigeria_LAMISPlus Mobile User Guide V.2_TL-24-11_KM revised.pdf", "page_label": "16"}}, "4d0239dc-1a6b-4bf9-9057-795128282e1d": {"node_ids": ["e661668d-5cdd-4824-96b0-6b0890c63be1", "cd046753-2159-428d-b8c9-725dba206a56"], "metadata": {"source": "Data.FI Nigeria_LAMISPlus Mobile User Guide V.2_TL-24-11_KM revised.pdf", "page_label": "17"}}, "85d58af4-3b02-4044-9918-549d94ae4597": {"node_ids": ["1098ee4c-cc4a-4fa4-a61e-08ebb06f9859"], "metadata": {"source": "Data.FI Nigeria_LAMISPlus Mobile User Guide V.2_TL-24-11_KM revised.pdf", "page_label": "18"}}, "e4c46efc-0f35-4a29-86f1-65aef502d37c": {"node_ids": ["baddc56b-8c64-4068-b306-f88fcefa0ee5", "c91099d5-b81b-42c7-a721-8add5215bfb4"], "metadata": {"source": "Data.FI Nigeria_LAMISPlus Mobile User Guide V.2_TL-24-11_KM revised.pdf", "page_label": "19"}}, "e6371965-5bfe-47d0-9767-59ab3816f25d": {"node_ids": ["369f0351-2c85-4b9b-9917-f7c937734690"], "metadata": {"source": "Data.FI Nigeria_LAMISPlus Mobile User Guide V.2_TL-24-11_KM revised.pdf", "page_label": "20"}}, "8e172500-8da7-4265-b4fd-0e01a6b90194": {"node_ids": ["88567eaf-e135-43b1-a9ac-99285c9b6d15"], "metadata": {"source": "Data.FI Nigeria_LAMISPlus Mobile User Guide V.2_TL-24-11_KM revised.pdf", "page_label": "21"}}, "363e1eb8-1ad6-4c2b-ab5b-d984c7e3ae18": {"node_ids": ["a6e38fcb-0a27-49d5-aab3-1efba5aa9376"], "metadata": {"source": "Data.FI Nigeria_LAMISPlus Mobile User Guide V.2_TL-24-11_KM revised.pdf", "page_label": "22"}}, "483f9eee-bb1b-4dd6-a8b5-fc84080aa764": {"node_ids": ["e3881d48-fff3-4801-81ba-04ef34258e2d"], "metadata": {"source": "Data.FI Nigeria_LAMISPlus Mobile User Guide V.2_TL-24-11_KM revised.pdf", "page_label": "23"}}, "706c9d10-8f5f-40d7-bcd4-8d1954d74ccb": {"node_ids": ["4897978d-c7a1-4bd9-880c-db86c00e386e"], "metadata": {"source": "Data.FI Nigeria_LAMISPlus Mobile User Guide V.2_TL-24-11_KM revised.pdf", "page_label": "24"}}, "534b29d7-3ad4-499d-8598-798ee3004ddb": {"node_ids": ["d4fb2855-9795-4388-8c11-de2f72ff19ab"], "metadata": {"source": "Data.FI Nigeria_LAMISPlus Mobile User Guide V.2_TL-24-11_KM revised.pdf", "page_label": "25"}}, "6f0bb102-26dc-4d53-8118-ce7e5ec2e6fa": {"node_ids": ["09d75f31-6eb3-4aff-8c9f-a78fbdabdf80"], "metadata": {"source": "Data.FI Nigeria_LAMISPlus Mobile User Guide V.2_TL-24-11_KM revised.pdf", "page_label": "26"}}, "b3b39082-bb34-46df-ab7c-515bebfd721c": {"node_ids": ["497e6490-1ed1-4933-bb46-cefdbed3c66d"], "metadata": {"source": "Data.FI Nigeria_LAMISPlus Mobile User Guide V.2_TL-24-11_KM revised.pdf", "page_label": "27"}}, "5916f592-b89c-463d-aca3-16d46036741f": {"node_ids": ["73965777-ae9f-4e50-a8bc-0996070aa62c"], "metadata": {"source": "Data.FI Nigeria_LAMISPlus Mobile User Guide V.2_TL-24-11_KM revised.pdf", "page_label": "28"}}, "9b5fa04d-bf79-4afe-b62d-d7a960e59f4e": {"node_ids": ["51e1e2a1-84b4-4f0f-a244-f0b8c1dce220"], "metadata": {"source": "Data.FI Nigeria_LAMISPlus Mobile User Guide V.2_TL-24-11_KM revised.pdf", "page_label": "29"}}, "e9466e68-19c6-4fb3-b354-f5472c997aa1": {"node_ids": ["c91c3709-ca09-41d5-8cef-6a0622e55dcd"], "metadata": {"source": "Data.FI Nigeria_LAMISPlus Mobile User Guide V.2_TL-24-11_KM revised.pdf", "page_label": "30"}}, "f3c32bbe-05d4-44cd-b05a-b02bd9d8068e": {"node_ids": ["f15b87a1-e498-44b4-a567-bf8b26c90bc3"], "metadata": {"source": "Data.FI Nigeria_LAMISPlus Mobile User Guide V.2_TL-24-11_KM revised.pdf", "page_label": "31"}}, "93f21b34-a1a4-48c4-b494-3ac20cd1ef45": {"node_ids": ["fae5aab6-515f-4110-a0d2-e42bf3c11fb5"], "metadata": {"source": "Data.FI Nigeria_LAMISPlus Mobile User Guide V.2_TL-24-11_KM revised.pdf", "page_label": "32"}}, "c0700c85-55a6-4343-9498-9140ce49596a": {"node_ids": ["79bf1dc7-78e7-4601-8dc4-5ffb469afcc3"], "metadata": {"source": "Data.FI Nigeria_LAMISPlus Mobile User Guide V.2_TL-24-11_KM revised.pdf", "page_label": "33"}}, "aea93032-3dad-4e39-b175-da0f3b305434": {"node_ids": ["2f1dfd95-94bd-4bcc-9aa0-880231d4d1e9"], "metadata": {"source": "Data.FI Nigeria_LAMISPlus Mobile User Guide V.2_TL-24-11_KM revised.pdf", "page_label": "34"}}, "a00b51d9-5ea3-448f-abf1-d7192d2d2d4b": {"node_ids": ["4e5a7826-a3ed-4947-9981-cc333bf0c006"], "metadata": {"source": "Data.FI Nigeria_LAMISPlus Mobile User Guide V.2_TL-24-11_KM revised.pdf", "page_label": "35"}}, "d3247f64-6274-4438-bb74-0524b6af3641": {"node_ids": ["1b8de6c2-23aa-4c85-a86d-dfe7e74165f2"], "metadata": {"source": "Data.FI Nigeria_LAMISPlus Mobile User Guide V.2_TL-24-11_KM revised.pdf", "page_label": "36"}}, "ef06c418-da71-4fef-9f7c-f445ce54f8ee": {"node_ids": ["df532087-72ba-4d31-8414-073ec200d3c2"], "metadata": {"source": "Data.FI Nigeria_LAMISPlus Mobile User Guide V.2_TL-24-11_KM revised.pdf", "page_label": "37"}}, "a22575b0-6773-4ddb-ab69-b23a7c9af473": {"node_ids": ["d7bc0c14-cd01-4d34-8cb2-a12bee562cae"], "metadata": {"source": "Data.FI Nigeria_LAMISPlus Mobile User Guide V.2_TL-24-11_KM revised.pdf", "page_label": "38"}}, "98fe2058-5865-4ec4-a278-702605d64998": {"node_ids": ["8f27a5dc-bb16-4518-9706-835da560527b"], "metadata": {"source": "Data.FI Nigeria_LAMISPlus Mobile User Guide V.2_TL-24-11_KM revised.pdf", "page_label": "39"}}, "a8492db5-e2d5-48fa-833a-9063c0bb44bf": {"node_ids": ["eadc4862-6600-4062-87ab-3b9b7689db0a"], "metadata": {"source": "Data.FI Nigeria_LAMISPlus Mobile User Guide V.2_TL-24-11_KM revised.pdf", "page_label": "40"}}, "cc0e96c3-6274-43b2-a897-5247c8aad6ea": {"node_ids": ["d443a6b8-d505-4d96-910d-591bf60ab08c"], "metadata": {"source": "Data.FI Nigeria_LAMISPlus Mobile User Guide V.2_TL-24-11_KM revised.pdf", "page_label": "41"}}, "5a15611e-286d-4f94-a182-168bde4d2ea2": {"node_ids": ["8071ab23-00d2-4ed7-9c5e-a61f3f8185e8"], "metadata": {"source": "Data.FI Nigeria_LAMISPlus Mobile User Guide V.2_TL-24-11_KM revised.pdf", "page_label": "42"}}, "363389a7-cc41-4927-baa5-b90552a62131": {"node_ids": ["ca62f555-e01e-40fe-9638-532092146784"], "metadata": {"source": "Data.FI Nigeria_LAMISPlus Mobile User Guide V.2_TL-24-11_KM revised.pdf", "page_label": "43"}}, "655b9702-cad0-4212-8c9b-73559011b941": {"node_ids": ["7a053b45-d71f-4aaa-bd21-68fba9936314"], "metadata": {"source": "Data.FI Nigeria_LAMISPlus Mobile User Guide V.2_TL-24-11_KM revised.pdf", "page_label": "44"}}, "33a76e83-b18f-4a99-b55d-322bb71774da": {"node_ids": ["ded2182e-77f9-4b4f-96a6-e0cea13c284e"], "metadata": {"source": "Data.FI Nigeria_LAMISPlus Mobile User Guide V.2_TL-24-11_KM revised.pdf", "page_label": "45"}}, "b8f0f2d0-0c91-43c4-8515-cfdec3f09737": {"node_ids": ["aa0f495d-e9bc-42bb-a7d5-47ec2c2e8390"], "metadata": {"source": "Data.FI Nigeria_LAMISPlus Mobile User Guide V.2_TL-24-11_KM revised.pdf", "page_label": "46"}}, "6c92f981-ed42-438a-bf4c-6bf56d956a1d": {"node_ids": ["0c2c9a9b-e858-444e-a0a7-a0b112005eeb"], "metadata": {"source": "Data.FI Nigeria_LAMISPlus Mobile User Guide V.2_TL-24-11_KM revised.pdf", "page_label": "47"}}, "39dce267-57a0-4fb1-ac51-76f577721550": {"node_ids": ["ce5ea23f-709c-4be4-9e25-6b27bbb2a251"], "metadata": {"source": "Data.FI Nigeria_LAMISPlus Mobile User Guide V.2_TL-24-11_KM revised.pdf", "page_label": "48"}}, "b999b205-e144-4245-9107-181e5dc5abb6": {"node_ids": ["db087328-49c9-4f57-9ee3-72c1e03ee1fc"], "metadata": {"source": "Data.FI Nigeria_LAMISPlus Mobile User Guide V.2_TL-24-11_KM revised.pdf", "page_label": "49"}}, "80ef6957-225f-4973-86c5-5f015bb439f3": {"node_ids": ["71fefab7-5f21-4cc5-b669-d5578ad0f891"], "metadata": {"source": "Data.FI Nigeria_LAMISPlus Mobile User Guide V.2_TL-24-11_KM revised.pdf", "page_label": "50"}}, "26f48a53-ead4-4644-b019-697d49cf85c8": {"node_ids": ["515cd16c-bd47-459f-b649-e1b6e319eb47"], "metadata": {"source": "Data.FI Nigeria_LAMISPlus Mobile User Guide V.2_TL-24-11_KM revised.pdf", "page_label": "51"}}, "abccca78-2ff9-4942-b9f3-b39cab0240ba": {"node_ids": ["76587d14-cedf-4272-9cb2-aa93845f7861"], "metadata": {"source": "Data.FI Nigeria_LAMISPlus Mobile User Guide V.2_TL-24-11_KM revised.pdf", "page_label": "52"}}, "7ae25cc6-5f07-4ef4-874a-95825f79171d": {"node_ids": ["0432597b-320d-4eab-84d1-8617b41c3bc0"], "metadata": {"source": "Data.FI Nigeria_LAMISPlus Mobile User Guide V.2_TL-24-11_KM revised.pdf", "page_label": "53"}}, "1507bdbb-4cbc-493e-b123-8e16993523da": {"node_ids": ["a460504b-ff2a-4081-a0a2-fdadf046ca6b"], "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "1"}}, "fe6b3108-616a-43b0-9bd2-4596b175e8c1": {"node_ids": ["65a4de50-405b-4c13-8f20-60112112a9a8"], "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "2"}}, "fb71b03f-5018-4516-bd78-44b5f932b6f4": {"node_ids": ["1d01d112-1e91-4b76-93cc-1837967f0166", "2e8bf8d5-9762-4752-b5c2-c6204a71a26e"], "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "3"}}, "c02786c3-e1cb-46bc-9780-4a425a99c063": {"node_ids": ["714548f2-e984-486d-8294-c4c8847814e9"], "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "4"}}, "c40f7665-4cd4-4afc-bfec-d6af3452c3cc": {"node_ids": ["6a31c926-9a66-4e21-b50a-096748e2e86a", "8eb3c645-2a60-4047-b445-d26cd87ed486"], "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "5"}}, "fce8dc94-f1eb-4132-be4e-22cce801620e": {"node_ids": ["5d625c9d-a782-43c7-8e7a-b50d1dd396af"], "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "6"}}, "6fc149aa-c829-4482-b779-0f9aea27357b": {"node_ids": ["47b79629-7d7e-4d81-907d-f1058f199cc5"], "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "7"}}, "ab0e4de8-321c-4733-af3a-5eae30cfe581": {"node_ids": ["66cd5319-fa32-41da-a606-1844b15b8e67", "075b3b31-93dd-460c-bf5f-6d6aa56bbda9"], "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "8"}}, "3ae57e02-320a-452e-93c4-fdd7d303e773": {"node_ids": ["d68ecb37-d7a8-4b80-9569-3e9260496f62", "b1ce24d4-aa5f-4ebf-96a3-6a94fa983f2b", "e60d60ff-1cb0-476d-9251-c41b6a0016d7", "dc913588-6fa4-4b63-82fe-638a6c62b661"], "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "9"}}, "3940fa73-df36-4c12-ac50-d8eeb5b80b07": {"node_ids": ["fabd3392-dc0a-430e-b01e-af8c62102ead"], "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "10"}}, "349a13db-2381-4ea4-b093-f882978006d5": {"node_ids": ["71cde287-8a10-4ff9-a726-242eff8874a5", "e17bbb93-259c-4fc1-8bb3-0c21fe858b69"], "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "11"}}, "d5b7f9bd-c988-4ad1-a3c2-0bf105a1c0ee": {"node_ids": ["25f2c40a-3b24-4c47-83f8-d60f86e55a12", "d16f899c-3ca5-45a6-b8c2-019a8fa6580b"], "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "12"}}, "035a0d1f-18d5-423e-a9b7-ee78ba2be488": {"node_ids": ["f9f78d36-11b6-4d59-8693-eb1dc862091c", "3fb203e3-7841-4564-ac7d-8e06dd9c751c"], "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "13"}}, "8cdcef1e-40b7-41a6-b303-f17a8fd785e7": {"node_ids": ["a7265232-49b2-45de-af78-14a9bc213cf8"], "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "14"}}, "6fa5849b-43eb-44b2-b32a-bb68edeaba16": {"node_ids": ["df41fe27-1008-4cd7-ace6-39214a032696"], "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "15"}}, "c5816b76-96d2-4e10-8bf4-4e39d5b65e8f": {"node_ids": ["d5fe4d38-8210-4adc-aed5-7605e096ed9a", "88de8c8f-9fbf-4dc7-a7f1-d6450bb818dd"], "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "16"}}, "21922845-92f7-4b0b-9a68-565b4698a080": {"node_ids": ["88ccce6e-b750-42c6-8219-c1ca56019a96", "a696c461-b9d5-4700-885f-7c0a261d29a4"], "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "17"}}, "db116fb9-dbdf-4caf-a9e7-41830ec22cd7": {"node_ids": ["1c48043f-2b2d-4c05-bf46-ecb25c7de621", "2a2c3453-2be4-4058-a91f-168c1e73e4a3"], "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "18"}}, "5837ff70-24ca-44c6-8fe1-5781c60ab4a4": {"node_ids": ["1ec4f19e-06bf-4ae4-b452-0538f409061a", "1fdd53db-e9b6-484a-ab14-0a483d2cb0e3"], "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "19"}}, "6408426f-40e8-4fbb-afcf-d90b4b419a1f": {"node_ids": ["be259450-aec9-4e34-aa9a-2bbcb2bc03a5", "47c01386-5879-48ed-a39b-70a263ea3222"], "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "20"}}, "1f5e5fb4-4ef3-40d3-beba-01b553677604": {"node_ids": ["973447f0-7edf-497d-80f4-27f6da1dbe8e", "0a58930e-29c2-474b-882a-283d5d830df4"], "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "21"}}, "56775138-d8d7-4bdc-9f96-5e87129bdbbd": {"node_ids": ["b6005d89-68ab-4eb2-8c65-493f7a2a7a32"], "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "22"}}, "eb34050c-8cda-444f-8acc-288aee6129cd": {"node_ids": ["381a11a1-bb4b-4be4-b4a0-387a80331ac2"], "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "23"}}, "fb8b7439-dcbd-44ea-95a6-2a3a1ac65cbf": {"node_ids": ["3d024a8e-daca-444b-8d18-aec7dc7aee5e", "eb38e7a3-760b-48b5-babb-c6ccaf6cedea"], "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "24"}}, "cc99a405-53cf-4854-b5d1-80c3dc9ee1bc": {"node_ids": ["5937fddf-7c87-44dc-8461-353fa0d80c4c", "ab791cfd-3ce7-4422-a34f-5ec98bf49597"], "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "25"}}, "51259645-995b-4f02-8a10-e641385258e3": {"node_ids": ["703118b6-256b-465b-9471-fc92def9d512", "fc6ef00f-e8df-4241-be1d-648eb49f53b3"], "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "26"}}, "dfcc96b8-71bd-4664-9e94-dce152098c4a": {"node_ids": ["728620d4-351f-4adb-879e-5949fe76f6f8", "b0026f6a-75ba-4e8b-b580-bc88925d8551"], "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "27"}}, "7fb21985-2a3c-41fa-9439-59933388b7ab": {"node_ids": ["97ed69eb-4cd3-46f4-ad83-66fabbd6d505", "6cff8427-ced7-41a3-aa0c-0400639c6612"], "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "28"}}, "f56d4435-5b05-4b84-b39b-5d9f48e61593": {"node_ids": ["5bd05fc3-ec6f-4f70-8aa2-45f1543036ff", "2107cd9f-a41e-455d-9f68-83269e72e446"], "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "29"}}, "09b84246-9dd9-4beb-a27d-959ce1ff617b": {"node_ids": ["723dc5de-91b4-4edb-8a0b-f5a949c4587f"], "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "30"}}, "5480768c-287f-4c19-86b8-b3787f4e8bdd": {"node_ids": ["ed45b48b-5eb1-4ef0-97f8-14f42b9b2301"], "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "31"}}, "2e614534-c2cb-4295-9518-283e94b93ab8": {"node_ids": ["fd729b2d-039a-411f-9fe2-62aa14c34989"], "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "32"}}, "768cdfe1-e04f-4f94-869b-289d45bcf568": {"node_ids": ["4a398e6a-65f2-4989-93b4-cf17b1f6a18e", "5ab1634d-f527-41cb-bd3c-e6aebac333e2"], "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "33"}}, "b66dc964-d18a-475b-b8ae-e29a58bf9a44": {"node_ids": ["d601492b-411f-4d54-b637-5cf886d720c2", "6ecadc27-9ad7-4d09-9484-cc2fc61be463"], "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "34"}}, "8e4cc579-deef-4b4f-89a0-0d01946d0015": {"node_ids": ["c3dc768d-c408-432b-bdaf-cf5a60a936ca", "983507b7-e8f3-4eca-8039-8e3f1376ebc8"], "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "35"}}, "3f20f726-b6b3-4128-a98d-ee247064acb1": {"node_ids": ["20e6c4b6-392d-4344-b798-00ac774d1b48", "e033d6c5-dfef-45ed-8160-3550aa0c8c16"], "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "36"}}, "709e5466-b7a0-4723-bfcc-64330017e4b5": {"node_ids": ["4a9166df-b4ee-4776-8277-37b1d4ccbe63", "3c8f7695-ed1f-4324-b36c-4c93079b0c82"], "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "37"}}, "63ea3d6e-79bd-4be6-8772-2f712e8f113b": {"node_ids": ["78538c2a-21c1-4485-ada3-26b84cc54f53", "391e091f-c15c-4c9a-aa30-31aeebc95b76"], "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "38"}}, "92bf2e05-3654-4dcf-899e-375b80e8a29d": {"node_ids": ["940814c5-8250-4d0a-826c-117acba7eae2", "908902d5-d79d-407e-817c-23f5ca168827"], "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "39"}}, "6343b313-1d0c-430a-ba16-ee3cda232e1c": {"node_ids": ["8188bafd-ffbb-4990-83d2-378eac86c42f"], "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "40"}}, "5fe73d90-810c-4f11-b0be-32f5ba5bf25e": {"node_ids": ["3d0d4905-7317-4170-8da8-4e01851fbaac", "016e2b9f-6077-4929-8b98-ff7c6ffcd3eb"], "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "41"}}, "7f69f97d-1b49-4ebe-b5b1-9df587747952": {"node_ids": ["610f6d17-09b3-4bd6-a083-272923bd4a27", "d71c3e4f-9694-45fb-8f08-499f7bbe305a"], "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "42"}}, "aeb9eaa1-4ca4-458e-b00f-109d950c9113": {"node_ids": ["bc6054f9-173a-4a32-9b2c-7445962c8cbd"], "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "43"}}, "6bfed05e-5bad-4e23-afc4-60b12f30e1b7": {"node_ids": ["eb7dcbd6-4b1c-400f-8613-186616908a45"], "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "44"}}, "c52b90a9-fcbe-4026-9ee1-adc00645fd88": {"node_ids": ["dca62519-9b42-497e-ab14-ba6ce95bb0b3", "81e39c90-0469-4853-afdc-9bea3e11d3de"], "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "45"}}, "a3745c4c-2e2e-44ef-8290-168409046fc7": {"node_ids": ["d0b0793e-88f9-4f4a-ac42-95fc26788971", "19c763a1-eb5c-40b7-b2df-0cba459a44f6", "a081cf28-ac17-41bd-939d-4e0f91718678"], "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "46"}}, "f0aae6a7-1a78-4f55-9ce4-44e6e43fd70c": {"node_ids": ["351f0b12-1d68-4094-946a-f0e593fd0c1f"], "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "47"}}, "9462f033-4b95-46c4-9dd5-8b57c1cda3ec": {"node_ids": ["f98cd470-7b07-4ea9-90d4-2d6238c700d6"], "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "48"}}, "54019822-f97c-4b6b-8a63-f536088a96d5": {"node_ids": ["74088410-1373-49fc-b5a8-7ad1a5799bf4", "94d6ca21-e99d-4e2e-ad30-6d6925b1f369"], "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "49"}}, "92fee59f-3be9-445a-97ee-b7879139f00b": {"node_ids": ["d92d1a3c-a38b-4943-8082-0655295b6a3b", "de62119d-d3e6-4a79-ba85-20927bf33dfc", "e43e550c-7c64-424d-a5d0-7418e7244f14"], "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "50"}}, "c11c9312-bd47-4e2a-abe0-d66cf1405f29": {"node_ids": ["95c9e048-42ce-4e47-86a2-3a7f232d5347", "bf4125f4-d8f1-4b70-a7ff-0c64ed1a5fde"], "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "51"}}, "e9dc1e80-2ec4-4a1f-8b91-02fc9fe5501d": {"node_ids": ["50a5a480-ae11-485e-ad7e-47aa19d95039", "257cae56-1a2c-47f2-b656-ad36404a5070"], "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "52"}}, "f3f07b7b-a491-40bb-9c9d-4f66d4441eb6": {"node_ids": ["a6dccf91-e425-482e-a821-de5ddc407696"], "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "53"}}, "d94e24f1-4e7a-4adb-af4c-589947368d23": {"node_ids": ["02b91b62-c8a9-46bc-9b76-f85dea6889ab", "862c25f6-832b-44cb-8b26-18036d960898"], "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "54"}}, "ed66a7fd-1c76-455d-a419-0dc3f4f0e288": {"node_ids": ["03948ff2-e987-4066-8693-093b8855f380", "2f7e4304-4ba9-4d8c-96f6-b4a2bab3a670"], "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "55"}}, "7599d2fd-8a00-492c-8a43-54bc8ab6a02d": {"node_ids": ["404fe7e3-0a0e-4372-bf99-1f517afe7297"], "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "56"}}, "b6d1f9e0-3fd2-4e04-a803-9e696a2a0b6f": {"node_ids": ["990fb0a7-6f29-4823-a0c8-081929a22106", "af76fee2-df75-4ba9-8988-8b5f6ad734b7"], "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "57"}}, "bbff61b3-7661-40d1-bc36-bb958fddf2e0": {"node_ids": ["14e49c6e-ff3d-4de0-8a0c-01aeb1f6f3c6", "35e5cfc5-20cc-4915-9e24-f348cfc1719b"], "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "58"}}, "62dd9a70-96cc-4c16-bd47-a2673523fa79": {"node_ids": ["28682727-e7f5-4fcb-a694-320ce7a127ca"], "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "59"}}, "9403a91f-f25b-4218-9f1f-847bc2c98097": {"node_ids": ["49df9570-f175-446b-ba5a-0ba18f2e11eb"], "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "60"}}, "de1db3f9-977c-460c-9185-896896b0292f": {"node_ids": ["49e813e7-8203-4b2a-8b34-a64c9e350c25"], "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "61"}}, "45531ce7-4604-45b4-b34d-c37333dd6245": {"node_ids": ["d135f1e3-90b4-40af-9dd9-b100b60510bd"], "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "62"}}, "6bdec29f-42fa-4b0a-8391-2b1523ad2eef": {"node_ids": ["344c5fdf-074e-435f-bbbc-859254826ae8", "01bf3547-2eee-403a-b3aa-d84a3afa4178"], "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "63"}}, "a651d5d3-ac2c-4a3c-aa9a-e71665b1505e": {"node_ids": ["e38e56ba-7633-4a53-9545-eec6eb530778", "e361b83e-9c4c-4727-bea9-7d3d48e3ffa4"], "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "64"}}, "b0259191-7df7-40bc-bfc4-929bf92e09be": {"node_ids": ["3e0159c2-cb80-4326-9ab9-ceee85fae64a", "ac7a54a0-1e58-42d5-bb71-2496aa62934f"], "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "65"}}, "97606e30-6cb6-4638-bd4f-44d732959551": {"node_ids": ["6911d3be-94c5-471d-b258-0353043a2eec", "28a66f32-6740-4c9a-ad58-215e23206741"], "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "66"}}, "314ee1c2-8961-40f3-8fc6-b023dde21d3e": {"node_ids": ["67062cb8-d337-4168-bb10-2cdad0cf2913"], "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "67"}}, "98ef12a0-1d70-4570-94fb-44fa17d8cc52": {"node_ids": ["b6c7efa0-7f7b-479e-9247-5bc871cb4a40", "be7725eb-ee1d-40ce-a5e2-e8b0be237353"], "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "68"}}, "fd21b16e-df81-40d5-bed7-6c2fe358c691": {"node_ids": ["907fb015-c204-4da5-aad2-4bfb7a82757f"], "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "69"}}, "02b5bbd0-2b23-427f-be27-6102fb479af6": {"node_ids": ["cdbb6fc1-c11d-4cd9-9ed0-39209b9d3d44", "653f7390-dba3-451b-b1c9-4376f61ae1c3"], "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "70"}}, "33befe0e-2f00-4148-a7ae-f887c8c49d53": {"node_ids": ["f9813d9a-9cb7-41b7-9cca-e9ef07f488ad", "ade98854-ef0a-4f0c-ba3b-2f057c5bf8be"], "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "71"}}, "236b607b-3370-4cb2-85db-8115efc9f614": {"node_ids": ["425114d5-9e8f-44f0-9cc8-873317c3cbe1", "e9973750-2a6d-418e-8a75-870c6ebc8b90"], "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "72"}}, "b294b949-7894-4967-9bf7-a108adea1a9b": {"node_ids": ["8fda0991-4276-4ad7-8bae-b923347ceb0f", "e739ef30-79aa-4070-91e5-f441bf447b73"], "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "73"}}, "9bc5d05e-bdf4-480d-9d17-94e59543ab04": {"node_ids": ["36bdbc73-3ef1-4335-8e05-f818fd151e83"], "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "74"}}, "2c254d85-2947-4aaa-a7c6-77bc40f88383": {"node_ids": ["e81417f3-5945-449a-ad1c-b33e540a7799"], "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "75"}}, "7508808c-84cc-4266-9c85-28a0b2536be8": {"node_ids": ["1b13e3c3-36d0-46f1-92cc-f4e5b7ef1335", "9886289b-cf8b-47f7-9a31-9579e6be0afd"], "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "76"}}, "b9aa4c94-93b3-4fac-9ab0-efd44e9534d0": {"node_ids": ["fb593958-d6e2-4ed2-ba8e-54f915e7ff14"], "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "77"}}, "0d56cc63-58fe-4e1f-bad2-40a348fc10f6": {"node_ids": ["9880e4c1-0f71-4712-96e8-86c722c0d1ed"], "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "78"}}, "f7fb7d50-71b5-4197-9b2e-afa11903fc62": {"node_ids": ["ccddd486-4eb8-403f-922c-e012811b9025", "b4631fe8-16eb-4e21-ae23-0750d18ca60b"], "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "79"}}, "c521f649-596f-42d1-9176-ca2684d23122": {"node_ids": ["9516df09-b3f9-4f97-9de2-01056e6a8dfe", "eeaec2c2-1720-4b81-9c45-a8ab1b8cd1ce"], "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "80"}}, "2327ed29-f55d-475e-a76e-ff446fbcace1": {"node_ids": ["0be6665f-bf00-4ebe-ade1-a55286506a3a", "9ff7cb3d-bffc-43d4-9af3-09d92160e8a4"], "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "81"}}, "9a65b5e3-fc9b-47fb-a3a9-ed87d4d6e5b7": {"node_ids": ["81085bbb-3bed-4285-bb79-6fbc9c5bc201", "933f5aea-ed26-4cdc-99d2-acee32956713"], "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "82"}}, "df65d194-a6d8-462a-8b37-109606ec933f": {"node_ids": ["f1bde30e-5d24-4dfe-95b4-4d384b944501", "6610dd6a-a931-429b-9665-cb862404fd49"], "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "83"}}, "d71d5fff-6c3c-4de5-a173-2cbb192590ed": {"node_ids": ["ebbc39e7-5985-434d-9f11-ad53441d5f88", "08a32125-94ff-423d-8f1a-f1cfb9cc8f27"], "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "84"}}, "285426ad-b2f5-4d2d-a184-ce62d5d57bb7": {"node_ids": ["1b149e22-88c1-40ae-a614-4203fadfb63f"], "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "85"}}, "d5ed7fa2-a099-4b27-b63f-5bbb5f196355": {"node_ids": ["459d3501-41f7-4244-89fd-49ce1c6219d9"], "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "86"}}, "175729ba-5bfe-4cac-9c51-acea1c635f08": {"node_ids": ["890eb3ab-daf8-4785-adab-7cfc8927df36"], "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "87"}}, "336bcbda-4e8e-4cc0-b232-eabf5c245c69": {"node_ids": ["3f7cde92-6a49-4b67-afdb-367c4e1ef04b", "3d21ce87-7b06-4751-bab5-544574ec7e15"], "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "88"}}, "69858e8f-8380-4ea3-9501-b98ec47b5945": {"node_ids": ["ddfb8ce9-5131-4d0a-8a10-22acc669941e", "95a8a6a6-0dff-42e1-9f3f-a12b9b038600"], "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "89"}}, "b5d68a78-a203-45b8-b224-334c0d39b6e8": {"node_ids": ["55025c85-3d8b-4487-afba-06cbd342b823"], "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "90"}}, "ef5dba80-8512-42ce-93af-7717b93dc385": {"node_ids": ["c55d5288-2b53-47f6-be5b-96ff143cf8c5"], "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "91"}}, "f385409c-f9d7-4fce-84d6-2e5bab74d88f": {"node_ids": ["2ef850d9-43c4-4b85-9985-5bc24867e47c"], "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "92"}}, "dc9b56b9-0ada-4d10-ae9c-5c82e13a80e1": {"node_ids": ["f40c7f39-5b2c-41b6-b773-f1c7e362396c"], "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "93"}}, "110ab407-9f8b-4ff1-a9dc-2020f75b7b9a": {"node_ids": ["f668eb49-3429-4155-b401-0953bf83f07e"], "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "94"}}, "52925b67-350f-4134-8ccd-5643edf2e960": {"node_ids": ["4d738674-2fd4-4072-9aa2-54580af97f98", "9c1d259f-f6d8-47c7-89a9-617b790232fe"], "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "95"}}, "b3e663b1-ec07-4f4e-83c3-f9bd9517de5e": {"node_ids": ["8c49a53c-7299-430d-9281-42a5cb3c8b92", "e183dd11-bf0f-4dce-a760-be066f89246b"], "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "96"}}, "accb8201-6bcf-4a12-b369-e1c7699808e9": {"node_ids": ["6a00cb70-0ef9-45aa-be55-e1e23d81ff8a", "615d31b8-ebb0-45e8-8125-cafee6eda8cf"], "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "97"}}, "6607394e-4a4e-404c-b0f8-9e2ae5ba31b6": {"node_ids": ["3e94feea-128f-4b9a-a395-47dfb1e906e0"], "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "98"}}, "9bc417ff-188d-4bcb-91f5-d132ae4d6104": {"node_ids": ["08e2f4da-d706-4557-bef6-6bc49295cb8e", "ef291609-ad4f-46ad-9d5c-f8a5a95177a1"], "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "99"}}, "2a6933f1-51ac-4477-aa0d-a434b4efa411": {"node_ids": ["0a19e4b3-3161-4d1b-bb9a-db12b68e96f5", "f19d0076-d34d-4fb9-8e59-1cac0215e2aa"], "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "100"}}, "c95aea0f-0245-4a66-b665-cf14b3ac5bae": {"node_ids": ["8f327443-6e71-4a86-8140-14cedf761502", "a61a696d-293a-4aa2-894a-633aa51d6743"], "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "101"}}, "27f17e90-1ae4-418e-8389-213079cfecab": {"node_ids": ["f800b041-4b81-428e-89e4-52c881825422", "8783871d-64e3-4d1e-b12a-29ad298454f1"], "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "102"}}, "7cef6422-89b7-4a55-8c3c-eee960af7db3": {"node_ids": ["57a7494d-489e-47c9-be03-c1a90f9e1e55", "07d4de22-1af3-4b3c-8750-403b68b3d8a3"], "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "103"}}, "cd65c9aa-e7d5-4407-b32b-142314582741": {"node_ids": ["a2878915-96f6-4299-9a8a-3399462b2db2", "393fb0f8-5997-437a-8af2-a13d371d1514"], "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "104"}}, "52cc1d62-e826-45ea-9a7c-e2c54ab0531f": {"node_ids": ["c4f1831f-ddee-49d4-a198-4d1f057639a3", "e15ce5fe-49ab-446c-8c62-1354ae71504c"], "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "105"}}, "c78852ad-f8b2-4549-9514-06188dbd5c64": {"node_ids": ["31fbc137-d1b3-40f8-9e4b-075acee83947", "a4af114e-4913-40e1-9aeb-9b630bdeffa5"], "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "106"}}, "59d553bf-b93e-40e1-856a-b1537b00c5bf": {"node_ids": ["b785705a-cb2f-4329-a651-b6c07b8d139e", "a7f50a94-2c8a-4d32-a83e-a521949008aa"], "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "107"}}, "459cb1ea-e0d6-4719-9c4d-00514e5ace41": {"node_ids": ["9431bc2d-e08e-46a3-bc80-d27cbaf386c4", "04d66de4-a4f3-4c7d-9833-ded920821f2a"], "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "108"}}, "af71b0c5-2326-4403-8d40-6e6bf9ccee93": {"node_ids": ["8720dfe8-db22-4d69-9a8d-0579e28b18f1", "ee17b38a-ca3c-42a3-8e16-b9a7bad1487d"], "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "109"}}, "74f5de9b-e37d-47b2-9a9b-48ced6817969": {"node_ids": ["bb84cb96-5271-4879-87c2-19adda414bda", "c11bd6d3-2248-4bc3-bd24-25bca91ce9b4"], "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "110"}}, "3fdba418-b989-4825-85f9-f6ad8d977382": {"node_ids": ["a760fef5-7e49-4468-9b03-668367d9fd52", "81305aad-4c02-4ca2-bc2a-5bb3626115ad"], "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "111"}}, "253c8ce6-0eb9-4343-92b9-80d3c99cb62a": {"node_ids": ["e6693d07-cbac-48fb-9574-a290228c7622", "b61696f7-ae28-4cde-9704-70c5e0c7b1d1"], "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "112"}}, "19c43fe0-1cfd-4d53-852a-aed8dad99770": {"node_ids": ["16048e6f-cdd1-402f-8bd4-2835626318da", "210754d4-5635-4563-81ce-37a73043cd62"], "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "113"}}, "f6dffcce-0d98-40c0-99de-73a85289bf80": {"node_ids": ["f4750933-4805-426e-802b-cb796833d767", "7625cd1f-1d8d-475a-aa15-a82a2b923a5d"], "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "114"}}, "a94b168c-0793-4138-934a-9034fa792009": {"node_ids": ["2246a2be-d002-48ac-8b2c-8afde8a192ba"], "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "115"}}, "22135a79-2828-4b0e-a1bf-3f86d8e82561": {"node_ids": ["8c95c435-ecae-458f-b93b-2a8e3e355ad5", "d258e18e-5dad-4b58-8cfb-1b6d4369fb47"], "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "116"}}, "3fa149b1-5966-4c8b-a44a-c6d042800518": {"node_ids": ["ad334e33-ebbf-4993-9877-5ad41b3db1cb", "f7b89b43-017c-4efc-b877-380025035b56"], "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "117"}}, "31b9b619-a63b-4330-96dc-4acb6d789f23": {"node_ids": ["0e6b8c23-d409-4e25-921a-b6696859794f", "f1a51a60-1f60-4511-9e5f-e2edaed13c49"], "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "118"}}, "6a0b6008-5a87-4a22-b09b-f557910361b3": {"node_ids": ["6d91b42b-6348-47a1-94a9-51cbd00386c9", "cbb0087f-08a9-4dd6-b133-1cfd8d04bbf0"], "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "119"}}, "502ad679-242f-4d03-8e19-4e1083741658": {"node_ids": ["0b169dee-4f40-401a-8764-416dbcb435ba"], "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "120"}}, "1da58ef8-8c2e-4a86-885f-06ad61b0456e": {"node_ids": ["100320dd-6521-475e-a469-ea2de2f092d9", "0eb0f91e-fca4-41cb-bfbc-e734507d1697"], "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "121"}}, "97a17099-6991-4c98-81f7-99105971fe95": {"node_ids": ["35776140-6314-4d8a-9b73-2df8ab54bb72", "e0c98463-de1e-400d-8f18-cd4a8cec5f31"], "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "122"}}, "de82a231-70c6-4856-96d5-2a1fd1de9e0a": {"node_ids": ["4e1cd198-b704-460e-8d0d-7631ac8bc072", "2b03485e-3474-4fb1-9f1f-59598bd9b704"], "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "123"}}, "1d02fefb-abe3-4ed3-86e7-26a4e79e7fbf": {"node_ids": ["35ccca7c-99bd-44db-a0d2-bcc050c6a42f", "76cc1574-73b8-4371-af21-5ff13d0074f9"], "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "124"}}, "bb5420f3-411a-464d-baf1-7d0df539fd05": {"node_ids": ["58afbb21-29e3-440a-a8fc-5c7191edd5fb"], "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "125"}}, "2f762054-3671-4809-a64e-4a4decb703a2": {"node_ids": ["ac099cdb-d5ad-4961-a31a-eb8200eea9c1"], "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "126"}}, "934015e6-7e39-400c-a5cc-9622a395898a": {"node_ids": ["eab98260-9f90-49bf-9064-b8f1223f5342", "e6416993-0972-46c8-9e79-afd0df3c23c8"], "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "127"}}, "ec8c0caa-a2ea-4e19-8641-274336c246d9": {"node_ids": ["6d06b256-ae19-4bed-b0fe-054b899505da"], "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "128"}}, "28974f4c-43ba-4540-ac54-4a9fbcef2018": {"node_ids": ["09aed8ba-78be-4c77-83af-a76ef42e8df8", "a7fc5a51-1c4c-47ed-a613-8ce989fee01f"], "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "129"}}, "78d61185-2e8c-4671-bb6e-c82de66a8652": {"node_ids": ["a9520765-1317-40b9-b4c3-2e7cd628e848", "2d14fd67-49a8-4f94-bf81-2d4bcaef52ee"], "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "130"}}, "8f408e3c-4df0-4b5f-b86a-caacf1d2b6b6": {"node_ids": ["b3bea509-671c-44a5-aaf2-736887b0a21e", "1a9836bc-e4f9-4152-befd-9fbd1c51cac4"], "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "131"}}, "91d1cd86-050c-4a0e-bb08-d3a7c5b1f98e": {"node_ids": ["27c77f31-1d9b-4a23-8719-f9bcb569bf57"], "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "132"}}, "74d66383-bdab-4939-bb9c-9276fe620f20": {"node_ids": ["2bd0463f-4929-45e4-bb73-2ea09d711740", "817a4c73-6152-4ab4-814a-e2bea8ff171d"], "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "133"}}, "e3cd6429-e1a9-47eb-8027-38fae61e9fde": {"node_ids": ["193ea219-1c85-4ea2-8795-0a0200488a2f"], "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "134"}}, "3fe57bf8-6506-48ed-8f46-0045f2fff9e7": {"node_ids": ["02a635bd-e16b-4539-9a16-f2e3ecad7227", "a6d380fd-9039-4be3-9e27-33d6fa885998"], "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "135"}}, "3ec60722-2882-47ca-be3f-bc3755bd7a84": {"node_ids": ["fed4779b-e013-466c-83f5-04d6f8faabfe", "1e0954d4-5eae-4c7e-a501-83d7dda2d8c5", "c83e71c1-7f1f-41c9-bcac-b33037dc8ed1"], "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "136"}}, "3b0b0a59-f43b-4fa0-87b7-22f81aa21f02": {"node_ids": ["2da84c07-4ebe-4211-b5b0-fd21486d6b5a", "5a30d31b-5559-4389-8785-720cd5dd7b54"], "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "137"}}, "e6880aff-f18b-416d-a983-308d199f0a6f": {"node_ids": ["4eca5a85-55fa-4496-8876-ddee5fbf1f20", "5eb7decb-77d0-43b0-bec9-fa685b72edd1"], "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "138"}}, "57f0c827-e783-4bf9-bfb8-bbefc04b1f3a": {"node_ids": ["cb2286b8-6bfc-42e7-ba49-82f29232984f", "6ffdfbf1-737c-40c4-9de9-6b2b8482aaad"], "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "139"}}, "a1a5c8d4-bbb4-40e6-adaa-3915caccfb58": {"node_ids": ["3cceab0d-8bbb-44a1-a2dc-f57c31632e82", "e91cfa5d-4214-4b71-9ca7-7fa32303ccac"], "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "140"}}, "d679af73-ea2d-4874-818b-94158008bfe6": {"node_ids": ["15416557-c23e-419e-abc9-9578e14ab17a", "f0bb644a-08b3-49eb-ac06-673962ac0baa"], "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "141"}}, "44714a06-f7fb-4eac-8510-fbeca8a3e72d": {"node_ids": ["118fd178-faa9-4705-beb9-69682dd25e69", "08c58623-d8a7-4551-8c94-ab7c16eb9e58"], "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "142"}}, "a81e2521-1bbc-44a6-b7c2-b67efef91218": {"node_ids": ["08fa4b6c-9807-4b4a-b5a6-c04319932126", "c5c145a4-29af-4775-9b3c-5ba827f4ba90", "5c5879bd-0e34-4ed1-9321-8e3a54ab2d9b"], "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "143"}}, "2e2ec4da-b5d0-4cfd-8f70-a85395e5e2c9": {"node_ids": ["0f06aedb-3f5e-44a2-ba9a-3d74ab1890a8", "238252a7-bb98-43f8-9227-994c3a9c6d19"], "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "144"}}, "41649b7d-774e-4dce-b744-e9bb756fa947": {"node_ids": ["bf83d6e8-4170-442a-8f94-2868e8b8cbd0", "99a3500a-4731-4286-9977-eb78277a1871"], "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "145"}}, "15e9446d-bc1c-4bfc-9b0d-755d73d2f052": {"node_ids": ["6222af72-5045-43a4-9230-8d13e6560624", "7174b84c-0bdd-4b90-b345-279a11a53946"], "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "146"}}, "0d440eb1-c44a-48a5-b7f9-05e70d8fd695": {"node_ids": ["cb944b09-95de-43bb-a556-7ab7d3775625", "aeb8da2f-379e-4b51-bcc9-61d9630b8d98"], "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "147"}}, "72248ba5-43b6-4b20-b425-2625127f975d": {"node_ids": ["683e059a-6fe7-48a2-b28f-028fc3e289cf", "011bee2b-28a8-49b6-86af-6aac23188582"], "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "148"}}, "9091ab65-582d-470f-8f37-50f989e629eb": {"node_ids": ["46f99a4b-76b1-426d-bd37-df3db3460903", "86eaf194-7fba-4bce-8ae6-b04714c08f02"], "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "149"}}, "50bbf825-0710-4a08-9782-b7ccb27c929c": {"node_ids": ["a7c6a127-f30a-4862-b0bb-8c9958a9159b", "1356d135-6985-4aa5-ae4e-6a6150f6b73b"], "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "150"}}, "cd642cb9-c157-4153-81a0-94bf149586c4": {"node_ids": ["019ba598-c8d0-4900-a5e1-4e344c4216fb", "73bb99a6-98dc-4f93-8bac-c593c5f770a3"], "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "151"}}, "ebd0eb68-51d8-421e-89d1-c6503aa22a20": {"node_ids": ["49528269-375f-4e87-9db1-521d9fff269d", "2f486d73-d2bb-4a5d-aa81-682dea6eaa29"], "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "152"}}, "53227f03-0b6b-4205-b7b5-b4329d0d70df": {"node_ids": ["d9aff44c-ac66-4082-9c24-f99af3add0c2", "f66ace3e-f075-43e3-b9a2-9fa29f751571"], "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "153"}}, "e024498a-153c-4b79-8074-2ab668ee5fed": {"node_ids": ["159d520b-bf8a-4d50-9e34-5cb865d66d45", "957ead0c-9e4e-4833-a99e-2d1f16bff36c"], "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "154"}}, "bbc6cd0e-eb61-4539-9c9c-62c1d548f002": {"node_ids": ["1f2d5787-aef0-4b9a-8238-f2365e362766", "80db4039-569d-4360-8bda-55eec2f6d612"], "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "155"}}, "7cea03c8-4dc6-44ce-961c-9038ff779864": {"node_ids": ["65d10243-f15d-4bce-bbc2-e106f3533b61", "9970512e-3eb7-47ad-9a30-c12d3b878f48"], "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "156"}}, "aa3dca8a-5e60-45ce-8aac-012c7dd140e2": {"node_ids": ["93da8cc7-87d3-490b-8951-60141efad62c"], "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "157"}}, "a7a21d13-887b-49f3-913a-8812bc22837a": {"node_ids": ["44c6acb1-b760-4408-b3fd-6a197204891c", "a36f1734-219c-49a1-95c6-9f9f5832704e"], "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "158"}}, "a80395d4-ee8c-42d0-82ff-8ba86116797e": {"node_ids": ["3e1a7525-f207-4824-98c0-bd1c44040906", "90849e80-dc64-43b4-b3a0-9a7a76d4c2d7"], "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "159"}}, "28155c3f-7d1a-449a-8234-b22f335c8147": {"node_ids": ["c28bf029-c532-4154-9766-e090e7bc7136"], "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "160"}}, "eab121bf-01a6-4981-bb92-f0d6aa9ba3f7": {"node_ids": ["e074bc41-cafe-4be4-b56f-588f9f15373a", "7c345bc1-163a-4ec7-bf34-7717e3ba570e"], "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "161"}}, "45cd944d-2c5a-4ead-bbe8-70af481b85a6": {"node_ids": ["6da50fab-5980-4c2c-84af-31918320c1d5", "4f7838a0-b176-4965-b8c0-685273a0447b"], "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "162"}}, "e8a10dae-2516-45da-acd4-0ee1cf985fec": {"node_ids": ["47391560-6334-47d5-9e62-6686f17e4f06", "c347c70f-8257-4b7e-a6d8-3af905c52495"], "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "163"}}, "26e48ada-ab03-42ed-9bee-26a3123d7a5f": {"node_ids": ["7da6e1b6-9f0b-43cf-8518-ac6ffc87ed63"], "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "164"}}, "3aa86a31-973c-4fce-ab66-f4aa7bff5043": {"node_ids": ["556f10bc-7d4e-458a-a0a0-f538ed644201", "bb94cf11-a258-4b70-81ac-9873bf3f873e"], "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "165"}}, "3cd572bc-021d-4450-807b-8020691904b4": {"node_ids": ["6415ca26-b722-4662-9a6a-d13e0d33aace", "5a8bee1d-c015-437f-9775-69993b402fb4"], "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "166"}}, "4e19f959-ebc1-4f57-8dd5-9234afd2eb1d": {"node_ids": ["e59fd1cc-d0b5-4df0-86aa-31f92f58f2ca", "5765ea47-1c9b-4937-b3c7-c70726de1f69"], "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "167"}}, "8845ef23-bac5-4a94-83fe-864068ff0ae6": {"node_ids": ["b4ad81ae-1a81-4289-9433-0fc3740b1f32", "b93f2ebe-a233-4c3b-8d25-2b11a2ba52c1"], "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "168"}}, "4a3165f7-60ef-4165-acbf-6f9a419e6b54": {"node_ids": ["382ab8aa-8fe1-4b7a-9fe9-093bdd4d20dd", "6e3d678b-a98b-457e-974d-38fe4314ae20"], "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "169"}}, "7251f124-7168-4ec5-807a-14a4ed7476ce": {"node_ids": ["2c691738-dc4b-4cbc-8882-78121574e5e9"], "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "170"}}, "d68cfc65-85b5-4234-88ae-0a3b989a0e69": {"node_ids": ["0378a33e-7743-4673-9c1a-ad55dbf0810a"], "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "171"}}, "234056e2-413f-41f7-aa87-1a4b4a508d4e": {"node_ids": ["91f262c2-39ed-4662-bbd5-2ecec9c26b0b", "c5d4e1fa-01d7-4b5a-9fb6-6466e430846f"], "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "172"}}, "83ff9d67-084f-45e2-91bd-9542ba422b41": {"node_ids": ["25a3054d-1c71-4bc8-aecb-4a27c9de691e", "b1eb4b3e-567e-4f17-877d-095f1809f230"], "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "173"}}, "1dcaa35b-e0bb-4635-8503-e752f6878893": {"node_ids": ["591fad25-4e6c-4337-868e-3d7a7279a2d9", "d67ccacd-0a5d-46e8-8290-e85878cfd945"], "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "174"}}, "dc3784ad-deb5-4bbe-88fc-ae486253e4c8": {"node_ids": ["a776e386-3461-47e8-ab19-abb143d86fc6"], "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "175"}}, "597f6fd3-b13f-445a-a547-e86c0068b20b": {"node_ids": ["4cdc837f-c000-49ad-b983-a17fcc373492", "1a125332-8d89-4302-927f-b116e893c6d5"], "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "176"}}, "450b659d-5a69-4bfe-b049-7a67a3a14eae": {"node_ids": ["932daae5-4796-4f35-88c8-040e867cb136", "955f6a4f-1e22-4141-b5c3-3a67c3a6f936"], "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "177"}}, "7a7b5fd3-fbd7-4001-9a24-3e9755b111f4": {"node_ids": ["a1c4a550-3889-4009-9833-172b16e0566d", "a215e493-b820-46c6-8c21-c461ab40661b"], "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "178"}}, "ec434ea7-d8fc-4be0-a63a-cd5d4fabfa06": {"node_ids": ["9fb267a4-f08d-4753-b774-f6847951b0b9", "d5bc45e6-b9ca-4574-ad1a-191c0993c8d6"], "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "179"}}, "f094c334-0898-440e-82dd-983151b82c98": {"node_ids": ["7352ca8c-463a-4789-87cd-29007b9c57cd", "5d936c1e-d077-4c5a-8b4f-0620578780ce"], "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "180"}}, "00bfb6e8-6eba-49f4-a85c-ec35a355053b": {"node_ids": ["0db5d2a8-780d-4765-b3ad-1950e5680a6c", "3d6506b9-0da1-4512-95b7-362a8f768b48"], "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "181"}}, "40248634-2aee-4ecb-a90c-5605ca8a7cde": {"node_ids": ["46ac092f-0d3a-428b-b2f2-04c0e351f128", "b9b98a4a-26e8-4818-971f-70b70c505552"], "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "182"}}, "edf9a86c-f9de-497d-b30e-68957387335b": {"node_ids": ["2abde0a5-fc07-42ae-966b-cf476439c776", "dff543c0-112b-4bfc-9ea6-02d098c47924"], "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "183"}}, "b92f8adb-2957-4154-9167-8e0db018db41": {"node_ids": ["b3419208-47cd-46f4-a0b6-d58583ac57a3", "5bd3588c-954f-474b-a367-59c6221bb051"], "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "184"}}, "44dfdbb7-31d7-44e0-8d98-8ed3836bc2e3": {"node_ids": ["8216c642-67e0-460d-bf97-d50d6802b845", "f0dce1ea-755c-418e-966e-01bc4708ff3e"], "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "185"}}, "0f587ed7-3674-457c-af4c-c28acb21276e": {"node_ids": ["45bb6def-f19b-49b0-a0c4-1adacee31023"], "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "186"}}, "e90314e1-14f1-4c1f-a8be-453d26509f50": {"node_ids": ["c12d2cdd-8f46-4487-831a-88c5a9012017", "bad0abb5-aca4-4329-a0af-102a03b07d23"], "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "187"}}, "4646dc06-b860-46aa-abb1-e1bdd7506144": {"node_ids": ["8cd0fb02-f656-4cd2-afe5-6f73df309dcf", "8e6622eb-c28c-4495-a3e1-38132d7a632d"], "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "188"}}, "12c6b0c9-86f8-48b8-a1db-018fee279d7e": {"node_ids": ["c3b13267-f840-48de-ade5-ae96a746d135"], "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "189"}}, "978a7020-a72d-43d7-b10a-ad804af6846a": {"node_ids": ["53557098-7254-4bc5-b4b5-094ee193e2b3", "a201247f-3973-4ee6-be77-1836943fb055"], "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "190"}}, "65e287af-c1f1-4dd9-8695-737aa98e0b75": {"node_ids": ["ac759fc7-42df-41ee-8b71-e91a5cb10858", "256e7148-5d6f-415a-a224-9b8771243c10"], "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "191"}}, "782057ad-51ec-4afd-b252-97ed9f6ecc0f": {"node_ids": ["cf4ebd45-e0be-4f3e-9abe-5e16d0746ea1"], "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "192"}}, "b9681a79-d47a-462e-a0d4-6e58a4d91c40": {"node_ids": ["c49e0122-9adb-4288-92f4-97d36142a55c", "d5c9a962-ce2d-4327-9bd8-18fff39d192a"], "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "193"}}, "9d8fed63-108a-4713-984b-4849a0c93d93": {"node_ids": ["534c08a5-1c4a-44e2-8145-6585465a9092", "afbcfc94-bd07-4b97-9f1d-572cfcc31a4c"], "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "194"}}, "f38adb69-52e3-4bb4-8799-b8ccfdb7a069": {"node_ids": ["fe0b450f-7112-4e84-b0c0-d2e8b48fdd28", "55dc894b-318e-48e7-8a65-a946d6273230"], "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "195"}}, "18e077a2-a4d9-4909-8c6b-35494d5ba0b2": {"node_ids": ["faa17b0f-4ca3-4367-9f5a-9d15003457d4"], "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "196"}}, "d1f797ff-1625-4757-8f13-f6f80526a9b3": {"node_ids": ["6d0b7261-7810-47f9-aac7-28b2efd64d3e", "517eefcf-7e93-4a38-a7e6-2a8874a70d0b"], "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "197"}}, "25bc5166-550b-4580-8e6d-dde3d6ba386c": {"node_ids": ["4c7d908f-b4a2-40da-87a5-3e19ff1bd043"], "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "198"}}, "bd086099-3f55-4263-8059-158420704be4": {"node_ids": ["4a1f28a9-be7f-478d-87a4-9ca78ee7b78a", "6b44b1c5-16c8-4cb0-ad25-a33e49bf4f7b"], "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "199"}}, "bdadc22a-0000-4cd1-a937-793a9afe85ed": {"node_ids": ["1756db42-47ab-49e4-b001-b3fe2212262f", "ea70f1f9-da2a-47d7-b250-a502f31295bb"], "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "200"}}, "4e180018-fbbf-43e8-a1ea-15cf6627a8f8": {"node_ids": ["c6754ee2-afe1-4935-9f64-bcdac692a0d4", "616c5b36-980f-4fe4-88b4-5c783ec57e63"], "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "201"}}, "b8539cb0-7426-419b-b170-de4567b073a3": {"node_ids": ["cc8fb98b-60fe-4174-ab94-99396a846c30", "8290b52f-ce85-48f0-9acb-ac6d915d401f"], "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "202"}}, "8b2f744a-0bcd-4408-9b89-2e4762db91ce": {"node_ids": ["083fd25e-254e-404b-bd4f-28ae3f7c4c07"], "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "203"}}, "9163314a-af75-4fa5-9076-af39d6c9dd46": {"node_ids": ["fea5705c-de9f-4a70-bfbc-527e61f089ef"], "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "204"}}, "f504e0ff-dfe9-4084-9e91-3537423ad842": {"node_ids": ["7b9fe65d-10d0-4a0e-90c4-8efd765732d4", "91e26530-b151-488c-a65c-0dcd2608ef5f"], "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "205"}}, "2f63e83e-49c0-4f12-8f48-25806f25b43b": {"node_ids": ["9ef78b46-7267-4cd0-82c3-c98141f0529a"], "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "206"}}, "3cc64a19-ea77-49da-a05f-ef6ac5e2ad80": {"node_ids": ["6e540052-01f2-4f78-888e-792941510760", "3ff1aa4b-f786-4648-a832-ffa6fe2d5e38"], "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "207"}}, "45d7e776-771a-46df-a08c-98b3fa4e8e31": {"node_ids": ["fbd8d84c-3423-4060-b7e3-67bf71aff80b"], "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "208"}}, "77e7257b-3bb4-43d8-aea4-976a73f41c70": {"node_ids": ["3577ddd8-a3ff-46d9-a733-08405eacaa91", "7dd51d13-583c-4a60-a6c2-d1a11c75027b", "aa8c86e2-fc29-4acd-80c7-8c479019d490"], "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "209"}}, "859d421e-5245-40b6-847a-6a62eb4cd6bd": {"node_ids": ["b43df622-c91e-408e-a646-f6febc686638", "6cf5bb9c-2c90-444d-80ea-fcbe435c2053", "56ef3328-76e1-4bca-87a9-bbda654cc6fb"], "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "210"}}, "400c0315-9b01-4364-a6d1-fbe4bfa116bb": {"node_ids": ["011cd2dc-5daa-4099-ae52-c422ea93665c"], "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "211"}}, "6a0fe561-167d-41d4-a792-6aa016cb2f89": {"node_ids": ["443480d9-8490-4c04-b8eb-608a5557f39a", "e65103d2-9d27-4d80-b330-a6f058f29760"], "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "212"}}, "06a807af-a1bb-4e3c-a47b-b3b0499c8f31": {"node_ids": ["5e3a72d7-0c87-4911-bafe-e9b0cd48002d", "8098cf99-80dd-4731-b554-d66d19f9e67e"], "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "213"}}, "340ea794-2988-449e-8d9c-cd76cac952dd": {"node_ids": ["7e3255d9-6fcf-4875-a214-1b2d44e89e21", "1a83fd36-9000-493d-95ec-5fa53f439cd3"], "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "214"}}, "7e32cd2e-1b1e-4732-9193-7a0ef26b5447": {"node_ids": ["4c4a0768-1bca-4f74-8f15-0dc150963178", "8d36f64b-9514-4036-9d79-021772b5a77a"], "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "215"}}, "9569d721-8a91-43a0-854b-076916ad2334": {"node_ids": ["e17646bd-5731-4469-abcb-85375c4b587a", "f4cfbbeb-2eda-48d6-b788-084c74ed6ffe"], "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "216"}}, "1117452e-2b19-4868-9ff4-260052446b71": {"node_ids": ["ef47eb3c-026d-4787-a438-b549e01ceca0", "122a1120-c052-4d90-96d7-b8c1b3f16f8c"], "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "217"}}, "9406704c-a3c5-4085-8d95-39644968bf9e": {"node_ids": ["f9935644-aebb-4a9a-92e7-bae20a49226d", "10a78eb7-9639-4842-8a00-a445a0ae2ad7", "8c262150-a2b3-435b-a71f-fd4e3b8f9a72"], "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "218"}}, "67038ab4-121a-43cd-a86b-f09cf60f4a09": {"node_ids": ["e7ca2172-90e8-4a47-892c-0c5a6f03e774", "2ad63c89-a59c-46cb-bee0-fc9ba90434cd"], "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "219"}}, "e3e28858-244d-4587-a781-7722c8e9b153": {"node_ids": ["9fd7a2cc-ed16-4e88-aae6-6cb7107c4deb", "c12fcee9-b5bb-4b2a-b4be-d72d46092a9d"], "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "220"}}, "cd162de7-556f-4dd8-8b33-28a367ef554b": {"node_ids": ["73a7f409-b431-49e6-8c1c-68e230ffebb1", "f0dce60d-5ad1-493d-801d-5d7e4cf8e44a"], "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "221"}}, "80a41d94-9d28-4157-ba0a-fbf85f1c7d5c": {"node_ids": ["5abbd6a7-21cd-43a2-9b78-f1dc99e43c32", "471e71e0-58c2-4646-93be-4b0d82358810"], "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "222"}}, "732bce29-a7a6-4e8a-a71c-c4957199ae29": {"node_ids": ["433064f1-cefd-4348-9bb5-a75f55bf1dac", "a44a9e60-a785-46b9-b3d3-2b97573e2709"], "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "223"}}, "6d2af672-ac27-499b-a420-7a2683e65e86": {"node_ids": ["c6d55ce3-e8ce-4f3e-9fc8-6829d85c7473"], "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "224"}}, "87414f2f-a2e6-41b7-b89e-b0324101029c": {"node_ids": ["13909637-aa38-493f-bc29-b03f285b950e"], "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "225"}}, "888b838f-619a-42ca-b02b-e0aa05be92e9": {"node_ids": ["53d10b46-b207-458c-ac52-7c6e3cf26a5a"], "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "226"}}, "540a07a9-1ac4-4b04-9d6a-3eaeb4aec50b": {"node_ids": ["a554d9fe-d6f7-407d-827f-6750409c9e23"], "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "227"}}, "eaf52094-1c59-4fcf-a559-dfe9f9d0d1aa": {"node_ids": ["c6d3bb5a-db7f-4681-b4f9-e30793afffbe"], "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "228"}}, "28f16f19-8eb6-4647-ba72-e7c9d32bbb99": {"node_ids": ["69aab10b-ffbc-4629-b7f5-fd11b30dad25"], "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "229"}}, "216625c0-c0eb-4f4d-b50b-05ecd7970ef3": {"node_ids": ["53569573-9409-42e8-944c-90be55b06552", "1ebfe15c-9949-4500-987b-323d16d35971"], "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "230"}}, "3f93b626-4976-4748-80b4-ba3cdecfad10": {"node_ids": ["6294f098-a86c-49f1-bfd7-c36a1ea01dd5"], "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "231"}}, "8a74ce19-e71e-4c07-9d07-68c714416ef0": {"node_ids": ["9dd4b5f5-f9ea-4605-82b4-b27474df43f5", "c6d9a079-8b91-4b5f-9540-8777b0f01195"], "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "232"}}, "bd20100a-1245-4eca-8cd2-d504ac7ca099": {"node_ids": ["9f2ed756-fb5c-46d3-b4ce-a001dda1cd11", "17a8c567-2856-4c2a-b440-3e6a8d968a38"], "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "233"}}, "17c7bdc9-14b2-40bb-9ea8-85158057cd7c": {"node_ids": ["a2a474fe-1dd7-418b-aed3-dc0950d7c607", "9c415600-8538-4b0c-aeb9-f263840c72b4"], "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "234"}}, "a8a09e86-3e26-4100-acdd-2b34deaae2cb": {"node_ids": ["20c2254e-cedc-4b42-9fb4-739da40e1b96"], "metadata": {"source": "Nigeria-Guidelines-for-HIV-Prevention-Treatment-and-Care.pdf", "page_label": "235"}}}}